<SEC-DOCUMENT>0001628280-23-026990.txt : 20230803
<SEC-HEADER>0001628280-23-026990.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803070350
ACCESSION NUMBER:		0001628280-23-026990
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avalo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001534120
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450705648
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37590
		FILM NUMBER:		231138006

	BUSINESS ADDRESS:	
		STREET 1:		540 GAITHER ROAD
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-522-8707

	MAIL ADDRESS:	
		STREET 1:		540 GAITHER ROAD
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerecor Inc.
		DATE OF NAME CHANGE:	20111102
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>avtx-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72,d:96f3b1523a8b4726a33c5f41798d50ce--><html xmlns:avtx="http://www.avalotherapeutics.com/20230630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>avtx-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001534120</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-164">0.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-263">0.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-346">0.0833</ix:nonFraction><ix:nonNumeric contextRef="c-3" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-406">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-413">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-453">http://www.avalotherapeutics.com/20230630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-454">http://www.avalotherapeutics.com/20230630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-457">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-458">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-461">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-462">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-111" name="avtx:RestructuringAndRelatedActivitiesPaymentTerm" id="f-509">P12M</ix:nonNumeric><ix:nonNumeric contextRef="c-158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-613">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="avtx-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-07</xbrli:startDate><xbrli:endDate>2022-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avtx:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:MillipredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avtx:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:MillipredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX611Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501AndAVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501AndAVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputSalesForecastPeakMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="property"><xbrli:measure>avtx:property</xbrli:measure></xbrli:unit><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>avtx:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2021-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-29</xbrli:startDate><xbrli:endDate>2021-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="business_day"><xbrli:measure>avtx:business_day</xbrli:measure></xbrli:unit><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2021-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:InitialNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:InitialNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:SecondNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:SecondNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:ThirdNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:ThirdNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="class_of_stock"><xbrli:measure>avtx:class_of_stock</xbrli:measure></xbrli:unit><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:VenrockHealthcareCapitalPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:VenrockHealthcareCapitalPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ArmisticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avtx:NantahalaCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationDateOfJune2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsNoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationJune2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationFebruary2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsNoExpiration2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avtx:SpecialAdvisorToTheBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-05</xbrli:startDate><xbrli:endDate>2016-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AstellasPharmaIncAstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX006AstellasLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AstellasPharmaIncAstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX006AstellasLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX301OutLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX301OutLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>avtx:milestone</xbrli:measure></xbrli:unit><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX801AVTX802AndAVTX803Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="therapy"><xbrli:measure>avtx:therapy</xbrli:measure></xbrli:unit><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX913Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:KarbinalAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:TRISPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>avtx:unit</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-156 f-159 f-157 f-158 f-162 f-163 f-160 f-161" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-250 f-251 f-232 f-254 f-233 f-252 f-236 f-258 f-259 f-234 f-229 f-227 f-228 f-240 f-260 f-241 f-242 f-247 f-245 f-246" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.777%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9745;</ix:nonNumeric><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">for the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37590</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">AVALO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">45-0705648</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">540 Gaither Road, Suite 400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">410</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">522-8707</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">including area code)</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.001 par value</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">AVTX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b&#8209;2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:26.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer &#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric> &#9745;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9745;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b&#8209;2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9745;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 2, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">20,249,447</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS, INC.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the Quarter Ended June&#160;30, 2023 </span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.869%"><tr><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_10">PART I.&#160;</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_10">FINANCIAL INFORMATION&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_13">Item 1.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16">, 2023 (Unaudited) and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">a</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">nd Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">Condensed Consolidated Statements of Changes in Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">(</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">) Equity</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28"> (Unaudited) for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">and Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">Condensed Consolidated Statements of Cash Flows (Unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_37">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_40">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_40">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_103">Item 2.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_103">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_106">Item 3.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_106">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_109">Item 4.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_109">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_112">PART II.&#160;</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_112">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_115">Item 1.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_118">Item 1A.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_118">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_121">Item 6.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_121">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_124">37</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements.</span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS, INC. and SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">6,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">13,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-32">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-34">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-36">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-37">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-40">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-41">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">7,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">16,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-44">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-45">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-46">14,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">14,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-48">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-49">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">24,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">33,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-52">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-55">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">7,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-57">13,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">14,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">5,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">22,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">22,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-63">13,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-66">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-67">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">31,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">44,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-77">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and December 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-79">14,036,940</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-81">9,430,535</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-82">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-83">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">314,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-85">292,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-86">321,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-87">303,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-88">6,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">10,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">24,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">33,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS,&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.944%"><tr><td style="width:1.0%"></td><td style="width:42.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-92">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-93">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-94">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-95">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-96">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-97">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-99">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-100">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-101">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-102">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-103">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-104">4,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-105">8,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-106">10,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-107">18,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">5,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">14,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-115">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-116">7,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">12,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-118">17,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-119">34,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">7,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">11,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">15,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">32,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-124">996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-125">1,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-126">1,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-127">2,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-128">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-130">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-134">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-135">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">1,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">1,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-138">2,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">2,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">8,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-141">12,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">18,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-143">35,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-144">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-145">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-146">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-147">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">8,193</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-151">12,987</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-152"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">18,148</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-154"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">35,038</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock, basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-156"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-157">0.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-158"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159">1.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-160"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-161">1.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-163">3.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> <ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</ix:footnote></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS,&#160;INC. and SUBSIDIARIES</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.041%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Three Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">13,200,535</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-166">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">307,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">313,779</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">6,267</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to ATM Program, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-170">2,044,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-171">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-172">6,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-173">6,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement of common shares in exchange for pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-174">1,300,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-175">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-176">3,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-177">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-178">3,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants in exchange for retirement of common shares </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-179">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-180">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of pre-funded warrants for common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="INF" name="avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-181">72,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares purchased through employee stock purchase plan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-182">19,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-183">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-184">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-185">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-186">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">8,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">8,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">14,036,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-190">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">314,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">321,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">6,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.041%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Six Months Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-194">9,430,535</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-195">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">292,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">303,824</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">10,915</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares of common stock and warrants in underwritten public offering, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" format="ixt:num-dot-decimal" scale="0" id="f-199">3,770,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" scale="3" id="f-200">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" format="ixt:num-dot-decimal" scale="3" id="f-201">13,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" format="ixt:num-dot-decimal" scale="3" id="f-202">13,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to ATM Program, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-203">2,044,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-204">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-205">6,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-206">6,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement of common shares in exchange for pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-207">1,300,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-208">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-209">3,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-210">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-211">3,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants in exchange for retirement of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-212">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-213">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of pre-funded warrants for common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="INF" name="avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-214">72,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares purchased through employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-215">19,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-216">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-217">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-218">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-219">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-220">18,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">18,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-222">14,036,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-223">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">314,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">321,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">6,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.041%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity (deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">9,399,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-228">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">290,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">284,217</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">6,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested during period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-232">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares purchased through employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-233">5,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-234">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-235">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-236">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-237">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">12,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">12,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-240">9,405,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">291,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">297,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">5,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.041%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity (deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-245">9,399,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-246">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-247">285,239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">262,166</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">23,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested during period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-250">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares purchased through employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-251">5,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-252">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-253">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-254">5,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-255">5,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-256">35,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">35,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-258">9,405,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-259">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">291,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">297,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">5,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> <ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</ix:footnote></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS,&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">18,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">35,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-266">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-267">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-268">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-269">5,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-270">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-271">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for other long-term asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="f-273">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-274">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-275">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-276">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-278">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-279">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-280">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-281">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-282">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-283">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-284">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-285">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="avtx:IncreaseDecreaseInLeaseIncentives" scale="3" id="f-286">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-11" sign="-" xsi:nil="true" name="avtx:IncreaseDecreaseInLeaseIncentives" id="f-287"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-288">2,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-289">1,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-290">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-292">5,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-293">3,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="avtx:IncreaseDecreaseInLeaseLiability" scale="3" id="f-294">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="avtx:IncreaseDecreaseInLeaseLiability" scale="3" id="f-295">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-296">21,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-297">28,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" scale="3" id="f-298">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposal of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-300">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="3" id="f-303">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-304">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-305">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepayment on Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-306">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-307">14,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and warrants in underwritten public offering, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avtx:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-308">13,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="avtx:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock pursuant to ATM Program, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram" format="ixt:num-dot-decimal" scale="3" id="f-310">6,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-312">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-313">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">14,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-315">14,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-316">6,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-317">43,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-318">13,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-319">54,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-320">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-321">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-322">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-323">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock retired in exchange for issuance of prefunded warrants </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" format="ixt:num-dot-decimal" scale="3" id="f-324">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-326">6,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-327">11,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-328">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-329">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-330">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-331">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-332">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-333">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_40"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVALO THERAPEUTICS,&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-334" continuedAt="i955de304f788418191ac1e8779f33572" escape="true">Business </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i955de304f788418191ac1e8779f33572" continuedAt="i8d50e8510c24411cb431b0ad9ac99d70"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Avalo&#8221; or &#8220;we&#8221;) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (&#8220;HVEM&#8221;), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin &#946; receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (&#8220;BTLA&#8221;), and CD160 (collectively, the &#8220;LIGHT-signaling network&#8221; or the &#8220;LIGHT network&#8221;). Accumulating evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo was incorporated in Delaware and commenced operation in 2011 and completed its initial public offering in October 2015. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, Avalo generated a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-335">18.1</ix:nonFraction> million and negative cash flows from operations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-336">21.1</ix:nonFraction> million. As of June 30, 2023, Avalo had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-337">6.3</ix:nonFraction> million in cash and cash equivalents. The future principal payments inclusive of the final payment fee under the Company&#8217;s Loan Agreement (as defined in Note 9) were $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-338">15.2</ix:nonFraction>&#160;million as of June&#160;30, 2023, which gives effect of the $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-339">6.0</ix:nonFraction>&#160;million partial prepayment in June of 2023, as collectively agreed upon with the Lenders (as defined in Note 9). On July 20, 2023, the Company entered into a forbearance agreement (the &#8220;Forbearance Agreement&#8221;) with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#8217;s business (the &#8220;Existing Default&#8221;) and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-340">15.2</ix:nonFraction>&#160;million, plus interest, fees, and other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-341">3.0</ix:nonFraction>&#160;million plus (b) one-hundred percent (<ix:nonFraction unitRef="number" contextRef="c-49" decimals="INF" name="avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" scale="-2" id="f-342">100</ix:nonFraction>%) of the aggregate cash proceeds received by the Company as a result of any future sale of the Company&#8217;s equity securities while the Forbearance Agreement is in effect. The Company closely monitors its cash and cash equivalents and intends to raise money through all means available to raise capital to meet its projected operating requirements, including but not limited to sale of equity securities under its &#8220;at-the-market&#8221; (or &#8220;ATM&#8221;) program or otherwise, out-licensing transactions, strategic alliances/collaborations, sale of its core and non-core programs, and/or mergers and acquisitions. If the Company is able to negotiate extensions to the Forbearance Agreement and absent future cash raises or modifications to the originally planned principal and interest payments, the Company has approximately 60 days of cash on hand as of the filing date of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future success and ability to fund its operations within one year following the date on which this Quarterly Report on Form 10-Q is issued depend on its ability to obtain additional capital. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be, or that any amount that the Company is able to raise will be adequate. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, the Loan Agreement prohibits the Company from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without the prior consent of the Lenders. If the Company requires but is unable to obtain additional funding, the Company may be forced to make further reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8d50e8510c24411cb431b0ad9ac99d70">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company&#8217;s ability to continue as a going concern is dependent upon its ability to obtain additional capital as described above. The unaudited financial statements as of June 30, 2023 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements and less than the amount of its outstanding debt, leaving no proceeds for stockholders.</ix:continuation></span></div><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-343" continuedAt="i87eaa4c989d24f739d858b5643173a7c" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i87eaa4c989d24f739d858b5643173a7c" continuedAt="i74127691876043339b5240a677c19126"><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-344" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2022 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2022 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2022, Avalo effected a 1-for-12 reverse stock split of the outstanding shares of the Company&#8217;s common stock. The Company retroactively applied the reverse stock split to common share and per share amounts for periods prior to July&#160;7, 2022, including the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July&#160;7, 2022, including the three and six months ended June&#160;30, 2022. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-345" continuedAt="i4fc413cdae48415aba7e3200b4e91c8d" escape="true">Accounting Pronouncements Adopted in 2023</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i4fc413cdae48415aba7e3200b4e91c8d" continuedAt="if992d73d876c45eabba88fd42c746009"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if992d73d876c45eabba88fd42c746009"> This guidance eliminates the requirement to calculate the implied fair value of goodwill of a reporting unit to measure a goodwill impairment charge. Instead, a company will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. This new standard was adopted effective January 1, 2023 and will be applied upon any recognition of any future goodwill impairment charge. This ASU has not had a material impact on our financial statements.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i74127691876043339b5240a677c19126">During the six months ended June&#160;30, 2023, there were no significant changes to the Company&#8217;s summary of significant accounting policies contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March 29, 2023.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-347" continuedAt="i59057bfc8f764ef5bc07167e6e62c96a" escape="true">Revenue</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i59057bfc8f764ef5bc07167e6e62c96a" continuedAt="ifb5c3dcc07d540c0a17482c958daddd3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Avalo generates its product revenue from sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors. Wholesale distributors account for substantially all of the Company&#8217;s net product revenues and trade </span></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="ifb5c3dcc07d540c0a17482c958daddd3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">receivables. For the three months ended June&#160;30, 2023, the Company&#8217;s two largest customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-50" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-348">65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-51" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-349">35</ix:nonFraction>% of the Company&#8217;s total net product revenues. For the six months ended June&#160;30, 2023, the Company&#8217;s two largest customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-52" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-350">63</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-351">37</ix:nonFraction>% of the Company&#8217;s total net product revenues. Net revenue from sales of prescription drugs was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-352">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-353">1.0</ix:nonFraction> million for the three months ended June&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-354">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-355">2.2</ix:nonFraction> million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license and supply agreement for the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;), which expires on September 30, 2023. Avalo is required to pay Teva <ix:nonFraction unitRef="number" contextRef="c-54" decimals="2" name="avtx:LicenseAgreementPercentOfNetProfitForInstallmentPayment" format="ixt-sec:numwordsen" scale="-2" id="f-356">fifty</ix:nonFraction> percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="avtx:LicenseAgreementInstallmentPayment" format="ixt:num-dot-decimal" scale="6" id="f-357">0.5</ix:nonFraction>&#160;million quarterly minimum payment, which commenced on July 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu BioScience, Inc. (&#8220;Aytu&#8221;), to which the Company sold its rights, title, and interests in assets relating to certain commercialized products in 2019 (the &#8220;Aytu Transaction&#8221;), managed Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations until August 31, 2021 pursuant to transition service agreements, which included managing the third-party logistics provider and providing accounting reporting services. Aytu collected cash on behalf of Avalo for revenue generated by sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the second quarter of 2020 through the third quarter of 2021 and is obligated to transfer cash generated by such sales to Avalo. In the third quarter of 2021, Avalo finalized its trade and distribution channel to allow it to control the third-party distribution and began managing Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations at that time. The transition services agreement allowed Aytu to withhold cash of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-358">2.0</ix:nonFraction>&#160;million until September 30, 2022, and allows withholding of  $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-359">1.0</ix:nonFraction>&#160;million until December 2024. As of June&#160;30, 2023, the total receivable balance, which represents revenue generated by sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the time Aytu was managing its commercial operations partially offset by minimal operational liabilities Aytu paid on our behalf, was estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-360">1.0</ix:nonFraction>&#160;million, all of which is due in December 2024. In the second quarter of 2022, Avalo fully reserved the $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="6" id="f-361">1.0</ix:nonFraction>&#160;million due in December 2024 as a result of Aytu&#8217;s conclusion within its Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, that substantial doubt existed with respect to its ability to continue as a going concern within one year after the date of financial statements were issued. This conclusion has remained unchanged within Aytu&#8217;s most recent publicly disclosed financial statements. We will continue to re-assess collectability each reporting period.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-362" continuedAt="i3a52e5d275004deda588c4f6b596984b" escape="true">Net Loss Per Share  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3a52e5d275004deda588c4f6b596984b" continuedAt="i3ea345e5218e41ec8d363372f0586a7a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS is provided below for common stock for the three and six months ended June 30, 2023 and June 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS for common stock is computed by dividing the sum of distributed earnings and undistributed earnings by the weighted average number of shares outstanding for the period. The weighted average number of common shares outstanding as of June&#160;30, 2023 and 2022 include the weighted average effect of pre-funded warrants, the exercise of which requires nominal consideration for the delivery of the shares of common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#8220;treasury stock method&#8221; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#8220;treasury stock method&#8221; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#8217;s losses.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-363" continuedAt="ic5499e7d365f48fbb18febbdd5b2e539" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of common stock for the three and six months ended June&#160;30, 2023 and June&#160;30, 2022 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-364">8,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-365">12,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-366"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-367">13,971,968</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-368"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-369">9,400,902</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-370"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-371">0.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-372"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-373">1.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i3ea345e5218e41ec8d363372f0586a7a"><div style="margin-top:5pt;text-align:center"><ix:continuation id="ic5499e7d365f48fbb18febbdd5b2e539"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-374">18,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-375">35,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-376"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-377">12,853,579</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-378"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-379">9,400,214</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-380"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-381">1.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-382"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-383">3.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-384" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June&#160;30, 2023 and 2022, as they could have been anti-dilutive:&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"><tr><td style="width:1.0%"></td><td style="width:59.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-385"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-386">1,849,229</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-387"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-388">1,379,570</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-389"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-390">4,136,990</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-391"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-392">366,990</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-393"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-394">&#8212;</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-395"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-396">&#8212;</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price is nominal. The weighted average shares outstanding for the three and six months ended June&#160;30, 2023 include the weighted average effect of <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" format="ixt:num-dot-decimal" scale="0" id="f-397">525,909</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" format="ixt:num-dot-decimal" scale="0" id="f-398">321,096</ix:nonFraction> pre-funded warrants, respectively. The weighted average shares outstanding for the three and six months ended June 30, 2022 included the weighted average effect of <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="0" name="avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" format="ixt:num-dot-decimal" scale="0" id="f-399"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="0" name="avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" format="ixt:num-dot-decimal" scale="0" id="f-400">114,007</ix:nonFraction></ix:nonFraction> pre-funded warrants.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-401" continuedAt="i97a75120e14f443899e65ca066824953" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i97a75120e14f443899e65ca066824953" continuedAt="i9c40bd63cd91424c98131f87f539b36c"><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC No. 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#8209;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#8209;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></div><div style="text-align:justify;text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-402" continuedAt="i0745ee1fb0054c18b7cce3e55c3b65dd" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-403">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-409">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i9c40bd63cd91424c98131f87f539b36c" continuedAt="i71fd392de1b44203800cf88acc8d5edd"><ix:continuation id="i0745ee1fb0054c18b7cce3e55c3b65dd"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-410">12,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-413">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-416">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying unaudited condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023 and December&#160;31, 2022, the Company&#8217;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities, derivative liability and debt. The carrying amounts reported in the accompanying unaudited condensed consolidated financial statements for cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The estimated fair value of the Company&#8217;s debt was approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-417">10</ix:nonFraction> million as of June&#160;30, 2023 and is in Level Two of the fair value hierarchy (refer to Note 9 for more information). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Valuation </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-418" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the derivative liability for the six months ended June&#160;30, 2023: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.444%"><tr><td style="width:1.0%"></td><td style="width:82.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-419">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-420">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-421">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, Avalo sold its economic rights to future milestone and royalty payments for previously out-licensed assets AVTX-501, AVTX-007, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and AVTX-611 to ES Therapeutics, LLC (&#8220;ES&#8221;), an affiliate of Armistice, in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-422">5.0</ix:nonFraction>&#160;million (the &#8220;ES Transaction&#8221;). At the time of the transaction, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Armistice was a significant stockholder of the Company and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#8217;s Board until August 8, 2022. The ES Transaction was approved in accordance with Avalo&#8217;s related party transaction policy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The economic rights sold include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (a) rights to a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-423">20.0</ix:nonFraction>&#160;million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., (the &#8220;AVTX-501 Milestone&#8221;) and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited, including up to $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-4" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-424">6.25</ix:nonFraction>&#160;million of development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-425">67.5</ix:nonFraction>&#160;million in sales-based milestones, and royalty payments of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the &#8220;AVTX-007 Milestones and Royalties&#8221;). In addition, Avalo waived all its rights to AVTX-611 sales-based payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-426">20.0</ix:nonFraction>&#160;million that were payable by ES. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exchange of the economic rights of the AVTX-501 Milestone and AVTX-007 Milestones and Royalties for cash meets the definition of a derivative instrument. The fair value of the derivative liability is determined using a combination of a scenario-based method and an option pricing method (implemented using a Monte Carlo simulation). The significant inputs including probabilities of success, expected timing, and forecasted sales as well as market-based inputs for volatility, risk-adjusted discount rates and allowance for counterparty credit risk are unobservable and based on the best information available to Avalo. Certain information used in the valuation is inherently limited in nature and could differ from Janssen and Apollo&#8217;s internal estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the derivative liability as of the transaction date was approximately $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-427">4.8</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-428">3.5</ix:nonFraction>&#160;million was attributable to the AVTX-501 Milestone and $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-429">1.3</ix:nonFraction>&#160;million was attributable to the AVX-007 Milestones and Royalties. Subsequent to the transaction date, at each reporting period, the derivative liability is remeasured at fair value. As of June&#160;30, 2023, the fair value of the derivative liability was $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-430">5.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-431">3.7</ix:nonFraction> million was attributable to the AVTX-501 Milestone and $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="6" id="f-432">1.3</ix:nonFraction> million was </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i71fd392de1b44203800cf88acc8d5edd" continuedAt="id5a5ff3dd472466d9de9f5b0985c78dc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">attributable to the AVTX-007 Milestones and Royalties. For the six months ended June&#160;30, 2023, the $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" format="ixt:num-dot-decimal" scale="6" id="f-433">0.2</ix:nonFraction>&#160;million change in fair value was recognized in other expense, net in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the AVTX-501 Milestone was primarily driven by an approximate <ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-434">23</ix:nonFraction>% probability of success to reach the milestone in approximately <ix:nonNumeric contextRef="c-98" name="avtx:DerivativeLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="f-435">4.3</ix:nonNumeric> years. The fair value of AVTX-007 Milestones and Royalties were primarily driven by an approximate <ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-436">17</ix:nonFraction>% probability of success, time to commercialization of approximately <ix:nonNumeric contextRef="c-100" name="avtx:DerivativeLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="f-437">5.3</ix:nonNumeric> years, and sales forecasts with peak annual net sales reaching $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DerivativeLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="6" id="f-438">300</ix:nonFraction>&#160;million. As discussed above, these unobservable inputs were estimated by Avalo based on limited publicly available information and therefore could differ from Janssen and Apollo&#8217;s internal development plans. Any changes to these inputs may result in significant changes to the fair value measurement. Notably, the probability of success is the largest driver of the fair value and therefore changes to such input would likely result in significant changes to such fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that Janssen and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those customers for that amount when it is no longer probable there would be a significant revenue reversal with any differences between the fair value of the derivative liability related to that payment immediately prior to the revenue recognition and revenue recognized to be recorded as other expense. However, given Avalo is no longer entitled to collect these payments, the potential ultimate settlement of the payments in the future from Janssen and/or Apollo to ES Therapeutics (and the future mark-to-market activity each reporting period) will not impact Avalo&#8217;s future cash flows. </span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5a5ff3dd472466d9de9f5b0985c78dc">No changes in valuation techniques or inputs occurred during the six months ended June&#160;30, 2023 and 2022. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the six months ended June&#160;30, 2023 and 2022.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-439" continuedAt="i95f689d13ca44ca3aa8d1eee4e281967" escape="true">Leases </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i95f689d13ca44ca3aa8d1eee4e281967" continuedAt="i2168bf06d73a4b7aba3a07696dc36838"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo currently occupies <ix:nonFraction unitRef="property" contextRef="c-3" decimals="INF" name="avtx:LesseeOperatingLeaseNumberOfLeasedProperties" format="ixt-sec:numwordsen" scale="0" id="f-440">two</ix:nonFraction> leased properties, both of which serve as administrative office space. The Company determined that both of these leases are operating leases based on the lease classification test performed at lease commencement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent for the Company&#8217;s office located in Rockville, Maryland is $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="avtx:LesseeOperatingLeaseLiabilityAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-441">0.2</ix:nonFraction> million, subject to annual <ix:nonFraction unitRef="number" contextRef="c-103" decimals="3" name="avtx:OperatingLeasesRentExpenseAnnualIncreasePercent" scale="-2" id="f-442">2.5</ix:nonFraction>% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of <ix:nonNumeric contextRef="c-103" name="avtx:LesseeOperatingLeaseRentAbatementPeriod" format="ixt-sec:durmonth" id="f-443">12</ix:nonNumeric> months following the Company&#8217;s date of occupancy. The lease has an initial term of <ix:nonNumeric contextRef="c-102" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-444">10</ix:nonNumeric> years from the date the Company made its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease <ix:nonFraction unitRef="renewal_option" contextRef="c-103" decimals="INF" name="avtx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-445">two</ix:nonFraction>&#160;times, each for a period of <ix:nonNumeric contextRef="c-102" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-446">five years</ix:nonNumeric>, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent for the Company&#8217;s office located in Chesterbrook, Pennsylvania is $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="avtx:LesseeOperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-447">0.2</ix:nonFraction>&#160;million and the annual operating expenses are approximately $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-448">0.1</ix:nonFraction>&#160;million. The annual base rent is subject to periodic increases of approximately <ix:nonFraction unitRef="number" contextRef="c-105" decimals="3" name="avtx:OperatingLeasesRentExpenseAnnualIncreasePercent" scale="-2" id="f-449">2.4</ix:nonFraction>% over the term of the lease. The lease has an initial term of <ix:nonNumeric contextRef="c-104" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-450">5.25</ix:nonNumeric> years from the lease commencement on December 1, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining term of the operating leases at June&#160;30, 2023 was <ix:nonNumeric contextRef="c-1" name="avtx:LesseeOperatingLeaseRemainingLeaseTeam" format="ixt-sec:duryear" id="f-451">5.1</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="avtx:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-452" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased properties include (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453"><span style="-sec-ix-hidden:f-454">Property and equipment, net</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-455">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-456">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-457"><span style="-sec-ix-hidden:f-458">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-459">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-460">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-461"><span style="-sec-ix-hidden:f-462">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-463">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-464">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-465">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-466">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease right-of-use (ROU) assets are included in property and equipment, net and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our unaudited condensed consolidated balance sheets. The Company utilized a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-467">9.1</ix:nonFraction>% to determine the present value of the lease payments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-468" continuedAt="i3f5a655e254a4308ae8633edd36754a7" escape="true">The components of lease expense for the three and six months ended June&#160;30, 2023 and 2022 were as follows (in thousands): </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i2168bf06d73a4b7aba3a07696dc36838"><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3f5a655e254a4308ae8633edd36754a7" continuedAt="i8ca2de8b3cfe44f090bdab0dcc7d6dc6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-469">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-470">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-471">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-472">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i8ca2de8b3cfe44f090bdab0dcc7d6dc6">*Includes short-term leases, which are immaterial.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-473" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of June&#160;30, 2023 (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2023 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-474">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-475">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-476">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-477">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-478">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-479">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="f-480">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-481">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-482">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-483">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-484" continuedAt="i4cb9ce688c314a879011d93fef6c90e6" escape="true">Accrued Expenses and Other Current Liabilities  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4cb9ce688c314a879011d93fef6c90e6"><ix:nonNumeric contextRef="c-1" name="avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="f-485" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June&#160;30, 2023 and December 31, 2022 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="avtx:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-486">3,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avtx:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-487">6,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-488">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-489">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="avtx:AccruedSellingGeneralAndAdministrativeExpenses" scale="3" id="f-490">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avtx:AccruedSellingGeneralAndAdministrativeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-491">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="avtx:CommercialOperationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avtx:CommercialOperationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-493">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-494">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-495">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-496">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-497">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="f-499">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-500">7,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-501">13,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_76"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-502" continuedAt="i12b1a25d92614f65957eb15026d978d7" escape="true">Cost Reduction Plan</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i12b1a25d92614f65957eb15026d978d7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first quarter of 2022, the Board approved a cost reduction plan to enable the Company to execute its strategy of prioritizing the development of its most promising programs (the &#8220;Plan&#8221;). A reduction in workforce plan was approved to reduce headcount and related expenses. The reduction in workforce plan was considered a one-time termination benefit as defined by ASC No. 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The one-time termination benefits mainly relate to severance payments to separated employees. As a result, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-503">1.5</ix:nonFraction>&#160;million of expense during the first quarter of 2022, of which $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-504">0.7</ix:nonFraction>&#160;million was recognized in research and development expense, and $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-505">0.8</ix:nonFraction>&#160;million was recognized in selling, general and administrative expense. $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="f-506">1.4</ix:nonFraction>&#160;million of severance payments were paid in the year ended December 31, 2022 and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="f-507">0.1</ix:nonFraction>&#160;million was paid in the six months ended June&#160;30, 2023. Additionally, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-508">0.4</ix:nonFraction>&#160;million of stock-based compensation expense was recognized in the first quarter of 2022 related to the Plan, which was mainly related to accelerated vesting of certain separated employees&#8217; stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, previously and separately, during the first quarter of 2022, the Company separated certain section 16 executive officers. Each of the former executives are entitled to the benefits provided in their respective separation agreements, which include severance payments to be paid over <span style="-sec-ix-hidden:f-509">twelve</span> to <ix:nonNumeric contextRef="c-112" name="avtx:RestructuringAndRelatedActivitiesPaymentTerm" format="ixt-sec:durwordsen" id="f-510">eighteen months</ix:nonNumeric>. As a result, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-511">1.7</ix:nonFraction>&#160;million expense during the first quarter of 2022 within selling, general and administrative expenses. Additionally, the Company accelerated the vesting of certain outstanding stock options and extended the exercisability periods, which resulted in $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-512">3.9</ix:nonFraction>&#160;million of compensation cost recognized in first quarter of 2022. Refer to Note 11 for information regarding stock compensation expense related to separations entered into the first quarter of 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 16</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_79"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-513" continuedAt="if019479de8d84cb89505f66708aaa38d" escape="true">Notes Payable</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="if019479de8d84cb89505f66708aaa38d" continuedAt="ifefdf79dba074a828495f8a51ec11000"> </ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="ifefdf79dba074a828495f8a51ec11000" continuedAt="i4c661cdab01145e3b15978cea7c89fc1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 4, 2021, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-514">35.0</ix:nonFraction>&#160;million venture loan and security agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;) and Powerscourt Investments XXV, LP (&#8220;Powerscourt&#8221;, and together with Horizon, the &#8220;Lenders&#8221;). In accordance with the Loan Agreement, $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-515">20.0</ix:nonFraction>&#160;million was funded on the closing date (the &#8220;Initial Note&#8221;), with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-516">15.0</ix:nonFraction>&#160;million fundable upon the Company achieving certain predetermined milestones, which the Company met in the third quarter of 2021. On July 30, 2021, after achieving a predetermined milestone, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-517">10.0</ix:nonFraction>&#160;million, which was evidenced by a second note payable (the &#8220;Second Note&#8221;). On September 29, 2021, after achieving a second predetermined milestone, the Company borrowed the remaining $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-518">5.0</ix:nonFraction>&#160;million, which was evidenced by a third note payable (the &#8220;Third Note&#8221;, and collectively with the Initial and Second Notes, the &#8220;Notes&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June of 2023, the Company, as collectively agreed upon with the Lenders, prepaid $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-519">6.0</ix:nonFraction>&#160;million of principal. Additionally, in the second quarter of 2022, the Company, as collectively agreed upon with the Lenders, prepaid $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-520">15.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="avtx:RepaymentOfDebtPrincipal" format="ixt:num-dot-decimal" scale="6" id="f-521">14.8</ix:nonFraction>&#160;million was applied to principal and the remainder applied to accrued interest. As of June&#160;30, 2023, the outstanding notes payable balance was $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-522">15.2</ix:nonFraction>&#160;million, inclusive of the final payment fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Each advance under the Loan Agreement will mature <ix:nonNumeric contextRef="c-115" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-523">42</ix:nonNumeric> months from the first day of the month following the funding of the advance. Each advance accrues interest at a per annum rate of interest equal to <ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-524">6.25</ix:nonFraction>% plus the prime rate, as reported in the Wall Street Journal (subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-121" decimals="4" name="avtx:DebtInstrumentInterestRateFloor" scale="-2" id="f-525">3.25</ix:nonFraction>%). The Loan Agreement provides for interest-only payments for each advance for the first <ix:nonNumeric contextRef="c-115" name="avtx:DebtInstrumentInterestOnlyPaymentPeriod" format="ixt-sec:durmonth" id="f-526">18</ix:nonNumeric> months, however the interest-only period was extended to <ix:nonNumeric contextRef="c-115" name="avtx:DebtInstrumentInterestOnlyPaymentExtensionPeriod" format="ixt-sec:durmonth" id="f-527">24</ix:nonNumeric> months as a result of the Company satisfying the Interest Only Extension Milestone (as defined in the Loan Agreement) in the third quarter of 2021. Thereafter, amortization payments will be payable in monthly installments of principal and interest through each advance&#8217;s maturity date. Upon <ix:nonFraction unitRef="business_day" contextRef="c-115" decimals="INF" name="avtx:DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" format="ixt-sec:numwordsen" scale="0" id="f-528">ten</ix:nonFraction> business days&#8217; prior written notice, the Company may prepay all of the outstanding advances by paying the entire principal balance and all accrued and unpaid interest, subject to prepayment charges of up to <ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="avtx:DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" scale="-2" id="f-529">3</ix:nonFraction>% of the then outstanding principal balance. Upon the earlier of (i) payment in full of the principal balance, (ii) an event of default (see below), or (iii) the maturity date, the Company will pay an additional final payment of <ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="avtx:DebtInstrumentAdditionalFinalPaymentPercentage" scale="-2" id="f-530">3</ix:nonFraction>% of the principal loan amount to the Lenders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Each advance of the loan is secured by a lien on substantially all of the assets of the Company, other than Intellectual Property and Excluded Collateral (in each case as defined in the Loan Agreement), and contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 20, 2023, the Company entered into a Forbearance Agreement with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#8217;s business and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-531">15.2</ix:nonFraction>&#160;million, plus interest, fees, other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-532">3.0</ix:nonFraction>&#160;million plus (b) one-hundred percent (<ix:nonFraction unitRef="number" contextRef="c-49" decimals="INF" name="avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" scale="-2" id="f-533">100</ix:nonFraction>%) of the aggregate cash proceeds received by Company as a result of the any future sale of the Company&#8217;s equity securities while the Forbearance Agreement is in effect. As of June 30, 2023, the carrying value of the notes payable was $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-534">14.1</ix:nonFraction>&#160;million and is classified as a current liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 4, 2021, pursuant to the Loan Agreement, the Company issued warrants to the Lenders to purchase <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-535">33,656</ix:nonFraction> shares of the Company&#8217;s common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-536">31.20</ix:nonFraction> per share (the &#8220;Warrants&#8221;). The Warrants are exercisable for <ix:nonNumeric contextRef="c-122" name="avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" format="ixt-sec:durwordsen" id="f-537">ten years</ix:nonNumeric> from the date of issuance. Debt issuance costs and the amount allocated to the warrants were recognized as a debt discount on the date of issuance and are amortized to interest expense using the effective interest method over the term of the loan. The $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="avtx:DebtInstrumentFinalPaymentFee" format="ixt:num-dot-decimal" scale="6" id="f-538">1.1</ix:nonFraction>&#160;million final payment fee is included in the contractual cash flows and is accreted to interest expense using the effective interest method over the term of the loan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The effective interest rate of the Notes was <ix:nonFraction unitRef="number" contextRef="c-47" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-539">17.1</ix:nonFraction>% as of June&#160;30, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-540" continuedAt="i2a255fd236be4542be7095783f430a98" escape="true">Balance sheet information related to the note payable for the Notes is as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i4c661cdab01145e3b15978cea7c89fc1"><ix:continuation id="i2a255fd236be4542be7095783f430a98"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:56.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-541">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-542">12,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-543">4,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-544">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-545">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-546">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-547">15,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-548">21,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-549">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-550">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-551">14,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-552">19,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-553">14,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-554">5,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-556">13,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="avtx:DebtInstrumentFinalPaymentFee" format="ixt:num-dot-decimal" scale="6" id="f-557">1.1</ix:nonFraction>&#160;million final payment fee for the Notes, which represents <ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="avtx:DebtInstrumentAdditionalFinalPaymentPercentage" scale="-2" id="f-558">3</ix:nonFraction>% of the original principal loan amount.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-559" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of June&#160;30, 2023, the contractual future principal payments, excluding the Lender&#8217;s right to accelerate the maturity of the obligations on the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement, were as follows (in thousands): </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:70.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-560">4,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-561">9,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="14" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-562">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-564">15,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="avtx:DebtInstrumentFinalPaymentFee" format="ixt:num-dot-decimal" scale="6" id="f-565">1.1</ix:nonFraction>&#160;million final payment fee, which represents <ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="avtx:DebtInstrumentAdditionalFinalPaymentPercentage" scale="-2" id="f-566">3</ix:nonFraction>% of the original principal loan amount.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Company is unable to reach an agreement with its Lenders to waive the Existing Default or extend the forbearance period prior to the expiration of the Forbearance Agreement on August 15, 2023, the Forbearance Agreement will terminate automatically and without further notice or action, the effect of which shall permit the Lenders to immediately exercise any and all rights and remedies available under the Loan Agreement, including acceleration of the outstanding principal payments and final payment fees, plus interest, fees, and other amounts accrued.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-567" continuedAt="i417b281e48c14874b0947499179a866d" escape="true">Capital Structure </ix:nonNumeric></span></div><ix:continuation id="i417b281e48c14874b0947499179a866d" continuedAt="i95a9b44ebbab43f7b79ddb2969e50a62"><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s amended and restated certificate of incorporation, the Company is authorized to issue <ix:nonFraction unitRef="class_of_stock" contextRef="c-3" decimals="INF" name="avtx:NumberOfClassOfStockAuthorized" format="ixt-sec:numwordsen" scale="0" id="f-568">two</ix:nonFraction> classes of stock, common stock and preferred stock. At June&#160;30, 2023, the total number of shares of capital stock the Company was authorized to issue was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="avtx:CapitalStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-569">205,000,000</ix:nonFraction>, of which <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-570">200,000,000</ix:nonFraction> was common stock and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-571">5,000,000</ix:nonFraction> was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock. All shares of common and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock have a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-572"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-573">0.001</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with entities affiliated with Venrock Healthcare Capital Partners (&#8220;Venrock&#8221;), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-574">1.3</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-575">0.001</ix:nonFraction> per share, owned by Venrock for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-576">1.3</ix:nonFraction>&#160;million shares of common stock (subject to adjustment in the event of stock splits, recapitlizations and other similar events affecting common stock), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-577">0.001</ix:nonFraction> per share. The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercisable by Venrock if, upon giving effect or immediately prior thereto, Venrock would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-135" decimals="4" name="avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" scale="-2" id="f-578">9.99</ix:nonFraction>% of the total number of issued and outstanding common stock, which percentage may change at the holders&#8217; election to any other number less than or equal to <ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" scale="-2" id="f-579">19.99</ix:nonFraction>% upon <ix:nonNumeric contextRef="c-137" name="avtx:ClassOfWarrantOrRightOwnershipExerciseThreshold" format="ixt-sec:durday" id="f-580">61</ix:nonNumeric> days&#8217; notice to the Company. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extend required by Delaware law. In accordance with ASC No. 505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i95a9b44ebbab43f7b79ddb2969e50a62"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares outstanding and a corresponding impact to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June 30, 2023, none of the Exchange Warrants have been exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into an &#8220;at-the-market&#8221; sales agreement with Oppenheimer &amp; Co. Inc. (&#8220;Oppenheimer&#8221;), pursuant to which the Company may sell from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="0" name="avtx:SaleOfStockMaximumAmountOfSharesToBeSold" format="ixt:num-dot-decimal" scale="0" id="f-581">9,032,567</ix:nonFraction> through Oppenheimer. In the second quarter of 2023, the Company sold approximately <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-582">2.0</ix:nonFraction>&#160;million shares under the ATM program for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-583">6.5</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2023 and as of the filing date of this Quarterly Report on Form 10-Q, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-584">6.2</ix:nonFraction>&#160;million shares under the ATM program for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-585">1.3</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Q1 2023 Financing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-586">3,770,000</ix:nonFraction> shares of its common stock and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-587">3,770,000</ix:nonFraction> shares of common stock, at a combined price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-588">3.98</ix:nonFraction> per share and warrant, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-589">13.7</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by us. The warrants were immediately exercisable at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-590">5.00</ix:nonFraction> per share and are exercisable for <ix:nonNumeric contextRef="c-144" name="avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" format="ixt-sec:durwordsen" id="f-591">one year</ix:nonNumeric> from the issuance date. Armistice, who was a significant stockholder of the Company at the time of the financing, participated in the offering by purchasing <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-592">0.5</ix:nonFraction>&#160;million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="f-593">0.5</ix:nonFraction>&#160;million warrants, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC and Point72 Asset Management, L.P., which each beneficially owned greater than <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="f-594">5</ix:nonFraction>% of the Company&#8217;s outstanding common stock at the time of the offering, participated in the offering on the same terms as all other investors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants were classified as a component of permanent stockholders&#8217; deficit within additional paid-in capital. The warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-595" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-596">333,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-597">150.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-598">41,701</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-599">0.012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-600">33,656</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-601">31.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-602">3,770,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-603">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-604">1,300,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-605">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-606">5,478,691</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-607" continuedAt="ia3b5f07cadc14b6cb21f6e3a0be0911f" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia3b5f07cadc14b6cb21f6e3a0be0911f" continuedAt="ic046493daf824fd68417b40c23bf466b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, our board of directors adopted the 2016 Equity Incentive Plan, which was approved by our stockholders in May 2016 and which was subsequently amended and restated in May 2018 and August 2019 with the approval of our board of directors and our stockholders (the &#8220;2016 Third Amended Plan&#8221;). During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year ending on (and including) January 1, 2026, by an amount equal to <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" scale="-2" id="f-608">4</ix:nonFraction>% of the total number of outstanding shares of common stock of the Company on the last trading day in December of the prior calendar year. On January 1, 2023, pursuant to the terms of the 2016 Third Amended and Restated Plan, an additional <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" format="ixt:num-dot-decimal" scale="0" id="f-609">377,221</ix:nonFraction> shares were </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="ic046493daf824fd68417b40c23bf466b" continuedAt="if647c873c8034bc29afd492553834637"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made available for issuance. As of June&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-610">41,183</ix:nonFraction> shares available for future issuance under the 2016 Third Amended Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants expire after <ix:nonNumeric contextRef="c-156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-611">ten years</ix:nonNumeric>. Employee options typically vest over <ix:nonNumeric contextRef="c-157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-612">four years</ix:nonNumeric>. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. In addition, in the first and fourth quarters of 2022 and second quarter of 2023, employees were also granted options that vest on the first anniversary of the grant date. Options granted to directors typically vest either immediately or over a period of <span style="-sec-ix-hidden:f-613">one</span> or <ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-614">three years</ix:nonNumeric>. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#8217;s stock-based awards is amortized ratably over the individuals&#8217; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options and employee stock purchase plan shares. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-615" continuedAt="if2dc7172bbdd442cb2ee4948d6ced348" escape="true">The amount of stock-based compensation expense recognized for the three and six months ended June&#160;30, 2023 and 2022 was as follows (in thousands):&#160;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="if2dc7172bbdd442cb2ee4948d6ced348"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-616">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-617">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-618">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-619">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-620">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-621">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-622">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-623">5,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-624">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-625">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-626">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-627">5,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of separation agreements that the Company entered into in the first quarter of 2022 and in accordance with the terms of the pre-existing employment agreements, the Company accelerated the vesting of certain separated employees&#8217; stock options and modified certain awards to extend the exercisability periods. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-628">4.3</ix:nonFraction>&#160;million of compensation cost in the first quarter of 2022, all of which was recognized in selling, general and administrative expense. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with service-based vesting conditions</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-629" continuedAt="ia4ae9ef061f54d919b32c0757bb94b20" escape="true">A summary of option activity for the six months ended June 30, 2023 is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ia4ae9ef061f54d919b32c0757bb94b20"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:39.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-630">1,345,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-631">28.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-632">17.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-633">6.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-634">760,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-635">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-636">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-637">339,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-638">42.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" scale="0" id="f-639">27.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-640">1,765,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-641">14.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-642">8.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-171" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-643">8.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-644">563,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-645">31.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="f-646">18.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-171" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-647">7.1</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-648">0.3</ix:nonFraction>&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award that vest over <ix:nonNumeric contextRef="c-173" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-649">four years</ix:nonNumeric>. In May 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-650">0.3</ix:nonFraction>&#160;million options with service-based vesting conditions to its employees that vest over <ix:nonNumeric contextRef="c-174" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-651">one year</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. As of June&#160;30, 2023, the aggregate intrinsic value of options outstanding was <ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt-sec:numwordsen" id="f-652">zero</ix:nonFraction>. There were <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="f-653">0.2</ix:nonFraction> million&#160;options that vested during the six months ended June 30, 2023 with a weighted average exercise price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-654">11.13</ix:nonFraction> per share. The total grant date fair value of shares which vested during the six months ended June 30, 2023&#160;was&#160;$<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-655">1.7</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-656">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-657">1.7</ix:nonFraction> million related to stock options with service-based vesting conditions for the three and six months ended June&#160;30, 2023, respectively. At June&#160;30, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-658">4.5</ix:nonFraction> million of total unrecognized compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-171" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-659">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="if647c873c8034bc29afd492553834637"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation assumptions</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-660" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-176" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-661">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-177" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-662">6.25</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-178" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-663">89.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-664">146.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-178" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-665">3.43</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-179" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-666">4.13</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-667">0</ix:nonFraction>%</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with market-based vesting conditions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="f-668">0.1</ix:nonFraction> million exercisable stock options that contained market-based vesting conditions (that had been previously satisfied). The options have a weighted average share price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-669">39.53</ix:nonFraction> and a weighted average remaining contractual term of <ix:nonNumeric contextRef="c-181" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-670">1.0</ix:nonNumeric> years. There were <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-671"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-672"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-673">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock options with market-based vesting conditions granted, exercised, or forfeited for the six months ended June&#160;30, 2023.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;ESPP Effective Date&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#8217;s board of directors. Under the ESPP, eligible employees may purchase stock at <ix:nonFraction unitRef="number" contextRef="c-182" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-674">85</ix:nonFraction>% of the lower of the fair market value of a share of the Company&#8217;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-675">15</ix:nonFraction>% of their earnings during the offering period. The Company&#8217;s board of directors may establish a maximum number of shares of the Company&#8217;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="avtx:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" format="ixt:num-dot-decimal" scale="0" id="f-676">25,000</ix:nonFraction> of the fair market value of the Company&#8217;s common stock for each calendar year in which such right is outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved and authorized up to <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-677">41,667</ix:nonFraction> shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP automatically increases by a number equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" scale="-2" id="f-678">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-679">41,667</ix:nonFraction> shares of the Company&#8217;s common stock, or (iii) a number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors or compensation committee. The number of shares were increased by <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-680">41,667</ix:nonFraction> on January 1, 2023. As of June&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-681">192,079</ix:nonFraction> shares remained available for issuance. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 718-50,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Employee Share Purchase Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-682">41</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-683">0.1</ix:nonFraction> million for the three and six months ended June&#160;30, 2023, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-684" continuedAt="i084d8dd0edd147bb94cb11a3a86c7d00" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="i084d8dd0edd147bb94cb11a3a86c7d00">The Company recognized minimal income tax expense for the three and six months ended June&#160;30, 2023 and 2022 due to the significant valuation allowance against the Company&#8217;s deferred tax assets and the current and prior period losses.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-685" continuedAt="iffb43d582e114fdaa9b3626433444664" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="iffb43d582e114fdaa9b3626433444664" continuedAt="ic0a4cf5e8507432b823015a033cd74f7"><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation - General</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="ic0a4cf5e8507432b823015a033cd74f7" continuedAt="i1e52e671517c4f428532ae4d325add5a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Payments for In-Licensed Compounds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo is a party to license and development agreements with various third parties, which contain future payment obligations such as royalties and milestone payments. The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-002 KKC License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) for exclusive worldwide rights to develop, manufacture and commercialize AVTX-002, KKC&#8217;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#8220;KKC License Agreement&#8221;). The KKC License Agreement replaced the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the KKC License Agreement, the Company paid KKC an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="f-686">10.0</ix:nonFraction>&#160;million, which we recognized within research and development expenses in 2021. The Company is also required to pay KKC up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-687">112.5</ix:nonFraction>&#160;million based on the achievement of specified development and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization, the Company is required to pay KKC sales-based milestones aggregating up to $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-688">75.0</ix:nonFraction>&#160;million tied to the achievement of annual net sales targets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is required to pay KKC royalties during a country-by-country royalty term equal to a mid-teen percentage of annual net sales. The Company is required to pay KKC a double-digit percentage (less than <ix:nonFraction unitRef="number" contextRef="c-188" decimals="2" name="avtx:CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" scale="-2" id="f-689">30</ix:nonFraction>%) of the payments that the Company receives from any sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Avalo is responsible for the development and commercialization of AVTX-002 in all indications worldwide (other than the option in the KKC License Agreement that, upon exercise by KKC, allows KKC to develop, manufacture and commercialize AVTX-002 in Japan). In addition to the KKC License Agreement, Avalo is subject to additional royalties upon commercialization of up to an amount of less than 10% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-690">No</ix:nonFraction> expense related to the KKC License Agreement was recognized in the six months ended June&#160;30, 2023. There has been <ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" format="ixt:fixed-zero" scale="0" id="f-691">no</ix:nonFraction> cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-006 Astellas License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#8220;Astellas&#8221;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (AVTX-006). Under the terms of the license agreement, there was an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="f-692">0.5</ix:nonFraction>&#160;million. The Company is required to pay Astellas up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-693">5.5</ix:nonFraction>&#160;million based on the achievement of specified development and regulatory milestones. The Company is also required to pay Astellas a tiered mid-to-high single digit percentage of the payments that Avalo receives from any sublicensing of its rights under the Astellas license agreement, subject to certain exclusions. Upon commercialization, the Company is required to pay Astellas royalties during a country-by-country royalty term equal to a tiered mid-to-high single digit percentage of annual net sales. Avalo is fully responsible for the development and commercialization of the program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-694">No</ix:nonFraction> expense related to this license agreement was recognized in the six months ended June&#160;30, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" format="ixt:num-dot-decimal" scale="6" id="f-695">0.5</ix:nonFraction>&#160;million of cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement, which was recognized in 2021. The Company will continue to monitor the remaining milestones at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-008 Sanford Burnham Prebys License Agreement</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i1e52e671517c4f428532ae4d325add5a" continuedAt="ibc2606e496ec4ac8a8502420fa1ce01e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an Exclusive Patent License Agreement with Sanford Burnham Prebys Medical Discovery Institute (the &#8220;Sanford Burnham Prebys License Agreement&#8221;) under which the Company obtained an exclusive license to a portfolio of issued patents and patent applications covering an immune checkpoint program (AVTX-008). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Sanford Burnham Prebys License Agreement, the Company incurred an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="f-696">0.4</ix:nonFraction>&#160;million, as well as patent costs of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsPatentCosts" format="ixt:num-dot-decimal" scale="6" id="f-697">0.5</ix:nonFraction>&#160;million, which we recognized within research and development expenses and within selling, general and administrative expenses, respectively, in 2021. The Company is required to pay Sanford Burnham Prebys up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-698">24.2</ix:nonFraction>&#160;million based on achievement of specified development and regulatory milestones. Upon commercialization, the Company is required to pay Sanford Burnham Prebys sales-based milestone payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-699">50.0</ix:nonFraction>&#160;million tied to annual net sales targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is required to pay Sanford Burnham Prebys royalties during a country-by-country royalty term equal to a low-to-mid single digit percentage of annual net sales. The Company is also required to pay Sanford Burnham Prebys a tiered low-double digit percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the payments that Avalo receives from sublicensing of its rights under the Sanford Burnham Prebys License Agreement, subject to certain exclusions. Avalo is fully responsible for the development and commercialization of the program.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="INF" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-700">No</ix:nonFraction> expense related to the Sanford Burnham Prebys License Agreement was recognized in the six months ended June&#160;30, 2023. There has been <ix:nonFraction unitRef="usd" contextRef="c-199" decimals="INF" name="avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" format="ixt:fixed-zero" scale="0" id="f-701">no</ix:nonFraction> cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Proceeds for Out-Licensed Compounds </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-301 Out-License</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 28, 2021, the Company out-licensed its rights in respect of its non-core asset, AVTX-301, to Alto Neuroscience, Inc. (&#8220;Alto&#8221;). The Company initially in-licensed the compound from an affiliate of Merck &amp; Co., Inc. in 2013.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the out-license agreement, the Company received a mid-six digit upfront payment from Alto, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-702">18.6</ix:nonFraction>&#160;million based on the achievement of specified development, regulatory and commercial sales milestones. Additionally, the Company is entitled to a less than single digit percentage royalty based on annual net sales. Alto is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has <ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" format="ixt:fixed-zero" scale="0" id="f-703">no</ix:nonFraction>t recognized any milestones as of June&#160;30, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-406 License Assignment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 9, 2021, the Company assigned its rights, title, interest, and obligations under an in-license covering its non-core asset, AVTX-406, to ES, a wholly owned subsidiary of Armistice, who was a significant stockholder of the Company at the time of the financing and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#8217;s Board until August 8, 2022. The transaction with ES was approved in accordance with Avalo&#8217;s related party transaction policy. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the assignment agreement, the Company received a low-six digit upfront payment from ES, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-704">6.0</ix:nonFraction>&#160;million based on the achievement of specified development and regulatory milestones. Upon commercialization, the Company is eligible to receive sales-based milestone payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-705">20.0</ix:nonFraction>&#160;million tied to annual net sales targets. ES is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" format="ixt:fixed-zero" scale="0" id="f-706">no</ix:nonFraction>t recognized any milestones as of June&#160;30, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Related and Other Contingent Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger Possible Future Milestone Payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#8220;Aevi&#8221;), in which Avalo acquired the rights to AVTX-002, AVTX-006 and AVTX-007 (the &#8220;Merger&#8221; or the &#8220;Aevi Merger&#8221;). A portion of the consideration for the Aevi Merger included <ix:nonFraction unitRef="milestone" contextRef="c-205" decimals="INF" name="avtx:AssetAcquisitionContingentValueRightNumberOfMilestones" format="ixt-sec:numwordsen" id="f-707">two</ix:nonFraction> future contingent development milestones worth up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-708">6.5</ix:nonFraction> million, payable in either shares of Avalo&#8217;s common stock or cash, at the election of Avalo. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="ibc2606e496ec4ac8a8502420fa1ce01e" continuedAt="i5f1a03a67a674122a58eb94ea8112c9b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first milestone was the enrollment of a patient in a Phase 2 study related to AVTX-002 (for treatment of pediatric onset Crohn&#8217;s disease), AVTX-006 (for treatment of any indication) or AVTX-007 (for treatment of any indication) prior to February 3, 2022, which would have resulted in a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-709">2.0</ix:nonFraction> million. The Company did not meet the first milestone prior to February 3, 2022. Therefore, <ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="0" id="f-710">no</ix:nonFraction> contingent consideration related to this milestone was recognized as of June&#160;30, 2023 and <ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="0" id="f-711">no</ix:nonFraction> future contingent consideration will be recognized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second milestone is the receipt of an NDA approval for either AVTX-006 or AVTX-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-712">4.5</ix:nonFraction> million. The contingent consideration related to the second development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="0" id="f-713">No</ix:nonFraction> contingent consideration related to the second development milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the second milestone at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ichorion Asset Acquisition Possible Future Milestone Payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company acquired Ichorion Therapeutics, Inc., including acquiring <ix:nonFraction unitRef="therapy" contextRef="c-209" decimals="INF" name="avtx:AssetAcquisitionNumberOfPreclinicalTherapies" format="ixt-sec:numwordsen" scale="0" id="f-714">three</ix:nonFraction> compounds for inherited metabolic disorders known as CDGs (AVTX-801, AVTX-802 and AVTX-803) and <ix:nonFraction unitRef="therapy" contextRef="c-210" decimals="INF" name="avtx:AssetAcquisitionNumberOfPreclinicalTherapies" format="ixt-sec:numwordsen" scale="0" id="f-715">one</ix:nonFraction> other preclinical compound. Consideration for the transaction included shares of Avalo common stock and <ix:nonFraction unitRef="milestone" contextRef="c-211" decimals="INF" name="avtx:AssetAcquisitionContingentValueRightNumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="f-716">three</ix:nonFraction> future contingent development milestones for the acquired compounds worth up to an additional&#160;$<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="6" id="f-717">15.0</ix:nonFraction> million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of Avalo.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first and second milestones were marketing approval of the first and second product, respectively, by the FDA on or prior to December 31, 2021, which would have resulted in milestone payments of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-718">6.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-719">5.0</ix:nonFraction>&#160;million, respectively. The Company did not meet the first or second milestone as of December 31, 2021. As a result, <ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="0" id="f-720">no</ix:nonFraction> contingent consideration related to these milestones was recognized as of June&#160;30, 2023 and <ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="0" id="f-721">no</ix:nonFraction> future contingent consideration will be recognized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third milestone is marketing approval of a protide molecule by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-722">4.0</ix:nonFraction>&#160;million. The contingent consideration related to the third development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" format="ixt-sec:numwordsen" id="f-723">No</ix:nonFraction> contingent consideration related to the third milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the third development milestone at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-006 Royalty Agreement with Certain Related Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Aevi entered into a royalty agreement, and liabilities thereunder were assumed by Avalo upon close of the Aevi Merger in February 2020. The royalty agreement provided certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil, the Company&#8217;s Chief Executive Officer and Chairman of the Board, and Mike Cola, the Company&#8217;s former Chief Executive Officer (collectively, the &#8220;Investors&#8221;), a royalty stream, in exchange for a one-time aggregate payment of $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="avtx:RoyaltyAgreementPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-724">2.0</ix:nonFraction>&#160;million (the &#8220;Royalty Agreement&#8221;). Pursuant to the Royalty Agreement, the Investors will be entitled collectively to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of the Company&#8217;s second generation mTORC1/2 inhibitor, AVTX-006. At any time beginning <ix:nonNumeric contextRef="c-218" name="avtx:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" format="ixt-sec:durwordsen" id="f-725">three years</ix:nonNumeric> after the date of the first public launch of AVTX-006, Avalo may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of <ix:nonFraction unitRef="number" contextRef="c-218" decimals="2" name="avtx:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" scale="-2" id="f-726">75</ix:nonFraction>% of the net present value of the royalty payments. A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company's accompanying unaudited condensed consolidated balance sheet as of June&#160;30, 2023 and December 31, 2022. Because there is a significant related party relationship between the Company and the Investors, the Company has treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which will result in a corresponding increase in the liability balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Karbinal Royalty Make-Whole Provision </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, in connection with the acquisition of certain commercialized products, the Company entered into a supply and distribution agreement (the &#8220;Karbinal Agreement&#8221;) with TRIS Pharma Inc. (&#8220;TRIS&#8221;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;<ix:nonFraction unitRef="unit" contextRef="c-219" decimals="INF" name="us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired" format="ixt:num-dot-decimal" scale="0" id="f-727">70,000</ix:nonFraction>&#160;units </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><ix:continuation id="i5f1a03a67a674122a58eb94ea8112c9b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2025. The Company was required to pay TRIS a royalty make whole payment (&#8220;Make-Whole Payments&#8221;) of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="0" name="avtx:CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" scale="0" id="f-728">30</ix:nonFraction>&#160;for each unit under the&#160;<ix:nonFraction unitRef="unit" contextRef="c-219" decimals="INF" name="us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired" format="ixt:num-dot-decimal" scale="0" id="f-729">70,000</ix:nonFraction>&#160;units annual minimum sales commitment through 2025.&#160; </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the Aytu transaction, the Company assigned all its payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#8220;TRIS Obligations&#8221;) to Aytu.&#160;However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 25</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as &#8220;projects,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;predicts,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;pro forma&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates; and other statements that are not historical. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II &#8211; Item 1A, &#8220;Risk Factors,&#8221; as well as in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 29, 2023, and in our other filings with the SEC. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.</span></div><div style="text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December&#160;31, 2022 appearing in our Annual Report on Form 10-K filed with the SEC on March&#160;29, 2023. &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Avalo&#8221; or &#8220;we&#8221;) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIGHT (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ymphotoxin-like, exhibits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nducible expression, and competes with HSV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lycoprotein D for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erpesvirus Entry Mediator (&#8220;HVEM&#8221;), a receptor expressed by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin &#946; receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (&#8220;BTLA&#8221;), and CD160 (collectively, the &#8220;LIGHT-signaling network&#8221; or the &#8220;LIGHT network&#8221;). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s primary evaluation of the success of the Company is the ability to progress its pipeline assets forward towards commercialization or opportunistically out-licensing rights to indications or geographies. This success depends not only on the operational execution of the programs, but also the ability to secure sufficient funding to support the programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following chart summarizes key information about our pipeline:</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="avtx-20230630_g1.jpg" alt="Pipeline Chart (July 2023)_V2_803 LOI.jpg" style="height:443px;margin-bottom:5pt;vertical-align:text-bottom;width:768px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2023, Avalo generated a net loss of $18.1 million and negative cash flows from operations of $21.1 million. As of June&#160;30, 2023, Avalo had $6.3 million in cash and cash equivalents. The future principal payments inclusive of the final payment fee under the Company&#8217;s Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements) were $15.2&#160;million as of June&#160;30, 2023, which gives effect to the $6.0&#160;million partial prepayment in June of 2023, as collectively agreed upon with the Lenders (as defined in Note 9 to the unaudited condensed consolidated financial statements). On July 20, 2023, the Company entered into a forbearance agreement (the &#8220;Forbearance Agreement&#8221;) with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#8217;s business (the &#8220;Existing Default&#8221;) and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $15.2&#160;million, plus interest, fees, and other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $3.0&#160;million plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by the Company as a result of any future sale of the Company&#8217;s equity securities while the Forbearance Agreement is in effect. The Company closely monitors its cash and cash equivalents and intends to raise money through all means available to raise capital to meet its projected operating requirements, including but not limited to sale of equity securities under its &#8220;at-the-market&#8221; (or &#8220;ATM&#8221;) program or otherwise, out-licensing transactions, strategic alliances/collaborations, sale of its core and non-core programs, and/or mergers and acquisitions. If the Company is able to negotiate extensions to the Forbearance Agreement and absent future cash raises or modifications to the originally planned principal and interest payments, the Company has approximately 60 days of cash on hand as of the filing date of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future success and ability to fund its operations within one year following the date on which this Quarterly Report on Form 10-Q is issued depend on its ability to obtain additional capital. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be, or that any amount that the Company is able to raise will be adequate. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, the Loan Agreement prohibits the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without the prior consent of the Lenders. If the Company requires but is unable to obtain additional funding, the Company may be forced to make further reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company&#8217;s ability to continue as a going concern is dependent upon its ability to obtain additional capital as described above. The unaudited financial statements as of June 30, 2023 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements and less than the amount of its outstanding debt, leaving no proceeds for stockholders.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Recent Developments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 26, 2023, the Company announced the topline data results from its Phase 2 randomized, double-blind, placebo-controlled parallel group trial (the &#8220;PEAK Trial&#8221;) evaluating AVTX-002 in poorly controlled non-eosinophilic asthma. The trial did not meet its primary endpoint, measured by the reduction in asthma-related events. AVTX-002 demonstrated a favorable safety and tolerability profile. AVTX-002 significantly reduced LIGHT levels for the study duration indicating target engagement. Additionally, an exploratory analysis revealed a positive trend in reduction of asthma-related events in patients treated with AVTX-002 as compared to placebo within a substantial sub-population of patients with elevated baseline LIGHT levels.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for increasing stockholder value includes: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advancing our pipeline of compounds through development and to regulatory approval; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing the go-to-market strategy to quickly and effectively market, launch, and distribute each of our compounds that receive regulatory approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Opportunistically out-licensing rights to indications or geographies; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquiring or licensing rights to targeted, complementary differentiated preclinical and clinical stage compounds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above under &#8220;Liquidity&#8221;, we need to raise money in the very near term in order to continue as a going concern and be able to execute on this strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2023 and 2022 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $0.6 million for the three months ended June&#160;30, 2023, compared to $1.0 million for the three months ended June 30, 2022. The decrease was mainly attributable to a decrease in units sold. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to only one commercial pharmaceutical product, Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which we consider non-core. Avalo&#8217;s license and supply agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expires on September 30, 2023. Therefore, we expect product revenue to decrease for the year ending December 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales were $0.7 million for the three months ended June 30, 2023, compared to $1.6&#160;million for the same period in 2022. The decrease was mainly attributable to a decrease in units sold, as discussed above. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo&#8217;s license and supply agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expires on September 30, 2023. Therefore, we expect cost of product sales to decrease for the year ending December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMC expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,658&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $3.9&#160;million for the three months ended June 30, 2023. This decrease was mainly driven by a $1.6&#160;million decrease in clinical expenses and a $1.3 million decrease in chemistry, manufacturing, and controls (&#8220;CMC&#8221;) expenses. The decrease in clinical expenses was primarily due to decreased spend on non-core programs in the current period and the decrease in CMC was primarily due to the timing of manufacturing runs, decreased activities for the AVTX-002 PEAK trial as it approached study completion and topline data readout in June 2023, and limited spend for AVTX-007 in the current period as a result of the out-license of the compound in July 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, salaries, benefits and related costs decreased $0.6 million primarily due to reduced headcount and reduced salary related costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future research and development expenses are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Selling, General and Administrative Expenses </span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our selling, general and administrative expenses for the three months ended June 30, 2023 and 2022 (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal, consulting and other professional expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising and marketing expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selling, general and administrative expenses decreased $0.4 million for the three months ended June&#160;30, 2023 compared to the prior period. The decrease was driven by the impact of cost savings initiatives across legal, consulting and other professional expenses. The decrease was partially offset by increased stock-based compensation expense during the period related to the options granted to employees in the second half of 2022 and first half of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future selling, general and administrative expenses are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other Expense, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other expense, net for the three months ended June 30, 2023 and 2022 (in thousands): </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(996)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,036)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was mainly comprised of interest expense related to the Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements) for the three months ended June&#160;30, 2023 and 2022. In June of 2022, the Company made a partial prepayment of $15.0&#160;million under the venture loan and security agreement which drove the $0.2 million decrease in interest expense compared to the prior period. In June of 2023, the Company prepaid an additional $6.0&#160;million of principal under the venture loan and security agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to decrease in the second half of 2023 as a result of the prepayment in June of 2023, paired with contractual principal payments beginning in the third quarter of 2023. The extent of the decrease is unknown given the contractual interest rate is tied to the prime rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized minimal income tax expense for both the three months ended June&#160;30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Six Months Ended June 30, 2023 and 2022 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $1.1 million for the six months ended June&#160;30, 2023, compared to $2.2 million for the six months ended June&#160;30, 2022. The decrease was mainly attributable to a decrease in units sold. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to only one commercial pharmaceutical product, Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which we consider non-core. Avalo&#8217;s license and supply agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expires on September 30, 2023. Therefore, we expect product revenue to decrease for the year ending December 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales were $1.3 million for the six months ended June&#160;30, 2023, compared to $2.3 million for the same period in 2022. The decrease was mainly attributable to a decrease in units sold, as discussed above. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo&#8217;s license and supply agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expires on September 30, 2023. Therefore, we expect cost of product sales to decrease for the year ending December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the six months ended June&#160;30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMC expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $7.4&#160;million for the six months ended June&#160;30, 2023 as compared to the prior period. This decrease was mainly driven by a $2.7&#160;million decrease of salaries, benefits and related costs due to severance expense recognized in the first quarter of 2022 from headcount reductions that did not repeat, paired with lower salary costs in the first half of 2023 driven by the reduced headcount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, CMC and clinical expenses decreased $2.1&#160;million and $1.6&#160;million, respectively. CMC and clinical expenses decreased due to the out-license of AVTX-007 in July of 2022, paired with decreased spend on non-core programs in 2023. The decrease in clinical expenses was partially offset by increased expenses for the AVTX-002 PEAK Trial as a result of the progression of trial as it approached completion and topline data readout in June of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future research and development expenses are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Selling, General and Administrative Expenses </span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our selling, general and administrative expenses for the six months ended June&#160;30, 2023 and 2022 (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal, consulting and other professional expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising and marketing expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selling, general and administrative expenses decreased $9.3&#160;million for the six months ended June&#160;30, 2023 due to severance and stock-based compensation recognized in the first quarter of 2022 from headcount reductions, paired with decreased headcount and cost savings initiatives in the first half of 2023. Notably, we recognized $4.3&#160;million of stock-based compensation in the first half of 2022 as a result of the acceleration and modification of certain separated employees&#8217; stock options that did not repeat. Additionally, salaries, benefits and related costs decreased $3.4&#160;million due to $2.4&#160;million of severance expense recognized in the first half of 2022 from headcount reductions that did not repeat, paired with lower salary costs in the first half of 2023 driven by the reduced headcount. Legal, consulting and other professional expenses decreased $1.5&#160;million due to cost savings initiatives. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future selling, general and administrative expenses are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our amortization expense for the six months ended June&#160;30, 2023 and 2022 (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo&#8217;s acquired assembled workforce was fully amortized in the first quarter of 2022, thus driving the decrease as compared to the prior period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other expense, net for the six months ended June&#160;30, 2023 and 2022 (in thousands): </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,945)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,323)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,190)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,343)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was mainly comprised of interest expense related to the Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements) for the six months ended June&#160;30, 2023 and 2022. In June 2022, the Company made a partial prepayment of $15.0&#160;million under the venture loan and security agreement which drove the decrease in interest expense compared to the prior period. In June of 2023, the Company prepaid an additional $6.0&#160;million of principal under the venture loan and security agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to decrease in the second half of 2023 as a result of the prepayment in June of 2023, paired with contractual principal payments beginning in the third quarter of 2023. The extent of the decrease is unknown given the contractual interest rate is tied to the prime rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized minimal income tax expense for both the six months ended June&#160;30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uses of Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cash to primarily fund the ongoing development of our research and development pipeline assets and costs associated with its organizational infrastructure. Future operating cash flows are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the six months ended June 30, 2023 and 2022 (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,865)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,374)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $21.1&#160;million for the six months ended June 30, 2023 and consisted primarily of a net loss of $18.1&#160;million and non-cash adjustments to reconcile net loss to net cash used in operating activities including stock-based compensation of $1.7 million. Additionally, changes in net liabilities decreased $5.8&#160;million driven by decreases in accrued expenses and other liabilities and accounts payable of $5.6&#160;million and $2.1&#160;million, respectively, partially offset by a $1.9&#160;million decrease in other receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $28.5 million for the six months ended June 30, 2022, and consisted primarily of a net loss of $35.0 million and non-cash adjustments to reconcile net loss to net cash used in operating activities including stock-based compensation of $6.0 million and a $1.3 million decrease in changes in net liabilities.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future operating cash flows are difficult to predict given they are highly dependent on the Company&#8217;s ability to obtain additional capital to fund its programs and operations, including but not limited to financings and/or out-licensing, strategic alliance/collaborations or sale of its core and non-core programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was minimal for the six months ended June&#160;30, 2023 and six months ended June 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et cash provided by (used in) financing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June&#160;30, 2023 consisted of net proceeds of $13.7&#160;million from an underwritten public offering closed in February 2023 and net proceeds of $6.5 million from the sale of common stock pursuant to the Company&#8217;s at-the-market program in the second quarter of 2023, partially offset by the $6.0&#160;million principal prepayment under the Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the six months ended June 30, 2022 consisted of the $14.8&#160;million partial prepayment applied to principal under the Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements). </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Estimates, and Assumptions </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared in accordance with GAAP.&#160;In preparing the financial statements in conformity with GAAP, the Company makes estimates and assumptions that have an impact on assets, liabilities, revenue and expenses reported. These estimates can also affect supplemental information disclosed by us, including information about contingencies, risk, and financial condition. In our unaudited condensed consolidated financial statements, estimates are used for, but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements, the valuation of derivative liabilities, cash flows used in management&#8217;s going concern assessment, income taxes, goodwill, and clinical trial accruals. The Company believes, given current facts and circumstances, that our estimates and assumptions are reasonable, adhere to GAAP and are consistently applied. Inherent in the nature of an estimate or assumption is the fact that actual results may differ from estimates, and estimates may vary as new facts and circumstances arise. Our most critical accounting estimates and assumptions are included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March&#160;29, 2023. There have been no material changes to our critical accounting policies during the six months ended June&#160;30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined by applicable SEC rules and regulations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 33</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide the information required by this Item.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;and Rule&#160;15d-15(b)&#160;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form&#160;10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 34</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.  </span></div><div><span><br/></span></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March&#160;29, 2023, which could materially affect our business, financial condition, or future results. The risks described in this Quarterly Report on 10-Q and Form 10-K referenced above are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, or future results of operations and the trading price of our common stock. Except for such additional information and the risk factor set forth below, we believe our risk factors as of the date of this Quarterly Report on Form 10-Q have not changed materially from those described in the Form 10-K referenced above. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the Company fails to reach an agreement with the Lender (as defined in Note 9 to the unaudited condensed consolidated financial statements) to waive defaults, extend its forbearance period or secure alternative financing, it may not be able to continue operating. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with its entry into the Forbearance Agreement (as defined in Note 1 to the unaudited condensed consolidated financial statements), the Company is evaluating available financial alternatives, including but not limited to sale of equity securities under its &#8220;at-the-market&#8221; (or &#8220;ATM&#8221;) program or otherwise, out-licensing transactions, strategic alliances/collaborations, sale of its core and non-core programs, and/or mergers and acquisitions as well as seeking additional waivers, forbearances or amendments to the covenants or other provisions of the Company&#8217;s Loan Agreement (as defined in Note 9 to the unaudited condensed consolidated financial statements) to address any future defaults and has engaged financial advisors to assist the Company. If the Company is unable to reach an agreement with its lender to waive the defaults, extend the forbearance period or find alternative financing prior to the expiration of the forbearance period, the Lender of the Loan Agreement may choose to accelerate repayment. The Company cannot provide assurances that it will be successful in negotiating such a waiver or extension of the forbearance period, restructuring of existing debt obligations, obtaining capital or entering into a strategic alternative transaction which provides sufficient funding for the refinancing of its outstanding indebtedness prior to the expiration of the forbearance period or prior to the maturity date of its obligations under the Loan Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">Form of Exchange Warrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm"> to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">Purchase Shares of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">Common Stock of Avalo T</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">herapeutics, I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">nc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm"> issued </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Partners III, L.P. and VHCP Co-Invest</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-41_venrockprexfundedwar.htm">ment Holdings, LLC. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on June 2, 2023).  </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023020611/ex-101_venrock3a9exchangea.htm">Exchange Agreement, dated as of May 31, 2023, between Avalo Therapeutics, Inc. and Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Partners III, L.P. and VHCP Co-Investement Holdings, LLC. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 2, 2023).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/ex-101forbearanceagreement.htm">Forbearance Agreement, dated as of July 20, 2023, between Avalo Therapeutics, Inc. and Horizon Credit II LLC, Horizon Funding Trust 2019-1, Horizon Funding I, LLC, Powerscourt Investments XXV Trust and Horizon Technology Finance Corporation (incorporated by reference to the Exhibit 10.1 to Form 8-K filed on July 21, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/ex-101forbearanceagreement.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1534120/000162828023025293/ex-101forbearanceagreement.htm">.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-3112q2023.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-3122q2023.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-3212q2023.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022; (ii) Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2023 and 2022; (iii) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2023 and 2022; (iv) Condensed Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity (Unaudited) for the Three and Six Months Ended June 30, 2023 and 2022; and (v) Notes to Unaudited Financial Statements.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in XBRL (included in Exhibit 101).</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+  Filed herewith.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;  This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i96f3b1523a8b4726a33c5f41798d50ce_124"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i96f3b1523a8b4726a33c5f41798d50ce_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Avalo Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Sullivan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Sullivan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(on behalf of the registrant and as the registrant&#8217;s principal financial officer)</span></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex-3112q2023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib15e90c8c71b4359bcff38b30ec5a477_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,&#160;Garry Neil, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Avalo Therapeutics,&#160;Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Garry Neil, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garry Neil, M.D.<br>Chief Executive Officer<br>(Registrant&#8217;s Principal Executive Officer)</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex-3122q2023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ief97eee5df2c4353b0f185128c5201a1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Sullivan, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Avalo Therapeutics,&#160;Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Sullivan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Sullivan<br>Chief Financial Officer<br>(Registrant&#8217;s Principal Financial Officer)</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex-3212q2023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaca5ce88d1e049c9affa8299c8b00c5e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<br>AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Avalo Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Garry Neil, Chief Executive Officer (principal executive officer) of the Registrant, and I, Christopher Sullivan, Chief Financial Officer (principal financial officer) of the Registrant, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition at the end of the period covered by the Report and the results of operations of the Registrant for the periods covered by the Report.</font></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Garry Neil, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garry Neil, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Registrant&#8217;s Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Sullivan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Sullivan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br>(Registrant&#8217;s Principal Financial Officer)</font></td></tr></table></div><div style="text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of section&#160;18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cerecor Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>avtx-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:avtx="http://www.avalotherapeutics.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.avalotherapeutics.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avtx-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.avalotherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://www.avalotherapeutics.com/role/Business">
        <link:definition>0000009 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.avalotherapeutics.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.avalotherapeutics.com/role/NetLossPerShare">
        <link:definition>0000012 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.avalotherapeutics.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CostReductionPlan" roleURI="http://www.avalotherapeutics.com/role/CostReductionPlan">
        <link:definition>0000016 - Disclosure - Cost Reduction Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.avalotherapeutics.com/role/NotesPayable">
        <link:definition>0000017 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructure" roleURI="http://www.avalotherapeutics.com/role/CapitalStructure">
        <link:definition>0000018 - Disclosure - Capital Structure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensation">
        <link:definition>0000019 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.avalotherapeutics.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.avalotherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareTables">
        <link:definition>9954702 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>9954703 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.avalotherapeutics.com/role/LeasesTables">
        <link:definition>9954704 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableTables" roleURI="http://www.avalotherapeutics.com/role/NotesPayableTables">
        <link:definition>9954706 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureTables" roleURI="http://www.avalotherapeutics.com/role/CapitalStructureTables">
        <link:definition>9954707 - Disclosure - Capital Structure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationTables">
        <link:definition>9954708 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://www.avalotherapeutics.com/role/BusinessDetails">
        <link:definition>9954709 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.avalotherapeutics.com/role/RevenueDetails">
        <link:definition>9954710 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofNetLossPerShareDetails" roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails">
        <link:definition>9954711 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>9954712 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954713 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofChangesintheFairValueDetails" roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails">
        <link:definition>9954714 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954715 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.avalotherapeutics.com/role/LeasesNarrativeDetails">
        <link:definition>9954716 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofAssetsandLiabilitiesLesseeDetails" roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails">
        <link:definition>9954717 - Disclosure - Leases - Schedule of Assets and Liabilities Lessee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseCostDetails" roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails">
        <link:definition>9954718 - Disclosure - Leases - Schedule of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseLiabilityDetails" roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails">
        <link:definition>9954719 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseLiabilityDetails_1" roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1">
        <link:definition>9954719 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954720 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CostReductionPlanDetails" roleURI="http://www.avalotherapeutics.com/role/CostReductionPlanDetails">
        <link:definition>9954721 - Disclosure - Cost Reduction Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableNarrativeDetails" roleURI="http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails">
        <link:definition>9954722 - Disclosure - Notes Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableScheduleofDebtDetails" roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails">
        <link:definition>9954723 - Disclosure - Notes Payable - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableScheduleofDebtDetails_1" roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1">
        <link:definition>9954723 - Disclosure - Notes Payable - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails">
        <link:definition>9954724 - Disclosure - Notes Payable - Schedule of Contractual Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureNarrativeDetails" roleURI="http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails">
        <link:definition>9954725 - Disclosure - Capital Structure - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails" roleURI="http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails">
        <link:definition>9954726 - Disclosure - Capital Structure - Schedule of Outstanding Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954727 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954728 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofOptionActivityDetails" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails">
        <link:definition>9954729 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails" roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails">
        <link:definition>9954730 - Disclosure - Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954731 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="avtx_AltoMember" abstract="true" name="AltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX913Member" abstract="true" name="AVTX913Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" abstract="false" name="ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_VenrockHealthcareCapitalPartnersMember" abstract="true" name="VenrockHealthcareCapitalPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="avtx_ESMember" abstract="true" name="ESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" abstract="false" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_RoyaltyAgreementPaymentReceived" abstract="false" name="RoyaltyAgreementPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_CommonStockWarrantsExpirationFebruary2024Member" abstract="true" name="CommonStockWarrantsExpirationFebruary2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" abstract="false" name="StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" abstract="false" name="PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_DebtInstrumentFinalPaymentFee" abstract="false" name="DebtInstrumentFinalPaymentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_IncreaseDecreaseInLeaseIncentives" abstract="false" name="IncreaseDecreaseInLeaseIncentives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_AVTX501AndAVTX007Member" abstract="true" name="AVTX501AndAVTX007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX611Member" abstract="true" name="AVTX611Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_SaleOfStockMaximumAmountOfSharesToBeSold" abstract="false" name="SaleOfStockMaximumAmountOfSharesToBeSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_KyowaKirinCoLtdKKCMember" abstract="true" name="KyowaKirinCoLtdKKCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_SecondNoteMember" abstract="true" name="SecondNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ESTherapeuticsMember" abstract="true" name="ESTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseAnnualBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avtx_DebtInstrumentAdditionalFinalPaymentPercentage" abstract="false" name="DebtInstrumentAdditionalFinalPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_RestructuringPlanOneTimeTerminationBenefitsMember" abstract="true" name="RestructuringPlanOneTimeTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_NantahalaCapitalManagementLLCMember" abstract="true" name="NantahalaCapitalManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_LicenseAgreementInstallmentPayment" abstract="false" name="LicenseAgreementInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_The2016PlanMember" abstract="true" name="The2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AccruedSellingGeneralAndAdministrativeExpenses" abstract="false" name="AccruedSellingGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" abstract="false" name="FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" abstract="false" name="DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_AVTX002KKCLicenseAgreementMember" abstract="true" name="AVTX002KKCLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="avtx_MeasurementInputProbabilityOfSuccessMember" abstract="true" name="MeasurementInputProbabilityOfSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_RepaymentOfDebtPrincipal" abstract="false" name="RepaymentOfDebtPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_KarbinalAgreementMember" abstract="true" name="KarbinalAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_DebtInstrumentInterestRateFloor" abstract="false" name="DebtInstrumentInterestRateFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_AssetAcquisitionNumberOfPreclinicalTherapies" abstract="false" name="AssetAcquisitionNumberOfPreclinicalTherapies" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_EmployeeStockPurchasePlanESPPMember" abstract="true" name="EmployeeStockPurchasePlanESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" abstract="false" name="CollaborativeArrangementRightsAndObligationsPatentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" abstract="false" name="AssetAcquisitionContingentValueRightNumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_DerivativeLiabilityMeasurementInputTerm" abstract="false" name="DerivativeLiabilityMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_MajorCustomerNumberTwoMember" abstract="true" name="MajorCustomerNumberTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_PediatricPortfolioMember" abstract="true" name="PediatricPortfolioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" abstract="false" name="CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseRentAbatementPeriod" abstract="false" name="LesseeOperatingLeaseRentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_CapitalStockSharesAuthorized" abstract="false" name="CapitalStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="avtx_AeviGenomicMedicineIncMember" abstract="true" name="AeviGenomicMedicineIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_WarrantCommonStockMember" abstract="false" name="WarrantCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX006AstellasLicenseAgreementMember" abstract="true" name="AVTX006AstellasLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_CommonStockWarrantsExpirationDateOfJune2024Member" abstract="true" name="CommonStockWarrantsExpirationDateOfJune2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" abstract="false" name="IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_TevaPharmaceuticalIndustriesLtd.Member" abstract="true" name="TevaPharmaceuticalIndustriesLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_MillipredMember" abstract="true" name="MillipredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ThirdNoteMember" abstract="true" name="ThirdNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_SpecialAdvisorToTheBoardMember" abstract="true" name="SpecialAdvisorToTheBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_InitialNoteMember" abstract="true" name="InitialNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" abstract="false" name="IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" abstract="false" name="ClassOfWarrantOrRightOwnershipExerciseThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_CommonStockWarrantsExpirationJune2031Member" abstract="true" name="CommonStockWarrantsExpirationJune2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_NumberOfClassOfStockAuthorized" abstract="false" name="NumberOfClassOfStockAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_AstellasPharmaIncAstellasMember" abstract="true" name="AstellasPharmaIncAstellasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="avtx_AVTX007Member" abstract="true" name="AVTX007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" abstract="false" name="RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" abstract="false" name="DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="avtx_ExchangeAgreementMember" abstract="true" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avtx_ArmisticeMember" abstract="true" name="ArmisticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_HorizonPowerscourtNotesMember" abstract="true" name="HorizonPowerscourtNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" abstract="false" name="OperatingLeasesRentExpenseAnnualIncreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" abstract="false" name="ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_ServiceBasedOptionsMember" abstract="true" name="ServiceBasedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avtx_RestructuringAndRelatedActivitiesPaymentTerm" abstract="false" name="RestructuringAndRelatedActivitiesPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX301OutLicenseMember" abstract="true" name="AVTX301OutLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseNumberOfLeasedProperties" abstract="false" name="LesseeOperatingLeaseNumberOfLeasedProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" abstract="false" name="RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_MajorCustomerNumberOneMember" abstract="true" name="MajorCustomerNumberOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX501Member" abstract="true" name="AVTX501Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" abstract="false" name="DebtInstrumentInterestOnlyPaymentExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_TRISPharmaMember" abstract="true" name="TRISPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" abstract="false" name="ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_IchorionMember" abstract="true" name="IchorionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_CommonStockWarrantsNoExpiration2Member" abstract="true" name="CommonStockWarrantsNoExpiration2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avtx_SeparationFromCertainSection16OfficersMember" abstract="true" name="SeparationFromCertainSection16OfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_StockOptionsWithMarketBasedVestingConditionsMember" abstract="true" name="StockOptionsWithMarketBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" abstract="false" name="RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_AVTX801AVTX802AndAVTX803Member" abstract="true" name="AVTX801AVTX802AndAVTX803Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX406LicenseAssignmentMember" abstract="true" name="AVTX406LicenseAssignmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseLiabilityAnnualBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_MeasurementInputSalesForecastPeakMember" abstract="true" name="MeasurementInputSalesForecastPeakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_CommonStockWarrantsNoExpirationMember" abstract="true" name="CommonStockWarrantsNoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" abstract="true" name="AVTX008SanfordBurnhamPrebysLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_DebtInstrumentInterestOnlyPaymentPeriod" abstract="false" name="DebtInstrumentInterestOnlyPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_ATMAgreementMember" abstract="true" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" abstract="true" name="SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" abstract="false" name="LicenseAgreementPercentOfNetProfitForInstallmentPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avtx_CommercialOperationsCurrent" abstract="false" name="CommercialOperationsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" abstract="false" name="ProceedsFromIssuanceOfCommonStockThroughATMProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avtx_LesseeOperatingLeaseRemainingLeaseTeam" abstract="false" name="LesseeOperatingLeaseRemainingLeaseTeam" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>avtx-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63009db2-75ad-4ce5-b3a3-f912552c2c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_12313f05-9ae1-4216-958d-d57ec445d773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63009db2-75ad-4ce5-b3a3-f912552c2c74" xlink:to="loc_us-gaap_Liabilities_12313f05-9ae1-4216-958d-d57ec445d773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_540bea7f-3437-4f74-97af-95746779646c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63009db2-75ad-4ce5-b3a3-f912552c2c74" xlink:to="loc_us-gaap_StockholdersEquity_540bea7f-3437-4f74-97af-95746779646c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_214d0ef4-bd32-448a-aa0b-b018217d7a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8a42771-2079-4378-ad02-6420bd421b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_214d0ef4-bd32-448a-aa0b-b018217d7a6f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8a42771-2079-4378-ad02-6420bd421b11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_38205264-0349-441f-89dd-2ad8981a9ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_214d0ef4-bd32-448a-aa0b-b018217d7a6f" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_38205264-0349-441f-89dd-2ad8981a9ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_8f18e806-a497-4ece-bece-dda29f121845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_214d0ef4-bd32-448a-aa0b-b018217d7a6f" xlink:to="loc_us-gaap_NotesPayableCurrent_8f18e806-a497-4ece-bece-dda29f121845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7931ae59-ad88-4a11-9088-7ecccf6e48f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_214d0ef4-bd32-448a-aa0b-b018217d7a6f" xlink:to="loc_us-gaap_AccountsPayableCurrent_7931ae59-ad88-4a11-9088-7ecccf6e48f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0799d87f-22bc-4943-b0e7-d6a9c229885d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_LiabilitiesCurrent_0799d87f-22bc-4943-b0e7-d6a9c229885d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_88d896e9-feb2-44bc-aa54-c935e99329fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_88d896e9-feb2-44bc-aa54-c935e99329fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_c813c0b3-1d66-409f-bf36-80279f806b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_LongTermNotesPayable_c813c0b3-1d66-409f-bf36-80279f806b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ee071652-dedf-4aa0-8030-ea3b27ac540b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ee071652-dedf-4aa0-8030-ea3b27ac540b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_cd8e30a0-5f99-4682-9ac1-3002529c6211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_cd8e30a0-5f99-4682-9ac1-3002529c6211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_114d627b-3196-4324-a0e7-b9ab09895be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed45ee11-1193-41bb-9d8a-2c8d838e71ea" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_114d627b-3196-4324-a0e7-b9ab09895be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e1110ce4-c12e-4efe-8acb-c29fdf6b7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_06cbd61d-5d20-4d38-bf6c-65eb8445afd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1110ce4-c12e-4efe-8acb-c29fdf6b7fe8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_06cbd61d-5d20-4d38-bf6c-65eb8445afd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8f58c37b-9ed2-4fe2-84cd-3643ade230d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1110ce4-c12e-4efe-8acb-c29fdf6b7fe8" xlink:to="loc_us-gaap_Goodwill_8f58c37b-9ed2-4fe2-84cd-3643ade230d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2be97e7-9f70-420c-9ca7-edd9a1caf6c7" xlink:href="avtx-20230630.xsd#avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1110ce4-c12e-4efe-8acb-c29fdf6b7fe8" xlink:to="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2be97e7-9f70-420c-9ca7-edd9a1caf6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f606afd-d77b-45b7-a1fb-8abc4740648a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1110ce4-c12e-4efe-8acb-c29fdf6b7fe8" xlink:to="loc_us-gaap_AssetsCurrent_3f606afd-d77b-45b7-a1fb-8abc4740648a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d59586e-f1c7-454f-b4c4-312336d16fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d59586e-f1c7-454f-b4c4-312336d16fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_711ff4b3-bc9d-4ea5-b5eb-c55f767741f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_711ff4b3-bc9d-4ea5-b5eb-c55f767741f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9aa8ffef-a898-48c7-bb8e-9d622ef9554e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_InventoryNet_9aa8ffef-a898-48c7-bb8e-9d622ef9554e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2869f228-8242-4f16-bb45-7d0131466163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2869f228-8242-4f16-bb45-7d0131466163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f99a3c4c-d5d5-45d8-812c-0d01175f55bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f99a3c4c-d5d5-45d8-812c-0d01175f55bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_23f709f2-ec5b-46a0-a039-3977fb7f4e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_54d883b5-aef5-40bf-97d7-03a74169cd76" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_23f709f2-ec5b-46a0-a039-3977fb7f4e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a545980d-46ad-4e9b-b373-9eabb3a09691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4e8641d3-1c35-4d81-a176-a0c3fbe39850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a545980d-46ad-4e9b-b373-9eabb3a09691" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4e8641d3-1c35-4d81-a176-a0c3fbe39850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ed4ea7aa-0502-421a-a916-d410a118ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a545980d-46ad-4e9b-b373-9eabb3a09691" xlink:to="loc_us-gaap_CommonStockValue_ed4ea7aa-0502-421a-a916-d410a118ac8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f987a9cb-f10d-4fc0-853f-4a4396513ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a545980d-46ad-4e9b-b373-9eabb3a09691" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f987a9cb-f10d-4fc0-853f-4a4396513ff9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_69daf816-9b24-4ffc-9526-030bfe622719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59689d2f-7b7a-4d3a-a96f-d1a91ed4fe38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_69daf816-9b24-4ffc-9526-030bfe622719" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59689d2f-7b7a-4d3a-a96f-d1a91ed4fe38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0b7c9d1e-3e6b-4550-b633-28e4a5c9a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_69daf816-9b24-4ffc-9526-030bfe622719" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0b7c9d1e-3e6b-4550-b633-28e4a5c9a5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_791af2fa-7a7e-4786-9379-c4a1d158252b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_69daf816-9b24-4ffc-9526-030bfe622719" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_791af2fa-7a7e-4786-9379-c4a1d158252b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_586ad844-85c7-46b4-a598-e2fdbc8c5651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c097115a-6bbc-48a9-9338-7794cff11712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_586ad844-85c7-46b4-a598-e2fdbc8c5651" xlink:to="loc_us-gaap_CostsAndExpenses_c097115a-6bbc-48a9-9338-7794cff11712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2cbcb7ff-ba74-4f9a-a1b7-795c625f9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_586ad844-85c7-46b4-a598-e2fdbc8c5651" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2cbcb7ff-ba74-4f9a-a1b7-795c625f9ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1d4cabee-cd0a-467f-964c-f48e0eb08558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ed092a8-b363-4d90-ab7d-3b809f9ad030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1d4cabee-cd0a-467f-964c-f48e0eb08558" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3ed092a8-b363-4d90-ab7d-3b809f9ad030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619dc58c-c861-494d-a20f-20df3424cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1d4cabee-cd0a-467f-964c-f48e0eb08558" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_619dc58c-c861-494d-a20f-20df3424cd8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e098f6e-6d17-48e0-b472-f9cef59d3792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3512b6f1-47f6-4b28-a137-311f553d87e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e098f6e-6d17-48e0-b472-f9cef59d3792" xlink:to="loc_us-gaap_NetIncomeLoss_3512b6f1-47f6-4b28-a137-311f553d87e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5f9d5274-53e6-4c83-86f9-a6f46d81136a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_10ef0cc5-7aa5-48d6-a3af-d69c3b0cc250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5f9d5274-53e6-4c83-86f9-a6f46d81136a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_10ef0cc5-7aa5-48d6-a3af-d69c3b0cc250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_190feef9-5edf-483a-b267-53ac080c485d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5f9d5274-53e6-4c83-86f9-a6f46d81136a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_190feef9-5edf-483a-b267-53ac080c485d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dd2e6cf0-93a7-4c86-bac8-67e4bda82925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5f9d5274-53e6-4c83-86f9-a6f46d81136a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dd2e6cf0-93a7-4c86-bac8-67e4bda82925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_80b33e69-a8c2-4a86-9473-af103d43976d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5f9d5274-53e6-4c83-86f9-a6f46d81136a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_80b33e69-a8c2-4a86-9473-af103d43976d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590eb781-be99-4800-ac41-1d6658745510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a59ce535-ba93-42c8-af61-0edae484de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590eb781-be99-4800-ac41-1d6658745510" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a59ce535-ba93-42c8-af61-0edae484de1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a887f36c-6d20-416e-bacc-ae51d39b3dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590eb781-be99-4800-ac41-1d6658745510" xlink:to="loc_us-gaap_OperatingIncomeLoss_a887f36c-6d20-416e-bacc-ae51d39b3dcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe31509e-86c7-49ee-a22a-59e84a8a5195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fe31509e-86c7-49ee-a22a-59e84a8a5195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_492306ba-90de-43b2-9f0b-0de2e73cf627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_492306ba-90de-43b2-9f0b-0de2e73cf627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_53122fab-4247-4d98-aab6-01b82d96cded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_53122fab-4247-4d98-aab6-01b82d96cded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bea57dbd-a9bf-44c7-b5bc-119b13dcb51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bea57dbd-a9bf-44c7-b5bc-119b13dcb51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b8e9a174-3284-43a4-8c05-6e5e5fa642d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b8e9a174-3284-43a4-8c05-6e5e5fa642d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af3b1c3a-6836-49c7-8c29-8b599d4bbeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af3b1c3a-6836-49c7-8c29-8b599d4bbeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4b5a2fe2-d7a6-4792-aef8-243837ed8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_ShareBasedCompensation_4b5a2fe2-d7a6-4792-aef8-243837ed8b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c4712fda-873d-4613-b47f-0be42978a1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c4712fda-873d-4613-b47f-0be42978a1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_65cbfe7d-a7a4-4aef-81bf-cc11c3d40bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_65cbfe7d-a7a4-4aef-81bf-cc11c3d40bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_a22d96a7-cde5-412a-878f-6d3c0a5e75bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_a22d96a7-cde5-412a-878f-6d3c0a5e75bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c2f22dc-b6e3-43ef-8e5b-f7221bf1365f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_NetIncomeLoss_3c2f22dc-b6e3-43ef-8e5b-f7221bf1365f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseLiability_74a69317-3c67-451b-9181-0e461f536faf" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_avtx_IncreaseDecreaseInLeaseLiability_74a69317-3c67-451b-9181-0e461f536faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_cc89753c-b21d-4053-af83-8a421c7714a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_cc89753c-b21d-4053-af83-8a421c7714a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bb860ad9-12c8-4ff3-b58e-05bac84cb027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bb860ad9-12c8-4ff3-b58e-05bac84cb027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseIncentives_1a286fe2-a554-479e-9f29-bf5bcdd212fd" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseIncentives"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_avtx_IncreaseDecreaseInLeaseIncentives_1a286fe2-a554-479e-9f29-bf5bcdd212fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a54a26b-9acf-491b-9bec-176461081b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416fa9c3-1061-4f53-ab8a-37f7f76b84ca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a54a26b-9acf-491b-9bec-176461081b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b64709d6-89fc-4023-acc0-113f9c598e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d725b0e7-aa52-43bf-9b35-4b73f6f80e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b64709d6-89fc-4023-acc0-113f9c598e48" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d725b0e7-aa52-43bf-9b35-4b73f6f80e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_d16d117d-6363-4672-9d08-3e65476273f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b64709d6-89fc-4023-acc0-113f9c598e48" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_d16d117d-6363-4672-9d08-3e65476273f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_da97fe4b-169d-4f2f-8f27-c343d446f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b64709d6-89fc-4023-acc0-113f9c598e48" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_da97fe4b-169d-4f2f-8f27-c343d446f75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daf3956d-0290-4520-8a24-f6276a5cbfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bce76496-63b4-4340-a583-92fb6e4980fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daf3956d-0290-4520-8a24-f6276a5cbfa3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bce76496-63b4-4340-a583-92fb6e4980fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_123b870f-1b48-4e54-97d6-574f0f61ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daf3956d-0290-4520-8a24-f6276a5cbfa3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_123b870f-1b48-4e54-97d6-574f0f61ee56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9db9e64f-c0cf-41fa-aa83-316b66120280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daf3956d-0290-4520-8a24-f6276a5cbfa3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9db9e64f-c0cf-41fa-aa83-316b66120280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3c2b9d18-f4e2-41f2-b9ca-c490e8f13cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14c2b9bd-db40-4210-a352-50e627ecef09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3c2b9d18-f4e2-41f2-b9ca-c490e8f13cc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14c2b9bd-db40-4210-a352-50e627ecef09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5421e784-79e7-4b90-957c-233fd9e1e888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3c2b9d18-f4e2-41f2-b9ca-c490e8f13cc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5421e784-79e7-4b90-957c-233fd9e1e888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c01bb1e5-c3b4-4c64-9362-7adc1a402078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3c2b9d18-f4e2-41f2-b9ca-c490e8f13cc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c01bb1e5-c3b4-4c64-9362-7adc1a402078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63333330-3982-479b-ac60-8a2a4d42a33b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_bf6d985c-6357-4ec4-953b-0c845561ec1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63333330-3982-479b-ac60-8a2a4d42a33b" xlink:to="loc_us-gaap_RepaymentsOfDebt_bf6d985c-6357-4ec4-953b-0c845561ec1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_c77fa9b3-5e95-4f03-969a-3c43b39ea38b" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63333330-3982-479b-ac60-8a2a4d42a33b" xlink:to="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_c77fa9b3-5e95-4f03-969a-3c43b39ea38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_3c3c1b58-cdff-4e11-b54c-3c5e86f9e557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63333330-3982-479b-ac60-8a2a4d42a33b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_3c3c1b58-cdff-4e11-b54c-3c5e86f9e557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_f429c11b-d9a4-4d78-919e-c129cd71459c" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63333330-3982-479b-ac60-8a2a4d42a33b" xlink:to="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_f429c11b-d9a4-4d78-919e-c129cd71459c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofAssetsandLiabilitiesLesseeDetails"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_17bec135-444d-4caf-8bdc-e94cff86c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_218fe7ed-a531-407b-b595-abc0ecaaef94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_17bec135-444d-4caf-8bdc-e94cff86c8b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_218fe7ed-a531-407b-b595-abc0ecaaef94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_71d92e92-608d-4597-acc3-0977c1447fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_17bec135-444d-4caf-8bdc-e94cff86c8b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_71d92e92-608d-4597-acc3-0977c1447fc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6381fbd2-7f26-4f2d-b005-c8c924d9c1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f4fde337-5c97-4fc4-8ef4-92e25d6fe7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6381fbd2-7f26-4f2d-b005-c8c924d9c1cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f4fde337-5c97-4fc4-8ef4-92e25d6fe7b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3f54c6cf-c830-4253-9e53-0655e4e00830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6381fbd2-7f26-4f2d-b005-c8c924d9c1cc" xlink:to="loc_us-gaap_OperatingLeaseLiability_3f54c6cf-c830-4253-9e53-0655e4e00830" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails_1"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61405e29-92e0-4fab-a730-6d766604dfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_61405e29-92e0-4fab-a730-6d766604dfe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_618afdde-57ad-4259-929d-8d86868dd9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_618afdde-57ad-4259-929d-8d86868dd9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_85d3b0a0-14a1-40c2-8100-512d72a59b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_85d3b0a0-14a1-40c2-8100-512d72a59b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6a6e4f76-75ab-492c-b38f-86ceac317b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6a6e4f76-75ab-492c-b38f-86ceac317b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb67e7cd-70c2-41d9-bef5-71e11831b7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb67e7cd-70c2-41d9-bef5-71e11831b7ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a1dad27-be52-410b-b2d5-6ab042454ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a1dad27-be52-410b-b2d5-6ab042454ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cf01c293-209b-4f44-befd-18d3dd728c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b98c4f03-1173-4e24-b2ba-1db1f8827a36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cf01c293-209b-4f44-befd-18d3dd728c7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommercialOperationsCurrent_60002407-8bbe-4a1b-9a85-4abe15301ae6" xlink:href="avtx-20230630.xsd#avtx_CommercialOperationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_avtx_CommercialOperationsCurrent_60002407-8bbe-4a1b-9a85-4abe15301ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses_5df7b415-f6b9-4114-a5e6-05a9198c7d89" xlink:href="avtx-20230630.xsd#avtx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses_5df7b415-f6b9-4114-a5e6-05a9198c7d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f984e0d9-886f-45fb-b29d-322a42a0502d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f984e0d9-886f-45fb-b29d-322a42a0502d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fe50d475-02ea-44bf-9d1b-8070a7818c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fe50d475-02ea-44bf-9d1b-8070a7818c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_73826493-fdd8-4f24-9fc1-a8d9a2a98add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_73826493-fdd8-4f24-9fc1-a8d9a2a98add" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedResearchAndDevelopment_19b3abea-faeb-406b-a9e9-f4c443cb3a02" xlink:href="avtx-20230630.xsd#avtx_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_avtx_AccruedResearchAndDevelopment_19b3abea-faeb-406b-a9e9-f4c443cb3a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f7a05e27-3407-4ba1-9230-258f47e5970c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f7ab8c69-8478-4a00-a2db-90eb4798e289" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f7a05e27-3407-4ba1-9230-258f47e5970c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_350e8644-0027-4ffe-8599-0ab184975226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_44a5a4ef-dba6-46d2-ae0c-50158f580ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_350e8644-0027-4ffe-8599-0ab184975226" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_44a5a4ef-dba6-46d2-ae0c-50158f580ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e528dc84-d657-4b15-b316-a0bcfb9e74dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_350e8644-0027-4ffe-8599-0ab184975226" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e528dc84-d657-4b15-b316-a0bcfb9e74dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3ddd6fb4-2955-4565-9ff3-d858f759c18b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2dcd35d2-9e33-4ce8-be42-4198acc4c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3ddd6fb4-2955-4565-9ff3-d858f759c18b" xlink:to="loc_us-gaap_LongTermDebtCurrent_2dcd35d2-9e33-4ce8-be42-4198acc4c83b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_643aa907-e79b-4700-b8e6-f9cd4e0963dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3ddd6fb4-2955-4565-9ff3-d858f759c18b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_643aa907-e79b-4700-b8e6-f9cd4e0963dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e7d4a52-7438-455c-a024-7851b7fdd005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_12846718-cbdc-48e4-96f4-4f3f0a220241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e7d4a52-7438-455c-a024-7851b7fdd005" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_12846718-cbdc-48e4-96f4-4f3f0a220241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_25632287-23a0-41d0-bc95-c13ff966006a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e7d4a52-7438-455c-a024-7851b7fdd005" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_25632287-23a0-41d0-bc95-c13ff966006a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_49d98d9f-bc52-4755-b308-013aefe37096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e7d4a52-7438-455c-a024-7851b7fdd005" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_49d98d9f-bc52-4755-b308-013aefe37096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2e4eca78-f145-4185-8b30-7863f3f18d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2e7d4a52-7438-455c-a024-7851b7fdd005" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2e4eca78-f145-4185-8b30-7863f3f18d02" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>avtx-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="i541a236d8d5540a7b266a90238cc14c5_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2d83e3-fa42-4bcc-a2c0-26c4d98f25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2d83e3-fa42-4bcc-a2c0-26c4d98f25e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3674d1e6-36f1-4c93-83f5-2d4519ebf512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3674d1e6-36f1-4c93-83f5-2d4519ebf512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_40cc1dff-351a-4f9a-8932-2d625bb30344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_40cc1dff-351a-4f9a-8932-2d625bb30344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dc934aa-2374-453b-b5fb-031f370e9467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dc934aa-2374-453b-b5fb-031f370e9467" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10f415d9-d921-4f8b-b48b-d39550369bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10f415d9-d921-4f8b-b48b-d39550369bd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_71e87e74-526b-40da-b190-4230ce9a1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_CostsAndExpenses_71e87e74-526b-40da-b190-4230ce9a1a2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1097dc0-3fcd-4c76-b55d-b156f78808e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1097dc0-3fcd-4c76-b55d-b156f78808e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c694d437-7125-42f2-a097-2fca162a3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c694d437-7125-42f2-a097-2fca162a3d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_62e1b3a5-148a-48b9-b275-a466b4558c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_62e1b3a5-148a-48b9-b275-a466b4558c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_662eae49-0d63-4f02-b6fc-c5c31acf1d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_662eae49-0d63-4f02-b6fc-c5c31acf1d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5192103f-a65e-4c8e-aba3-51e98cece77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5192103f-a65e-4c8e-aba3-51e98cece77c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd3f68e-0a8d-42db-bf9c-4dcd6808a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd3f68e-0a8d-42db-bf9c-4dcd6808a2a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09840104-f356-49b2-a7c3-b8b70cd8d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09840104-f356-49b2-a7c3-b8b70cd8d7c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_13e54aef-450a-470e-a4cc-add9d7db82bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_NetIncomeLoss_13e54aef-450a-470e-a4cc-add9d7db82bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb7d25cc-6adc-4856-a46d-6200364d6a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb7d25cc-6adc-4856-a46d-6200364d6a70" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c8c09bf2-f3fd-4bb3-82e1-fde5d6e8e639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_EarningsPerShareBasic_c8c09bf2-f3fd-4bb3-82e1-fde5d6e8e639" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6c66dbd3-a682-4815-81ab-dae82c208f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6c66dbd3-a682-4815-81ab-dae82c208f5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:to="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd892539-fa07-47eb-b203-9be332d0dc91_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:to="loc_srt_ProductsAndServicesDomain_bd892539-fa07-47eb-b203-9be332d0dc91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:to="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_09595220-4b36-4031-ada7-27f9cbcf50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:to="loc_us-gaap_ProductMember_09595220-4b36-4031-ada7-27f9cbcf50bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d4ad663a-9f92-47b0-8793-94b1c9936a36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:to="loc_us-gaap_EquityComponentDomain_d4ad663a-9f92-47b0-8793-94b1c9936a36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:to="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b208c344-2b58-4482-94cc-c4a862959cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:to="loc_us-gaap_RetainedEarningsMember_b208c344-2b58-4482-94cc-c4a862959cb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited" xlink:type="extended" id="ie32cd12fa1f944fab68205f5cc864442_CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_23b88e20-7219-40b3-9218-b05e76da15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_SharesOutstanding_23b88e20-7219-40b3-9218-b05e76da15b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c916b34b-c959-46e9-9057-4c56fe8a70b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockholdersEquity_c916b34b-c959-46e9-9057-4c56fe8a70b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_66faf74a-9813-47f9-bd3d-acf419fdb827" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_66faf74a-9813-47f9-bd3d-acf419fdb827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_060d3383-c7b0-483d-b226-0bdc91878b69" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_060d3383-c7b0-483d-b226-0bdc91878b69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fc09aaa-c822-45b8-8adb-7a0bc106c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fc09aaa-c822-45b8-8adb-7a0bc106c8cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ecc5cf3d-84cc-47ab-812c-7b714fbaf582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ecc5cf3d-84cc-47ab-812c-7b714fbaf582" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4ec9df29-c898-42d2-824e-66b198be330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4ec9df29-c898-42d2-824e-66b198be330e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_41b87635-3b92-4a62-a831-8317fc6073d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_41b87635-3b92-4a62-a831-8317fc6073d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_659ded22-2cb3-48f2-9929-32c41a26b8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_659ded22-2cb3-48f2-9929-32c41a26b8fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_e34d725a-d36b-402b-88ef-17874f8e326f" xlink:href="avtx-20230630.xsd#avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_e34d725a-d36b-402b-88ef-17874f8e326f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_546f31f9-e631-4354-b92e-122f89dae5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_546f31f9-e631-4354-b92e-122f89dae5b2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_11516682-1311-4b4a-8d41-c148cba85c40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_11516682-1311-4b4a-8d41-c148cba85c40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_54a39dd9-e95b-43d7-afa1-210cb98af0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_54a39dd9-e95b-43d7-afa1-210cb98af0ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3aa498c5-b978-46e3-9328-64f8cde25655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3aa498c5-b978-46e3-9328-64f8cde25655" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_784710fe-2552-4b69-889c-6386a8ad80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_NetIncomeLoss_784710fe-2552-4b69-889c-6386a8ad80ef" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_56288d71-dea2-47a9-ad15-a1a942c969e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_30db5b49-76ba-49db-8474-dbda912d531d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:to="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:to="loc_us-gaap_EquityComponentDomain_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:to="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aa437e50-bf5e-4652-b4ba-320eb637d59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_CommonStockMember_aa437e50-bf5e-4652-b4ba-320eb637d59b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a2414934-e53f-443d-82c0-59b575e6d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a2414934-e53f-443d-82c0-59b575e6d5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ef6d6cae-a516-477d-bbfb-588c37039764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_RetainedEarningsMember_ef6d6cae-a516-477d-bbfb-588c37039764" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/BusinessDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#BusinessDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/BusinessDetails" xlink:type="extended" id="i61fa84d2c4be439f84443a61ed9d8a2e_BusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fd03621-2853-4fe1-b764-0e59c8ab5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_NetIncomeLoss_5fd03621-2853-4fe1-b764-0e59c8ab5c99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_315c705a-b84e-40b4-8497-935beeeb1676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_315c705a-b84e-40b4-8497-935beeeb1676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eecc60ca-27a0-4592-b257-b1b14c303868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eecc60ca-27a0-4592-b257-b1b14c303868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b0a75e16-cea9-4e2b-9960-e0841499ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b0a75e16-cea9-4e2b-9960-e0841499ebd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_2eb01b73-dfb0-4971-a0a2-e0db4443e244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_RepaymentsOfDebt_2eb01b73-dfb0-4971-a0a2-e0db4443e244" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e0b78e98-964c-4c6f-aca3-d7f47683357e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e0b78e98-964c-4c6f-aca3-d7f47683357e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_e18cb1c7-bdd6-4336-af43-9a05a65c9123" xlink:href="avtx-20230630.xsd#avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_e18cb1c7-bdd6-4336-af43-9a05a65c9123" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f51d64a-6a87-4dd0-839d-e3c75235d7d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f51d64a-6a87-4dd0-839d-e3c75235d7d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_02a6b5dd-986a-46d6-9dba-f7419e2b4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:to="loc_us-gaap_LoansPayableMember_02a6b5dd-986a-46d6-9dba-f7419e2b4cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08231594-c0c7-42ef-865c-09e12fb442d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08231594-c0c7-42ef-865c-09e12fb442d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_e707691a-545a-4ac7-b115-82bbb6e0a2e4" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_e707691a-545a-4ac7-b115-82bbb6e0a2e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_345a4503-8c17-4fea-a4ac-5794d88cc1b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_345a4503-8c17-4fea-a4ac-5794d88cc1b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_464a31d2-f71f-4f49-9431-fa4a5171fb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:to="loc_us-gaap_SubsequentEventMember_464a31d2-f71f-4f49-9431-fa4a5171fb2f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/RevenueDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/RevenueDetails" xlink:type="extended" id="ia024d2ea5b0a4216aacaee9e3250314b_RevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a7b5d6bc-c716-4693-88b4-c5b3b031bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a7b5d6bc-c716-4693-88b4-c5b3b031bc58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e235d9e-c127-43b4-b8c0-126b288e1b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e235d9e-c127-43b4-b8c0-126b288e1b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_507e7daa-4579-48c1-952d-512007c589de" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_507e7daa-4579-48c1-952d-512007c589de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementInstallmentPayment_d743d1b9-6ddd-4e39-b0e4-33c999c5d0b7" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_avtx_LicenseAgreementInstallmentPayment_d743d1b9-6ddd-4e39-b0e4-33c999c5d0b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a6fd767c-2244-46ef-9280-3e8072860103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a6fd767c-2244-46ef-9280-3e8072860103" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_817ca233-5e10-43e9-8b67-0b8acdbaea71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_817ca233-5e10-43e9-8b67-0b8acdbaea71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_2efa961c-5a8e-495a-8485-fc439b9f2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_2efa961c-5a8e-495a-8485-fc439b9f2cf4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_514e8561-f38b-4c65-997c-d58a5f9d52b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_514e8561-f38b-4c65-997c-d58a5f9d52b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberOneMember_ba714350-726d-4c1c-bd9d-e325e5a86ddd" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:to="loc_avtx_MajorCustomerNumberOneMember_ba714350-726d-4c1c-bd9d-e325e5a86ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberTwoMember_c818151a-de1f-4a82-a4ac-2aa6d107e60b" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:to="loc_avtx_MajorCustomerNumberTwoMember_c818151a-de1f-4a82-a4ac-2aa6d107e60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ddeb51c7-db14-4434-aa4e-100aadb8b313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ddeb51c7-db14-4434-aa4e-100aadb8b313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6b899fc7-8826-4f82-8964-2957f2a94146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:to="loc_us-gaap_SalesRevenueNetMember_6b899fc7-8826-4f82-8964-2957f2a94146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f0c7ffb4-07db-49dd-a729-852b1cc5fccd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f0c7ffb4-07db-49dd-a729-852b1cc5fccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ee466010-5190-45e7-8a76-e29964a109c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ee466010-5190-45e7-8a76-e29964a109c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a60e6c91-a746-4a5e-aee1-99c313f45a1e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:to="loc_srt_ProductsAndServicesDomain_a60e6c91-a746-4a5e-aee1-99c313f45a1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:to="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_50b8346f-40a9-4dff-9d2a-7e2a3c9587a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:to="loc_us-gaap_ProductMember_50b8346f-40a9-4dff-9d2a-7e2a3c9587a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MillipredMember_88f33104-5c8a-4294-8aa6-00c95129662d" xlink:href="avtx-20230630.xsd#avtx_MillipredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:to="loc_avtx_MillipredMember_88f33104-5c8a-4294-8aa6-00c95129662d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e4ee84f8-0925-4042-a029-e46634164e48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:to="loc_us-gaap_RelatedPartyDomain_e4ee84f8-0925-4042-a029-e46634164e48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:to="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member_1770da7b-d515-4f72-8620-c739574378d1" xlink:href="avtx-20230630.xsd#avtx_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:to="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member_1770da7b-d515-4f72-8620-c739574378d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_74b00bc5-4549-4028-8f8f-2fe00937b0a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_74b00bc5-4549-4028-8f8f-2fe00937b0a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b3d982e6-945e-40a8-8f98-44290c0fe507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b3d982e6-945e-40a8-8f98-44290c0fe507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a5be499a-bf4a-4001-8cb0-28edf90f961c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a5be499a-bf4a-4001-8cb0-28edf90f961c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PediatricPortfolioMember_bf9197b9-2ed6-43d2-a8e0-ce73ef7544cc" xlink:href="avtx-20230630.xsd#avtx_PediatricPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:to="loc_avtx_PediatricPortfolioMember_bf9197b9-2ed6-43d2-a8e0-ce73ef7544cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_53b2cf79-d926-4c95-b9a4-65dc1768944f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_53b2cf79-d926-4c95-b9a4-65dc1768944f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2e4361dc-5707-4ce4-ba02-e92bf231d163" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:to="loc_srt_ScenarioForecastMember_2e4361dc-5707-4ce4-ba02-e92bf231d163" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="ia966e6d16d8d407382c975d562eb174e_NetLossPerShareScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fafd33a1-a460-4eb3-9667-219eee025608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fafd33a1-a460-4eb3-9667-219eee025608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_9f6b7562-0103-48f4-b852-73eef5064353" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_9f6b7562-0103-48f4-b852-73eef5064353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f83937a5-58e3-40ae-8ce1-86d9089b61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f83937a5-58e3-40ae-8ce1-86d9089b61eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_f4ef5867-0ca1-40a2-a983-74ba8239f338" xlink:href="avtx-20230630.xsd#avtx_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_f4ef5867-0ca1-40a2-a983-74ba8239f338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_WarrantCommonStockMember_584a64ff-063e-4726-95a5-dc8e0452296e" xlink:href="avtx-20230630.xsd#avtx_WarrantCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_WarrantCommonStockMember_584a64ff-063e-4726-95a5-dc8e0452296e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf830709-7030-4d88-9c2c-27baf88f07c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf830709-7030-4d88-9c2c-27baf88f07c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PreFundedWarrantsMember_c02c343d-d835-4756-9e11-6fb3ae3d4447" xlink:href="avtx-20230630.xsd#avtx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_PreFundedWarrantsMember_c02c343d-d835-4756-9e11-6fb3ae3d4447" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i984bb94e726448b89b1d885d5502e99d_FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_018c184b-3caa-4071-8e28-02afcdedd05f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_018c184b-3caa-4071-8e28-02afcdedd05f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_660234e6-be5a-4783-8031-4389afc53e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_DerivativeLiabilities_660234e6-be5a-4783-8031-4389afc53e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_c1f3eac3-d381-47d5-8844-5e320e0a475d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_c1f3eac3-d381-47d5-8844-5e320e0a475d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_afb9d74e-9346-4dda-8d88-72394d9ad499_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_afb9d74e-9346-4dda-8d88-72394d9ad499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1cdfccbe-8106-4d1e-ad1f-8993c4da11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1cdfccbe-8106-4d1e-ad1f-8993c4da11a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f566feac-7179-41b6-a97f-f8976683f714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f566feac-7179-41b6-a97f-f8976683f714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3afb75b3-2ae9-4f47-8f92-6fbe05abdb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3afb75b3-2ae9-4f47-8f92-6fbe05abdb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6965f4f8-237d-4d6f-8a9f-2fdfed678ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6965f4f8-237d-4d6f-8a9f-2fdfed678ef6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsScheduleofChangesintheFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails" xlink:type="extended" id="idd378ef28a3346938bccbb0b2f222542_FairValueMeasurementsScheduleofChangesintheFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e06d4d44-c3d5-4f4d-85bc-fdb7419a71f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e06d4d44-c3d5-4f4d-85bc-fdb7419a71f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_470daabb-02ec-45ef-a491-e6f6ee0e10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_470daabb-02ec-45ef-a491-e6f6ee0e10c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d70df108-f827-422c-b39f-46651aaad7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a1dfa21c-4487-49f8-890d-c4a77d46ae03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a1dfa21c-4487-49f8-890d-c4a77d46ae03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_52649cc5-4dc4-4d9c-9d1c-5cbef3be856b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_52649cc5-4dc4-4d9c-9d1c-5cbef3be856b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i12331fded04b424f8a39c4f0ddac4d82_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_88da0c44-78b3-42e6-b570-04cb1fa1a8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_LongTermDebtFairValue_88da0c44-78b3-42e6-b570-04cb1fa1a8c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_0eb41760-d460-478f-804b-a0c991e3afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_0eb41760-d460-478f-804b-a0c991e3afb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_353ca142-62a9-408d-81af-907b7fb0b220" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_353ca142-62a9-408d-81af-907b7fb0b220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_ff60910b-e616-4eb6-a0bd-252ead0cb607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_ff60910b-e616-4eb6-a0bd-252ead0cb607" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_a4146722-9fbc-49ed-aedb-9d2aa3513784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_a4146722-9fbc-49ed-aedb-9d2aa3513784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DerivativeLiabilityMeasurementInputTerm_c19e3836-fc6d-4a55-abd7-4dba704ebdfe" xlink:href="avtx-20230630.xsd#avtx_DerivativeLiabilityMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_avtx_DerivativeLiabilityMeasurementInputTerm_c19e3836-fc6d-4a55-abd7-4dba704ebdfe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_391e3735-7ad0-460e-a422-4aa467307eff_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_391e3735-7ad0-460e-a422-4aa467307eff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESTherapeuticsMember_1a61fc6b-9f1e-4f70-bc20-904b7210dfee" xlink:href="avtx-20230630.xsd#avtx_ESTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:to="loc_avtx_ESTherapeuticsMember_1a61fc6b-9f1e-4f70-bc20-904b7210dfee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3c88a937-41ff-4f42-88b0-9d4665eeddd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3c88a937-41ff-4f42-88b0-9d4665eeddd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_fe800ecd-cdd2-4ce2-b7b5-eb04f26bbd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_fe800ecd-cdd2-4ce2-b7b5-eb04f26bbd40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:href="avtx-20230630.xsd#avtx_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_84127756-4ade-4410-8550-22d68d2f4dcb_default" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:to="loc_avtx_MilestoneDomain_84127756-4ade-4410-8550-22d68d2f4dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:to="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneOneMember_041174b9-ccea-416d-9807-334f8882742b" xlink:href="avtx-20230630.xsd#avtx_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:to="loc_avtx_MilestoneOneMember_041174b9-ccea-416d-9807-334f8882742b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneTwoMember_5105000f-bf5e-42ee-b630-22113b9558a8" xlink:href="avtx-20230630.xsd#avtx_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:to="loc_avtx_MilestoneTwoMember_5105000f-bf5e-42ee-b630-22113b9558a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feea3f2f-2ef2-4c21-832c-fb17f3c259af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:to="loc_srt_ProductsAndServicesDomain_feea3f2f-2ef2-4c21-832c-fb17f3c259af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:to="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:href="avtx-20230630.xsd#avtx_AVTX501AndAVTX007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:to="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501Member_2f0b3343-72fc-4c86-b3fe-43612c0d1bdd" xlink:href="avtx-20230630.xsd#avtx_AVTX501Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:to="loc_avtx_AVTX501Member_2f0b3343-72fc-4c86-b3fe-43612c0d1bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX007Member_09cb9bbe-bc9e-4918-b1cf-1a2e1e4dc4c9" xlink:href="avtx-20230630.xsd#avtx_AVTX007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:to="loc_avtx_AVTX007Member_09cb9bbe-bc9e-4918-b1cf-1a2e1e4dc4c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX611Member_85527df8-e723-44d1-9f2c-3346b963a1d0" xlink:href="avtx-20230630.xsd#avtx_AVTX611Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:to="loc_avtx_AVTX611Member_85527df8-e723-44d1-9f2c-3346b963a1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputProbabilityOfSuccessMember_397dd245-379e-488b-9d7d-ae12deb29499" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_avtx_MeasurementInputProbabilityOfSuccessMember_397dd245-379e-488b-9d7d-ae12deb29499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d7955c07-36bf-4ba0-afeb-1ac7c176666e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d7955c07-36bf-4ba0-afeb-1ac7c176666e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputSalesForecastPeakMember_097262e6-0562-4dcd-8bbf-b47e60c5b931" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputSalesForecastPeakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_avtx_MeasurementInputSalesForecastPeakMember_097262e6-0562-4dcd-8bbf-b47e60c5b931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24057853-d340-4be8-82db-55d9d64777e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24057853-d340-4be8-82db-55d9d64777e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1bdcf3de-d680-4792-9e68-a20a189edce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1bdcf3de-d680-4792-9e68-a20a189edce8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i48eb23388f9d4aa1a7d4a82c94d9ad01_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_eb532c03-b155-46c2-806e-b6a20e583bdf" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfLeasedProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_eb532c03-b155-46c2-806e-b6a20e583bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_7c38c1e9-3a9c-4fe3-b382-d66a88a4bfa8" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_7c38c1e9-3a9c-4fe3-b382-d66a88a4bfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_f024f2ba-8046-40fb-88c6-aa1f3537a738" xlink:href="avtx-20230630.xsd#avtx_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_f024f2ba-8046-40fb-88c6-aa1f3537a738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod_4bdf2d1f-a39c-4263-bccc-b075c4ad6051" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod_4bdf2d1f-a39c-4263-bccc-b075c4ad6051" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1dbc5584-dd12-4c52-a06a-4d4fbdc8dada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1dbc5584-dd12-4c52-a06a-4d4fbdc8dada" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_f7f6db69-2d4e-41c1-a4ac-d4d8235074fe" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_f7f6db69-2d4e-41c1-a4ac-d4d8235074fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c338eae0-cb9e-49c9-a053-78761dc7b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c338eae0-cb9e-49c9-a053-78761dc7b34a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseAnnualBaseRent_44554bd7-cd63-4252-84b6-1358b8c37233" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseAnnualBaseRent_44554bd7-cd63-4252-84b6-1358b8c37233" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f1354535-64c2-4de2-a353-82134688d3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_OperatingLeaseExpense_f1354535-64c2-4de2-a353-82134688d3f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam_e690400a-274f-49d1-9f6e-154278469e0a" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam_e690400a-274f-49d1-9f6e-154278469e0a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_797ee677-536f-475e-b292-dcc4db612ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_797ee677-536f-475e-b292-dcc4db612ab2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d42215c2-b724-407d-959b-088f6b7ed49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:to="loc_us-gaap_BuildingMember_d42215c2-b724-407d-959b-088f6b7ed49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:to="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:to="loc_srt_SegmentGeographicalDomain_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:to="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_cca244b7-0050-47d6-ad24-6b73d92dc541" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:to="loc_stpr_MD_cca244b7-0050-47d6-ad24-6b73d92dc541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_ee77b1ef-479e-48b9-ae9b-2cc00e014498" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:to="loc_stpr_PA_ee77b1ef-479e-48b9-ae9b-2cc00e014498" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CostReductionPlanDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CostReductionPlanDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CostReductionPlanDetails" xlink:type="extended" id="i389f69fb61f142b189695f010bcb6fce_CostReductionPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a584e36-eaa9-47c1-9117-9bedf392edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_RestructuringCharges_3a584e36-eaa9-47c1-9117-9bedf392edd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_39eff4a9-522b-488a-bf87-cfda85cc6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_PaymentsForRestructuring_39eff4a9-522b-488a-bf87-cfda85cc6b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c24705f6-16fa-4881-a2f3-d01b4bacd987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c24705f6-16fa-4881-a2f3-d01b4bacd987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm_f749b84a-c584-478c-b661-126eac8c9d49" xlink:href="avtx-20230630.xsd#avtx_RestructuringAndRelatedActivitiesPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm_f749b84a-c584-478c-b661-126eac8c9d49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_428d3ff6-7dca-4603-8251-0a32c4463d95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_428d3ff6-7dca-4603-8251-0a32c4463d95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9f3c4506-22ff-4453-ae45-25ea84b83c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9f3c4506-22ff-4453-ae45-25ea84b83c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_b2527ed8-ffd6-4c5b-a025-a8db50bfa099" xlink:href="avtx-20230630.xsd#avtx_RestructuringPlanOneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:to="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_b2527ed8-ffd6-4c5b-a025-a8db50bfa099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SeparationFromCertainSection16OfficersMember_106fc4ca-32af-4433-98be-98b65e3d21b1" xlink:href="avtx-20230630.xsd#avtx_SeparationFromCertainSection16OfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:to="loc_avtx_SeparationFromCertainSection16OfficersMember_106fc4ca-32af-4433-98be-98b65e3d21b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_927aa3f5-500b-43c5-9bde-81f76a8d163a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_927aa3f5-500b-43c5-9bde-81f76a8d163a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5b58ff5-49b9-459d-a25d-0b3990ad1ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5b58ff5-49b9-459d-a25d-0b3990ad1ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bcc5bb86-ea5b-4725-a03c-efd89ae15653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bcc5bb86-ea5b-4725-a03c-efd89ae15653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5da744f-1fd9-46d0-9614-ddc08d42d5d0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:to="loc_srt_RangeMember_d5da744f-1fd9-46d0-9614-ddc08d42d5d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:to="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6921caf-008b-4ae6-bb91-6e155bd14357" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:to="loc_srt_MinimumMember_b6921caf-008b-4ae6-bb91-6e155bd14357" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0965c9ba-fc55-4828-9c19-e86637b6f062" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:to="loc_srt_MaximumMember_0965c9ba-fc55-4828-9c19-e86637b6f062" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="extended" id="id7a4885509d549ffb7af0435bd17d4ea_NotesPayableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_52bfc444-b9db-4d7b-bac8-1802e4871055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_52bfc444-b9db-4d7b-bac8-1802e4871055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b340eb5c-2304-44b8-8082-06d3a8d34ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b340eb5c-2304-44b8-8082-06d3a8d34ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_efdb6ce3-0522-44e3-be0b-30a11596cc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_RepaymentsOfDebt_efdb6ce3-0522-44e3-be0b-30a11596cc04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RepaymentOfDebtPrincipal_007a40d6-7f1a-47b5-85b0-ab823adff9a7" xlink:href="avtx-20230630.xsd#avtx_RepaymentOfDebtPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_RepaymentOfDebtPrincipal_007a40d6-7f1a-47b5-85b0-ab823adff9a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_975a0914-d926-483f-954f-629830ee45f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_975a0914-d926-483f-954f-629830ee45f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_28035f1c-e88d-47e3-b57e-d977a473306e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentTerm_28035f1c-e88d-47e3-b57e-d977a473306e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55743f2b-3693-410f-a7a0-9cb218b926d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55743f2b-3693-410f-a7a0-9cb218b926d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestRateFloor_452de0cd-7cb9-4a14-a59a-d21b765d4d66" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestRateFloor_452de0cd-7cb9-4a14-a59a-d21b765d4d66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod_39d30e39-bfd9-4163-9f55-f5b13e2ddc5e" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod_39d30e39-bfd9-4163-9f55-f5b13e2ddc5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_b339f6ad-3d5d-42dd-93f4-874bb0f485a9" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_b339f6ad-3d5d-42dd-93f4-874bb0f485a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_b1dd2bd4-d75f-4131-819c-fa77f0080626" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_b1dd2bd4-d75f-4131-819c-fa77f0080626" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_2c229e4d-ba4e-4c87-979d-a077fce8dc67" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_2c229e4d-ba4e-4c87-979d-a077fce8dc67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_0b66f2ee-e0c5-4f8c-8c8a-7af60dc9f0a4" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_0b66f2ee-e0c5-4f8c-8c8a-7af60dc9f0a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_300fa349-8deb-4f73-8f1e-01ff56756ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_300fa349-8deb-4f73-8f1e-01ff56756ddd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_6b8328e9-6b2d-44da-bbe4-b1c98dee5851" xlink:href="avtx-20230630.xsd#avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_6b8328e9-6b2d-44da-bbe4-b1c98dee5851" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b6fb41ce-45ee-48c7-8565-cd87f9ad745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_LongTermDebt_b6fb41ce-45ee-48c7-8565-cd87f9ad745d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36678d4d-17f8-4e7b-a53e-c5d18ad9be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36678d4d-17f8-4e7b-a53e-c5d18ad9be7c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fe6fba95-c998-477e-b75c-6f00f98aec28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fe6fba95-c998-477e-b75c-6f00f98aec28" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_085966c5-7970-4647-badf-6e25dced3976" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_085966c5-7970-4647-badf-6e25dced3976" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_e1bcb2ba-f3f4-4e35-958a-8752e0d4c610" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_e1bcb2ba-f3f4-4e35-958a-8752e0d4c610" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b2864ecb-1be2-48bb-bf53-218f25569c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b2864ecb-1be2-48bb-bf53-218f25569c9a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c769dce1-54b2-48bb-b118-10f9c3b6d835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c769dce1-54b2-48bb-b118-10f9c3b6d835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_098c8334-288a-451c-891b-5f87136f3575" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_098c8334-288a-451c-891b-5f87136f3575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91660e05-3c7c-4a32-811e-48de8d599acd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91660e05-3c7c-4a32-811e-48de8d599acd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b94402a0-4b44-4bd9-8ae4-3f7fdded3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:to="loc_us-gaap_LoansPayableMember_b94402a0-4b44-4bd9-8ae4-3f7fdded3a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_16be1208-7ed4-4323-b3ba-7ea475eb200b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:to="loc_us-gaap_VariableRateDomain_16be1208-7ed4-4323-b3ba-7ea475eb200b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:to="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_4e0b1f23-0e2c-4d1d-90a6-aba148eccb37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:to="loc_us-gaap_PrimeRateMember_4e0b1f23-0e2c-4d1d-90a6-aba148eccb37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_66a7c8d8-3f3f-462d-928b-cd90cb9abc33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_66a7c8d8-3f3f-462d-928b-cd90cb9abc33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bcd6b678-59d6-494f-b43a-b6205e6789c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:to="loc_us-gaap_WarrantMember_bcd6b678-59d6-494f-b43a-b6205e6789c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f385a2a-bf5d-42e8-a568-5870a7641851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:to="loc_us-gaap_SubsequentEventMember_2f385a2a-bf5d-42e8-a568-5870a7641851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="extended" id="i344e36f3b5634e40984afbb34d23a72e_NotesPayableScheduleofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_092e059b-d38b-4fc4-90d4-427a23bccdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_092e059b-d38b-4fc4-90d4-427a23bccdb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b3a8e9bf-b0f2-498a-8239-263b41c29e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b3a8e9bf-b0f2-498a-8239-263b41c29e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ad1e996b-6648-4078-992f-62bf7dea3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebt_ad1e996b-6648-4078-992f-62bf7dea3ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_520a8e57-5141-4c01-861d-dee5202560ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebtCurrent_520a8e57-5141-4c01-861d-dee5202560ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3ba4ece5-6bbd-45d0-b7fa-d6dc2baa6c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3ba4ece5-6bbd-45d0-b7fa-d6dc2baa6c78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_61ff22d2-989a-444d-a9e4-ecf9c74c2627" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_61ff22d2-989a-444d-a9e4-ecf9c74c2627" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_55d9b4b9-e9e6-4274-bb03-55fcd4a65bed" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_55d9b4b9-e9e6-4274-bb03-55fcd4a65bed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db9213ef-e836-447d-916a-8c37d9373ecc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db9213ef-e836-447d-916a-8c37d9373ecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:to="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_InitialNoteMember_f7267eb9-8e41-4cab-90ef-43071bace1ca" xlink:href="avtx-20230630.xsd#avtx_InitialNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_InitialNoteMember_f7267eb9-8e41-4cab-90ef-43071bace1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SecondNoteMember_a912c0de-16ec-40eb-b5f4-cc19320d7721" xlink:href="avtx-20230630.xsd#avtx_SecondNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_SecondNoteMember_a912c0de-16ec-40eb-b5f4-cc19320d7721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ThirdNoteMember_c39f3c6e-abd6-4c20-8ef8-92cf0682f9df" xlink:href="avtx-20230630.xsd#avtx_ThirdNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_ThirdNoteMember_c39f3c6e-abd6-4c20-8ef8-92cf0682f9df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:to="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_c6f5059d-3975-4399-887e-a5243cfd1920" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_c6f5059d-3975-4399-887e-a5243cfd1920" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="extended" id="icf8e9fcc1e0446d3a2cb08da10baf2b6_NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_963e47d9-52d1-4770-8e63-7a33353cd17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_963e47d9-52d1-4770-8e63-7a33353cd17b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_452be913-7f2d-4c75-83a7-b42844e3daff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_452be913-7f2d-4c75-83a7-b42844e3daff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f8558e-fac4-411d-ae34-435ba8aee5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f8558e-fac4-411d-ae34-435ba8aee5c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a24984cd-d17d-4eda-8033-7b0aac949d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a24984cd-d17d-4eda-8033-7b0aac949d3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fdb62c78-b1cb-4f65-aed9-1eb7dd9424fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fdb62c78-b1cb-4f65-aed9-1eb7dd9424fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_3251ffdc-3c3a-4d32-bd25-b5cacec289ff" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_3251ffdc-3c3a-4d32-bd25-b5cacec289ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_d974713a-d7d6-4135-ac12-752948309d9e" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_d974713a-d7d6-4135-ac12-752948309d9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6dd44d0-768d-4983-82f7-b3c61cbbd116_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6dd44d0-768d-4983-82f7-b3c61cbbd116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_5c12925a-2e46-4f65-be79-d4753d3e64b4" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_5c12925a-2e46-4f65-be79-d4753d3e64b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7834fd7b-e83b-416d-a0f6-3b0401e79b1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7834fd7b-e83b-416d-a0f6-3b0401e79b1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4aa0f9bb-bc54-4727-8f91-560f81bc0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:to="loc_us-gaap_LoansPayableMember_4aa0f9bb-bc54-4727-8f91-560f81bc0a15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails" xlink:type="extended" id="ibbec8888dcf1439ba481f663948cd71c_CapitalStructureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NumberOfClassOfStockAuthorized_4696536c-468b-401d-a8e8-4ad476c5b786" xlink:href="avtx-20230630.xsd#avtx_NumberOfClassOfStockAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_NumberOfClassOfStockAuthorized_4696536c-468b-401d-a8e8-4ad476c5b786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CapitalStockSharesAuthorized_9482ca6f-d260-474a-b146-068b3fb4721a" xlink:href="avtx-20230630.xsd#avtx_CapitalStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_CapitalStockSharesAuthorized_9482ca6f-d260-474a-b146-068b3fb4721a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_00301585-bfdc-422d-8ea7-e68f07829c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_00301585-bfdc-422d-8ea7-e68f07829c71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eb9342d5-6f29-4e39-ab41-579fbe88b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eb9342d5-6f29-4e39-ab41-579fbe88b21e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_81f978fe-2ab6-4ec1-b402-8e4a2a3d5dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_81f978fe-2ab6-4ec1-b402-8e4a2a3d5dfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e22c1ba6-6823-40f8-8590-b40e328c2332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e22c1ba6-6823-40f8-8590-b40e328c2332" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a79531bb-1d53-4f67-89f6-295f03f04fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a79531bb-1d53-4f67-89f6-295f03f04fa4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_807a8ad3-bb9b-445a-899b-646fda9d0c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_807a8ad3-bb9b-445a-899b-646fda9d0c5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3a212405-7d4a-47cc-8674-5e4b92e481a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3a212405-7d4a-47cc-8674-5e4b92e481a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_2030ad0e-f619-4b2f-ad72-5a50d070cf64" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_2030ad0e-f619-4b2f-ad72-5a50d070cf64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_63555a22-5b69-412e-bbb2-6b9bba01d8f3" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_63555a22-5b69-412e-bbb2-6b9bba01d8f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_0f50ecf7-aee6-45ac-b15d-2e0b0b540d15" xlink:href="avtx-20230630.xsd#avtx_SaleOfStockMaximumAmountOfSharesToBeSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_0f50ecf7-aee6-45ac-b15d-2e0b0b540d15" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f217778a-5497-444e-ac9c-a82c14ea856c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f217778a-5497-444e-ac9c-a82c14ea856c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_32f090db-a2d1-4602-8260-8a9ec0d5fa41" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_32f090db-a2d1-4602-8260-8a9ec0d5fa41" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_09735550-94f2-43ff-9741-088e0f0f642c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_09735550-94f2-43ff-9741-088e0f0f642c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_5b2436e1-2c74-4b36-832f-0cbec44467ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_5b2436e1-2c74-4b36-832f-0cbec44467ce" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b18953-e0c0-417c-812a-9f3039297849_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20b18953-e0c0-417c-812a-9f3039297849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_UnderwrittenPublicOfferingMember_3b6a656f-0745-47c4-87b1-0bcbfc9e14ce" xlink:href="avtx-20230630.xsd#avtx_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_UnderwrittenPublicOfferingMember_3b6a656f-0745-47c4-87b1-0bcbfc9e14ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ATMAgreementMember_c32002a0-b2d7-4106-a981-f30e144a79a8" xlink:href="avtx-20230630.xsd#avtx_ATMAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_ATMAgreementMember_c32002a0-b2d7-4106-a981-f30e144a79a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ExchangeAgreementMember_72f3f023-da8c-41bd-937f-892045e1f981" xlink:href="avtx-20230630.xsd#avtx_ExchangeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_ExchangeAgreementMember_72f3f023-da8c-41bd-937f-892045e1f981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_72ae84d5-1315-45fc-b578-4fa3df5795eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_72ae84d5-1315-45fc-b578-4fa3df5795eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f71cb84-cab7-4c16-add0-c826c50cbefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:to="loc_us-gaap_WarrantMember_6f71cb84-cab7-4c16-add0-c826c50cbefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6143b3c-648f-488e-9530-639437971bef_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6143b3c-648f-488e-9530-639437971bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ArmisticeMember_17f3807e-a007-4105-aa19-58a91a863b4b" xlink:href="avtx-20230630.xsd#avtx_ArmisticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:to="loc_avtx_ArmisticeMember_17f3807e-a007-4105-aa19-58a91a863b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_VenrockHealthcareCapitalPartnersMember_b5df658d-8df8-4a82-8450-4cc45820c130" xlink:href="avtx-20230630.xsd#avtx_VenrockHealthcareCapitalPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:to="loc_avtx_VenrockHealthcareCapitalPartnersMember_b5df658d-8df8-4a82-8450-4cc45820c130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_07f7549e-23f4-4fab-9128-1e79cadcce45_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:to="loc_dei_EntityDomain_07f7549e-23f4-4fab-9128-1e79cadcce45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:to="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NantahalaCapitalManagementLLCMember_907096cf-5e5d-45db-8735-7a2ce7cb6b88" xlink:href="avtx-20230630.xsd#avtx_NantahalaCapitalManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:to="loc_avtx_NantahalaCapitalManagementLLCMember_907096cf-5e5d-45db-8735-7a2ce7cb6b88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba40b29c-ef78-440a-a683-34d0a6b40887_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:to="loc_srt_RangeMember_ba40b29c-ef78-440a-a683-34d0a6b40887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:to="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_374d742a-24f5-4f28-8478-d2ed5fee9e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:to="loc_srt_MinimumMember_374d742a-24f5-4f28-8478-d2ed5fee9e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73919739-499d-4ff8-be75-149505df032e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:to="loc_srt_MaximumMember_73919739-499d-4ff8-be75-149505df032e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_94cae510-2cd9-4aef-8ad0-08382e7ef133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:to="loc_us-gaap_SubsequentEventMember_94cae510-2cd9-4aef-8ad0-08382e7ef133" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails" xlink:type="extended" id="i34d0a1d5c467425288536e401cf57936_CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9ec9ab95-0122-4e89-819c-5f1d3edb710d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9ec9ab95-0122-4e89-819c-5f1d3edb710d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8a9a1c1-a105-4afc-9c67-fffc1ffe079f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8a9a1c1-a105-4afc-9c67-fffc1ffe079f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_40321767-8331-4aa4-ba82-14088aced26e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_40321767-8331-4aa4-ba82-14088aced26e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_1d1ff90d-b890-4c91-a7c1-c56a8a633294" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_1d1ff90d-b890-4c91-a7c1-c56a8a633294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpirationMember_561dbaef-7ad8-4b21-8007-089c93fe7629" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsNoExpirationMember_561dbaef-7ad8-4b21-8007-089c93fe7629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationJune2031Member_cf1d707b-55fe-4307-ab1f-6194a633c150" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationJune2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationJune2031Member_cf1d707b-55fe-4307-ab1f-6194a633c150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member_e40bb830-0af2-46da-8e0b-622b9bd63326" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationFebruary2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member_e40bb830-0af2-46da-8e0b-622b9bd63326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpiration2Member_549c36bd-0953-466c-b9c7-fdd894bdf9f8" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpiration2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsNoExpiration2Member_549c36bd-0953-466c-b9c7-fdd894bdf9f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_314caa5b-e76f-49be-9a50-728f19c6976f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:to="loc_us-gaap_ClassOfStockDomain_314caa5b-e76f-49be-9a50-728f19c6976f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:to="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0ca06691-8140-4a42-bbf9-402bc31fc97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:to="loc_us-gaap_CommonClassAMember_0ca06691-8140-4a42-bbf9-402bc31fc97f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ia2aeb8ee60294587a3652be83a6a5e79_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_ab23d0f0-a440-42f0-bbfe-7c0bf47c4d03" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_ab23d0f0-a440-42f0-bbfe-7c0bf47c4d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_c8bf1815-5abb-4739-a65f-f676b84a9b42" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_c8bf1815-5abb-4739-a65f-f676b84a9b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d8470819-4471-4008-bfc1-31671a6112ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d8470819-4471-4008-bfc1-31671a6112ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d9b9d9d-d773-4dc0-b005-a84b47169a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d9b9d9d-d773-4dc0-b005-a84b47169a72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51750b51-70a6-4234-9dec-a25039c717ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51750b51-70a6-4234-9dec-a25039c717ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1b3acab-7de3-430e-81a0-7e22472dd8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1b3acab-7de3-430e-81a0-7e22472dd8b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fd64782d-ebf4-4224-a375-96cb5cb0d3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fd64782d-ebf4-4224-a375-96cb5cb0d3a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7dd94dfb-975b-4ebc-9cb0-93b4ec6e256c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7dd94dfb-975b-4ebc-9cb0-93b4ec6e256c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4dba8baa-9b4d-419d-b39b-25162c957fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4dba8baa-9b4d-419d-b39b-25162c957fd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f516c782-7898-44d0-b171-8aa6edd06074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f516c782-7898-44d0-b171-8aa6edd06074" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d419a13b-97f6-472f-a230-d058a1431276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d419a13b-97f6-472f-a230-d058a1431276" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8d211a4b-b323-401f-8788-1da18bdcbd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8d211a4b-b323-401f-8788-1da18bdcbd62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bf67d6e-b0cd-4ff1-9fcd-4d17ea0318c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bf67d6e-b0cd-4ff1-9fcd-4d17ea0318c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20eea26c-fa36-4770-b73d-b75b7b0d501a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20eea26c-fa36-4770-b73d-b75b7b0d501a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c3ce6e9-f34f-47cb-9544-c3b7dd5a31bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c3ce6e9-f34f-47cb-9544-c3b7dd5a31bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66214a93-91ec-4214-8879-881ad5117346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66214a93-91ec-4214-8879-881ad5117346" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89dfc0f2-a404-428b-971b-4f6eb85ca41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89dfc0f2-a404-428b-971b-4f6eb85ca41f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8b52cf2-3bf7-43a6-89dd-84e932081cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8b52cf2-3bf7-43a6-89dd-84e932081cb4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca008a37-6d61-4d6a-8c6c-f6ae6e659167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca008a37-6d61-4d6a-8c6c-f6ae6e659167" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_81a914f8-5a84-4a07-af1e-b3ccb58a34e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_81a914f8-5a84-4a07-af1e-b3ccb58a34e2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a7b9fef8-4042-4ea6-b760-02f74124f718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a7b9fef8-4042-4ea6-b760-02f74124f718" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_43560492-9a11-40ca-8f8d-a409a4ad2458" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_43560492-9a11-40ca-8f8d-a409a4ad2458" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44ffbc20-bfcb-43e6-bd82-56329b463503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44ffbc20-bfcb-43e6-bd82-56329b463503" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_c307e902-0265-4fa5-b568-4fdf714f38df" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_c307e902-0265-4fa5-b568-4fdf714f38df" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_92c756ba-1d46-4dd2-ba8a-aae46e6da4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_92c756ba-1d46-4dd2-ba8a-aae46e6da4d7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fb76fe7-271a-421c-914e-37d4539ac3ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:to="loc_us-gaap_PlanNameDomain_2fb76fe7-271a-421c-914e-37d4539ac3ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:to="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_The2016PlanMember_388737ba-4108-4f2c-81aa-547155e0c8cb" xlink:href="avtx-20230630.xsd#avtx_The2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:to="loc_avtx_The2016PlanMember_388737ba-4108-4f2c-81aa-547155e0c8cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bcd8c7-cc0b-43d0-844e-fd07feb79678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bcd8c7-cc0b-43d0-844e-fd07feb79678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_704b0534-7077-4dfb-9e41-aba57c1869bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_us-gaap_StockOptionMember_704b0534-7077-4dfb-9e41-aba57c1869bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_1ac4e865-3af9-4196-be00-87e05f84f346" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_ServiceBasedOptionsMember_1ac4e865-3af9-4196-be00-87e05f84f346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember_86f99186-c008-4606-914c-6d472b103163" xlink:href="avtx-20230630.xsd#avtx_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember_86f99186-c008-4606-914c-6d472b103163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeStockPurchasePlanESPPMember_8da39538-be98-476e-804a-bf95290cdbe8" xlink:href="avtx-20230630.xsd#avtx_EmployeeStockPurchasePlanESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_EmployeeStockPurchasePlanESPPMember_8da39538-be98-476e-804a-bf95290cdbe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:to="loc_srt_RangeMember_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:to="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_072c8882-1b57-47e4-923f-14802932cd75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:to="loc_srt_MaximumMember_072c8882-1b57-47e4-923f-14802932cd75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7aacfd8-ee6b-48de-8e78-4f70eddf9b4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:to="loc_srt_MinimumMember_b7aacfd8-ee6b-48de-8e78-4f70eddf9b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_bad21a74-49a2-4702-8823-726de220eeea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:to="loc_us-gaap_GranteeStatusDomain_bad21a74-49a2-4702-8823-726de220eeea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:to="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_9152d595-2291-4053-942d-3dd73db69d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_9152d595-2291-4053-942d-3dd73db69d0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_11289b55-5594-4ae0-a408-c5b7801115c7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_11289b55-5594-4ae0-a408-c5b7801115c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_be9ad5d4-9c63-4655-8451-831f1f31cbd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:to="loc_srt_DirectorMember_be9ad5d4-9c63-4655-8451-831f1f31cbd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SpecialAdvisorToTheBoardMember_87cdb03e-d6f4-47b0-8c4e-4607d8f51e72" xlink:href="avtx-20230630.xsd#avtx_SpecialAdvisorToTheBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:to="loc_avtx_SpecialAdvisorToTheBoardMember_87cdb03e-d6f4-47b0-8c4e-4607d8f51e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ef074a2-6cf3-4130-94e1-8fd4152d4010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ef074a2-6cf3-4130-94e1-8fd4152d4010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeStockPurchasePlanESPPMember_204159f4-19fd-4d49-8e00-95632ee2b0ca" xlink:href="avtx-20230630.xsd#avtx_EmployeeStockPurchasePlanESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:to="loc_avtx_EmployeeStockPurchasePlanESPPMember_204159f4-19fd-4d49-8e00-95632ee2b0ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="iea9fd1b993d245ee8a5345603cfdcc01_StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cc9c51db-22dc-49ee-ba23-cc75c1df3581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cc9c51db-22dc-49ee-ba23-cc75c1df3581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_896bf931-d973-4178-9e6f-85a171932b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_896bf931-d973-4178-9e6f-85a171932b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_20481c7f-930b-4d3c-89d3-f2db64eb577d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_20481c7f-930b-4d3c-89d3-f2db64eb577d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails" xlink:type="extended" id="i634ca5e485464aed80e5451915dae954_StockBasedCompensationScheduleofOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_08fba273-f7af-44a4-8d58-32e65310975b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_08fba273-f7af-44a4-8d58-32e65310975b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_972869f1-c71b-405f-93c0-81a4e93e2c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_972869f1-c71b-405f-93c0-81a4e93e2c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_be358cb7-4e83-4862-825f-28361d79c696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_be358cb7-4e83-4862-825f-28361d79c696" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77f97193-abf8-41cd-b457-3665519cc714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb937caa-2d91-4a3d-9403-932f6dce6fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb937caa-2d91-4a3d-9403-932f6dce6fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3459320a-3746-4a01-ac79-87aa596ee4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3459320a-3746-4a01-ac79-87aa596ee4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d29fb390-7c5e-4f83-8fec-45328df429e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d29fb390-7c5e-4f83-8fec-45328df429e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_95babb56-c8c5-4b16-ac16-96789401acef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_95babb56-c8c5-4b16-ac16-96789401acef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17544097-cc2c-4680-80e6-c2f7c6685001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07e2b935-ef3a-450b-9169-e6d49b9bf088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07e2b935-ef3a-450b-9169-e6d49b9bf088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2419e78d-122f-4e02-8882-e4277218c775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2419e78d-122f-4e02-8882-e4277218c775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39c662a6-5396-4dcc-acb8-5317bf3392c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39c662a6-5396-4dcc-acb8-5317bf3392c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_0378667b-c5e7-4b54-aea1-dddddce862c5" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_0378667b-c5e7-4b54-aea1-dddddce862c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a0c3e3a1-347c-4573-85e9-f65efc0a9509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_5f75dad5-4a08-4945-8c55-6303632704b4" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_5f75dad5-4a08-4945-8c55-6303632704b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1e835bc-0a06-4db9-a6e4-138e146e5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1e835bc-0a06-4db9-a6e4-138e146e5cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc6f2ec8-b93c-4a30-accf-406e99173d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc6f2ec8-b93c-4a30-accf-406e99173d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:to="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc7d96af-209f-4773-8108-615d477129ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc7d96af-209f-4773-8108-615d477129ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_096a57b4-c177-4085-8d9b-ba5847cdf3f4" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:to="loc_avtx_ServiceBasedOptionsMember_096a57b4-c177-4085-8d9b-ba5847cdf3f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails" xlink:type="extended" id="i753dba45f10a4668a35a5d35f4371124_StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_99f123bc-cf78-4341-9029-ad29ff0b50e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_99f123bc-cf78-4341-9029-ad29ff0b50e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a1545830-7e06-4526-a340-57c04ff22ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a1545830-7e06-4526-a340-57c04ff22ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331d059b-2b7d-4a6c-aeff-fca23758eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331d059b-2b7d-4a6c-aeff-fca23758eb9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1cd82190-5c7d-4fc6-963f-08b59c6b8902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1cd82190-5c7d-4fc6-963f-08b59c6b8902" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:to="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b843bd69-f836-4e98-a4d0-db258e5273a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b843bd69-f836-4e98-a4d0-db258e5273a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_d21ab4d7-2945-4267-aaf3-8a77c9afa74e" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:to="loc_avtx_ServiceBasedOptionsMember_d21ab4d7-2945-4267-aaf3-8a77c9afa74e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:to="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f312bad-ba68-4587-95f5-9c694958bec5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:to="loc_srt_RangeMember_6f312bad-ba68-4587-95f5-9c694958bec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:to="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5f3499e-e67b-4cfa-b6d3-87a2851d32f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:to="loc_srt_MinimumMember_c5f3499e-e67b-4cfa-b6d3-87a2851d32f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f5c025b-5917-455c-b09b-9ed7467bbc72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:to="loc_srt_MaximumMember_2f5c025b-5917-455c-b09b-9ed7467bbc72" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ib62082bc051e46fcb931c468c3d4ca5b_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_1ea4edbd-a516-46cc-a6dc-42e8ee12a3a0" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_1ea4edbd-a516-46cc-a6dc-42e8ee12a3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_90d5d783-da07-40c7-8f32-74e094cd7279" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_90d5d783-da07-40c7-8f32-74e094cd7279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_87e0af6a-7f58-4862-8465-2a3150f4cae0" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_87e0af6a-7f58-4862-8465-2a3150f4cae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14e67041-4e3c-4280-ae32-263b5abcdf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14e67041-4e3c-4280-ae32-263b5abcdf7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_ceb18ae6-41e2-4822-969c-c51f0d048d9d" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_ceb18ae6-41e2-4822-969c-c51f0d048d9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_0cbc9cbe-23a4-4f52-a2ef-5c0b9b40b7a4" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPatentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_0cbc9cbe-23a4-4f52-a2ef-5c0b9b40b7a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f191f738-7972-45c5-bbdb-198ad352b1e4" xlink:href="avtx-20230630.xsd#avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f191f738-7972-45c5-bbdb-198ad352b1e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_25a1685b-7887-4b43-81d3-96e6666ea424" xlink:href="avtx-20230630.xsd#avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_25a1685b-7887-4b43-81d3-96e6666ea424" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_9258888d-0d40-44c4-b049-6eb451d379ba" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_9258888d-0d40-44c4-b049-6eb451d379ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f3b12fc9-f764-4663-8dcf-2eaffcf57a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f3b12fc9-f764-4663-8dcf-2eaffcf57a37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_ec75b0f6-97a3-4ecf-834a-b80ddd386cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_ec75b0f6-97a3-4ecf-834a-b80ddd386cde" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_7bb3ad90-e7b3-483b-a61e-6dc84e8974ca" xlink:href="avtx-20230630.xsd#avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_7bb3ad90-e7b3-483b-a61e-6dc84e8974ca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_9e7f19aa-ecbb-48f2-9f07-5ae10866eab6" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionNumberOfPreclinicalTherapies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_9e7f19aa-ecbb-48f2-9f07-5ae10866eab6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPaymentReceived_13eff1d3-b4bb-4935-b624-8553de487750" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementPaymentReceived_13eff1d3-b4bb-4935-b624-8553de487750" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_736c260f-035f-45a8-b9a1-8a804c7815ed" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_736c260f-035f-45a8-b9a1-8a804c7815ed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_4e7164b5-e939-4649-bef6-893c757c98e5" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_4e7164b5-e939-4649-bef6-893c757c98e5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_74bff692-d04a-41df-b0be-7aba72347fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_74bff692-d04a-41df-b0be-7aba72347fd3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_d8d10410-3ea3-43a6-a1e0-7d93e95fafb7" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_d8d10410-3ea3-43a6-a1e0-7d93e95fafb7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_622dddc1-b5d1-461a-839a-0c613bfab71e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:to="loc_srt_ProductsAndServicesDomain_622dddc1-b5d1-461a-839a-0c613bfab71e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:to="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX301OutLicenseMember_4fc912a3-1a5b-46b3-aab0-1a8ffaa45ea0" xlink:href="avtx-20230630.xsd#avtx_AVTX301OutLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX301OutLicenseMember_4fc912a3-1a5b-46b3-aab0-1a8ffaa45ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX406LicenseAssignmentMember_e79f7934-88fe-41a8-81d5-255b961999b8" xlink:href="avtx-20230630.xsd#avtx_AVTX406LicenseAssignmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX406LicenseAssignmentMember_e79f7934-88fe-41a8-81d5-255b961999b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX801AVTX802AndAVTX803Member_251fc670-6446-4372-b13e-597576919655" xlink:href="avtx-20230630.xsd#avtx_AVTX801AVTX802AndAVTX803Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX801AVTX802AndAVTX803Member_251fc670-6446-4372-b13e-597576919655" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX913Member_94609668-c7dd-4de2-8575-6ed7b4c07f5e" xlink:href="avtx-20230630.xsd#avtx_AVTX913Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX913Member_94609668-c7dd-4de2-8575-6ed7b4c07f5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eece90d0-1c69-491d-bb7c-280694d57609_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eece90d0-1c69-491d-bb7c-280694d57609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KyowaKirinCoLtdKKCMember_0d82385e-ace1-4565-9826-09c47388d974" xlink:href="avtx-20230630.xsd#avtx_KyowaKirinCoLtdKKCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_KyowaKirinCoLtdKKCMember_0d82385e-ace1-4565-9826-09c47388d974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AstellasPharmaIncAstellasMember_eb082512-3408-43b8-b4d9-12334be38fbb" xlink:href="avtx-20230630.xsd#avtx_AstellasPharmaIncAstellasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_AstellasPharmaIncAstellasMember_eb082512-3408-43b8-b4d9-12334be38fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_a73de411-7990-497a-b429-f347ff4c0d43" xlink:href="avtx-20230630.xsd#avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_a73de411-7990-497a-b429-f347ff4c0d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AltoMember_24284f00-e736-46a1-9ba6-db8cdd1affc7" xlink:href="avtx-20230630.xsd#avtx_AltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_AltoMember_24284f00-e736-46a1-9ba6-db8cdd1affc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESMember_784b2502-b32c-4a98-9217-546fc95eb394" xlink:href="avtx-20230630.xsd#avtx_ESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_ESMember_784b2502-b32c-4a98-9217-546fc95eb394" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TRISPharmaMember_25c98a55-0947-43a9-9848-aa143b96645b" xlink:href="avtx-20230630.xsd#avtx_TRISPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_TRISPharmaMember_25c98a55-0947-43a9-9848-aa143b96645b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dca4293f-27a9-4678-9248-e691378d1df4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dca4293f-27a9-4678-9248-e691378d1df4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX002KKCLicenseAgreementMember_f239f279-20a5-47c6-a41e-a7c5e4c797b5" xlink:href="avtx-20230630.xsd#avtx_AVTX002KKCLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX002KKCLicenseAgreementMember_f239f279-20a5-47c6-a41e-a7c5e4c797b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX006AstellasLicenseAgreementMember_47837fe0-fd07-481a-b969-85f5e22a9541" xlink:href="avtx-20230630.xsd#avtx_AVTX006AstellasLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX006AstellasLicenseAgreementMember_47837fe0-fd07-481a-b969-85f5e22a9541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_80df3fba-26bf-4321-82d8-3faee44ed8b6" xlink:href="avtx-20230630.xsd#avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_80df3fba-26bf-4321-82d8-3faee44ed8b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KarbinalAgreementMember_7bcb9ba1-f75b-4f0f-8929-b751477e06cc" xlink:href="avtx-20230630.xsd#avtx_KarbinalAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_KarbinalAgreementMember_7bcb9ba1-f75b-4f0f-8929-b751477e06cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:href="avtx-20230630.xsd#avtx_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_cc00c54d-d52d-4910-9434-318ce5072ff1_default" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:to="loc_avtx_MilestoneDomain_cc00c54d-d52d-4910-9434-318ce5072ff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:to="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneOneMember_b8874a5e-393d-41a8-9804-2e6ea93ae708" xlink:href="avtx-20230630.xsd#avtx_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneOneMember_b8874a5e-393d-41a8-9804-2e6ea93ae708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneTwoMember_dde6c729-d749-4976-bcfd-8ed865fd9a00" xlink:href="avtx-20230630.xsd#avtx_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneTwoMember_dde6c729-d749-4976-bcfd-8ed865fd9a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneThreeMember_b79a2c25-4bbe-46d6-b5da-b5cdf29a5ed1" xlink:href="avtx-20230630.xsd#avtx_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneThreeMember_b79a2c25-4bbe-46d6-b5da-b5cdf29a5ed1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_086bae2f-3200-4798-897c-c028def979c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_086bae2f-3200-4798-897c-c028def979c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AeviGenomicMedicineIncMember_e0346d22-9d2a-42a7-bdee-00baf927a10c" xlink:href="avtx-20230630.xsd#avtx_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:to="loc_avtx_AeviGenomicMedicineIncMember_e0346d22-9d2a-42a7-bdee-00baf927a10c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IchorionMember_d910636e-95c8-4568-8d05-1aa45dc8b2f5" xlink:href="avtx-20230630.xsd#avtx_IchorionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:to="loc_avtx_IchorionMember_d910636e-95c8-4568-8d05-1aa45dc8b2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0806e7cf-12f9-465e-a197-bb85aeea17f7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:to="loc_dei_EntityDomain_0806e7cf-12f9-465e-a197-bb85aeea17f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:to="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AeviGenomicMedicineIncMember_f4702462-2b38-4619-ab08-6e004c724f87" xlink:href="avtx-20230630.xsd#avtx_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:to="loc_avtx_AeviGenomicMedicineIncMember_f4702462-2b38-4619-ab08-6e004c724f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a1f40e54-41b0-4547-a617-c9da985b3ce3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a1f40e54-41b0-4547-a617-c9da985b3ce3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5a41d4f1-8ec0-40b6-8a6c-af3f567b9fca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:to="loc_srt_ScenarioForecastMember_5a41d4f1-8ec0-40b6-8a6c-af3f567b9fca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bb271169-b703-4257-b428-ab5b819fe5c6" xlink:href="avtx-20230630.xsd#avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bb271169-b703-4257-b428-ab5b819fe5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>avtx-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_270dc05d-aae0-4ee3-95f9-ed386fb1cd1a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a6915d82-f43e-4653-92fc-c334c2fa21c9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e4162fe6-bb74-4042-a75c-ad0104f41b7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_553c59de-e209-4ede-89e3-f67ee6a7f307_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares available (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AccruedResearchAndDevelopment_54c39377-6f76-441d-801a-eae028247644_terseLabel_en-US" xlink:label="lab_avtx_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_avtx_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_avtx_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development</link:label>
    <link:label id="lab_avtx_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_avtx_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedResearchAndDevelopment" xlink:href="avtx-20230630.xsd#avtx_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AccruedResearchAndDevelopment" xlink:to="lab_avtx_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_74f85f50-8ebf-49ad-9078-adb1ba680d1c_terseLabel_en-US" xlink:label="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the components of accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="avtx-20230630.xsd#avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a75c369e-26ac-4c7a-87e3-d65dc2003cf5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_207cb282-e585-43ee-8a09-292a46c5c344_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ad805796-84b2-47bd-8c6e-533d7c8e2485_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial valuation of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1d2dff1-8abb-4b6d-909a-e754980af29f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ddb7d046-c373-433b-ae32-e4c68c9ddd07_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_bcffe03d-dc49-4033-a542-714bf6d31473_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10cae87f-2277-4616-bec7-e9ae2e3cca07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod_3c010249-ba37-44f9-a293-47b9c3fbd668_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment period</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod_label_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payment Period</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:to="lab_avtx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_12437a06-ef1e-4ad2-9947-3ca8d9ab9ec1_netLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_097a3c41-5279-4484-9c37-32d0534baaef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_KyowaKirinCoLtdKKCMember_5c139a11-d489-41b8-806a-907e7ee230bf_terseLabel_en-US" xlink:label="lab_avtx_KyowaKirinCoLtdKKCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co., Ltd. (KKC)</link:label>
    <link:label id="lab_avtx_KyowaKirinCoLtdKKCMember_label_en-US" xlink:label="lab_avtx_KyowaKirinCoLtdKKCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co., Ltd. (KKC) [Member]</link:label>
    <link:label id="lab_avtx_KyowaKirinCoLtdKKCMember_documentation_en-US" xlink:label="lab_avtx_KyowaKirinCoLtdKKCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co., Ltd. (KKC) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KyowaKirinCoLtdKKCMember" xlink:href="avtx-20230630.xsd#avtx_KyowaKirinCoLtdKKCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_KyowaKirinCoLtdKKCMember" xlink:to="lab_avtx_KyowaKirinCoLtdKKCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ec711c2b-befa-4a36-a70c-edc4b312fd91_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_22b357a4-3ef7-401d-8b33-a896fb04ead4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7cdb082f-873d-4c7a-8b21-aaa8316b1c13_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ServiceBasedOptionsMember_da8b7c03-be63-4d80-ae0d-49d3bd8a2a7f_terseLabel_en-US" xlink:label="lab_avtx_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based options</link:label>
    <link:label id="lab_avtx_ServiceBasedOptionsMember_label_en-US" xlink:label="lab_avtx_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Options [Member]</link:label>
    <link:label id="lab_avtx_ServiceBasedOptionsMember_documentation_en-US" xlink:label="lab_avtx_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ServiceBasedOptionsMember" xlink:to="lab_avtx_ServiceBasedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ec340e2e-1a87-48dc-a2ba-e570c21643a6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_79ae32d4-18b8-4178-89e3-367a760da3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_68997948-04ac-4166-9760-da21678591ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a344bb03-069f-4c9e-bf6d-254744f92283_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_648642dd-53b5-4110-866f-a1f739e7cf6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Structure</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_645dc543-a6b3-4c0d-955c-0dbdc8320824_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_3a36c43c-78ed-461b-8c15-670a8000cb38_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e15896b3-a602-4517-8434-d28438bccd18_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2315ca79-f8d6-42cf-893a-6304b2a0c6fb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_4618b49c-e06d-4b7d-8050-68997903e02f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7e46ff80-000e-46fe-8953-37b7ef96f826_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a159d2d7-617e-4052-814e-95f369be4ea5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f924d4b2-3d73-4de5-b393-d7c8668ad840_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_456c449a-b349-4571-a241-854c210ff47b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_842ae447-5bce-4b97-b049-2a8a0b44b504_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, net of current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6e90ee68-bb15-4d6d-85d6-3851a9cd410d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_50c41b13-40a9-4d24-a8df-567c2afc5ebb_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_380c27bb-c13e-4e3d-8f06-ed1b418d44ef_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_095a1df7-9c36-46fa-98f2-c5e78a8ac554_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_NantahalaCapitalManagementLLCMember_31b0ee16-3600-44a2-baf1-14938848941e_terseLabel_en-US" xlink:label="lab_avtx_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC</link:label>
    <link:label id="lab_avtx_NantahalaCapitalManagementLLCMember_label_en-US" xlink:label="lab_avtx_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC [Member]</link:label>
    <link:label id="lab_avtx_NantahalaCapitalManagementLLCMember_documentation_en-US" xlink:label="lab_avtx_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NantahalaCapitalManagementLLCMember" xlink:href="avtx-20230630.xsd#avtx_NantahalaCapitalManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_NantahalaCapitalManagementLLCMember" xlink:to="lab_avtx_NantahalaCapitalManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_63243e45-dac4-4ef5-a572-17fd81153fc8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4bfddebf-1d9e-4183-b6ac-43eb2c405ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_af6d250f-2c58-4a9b-a4a9-86ea1e37d748_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6c13994b-e685-4fc4-b5ab-9fca680a3f72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_04598b93-a4e7-4621-bb6c-0b8b295d23f5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivable balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6063ff31-9528-42eb-88be-b6fd6dc9d285_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f04ba7c7-9dfa-444f-b6bd-b4ffa624c0fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_71c0ff85-daa5-451b-af09-6285b02fee8c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f13222f3-25d0-4ba0-8859-13d92cc0c2d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_a653f1bb-9952-4cc7-b5f6-08c54b7b2193_terseLabel_en-US" xlink:label="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys Medical Discovery Institute</link:label>
    <link:label id="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_label_en-US" xlink:label="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys Medical Discovery Institute [Member]</link:label>
    <link:label id="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_documentation_en-US" xlink:label="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys Medical Discovery Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:href="avtx-20230630.xsd#avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:to="lab_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_688f32d1-8fe0-46c4-84b5-1a78ff76ea53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_70d824b2-8e71-4cef-a11f-481e7ad6f464_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d049fb67-ac32-4351-bfb3-ae65511b3838_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_92542977-cd5b-4e8b-8cbe-0fbc51e9ecba_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b889979-1ace-4e99-8e3a-0b450b1a3a9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a11c9f8a-c935-4bbc-9f82-819834778fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, accelerated cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MeasurementInputSalesForecastPeakMember_9e1f4909-4a8b-4b94-8351-99274190c1f5_terseLabel_en-US" xlink:label="lab_avtx_MeasurementInputSalesForecastPeakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Sales Forecast Peak</link:label>
    <link:label id="lab_avtx_MeasurementInputSalesForecastPeakMember_label_en-US" xlink:label="lab_avtx_MeasurementInputSalesForecastPeakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Sales Forecast Peak [Member]</link:label>
    <link:label id="lab_avtx_MeasurementInputSalesForecastPeakMember_documentation_en-US" xlink:label="lab_avtx_MeasurementInputSalesForecastPeakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Sales Forecast Peak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputSalesForecastPeakMember" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputSalesForecastPeakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MeasurementInputSalesForecastPeakMember" xlink:to="lab_avtx_MeasurementInputSalesForecastPeakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_e2d975bc-2be1-4aa9-ae61-9d2269dc39ef_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leased properties</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leased Properties</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leased Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfLeasedProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:to="lab_avtx_LesseeOperatingLeaseNumberOfLeasedProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_aca247ab-1db3-4489-bfd7-5650a07f2488_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_c7a8b6c4-6827-434c-8a88-716f972a8441_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f0a9602-7bb5-4595-a728-b8f16ea3d5cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ceef6e57-395f-4250-801c-6faf40f11bf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_f1bfa45a-8a53-4541-9339-2c13a9d83407_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9cfae069-ce7f-4334-9de9-f41a329a73a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_99831cc5-f770-471a-8c4c-1f4f0929701c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c3e299ae-0cae-4ea7-8b59-756dbfdf6b0e_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a56ec7c7-49b5-4177-b592-48a83e48a404_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3528ee57-d46a-46b8-8b02-93056f30c6d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2a9dd7f1-0a2d-4bec-bd3a-60a15f3fd2d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_6c5fdf94-7778-4e9d-9eba-08091f7e9bbc_terseLabel_en-US" xlink:label="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from milestones to date</link:label>
    <link:label id="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_label_en-US" xlink:label="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Revenue Recognized to Date From Milestone Payments</link:label>
    <link:label id="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_documentation_en-US" xlink:label="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Revenue Recognized to Date From Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:href="avtx-20230630.xsd#avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:to="lab_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ffbb85-c173-46aa-8f99-3f8339ea4a06_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_cb4ed791-fba1-46ef-b368-9f5f1dd1b823_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_8516c0a9-ffdc-4a6d-8c37-ca190599c4d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_83ad56c3-6539-41d2-996d-3a0be0d72660_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6b2c550b-b98e-47a8-a080-02b1b028451e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_fab1d643-fac7-4050-9931-abf2da17c217_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5609a26f-ed44-4fe8-b0c2-1544bb769ca5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5f462881-cc9b-4178-933c-c6148169870d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8308bb2c-7a25-4f00-8583-82c1bdce8492_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member_1832c896-162d-4501-8357-9a01886622a5_terseLabel_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration February 2024</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member_label_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration February 2024 [Member]</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member_documentation_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration February 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationFebruary2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:to="lab_avtx_CommonStockWarrantsExpirationFebruary2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_543f4272-11ed-4509-a869-22e9053ccd4d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_482cf051-efa0-4ab7-89ce-be68eaee3bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MilestoneAxis_a37914ed-124c-4d68-958f-4f24e6aaa3c7_terseLabel_en-US" xlink:label="lab_avtx_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_avtx_MilestoneAxis_label_en-US" xlink:label="lab_avtx_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_avtx_MilestoneAxis_documentation_en-US" xlink:label="lab_avtx_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneAxis" xlink:href="avtx-20230630.xsd#avtx_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MilestoneAxis" xlink:to="lab_avtx_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_c870f555-b508-45bc-b0e3-637c9aaf05cf_terseLabel_en-US" xlink:label="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase (as a percent)</link:label>
    <link:label id="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_label_en-US" xlink:label="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Annual Increase, Percent</link:label>
    <link:label id="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_documentation_en-US" xlink:label="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Annual Increase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:href="avtx-20230630.xsd#avtx_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:to="lab_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_9eee4042-3c01-4e1b-b098-aab82a3a48f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants_e2c19e2a-ca14-4110-95fb-4943246e8ab5_terseLabel_en-US" xlink:label="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock retired in exchange for issuance of prefunded warrants</link:label>
    <link:label id="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants_label_en-US" xlink:label="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Common Stock Retired in Exchange for Issuance of Prefunded Warrants</link:label>
    <link:label id="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants_documentation_en-US" xlink:label="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Common Stock Retired in Exchange for Issuance of Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:href="avtx-20230630.xsd#avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:to="lab_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_70942a2c-2b9b-4e7a-8e59-f8e5736340a6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm_f817318f-680e-421c-ae88-4f383c87aeb4_terseLabel_en-US" xlink:label="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term</link:label>
    <link:label id="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm_label_en-US" xlink:label="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities, Payment Term</link:label>
    <link:label id="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm_documentation_en-US" xlink:label="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:href="avtx-20230630.xsd#avtx_RestructuringAndRelatedActivitiesPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:to="lab_avtx_RestructuringAndRelatedActivitiesPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9480ffe6-ecfa-4acb-baf1-4ee6653ef8ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active&#160;markets&#160;for identical&#160;assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MillipredMember_ed39f547-8cd5-4343-b6e4-80c275a3fd1f_terseLabel_en-US" xlink:label="lab_avtx_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred</link:label>
    <link:label id="lab_avtx_MillipredMember_label_en-US" xlink:label="lab_avtx_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred [Member]</link:label>
    <link:label id="lab_avtx_MillipredMember_documentation_en-US" xlink:label="lab_avtx_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MillipredMember" xlink:href="avtx-20230630.xsd#avtx_MillipredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MillipredMember" xlink:to="lab_avtx_MillipredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7d7fbb36-6fe1-4daa-bdbf-7f344dc9186f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of pre-funded warrants in exchange for retirement of common shares</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a370d363-a7b4-4bd1-b8bb-ac5080464795_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b45bf83e-2d93-4b1a-8b22-31cec64ae70a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1a3f8933-c7fb-4aa5-89d0-5d561ef75867_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_52a103c3-2a6c-4460-9333-4537341b8555_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX501AndAVTX007Member_12b8bc9a-f8f6-48bd-8f01-6c1aa3319668_terseLabel_en-US" xlink:label="lab_avtx_AVTX501AndAVTX007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501 And AVTX-007</link:label>
    <link:label id="lab_avtx_AVTX501AndAVTX007Member_label_en-US" xlink:label="lab_avtx_AVTX501AndAVTX007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501 And AVTX-007 [Member]</link:label>
    <link:label id="lab_avtx_AVTX501AndAVTX007Member_documentation_en-US" xlink:label="lab_avtx_AVTX501AndAVTX007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501 And AVTX-007</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501AndAVTX007Member" xlink:href="avtx-20230630.xsd#avtx_AVTX501AndAVTX007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX501AndAVTX007Member" xlink:to="lab_avtx_AVTX501AndAVTX007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX006AstellasLicenseAgreementMember_6c1d66ec-ae35-440f-87dd-f1acdee77e9b_terseLabel_en-US" xlink:label="lab_avtx_AVTX006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-006 Astellas License Agreement</link:label>
    <link:label id="lab_avtx_AVTX006AstellasLicenseAgreementMember_label_en-US" xlink:label="lab_avtx_AVTX006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-006 Astellas License Agreement [Member]</link:label>
    <link:label id="lab_avtx_AVTX006AstellasLicenseAgreementMember_documentation_en-US" xlink:label="lab_avtx_AVTX006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-006 Astellas License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX006AstellasLicenseAgreementMember" xlink:href="avtx-20230630.xsd#avtx_AVTX006AstellasLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX006AstellasLicenseAgreementMember" xlink:to="lab_avtx_AVTX006AstellasLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_615bd94b-cc02-4168-ac96-61ea752223b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock remaining for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c8398062-a56c-4672-88af-7eca0df68848_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_74532c40-fe33-4ef5-af9e-f7f07e749fc9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1907db6f-8e36-4dfb-b2af-9de6943d250b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_69609e6d-b58d-4dfb-98d3-744fad853b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2b3bad51-2978-493b-a8a0-fa84cc22d6b1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member_fcbf87b9-9de4-49cf-ba43-cf814984886a_terseLabel_en-US" xlink:label="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva</link:label>
    <link:label id="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member_label_en-US" xlink:label="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceutical Industries Ltd. [Member]</link:label>
    <link:label id="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member_documentation_en-US" xlink:label="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceutical Industries Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:href="avtx-20230630.xsd#avtx_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:to="lab_avtx_TevaPharmaceuticalIndustriesLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_346a97ef-bb32-4e4e-bea9-7c1e7673ebd6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_a90a3819-4af9-478a-91b6-8cc7ced38a9b_terseLabel_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded warrants exercised (in shares)</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_label_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Exercised</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:to="lab_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4e72e454-67b1-4f0e-b507-0ac433daa0e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_143c7eed-20a9-42ff-9ef0-22af9b5b3fa1_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6c76b9f1-2a56-4899-9465-18ac3590797b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fa8039de-448f-4694-bb0a-f9ce80097934_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9188bde6-087e-4db8-9d38-7ded2a609949_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7c126418-0bf7-46c7-8090-0fd5f2c1ff78_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_42f3ac20-034a-4c82-b5a4-6ffa6713be36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ESTherapeuticsMember_4a7df52d-3352-47a3-a808-37b8bd94f4e6_terseLabel_en-US" xlink:label="lab_avtx_ESTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES</link:label>
    <link:label id="lab_avtx_ESTherapeuticsMember_label_en-US" xlink:label="lab_avtx_ESTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES Therapeutics [Member]</link:label>
    <link:label id="lab_avtx_ESTherapeuticsMember_documentation_en-US" xlink:label="lab_avtx_ESTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESTherapeuticsMember" xlink:href="avtx-20230630.xsd#avtx_ESTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ESTherapeuticsMember" xlink:to="lab_avtx_ESTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4286cb78-3b94-4b67-8b06-64785dc5f2a1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bc754ec6-6823-4d61-8454-f163a7f00468_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d3bb6cb3-2f44-402c-9415-9fe9e7ca3610_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_f30bb35a-82d6-4d78-9aeb-0939325333df_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_00752e10-d066-4d6f-a2c5-63833e6bcd9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2699d362-c40f-450b-a238-b57986afaf25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_EmployeeStockPurchasePlanESPPMember_2907e1ec-51ec-4a7a-bf70-fa91f7c1a920_terseLabel_en-US" xlink:label="lab_avtx_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP)</link:label>
    <link:label id="lab_avtx_EmployeeStockPurchasePlanESPPMember_label_en-US" xlink:label="lab_avtx_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) [Member]</link:label>
    <link:label id="lab_avtx_EmployeeStockPurchasePlanESPPMember_documentation_en-US" xlink:label="lab_avtx_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeStockPurchasePlanESPPMember" xlink:href="avtx-20230630.xsd#avtx_EmployeeStockPurchasePlanESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_EmployeeStockPurchasePlanESPPMember" xlink:to="lab_avtx_EmployeeStockPurchasePlanESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_39ae64d7-1ed2-4ffa-9dbe-03a9a8f3f9e1_terseLabel_en-US" xlink:label="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment and Operating Lease Right-of-use Asset, After Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment and Operating Lease Right-of-use Asset, After Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="avtx-20230630.xsd#avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_8c5947f1-9205-4054-8f12-17581d471f2c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f05ff078-b192-4b29-baf1-e6ff0412ce57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a552f98-d5e5-4d5d-bf75-b6f3f4f0d515_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_521be929-0297-4424-bf63-132f2406a15c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bf8fff4f-ffcf-4442-b4c4-e3de8f274778_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b1602f27-ba88-47be-a61d-981b8ec993bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8efaa878-f17b-4f68-ac54-8df997cf56a0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MilestoneOneMember_68eb7249-a11f-43d8-b08f-53a4929214f9_terseLabel_en-US" xlink:label="lab_avtx_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_avtx_MilestoneOneMember_label_en-US" xlink:label="lab_avtx_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_avtx_MilestoneOneMember_documentation_en-US" xlink:label="lab_avtx_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneOneMember" xlink:href="avtx-20230630.xsd#avtx_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MilestoneOneMember" xlink:to="lab_avtx_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_InitialNoteMember_8500ff5c-9fae-43f9-969a-85ffeb470165_terseLabel_en-US" xlink:label="lab_avtx_InitialNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Note</link:label>
    <link:label id="lab_avtx_InitialNoteMember_label_en-US" xlink:label="lab_avtx_InitialNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Note [Member]</link:label>
    <link:label id="lab_avtx_InitialNoteMember_documentation_en-US" xlink:label="lab_avtx_InitialNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_InitialNoteMember" xlink:href="avtx-20230630.xsd#avtx_InitialNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_InitialNoteMember" xlink:to="lab_avtx_InitialNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d9b50ebd-14cf-438a-8476-a32d618bdc70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e6a6e3d8-ec8d-4e28-88d2-c00598a0c504_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e9ebd2ab-b609-445a-a6ba-a14405eb6cc8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_880a0783-4f04-4c35-baa3-98020ca91556_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_4b8e6b76-6c23-4424-9de4-0e0123176df1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ac55d514-a394-47fc-a49c-82ab8ac1dcae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_49be730b-c1e7-4d0e-871e-e5e921a558eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_bef3da04-a85f-4255-85d2-868596c8d3bc_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment extension period</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_label_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payment Extension Period</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payment Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:to="lab_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_54998c79-8c0d-489a-bdf5-f51da09c7072_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6e904948-467c-4911-9dd4-58233aa67e01_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ff2daa55-c175-449d-947e-25f9c1a3c880_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_135b5bcd-fc9d-4d24-a1b5-92b08c717e8d_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0b93ee56-343b-4efe-a7e4-16df7f6b187d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_TRISPharmaMember_d5d9dbd4-3622-4bb1-8d38-c41e770bcf40_terseLabel_en-US" xlink:label="lab_avtx_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma</link:label>
    <link:label id="lab_avtx_TRISPharmaMember_label_en-US" xlink:label="lab_avtx_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma [Member]</link:label>
    <link:label id="lab_avtx_TRISPharmaMember_documentation_en-US" xlink:label="lab_avtx_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TRISPharmaMember" xlink:href="avtx-20230630.xsd#avtx_TRISPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_TRISPharmaMember" xlink:to="lab_avtx_TRISPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4792fdb9-4909-468d-8a04-b9b557f3df63_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a2d14ffa-00ef-4975-92c8-9d96c71db3cf_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0dbd5a9-5e00-4c9e-8d69-1ba8b669879d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_965cbbee-f5cb-48f0-9965-851a1a00c6a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3f375479-5354-41f0-8fee-246bb24bafe8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less implied interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_a056648c-b161-4d4f-bcbf-8a9c42d1ddf1_terseLabel_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock pursuant to ATM Program, net</link:label>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_label_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock Through ATM Program</link:label>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_documentation_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock Through ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:to="lab_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1eedfb86-2213-4c3f-86bd-81d473a0d42e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_01ab6365-aeca-4bcb-9fd5-b6dfc3cac240_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e367157a-9c6e-468c-8c97-09e56355bb3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ceba1346-8f32-4e28-bae8-d8a4d672d1ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9fc54433-6042-43a4-bf3f-1b2b12beeae6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a2c114d2-c73d-4d68-8e97-1e45f35120f7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f76da62a-6b3b-49d5-a425-e6ff99e5edc1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AeviGenomicMedicineIncMember_52747aba-4cb1-48f5-8c21-41d4b843504b_terseLabel_en-US" xlink:label="lab_avtx_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi</link:label>
    <link:label id="lab_avtx_AeviGenomicMedicineIncMember_label_en-US" xlink:label="lab_avtx_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi Genomic Medicine Inc [Member]</link:label>
    <link:label id="lab_avtx_AeviGenomicMedicineIncMember_documentation_en-US" xlink:label="lab_avtx_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi Genomic Medicine Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AeviGenomicMedicineIncMember" xlink:href="avtx-20230630.xsd#avtx_AeviGenomicMedicineIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AeviGenomicMedicineIncMember" xlink:to="lab_avtx_AeviGenomicMedicineIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38e39051-48eb-4b53-b18a-cc1c9a7a6f83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased through employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_49222a08-f004-49a1-ada8-d010e830ab75_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_36739347-a7b4-4886-9a0b-d6d8d5c2a307_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_608c10c3-e21e-4e6e-a576-3281a6c6fde0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ee18e43c-4413-463a-914d-906561e7586c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Adopted in 2023</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_PreFundedWarrantsMember_ac20d757-19e8-45e1-9926-5607eb58b818_terseLabel_en-US" xlink:label="lab_avtx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_avtx_PreFundedWarrantsMember_label_en-US" xlink:label="lab_avtx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_avtx_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_avtx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PreFundedWarrantsMember" xlink:href="avtx-20230630.xsd#avtx_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_PreFundedWarrantsMember" xlink:to="lab_avtx_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CapitalStockSharesAuthorized_10cad9b9-c961-41d5-a8e4-4414665dc663_terseLabel_en-US" xlink:label="lab_avtx_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of capital stock authorized to issue (in shares)</link:label>
    <link:label id="lab_avtx_CapitalStockSharesAuthorized_label_en-US" xlink:label="lab_avtx_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock Shares Authorized</link:label>
    <link:label id="lab_avtx_CapitalStockSharesAuthorized_documentation_en-US" xlink:label="lab_avtx_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CapitalStockSharesAuthorized" xlink:href="avtx-20230630.xsd#avtx_CapitalStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CapitalStockSharesAuthorized" xlink:to="lab_avtx_CapitalStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1012df51-1b94-45a7-ae7f-99cd319b97dc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_318a1b31-b86a-4143-bcf5-374df6438846_terseLabel_en-US" xlink:label="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after public launch to terminate agreement</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_label_en-US" xlink:label="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Period After Public Launch to Terminate Agreement</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_documentation_en-US" xlink:label="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Period After Public Launch to Terminate Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:to="lab_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_07be6208-6b33-40cb-b305-5e22914b190c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95571a1d-5379-4e30-a767-c1d8012ea4f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c45aaa30-b945-4ad6-bcdc-35e95bb5fa1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cae8a1ee-2c5d-4593-ae41-f18ff51a8d0c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d0a7c42-c714-452a-a154-9a7366b4e408_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseAnnualBaseRent_e1f1a6e8-3086-4b6d-9703-b3813c57c3ab_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, annual base rent</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseAnnualBaseRent_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Base Rent</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseAnnualBaseRent_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:to="lab_avtx_LesseeOperatingLeaseAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_0c9ae33b-427c-48c0-8ff2-9a180e157789_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5ad16992-b279-4e7a-a60f-d12144a4e64a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_b5b92776-c9d5-46d4-a88c-caec226d8281_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_e512493e-1931-4bd9-9152-cbe5d3168f1f_terseLabel_en-US" xlink:label="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_label_en-US" xlink:label="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Number of Milestones</link:label>
    <link:label id="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_documentation_en-US" xlink:label="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:to="lab_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_b9b8b430-c4f6-44e5-9e2a-b99d3cae2372_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8bd33084-c6ca-479f-abb3-3e9135a4c52f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d350b336-18a1-496d-8a74-8b2b7cc15092_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_de6044bc-8e87-45f6-865a-9e87ee9a3695_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions for Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_54b6f1bf-1ef9-43ff-9e8a-92a026e12305_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_705a2563-9941-477a-abfe-c0f95987e6e8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_3c2fc0b2-5269-462c-a36f-d5ed7629b9e7_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of notes payable, current</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a5103332-c50f-460b-bb34-ce824a64f0a3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_b00c4b4a-58e8-4895-9869-a4d459ffeb59_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_efa1a740-8af6-406d-8eeb-cf0b342a8c30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_49a18852-f788-47b6-90b9-36e57ca9e769_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number of Renewal Options</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_avtx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4bb9472-978a-4b57-9c68-2cea98353ad2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ThirdNoteMember_a021e9a1-66c7-460b-99dc-72defbb181d9_terseLabel_en-US" xlink:label="lab_avtx_ThirdNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Note</link:label>
    <link:label id="lab_avtx_ThirdNoteMember_label_en-US" xlink:label="lab_avtx_ThirdNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Note [Member]</link:label>
    <link:label id="lab_avtx_ThirdNoteMember_documentation_en-US" xlink:label="lab_avtx_ThirdNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ThirdNoteMember" xlink:href="avtx-20230630.xsd#avtx_ThirdNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ThirdNoteMember" xlink:to="lab_avtx_ThirdNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_66755a59-084d-4d2d-8c1e-37b89f507694_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_19166cf4-9cb6-43f0-88f3-ae406c6b7246_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_be5c88c1-6e34-4ae8-a6c3-dff21fdb4297_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d80ab73a-266e-457a-a1f8-85ada06c019c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2fe64d22-28c2-4afc-87b9-5bade229c6f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AstellasPharmaIncAstellasMember_38ec3938-385a-4f55-a8cd-af0644c8d925_terseLabel_en-US" xlink:label="lab_avtx_AstellasPharmaIncAstellasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astellas Pharma, Inc. (Astellas)</link:label>
    <link:label id="lab_avtx_AstellasPharmaIncAstellasMember_label_en-US" xlink:label="lab_avtx_AstellasPharmaIncAstellasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astellas Pharma, Inc. (Astellas) [Member]</link:label>
    <link:label id="lab_avtx_AstellasPharmaIncAstellasMember_documentation_en-US" xlink:label="lab_avtx_AstellasPharmaIncAstellasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astellas Pharma, Inc. (Astellas) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AstellasPharmaIncAstellasMember" xlink:href="avtx-20230630.xsd#avtx_AstellasPharmaIncAstellasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AstellasPharmaIncAstellasMember" xlink:to="lab_avtx_AstellasPharmaIncAstellasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_c0ef1e32-9c3d-45b5-b397-df473f72388d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a0b5495c-8ab0-4756-bb87-c610526375cf_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e770328a-c2f7-4979-87c6-c3867e4e1bae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e7e0bc5d-cabf-42e6-ae68-ce6c2c6cfbed_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_90ee6fe5-13d8-422c-92d0-deb03665e522_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_238fb989-4a3b-46b5-9561-3f5293a486a6_terseLabel_en-US" xlink:label="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net present value of royalty payments</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_label_en-US" xlink:label="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_documentation_en-US" xlink:label="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:to="lab_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ef1852bc-28b5-4e03-a88c-ba310a085be2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_906733b4-d30f-433d-8e3e-a8ca36d08f37_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for other long-term asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal" xlink:to="lab_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_83a6a28b-dbc8-4279-b044-d27f5fc66e12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b312da15-a2bd-40b0-b825-f3e8bdafaa8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum portion of earning an employee may contribute to the ESPP Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_40808446-cf49-4ff6-a0e1-2b385f296146_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_1c5066da-025e-4771-9540-f50746e1edea_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseLiability_5a9685fb-9980-47fd-b938-9b75dfb6b9da_terseLabel_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net</link:label>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Liability</link:label>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseLiability" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_IncreaseDecreaseInLeaseLiability" xlink:to="lab_avtx_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f2828776-1a4a-4167-a575-05b31ef48e41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d496d1fd-94a5-4728-af8c-1d3360c2ca52_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to ATM Program, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_57948565-bba5-45ce-8c9d-882f598c8b93_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_6365c6ad-5f80-479e-a286-3e29a0ca48e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX007Member_85705137-ce3d-4354-a8a4-6202695be66c_terseLabel_en-US" xlink:label="lab_avtx_AVTX007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-007</link:label>
    <link:label id="lab_avtx_AVTX007Member_label_en-US" xlink:label="lab_avtx_AVTX007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-007 [Member]</link:label>
    <link:label id="lab_avtx_AVTX007Member_documentation_en-US" xlink:label="lab_avtx_AVTX007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-007</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX007Member" xlink:href="avtx-20230630.xsd#avtx_AVTX007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX007Member" xlink:to="lab_avtx_AVTX007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_770a3591-e57c-44c0-9f35-c3c9ea950615_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8a06a337-3218-4a11-8559-ac114c9d5664_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a3eda99a-7d24-4a3e-acff-38d4ac6d5ca3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_25321a23-2704-4df1-b9a1-f6123b768ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9b3f8f4a-8ec0-45a3-9044-c6d2a2bde970_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationJune2031Member_3b64cb96-ec88-4d35-9e26-60cf118abd63_terseLabel_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration June 2031</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationJune2031Member_label_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration June 2031 [Member]</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationJune2031Member_documentation_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration June 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationJune2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:to="lab_avtx_CommonStockWarrantsExpirationJune2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fa6aa1e2-a097-43d0-9d77-8d4a672ed669_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4ecaad97-47ca-4bd2-b48b-b08e034be912_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a39bdc14-2bd2-4671-8910-986658fbe0c8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_8a342d86-f722-4d3c-bbba-cda0a0c92f8e_terseLabel_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, ownership percentage, exercise threshold</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_label_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Ownership Percentage, Exercise Threshold</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_documentation_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Ownership Percentage, Exercise Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:to="lab_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bc75ed35-9b4c-4f3a-9647-595fb7850f99_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_f90c83df-409b-4694-a382-9315f9ac15c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_a4818b19-afc2-4ce1-b879-f92bc12fafcb_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f6dc6c3f-ecb7-42e4-b79c-28514edf8211_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RoyaltyAgreementPaymentReceived_89a9de7e-28f8-452c-b954-f7613e965f88_terseLabel_en-US" xlink:label="lab_avtx_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementPaymentReceived_label_en-US" xlink:label="lab_avtx_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Payment Received</link:label>
    <link:label id="lab_avtx_RoyaltyAgreementPaymentReceived_documentation_en-US" xlink:label="lab_avtx_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPaymentReceived" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RoyaltyAgreementPaymentReceived" xlink:to="lab_avtx_RoyaltyAgreementPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4503fa6f-1723-4f1c-964f-b9ad64de6fa1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c092b3f-99db-4e91-882e-f6d722e39121_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_630f340e-7bcf-4a60-a54b-d4768f21b790_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83a5dcc1-48d2-4f61-8e5d-c852ae325d45_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_cff3b00a-b4c8-46ad-8b8f-c96257f6a048_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7008b8de-0421-4279-82be-3bb257555a36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_25eeafa7-c6ed-4839-b79e-eabab6650ad5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a545ac60-bdb3-4ba2-b81e-a3c4ea3546da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_fb4debf9-95a9-4a46-a554-7c7c8b97b789_terseLabel_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_label_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized Increase</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_documentation_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the increase in the number of shares reserved for issuance under the incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:to="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_HorizonPowerscourtNotesMember_b20f3787-b049-47f6-b89e-2eb131142ce3_terseLabel_en-US" xlink:label="lab_avtx_HorizonPowerscourtNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon &amp; Powerscourt Notes</link:label>
    <link:label id="lab_avtx_HorizonPowerscourtNotesMember_label_en-US" xlink:label="lab_avtx_HorizonPowerscourtNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon &amp; Powerscourt Notes [Member]</link:label>
    <link:label id="lab_avtx_HorizonPowerscourtNotesMember_documentation_en-US" xlink:label="lab_avtx_HorizonPowerscourtNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon &amp; Powerscourt Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_HorizonPowerscourtNotesMember" xlink:to="lab_avtx_HorizonPowerscourtNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0ddfa9cd-93c4-49f9-80bd-3ca026479352_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f5616745-90d7-4413-ae93-36b1583999a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b2ce1e6c-7417-4e06-81c9-92d9591730b5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_edc4ccac-4b8a-4921-889e-e561b30f70be_terseLabel_en-US" xlink:label="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of pre-funded warrants for common shares (in shares)</link:label>
    <link:label id="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_label_en-US" xlink:label="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Exercise Of Prefunded Warrants</link:label>
    <link:label id="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_documentation_en-US" xlink:label="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Exercise Of Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:href="avtx-20230630.xsd#avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:to="lab_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ESMember_34d5e134-1de8-450d-ada3-cd88f578b58d_terseLabel_en-US" xlink:label="lab_avtx_ESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES</link:label>
    <link:label id="lab_avtx_ESMember_label_en-US" xlink:label="lab_avtx_ESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES [Member]</link:label>
    <link:label id="lab_avtx_ESMember_documentation_en-US" xlink:label="lab_avtx_ESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESMember" xlink:href="avtx-20230630.xsd#avtx_ESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ESMember" xlink:to="lab_avtx_ESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_09e4acd3-9697-4fa0-9615-2c59e71a28b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_890215a0-bb0d-4af9-ba25-5719873feff3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5f0cbcb3-23ff-4209-8a63-f06b874d0ef7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cdfd519-2374-400b-b804-69411ee4bdf7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DerivativeLiabilityMeasurementInputTerm_80e474db-1c96-41fd-915d-f12a8ee95f5b_terseLabel_en-US" xlink:label="lab_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, measurement input, term</link:label>
    <link:label id="lab_avtx_DerivativeLiabilityMeasurementInputTerm_label_en-US" xlink:label="lab_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input, Term</link:label>
    <link:label id="lab_avtx_DerivativeLiabilityMeasurementInputTerm_documentation_en-US" xlink:label="lab_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:href="avtx-20230630.xsd#avtx_DerivativeLiabilityMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:to="lab_avtx_DerivativeLiabilityMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_1ac53049-62e2-4639-ab4b-3c5affa6a7d8_terseLabel_en-US" xlink:label="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_label_en-US" xlink:label="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Consultants and Directors Stock Options [Member]</link:label>
    <link:label id="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_documentation_en-US" xlink:label="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:href="avtx-20230630.xsd#avtx_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="lab_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_ae31896b-73e2-4566-b20a-a344da0c6a78_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f6ad9c26-c701-44b8-95c8-e5495c7b839d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_9e79aa90-a236-4fd6-8902-52145819ac88_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum quantity required</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Minimum Quantity Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7c04cbfb-131d-4bef-84b6-3402c6efb754_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cec42c8b-cafa-44fa-b17a-a27f6799e26b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_84787c18-a795-4212-9c60-3fe5613905fe_terseLabel_en-US" xlink:label="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net profit for installment payments</link:label>
    <link:label id="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_label_en-US" xlink:label="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent of Net Profit for Installment Payment</link:label>
    <link:label id="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_documentation_en-US" xlink:label="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent of Net Profit for Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:to="lab_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ab951ae9-3a1d-41d2-a155-0df03f7c8e18_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fabcff5-f9cd-4a93-ae8e-39b5e725d203_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f876749f-e280-4356-bbd7-207af6fb348d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_5c8cbf81-534d-47c5-b13e-c51839cafe41_terseLabel_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock and warrants in underwritten public offering, net (in shares)</link:label>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_label_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Share</link:label>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_documentation_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:to="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_527492f2-9021-4f2b-988d-b7b370e6511d_terseLabel_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_label_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Automatic Increase to Shares Authorized as Percentage of Outstanding Stock at End of Preceding Year</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_documentation_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Automatic Increase to Shares Authorized as Percentage of Outstanding Stock at End of Preceding Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:to="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d8da1b49-7b51-49d3-9df2-f49161359880_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_427f85f8-1c82-4de4-ab59-13521247d3fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_853fe78d-be49-4df2-9769-f004b14946cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common shares in exchange for pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_55994a71-929b-4fd2-9453-c937019b68c5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ExchangeAgreementMember_8eab4007-db02-4ef9-9fe6-99776114ef68_terseLabel_en-US" xlink:label="lab_avtx_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement</link:label>
    <link:label id="lab_avtx_ExchangeAgreementMember_label_en-US" xlink:label="lab_avtx_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:label id="lab_avtx_ExchangeAgreementMember_documentation_en-US" xlink:label="lab_avtx_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ExchangeAgreementMember" xlink:href="avtx-20230630.xsd#avtx_ExchangeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ExchangeAgreementMember" xlink:to="lab_avtx_ExchangeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f45a91e2-094f-4efe-adea-0ce81888aa66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment on Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_30d0dbb3-21b9-482a-ae32-49644b8b7a18_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial prepayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_c2f72ee2-2912-45f6-8c13-9fe97d1d7c53_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment on Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5eecfae2-2946-46e6-8f12-eb5564ce68ca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_49689fe7-0d31-485a-9d91-ec6f9d85f6b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_cb7f3990-6eb3-4a08-ba11-b438858710d3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d8ebc655-7aea-4b35-960e-be2721c953d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Future Principal Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3f861e39-fb50-4d49-91cf-220f5cff4588_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_28c50a44-19b3-4acb-990d-9f6c618839ca_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1f41ccac-cc4a-4b31-aa13-5f422a95824d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AltoMember_0718a866-48f6-4b36-b240-0ad781b15135_terseLabel_en-US" xlink:label="lab_avtx_AltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alto</link:label>
    <link:label id="lab_avtx_AltoMember_label_en-US" xlink:label="lab_avtx_AltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alto [Member]</link:label>
    <link:label id="lab_avtx_AltoMember_documentation_en-US" xlink:label="lab_avtx_AltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AltoMember" xlink:href="avtx-20230630.xsd#avtx_AltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AltoMember" xlink:to="lab_avtx_AltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a2a7e145-3c92-4f61-b15e-82256dca2a68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_288062a0-da5e-4c44-a4a6-b496a0b4b5fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3df9e31d-a2c3-4462-8d8d-80ae26e121f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_1062a4e1-802c-4fcf-b658-3fd66ae17f54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_bf2dcfea-dafa-489d-a216-a0bfb241e9e4_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d48f7abc-b341-4ccd-8284-40737bc7eaa4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_8c9d8c9e-2198-4656-8dc8-7079d09d2321_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e13883fc-1498-4a92-ad5a-9522d84dfad1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_85990ad5-caee-4ae1-9c8b-eff6ec4412ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX501Member_1aac796f-2808-432c-826f-de07928604c9_terseLabel_en-US" xlink:label="lab_avtx_AVTX501Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501</link:label>
    <link:label id="lab_avtx_AVTX501Member_label_en-US" xlink:label="lab_avtx_AVTX501Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501 [Member]</link:label>
    <link:label id="lab_avtx_AVTX501Member_documentation_en-US" xlink:label="lab_avtx_AVTX501Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-501</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501Member" xlink:href="avtx-20230630.xsd#avtx_AVTX501Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX501Member" xlink:to="lab_avtx_AVTX501Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5accdf5d-aa66-4cf7-8a9d-62a22a2f9c30_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_61342b99-343f-4507-a39c-1f213677a5ea_terseLabel_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cef0763d-85bf-412a-a478-199ad9f1b125_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;$0.001 par value; 200,000,000 shares authorized at June 30, 2023 and December 31, 2022; 14,036,940 and 9,430,535 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX611Member_5a1100ae-a6a4-4bc0-ab17-e718dcfbfee5_terseLabel_en-US" xlink:label="lab_avtx_AVTX611Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-611</link:label>
    <link:label id="lab_avtx_AVTX611Member_label_en-US" xlink:label="lab_avtx_AVTX611Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-611 [Member]</link:label>
    <link:label id="lab_avtx_AVTX611Member_documentation_en-US" xlink:label="lab_avtx_AVTX611Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-611</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX611Member" xlink:href="avtx-20230630.xsd#avtx_AVTX611Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX611Member" xlink:to="lab_avtx_AVTX611Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3224440e-b58a-49b6-9342-ca6c0b5adcf6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_87d7e494-45ab-461a-b5d7-3fa78f15b88a_terseLabel_en-US" xlink:label="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional resticted cash, percentage of aggregate cash proceeds</link:label>
    <link:label id="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_label_en-US" xlink:label="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage</link:label>
    <link:label id="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_documentation_en-US" xlink:label="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:href="avtx-20230630.xsd#avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:to="lab_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseIncentives_dd3928c0-6c8e-4d2f-9550-896c81bf25ca_negatedTerseLabel_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseIncentives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive</link:label>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseIncentives_label_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Incentives</link:label>
    <link:label id="lab_avtx_IncreaseDecreaseInLeaseIncentives_documentation_en-US" xlink:label="lab_avtx_IncreaseDecreaseInLeaseIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Lease Incentives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseIncentives" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_IncreaseDecreaseInLeaseIncentives" xlink:to="lab_avtx_IncreaseDecreaseInLeaseIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_66ee06f8-34b6-4c72-a034-ed99cf10527e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_8f571a1c-74d9-4d7e-a16e-634d2dec15b4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_d3896a76-87bf-4fa5-a428-ae09076df1f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c3fedf1c-1e82-445e-97aa-46913d98e2a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2f086103-7a74-4d5f-ab51-801951920d67_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cffbe6c6-af62-4b08-821b-0641d580543d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fe0a32ad-d4f4-456d-8e40-15230225778c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c07e48ae-a024-4e65-9c42-eef24b63a361_terseLabel_en-US" xlink:label="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum proceeds from milestones</link:label>
    <link:label id="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="avtx-20230630.xsd#avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b6a27ba0-a510-47ee-bd39-fc7a3778c721_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_93c25089-b72b-4ed5-ba9e-64429eb55214_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_f46fb3b6-7222-49b0-a61a-a5b525ca49b5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_601096a3-9b70-4020-b824-c090be0b3fd0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_868ad371-4a1b-4fef-a8c0-5e3c0bba4ee4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_5cf2ab70-2c6b-4c9e-a384-44788df1b3cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_480662b0-7c9f-4330-bd1a-0ba6e1776562_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a88316a7-045b-463a-a9c1-0a00832eb4b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8383f31e-0b18-49df-92e8-958f308a7f7b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_790e6041-a937-4b52-8abf-4cf445115d0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_d5382774-ca8d-4833-816a-c160282fe747_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod_056f7759-7426-4abc-8e2b-861f2362a16d_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent abatement period</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Abatement Period</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:to="lab_avtx_LesseeOperatingLeaseRentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_23522523-662b-490a-b635-fa3158ace9c5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5279f973-8f73-4419-8867-803b1e58046e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3f3c2d97-1d6e-48a8-9fff-aa6b0e1047c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2622f044-4e00-4d22-b46c-81df799a6fb6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ArmisticeMember_234d2793-b81a-4ac5-98e8-3f588f48bcd7_terseLabel_en-US" xlink:label="lab_avtx_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice</link:label>
    <link:label id="lab_avtx_ArmisticeMember_label_en-US" xlink:label="lab_avtx_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice [Member]</link:label>
    <link:label id="lab_avtx_ArmisticeMember_documentation_en-US" xlink:label="lab_avtx_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ArmisticeMember" xlink:href="avtx-20230630.xsd#avtx_ArmisticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ArmisticeMember" xlink:to="lab_avtx_ArmisticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MilestoneTwoMember_b3c6ed8a-33d6-4e81-a523-52fa43de9a1b_terseLabel_en-US" xlink:label="lab_avtx_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_avtx_MilestoneTwoMember_label_en-US" xlink:label="lab_avtx_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_avtx_MilestoneTwoMember_documentation_en-US" xlink:label="lab_avtx_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneTwoMember" xlink:href="avtx-20230630.xsd#avtx_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MilestoneTwoMember" xlink:to="lab_avtx_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_8ea232d9-8c6c-4aca-ab85-40b521e33d0c_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bf4d7e4a-d699-4dce-b72c-b4c65b6d58ed_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_635c5414-52bb-42aa-8022-6aff0cff740a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_8e891776-76ea-4be2-a006-ba8536e2235b_terseLabel_en-US" xlink:label="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, One-Time Termination Benefits</link:label>
    <link:label id="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, One-Time Termination Benefits [Member]</link:label>
    <link:label id="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_documentation_en-US" xlink:label="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, One-Time Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:href="avtx-20230630.xsd#avtx_RestructuringPlanOneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:to="lab_avtx_RestructuringPlanOneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_78fd5f3e-1431-40aa-b93a-1526374fb2aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_141f603a-a646-4959-b579-fcd7d9bcb83d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_459dde5c-c7c4-4057-89f6-a97c667111ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4e276cca-9e65-4761-9203-301eecc471ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_9a50dd68-8220-4356-8e66-1ec767d1ec19_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of payments received from sublicensing</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_3281e7f7-42e8-44ad-b60a-2ae6ac69b03c_terseLabel_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="lab_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MajorCustomerNumberTwoMember_ba5f392e-d1e9-41f7-9001-69dca231278f_terseLabel_en-US" xlink:label="lab_avtx_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two</link:label>
    <link:label id="lab_avtx_MajorCustomerNumberTwoMember_label_en-US" xlink:label="lab_avtx_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two [Member]</link:label>
    <link:label id="lab_avtx_MajorCustomerNumberTwoMember_documentation_en-US" xlink:label="lab_avtx_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberTwoMember" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MajorCustomerNumberTwoMember" xlink:to="lab_avtx_MajorCustomerNumberTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17bbe6b5-a94b-41e3-9829-8f9128ca57fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_2f0e13ff-5711-4fb5-b71b-7fe376af2172_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in deposit account</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_28410f14-0f3d-4e82-8298-d754a7bc90ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0c0879a7-466f-4f3d-a290-71a4c8425598_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6505a0a4-dc9e-474a-9aa2-54d4646e39e0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_a4497d15-43f5-468d-8652-9bbb22eb592f_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make whole payment per unit (in dollars per share)</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_26de2b5f-8557-42e3-8ae3-743d43bc659d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Plan</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_de7a31e4-40e5-4a28-bb7e-4bcf45494f58_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_307cc891-5778-48e4-a75f-5341dffa83cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_11011ef6-2fc7-4883-b6c7-4f89cca853ce_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base rent</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Annual Base Rent</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:to="lab_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4a901761-9efd-4479-a9af-b0878863505f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;other observable inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a57829ad-3ffe-45bd-a4bb-72d32fcfb0ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MeasurementInputProbabilityOfSuccessMember_d4ba40f7-efce-43e2-8915-06e135dad4f9_terseLabel_en-US" xlink:label="lab_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:label id="lab_avtx_MeasurementInputProbabilityOfSuccessMember_label_en-US" xlink:label="lab_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Success [Member]</link:label>
    <link:label id="lab_avtx_MeasurementInputProbabilityOfSuccessMember_documentation_en-US" xlink:label="lab_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputProbabilityOfSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_avtx_MeasurementInputProbabilityOfSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_PediatricPortfolioMember_ffdd7fbb-6677-442d-b842-f2123dbb3c7b_terseLabel_en-US" xlink:label="lab_avtx_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio</link:label>
    <link:label id="lab_avtx_PediatricPortfolioMember_label_en-US" xlink:label="lab_avtx_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio [Member]</link:label>
    <link:label id="lab_avtx_PediatricPortfolioMember_documentation_en-US" xlink:label="lab_avtx_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PediatricPortfolioMember" xlink:href="avtx-20230630.xsd#avtx_PediatricPortfolioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_PediatricPortfolioMember" xlink:to="lab_avtx_PediatricPortfolioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_4727bde4-8fde-4a03-8ce0-45fc3585340b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4c95ff45-210a-4b03-8495-cc5e64620466_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_71d59b36-2396-4116-b527-dcbd6b6ca609_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpirationMember_e763a6e7-0547-49ca-bedb-abc5276dafe7_terseLabel_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpirationMember_label_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration [Member]</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpirationMember_documentation_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpirationMember" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommonStockWarrantsNoExpirationMember" xlink:to="lab_avtx_CommonStockWarrantsNoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3b7c6148-9fd1-4916-831b-89401b06adbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6651415c-fc6b-4230-b016-40f18dbfb6c4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_935f05ac-8738-4faf-98ef-02225a0f4894_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpiration2Member_991a8a10-f61c-49e3-a423-18466cdcc84c_terseLabel_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpiration2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration 2</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpiration2Member_label_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpiration2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration 2 [Member]</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsNoExpiration2Member_documentation_en-US" xlink:label="lab_avtx_CommonStockWarrantsNoExpiration2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpiration2Member" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpiration2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommonStockWarrantsNoExpiration2Member" xlink:to="lab_avtx_CommonStockWarrantsNoExpiration2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48bf3944-5e41-4be6-870b-b9ed8639dd7d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f1cabc39-31bc-4315-81ab-2b28cc326c34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e919c2d9-3ea4-4888-88f9-1f6a6b35da3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ffcd1113-4555-4d11-846c-be346dce3583_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6942576e-8a60-4dac-b134-c6bead50c4c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_6e0a1658-4231-4427-ac7e-49c5b6159860_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1bba4053-3070-4f72-93db-1c0018e98de6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam_83473608-e8fc-4a37-a992-2672bbf6170a_terseLabel_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease team</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam_label_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Remaining Lease Team</link:label>
    <link:label id="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam_documentation_en-US" xlink:label="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Remaining Lease Team</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:to="lab_avtx_LesseeOperatingLeaseRemainingLeaseTeam" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_857ba5f6-6607-4fd4-9384-39d51ecabac2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f752a5db-88dc-4236-904e-150c01ece2b7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1e78bea3-fe94-4142-b91d-d15880d5bbec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_faf35681-a541-4424-a350-93e839a2e5da_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8b124465-23e1-48cd-ac95-a643c8a1c46e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_32910f3b-8716-44ac-a8ba-0c56237501a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3fc3598c-26ca-43e5-84dc-bcb0767d0b7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_RepaymentOfDebtPrincipal_5981ef12-a029-499f-9d08-c10b8f7f7385_terseLabel_en-US" xlink:label="lab_avtx_RepaymentOfDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt, principal</link:label>
    <link:label id="lab_avtx_RepaymentOfDebtPrincipal_label_en-US" xlink:label="lab_avtx_RepaymentOfDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Debt, Principal</link:label>
    <link:label id="lab_avtx_RepaymentOfDebtPrincipal_documentation_en-US" xlink:label="lab_avtx_RepaymentOfDebtPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Debt, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RepaymentOfDebtPrincipal" xlink:href="avtx-20230630.xsd#avtx_RepaymentOfDebtPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_RepaymentOfDebtPrincipal" xlink:to="lab_avtx_RepaymentOfDebtPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_52758421-8af3-4c8e-9b5c-0e90fba28458_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_389e5122-a5ff-49cf-ab57-212ad175b492_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business days required for prepayment</link:label>
    <link:label id="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_label_en-US" xlink:label="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Business Days Required for Prepayment</link:label>
    <link:label id="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Business Days Required for Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:to="lab_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4a49682e-07dc-4404-8539-fb05db3a66b3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_LicenseAgreementInstallmentPayment_ac299688-322f-4675-96c7-5e130ffb9577_terseLabel_en-US" xlink:label="lab_avtx_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment payment</link:label>
    <link:label id="lab_avtx_LicenseAgreementInstallmentPayment_label_en-US" xlink:label="lab_avtx_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Installment Payment</link:label>
    <link:label id="lab_avtx_LicenseAgreementInstallmentPayment_documentation_en-US" xlink:label="lab_avtx_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementInstallmentPayment" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_LicenseAgreementInstallmentPayment" xlink:to="lab_avtx_LicenseAgreementInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_83a0ef14-4012-4ad2-b225-eb042ae498b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_af91bb31-b1d9-402e-a9b4-b650a05d73e8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX301OutLicenseMember_b5bdfc1b-7970-45a5-bade-ca30bdc3213d_terseLabel_en-US" xlink:label="lab_avtx_AVTX301OutLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-301 Out-License</link:label>
    <link:label id="lab_avtx_AVTX301OutLicenseMember_label_en-US" xlink:label="lab_avtx_AVTX301OutLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-301 Out-License [Member]</link:label>
    <link:label id="lab_avtx_AVTX301OutLicenseMember_documentation_en-US" xlink:label="lab_avtx_AVTX301OutLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-301 Out-License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX301OutLicenseMember" xlink:href="avtx-20230630.xsd#avtx_AVTX301OutLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX301OutLicenseMember" xlink:to="lab_avtx_AVTX301OutLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_22ce6107-61d1-45c8-86dd-6f616e37f738_terseLabel_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants in underwritten public offering, net</link:label>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants</link:label>
    <link:label id="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance of Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b0eaa5c1-86f0-43cb-882b-45610cba655d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6498a54b-1e88-4ee9-9b7e-87a5b4ef7951_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_48ec57f0-8037-4ed5-8ec6-74c85e32c1a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_cfe2deaf-e149-4c3f-acaa-947434e9487a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_76b2e7ea-717b-4282-9ff7-553d62560306_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_05d6d3f9-b3f0-4eea-8e9a-5c4da9a27492_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1767e7c4-4b3a-4a11-b957-c8ed458260fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_15697cf7-03b7-4ee8-82a2-3f8333021e54_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_a526a063-ac0a-4835-a330-9cd754307a27_terseLabel_en-US" xlink:label="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-008 Sanford Burnham Prebys License Agreement</link:label>
    <link:label id="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_label_en-US" xlink:label="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-008 Sanford Burnham Prebys License Agreement [Member]</link:label>
    <link:label id="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_documentation_en-US" xlink:label="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-008 Sanford Burnham Prebys License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:href="avtx-20230630.xsd#avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:to="lab_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5a0a9bab-8937-4fba-a07e-a93971c5cb36_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_106d8c84-766a-463b-aa92-f81a6b0ae440_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f0e4874-d580-4a26-9a9f-79f66ea837f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8fd1a28b-de18-442b-b7a1-08d9df06b5c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69979abf-7c48-4a6e-91df-bc5232d198b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX801AVTX802AndAVTX803Member_8b4df749-790f-4f4e-b65b-81cf6bdbdeb6_terseLabel_en-US" xlink:label="lab_avtx_AVTX801AVTX802AndAVTX803Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-801, AVTX-802, And AVTX-803</link:label>
    <link:label id="lab_avtx_AVTX801AVTX802AndAVTX803Member_label_en-US" xlink:label="lab_avtx_AVTX801AVTX802AndAVTX803Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-801, AVTX-802, And AVTX-803 [Member]</link:label>
    <link:label id="lab_avtx_AVTX801AVTX802AndAVTX803Member_documentation_en-US" xlink:label="lab_avtx_AVTX801AVTX802AndAVTX803Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-801, AVTX-802, And AVTX-803</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX801AVTX802AndAVTX803Member" xlink:href="avtx-20230630.xsd#avtx_AVTX801AVTX802AndAVTX803Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX801AVTX802AndAVTX803Member" xlink:to="lab_avtx_AVTX801AVTX802AndAVTX803Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a1bf6ab9-4674-4f29-81b6-26a5314c3116_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b4f65d71-4819-41e6-9543-45180b1d9bef_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX002KKCLicenseAgreementMember_78fdd6b1-e7a4-483b-a736-cc41eb969de5_terseLabel_en-US" xlink:label="lab_avtx_AVTX002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-002 KKC License Agreement</link:label>
    <link:label id="lab_avtx_AVTX002KKCLicenseAgreementMember_label_en-US" xlink:label="lab_avtx_AVTX002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-002 KKC License Agreement [Member]</link:label>
    <link:label id="lab_avtx_AVTX002KKCLicenseAgreementMember_documentation_en-US" xlink:label="lab_avtx_AVTX002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-002 KKC License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX002KKCLicenseAgreementMember" xlink:href="avtx-20230630.xsd#avtx_AVTX002KKCLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX002KKCLicenseAgreementMember" xlink:to="lab_avtx_AVTX002KKCLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2763c50b-dcb5-4a60-9cf8-196ad31e6e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_20b3fe7e-0bfd-4435-bdc7-3c70bb7c443c_terseLabel_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of June 2024</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_label_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date of June 2024 [Member]</link:label>
    <link:label id="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_documentation_en-US" xlink:label="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date of June 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:to="lab_avtx_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a1e40fca-3d92-449d-8c45-135ce1e37920_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0f696f63-891e-42f6-86b6-5ff3e6569e98_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cecb2312-12b6-470a-8be8-214b00ebaf1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_565fbb14-d522-410c-beb7-0c1703b65b9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ff9986f6-c608-40b1-94c3-03e3109974f6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bb755fc7-14d1-4c7d-a2f0-bc1f138176ef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cf8abc37-1f6f-44ef-9f59-3bb9ab5429b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_63099a02-0e41-479d-8a75-246fcf3febe2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b169b8f0-bf5f-4e0c-97e3-b03b3c565662_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased through employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_cf5eb0f9-aa28-473c-81a5-aa92c962ece3_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_796f7eb9-c1e1-4c31-a460-2722fb2b6d4c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5f16626f-4078-4461-a9f3-9ce55a8fc55d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_194c2af4-ca0d-4a15-bc7f-c848e9a06b31_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of option (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ba4a1fc-7eef-400a-a9fd-7613028d707a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 1, 2023 through December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39f31720-4264-4577-a800-18d6d4fd4854_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available under warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fa2c32b7-172f-4476-956b-bd9571acf5d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_60cb693c-9862-471a-91d8-586976c20484_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentInterestRateFloor_2753de5b-356b-4739-a55b-db65bf6cbbdd_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floor interest rate</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestRateFloor_label_en-US" xlink:label="lab_avtx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor</link:label>
    <link:label id="lab_avtx_DebtInstrumentInterestRateFloor_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestRateFloor" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentInterestRateFloor" xlink:to="lab_avtx_DebtInstrumentInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d21d41b5-d594-4d5b-bf3f-3a55d62a21c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_53bb5cf0-02cd-4f95-94b7-0831abc694bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_5cd95dad-3125-4754-b754-6c04c478b6a2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ad490e71-4b41-4399-8efb-92796532f518_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c029094f-6a1c-4271-abbf-8b225f674971_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_7e4660be-2d65-4406-af28-ca4210fa7231_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative expense recognized to date</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0be8a31b-f299-4b72-983d-81e848062f14_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_40492e31-cc59-4f20-bdcb-7d6c913ada00_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_a858d32d-b69f-49bf-a030-6c3e9feb3c51_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, measurement input</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_IchorionMember_64b8b785-a18f-4ac5-b4da-d398e964b2f0_terseLabel_en-US" xlink:label="lab_avtx_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion</link:label>
    <link:label id="lab_avtx_IchorionMember_label_en-US" xlink:label="lab_avtx_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion [Member]</link:label>
    <link:label id="lab_avtx_IchorionMember_documentation_en-US" xlink:label="lab_avtx_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IchorionMember" xlink:href="avtx-20230630.xsd#avtx_IchorionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_IchorionMember" xlink:to="lab_avtx_IchorionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_297e0780-7ba6-40ee-9b7d-2c8eed4da25d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_eb367b5c-a740-4cab-ab90-c5f8b24653e6_terseLabel_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual share reserve increase</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_label_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Share Reserve Increase as Percent</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_documentation_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:to="lab_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b40f2c56-21e4-4d7f-a481-0e93f2c7e572_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_The2016PlanMember_fea13537-cb80-4545-99b0-6963168c6121_terseLabel_en-US" xlink:label="lab_avtx_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_avtx_The2016PlanMember_label_en-US" xlink:label="lab_avtx_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2016 Plan [Member]</link:label>
    <link:label id="lab_avtx_The2016PlanMember_documentation_en-US" xlink:label="lab_avtx_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2016 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_The2016PlanMember" xlink:href="avtx-20230630.xsd#avtx_The2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_The2016PlanMember" xlink:to="lab_avtx_The2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SpecialAdvisorToTheBoardMember_48ce717d-ce92-4cc2-bc0f-ddf3fb2ff3ab_terseLabel_en-US" xlink:label="lab_avtx_SpecialAdvisorToTheBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Advisor To The Board</link:label>
    <link:label id="lab_avtx_SpecialAdvisorToTheBoardMember_label_en-US" xlink:label="lab_avtx_SpecialAdvisorToTheBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Advisor to the Board [Member]</link:label>
    <link:label id="lab_avtx_SpecialAdvisorToTheBoardMember_documentation_en-US" xlink:label="lab_avtx_SpecialAdvisorToTheBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Advisor to the Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SpecialAdvisorToTheBoardMember" xlink:href="avtx-20230630.xsd#avtx_SpecialAdvisorToTheBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SpecialAdvisorToTheBoardMember" xlink:to="lab_avtx_SpecialAdvisorToTheBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1f4d0249-0fc0-4236-ab2b-c557b08fa823_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a7d8fd5f-07ef-4a94-beaf-a15fb30fa23e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e302c66b-a50b-4ea8-80fb-d32677683e21_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_8f07aa01-095d-4adf-9f89-c34eeadaaf2d_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment charges percentage</link:label>
    <link:label id="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_label_en-US" xlink:label="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued And Unpaid Interest, Subject to Prepayment Charges, Percentage</link:label>
    <link:label id="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued And Unpaid Interest, Subject to Prepayment Charges, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:to="lab_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09e60db7-df93-405b-b680-4313871f4014_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_f7260d92-f6cd-49ad-a07c-2dd0a9ae0ba4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b38f23bd-e1d4-4940-9822-09ae7ef24b5b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_7f31cb07-70e7-4f82-a86c-3f40eaf3eabf_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2a1252ad-5871-4a98-8338-4afbb29a89bd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cded7e09-3d74-44ed-8a6f-ffd34b6f8944_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SecondNoteMember_b76ce1ff-bed9-4706-aedb-20a2b773c158_terseLabel_en-US" xlink:label="lab_avtx_SecondNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Note</link:label>
    <link:label id="lab_avtx_SecondNoteMember_label_en-US" xlink:label="lab_avtx_SecondNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Note [Member]</link:label>
    <link:label id="lab_avtx_SecondNoteMember_documentation_en-US" xlink:label="lab_avtx_SecondNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SecondNoteMember" xlink:href="avtx-20230630.xsd#avtx_SecondNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SecondNoteMember" xlink:to="lab_avtx_SecondNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_17c49e84-42a2-4228-a023-aa9f92ca9c5c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_bb0b42c9-4891-40eb-849b-527bea05d195_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_71a5e80e-faff-482a-8d5e-1afcef14de7b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f4ee1de0-8f6f-4dac-b2a3-60cb5c288bac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_0789cb7d-1b48-408f-a1bb-bb948b626edb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_5d01940a-ef19-4e5e-a2f6-34b2dec51b59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_6ccb5442-2c64-474a-882a-081126d31284_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_2f9bb8fb-303c-422c-8d17-f6d1c5f74b36_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value was recognized</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55f6439e-a7e6-42aa-ae90-0249c0e3cee9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_39fc095d-55b4-4e2d-84af-1254845d7e99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ATMAgreementMember_1c447c8a-7bf9-401f-af10-c1d4475c8ee7_terseLabel_en-US" xlink:label="lab_avtx_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_avtx_ATMAgreementMember_label_en-US" xlink:label="lab_avtx_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement [Member]</link:label>
    <link:label id="lab_avtx_ATMAgreementMember_documentation_en-US" xlink:label="lab_avtx_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ATMAgreementMember" xlink:href="avtx-20230630.xsd#avtx_ATMAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ATMAgreementMember" xlink:to="lab_avtx_ATMAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b581a982-a8f3-4bce-a76d-ade5be20f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_75d813d5-e4a4-4d41-bdbd-900a5fb65f06_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8c69a6a5-4143-4d6b-b675-2b77fd26a820_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_aa172b2c-2395-47f3-87e3-00f230d190a2_terseLabel_en-US" xlink:label="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of preclinical therapies</link:label>
    <link:label id="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_label_en-US" xlink:label="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Number of Preclinical Therapies</link:label>
    <link:label id="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_documentation_en-US" xlink:label="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Number of Preclinical Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionNumberOfPreclinicalTherapies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:to="lab_avtx_AssetAcquisitionNumberOfPreclinicalTherapies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_df70abaa-dc7b-4b5f-9280-67710853754c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_1bdee349-2cad-448e-9655-b8bc0e3f9921_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_63811ae8-ef98-45f5-937d-39b8212d4aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_839eb550-59d8-4000-9008-e3a71218d80e_terseLabel_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock and warrants in underwritten public offering, net</link:label>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_label_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Value</link:label>
    <link:label id="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_documentation_en-US" xlink:label="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:to="lab_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_8e0a22ab-b3a0-493f-b6a4-b941cc945036_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_50c62e90-3f67-4721-9c71-e9028118ed71_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6df33419-daa2-472a-8b3f-c5b13f13aaef_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a306c562-2a56-4be5-a8f9-d53c431e3f00_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3914c400-279a-4a9d-9e6e-cd891fbab6b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4d62085c-7e45-4b03-8d1d-e23611b1cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_98a899ec-d906-4239-bd19-1b790da4e767_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember_1c5d4747-4f22-495f-9a8e-ec1d211ff19d_terseLabel_en-US" xlink:label="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Based Options</link:label>
    <link:label id="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember_label_en-US" xlink:label="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options With Market Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options With Market Based Vesting Conditions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:href="avtx-20230630.xsd#avtx_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:to="lab_avtx_StockOptionsWithMarketBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_fd70888e-585b-4409-9af7-c4a67d078956_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6ec90fbd-dbf3-4282-ab6a-99e32f627361_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e7e112ad-e669-4e46-9750-03439a21ade4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6d48a74b-f116-41b2-8fcd-154449740e06_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1ecc5b69-b9a6-4aaf-adfa-f9ea4ff5516e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_785a0bf0-38e5-40b8-a94a-c5477e3e5588_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_13fe9c34-aa7b-4dcc-a9c6-795ae50db8e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to ATM Program, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CommercialOperationsCurrent_7e6313b0-d504-4fb6-9c49-0a408d747cb3_terseLabel_en-US" xlink:label="lab_avtx_CommercialOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial operations</link:label>
    <link:label id="lab_avtx_CommercialOperationsCurrent_label_en-US" xlink:label="lab_avtx_CommercialOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Operations, Current</link:label>
    <link:label id="lab_avtx_CommercialOperationsCurrent_documentation_en-US" xlink:label="lab_avtx_CommercialOperationsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Operations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommercialOperationsCurrent" xlink:href="avtx-20230630.xsd#avtx_CommercialOperationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CommercialOperationsCurrent" xlink:to="lab_avtx_CommercialOperationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eef73a40-84bc-465e-b337-51fbfa0b5a70_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a94b31e9-d9b5-4ef2-a026-5ad2e89c6b34_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_863a5bdc-4107-4a5a-8fd1-ab7284f6037e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_47a1c652-7629-4cf6-bc4b-92c6f4b99133_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b5484a46-11b1-4770-b712-0452a38d4d76_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a20827a4-0f65-477c-9025-40eab972df4e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_4b6d3962-9fe0-4c81-a10b-206e51afa6e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_db921d3c-831e-4b66-ae91-95e5f9f1c5b9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SeparationFromCertainSection16OfficersMember_bb0c9f84-8f38-40d5-bee7-7badb32f1174_terseLabel_en-US" xlink:label="lab_avtx_SeparationFromCertainSection16OfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation From Certain Section 16 Officers</link:label>
    <link:label id="lab_avtx_SeparationFromCertainSection16OfficersMember_label_en-US" xlink:label="lab_avtx_SeparationFromCertainSection16OfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation From Certain Section 16 Officers [Member]</link:label>
    <link:label id="lab_avtx_SeparationFromCertainSection16OfficersMember_documentation_en-US" xlink:label="lab_avtx_SeparationFromCertainSection16OfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation From Certain Section 16 Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SeparationFromCertainSection16OfficersMember" xlink:href="avtx-20230630.xsd#avtx_SeparationFromCertainSection16OfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SeparationFromCertainSection16OfficersMember" xlink:to="lab_avtx_SeparationFromCertainSection16OfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_KarbinalAgreementMember_5ab3153a-5508-4e28-9e1b-6ec1ada41194_terseLabel_en-US" xlink:label="lab_avtx_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement</link:label>
    <link:label id="lab_avtx_KarbinalAgreementMember_label_en-US" xlink:label="lab_avtx_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement [Member]</link:label>
    <link:label id="lab_avtx_KarbinalAgreementMember_documentation_en-US" xlink:label="lab_avtx_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KarbinalAgreementMember" xlink:href="avtx-20230630.xsd#avtx_KarbinalAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_KarbinalAgreementMember" xlink:to="lab_avtx_KarbinalAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e45340ab-23cb-46c4-b2c8-9ae6f536b9c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_658fa8cd-19b5-4c07-91f4-48b574045613_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0fc96157-95cb-4cc6-ae24-de1b3aff57c5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_d203c9c6-4b99-49ac-b15a-630373caf739_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common shares in exchange for pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_e1b253b8-97f8-4318-8d3b-83d9e8af809a_terseLabel_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_label_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</link:label>
    <link:label id="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_documentation_en-US" xlink:label="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:to="lab_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_866b50ef-f256-420b-9d3b-8f3212b8b1c3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of notes payable, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_2be71a9b-e859-4d66-b1fe-8b253cb9e098_terseLabel_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, ownership, exercise threshold</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_label_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Ownership, Exercise Threshold</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_documentation_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Ownership, Exercise Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:to="lab_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9e7851e-b750-4801-b49e-5e0aa6f002a8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX406LicenseAssignmentMember_dadfbf7b-4e58-47fb-970f-5ca84657844f_terseLabel_en-US" xlink:label="lab_avtx_AVTX406LicenseAssignmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-406 License Assignment</link:label>
    <link:label id="lab_avtx_AVTX406LicenseAssignmentMember_label_en-US" xlink:label="lab_avtx_AVTX406LicenseAssignmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-406 License Assignment [Member]</link:label>
    <link:label id="lab_avtx_AVTX406LicenseAssignmentMember_documentation_en-US" xlink:label="lab_avtx_AVTX406LicenseAssignmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-406 License Assignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX406LicenseAssignmentMember" xlink:href="avtx-20230630.xsd#avtx_AVTX406LicenseAssignmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX406LicenseAssignmentMember" xlink:to="lab_avtx_AVTX406LicenseAssignmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_248edc1b-461a-4245-bdcd-ccd1d085a6c7_terseLabel_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants or rights exercisable term</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_label_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants or Rights Exercisable, Term</link:label>
    <link:label id="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_documentation_en-US" xlink:label="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants or Rights Exercisable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:to="lab_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_639a131a-02f7-4f9d-8c2d-46c0df56c741_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_UnderwrittenPublicOfferingMember_e19af7ec-a2d0-4a80-ae41-46c1cdc63395_terseLabel_en-US" xlink:label="lab_avtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_avtx_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_avtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_avtx_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_avtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_UnderwrittenPublicOfferingMember" xlink:href="avtx-20230630.xsd#avtx_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_UnderwrittenPublicOfferingMember" xlink:to="lab_avtx_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8477dc82-8f39-455e-b1f4-f5625e8dd670_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a0de78d4-6407-4502-b93a-aed52695112a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_d1b1807c-b5e4-48ac-8cbd-e7429f9aee2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_VenrockHealthcareCapitalPartnersMember_f5c528ec-d700-449a-a54c-08422fe5fa6e_terseLabel_en-US" xlink:label="lab_avtx_VenrockHealthcareCapitalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Venrock</link:label>
    <link:label id="lab_avtx_VenrockHealthcareCapitalPartnersMember_label_en-US" xlink:label="lab_avtx_VenrockHealthcareCapitalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Venrock Healthcare Capital Partners [Member]</link:label>
    <link:label id="lab_avtx_VenrockHealthcareCapitalPartnersMember_documentation_en-US" xlink:label="lab_avtx_VenrockHealthcareCapitalPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Venrock Healthcare Capital Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_VenrockHealthcareCapitalPartnersMember" xlink:href="avtx-20230630.xsd#avtx_VenrockHealthcareCapitalPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_VenrockHealthcareCapitalPartnersMember" xlink:to="lab_avtx_VenrockHealthcareCapitalPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f6bafa88-923e-4d8c-bc5e-c233f3649f49_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_19470afc-a6ed-4463-bb12-8c3582a72b20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_df15c46e-8849-461b-8113-7828613a18c1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b6d2f8ee-3c55-4316-b650-0a9a9f1deb63_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_137096c6-4dca-46e5-b6ce-f90af14b11c5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_WarrantCommonStockMember_bf70202e-55f2-4aec-aa86-89525f3749a4_terseLabel_en-US" xlink:label="lab_avtx_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants on common stock</link:label>
    <link:label id="lab_avtx_WarrantCommonStockMember_label_en-US" xlink:label="lab_avtx_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Common Stock [Member]</link:label>
    <link:label id="lab_avtx_WarrantCommonStockMember_documentation_en-US" xlink:label="lab_avtx_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to warrant common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_WarrantCommonStockMember" xlink:href="avtx-20230630.xsd#avtx_WarrantCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_WarrantCommonStockMember" xlink:to="lab_avtx_WarrantCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_78ff28f2-e594-4378-baa9-960d48f63f0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2bfa00eb-5d77-4c97-a34d-e97295f72828_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_30152839-5d8e-446e-ab5a-e8cf73a659d8_terseLabel_en-US" xlink:label="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, maximum amount of shares to be sold</link:label>
    <link:label id="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_label_en-US" xlink:label="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Maximum Amount Of Shares To Be Sold</link:label>
    <link:label id="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_documentation_en-US" xlink:label="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Maximum Amount Of Shares To Be Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:href="avtx-20230630.xsd#avtx_SaleOfStockMaximumAmountOfSharesToBeSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:to="lab_avtx_SaleOfStockMaximumAmountOfSharesToBeSold" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MilestoneThreeMember_d465502d-a7d2-4cb4-846d-fb471cf42d9c_terseLabel_en-US" xlink:label="lab_avtx_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_avtx_MilestoneThreeMember_label_en-US" xlink:label="lab_avtx_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_avtx_MilestoneThreeMember_documentation_en-US" xlink:label="lab_avtx_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneThreeMember" xlink:href="avtx-20230630.xsd#avtx_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MilestoneThreeMember" xlink:to="lab_avtx_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_46b78c6f-ce9b-4937-8974-664e8e654425_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_333a6dcd-df66-480f-b63d-6fc0d880039e_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent costs</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Patent Costs</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Patent Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPatentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_65088d47-23c0-4666-b392-4a394ee8e37b_terseLabel_en-US" xlink:label="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Asset Acquisition Contingent Consideration Liability Operating Activities</link:label>
    <link:label id="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_documentation_en-US" xlink:label="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Asset Acquisition Contingent Consideration Liability Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:href="avtx-20230630.xsd#avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_e56b7396-6051-498b-ad20-343fd9cccf54_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Fee</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentFinalPaymentFee_2720ee52-1159-4a69-8a1d-b456b2d14571_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentFinalPaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment fee</link:label>
    <link:label id="lab_avtx_DebtInstrumentFinalPaymentFee_label_en-US" xlink:label="lab_avtx_DebtInstrumentFinalPaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment Fee</link:label>
    <link:label id="lab_avtx_DebtInstrumentFinalPaymentFee_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentFinalPaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentFinalPaymentFee" xlink:to="lab_avtx_DebtInstrumentFinalPaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_b1b055eb-329a-4459-b4d8-2511255e1570_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_668fc725-2214-4de6-84b6-815e4d8a18f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3bef645-9529-49ee-8d23-ec617a1df10b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_983b613c-6c3f-41fd-ac8a-746090be466a_terseLabel_en-US" xlink:label="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional final payment percentage</link:label>
    <link:label id="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_label_en-US" xlink:label="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Final Payment, Percentage</link:label>
    <link:label id="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_documentation_en-US" xlink:label="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Final Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:to="lab_avtx_DebtInstrumentAdditionalFinalPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses_f4b59766-a83e-4ae4-b52d-f1ad7cee88db_terseLabel_en-US" xlink:label="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses_label_en-US" xlink:label="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Selling, General And Administrative Expenses</link:label>
    <link:label id="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses_documentation_en-US" xlink:label="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Selling, General And Administrative Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:href="avtx-20230630.xsd#avtx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:to="lab_avtx_AccruedSellingGeneralAndAdministrativeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MilestoneDomain_c37dbf7a-9b74-416b-8185-bf69a26e6abf_terseLabel_en-US" xlink:label="lab_avtx_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_avtx_MilestoneDomain_label_en-US" xlink:label="lab_avtx_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_avtx_MilestoneDomain_documentation_en-US" xlink:label="lab_avtx_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MilestoneDomain" xlink:to="lab_avtx_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8422d030-e2cc-4484-bed6-a24d26dba078_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0ed4d351-51d8-4370-b7bd-99c5a9f2b6ef_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_68d49733-9387-471e-a3cb-a9f0434721c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5be357a-a111-4ce9-abe7-79af02ba80f6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_90664d15-dfc7-4758-ba9f-a663769b2a78_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7f1390d6-735b-4f5d-a68a-3dcdf9142907_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_235ceb3e-6005-4f31-891e-0e5ffba51479_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_fab0a0e0-3a37-4479-bc0e-b42505e1b9ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_423b97d9-1e67-4757-8386-fcf3d6b4ea5f_terseLabel_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate milestone payment</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_label_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:label id="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_documentation_en-US" xlink:label="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:to="lab_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2e044d9d-b175-4c5e-8f98-ab3c18f65462_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0742b2af-099e-4743-987d-fa0e499bf610_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AVTX913Member_25b55919-7d0c-4feb-8533-7bf98206e69e_terseLabel_en-US" xlink:label="lab_avtx_AVTX913Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-913</link:label>
    <link:label id="lab_avtx_AVTX913Member_label_en-US" xlink:label="lab_avtx_AVTX913Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-913 [Member]</link:label>
    <link:label id="lab_avtx_AVTX913Member_documentation_en-US" xlink:label="lab_avtx_AVTX913Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVTX-913</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX913Member" xlink:href="avtx-20230630.xsd#avtx_AVTX913Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AVTX913Member" xlink:to="lab_avtx_AVTX913Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_77de6dc6-39e2-434b-8671-73346772955a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e42a43d4-22ca-4329-a12b-eb723162fc02_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_67a065e5-5747-4bf8-8057-7fb4b91c5bdc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock_e143d7fb-442a-4ec5-89d2-a99641169300_terseLabel_en-US" xlink:label="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Lessee</link:label>
    <link:label id="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Lessee [Table Text Block]</link:label>
    <link:label id="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="avtx-20230630.xsd#avtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_avtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_8a5b35c8-a5a8-48b7-8657-56bfa4717462_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_592bac21-1c24-4018-9ea7-f3ec1533be59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_ac332d93-29f2-4c33-b1f8-c23fdb66e732_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_NumberOfClassOfStockAuthorized_c249f198-7598-46aa-b76f-d36b4c3eddfb_terseLabel_en-US" xlink:label="lab_avtx_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of stock authorized to issue</link:label>
    <link:label id="lab_avtx_NumberOfClassOfStockAuthorized_label_en-US" xlink:label="lab_avtx_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Class of Stock Authorized</link:label>
    <link:label id="lab_avtx_NumberOfClassOfStockAuthorized_documentation_en-US" xlink:label="lab_avtx_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of classes of stock permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NumberOfClassOfStockAuthorized" xlink:href="avtx-20230630.xsd#avtx_NumberOfClassOfStockAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_NumberOfClassOfStockAuthorized" xlink:to="lab_avtx_NumberOfClassOfStockAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_57e12bcf-14ba-4f3d-a959-059465a1e5ca_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avtx_MajorCustomerNumberOneMember_ad087c2f-25bb-4161-b407-f3d720625dfd_terseLabel_en-US" xlink:label="lab_avtx_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One</link:label>
    <link:label id="lab_avtx_MajorCustomerNumberOneMember_label_en-US" xlink:label="lab_avtx_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One [Member]</link:label>
    <link:label id="lab_avtx_MajorCustomerNumberOneMember_documentation_en-US" xlink:label="lab_avtx_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberOneMember" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avtx_MajorCustomerNumberOneMember" xlink:to="lab_avtx_MajorCustomerNumberOneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>avtx-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b25e7887-f18f-455e-b804-37209951379a,g:9803074a-3323-4bc5-a461-70e4fb29da72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/Cover" xlink:type="simple" xlink:href="avtx-20230630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b3a5cb6a-defe-4cbc-b5fc-6b7bd28b2865" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentType_b3a5cb6a-defe-4cbc-b5fc-6b7bd28b2865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e846636b-e331-4dbb-b7d5-abea0f25c7ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentQuarterlyReport_e846636b-e331-4dbb-b7d5-abea0f25c7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_52b49572-a90b-4cc2-b6f8-a01f525dc479" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentPeriodEndDate_52b49572-a90b-4cc2-b6f8-a01f525dc479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4df8c96e-64b0-46e3-a477-70ac8a9f7381" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentTransitionReport_4df8c96e-64b0-46e3-a477-70ac8a9f7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a3054232-2b39-439c-81c2-2674811c9e6a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityFileNumber_a3054232-2b39-439c-81c2-2674811c9e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_871e186f-7964-4a68-8e98-884b4a00e186" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityRegistrantName_871e186f-7964-4a68-8e98-884b4a00e186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0866254c-3c28-495b-a792-754103411648" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0866254c-3c28-495b-a792-754103411648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5a523f0a-87f5-45ce-9521-80c31dd6b8c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityTaxIdentificationNumber_5a523f0a-87f5-45ce-9521-80c31dd6b8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e6e8ad8f-bf2d-4b7b-abb1-56b73a9d665a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityAddressAddressLine1_e6e8ad8f-bf2d-4b7b-abb1-56b73a9d665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_93487894-37fd-424a-9c1a-9cc18b907d6b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityAddressCityOrTown_93487894-37fd-424a-9c1a-9cc18b907d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_77044ce7-5d7c-4499-be8c-9c8d5243ce05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityAddressStateOrProvince_77044ce7-5d7c-4499-be8c-9c8d5243ce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c2271160-3f9f-4765-abf8-fcfe816fadf1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityAddressPostalZipCode_c2271160-3f9f-4765-abf8-fcfe816fadf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_759e513d-3170-4164-b8f9-f8e5c950930d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_CityAreaCode_759e513d-3170-4164-b8f9-f8e5c950930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cfd86796-941a-4619-a5de-6cf8cffed1a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_LocalPhoneNumber_cfd86796-941a-4619-a5de-6cf8cffed1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2593647e-4313-450b-b21a-174f2fa15b5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_Security12bTitle_2593647e-4313-450b-b21a-174f2fa15b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5fd9cc93-41db-4cd1-b4d8-a43808dd36e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_TradingSymbol_5fd9cc93-41db-4cd1-b4d8-a43808dd36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_55a95adb-c4de-4811-af5f-7158afd5ead3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_SecurityExchangeName_55a95adb-c4de-4811-af5f-7158afd5ead3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_03b3d2b0-eee0-4d90-b861-b719d58427f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityCurrentReportingStatus_03b3d2b0-eee0-4d90-b861-b719d58427f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b2860678-c129-4d65-85f9-b368286c6d95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityInteractiveDataCurrent_b2860678-c129-4d65-85f9-b368286c6d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b1e7520d-9219-4189-b10f-3eed34a01e98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityFilerCategory_b1e7520d-9219-4189-b10f-3eed34a01e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_14daafc1-358f-41bc-8a44-74af17911e4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntitySmallBusiness_14daafc1-358f-41bc-8a44-74af17911e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fd37f913-05dd-4508-948e-298fc7f74839" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityEmergingGrowthCompany_fd37f913-05dd-4508-948e-298fc7f74839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9cd32d71-81da-4775-bbcb-9f842c3e25b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityShellCompany_9cd32d71-81da-4775-bbcb-9f842c3e25b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4207c495-01a5-48a3-a37f-0e7b96870ce5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4207c495-01a5-48a3-a37f-0e7b96870ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7dc7cb77-3919-41bf-a5a7-746225dfcdd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_EntityCentralIndexKey_7dc7cb77-3919-41bf-a5a7-746225dfcdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_52c182ba-e1f2-4089-8c0b-3ec336ad02b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_CurrentFiscalYearEndDate_52c182ba-e1f2-4089-8c0b-3ec336ad02b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c2c0acae-026a-45a3-8728-c2f0dba5e94d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentFiscalYearFocus_c2c0acae-026a-45a3-8728-c2f0dba5e94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4c66dbfc-ff07-4dee-b5e3-b7a5224659ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4c66dbfc-ff07-4dee-b5e3-b7a5224659ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3149aee1-ddca-4a5f-b3b6-fc1d8e6bb5a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0e241a1d-9b04-4aae-82b5-66d049b342c5" xlink:to="loc_dei_AmendmentFlag_3149aee1-ddca-4a5f-b3b6-fc1d8e6bb5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ccd88687-59f9-4f1e-893f-07f69d2add5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ccd88687-59f9-4f1e-893f-07f69d2add5e" xlink:to="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b038f9c0-03bd-4deb-9b84-9178b1cc55ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b038f9c0-03bd-4deb-9b84-9178b1cc55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c71c97ee-e892-47b8-9c9b-95384b70de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c71c97ee-e892-47b8-9c9b-95384b70de1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_76ea939e-217a-4e08-b908-3e37680204de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_76ea939e-217a-4e08-b908-3e37680204de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_62cacb82-1f27-4d1d-b897-73d71e3b2bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_InventoryNet_62cacb82-1f27-4d1d-b897-73d71e3b2bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84624243-348c-4af6-8dfe-3c27df7e8582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84624243-348c-4af6-8dfe-3c27df7e8582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_af23ef73-5d49-4a4b-8f42-917c7e8b380b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_af23ef73-5d49-4a4b-8f42-917c7e8b380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1e4f11a0-0fde-4f1e-bfd3-74c20ebd6d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b965271-1cd6-49c1-b066-d3e87971f6f9" xlink:to="loc_us-gaap_AssetsCurrent_1e4f11a0-0fde-4f1e-bfd3-74c20ebd6d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e8bb9543-3d60-4b38-b73a-0743b133f230" xlink:href="avtx-20230630.xsd#avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:to="loc_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e8bb9543-3d60-4b38-b73a-0743b133f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a488b5c5-4738-4397-bc11-160a6e648fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:to="loc_us-gaap_Goodwill_a488b5c5-4738-4397-bc11-160a6e648fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bb41e51c-9d2a-4b34-8b10-224d1e89b1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bb41e51c-9d2a-4b34-8b10-224d1e89b1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5f268553-6385-4fe5-94cc-d827e23b56aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bf11be0-0eaa-4cad-b91c-e6ea539f9e2d" xlink:to="loc_us-gaap_Assets_5f268553-6385-4fe5-94cc-d827e23b56aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ccd88687-59f9-4f1e-893f-07f69d2add5e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6f5df95f-eb85-4697-9f68-af382f70ee3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:to="loc_us-gaap_AccountsPayableCurrent_6f5df95f-eb85-4697-9f68-af382f70ee3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1cdb1f7-35a1-4904-b030-3884c6cddec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c1cdb1f7-35a1-4904-b030-3884c6cddec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fb783a79-1d42-489e-8397-5811ebb8585d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fb783a79-1d42-489e-8397-5811ebb8585d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_59ba17dc-1143-46fb-87a1-2ecf6999de64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:to="loc_us-gaap_NotesPayableCurrent_59ba17dc-1143-46fb-87a1-2ecf6999de64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e240a7c1-3c85-4d19-9db3-eef3ad6bad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_58563dbf-7fd1-4ed1-a66f-112d5126befc" xlink:to="loc_us-gaap_LiabilitiesCurrent_e240a7c1-3c85-4d19-9db3-eef3ad6bad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_828535e4-2a22-4f16-ab87-6e9a66cb309d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_LongTermNotesPayable_828535e4-2a22-4f16-ab87-6e9a66cb309d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_642d1430-4917-4ac1-bdbf-2f3f3ff48005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_642d1430-4917-4ac1-bdbf-2f3f3ff48005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a564c9bb-bc08-45b8-b8fa-17b0909e7044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a564c9bb-bc08-45b8-b8fa-17b0909e7044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ab6ee235-f01a-46e2-af16-436be2cdfe13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ab6ee235-f01a-46e2-af16-436be2cdfe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22f29132-6886-49dd-afbc-5b1fc3b97068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22f29132-6886-49dd-afbc-5b1fc3b97068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d71c0be9-2c79-41df-abd2-966eabb12c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_Liabilities_d71c0be9-2c79-41df-abd2-966eabb12c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eff73eb1-4b31-463f-a28c-022fdca0d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:to="loc_us-gaap_CommonStockValue_eff73eb1-4b31-463f-a28c-022fdca0d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_591e1eb5-d2ed-456f-863a-5ba096a3c573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:to="loc_us-gaap_AdditionalPaidInCapital_591e1eb5-d2ed-456f-863a-5ba096a3c573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c33fc9ee-bcae-4f20-8334-ca98f6a46466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c33fc9ee-bcae-4f20-8334-ca98f6a46466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b54e558d-2918-443a-8e26-5bc727b4e491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99667a37-d1a6-47a2-af42-7096e0240117" xlink:to="loc_us-gaap_StockholdersEquity_b54e558d-2918-443a-8e26-5bc727b4e491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed5ec36a-f4c5-4537-b5a1-4df682740db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96d4f071-b02e-4443-96d1-2063115f1d34" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed5ec36a-f4c5-4537-b5a1-4df682740db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e6e11725-4dee-449b-9473-25f712997e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c5b47f12-fc97-4e98-9f30-04dcfa67a5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6e11725-4dee-449b-9473-25f712997e2d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c5b47f12-fc97-4e98-9f30-04dcfa67a5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_562938ba-090b-466c-a540-1db5519d3db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6e11725-4dee-449b-9473-25f712997e2d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_562938ba-090b-466c-a540-1db5519d3db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a753495a-fee6-44af-8e5d-c0991b78fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6e11725-4dee-449b-9473-25f712997e2d" xlink:to="loc_us-gaap_CommonStockSharesIssued_a753495a-fee6-44af-8e5d-c0991b78fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6ec6c54d-0681-4ce3-8a44-83e47c5e0191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6e11725-4dee-449b-9473-25f712997e2d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6ec6c54d-0681-4ce3-8a44-83e47c5e0191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c8ab220a-51c6-4388-8fce-f921da03a408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c8ab220a-51c6-4388-8fce-f921da03a408" xlink:to="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:to="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bd892539-fa07-47eb-b203-9be332d0dc91" xlink:to="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_09595220-4b36-4031-ada7-27f9cbcf50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4ff644c-ac2a-4d2f-bcf0-62b00b44438e" xlink:to="loc_us-gaap_ProductMember_09595220-4b36-4031-ada7-27f9cbcf50bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4ad663a-9f92-47b0-8793-94b1c9936a36" xlink:to="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b208c344-2b58-4482-94cc-c4a862959cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a91e5011-2bcc-4059-b3de-e4fab71c356d" xlink:to="loc_us-gaap_RetainedEarningsMember_b208c344-2b58-4482-94cc-c4a862959cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_027c26d8-15ed-41b4-9b98-7cd24c0188b8" xlink:to="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2d83e3-fa42-4bcc-a2c0-26c4d98f25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_45e2ce47-0895-4620-8127-3120f1b622b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2d83e3-fa42-4bcc-a2c0-26c4d98f25e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3674d1e6-36f1-4c93-83f5-2d4519ebf512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3674d1e6-36f1-4c93-83f5-2d4519ebf512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_40cc1dff-351a-4f9a-8932-2d625bb30344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_40cc1dff-351a-4f9a-8932-2d625bb30344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dc934aa-2374-453b-b5fb-031f370e9467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dc934aa-2374-453b-b5fb-031f370e9467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10f415d9-d921-4f8b-b48b-d39550369bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10f415d9-d921-4f8b-b48b-d39550369bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_71e87e74-526b-40da-b190-4230ce9a1a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c71af06f-5325-4c3c-aec9-36448f3c51f4" xlink:to="loc_us-gaap_CostsAndExpenses_71e87e74-526b-40da-b190-4230ce9a1a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1097dc0-3fcd-4c76-b55d-b156f78808e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1097dc0-3fcd-4c76-b55d-b156f78808e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c694d437-7125-42f2-a097-2fca162a3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c694d437-7125-42f2-a097-2fca162a3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_62e1b3a5-148a-48b9-b275-a466b4558c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_62e1b3a5-148a-48b9-b275-a466b4558c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_662eae49-0d63-4f02-b6fc-c5c31acf1d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_662eae49-0d63-4f02-b6fc-c5c31acf1d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5192103f-a65e-4c8e-aba3-51e98cece77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e5ded1d2-d7a5-4539-87f3-ae1c4d99e244" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5192103f-a65e-4c8e-aba3-51e98cece77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd3f68e-0a8d-42db-bf9c-4dcd6808a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd3f68e-0a8d-42db-bf9c-4dcd6808a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09840104-f356-49b2-a7c3-b8b70cd8d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09840104-f356-49b2-a7c3-b8b70cd8d7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_13e54aef-450a-470e-a4cc-add9d7db82bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_NetIncomeLoss_13e54aef-450a-470e-a4cc-add9d7db82bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb7d25cc-6adc-4856-a46d-6200364d6a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb7d25cc-6adc-4856-a46d-6200364d6a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c8c09bf2-f3fd-4bb3-82e1-fde5d6e8e639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_EarningsPerShareBasic_c8c09bf2-f3fd-4bb3-82e1-fde5d6e8e639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6c66dbd3-a682-4815-81ab-dae82c208f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94f0713a-2f59-4de3-bf06-d2983d9f050c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6c66dbd3-a682-4815-81ab-dae82c208f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_643fc4bc-5837-40d9-8cee-8177e9b5cd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2ac8be84-88c9-457b-99cf-ee6f6495d9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_643fc4bc-5837-40d9-8cee-8177e9b5cd52" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2ac8be84-88c9-457b-99cf-ee6f6495d9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2b8d63d-c421-490b-b7bb-e2b6827f04f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2b8d63d-c421-490b-b7bb-e2b6827f04f5" xlink:to="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb1a8b35-ecd3-46b0-9aa2-876c6ee06330" xlink:to="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aa437e50-bf5e-4652-b4ba-320eb637d59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_CommonStockMember_aa437e50-bf5e-4652-b4ba-320eb637d59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a2414934-e53f-443d-82c0-59b575e6d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a2414934-e53f-443d-82c0-59b575e6d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ef6d6cae-a516-477d-bbfb-588c37039764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82744643-c043-4ec5-8ead-3d59a694286e" xlink:to="loc_us-gaap_RetainedEarningsMember_ef6d6cae-a516-477d-bbfb-588c37039764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ada2389-6649-47eb-ac52-f977b72886c9" xlink:to="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e218a54f-a027-496b-a143-7513708b616c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_23b88e20-7219-40b3-9218-b05e76da15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_SharesOutstanding_23b88e20-7219-40b3-9218-b05e76da15b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c916b34b-c959-46e9-9057-4c56fe8a70b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockholdersEquity_c916b34b-c959-46e9-9057-4c56fe8a70b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_66faf74a-9813-47f9-bd3d-acf419fdb827" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare_66faf74a-9813-47f9-bd3d-acf419fdb827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_060d3383-c7b0-483d-b226-0bdc91878b69" xlink:href="avtx-20230630.xsd#avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue_060d3383-c7b0-483d-b226-0bdc91878b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fc09aaa-c822-45b8-8adb-7a0bc106c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1fc09aaa-c822-45b8-8adb-7a0bc106c8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ecc5cf3d-84cc-47ab-812c-7b714fbaf582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ecc5cf3d-84cc-47ab-812c-7b714fbaf582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4ec9df29-c898-42d2-824e-66b198be330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4ec9df29-c898-42d2-824e-66b198be330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_41b87635-3b92-4a62-a831-8317fc6073d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_41b87635-3b92-4a62-a831-8317fc6073d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_659ded22-2cb3-48f2-9929-32c41a26b8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_659ded22-2cb3-48f2-9929-32c41a26b8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_e34d725a-d36b-402b-88ef-17874f8e326f" xlink:href="avtx-20230630.xsd#avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants_e34d725a-d36b-402b-88ef-17874f8e326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_546f31f9-e631-4354-b92e-122f89dae5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_546f31f9-e631-4354-b92e-122f89dae5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_11516682-1311-4b4a-8d41-c148cba85c40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_11516682-1311-4b4a-8d41-c148cba85c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_54a39dd9-e95b-43d7-afa1-210cb98af0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_54a39dd9-e95b-43d7-afa1-210cb98af0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3aa498c5-b978-46e3-9328-64f8cde25655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3aa498c5-b978-46e3-9328-64f8cde25655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_784710fe-2552-4b69-889c-6386a8ad80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_NetIncomeLoss_784710fe-2552-4b69-889c-6386a8ad80ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_56288d71-dea2-47a9-ad15-a1a942c969e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_SharesOutstanding_56288d71-dea2-47a9-ad15-a1a942c969e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_30db5b49-76ba-49db-8474-dbda912d531d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec7cc039-136c-4327-9237-29d804c3a2a7" xlink:to="loc_us-gaap_StockholdersEquity_30db5b49-76ba-49db-8474-dbda912d531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_64487429-3d14-4ee4-b0ba-bd0a6ac4f924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_14bfc1ce-0ef9-4516-8d8e-dcf51090a9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_64487429-3d14-4ee4-b0ba-bd0a6ac4f924" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_14bfc1ce-0ef9-4516-8d8e-dcf51090a9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="avtx-20230630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_aaf540a4-97a1-4eba-9469-5609969ac815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_aaf540a4-97a1-4eba-9469-5609969ac815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_82b18af5-aca0-4959-8d86-b67b1fd2f93b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_aaf540a4-97a1-4eba-9469-5609969ac815" xlink:to="loc_us-gaap_NetIncomeLoss_82b18af5-aca0-4959-8d86-b67b1fd2f93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_aaf540a4-97a1-4eba-9469-5609969ac815" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e14b1043-58a6-4cb0-ac96-f12194c4ce27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e14b1043-58a6-4cb0-ac96-f12194c4ce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ab52e03a-fe7b-4ff2-9b42-4487d41bf4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_ShareBasedCompensation_ab52e03a-fe7b-4ff2-9b42-4487d41bf4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c1ba20d-8805-42b6-a4d3-558f24a3f82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c1ba20d-8805-42b6-a4d3-558f24a3f82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_bbd73360-e94a-444f-bfb8-98feb2aa2634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_bbd73360-e94a-444f-bfb8-98feb2aa2634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7df1608-47c9-4f35-82ea-cd97a332c742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7df1608-47c9-4f35-82ea-cd97a332c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_1f4e0437-abc3-4af1-a6d0-2929f66eb2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_1f4e0437-abc3-4af1-a6d0-2929f66eb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_332fd9a7-14dd-4454-b4d1-71a4bedbd9cb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_660cd941-aeea-4362-bb6d-aac58cda4698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_660cd941-aeea-4362-bb6d-aac58cda4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_186eb42e-c3cf-424a-bac0-f3361f3baf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_186eb42e-c3cf-424a-bac0-f3361f3baf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1932e1cd-a994-4ca8-9eff-2ab588b9632f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1932e1cd-a994-4ca8-9eff-2ab588b9632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7254cbe4-5eb5-4855-909b-456f69dec3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7254cbe4-5eb5-4855-909b-456f69dec3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseIncentives_5f1e7924-a29d-4740-8b60-0f1f26ecbaaa" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseIncentives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_avtx_IncreaseDecreaseInLeaseIncentives_5f1e7924-a29d-4740-8b60-0f1f26ecbaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c2185cd8-0235-49d6-862a-900ec00b6002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c2185cd8-0235-49d6-862a-900ec00b6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f91de0a-fdef-45fa-ab16-709ff3cce379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f91de0a-fdef-45fa-ab16-709ff3cce379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_265dae18-84ba-4e6b-87bf-40a8a8e2288e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_265dae18-84ba-4e6b-87bf-40a8a8e2288e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IncreaseDecreaseInLeaseLiability_9b14fea6-fd4e-4a3d-b1cd-4dd6c4873445" xlink:href="avtx-20230630.xsd#avtx_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bf20b6f-11db-4512-8190-db35d3e11920" xlink:to="loc_avtx_IncreaseDecreaseInLeaseLiability_9b14fea6-fd4e-4a3d-b1cd-4dd6c4873445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_624f4ce2-f816-49bd-9d71-4dc01e64b5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_aaf540a4-97a1-4eba-9469-5609969ac815" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_624f4ce2-f816-49bd-9d71-4dc01e64b5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_d083719e-79d9-43e0-871e-9cb43998af5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_d083719e-79d9-43e0-871e-9cb43998af5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a8b9a74f-19ba-40dc-9b50-f37e8b3a9053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a8b9a74f-19ba-40dc-9b50-f37e8b3a9053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_4fc9f90d-77a1-495c-bcf5-911486de8ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_4fc9f90d-77a1-495c-bcf5-911486de8ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76e2935f-791b-4853-a00b-347dc76b3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5fa4f030-9795-4adc-a903-93cb1068b9e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76e2935f-791b-4853-a00b-347dc76b3c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_bde20d0d-53ef-411a-b44e-5ae9a86b89c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:to="loc_us-gaap_RepaymentsOfDebt_bde20d0d-53ef-411a-b44e-5ae9a86b89c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_9aa2e603-c31d-44f4-9311-f938eee165a1" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:to="loc_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants_9aa2e603-c31d-44f4-9311-f938eee165a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_48cdcfb4-939e-4dfc-8d65-a05dbc7eaf0b" xlink:href="avtx-20230630.xsd#avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:to="loc_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram_48cdcfb4-939e-4dfc-8d65-a05dbc7eaf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_61434fbc-146a-4dec-81d9-b138cbd89bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:to="loc_us-gaap_ProceedsFromStockPlans_61434fbc-146a-4dec-81d9-b138cbd89bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_943312dd-302c-4ab6-9467-773cfef9b45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa4f500c-979c-46a0-a3c7-2da79b324304" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_943312dd-302c-4ab6-9467-773cfef9b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5069b548-379b-4407-a01c-d8c730c485de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5069b548-379b-4407-a01c-d8c730c485de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a13ea6-efb7-4aeb-ac50-d59d0c6d9ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a13ea6-efb7-4aeb-ac50-d59d0c6d9ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b7c97b9-6d4e-45be-b3f3-b6f8bb094f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b7c97b9-6d4e-45be-b3f3-b6f8bb094f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_921fb879-4103-4f75-8ead-55d740d1858e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_921fb879-4103-4f75-8ead-55d740d1858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_77d6aba7-5a23-47a6-bfad-f6ec1acf0f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_921fb879-4103-4f75-8ead-55d740d1858e" xlink:to="loc_us-gaap_InterestPaidNet_77d6aba7-5a23-47a6-bfad-f6ec1acf0f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants_83ff2cb5-cd2e-4a3a-9ae4-070acc7a3048" xlink:href="avtx-20230630.xsd#avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_921fb879-4103-4f75-8ead-55d740d1858e" xlink:to="loc_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants_83ff2cb5-cd2e-4a3a-9ae4-070acc7a3048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1245d31-068f-494e-a189-dcddeaca9a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1245d31-068f-494e-a189-dcddeaca9a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_322382c4-e2be-495a-a4e3-fe5b199ea6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_322382c4-e2be-495a-a4e3-fe5b199ea6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2af3151-2b2a-4f69-ba6f-c2df42a7afff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2af3151-2b2a-4f69-ba6f-c2df42a7afff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bdd1ec7c-c6dc-4c6b-8619-d1e32a9f2127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6f961a05-4f7e-40c5-bd4a-23098ea478ef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bdd1ec7c-c6dc-4c6b-8619-d1e32a9f2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/Business" xlink:type="simple" xlink:href="avtx-20230630.xsd#Business"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/Business" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c88452fc-c093-4d26-941f-20bdb290cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_277d9bb5-ed26-4218-85c6-97ca4bdb3a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c88452fc-c093-4d26-941f-20bdb290cf64" xlink:to="loc_us-gaap_NatureOfOperations_277d9bb5-ed26-4218-85c6-97ca4bdb3a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="avtx-20230630.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1f179d6-b867-4a62-870c-f25a4193f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bbac34f5-fbb7-4cb2-85fa-617e50a51364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1f179d6-b867-4a62-870c-f25a4193f71c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bbac34f5-fbb7-4cb2-85fa-617e50a51364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/Revenue" xlink:type="simple" xlink:href="avtx-20230630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6c738e1-8fbb-4c60-b029-2a47cc6aae2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3daf68ad-08c0-4341-9517-540e80b7eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6c738e1-8fbb-4c60-b029-2a47cc6aae2f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3daf68ad-08c0-4341-9517-540e80b7eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="avtx-20230630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d5fe317-8b25-4904-8846-6eeed2ea3f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b7b9a328-0f2e-4d72-b482-bd24ffe77168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d5fe317-8b25-4904-8846-6eeed2ea3f8c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b7b9a328-0f2e-4d72-b482-bd24ffe77168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fc96595-f905-4fc3-a350-dcd39886369b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_72aa01e8-9f0b-4303-87c5-97e570f7d3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fc96595-f905-4fc3-a350-dcd39886369b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_72aa01e8-9f0b-4303-87c5-97e570f7d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/Leases" xlink:type="simple" xlink:href="avtx-20230630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d7a99f2c-1d40-4f33-afae-e3aaf012fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b2276d4e-a06f-4a06-a54d-3a1cdbb67b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d7a99f2c-1d40-4f33-afae-e3aaf012fc97" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b2276d4e-a06f-4a06-a54d-3a1cdbb67b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="avtx-20230630.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ffcb6ef8-4acc-47f9-920a-537b3893742b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_84f02b3d-2584-4144-ade3-67847aa3424a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ffcb6ef8-4acc-47f9-920a-537b3893742b" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_84f02b3d-2584-4144-ade3-67847aa3424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CostReductionPlan" xlink:type="simple" xlink:href="avtx-20230630.xsd#CostReductionPlan"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CostReductionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_574659fd-52d2-41df-9e70-57b3a4ff0299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3c17f4a6-c5b6-4b2e-8f50-60e257327296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_574659fd-52d2-41df-9e70-57b3a4ff0299" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3c17f4a6-c5b6-4b2e-8f50-60e257327296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayable" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayable"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4e54249c-de3d-4fbe-9734-a05212f7bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6f17d123-52f4-4111-bb8c-99bd54140be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4e54249c-de3d-4fbe-9734-a05212f7bb20" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6f17d123-52f4-4111-bb8c-99bd54140be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructure" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructure"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6db1228-6683-4ca6-9432-a915b6d76354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_01ac3f6f-dff2-4f21-b450-4cce958f3c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6db1228-6683-4ca6-9432-a915b6d76354" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_01ac3f6f-dff2-4f21-b450-4cce958f3c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9401c403-8486-4abb-b942-a014171b2566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a663934-a8d5-4909-a2f1-2029a7313ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9401c403-8486-4abb-b942-a014171b2566" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a663934-a8d5-4909-a2f1-2029a7313ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="avtx-20230630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_770a1024-3f68-4737-b566-c10eaf99db28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d06e6171-33f4-47de-b175-541bf1f0ec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_770a1024-3f68-4737-b566-c10eaf99db28" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d06e6171-33f4-47de-b175-541bf1f0ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="avtx-20230630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac21e57c-7939-4869-99fb-c7fcb4154ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4de670cc-cb6d-4718-8c93-c0344e102408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac21e57c-7939-4869-99fb-c7fcb4154ad9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4de670cc-cb6d-4718-8c93-c0344e102408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="avtx-20230630.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2616d56b-7965-49a4-801b-208255800273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f02f51b9-4000-440c-a440-aff0663c49b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2616d56b-7965-49a4-801b-208255800273" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f02f51b9-4000-440c-a440-aff0663c49b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7dd0dd10-eb9f-44c8-a101-8e16bb9cb07f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2616d56b-7965-49a4-801b-208255800273" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7dd0dd10-eb9f-44c8-a101-8e16bb9cb07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_52cbc01b-b097-4173-8103-2057d5a86f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be6712cb-ab67-4ef2-88cb-927993164bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_52cbc01b-b097-4173-8103-2057d5a86f3f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be6712cb-ab67-4ef2-88cb-927993164bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_970c05e8-3119-4f56-806f-ed355e2375a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_52cbc01b-b097-4173-8103-2057d5a86f3f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_970c05e8-3119-4f56-806f-ed355e2375a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1d821e7d-36b0-4bb9-a2a0-7ece8bc46e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a5463fc0-4305-4d33-b716-20bce2a66b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d821e7d-36b0-4bb9-a2a0-7ece8bc46e5a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a5463fc0-4305-4d33-b716-20bce2a66b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a657b798-dc5b-4d38-a099-2bf7d21d52e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d821e7d-36b0-4bb9-a2a0-7ece8bc46e5a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a657b798-dc5b-4d38-a099-2bf7d21d52e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_82c2f557-d661-4cdb-986a-41064448f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetsAndLiabilitiesLesseeTableTextBlock_204401e7-efce-4b57-9680-6118ab5a3f95" xlink:href="avtx-20230630.xsd#avtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82c2f557-d661-4cdb-986a-41064448f5a9" xlink:to="loc_avtx_AssetsAndLiabilitiesLesseeTableTextBlock_204401e7-efce-4b57-9680-6118ab5a3f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_94c986b3-4dc1-458a-b7f7-f4ffcba6f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82c2f557-d661-4cdb-986a-41064448f5a9" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_94c986b3-4dc1-458a-b7f7-f4ffcba6f36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c4eba7e1-5a94-4a25-8c1d-d096fee099c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82c2f557-d661-4cdb-986a-41064448f5a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c4eba7e1-5a94-4a25-8c1d-d096fee099c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_9cfbd566-71e2-444b-9c95-6536585135ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_cab05f90-7b00-49b8-a240-7073598229e0" xlink:href="avtx-20230630.xsd#avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_9cfbd566-71e2-444b-9c95-6536585135ca" xlink:to="loc_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_cab05f90-7b00-49b8-a240-7073598229e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4f83c3e0-1277-4e4e-b039-358266b94289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_c1ed6249-d268-4fb0-a96e-18492f4d0ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f83c3e0-1277-4e4e-b039-358266b94289" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_c1ed6249-d268-4fb0-a96e-18492f4d0ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fb24d97c-16fc-4a39-930e-c6cd378e7fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f83c3e0-1277-4e4e-b039-358266b94289" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fb24d97c-16fc-4a39-930e-c6cd378e7fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructureTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructureTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c770ae21-5f00-4906-819f-841676830386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b2e899fe-45f0-44b3-9d5d-2eb4ecde331d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c770ae21-5f00-4906-819f-841676830386" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b2e899fe-45f0-44b3-9d5d-2eb4ecde331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b94f51-4d6a-47fb-b456-d3c215732c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e8062ce3-47af-44bf-a8f9-b48a5d6e0026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b94f51-4d6a-47fb-b456-d3c215732c50" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e8062ce3-47af-44bf-a8f9-b48a5d6e0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16ae2068-c1dc-48a9-80ea-34e199509cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b94f51-4d6a-47fb-b456-d3c215732c50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16ae2068-c1dc-48a9-80ea-34e199509cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_46efc5e5-11b6-4108-89c7-ab46797db941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62b94f51-4d6a-47fb-b456-d3c215732c50" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_46efc5e5-11b6-4108-89c7-ab46797db941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/BusinessDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#BusinessDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b7485-3c93-4a6d-8e34-610b40e65cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b7485-3c93-4a6d-8e34-610b40e65cc2" xlink:to="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f51d64a-6a87-4dd0-839d-e3c75235d7d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_02a6b5dd-986a-46d6-9dba-f7419e2b4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b6b477d6-6468-418f-8f44-411663cf2242" xlink:to="loc_us-gaap_LoansPayableMember_02a6b5dd-986a-46d6-9dba-f7419e2b4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_08231594-c0c7-42ef-865c-09e12fb442d5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_e707691a-545a-4ac7-b115-82bbb6e0a2e4" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b5368f81-6e8c-4964-a2ad-c347eae1ea1f" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_e707691a-545a-4ac7-b115-82bbb6e0a2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_345a4503-8c17-4fea-a4ac-5794d88cc1b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_464a31d2-f71f-4f49-9431-fa4a5171fb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c86f9c83-2b7c-43a5-a079-50e7d10b1401" xlink:to="loc_us-gaap_SubsequentEventMember_464a31d2-f71f-4f49-9431-fa4a5171fb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c829b2-646e-4a57-a462-6686245d9227" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fd03621-2853-4fe1-b764-0e59c8ab5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_NetIncomeLoss_5fd03621-2853-4fe1-b764-0e59c8ab5c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_315c705a-b84e-40b4-8497-935beeeb1676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_315c705a-b84e-40b4-8497-935beeeb1676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eecc60ca-27a0-4592-b257-b1b14c303868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eecc60ca-27a0-4592-b257-b1b14c303868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b0a75e16-cea9-4e2b-9960-e0841499ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b0a75e16-cea9-4e2b-9960-e0841499ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_2eb01b73-dfb0-4971-a0a2-e0db4443e244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_RepaymentsOfDebt_2eb01b73-dfb0-4971-a0a2-e0db4443e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e0b78e98-964c-4c6f-aca3-d7f47683357e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e0b78e98-964c-4c6f-aca3-d7f47683357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_e18cb1c7-bdd6-4336-af43-9a05a65c9123" xlink:href="avtx-20230630.xsd#avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a08d57ee-1b6d-4478-bc64-0e87b8a4c87a" xlink:to="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_e18cb1c7-bdd6-4336-af43-9a05a65c9123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/RevenueDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ad7ac5d0-c30e-4047-b058-51f9d452d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ad7ac5d0-c30e-4047-b058-51f9d452d20a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_514e8561-f38b-4c65-997c-d58a5f9d52b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberOneMember_ba714350-726d-4c1c-bd9d-e325e5a86ddd" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:to="loc_avtx_MajorCustomerNumberOneMember_ba714350-726d-4c1c-bd9d-e325e5a86ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MajorCustomerNumberTwoMember_c818151a-de1f-4a82-a4ac-2aa6d107e60b" xlink:href="avtx-20230630.xsd#avtx_MajorCustomerNumberTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d5157b3-ee55-4bd7-940b-76398c4bdc33" xlink:to="loc_avtx_MajorCustomerNumberTwoMember_c818151a-de1f-4a82-a4ac-2aa6d107e60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddeb51c7-db14-4434-aa4e-100aadb8b313" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6b899fc7-8826-4f82-8964-2957f2a94146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a907cb2-55ce-4ca1-98b6-31ad8b7d22f4" xlink:to="loc_us-gaap_SalesRevenueNetMember_6b899fc7-8826-4f82-8964-2957f2a94146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f0c7ffb4-07db-49dd-a729-852b1cc5fccd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ee466010-5190-45e7-8a76-e29964a109c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b1c8af4-1188-44e0-a613-045a93840a90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ee466010-5190-45e7-8a76-e29964a109c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a60e6c91-a746-4a5e-aee1-99c313f45a1e" xlink:to="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_50b8346f-40a9-4dff-9d2a-7e2a3c9587a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:to="loc_us-gaap_ProductMember_50b8346f-40a9-4dff-9d2a-7e2a3c9587a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MillipredMember_88f33104-5c8a-4294-8aa6-00c95129662d" xlink:href="avtx-20230630.xsd#avtx_MillipredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_934e2acb-4c4b-4b21-aaa2-9d167cac7787" xlink:to="loc_avtx_MillipredMember_88f33104-5c8a-4294-8aa6-00c95129662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e4ee84f8-0925-4042-a029-e46634164e48" xlink:to="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member_1770da7b-d515-4f72-8620-c739574378d1" xlink:href="avtx-20230630.xsd#avtx_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7831896a-53b0-46d0-9cbe-5777046e1b5d" xlink:to="loc_avtx_TevaPharmaceuticalIndustriesLtd.Member_1770da7b-d515-4f72-8620-c739574378d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_74b00bc5-4549-4028-8f8f-2fe00937b0a5" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b3d982e6-945e-40a8-8f98-44290c0fe507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_349c9482-89b1-494e-b779-6c9ec221c658" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b3d982e6-945e-40a8-8f98-44290c0fe507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a5be499a-bf4a-4001-8cb0-28edf90f961c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PediatricPortfolioMember_bf9197b9-2ed6-43d2-a8e0-ce73ef7544cc" xlink:href="avtx-20230630.xsd#avtx_PediatricPortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9382cf8a-ae58-492c-8e30-78abe7f9073c" xlink:to="loc_avtx_PediatricPortfolioMember_bf9197b9-2ed6-43d2-a8e0-ce73ef7544cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_53b2cf79-d926-4c95-b9a4-65dc1768944f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2e4361dc-5707-4ce4-ba02-e92bf231d163" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1bf280ce-aac1-49c3-83db-49f9f9fd977a" xlink:to="loc_srt_ScenarioForecastMember_2e4361dc-5707-4ce4-ba02-e92bf231d163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5e03854e-f9a4-48c4-bca4-74ce2b4b8a18" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a7b5d6bc-c716-4693-88b4-c5b3b031bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a7b5d6bc-c716-4693-88b4-c5b3b031bc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e235d9e-c127-43b4-b8c0-126b288e1b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e235d9e-c127-43b4-b8c0-126b288e1b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_507e7daa-4579-48c1-952d-512007c589de" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment_507e7daa-4579-48c1-952d-512007c589de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LicenseAgreementInstallmentPayment_d743d1b9-6ddd-4e39-b0e4-33c999c5d0b7" xlink:href="avtx-20230630.xsd#avtx_LicenseAgreementInstallmentPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_avtx_LicenseAgreementInstallmentPayment_d743d1b9-6ddd-4e39-b0e4-33c999c5d0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a6fd767c-2244-46ef-9280-3e8072860103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_a6fd767c-2244-46ef-9280-3e8072860103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_817ca233-5e10-43e9-8b67-0b8acdbaea71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss_817ca233-5e10-43e9-8b67-0b8acdbaea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_2efa961c-5a8e-495a-8485-fc439b9f2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c8d74401-15a4-4a02-9f5e-bca493cbc25a" xlink:to="loc_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal_2efa961c-5a8e-495a-8485-fc439b9f2cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NetLossPerShareScheduleofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0a7b8b9-b7cd-4fa4-bf50-4e53cdac03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:to="loc_us-gaap_NetIncomeLoss_d0a7b8b9-b7cd-4fa4-bf50-4e53cdac03d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_898935fa-7a5d-4813-bc4c-ff8b15acbc17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_898935fa-7a5d-4813-bc4c-ff8b15acbc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7a7b7b1-f130-4369-b12e-460c25a4bf99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7a7b7b1-f130-4369-b12e-460c25a4bf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_10205247-f964-4315-befb-974d7dd6b71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:to="loc_us-gaap_EarningsPerShareBasic_10205247-f964-4315-befb-974d7dd6b71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_05c8e616-b06c-4c28-86a9-bd542a49db72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a6f999e-92aa-4bc8-8e27-c8406030dd1b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_05c8e616-b06c-4c28-86a9-bd542a49db72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a88b21df-e69c-4657-abb7-96465b086ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a88b21df-e69c-4657-abb7-96465b086ef4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4c0a1ec-e570-4993-a1fc-b01d2bfb2ed1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_f4ef5867-0ca1-40a2-a983-74ba8239f338" xlink:href="avtx-20230630.xsd#avtx_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_EmployeeConsultantsAndDirectorsStockOptionsMember_f4ef5867-0ca1-40a2-a983-74ba8239f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_WarrantCommonStockMember_584a64ff-063e-4726-95a5-dc8e0452296e" xlink:href="avtx-20230630.xsd#avtx_WarrantCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_WarrantCommonStockMember_584a64ff-063e-4726-95a5-dc8e0452296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf830709-7030-4d88-9c2c-27baf88f07c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf830709-7030-4d88-9c2c-27baf88f07c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PreFundedWarrantsMember_c02c343d-d835-4756-9e11-6fb3ae3d4447" xlink:href="avtx-20230630.xsd#avtx_PreFundedWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bee0c6b-bef6-46af-8971-a7b1dc7072da" xlink:to="loc_avtx_PreFundedWarrantsMember_c02c343d-d835-4756-9e11-6fb3ae3d4447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_825ff098-cf47-4a08-8fac-5bb95bbb50b8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fafd33a1-a460-4eb3-9667-219eee025608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fafd33a1-a460-4eb3-9667-219eee025608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_9f6b7562-0103-48f4-b852-73eef5064353" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_9f6b7562-0103-48f4-b852-73eef5064353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f83937a5-58e3-40ae-8ce1-86d9089b61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7906e9-66d7-43e6-a037-a98017dc4c92" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f83937a5-58e3-40ae-8ce1-86d9089b61eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e4fb31f-dfe2-4d2b-9afc-4c6a72d8682b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e4fb31f-dfe2-4d2b-9afc-4c6a72d8682b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_afb9d74e-9346-4dda-8d88-72394d9ad499" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1cdfccbe-8106-4d1e-ad1f-8993c4da11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58f67a01-db8c-4ff4-8bb1-04e601fe9c5a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1cdfccbe-8106-4d1e-ad1f-8993c4da11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e713c08b-0de7-4f6e-b6b9-e9cf4c8a6aed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f566feac-7179-41b6-a97f-f8976683f714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f566feac-7179-41b6-a97f-f8976683f714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3afb75b3-2ae9-4f47-8f92-6fbe05abdb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3afb75b3-2ae9-4f47-8f92-6fbe05abdb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6965f4f8-237d-4d6f-8a9f-2fdfed678ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d300b70-d2df-4c04-a0fc-ffb4cb3ba61c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6965f4f8-237d-4d6f-8a9f-2fdfed678ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3ef95e8a-3000-43b2-b593-a6a23c3aedbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_018c184b-3caa-4071-8e28-02afcdedd05f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_018c184b-3caa-4071-8e28-02afcdedd05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_660234e6-be5a-4783-8031-4389afc53e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_DerivativeLiabilities_660234e6-be5a-4783-8031-4389afc53e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_c1f3eac3-d381-47d5-8844-5e320e0a475d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35639303-1183-4614-9c54-cfb895cfc763" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_c1f3eac3-d381-47d5-8844-5e320e0a475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsScheduleofChangesintheFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5788cc5-1452-400b-bf80-ff17590cc7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5788cc5-1452-400b-bf80-ff17590cc7e6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a1dfa21c-4487-49f8-890d-c4a77d46ae03" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_52649cc5-4dc4-4d9c-9d1c-5cbef3be856b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_58f3fe22-81c0-48fb-98f0-7327ef328757" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_52649cc5-4dc4-4d9c-9d1c-5cbef3be856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_34093bdf-68c8-4167-ba03-c40d71543f9b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_70f7ac28-9b34-4a83-a626-bfff4c135002" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e06d4d44-c3d5-4f4d-85bc-fdb7419a71f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e06d4d44-c3d5-4f4d-85bc-fdb7419a71f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_470daabb-02ec-45ef-a491-e6f6ee0e10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_470daabb-02ec-45ef-a491-e6f6ee0e10c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d70df108-f827-422c-b39f-46651aaad7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bda0b296-a968-40ee-a941-295eb1109666" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d70df108-f827-422c-b39f-46651aaad7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0df0baec-fbb6-4e2e-bb0f-c13eae385483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0df0baec-fbb6-4e2e-bb0f-c13eae385483" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_391e3735-7ad0-460e-a422-4aa467307eff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESTherapeuticsMember_1a61fc6b-9f1e-4f70-bc20-904b7210dfee" xlink:href="avtx-20230630.xsd#avtx_ESTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e053afc0-7b21-4dc5-8046-43353bd4d272" xlink:to="loc_avtx_ESTherapeuticsMember_1a61fc6b-9f1e-4f70-bc20-904b7210dfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3c88a937-41ff-4f42-88b0-9d4665eeddd8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_fe800ecd-cdd2-4ce2-b7b5-eb04f26bbd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6a7538c5-fbd6-4fdd-9a74-e5b2eb24caee" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_fe800ecd-cdd2-4ce2-b7b5-eb04f26bbd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:href="avtx-20230630.xsd#avtx_MilestoneAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneAxis_84127756-4ade-4410-8550-22d68d2f4dcb" xlink:to="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneOneMember_041174b9-ccea-416d-9807-334f8882742b" xlink:href="avtx-20230630.xsd#avtx_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:to="loc_avtx_MilestoneOneMember_041174b9-ccea-416d-9807-334f8882742b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneTwoMember_5105000f-bf5e-42ee-b630-22113b9558a8" xlink:href="avtx-20230630.xsd#avtx_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneDomain_8f67b7e4-cced-411b-a748-55fa0bec4407" xlink:to="loc_avtx_MilestoneTwoMember_5105000f-bf5e-42ee-b630-22113b9558a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_feea3f2f-2ef2-4c21-832c-fb17f3c259af" xlink:to="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:href="avtx-20230630.xsd#avtx_AVTX501AndAVTX007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:to="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX501Member_2f0b3343-72fc-4c86-b3fe-43612c0d1bdd" xlink:href="avtx-20230630.xsd#avtx_AVTX501Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:to="loc_avtx_AVTX501Member_2f0b3343-72fc-4c86-b3fe-43612c0d1bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX007Member_09cb9bbe-bc9e-4918-b1cf-1a2e1e4dc4c9" xlink:href="avtx-20230630.xsd#avtx_AVTX007Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_AVTX501AndAVTX007Member_17f9a247-e9f5-4482-a5f2-6dc35a05fdd0" xlink:to="loc_avtx_AVTX007Member_09cb9bbe-bc9e-4918-b1cf-1a2e1e4dc4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX611Member_85527df8-e723-44d1-9f2c-3346b963a1d0" xlink:href="avtx-20230630.xsd#avtx_AVTX611Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45e19ef4-7625-462b-b058-707a8f972de1" xlink:to="loc_avtx_AVTX611Member_85527df8-e723-44d1-9f2c-3346b963a1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cbcd8e43-2d04-4fdb-aca3-d32cf92ca6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputProbabilityOfSuccessMember_397dd245-379e-488b-9d7d-ae12deb29499" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputProbabilityOfSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_avtx_MeasurementInputProbabilityOfSuccessMember_397dd245-379e-488b-9d7d-ae12deb29499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d7955c07-36bf-4ba0-afeb-1ac7c176666e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d7955c07-36bf-4ba0-afeb-1ac7c176666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MeasurementInputSalesForecastPeakMember_097262e6-0562-4dcd-8bbf-b47e60c5b931" xlink:href="avtx-20230630.xsd#avtx_MeasurementInputSalesForecastPeakMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc3668da-96e2-4e0f-ac9d-d485979cee0c" xlink:to="loc_avtx_MeasurementInputSalesForecastPeakMember_097262e6-0562-4dcd-8bbf-b47e60c5b931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24057853-d340-4be8-82db-55d9d64777e6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1bdcf3de-d680-4792-9e68-a20a189edce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e21aa14-509b-4b5a-be14-d7fdcbd49623" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1bdcf3de-d680-4792-9e68-a20a189edce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f3139a3-e029-4e49-a605-4ec45e4bc57d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_88da0c44-78b3-42e6-b570-04cb1fa1a8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_LongTermDebtFairValue_88da0c44-78b3-42e6-b570-04cb1fa1a8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_0eb41760-d460-478f-804b-a0c991e3afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_0eb41760-d460-478f-804b-a0c991e3afb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_353ca142-62a9-408d-81af-907b7fb0b220" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_353ca142-62a9-408d-81af-907b7fb0b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_ff60910b-e616-4eb6-a0bd-252ead0cb607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral_ff60910b-e616-4eb6-a0bd-252ead0cb607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_a4146722-9fbc-49ed-aedb-9d2aa3513784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_a4146722-9fbc-49ed-aedb-9d2aa3513784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DerivativeLiabilityMeasurementInputTerm_c19e3836-fc6d-4a55-abd7-4dba704ebdfe" xlink:href="avtx-20230630.xsd#avtx_DerivativeLiabilityMeasurementInputTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_578dcf73-a485-4ec2-a627-fa0a97304855" xlink:to="loc_avtx_DerivativeLiabilityMeasurementInputTerm_c19e3836-fc6d-4a55-abd7-4dba704ebdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_907fc149-4bc7-4e38-80e1-0cc493819742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_907fc149-4bc7-4e38-80e1-0cc493819742" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e6de4e2c-03f3-4d09-9a3d-2e7d0df8b5cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d42215c2-b724-407d-959b-088f6b7ed49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cd61eaa5-b165-41d0-8b92-be0dfeb4dbf7" xlink:to="loc_us-gaap_BuildingMember_d42215c2-b724-407d-959b-088f6b7ed49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:to="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f53a7bc8-afcc-4c72-a42a-be71a19e2a8f" xlink:to="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_cca244b7-0050-47d6-ad24-6b73d92dc541" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:to="loc_stpr_MD_cca244b7-0050-47d6-ad24-6b73d92dc541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_ee77b1ef-479e-48b9-ae9b-2cc00e014498" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_139b562f-07f3-4dab-a4af-06314cfc237c" xlink:to="loc_stpr_PA_ee77b1ef-479e-48b9-ae9b-2cc00e014498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_60475022-0128-48b7-a144-365d6aeedcb5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_eb532c03-b155-46c2-806e-b6a20e583bdf" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfLeasedProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseNumberOfLeasedProperties_eb532c03-b155-46c2-806e-b6a20e583bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_7c38c1e9-3a9c-4fe3-b382-d66a88a4bfa8" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent_7c38c1e9-3a9c-4fe3-b382-d66a88a4bfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_f024f2ba-8046-40fb-88c6-aa1f3537a738" xlink:href="avtx-20230630.xsd#avtx_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent_f024f2ba-8046-40fb-88c6-aa1f3537a738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod_4bdf2d1f-a39c-4263-bccc-b075c4ad6051" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseRentAbatementPeriod_4bdf2d1f-a39c-4263-bccc-b075c4ad6051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1dbc5584-dd12-4c52-a06a-4d4fbdc8dada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1dbc5584-dd12-4c52-a06a-4d4fbdc8dada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_f7f6db69-2d4e-41c1-a4ac-d4d8235074fe" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseNumberOfRenewalOptions_f7f6db69-2d4e-41c1-a4ac-d4d8235074fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c338eae0-cb9e-49c9-a053-78761dc7b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c338eae0-cb9e-49c9-a053-78761dc7b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseAnnualBaseRent_44554bd7-cd63-4252-84b6-1358b8c37233" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseAnnualBaseRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseAnnualBaseRent_44554bd7-cd63-4252-84b6-1358b8c37233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f1354535-64c2-4de2-a353-82134688d3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_OperatingLeaseExpense_f1354535-64c2-4de2-a353-82134688d3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam_e690400a-274f-49d1-9f6e-154278469e0a" xlink:href="avtx-20230630.xsd#avtx_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_avtx_LesseeOperatingLeaseRemainingLeaseTeam_e690400a-274f-49d1-9f6e-154278469e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_797ee677-536f-475e-b292-dcc4db612ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4100d008-1277-4904-bb70-500b373ed699" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_797ee677-536f-475e-b292-dcc4db612ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofAssetsandLiabilitiesLesseeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_29144033-3f6f-4fe3-a4f8-58529b175d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_29144033-3f6f-4fe3-a4f8-58529b175d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_abde9df7-cc65-4b78-a83c-46f2462660c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_abde9df7-cc65-4b78-a83c-46f2462660c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5759f61-7b72-484b-b9df-d5381e92f948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5759f61-7b72-484b-b9df-d5381e92f948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ee441c62-2e2a-477b-8362-ce06b3acd381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseLiability_ee441c62-2e2a-477b-8362-ce06b3acd381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8b7775a9-e973-4398-8fb5-1b528b3b8aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8b7775a9-e973-4398-8fb5-1b528b3b8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce01b84-c7eb-4ecc-9ed6-d78d64cbd84e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bce01b84-c7eb-4ecc-9ed6-d78d64cbd84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_033fbd27-2bbd-45e1-a367-9defb4f314dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2401cc69-20d0-45b7-88b9-a2d620366da6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_033fbd27-2bbd-45e1-a367-9defb4f314dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d201a7e-0c2d-4a1c-9af1-62bf93887751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3f5df83d-41cc-4b88-92c4-8b9975da6ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d201a7e-0c2d-4a1c-9af1-62bf93887751" xlink:to="loc_us-gaap_OperatingLeaseCost_3f5df83d-41cc-4b88-92c4-8b9975da6ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ac0e900-408f-40d8-b8df-6f10e6324bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ac0e900-408f-40d8-b8df-6f10e6324bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4ec586d-3729-480b-9cb3-f4ed9fe73b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4ec586d-3729-480b-9cb3-f4ed9fe73b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_03cb7f5e-ae7f-4b73-8122-406aae635cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_03cb7f5e-ae7f-4b73-8122-406aae635cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a87f53b3-bd46-48ae-a456-3ba15da3fa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a87f53b3-bd46-48ae-a456-3ba15da3fa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9c3b7545-3baa-4cd3-b0be-3e38ec2f0d15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9c3b7545-3baa-4cd3-b0be-3e38ec2f0d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_724772c2-3b81-441a-8535-5b5fe86591cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_724772c2-3b81-441a-8535-5b5fe86591cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d0bfff2c-e7e8-4c25-a9bc-71766352b443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d0bfff2c-e7e8-4c25-a9bc-71766352b443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97847019-db6e-4eba-9ec8-9612e2876644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97847019-db6e-4eba-9ec8-9612e2876644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5e35698-4db8-4c74-9f89-2cb8a070980a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5e35698-4db8-4c74-9f89-2cb8a070980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f0e695d3-b33d-4d2c-9a70-e928ebffa655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3c4d1ef-5654-43f1-86c5-81b05d219d16" xlink:to="loc_us-gaap_OperatingLeaseLiability_f0e695d3-b33d-4d2c-9a70-e928ebffa655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1" xlink:type="simple" xlink:href="avtx-20230630.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails_1"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedResearchAndDevelopment_5dd7de40-58c2-438c-bef1-9771e71ce54e" xlink:href="avtx-20230630.xsd#avtx_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_avtx_AccruedResearchAndDevelopment_5dd7de40-58c2-438c-bef1-9771e71ce54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ee9aab8-48b3-4be7-9541-be062f99e429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ee9aab8-48b3-4be7-9541-be062f99e429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses_b0e742e6-64ff-4cc5-922e-e690397deee1" xlink:href="avtx-20230630.xsd#avtx_AccruedSellingGeneralAndAdministrativeExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_avtx_AccruedSellingGeneralAndAdministrativeExpenses_b0e742e6-64ff-4cc5-922e-e690397deee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommercialOperationsCurrent_2c9dc114-ab1b-48bc-964b-83ff3610da5b" xlink:href="avtx-20230630.xsd#avtx_CommercialOperationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_avtx_CommercialOperationsCurrent_2c9dc114-ab1b-48bc-964b-83ff3610da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_d4cc238c-3f65-4086-9b16-2ef4120f7693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_d4cc238c-3f65-4086-9b16-2ef4120f7693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5073a3a5-9537-4383-af8a-d6c34ef3d638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5073a3a5-9537-4383-af8a-d6c34ef3d638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3e3da0f3-adfe-40ca-84c1-00289862ef11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3e3da0f3-adfe-40ca-84c1-00289862ef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ea30cef6-a12c-4d75-b526-769c31ff7bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_d1d82ad0-a91a-49d6-a16d-a5a5f574a29d" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ea30cef6-a12c-4d75-b526-769c31ff7bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CostReductionPlanDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CostReductionPlanDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CostReductionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5678d2ab-6d6f-4f27-9834-8a588b358320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5678d2ab-6d6f-4f27-9834-8a588b358320" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_428d3ff6-7dca-4603-8251-0a32c4463d95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9f3c4506-22ff-4453-ae45-25ea84b83c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_95bfb079-0c2b-4951-aef4-f83a8ea9fc3b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9f3c4506-22ff-4453-ae45-25ea84b83c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_0393bfd4-5b4d-40a6-81b9-b7777c3ff7ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_b2527ed8-ffd6-4c5b-a025-a8db50bfa099" xlink:href="avtx-20230630.xsd#avtx_RestructuringPlanOneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:to="loc_avtx_RestructuringPlanOneTimeTerminationBenefitsMember_b2527ed8-ffd6-4c5b-a025-a8db50bfa099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SeparationFromCertainSection16OfficersMember_106fc4ca-32af-4433-98be-98b65e3d21b1" xlink:href="avtx-20230630.xsd#avtx_SeparationFromCertainSection16OfficersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_30149416-9d22-4a0c-be4a-5e13380590ac" xlink:to="loc_avtx_SeparationFromCertainSection16OfficersMember_106fc4ca-32af-4433-98be-98b65e3d21b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_927aa3f5-500b-43c5-9bde-81f76a8d163a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5b58ff5-49b9-459d-a25d-0b3990ad1ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f5b58ff5-49b9-459d-a25d-0b3990ad1ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bcc5bb86-ea5b-4725-a03c-efd89ae15653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6aaa9d04-8cd3-462a-8df6-ed1829bfcde8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bcc5bb86-ea5b-4725-a03c-efd89ae15653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5da744f-1fd9-46d0-9614-ddc08d42d5d0" xlink:to="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6921caf-008b-4ae6-bb91-6e155bd14357" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:to="loc_srt_MinimumMember_b6921caf-008b-4ae6-bb91-6e155bd14357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0965c9ba-fc55-4828-9c19-e86637b6f062" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92b6dbb7-dd7d-4e77-ab3f-14ba37f6a7d7" xlink:to="loc_srt_MaximumMember_0965c9ba-fc55-4828-9c19-e86637b6f062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_65ab8a7a-236b-4243-9d65-3aa0f32b5371" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a584e36-eaa9-47c1-9117-9bedf392edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_RestructuringCharges_3a584e36-eaa9-47c1-9117-9bedf392edd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_39eff4a9-522b-488a-bf87-cfda85cc6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_PaymentsForRestructuring_39eff4a9-522b-488a-bf87-cfda85cc6b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c24705f6-16fa-4881-a2f3-d01b4bacd987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c24705f6-16fa-4881-a2f3-d01b4bacd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm_f749b84a-c584-478c-b661-126eac8c9d49" xlink:href="avtx-20230630.xsd#avtx_RestructuringAndRelatedActivitiesPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b7853ded-b5a2-47e7-aca5-b5c3707dd523" xlink:to="loc_avtx_RestructuringAndRelatedActivitiesPaymentTerm_f749b84a-c584-478c-b661-126eac8c9d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2be188e8-b049-430f-a137-59034516db4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2be188e8-b049-430f-a137-59034516db4f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c769dce1-54b2-48bb-b118-10f9c3b6d835" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_098c8334-288a-451c-891b-5f87136f3575" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bc44478-7dcd-4c99-82c9-d10a88e666c1" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_098c8334-288a-451c-891b-5f87136f3575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_91660e05-3c7c-4a32-811e-48de8d599acd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b94402a0-4b44-4bd9-8ae4-3f7fdded3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efd04061-ebf5-4be5-8103-aeba942cfaff" xlink:to="loc_us-gaap_LoansPayableMember_b94402a0-4b44-4bd9-8ae4-3f7fdded3a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_16be1208-7ed4-4323-b3ba-7ea475eb200b" xlink:to="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_4e0b1f23-0e2c-4d1d-90a6-aba148eccb37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_51767af5-f44e-4122-b3ea-262df8506be1" xlink:to="loc_us-gaap_PrimeRateMember_4e0b1f23-0e2c-4d1d-90a6-aba148eccb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_66a7c8d8-3f3f-462d-928b-cd90cb9abc33" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bcd6b678-59d6-494f-b43a-b6205e6789c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3749c8b2-50b2-40e5-8559-4bf9868c76d5" xlink:to="loc_us-gaap_WarrantMember_bcd6b678-59d6-494f-b43a-b6205e6789c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ac86c97f-93b4-4f73-9d2a-9be1c0c8d4c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f385a2a-bf5d-42e8-a568-5870a7641851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3c719625-8efa-465b-b60c-8a6bd6835859" xlink:to="loc_us-gaap_SubsequentEventMember_2f385a2a-bf5d-42e8-a568-5870a7641851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_57a7f8a0-3d98-41a2-93bf-784b1105ddde" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_52bfc444-b9db-4d7b-bac8-1802e4871055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_52bfc444-b9db-4d7b-bac8-1802e4871055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_b340eb5c-2304-44b8-8082-06d3a8d34ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_b340eb5c-2304-44b8-8082-06d3a8d34ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_efdb6ce3-0522-44e3-be0b-30a11596cc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_RepaymentsOfDebt_efdb6ce3-0522-44e3-be0b-30a11596cc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RepaymentOfDebtPrincipal_007a40d6-7f1a-47b5-85b0-ab823adff9a7" xlink:href="avtx-20230630.xsd#avtx_RepaymentOfDebtPrincipal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_RepaymentOfDebtPrincipal_007a40d6-7f1a-47b5-85b0-ab823adff9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_975a0914-d926-483f-954f-629830ee45f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_975a0914-d926-483f-954f-629830ee45f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_28035f1c-e88d-47e3-b57e-d977a473306e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentTerm_28035f1c-e88d-47e3-b57e-d977a473306e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55743f2b-3693-410f-a7a0-9cb218b926d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55743f2b-3693-410f-a7a0-9cb218b926d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestRateFloor_452de0cd-7cb9-4a14-a59a-d21b765d4d66" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestRateFloor"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestRateFloor_452de0cd-7cb9-4a14-a59a-d21b765d4d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod_39d30e39-bfd9-4163-9f55-f5b13e2ddc5e" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestOnlyPaymentPeriod_39d30e39-bfd9-4163-9f55-f5b13e2ddc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_b339f6ad-3d5d-42dd-93f4-874bb0f485a9" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod_b339f6ad-3d5d-42dd-93f4-874bb0f485a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_b1dd2bd4-d75f-4131-819c-fa77f0080626" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment_b1dd2bd4-d75f-4131-819c-fa77f0080626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_2c229e4d-ba4e-4c87-979d-a077fce8dc67" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage_2c229e4d-ba4e-4c87-979d-a077fce8dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_0b66f2ee-e0c5-4f8c-8c8a-7af60dc9f0a4" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_0b66f2ee-e0c5-4f8c-8c8a-7af60dc9f0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_300fa349-8deb-4f73-8f1e-01ff56756ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_300fa349-8deb-4f73-8f1e-01ff56756ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_6b8328e9-6b2d-44da-bbe4-b1c98dee5851" xlink:href="avtx-20230630.xsd#avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage_6b8328e9-6b2d-44da-bbe4-b1c98dee5851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b6fb41ce-45ee-48c7-8565-cd87f9ad745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_LongTermDebt_b6fb41ce-45ee-48c7-8565-cd87f9ad745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36678d4d-17f8-4e7b-a53e-c5d18ad9be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36678d4d-17f8-4e7b-a53e-c5d18ad9be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fe6fba95-c998-477e-b75c-6f00f98aec28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fe6fba95-c998-477e-b75c-6f00f98aec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_085966c5-7970-4647-badf-6e25dced3976" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_085966c5-7970-4647-badf-6e25dced3976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_e1bcb2ba-f3f4-4e35-958a-8752e0d4c610" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_e1bcb2ba-f3f4-4e35-958a-8752e0d4c610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b2864ecb-1be2-48bb-bf53-218f25569c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_122d7441-14e9-456f-b688-fdde0e0f886d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b2864ecb-1be2-48bb-bf53-218f25569c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b002b8de-0e4a-40ca-a353-c7719140fbac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b002b8de-0e4a-40ca-a353-c7719140fbac" xlink:to="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_db9213ef-e836-447d-916a-8c37d9373ecc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_50c427b8-001d-4bf6-9b66-54c87f86aa09" xlink:to="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_InitialNoteMember_f7267eb9-8e41-4cab-90ef-43071bace1ca" xlink:href="avtx-20230630.xsd#avtx_InitialNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_InitialNoteMember_f7267eb9-8e41-4cab-90ef-43071bace1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SecondNoteMember_a912c0de-16ec-40eb-b5f4-cc19320d7721" xlink:href="avtx-20230630.xsd#avtx_SecondNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_SecondNoteMember_a912c0de-16ec-40eb-b5f4-cc19320d7721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ThirdNoteMember_c39f3c6e-abd6-4c20-8ef8-92cf0682f9df" xlink:href="avtx-20230630.xsd#avtx_ThirdNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoansPayableMember_5a7cc1b9-c282-4f8d-ac33-b742eb4c4337" xlink:to="loc_avtx_ThirdNoteMember_c39f3c6e-abd6-4c20-8ef8-92cf0682f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:to="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_be356d3f-e2d0-41a3-ac2e-76c1cdf062a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_c6f5059d-3975-4399-887e-a5243cfd1920" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29c14a9d-6368-4774-a46e-e834f77eebca" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_c6f5059d-3975-4399-887e-a5243cfd1920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8a99bf6a-e831-4253-a4f9-2eb27abc2c0f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_092e059b-d38b-4fc4-90d4-427a23bccdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_092e059b-d38b-4fc4-90d4-427a23bccdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b3a8e9bf-b0f2-498a-8239-263b41c29e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b3a8e9bf-b0f2-498a-8239-263b41c29e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ad1e996b-6648-4078-992f-62bf7dea3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebt_ad1e996b-6648-4078-992f-62bf7dea3ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_520a8e57-5141-4c01-861d-dee5202560ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebtCurrent_520a8e57-5141-4c01-861d-dee5202560ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3ba4ece5-6bbd-45d0-b7fa-d6dc2baa6c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3ba4ece5-6bbd-45d0-b7fa-d6dc2baa6c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_61ff22d2-989a-444d-a9e4-ecf9c74c2627" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_61ff22d2-989a-444d-a9e4-ecf9c74c2627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_55d9b4b9-e9e6-4274-bb03-55fcd4a65bed" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4249c404-3075-4c44-a20b-f1518e2cd362" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_55d9b4b9-e9e6-4274-bb03-55fcd4a65bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b575993e-7d3e-4e39-b63d-a7b60f444646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b575993e-7d3e-4e39-b63d-a7b60f444646" xlink:to="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6dd44d0-768d-4983-82f7-b3c61cbbd116" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_HorizonPowerscourtNotesMember_5c12925a-2e46-4f65-be79-d4753d3e64b4" xlink:href="avtx-20230630.xsd#avtx_HorizonPowerscourtNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7bfa9ce-e21e-4893-9b65-425f0b4df21d" xlink:to="loc_avtx_HorizonPowerscourtNotesMember_5c12925a-2e46-4f65-be79-d4753d3e64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7834fd7b-e83b-416d-a0f6-3b0401e79b1f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4aa0f9bb-bc54-4727-8f91-560f81bc0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9ec61-83b2-480d-82f3-251da9e96ab7" xlink:to="loc_us-gaap_LoansPayableMember_4aa0f9bb-bc54-4727-8f91-560f81bc0a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_15d15af7-f17b-487a-9537-fc72b950943f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_963e47d9-52d1-4770-8e63-7a33353cd17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_963e47d9-52d1-4770-8e63-7a33353cd17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_452be913-7f2d-4c75-83a7-b42844e3daff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_452be913-7f2d-4c75-83a7-b42844e3daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f8558e-fac4-411d-ae34-435ba8aee5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f8558e-fac4-411d-ae34-435ba8aee5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a24984cd-d17d-4eda-8033-7b0aac949d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a24984cd-d17d-4eda-8033-7b0aac949d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fdb62c78-b1cb-4f65-aed9-1eb7dd9424fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_fdb62c78-b1cb-4f65-aed9-1eb7dd9424fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentFinalPaymentFee_3251ffdc-3c3a-4d32-bd25-b5cacec289ff" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentFinalPaymentFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_avtx_DebtInstrumentFinalPaymentFee_3251ffdc-3c3a-4d32-bd25-b5cacec289ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_d974713a-d7d6-4135-ac12-752948309d9e" xlink:href="avtx-20230630.xsd#avtx_DebtInstrumentAdditionalFinalPaymentPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fac19db-992e-444a-9474-78e9ce98d355" xlink:to="loc_avtx_DebtInstrumentAdditionalFinalPaymentPercentage_d974713a-d7d6-4135-ac12-752948309d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ee6fba0-c10f-487a-8790-c30b43252800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ee6fba0-c10f-487a-8790-c30b43252800" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20b18953-e0c0-417c-812a-9f3039297849" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_UnderwrittenPublicOfferingMember_3b6a656f-0745-47c4-87b1-0bcbfc9e14ce" xlink:href="avtx-20230630.xsd#avtx_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_UnderwrittenPublicOfferingMember_3b6a656f-0745-47c4-87b1-0bcbfc9e14ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ATMAgreementMember_c32002a0-b2d7-4106-a981-f30e144a79a8" xlink:href="avtx-20230630.xsd#avtx_ATMAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_ATMAgreementMember_c32002a0-b2d7-4106-a981-f30e144a79a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ExchangeAgreementMember_72f3f023-da8c-41bd-937f-892045e1f981" xlink:href="avtx-20230630.xsd#avtx_ExchangeAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_822c27fa-e324-42f6-9770-92df94df88aa" xlink:to="loc_avtx_ExchangeAgreementMember_72f3f023-da8c-41bd-937f-892045e1f981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72ae84d5-1315-45fc-b578-4fa3df5795eb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f71cb84-cab7-4c16-add0-c826c50cbefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_da88ab75-47ea-44d7-8065-fbcab99a37ac" xlink:to="loc_us-gaap_WarrantMember_6f71cb84-cab7-4c16-add0-c826c50cbefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a6143b3c-648f-488e-9530-639437971bef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ArmisticeMember_17f3807e-a007-4105-aa19-58a91a863b4b" xlink:href="avtx-20230630.xsd#avtx_ArmisticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:to="loc_avtx_ArmisticeMember_17f3807e-a007-4105-aa19-58a91a863b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_VenrockHealthcareCapitalPartnersMember_b5df658d-8df8-4a82-8450-4cc45820c130" xlink:href="avtx-20230630.xsd#avtx_VenrockHealthcareCapitalPartnersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffeef6a-784b-4375-b022-a8e2b2c1a248" xlink:to="loc_avtx_VenrockHealthcareCapitalPartnersMember_b5df658d-8df8-4a82-8450-4cc45820c130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_07f7549e-23f4-4fab-9128-1e79cadcce45" xlink:to="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NantahalaCapitalManagementLLCMember_907096cf-5e5d-45db-8735-7a2ce7cb6b88" xlink:href="avtx-20230630.xsd#avtx_NantahalaCapitalManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0afb2210-ca8b-4d66-9476-c2468515c65c" xlink:to="loc_avtx_NantahalaCapitalManagementLLCMember_907096cf-5e5d-45db-8735-7a2ce7cb6b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba40b29c-ef78-440a-a683-34d0a6b40887" xlink:to="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_374d742a-24f5-4f28-8478-d2ed5fee9e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:to="loc_srt_MinimumMember_374d742a-24f5-4f28-8478-d2ed5fee9e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73919739-499d-4ff8-be75-149505df032e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a04d857-6a50-4d64-a1e1-e5a627e502c3" xlink:to="loc_srt_MaximumMember_73919739-499d-4ff8-be75-149505df032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3d28638-aaf9-4bb1-a0d9-2b3ad48812df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_94cae510-2cd9-4aef-8ad0-08382e7ef133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e6e29db6-2a5e-4146-8e28-dd1c389f876e" xlink:to="loc_us-gaap_SubsequentEventMember_94cae510-2cd9-4aef-8ad0-08382e7ef133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a96a186c-1fb1-47a1-a365-7748ccc36cc1" xlink:to="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_NumberOfClassOfStockAuthorized_4696536c-468b-401d-a8e8-4ad476c5b786" xlink:href="avtx-20230630.xsd#avtx_NumberOfClassOfStockAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_NumberOfClassOfStockAuthorized_4696536c-468b-401d-a8e8-4ad476c5b786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CapitalStockSharesAuthorized_9482ca6f-d260-474a-b146-068b3fb4721a" xlink:href="avtx-20230630.xsd#avtx_CapitalStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_CapitalStockSharesAuthorized_9482ca6f-d260-474a-b146-068b3fb4721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_00301585-bfdc-422d-8ea7-e68f07829c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_00301585-bfdc-422d-8ea7-e68f07829c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eb9342d5-6f29-4e39-ab41-579fbe88b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eb9342d5-6f29-4e39-ab41-579fbe88b21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_81f978fe-2ab6-4ec1-b402-8e4a2a3d5dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_81f978fe-2ab6-4ec1-b402-8e4a2a3d5dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e22c1ba6-6823-40f8-8590-b40e328c2332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e22c1ba6-6823-40f8-8590-b40e328c2332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a79531bb-1d53-4f67-89f6-295f03f04fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a79531bb-1d53-4f67-89f6-295f03f04fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_807a8ad3-bb9b-445a-899b-646fda9d0c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_807a8ad3-bb9b-445a-899b-646fda9d0c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3a212405-7d4a-47cc-8674-5e4b92e481a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3a212405-7d4a-47cc-8674-5e4b92e481a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_2030ad0e-f619-4b2f-ad72-5a50d070cf64" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold_2030ad0e-f619-4b2f-ad72-5a50d070cf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_63555a22-5b69-412e-bbb2-6b9bba01d8f3" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold_63555a22-5b69-412e-bbb2-6b9bba01d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_0f50ecf7-aee6-45ac-b15d-2e0b0b540d15" xlink:href="avtx-20230630.xsd#avtx_SaleOfStockMaximumAmountOfSharesToBeSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_SaleOfStockMaximumAmountOfSharesToBeSold_0f50ecf7-aee6-45ac-b15d-2e0b0b540d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f217778a-5497-444e-ac9c-a82c14ea856c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f217778a-5497-444e-ac9c-a82c14ea856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_32f090db-a2d1-4602-8260-8a9ec0d5fa41" xlink:href="avtx-20230630.xsd#avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm_32f090db-a2d1-4602-8260-8a9ec0d5fa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_09735550-94f2-43ff-9741-088e0f0f642c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_09735550-94f2-43ff-9741-088e0f0f642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_5b2436e1-2c74-4b36-832f-0cbec44467ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6d1b433c-5934-4a31-b1e8-63ea4b0710f3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_5b2436e1-2c74-4b36-832f-0cbec44467ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9110d029-eb17-4e4c-9138-3710c6507bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9110d029-eb17-4e4c-9138-3710c6507bd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_40321767-8331-4aa4-ba82-14088aced26e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_1d1ff90d-b890-4c91-a7c1-c56a8a633294" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationDateOfJune2024Member_1d1ff90d-b890-4c91-a7c1-c56a8a633294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpirationMember_561dbaef-7ad8-4b21-8007-089c93fe7629" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpirationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsNoExpirationMember_561dbaef-7ad8-4b21-8007-089c93fe7629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationJune2031Member_cf1d707b-55fe-4307-ab1f-6194a633c150" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationJune2031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationJune2031Member_cf1d707b-55fe-4307-ab1f-6194a633c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member_e40bb830-0af2-46da-8e0b-622b9bd63326" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsExpirationFebruary2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsExpirationFebruary2024Member_e40bb830-0af2-46da-8e0b-622b9bd63326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CommonStockWarrantsNoExpiration2Member_549c36bd-0953-466c-b9c7-fdd894bdf9f8" xlink:href="avtx-20230630.xsd#avtx_CommonStockWarrantsNoExpiration2Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_48a1312b-16d5-4ba2-87ad-b048c2c15126" xlink:to="loc_avtx_CommonStockWarrantsNoExpiration2Member_549c36bd-0953-466c-b9c7-fdd894bdf9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314caa5b-e76f-49be-9a50-728f19c6976f" xlink:to="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0ca06691-8140-4a42-bbf9-402bc31fc97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_02fa93fe-3f69-4904-a2b9-e5e3ccc39e2b" xlink:to="loc_us-gaap_CommonClassAMember_0ca06691-8140-4a42-bbf9-402bc31fc97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d7b3c493-94c1-4710-9b4c-fe0f98896d32" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9ec9ab95-0122-4e89-819c-5f1d3edb710d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9ec9ab95-0122-4e89-819c-5f1d3edb710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8a9a1c1-a105-4afc-9c67-fffc1ffe079f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2b447da0-926f-4246-a192-999fa0d934b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8a9a1c1-a105-4afc-9c67-fffc1ffe079f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ec18110-dc30-48d4-9bc5-f6b65c8e806c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ec18110-dc30-48d4-9bc5-f6b65c8e806c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2fb76fe7-271a-421c-914e-37d4539ac3ad" xlink:to="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_The2016PlanMember_388737ba-4108-4f2c-81aa-547155e0c8cb" xlink:href="avtx-20230630.xsd#avtx_The2016PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0bc17f1f-391f-4ad2-afc0-fb2ae224f989" xlink:to="loc_avtx_The2016PlanMember_388737ba-4108-4f2c-81aa-547155e0c8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86bcd8c7-cc0b-43d0-844e-fd07feb79678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_704b0534-7077-4dfb-9e41-aba57c1869bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_us-gaap_StockOptionMember_704b0534-7077-4dfb-9e41-aba57c1869bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_1ac4e865-3af9-4196-be00-87e05f84f346" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_ServiceBasedOptionsMember_1ac4e865-3af9-4196-be00-87e05f84f346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember_86f99186-c008-4606-914c-6d472b103163" xlink:href="avtx-20230630.xsd#avtx_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_StockOptionsWithMarketBasedVestingConditionsMember_86f99186-c008-4606-914c-6d472b103163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeStockPurchasePlanESPPMember_8da39538-be98-476e-804a-bf95290cdbe8" xlink:href="avtx-20230630.xsd#avtx_EmployeeStockPurchasePlanESPPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_082debcf-b2b6-4fef-b86f-1bf9747f5fa5" xlink:to="loc_avtx_EmployeeStockPurchasePlanESPPMember_8da39538-be98-476e-804a-bf95290cdbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fbe3b507-91f4-4c7f-999c-3f1af00f7ad0" xlink:to="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_072c8882-1b57-47e4-923f-14802932cd75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:to="loc_srt_MaximumMember_072c8882-1b57-47e4-923f-14802932cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b7aacfd8-ee6b-48de-8e78-4f70eddf9b4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a8b3d7c-2efa-4c76-9695-ddb12e3f3885" xlink:to="loc_srt_MinimumMember_b7aacfd8-ee6b-48de-8e78-4f70eddf9b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_bad21a74-49a2-4702-8823-726de220eeea" xlink:to="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_9152d595-2291-4053-942d-3dd73db69d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_7dab6e0f-e5df-4da7-abdc-d813bf426614" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_9152d595-2291-4053-942d-3dd73db69d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_11289b55-5594-4ae0-a408-c5b7801115c7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_be9ad5d4-9c63-4655-8451-831f1f31cbd7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:to="loc_srt_DirectorMember_be9ad5d4-9c63-4655-8451-831f1f31cbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SpecialAdvisorToTheBoardMember_87cdb03e-d6f4-47b0-8c4e-4607d8f51e72" xlink:href="avtx-20230630.xsd#avtx_SpecialAdvisorToTheBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb90ccd-a092-4db0-b71b-4eb087b8d393" xlink:to="loc_avtx_SpecialAdvisorToTheBoardMember_87cdb03e-d6f4-47b0-8c4e-4607d8f51e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2ef074a2-6cf3-4130-94e1-8fd4152d4010" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_EmployeeStockPurchasePlanESPPMember_204159f4-19fd-4d49-8e00-95632ee2b0ca" xlink:href="avtx-20230630.xsd#avtx_EmployeeStockPurchasePlanESPPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f97551f1-8137-484f-83d6-cfdbb263153c" xlink:to="loc_avtx_EmployeeStockPurchasePlanESPPMember_204159f4-19fd-4d49-8e00-95632ee2b0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_13dca3fa-514c-401e-b867-9bc80a171aa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_ab23d0f0-a440-42f0-bbfe-7c0bf47c4d03" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_ab23d0f0-a440-42f0-bbfe-7c0bf47c4d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_c8bf1815-5abb-4739-a65f-f676b84a9b42" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_c8bf1815-5abb-4739-a65f-f676b84a9b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d8470819-4471-4008-bfc1-31671a6112ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d8470819-4471-4008-bfc1-31671a6112ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d9b9d9d-d773-4dc0-b005-a84b47169a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d9b9d9d-d773-4dc0-b005-a84b47169a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51750b51-70a6-4234-9dec-a25039c717ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51750b51-70a6-4234-9dec-a25039c717ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1b3acab-7de3-430e-81a0-7e22472dd8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1b3acab-7de3-430e-81a0-7e22472dd8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fd64782d-ebf4-4224-a375-96cb5cb0d3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fd64782d-ebf4-4224-a375-96cb5cb0d3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7dd94dfb-975b-4ebc-9cb0-93b4ec6e256c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7dd94dfb-975b-4ebc-9cb0-93b4ec6e256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4dba8baa-9b4d-419d-b39b-25162c957fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4dba8baa-9b4d-419d-b39b-25162c957fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f516c782-7898-44d0-b171-8aa6edd06074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f516c782-7898-44d0-b171-8aa6edd06074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d419a13b-97f6-472f-a230-d058a1431276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d419a13b-97f6-472f-a230-d058a1431276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8d211a4b-b323-401f-8788-1da18bdcbd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8d211a4b-b323-401f-8788-1da18bdcbd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bf67d6e-b0cd-4ff1-9fcd-4d17ea0318c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6bf67d6e-b0cd-4ff1-9fcd-4d17ea0318c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20eea26c-fa36-4770-b73d-b75b7b0d501a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20eea26c-fa36-4770-b73d-b75b7b0d501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c3ce6e9-f34f-47cb-9544-c3b7dd5a31bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c3ce6e9-f34f-47cb-9544-c3b7dd5a31bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66214a93-91ec-4214-8879-881ad5117346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_66214a93-91ec-4214-8879-881ad5117346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89dfc0f2-a404-428b-971b-4f6eb85ca41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89dfc0f2-a404-428b-971b-4f6eb85ca41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8b52cf2-3bf7-43a6-89dd-84e932081cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8b52cf2-3bf7-43a6-89dd-84e932081cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca008a37-6d61-4d6a-8c6c-f6ae6e659167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca008a37-6d61-4d6a-8c6c-f6ae6e659167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_81a914f8-5a84-4a07-af1e-b3ccb58a34e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_81a914f8-5a84-4a07-af1e-b3ccb58a34e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a7b9fef8-4042-4ea6-b760-02f74124f718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a7b9fef8-4042-4ea6-b760-02f74124f718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_43560492-9a11-40ca-8f8d-a409a4ad2458" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_43560492-9a11-40ca-8f8d-a409a4ad2458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44ffbc20-bfcb-43e6-bd82-56329b463503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44ffbc20-bfcb-43e6-bd82-56329b463503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_c307e902-0265-4fa5-b568-4fdf714f38df" xlink:href="avtx-20230630.xsd#avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_c307e902-0265-4fa5-b568-4fdf714f38df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_92c756ba-1d46-4dd2-ba8a-aae46e6da4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a260dbd7-0a8a-4801-a6e2-16e12fd1a066" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_92c756ba-1d46-4dd2-ba8a-aae46e6da4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a517a860-a61a-4695-b1aa-b9906e1ebc01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a517a860-a61a-4695-b1aa-b9906e1ebc01" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20d6fe8f-695a-4eb4-98cb-ee50f75e1c18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_896bf931-d973-4178-9e6f-85a171932b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_896bf931-d973-4178-9e6f-85a171932b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_20481c7f-930b-4d3c-89d3-f2db64eb577d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80222fe8-afad-4be4-922a-9234fef8be20" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_20481c7f-930b-4d3c-89d3-f2db64eb577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b540c69-a6b4-485b-a443-3c071e84d119" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cc9c51db-22dc-49ee-ba23-cc75c1df3581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bd52776-3708-4f8a-9a9e-b835257d8152" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cc9c51db-22dc-49ee-ba23-cc75c1df3581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4a97069-08c0-40e0-b23e-b62adea5b1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4a97069-08c0-40e0-b23e-b62adea5b1b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:to="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fc7d96af-209f-4773-8108-615d477129ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_096a57b4-c177-4085-8d9b-ba5847cdf3f4" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44995f95-f9e9-48a5-a423-f046fcbd4073" xlink:to="loc_avtx_ServiceBasedOptionsMember_096a57b4-c177-4085-8d9b-ba5847cdf3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8ef9e9-d2cb-43f3-8349-e45fabbb159c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_08fba273-f7af-44a4-8d58-32e65310975b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_08fba273-f7af-44a4-8d58-32e65310975b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_972869f1-c71b-405f-93c0-81a4e93e2c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_972869f1-c71b-405f-93c0-81a4e93e2c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_be358cb7-4e83-4862-825f-28361d79c696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_be358cb7-4e83-4862-825f-28361d79c696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77f97193-abf8-41cd-b457-3665519cc714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aca32a5a-f146-452a-8a6b-a7f2b7ca1d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77f97193-abf8-41cd-b457-3665519cc714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb937caa-2d91-4a3d-9403-932f6dce6fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb937caa-2d91-4a3d-9403-932f6dce6fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3459320a-3746-4a01-ac79-87aa596ee4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3459320a-3746-4a01-ac79-87aa596ee4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d29fb390-7c5e-4f83-8fec-45328df429e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d29fb390-7c5e-4f83-8fec-45328df429e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_95babb56-c8c5-4b16-ac16-96789401acef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_95babb56-c8c5-4b16-ac16-96789401acef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17544097-cc2c-4680-80e6-c2f7c6685001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e741527-1de7-47a5-a390-49a4dc5bb261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17544097-cc2c-4680-80e6-c2f7c6685001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07e2b935-ef3a-450b-9169-e6d49b9bf088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07e2b935-ef3a-450b-9169-e6d49b9bf088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2419e78d-122f-4e02-8882-e4277218c775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2419e78d-122f-4e02-8882-e4277218c775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39c662a6-5396-4dcc-acb8-5317bf3392c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39c662a6-5396-4dcc-acb8-5317bf3392c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_0378667b-c5e7-4b54-aea1-dddddce862c5" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_0378667b-c5e7-4b54-aea1-dddddce862c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a0c3e3a1-347c-4573-85e9-f65efc0a9509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_16b9f8ff-7ff5-4b72-9b32-0cdd85dfa297" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a0c3e3a1-347c-4573-85e9-f65efc0a9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_5f75dad5-4a08-4945-8c55-6303632704b4" xlink:href="avtx-20230630.xsd#avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_5f75dad5-4a08-4945-8c55-6303632704b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5659bb0e-4a49-41f0-80be-3341b148611e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1e835bc-0a06-4db9-a6e4-138e146e5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1e835bc-0a06-4db9-a6e4-138e146e5cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc6f2ec8-b93c-4a30-accf-406e99173d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a6e1d7fd-5740-42e3-a4ed-79fc44eae8f0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc6f2ec8-b93c-4a30-accf-406e99173d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15b66053-a900-4725-a5f7-728d98288955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15b66053-a900-4725-a5f7-728d98288955" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:to="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b843bd69-f836-4e98-a4d0-db258e5273a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ServiceBasedOptionsMember_d21ab4d7-2945-4267-aaf3-8a77c9afa74e" xlink:href="avtx-20230630.xsd#avtx_ServiceBasedOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e92ab3a-4fa3-4ffd-9dea-eedd91c72149" xlink:to="loc_avtx_ServiceBasedOptionsMember_d21ab4d7-2945-4267-aaf3-8a77c9afa74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:to="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f312bad-ba68-4587-95f5-9c694958bec5" xlink:to="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5f3499e-e67b-4cfa-b6d3-87a2851d32f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:to="loc_srt_MinimumMember_c5f3499e-e67b-4cfa-b6d3-87a2851d32f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f5c025b-5917-455c-b09b-9ed7467bbc72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d7e08606-033c-429a-a632-263c494b0b34" xlink:to="loc_srt_MaximumMember_2f5c025b-5917-455c-b09b-9ed7467bbc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd14b1bd-2d38-4078-8665-e250a35623aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_99f123bc-cf78-4341-9029-ad29ff0b50e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_99f123bc-cf78-4341-9029-ad29ff0b50e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a1545830-7e06-4526-a340-57c04ff22ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a1545830-7e06-4526-a340-57c04ff22ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331d059b-2b7d-4a6c-aeff-fca23758eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_331d059b-2b7d-4a6c-aeff-fca23758eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1cd82190-5c7d-4fc6-963f-08b59c6b8902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccacefc4-24f1-4b12-877a-b074d56b80b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1cd82190-5c7d-4fc6-963f-08b59c6b8902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="avtx-20230630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe421573-03ad-4a11-b2c9-f82c547d5b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe421573-03ad-4a11-b2c9-f82c547d5b3a" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_622dddc1-b5d1-461a-839a-0c613bfab71e" xlink:to="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX301OutLicenseMember_4fc912a3-1a5b-46b3-aab0-1a8ffaa45ea0" xlink:href="avtx-20230630.xsd#avtx_AVTX301OutLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX301OutLicenseMember_4fc912a3-1a5b-46b3-aab0-1a8ffaa45ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX406LicenseAssignmentMember_e79f7934-88fe-41a8-81d5-255b961999b8" xlink:href="avtx-20230630.xsd#avtx_AVTX406LicenseAssignmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX406LicenseAssignmentMember_e79f7934-88fe-41a8-81d5-255b961999b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX801AVTX802AndAVTX803Member_251fc670-6446-4372-b13e-597576919655" xlink:href="avtx-20230630.xsd#avtx_AVTX801AVTX802AndAVTX803Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX801AVTX802AndAVTX803Member_251fc670-6446-4372-b13e-597576919655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX913Member_94609668-c7dd-4de2-8575-6ed7b4c07f5e" xlink:href="avtx-20230630.xsd#avtx_AVTX913Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99a32553-4d27-41d2-bcd0-ad789a6d0c0e" xlink:to="loc_avtx_AVTX913Member_94609668-c7dd-4de2-8575-6ed7b4c07f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_eece90d0-1c69-491d-bb7c-280694d57609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KyowaKirinCoLtdKKCMember_0d82385e-ace1-4565-9826-09c47388d974" xlink:href="avtx-20230630.xsd#avtx_KyowaKirinCoLtdKKCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_KyowaKirinCoLtdKKCMember_0d82385e-ace1-4565-9826-09c47388d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AstellasPharmaIncAstellasMember_eb082512-3408-43b8-b4d9-12334be38fbb" xlink:href="avtx-20230630.xsd#avtx_AstellasPharmaIncAstellasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_AstellasPharmaIncAstellasMember_eb082512-3408-43b8-b4d9-12334be38fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_a73de411-7990-497a-b429-f347ff4c0d43" xlink:href="avtx-20230630.xsd#avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember_a73de411-7990-497a-b429-f347ff4c0d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AltoMember_24284f00-e736-46a1-9ba6-db8cdd1affc7" xlink:href="avtx-20230630.xsd#avtx_AltoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_AltoMember_24284f00-e736-46a1-9ba6-db8cdd1affc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ESMember_784b2502-b32c-4a98-9217-546fc95eb394" xlink:href="avtx-20230630.xsd#avtx_ESMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_ESMember_784b2502-b32c-4a98-9217-546fc95eb394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_TRISPharmaMember_25c98a55-0947-43a9-9848-aa143b96645b" xlink:href="avtx-20230630.xsd#avtx_TRISPharmaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f6f6925-9d44-4c32-8938-da22a84eb8f5" xlink:to="loc_avtx_TRISPharmaMember_25c98a55-0947-43a9-9848-aa143b96645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dca4293f-27a9-4678-9248-e691378d1df4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX002KKCLicenseAgreementMember_f239f279-20a5-47c6-a41e-a7c5e4c797b5" xlink:href="avtx-20230630.xsd#avtx_AVTX002KKCLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX002KKCLicenseAgreementMember_f239f279-20a5-47c6-a41e-a7c5e4c797b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX006AstellasLicenseAgreementMember_47837fe0-fd07-481a-b969-85f5e22a9541" xlink:href="avtx-20230630.xsd#avtx_AVTX006AstellasLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX006AstellasLicenseAgreementMember_47837fe0-fd07-481a-b969-85f5e22a9541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_80df3fba-26bf-4321-82d8-3faee44ed8b6" xlink:href="avtx-20230630.xsd#avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember_80df3fba-26bf-4321-82d8-3faee44ed8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_KarbinalAgreementMember_7bcb9ba1-f75b-4f0f-8929-b751477e06cc" xlink:href="avtx-20230630.xsd#avtx_KarbinalAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2952a66-c2c6-4cde-b661-863914f4aba0" xlink:to="loc_avtx_KarbinalAgreementMember_7bcb9ba1-f75b-4f0f-8929-b751477e06cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:href="avtx-20230630.xsd#avtx_MilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:href="avtx-20230630.xsd#avtx_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneAxis_cc00c54d-d52d-4910-9434-318ce5072ff1" xlink:to="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneOneMember_b8874a5e-393d-41a8-9804-2e6ea93ae708" xlink:href="avtx-20230630.xsd#avtx_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneOneMember_b8874a5e-393d-41a8-9804-2e6ea93ae708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneTwoMember_dde6c729-d749-4976-bcfd-8ed865fd9a00" xlink:href="avtx-20230630.xsd#avtx_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneTwoMember_dde6c729-d749-4976-bcfd-8ed865fd9a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_MilestoneThreeMember_b79a2c25-4bbe-46d6-b5da-b5cdf29a5ed1" xlink:href="avtx-20230630.xsd#avtx_MilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avtx_MilestoneDomain_ff2cb7ff-e68f-45d7-834c-e394b1688f2d" xlink:to="loc_avtx_MilestoneThreeMember_b79a2c25-4bbe-46d6-b5da-b5cdf29a5ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_086bae2f-3200-4798-897c-c028def979c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AeviGenomicMedicineIncMember_e0346d22-9d2a-42a7-bdee-00baf927a10c" xlink:href="avtx-20230630.xsd#avtx_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:to="loc_avtx_AeviGenomicMedicineIncMember_e0346d22-9d2a-42a7-bdee-00baf927a10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_IchorionMember_d910636e-95c8-4568-8d05-1aa45dc8b2f5" xlink:href="avtx-20230630.xsd#avtx_IchorionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b3f4c508-9d1a-4a99-9557-55bb0fd7ee6e" xlink:to="loc_avtx_IchorionMember_d910636e-95c8-4568-8d05-1aa45dc8b2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0806e7cf-12f9-465e-a197-bb85aeea17f7" xlink:to="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AeviGenomicMedicineIncMember_f4702462-2b38-4619-ab08-6e004c724f87" xlink:href="avtx-20230630.xsd#avtx_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8dfddff8-6c0e-4135-bf1b-faaec0328c94" xlink:to="loc_avtx_AeviGenomicMedicineIncMember_f4702462-2b38-4619-ab08-6e004c724f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a1f40e54-41b0-4547-a617-c9da985b3ce3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5a41d4f1-8ec0-40b6-8a6c-af3f567b9fca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ee3905fc-ae21-4a2e-ad7d-351188f55309" xlink:to="loc_srt_ScenarioForecastMember_5a41d4f1-8ec0-40b6-8a6c-af3f567b9fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f15658cc-07ef-4863-85f0-b5a5a8aa8326" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_1ea4edbd-a516-46cc-a6dc-42e8ee12a3a0" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee_1ea4edbd-a516-46cc-a6dc-42e8ee12a3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_90d5d783-da07-40c7-8f32-74e094cd7279" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_90d5d783-da07-40c7-8f32-74e094cd7279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_87e0af6a-7f58-4862-8465-2a3150f4cae0" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing_87e0af6a-7f58-4862-8465-2a3150f4cae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14e67041-4e3c-4280-ae32-263b5abcdf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14e67041-4e3c-4280-ae32-263b5abcdf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_ceb18ae6-41e2-4822-969c-c51f0d048d9d" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate_ceb18ae6-41e2-4822-969c-c51f0d048d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_0cbc9cbe-23a4-4f52-a2ef-5c0b9b40b7a4" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsPatentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts_0cbc9cbe-23a4-4f52-a2ef-5c0b9b40b7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f191f738-7972-45c5-bbdb-198ad352b1e4" xlink:href="avtx-20230630.xsd#avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f191f738-7972-45c5-bbdb-198ad352b1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_25a1685b-7887-4b43-81d3-96e6666ea424" xlink:href="avtx-20230630.xsd#avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments_25a1685b-7887-4b43-81d3-96e6666ea424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_9258888d-0d40-44c4-b049-6eb451d379ba" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones_9258888d-0d40-44c4-b049-6eb451d379ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f3b12fc9-f764-4663-8dcf-2eaffcf57a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f3b12fc9-f764-4663-8dcf-2eaffcf57a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_ec75b0f6-97a3-4ecf-834a-b80ddd386cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_ec75b0f6-97a3-4ecf-834a-b80ddd386cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_7bb3ad90-e7b3-483b-a61e-6dc84e8974ca" xlink:href="avtx-20230630.xsd#avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_7bb3ad90-e7b3-483b-a61e-6dc84e8974ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_9e7f19aa-ecbb-48f2-9f07-5ae10866eab6" xlink:href="avtx-20230630.xsd#avtx_AssetAcquisitionNumberOfPreclinicalTherapies"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_AssetAcquisitionNumberOfPreclinicalTherapies_9e7f19aa-ecbb-48f2-9f07-5ae10866eab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPaymentReceived_13eff1d3-b4bb-4935-b624-8553de487750" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPaymentReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementPaymentReceived_13eff1d3-b4bb-4935-b624-8553de487750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_736c260f-035f-45a8-b9a1-8a804c7815ed" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_736c260f-035f-45a8-b9a1-8a804c7815ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_4e7164b5-e939-4649-bef6-893c757c98e5" xlink:href="avtx-20230630.xsd#avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_4e7164b5-e939-4649-bef6-893c757c98e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_74bff692-d04a-41df-b0be-7aba72347fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_74bff692-d04a-41df-b0be-7aba72347fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_d8d10410-3ea3-43a6-a1e0-7d93e95fafb7" xlink:href="avtx-20230630.xsd#avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_25f3ed6a-d8d6-4deb-b652-7d4665256574" xlink:to="loc_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit_d8d10410-3ea3-43a6-a1e0-7d93e95fafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>avtx-20230630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avtx-20230630_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M^J:!'*?\+8T?_H(6?_@3#_\ %T##_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
M00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #
M_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)
MA_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__
M $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@
M _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\
M"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
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M_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\
M[HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?
M\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(
M_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R
M6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=
M% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH
M/^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?
M]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#D
MM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\
MNB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_
MPPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&
M/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_
M ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\
M=% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@
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M,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\
MJ(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_
M^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W1
M0 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X8
M8_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\
M41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^
M2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z*
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M_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\
M[HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?
M\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(
M_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R
M6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=
M% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH
M/^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?
M]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#D
MM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\
MNB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_
MPPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&
M/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_
M ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\
M=% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@
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M,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\
MJ(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_
M^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W1
M0 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X8
M8_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\
M41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^
M2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z*
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M_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\
M[HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?
M\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(
M_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R
M6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=
M% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH
M/^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?
M]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#D
MM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\
MNB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_
MPPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&
M/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_
M ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\
M=% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@
M_P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_
MU$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC
M_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO
M_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !
M_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&
M&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_
M "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2
MW_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@
M _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,
M,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\
MJ(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_
M^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\ [HH /^&&/^HC_P"2W_W1
M0 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^2W_W10 ?\,,?]1'_ ,EO_NB@ _X8
M8_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\
M41_\EO\ [HH /^&&/^HC_P"2W_W10 ?\,,?]1'_R6_\ NB@ _P"&&/\ J(_^
M2W_W10 ?\,,?]1'_ ,EO_NB@ _X88_ZB/_DM_P#=% !_PPQ_U$?_ "6_^Z*
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M_P#=% !_PPQ_U$?_ "6_^Z* #_AAC_J(_P#DM_\ =% !_P ,,?\ 41_\EO\
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MO^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y5^U'_ ,B[>?\
M;O\ ^E$5 SRK]AC_ )B/_;I_[<4 ?55 @H ^ /V7/^1BL_\ MX_])Y:!GW_0
M(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \J_:C_P"1=O/^W?\
M]*(J!GE7[#'_ #$?^W3_ -N* /JJ@04 ? '[+G_(Q6?_ &\?^D\M S[_ *!!
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'E7[4?_ "+MY_V[_P#I
M1%0,\J_88_YB/_;I_P"W% 'U50(* /@#]ES_ )&*S_[>/_2>6@9]_P! @H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#RK]J/_D7;S_MW_P#2B*@9
MY5^PQ_S$?^W3_P!N* /JJ@04 ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 >5?M1_\B[>?]N__ *414#/*OV&/
M^8C_ -NG_MQ0!]54""@#X _9<_Y&*S_[>/\ TGEH&??] @H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * ,KQ3XIM_"MN][>OY<$>W>^UFQN8(O"!F/
MS,!P/TH J>"O'MEXWA:YT^7S8ED,9;:Z88!6(Q(JGHP.<8YZ]: .@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#/T3Q#;:\AELYHYT#%2
MT3K(H8 $J2A(S@@XZX(]: -"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#RK]J/_D7;S_MW_\ 2B*@9Y5^PQ_S$?\
MMT_]N* /JJ@04 ? '[+G_(Q6?_;Q_P"D\M S[_H$% !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ML1J2<@N X!G_ !%\%77P2U2-;>YW2K&DT4R+L;!+(0RDL.JL"N65D/S?>*@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#RK]J/_D7;S_MW_P#2B*@9Y5^PQ_S$
M?^W3_P!N* /JJ@04 ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT ?*W[%7_(8G_P"O"3_T=!0!U7[<_P#S#O\ M[_]MZ #_FGG^?\ H(T >8?
M[X$I\4TG(NC \#1[E\D2*5<-M(;SD.<HV1MP!@@G)  /3_\ AAC_ *B/_DM_
M]T4 >B_M!:(F@^%)K.(DI!#9Q*6P6*I- @)P ,X'. !GL* ,7]BK_D#S_P#7
M_)_Z)@H \J_;5_Y#$'_7A'_Z.GH ^J?A/_R!]/\ ^O"T_P#1*4 ?)?[&VJ1V
M6M-'(V&FM)8XQ@G<P:.4C@''R1L<G XQG) (!]OT"(KN[2S1I96"(BEF9B%5
M5 R6)/  '))X H R=$U^R\:6QDMGCN;>12K 8=2&4$QNIZ':PW(X! .& H ^
M0/VM/AYIW@^YMVT]1$\ZS-+"K9489=CA#DH&+.H PF$PBC:V09]"_LN?\B[9
M_P#;Q_Z42T ?.O[&VJ1V6M-'(V&FM)8XQ@G<P:.4C@''R1L<G XQG) (!]5?
M&CQC)X-TBZOH!^]2,!#Q\K2.L2ORK [2X;!&&Q@XSF@#Y@^'7PFU#X\0R:AJ
M&HN%CG=$5U:?#,%>3:F^-(E^9,!.#C&%"KD \J^*7@7_ (0349M-\SS?*\O]
MYMV9WQI)]W<V,;L=3G&?:@#Z*_;>UV$0V=EM1IS))+OROF(@&S;C&X+(S9SD
M F+HQ'R@'/Z3\+/%]S9QZ9%=(VGW,",7\])(T0H,0[P&EV[55=L.Z$AL E6<
MT >W_ 7X+#X86TB/();B=D:5U#*H"KA8QECN"LSD/A2P;E1@  'RM^TPJ-XE
MNA*2J%K;<RJ'8+]GAR0I90Q Z LH)XR.M 'I_P#PPQ_U$?\ R6_^Z* /1?@E
M^SBGPQN9;PW)G=X?*4>6(E52RNQ/SR%CE%QR !G(.1@ ]EH$% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'E7[4?\ R+MY_P!N_P#Z414#/*OV&/\ F(_]
MNG_MQ0!]54""@#X _9<_Y&*S_P"WC_TGEH&??] @H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-?C_\
M"V;XDZ>MI;2)'*DZ2KYF[8V%="I*@E>')!"MR ,#.0#/G7_ABK6/^>]G_P!_
M)O\ XQ0!TOA#]B-R0VJW0 #-F.W!)*[?E/F2*-IW=1Y;# X.3\H!]/Z!H$'A
MZ!+2T01PQKM1%Z =>_)).22<EB222230(\5^.O[,(\>3MJ-C*(KIE42+)N,4
MA7:JMN&6C(08.%8-A>%.YB#.%LOV??%UIBWCU+9%'&@3;>72QXY41JJID;0H
MXVA<,H4G#!0#V_X%_#BY\!64D-],)KB:YEGD=2S#<X5?O/AG)V;BQ .6(YQN
M(!B?M&?!2;XFPV_V1T2>"1\>8S+&4<#?]V-VW;D3;T&-V<G% '(? ;]F6[\"
M:B+^_>"0)#((O*>4LLC87<0T: CRRXY)Y(.,@$ 'T)JVEQZO#);3KNBEC>-U
MR1E6!5AD$$9!(R"#Z&@1\K:C^QWJ6BW7GZ->HJC<4=WE@G3.X;=T2/GY" 6&
MS=DC8!U!@O[.'BCQ!&L6H:C^XD\LRQR7-Q,5&0Q!3!C=E(R!OVE@,/C#4 >_
M_&;P5-XWTJXT^V9%EE\K:9"P0;94D.2JL>BG& ><?6@#$_9Z^%]S\.+"2SO&
MC=WN7E!B+,NTQQH =Z(<Y0]L8QS0!YU\8/V1F\1W4E_I<R1O-(7DBFW[-S;C
M(ZNH=AEL'85P"6(8#:@ .5_X9K\3>*OW.IWO[A)\8EN)KC(''GQI\RGY6.T.
M8WZA@@.: /HKX4?"BU^&]J+:V&Z1L&:8C#R,.YZX49(1 2%!/)8LS 'QVG@=
M/'/BJZTZ1S&)KW4<.H!*LOGNAP>HW*,C()&0"I.0 =?JW[(FN3,EJMS#+:Q>
M<82\LH1 74X\O8VQGSN(3<N5.Y\[=P!]%?!CX00_#&U:WC?SI9)"\DI14+=D
M4 %B%4= 6;YF=AC=@ 'G7B_]GJ_UGQ(NN1R0"W6YLY2K-()=L*Q!Q@1E<G8<
M?-CIDCL >U>-]$?7K"ZLXB \]M/$I;(4,\;("< G&3S@$X[&@1XK^SU^SU?_
M  XOY+R\D@='MGB B:1FW&2-P3OC08PA[YSCB@9M_M(?!2\^)OV3[$\*>1Y^
M_P UG7._RMN-D;_W#G..W6@#JOA?\-6\/Z)'HVH;)/W=Q'+Y;/L999)&(#81
MONO@G (.<'H: /"]1_8[U+1;KS]&O451N*.[RP3IG<-NZ)'S\A +#9NR1L Z
M@ O[.'BCQ!&L6H:C^XD\LRQR7-Q,5&0Q!3!C=E(R!OVE@,/C#4 >_P#QF\%3
M>-]*N-/MF199?*VF0L$&V5)#DJK'HIQ@'G'UH Q/V>OA?<_#BPDL[QHW=[EY
M08BS+M,<: '>B'.4/;&,<T <5^T+^SU?_$>_CO+.2!$2V2(B5I%;<))')&R-
MQC#COG.>* /:O!&B/H-A:V<I!>"V@B8KDJ62-4)&0#C(XR <=A0(^8-?_8YU
M&"]>?2IX(X1-O@W/.DL8SN49"2'*'@-N). QP3@ SWKX(^ [SP38FWU"X^T3
MO/+*6#.ZKO()4-)ACE@9&.%^=VX)RS ':ZMI<>KPR6TZ[HI8WC=<D95@589!
M!&02,@@^AH$?)<O[)NN>%I))M)O4XC(5DDEM9Y!@,8\*"HRPP 9-IP&8KV!E
MO3OV.]2UJZ\_6;U&4[2[H\L\[XVC;NE1,?(" QW[< ;".@!]4Z3I<>D0QVT"
M[8HHTC1<DX50%49)).  ,DD^IH$?*&O_ +'.HP7KSZ5/!'")M\&YYTEC&=RC
M(20Y0\!MQ)P&."< &>J^&?@7<OH-QHNJW9DEN)GE,JEI!&Q=)% ,F"X,B>8_
M"%B[@$'YR >5:-^S'XC\)3NNF7L<<<BR R+++$&491-Z!&PY61F3&\1D,0ZM
ML+ $7B']C/4KIDDBNH9)7CW7#S/+DS,[,Y7$3DK@K\S'<S;F(7(4 &A^VYXC
M@D>UL/+)N$5IA+NPJQN60QA<_,6:,$D@;0H"YWM@ BTG]B&2YACDGO?*E:-"
M\?D!]C$ LFX3X;!R,C@XR* .?^ /CK4/ ^M#0I'>>W\^2W>)-TJHRL^98PQ7
M8H?+2' !CW,RE@I ![I\>/V?(_B9LN8I/)O(HRBLP+1NHW,J, ?EP[9WJ"0"
MV5?Y=H!Y+IO[.7BO1PEK;:@(X0KD".[N4B0[@=NT(""Q8L-JD<-N()7< >P?
M 7X47_@@W=QJMR+BXNFARP:24[8E8*2\@5B3OQC&%"C!.<* >M4""@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#RK]J/\ Y%V\_P"W?_THBH&>5?L,?\Q'
M_MT_]N* /JJ@04 ? '[+G_(Q6?\ V\?^D\M S[_H$% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SUX0_9ZO]&\2-KDDD!MVN;R4*
MK2&7;,LH08,87(WC/S8ZX)[@SZ%H$% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % 'C7QV_9U3XEN+R*<Q720B-0P#0LJF1PIP ZDN_+@
ML H_U9- SS6T_9W\6V:+%%J@1$4*JK=WBJJ@8"@"+  '  X H [_ ."W[,,'
M@&5+^YE,UXJMMV_)"A= K8'WG(RX#,0"K9\M6 ( /<*!!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!Y5^U'_R+MY_V[_\ I1%0,\J_88_YB/\
MVZ?^W% 'U50(* /@#]ES_D8K/_MX_P#2>6@9]_T""@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /*OVH_^1=O/^W?_P!*(J!GE7[#'_,1_P"W3_VX
MH ^JJ!!0!\ ?LN?\C%9_]O'_ *3RT#/O^@04 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!Y5^U'_R+MY_V[_^E$5 SRK]AC_F(_\ ;I_[<4 ?55 @
MH ^ /V7/^1BL_P#MX_\ 2>6@9]_T""@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * *FJ:M#I$;3W,B11+C<\C*B#) &68@#)( SW(% $6B>(;;7D,MG-'.@8J6
MB=9%#  E24)&<$''7!'K0!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!RG_"V-'_ .@A9_\ @3#_ /%T#.KH$% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y5^U'_P B
M[>?]N_\ Z414#/*OV&/^8C_VZ?\ MQ0!]54""@#X _9<_P"1BL_^WC_TGEH&
M??\ 0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M20,.0V0 '[-WQKO/#M\FB:DSM!)((5$N\R02@>6D8!!8*6 C,9PJ'# J X8
MB_:V^%]SIUY+KCM&;>XF@B106\T,+<#)!0*!^Z;HQ/(XZX ,3]GCX*7GBJ:#
M5X'A6"VOXMZNSB0^48Y6V@1LI^5@!EASUP.: /NJ@04 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8?_"<V'_/U;_\ ?Z/_
M .*H&'_"<V'_ #]6_P#W^C_^*H /^$YL/^?JW_[_ $?_ ,50 ?\ "<V'_/U;
M_P#?Z/\ ^*H /^$YL/\ GZM_^_T?_P 50 ?\)S8?\_5O_P!_H_\ XJ@ _P"$
MYL/^?JW_ ._T?_Q5 !_PG-A_S]6__?Z/_P"*H /^$YL/^?JW_P"_T?\ \50
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MV'_/U;_]_H__ (J@ _X3FP_Y^K?_ +_1_P#Q5 !_PG-A_P _5O\ ]_H__BJ
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M6_\ W^C_ /BJ #_A.;#_ )^K?_O]'_\ %4 '_"<V'_/U;_\ ?Z/_ .*H /\
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MJ@ _X3FP_P"?JW_[_1__ !5 !_PG-A_S]6__ '^C_P#BJ #_ (3FP_Y^K?\
M[_1__%4 '_"<V'_/U;_]_H__ (J@ _X3FP_Y^K?_ +_1_P#Q5 !_PG-A_P _
M5O\ ]_H__BJ #_A.;#_GZM_^_P!'_P#%4 '_  G-A_S]6_\ W^C_ /BJ #_A
M.;#_ )^K?_O]'_\ %4 '_"<V'_/U;_\ ?Z/_ .*H /\ A.;#_GZM_P#O]'_\
M50 ?\)S8?\_5O_W^C_\ BJ #_A.;#_GZM_\ O]'_ /%4 '_"<V'_ #]6_P#W
M^C_^*H /^$YL/^?JW_[_ $?_ ,50 ?\ "<V'_/U;_P#?Z/\ ^*H /^$YL/\
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M;#_GZM_^_P!'_P#%4 '_  G-A_S]6_\ W^C_ /BJ #_A.;#_ )^K?_O]'_\
M%4 '_"<V'_/U;_\ ?Z/_ .*H /\ A.;#_GZM_P#O]'_\50 ?\)S8?\_5O_W^
MC_\ BJ #_A.;#_GZM_\ O]'_ /%4 '_"<V'_ #]6_P#W^C_^*H /^$YL/^?J
MW_[_ $?_ ,50 ?\ "<V'_/U;_P#?Z/\ ^*H /^$YL/\ GZM_^_T?_P 50 ?\
M)S8?\_5O_P!_H_\ XJ@ _P"$YL/^?JW_ ._T?_Q5 !_PG-A_S]6__?Z/_P"*
MH /^$YL/^?JW_P"_T?\ \50 ?\)S8?\ /U;_ /?Z/_XJ@ _X3FP_Y^K?_O\
M1_\ Q5 !_P )S8?\_5O_ -_H_P#XJ@ _X3FP_P"?JW_[_1__ !5 !_PG-A_S
M]6__ '^C_P#BJ #_ (3FP_Y^K?\ [_1__%4 '_"<V'_/U;_]_H__ (J@ _X3
MFP_Y^K?_ +_1_P#Q5 !_PG-A_P _5O\ ]_H__BJ #_A.;#_GZM_^_P!'_P#%
M4 '_  G-A_S]6_\ W^C_ /BJ #_A.;#_ )^K?_O]'_\ %4 '_"<V'_/U;_\
M?Z/_ .*H /\ A.;#_GZM_P#O]'_\50 ?\)S8?\_5O_W^C_\ BJ #_A.;#_GZ
MM_\ O]'_ /%4 '_"<V'_ #]6_P#W^C_^*H /^$YL/^?JW_[_ $?_ ,50 ?\
M"<V'_/U;_P#?Z/\ ^*H /^$YL/\ GZM_^_T?_P 50 ?\)S8?\_5O_P!_H_\
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MO^0//_U_R?\ HF"@#W^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >$?\,Z?]/7_ )!_^VT##_AG3_IZ_P#(/_VV@ _X
M9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\
MR#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /
M^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_
M ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;:
M#_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ
M_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV
M@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z
M>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]
MMH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/
M^GK_ ,@__;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@_
M_;: #_AG3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG
M3_IZ_P#(/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: #_AG3_IZ_P#(
M/_VV@ _X9T_Z>O\ R#_]MH /^&=/^GK_ ,@__;: )9?V;?+&?M?_ )!_^VT
M1?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0 ?\ #.G_ $]?^0?_ +;0
M!(G[-^X$_:^G_3'_ .VT 1_\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]
M/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\
M,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;
M0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D
M'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]
M/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\
M,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;
M0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D
M'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]
M/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\
M,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;
M0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D'_[;0 ?\,Z?]/7_D
M'_[;0 ?\,Z?]/7_D'_[;0 ^+]G#S#C[7_P"0?_MM #6_9SVG'VK_ ,@__;:
M$_X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>
MO_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!M
MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^
MGK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\
M;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3
M_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__
M &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9
MT_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/
M_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^
M&=/^GK_R#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R
M#_\ ;: #_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #
M_AG3_IZ_\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: #_AG3_IZ_
M\@__ &V@ _X9T_Z>O_(/_P!MH /^&=/^GK_R#_\ ;: .(^-7P7_X1O2;B[^T
M;]GE?+Y>W.Z:->N\XZYZ4 2?L,?\Q'_MT_\ ;B@#ZJH$% 'P!^RY_P C%9_]
MO'_I/+0,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MGF7QHZZEI@!N@JI+%\B>:H.%<,=HWJ#@[S@H  04"N <!:>#O'=G:+I\7F)
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % &=0,* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H MW?3\: *E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 6(?NG\?Y4 5Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H F
MM.OX4 1R=3]30 V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \N_
M:;_Y%^[_ .W?_P!*(J /-_V&/^8C_P!NG_MQ0!]54""@#X _9<_Y&*S_ .WC
M_P!)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#.H&% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 6[OI^- %2@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * +$/W3^/\J *] !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 36G7\* (Y.I^IH ;0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 >7?M-_\ (OW?_;O_ .E$5 'F_P"PQ_S$?^W3_P!N
M* /JJ@04 ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!G4#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * +=WT
M_&@"I0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %B'[I_'^5 %
M>@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * )K3K^% $<G4_4T
M-H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_P#D7[O_ +=_
M_2B*@#S?]AC_ )B/_;I_[<4 ?55 @H ^ /V7/^1BL_\ MX_])Y:!GW_0(* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,K7?%EGX?V_;;
MB&#?G9YLB1;L8W8WD9QD9QTR/6@"UI>K0ZO&L]M(DL39VO&RNAP2#AE)!P00
M<=P10!;H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * //\
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M45PZVYGLH3%\ICV2>2S_ "D$;B6/S_? .T,%P* /J&@ H * "@ H * "@ H
M* "@ H * +=WT_&@"I0 4 % !0 4 % !0 4 % !0 4 % !0 4 >/_M#_ !GN
M/AJEL+2.-WG:7)DW%0L83(VJRDDEQSNP ",'.0 >2:-^VC?0N3=VL$B;3@1F
M2%MV1@[F,P(QGC:#D@YXP0#W3X/?&ZU^)4;!%\FYCR7@+;CMS@.K87<O(!X!
M5N",%68 \E\:_$_4M-\7I917#K;F>RA,7RF/9)Y+/\I!&XEC\_WP#M#!<"@#
MZAH * "@ H * "@ H * "@ H YSQS\0K/P1 ;B^D"#:Q1,CS9",#:BD@L<L
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MRJ >(> OB?J5WXMFL)+AVMGN[M#$=I0+"DWEA01\F-HR4VER,ON- 'U#0 4
M% !0 4 % !0 4 % !0!XA\9/VC&\(W7]EZ;!]HO?D!W!RBL^TH@1<-(S*?X2
MH!9<%CN4 'G/_#76KZ+<>5J-G$NW[\6V:WFY7*\R.^WJ#RAR.F,@@ ^G/!WB
MV#Q=:17]J28I5)&X;6!!*LI'J&!!P2"1D$C!(!LT ?&O@S_BZ/B]KQ>88YS/
MN3Y/W=OM2!B),M\S+$'&,_,V H^Z >H_M _M W?P\NXK.SBB;= )6:4.WWG9
M H",F,;"223G(X&.0#@]$_;3NX=WVRTBESC;Y3O#CKG._P [=GC&-N,'KG@
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M!JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'RA^VYXO)>UTI20
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M?2@"I_PL+3?.^R_;+;S_ #/+\KSXO,WYV[-N[=NW<;<9SQC- '04 % !0 4
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M % !0 4 % !0 4 % !0 4 % !0 4 % 'QA^VO=NVJV\18E%LE95R=H9I90S
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MG^P[3[3L\G^S;?S/,QY>SR%W[MWR[=N=V>,9SQ0!\B?LO6CSZ_;,BDA%G9R
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MJW[-/QOG\<B6RU AKJ)?,5PNTR1EL-D*H0%"5&1C<&'RY5F(!+\7?'NOI?\
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MXW ,IRI_H1T925;*L00#EOC(MKI>A7B2JBPK:,B+LRBL0$@ 4 @8D*;2  I
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M+_Y"\/\ UXQ_^CIZ /ICXS>3_8U]]HV;/LDV-^-N_:?*QNXW>9MV=]^W'.*
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M'E^<6%O-&)6B'^M@?9(RE7.,F,CY2<*X!5LJKT ?H)0(* "@ H * "@ H *
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M@ >=>'/$=W\!M;DMV8M$DRI<( ")8<AE<+OP'\MMZ?-E"=K'!=2 >G_MS_\
M,._[>_\ VWH YKP#^SCJ/Q1MH[_4;DVZ"&**U#1^8QA1=J$+OC")C&WJ9"6D
M(^8,X!S7P4\177PW\0+8;MRO=_9+A%;]VY\PQ!_F7^!SO4X5B,KE0[4 ?>E
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M "%YO^O&3_T=!0 ?$?\ Y'>/_K^TW_T&WH ^RJ "@ H * "@ H * "@ H *
M"@ H MW?3\: *E !0 4 % !0 4 % !0 4 % !0 4 % !0!\O?MM_\P__ +>_
M_:% &!HG[.VN>+[2U,U\ALGC@D2-YIY/+1D&W;&4";E1L !@/X0P!S0![S\'
MO@C:_#6-BC>=<R9#SE=IVYR$5<MM7@$\DLW). JJ ?/GQ'_Y'>/_ *_M-_\
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MNQGWLTL<BDA?)1?O/DC@ =/2@#Z-H * /C7XC_\ ([Q_]?VF_P#H-O0!]E4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!8A^Z?Q_E0!7H * "@ H * "@ H
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M)Q]XGDT >F?L:?\ ((F_Z_I/_1,% 'EW[&G_ "%YO^O&3_T=!0!]E4 % !0
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M ",5Y_V[_P#I/%0!]_T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+
M_P!I3Q>/#.B7)R-\Z_9T#!B"900X^7H1%O8$D#(&<_=(,^4/@IX6\1?/J7AY
M/[T#R;K;_IG(R[9S_N'('L#U% &W\8- \5W]I]HUY UO;L&W_P"A;D+D1\&'
M]Y@DJ"!P2 2/E! !Z?\ L4^,_M=K<:9(WS0R"6,%\G9)PZJAZ*KKN)'&Z7D
MG+ 'DO[)GBA-"UM$DP!<PR0!F8(%8E9$ZCYBS1A O!)88R>" ?<FJ:M#I$;3
MW,B11+C<\C*B#) &68@#)( SW(% CS7]J/\ Y%V\_P"W?_THBH&<5^Q+JD<F
MFW-L&_>I=^8RX/"R1HJ'.,')B<8!R,<@9&0#G_VY_P#F'?\ ;W_[;T >J_\
M,G_]P'_VSH \*_8IUV&TU"XM9%3S9H 8Y"5#_NVR\2@C)W!MY /2+)!QE0#V
MK]K#5([+0)XY&PTTD$<8P3N82K*1P#CY(V.3@<8SD@$ X#]AW2Y(H;ZY*_NG
MD@C5LCEHQ(SC&<C E0Y(P<\$X. #BOV*O^0Q/_UX2?\ HZ"@#U7]M7_D#P?]
M?\?_ *)GH /V*O\ D#S_ /7_ "?^B8* /?Z!!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*?%C_D
M#ZA_UX7?_HEZ!GRM^Q5_R&)_^O"3_P!'04 '[:O_ "&(/^O"/_T=/0!]J4"/
M@#]ES_D8K/\ [>/_ $GEH&=7^VK_ ,AB#_KPC_\ 1T] 'U3\/O$T-_I-M?$P
MQQ?9(W?RRJ01[4'F*.2$5""I!/R;2#T- 'Q#I.J1ZOXJCN8&W12ZTDB-@C*M
M=!E." 1D$'! /J* /7_VY_\ F'?]O?\ [;T >J_\R?\ ]P'_ -LZ /$/V)_%
M"65[<V#X!N(4=&+ $M"6^0*1\Q*R,W!R A.",D 'USJ&K0Z=L\^1(_,D6--[
M*NYVSM1<D98X.%')["@1\K?M ?$S5-2UU=!T^X>V026L8*.8]TLH!#L\:B0+
MB4*4RR_+NQG  ,Y_XI?LI?\ "":=-J7VWS?*\O\ =^1LSOD2/[WG-C&[/0YQ
MCWH ZK]AC_F(_P#;I_[<4 <5\8=4CTCQG]IG;;%%=Z?([8)PJQV[,< $G !.
M "?04 ?;] CXK^&G_(\R?]?^I_\ H-Q0,/VU?^0Q!_UX1_\ HZ>@#ZT^'VNP
MZ]I]M=6RHD4D$96.,JR1_* 8@5 'R$%" !@J1@8P 1\0?'K_ (JKQ+<Q67[Q
MY)X8$'W<RJD<#+E]H'[Q2N3\O?..:!GT!^VK_P @>#_K_C_]$ST =5^RY_R+
MMG_V\?\ I1+0!\J_M1_\C%>?]N__ *3Q4 ??] @H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /BO]M7_ )#$'_7A'_Z.GH&?5/PG_P"0/I__
M %X6G_HE* /G#]L3XJP:N8]&M6#F"8R7# 9"R!2BQALX) 9_,&#@[1N#!U !
MU?PD\+OH7@R]>3(-S;7TX5E*%5,!C3J?F#+&'#8 (88R.2 ?/_P2^$R?$ZYE
MLS<&!TA\U3Y0E5E#*C _O8RIRZXX((SDC R >R_\,,?]1'_R6_\ NB@#W7PM
M\*+71](30YQ]HMQ&ROO&-Y9S(Q 'W<.Q*8.Y,+ABPW4 ?.OQ0_8^_L"WGOM/
MNMT4,;2-%,N'")&6?$B##,2ORKL08/+<9(!TO[)'QBO?$<LNE7SF<)"TT<SL
M6E #HK1L3DN,OE23E<%>5*A #A?AI_R/,G_7_J?_ *#<4 :'[9>IQ:KJ=K8P
MK'YT</SR;T4YE?Y(I"V @4#>"[  2[OE'+ &AJGP;\8^((VTB[ND>S7#^;)-
MN20Y#!2P0W+X+$@2+L!08^ZE 'O_ ,(?AC'\-[$6,;^8WF/)))M*;V8X!VEW
MVX0*N <';G&2: /F#XE_\CS'_P!?^F?^@V] 'U3\6/\ D#ZA_P!>%W_Z)>@#
MY6_8J_Y#$_\ UX2?^CH* +7C7Q?JGQ2\0R:#!=/;6WGW$ 0,0FR-2LQ;RPAE
MW")F".2 6V;@I+4 <_\ &O\ 9O\ ^%96:7OVOS]\ZQ;/)\K&4D?=GS7_ +F,
M8[]>* /:_P!BK_D#S_\ 7_)_Z)@H \?^,.J1Z1XS^TSMMBBN]/D=L$X58[=F
M. "3@ G !/H* /M^@1\5_#3_ )'F3_K_ -3_ /0;B@8?MJ_\AB#_ *\(_P#T
M=/0!]:?#[78=>T^VNK942*2",K'&59(_E ,0*@#Y""A  P5(P,8 (^(/CU_Q
M57B6YBLOWCR3PP(/NYE5(X&7+[0/WBE<GY>^<<T#/5?VY_\ F'?]O?\ [;T
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M77[ORAMP3*@4 >#>%?AMXR\!>;!IJ[8FDR<26KQL1\H=5F.5R,?PJQ 4,/E
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MT<DA6-Y+=H6SD94M(DJJ3\X4%.>67)8$ [?X5Z5XLGOX[C6I0MK&KJT9,&9
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M) R3D ]"\!_\)M]N@_M#9]E\P>=O^R;=F#NQY'[S=C[F.-^W=\FZ@#Z#H *
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M9_ ?7AJ]EJ=X/M#M/;3W4GF1#RR)LM'@N"VV-5^XNP9V)D*"0#V3XW6&O/\
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M#JIXSGB@#@_V9_@]JG@O49;C4(/*B:T= WF1/EC)$P&$=CT4\XQQ0!]+T %
M!0 4 % 'EW[3?_(OW?\ V[_^E$5 'F_[#'_,1_[=/_;B@#ZJH$% 'P!^RY_R
M,5G_ -O'_I/+0,^_Z!!0 4 ?,'QF_9?U+QOJMQJ%M+;+%+Y6T2/*'&V)(SD+
M$PZJ<8)XQ]*!GT_0(* /GKQ?^SU?ZSXD77(Y(!;K<V<I5FD$NV%8@XP(RN3L
M./FQTR1V!GT+0(\?^/'[/D?Q,V7,4GDWD49168%HW4;F5& /RX=L[U!(!;*O
M\NT&>-VW[-OBFU']G1W@6T,+9VW4PMOF8AXO+"[LG)8_N]A!.6W'% 'K_P #
M?V<8/AT?M=PPGO2H ?;A(@5 =8\\DDY!D."5X"H"X8 \ ^*MBGQ2\5-96,9B
M=IA;RNQ#%FARLL^TL  L:<(&!8(#P[D  Z#QM^QN_AVRGO8[X2&"%Y2C0&,,
MJ#<XW"5\':#CY<$X!(!R #M?V1/BK>^)A/87S23B%5DCG8%R S$-&\A.22>8
MP03@2#=M50 "UX0_9ZO]&\2-KDDD!MVN;R4*K2&7;,LH08,87(WC/S8ZX)[@
M'T+0(^1=;_9"U/P_<BXT2[& PV,7>"X0.Q0_,@(8+&V78%2PW!8\X5@9;\1_
MLI:SXG1KJ_O8YK]I@%W/(85AP[, ?*R#YC#:BJL:+NQG< H![U\&?!4W@C2K
M?3[ED:6+S=QC+%#NE>08+*IZ,,Y YS]: /+_ -GK]GJ_^'%_)>7DD#H]L\0$
M32,VXR1N"=\:#&$/?.<<4 =K^T+\+[GXCV$=G9M&CI<I*3*65=HCD0@;$<YR
MX[8QGF@ _9Z^%]S\.+"2SO&C=WN7E!B+,NTQQH =Z(<Y0]L8QS0!YA\9OV7]
M2\;ZK<:A;2VRQ2^5M$CRAQMB2,Y"Q,.JG&">,?2@#Z?H$% !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZA0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ME\S9Y_FXQY6W=MXQNQGOCF@9]/T""@ H * "@ H SJ!A0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % %N[Z?C0!4H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@"Q#]T_C_*@"O0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >
M?&[]EO\ X3FXDU*RN-EU)LWQRC,+;5CC7#(NY,*I)R)-S8'RCF@9Q]W^SOXM
MO$:*75 Z.I5E:[O&5E(P5(,6""."#P10!ZU\&/V?+7X9,UPLCSW3QF-I"-B!
M=^["H"<9PN2S.<KE2H)% 'JM @H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * ,Z@84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!;N^GXT 5* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H L0_=/X
M_P J *] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 36G7\* (Y
M.I^IH ;0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_\B_=_
M]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V\?\ I/+0,^_Z
M!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9U PH * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@"W=]/QH J4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!8A^Z?Q_E0!7H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@":TZ_A0!')U/U- #: "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#R[]IO_ )%^[_[=_P#THBH \W_88_YB/_;I_P"W% 'U50(* /SE
M^"/B;_A&=7M[S9YGE^;\N[;G=#(O7#8^]GI0,^J_^&EO^G3_ ,C?_:J #_AI
M;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(
MW_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X
M:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\
MR-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /
M^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_
M ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J
M#_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT
M_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ
M@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z
M=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]
MJH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO
M^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?
M_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI
M;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(
MW_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X
M:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\
MR-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /
M^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_
M ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J
M#_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT
M_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ
M@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z
M=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]
MJH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO
M^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?
M_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI
M;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(
MW_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X
M:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\
MR-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /
M^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_
M ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J
M#_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT
M_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ
M@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z
M=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]
MJH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO
M^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?
M_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI
M;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(
MW_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X
M:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\
MR-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /
M^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_
M ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J
M#_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT
M_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ
M@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z
M=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]
MJH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO
M^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?
M_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI
M;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(
MW_VJ@ _X:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X
M:6_Z=/\ R-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\
MR-_]JH /^&EO^G3_ ,C?_:J #_AI;_IT_P#(W_VJ@ _X:6_Z=/\ R-_]JH K
M_P##1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#
M1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\
MTZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^
M1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\
M[50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50
M?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%
M_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3
MK_Y&_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&
M_P#M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M
M5 !_PT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_
MPT7_ -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_
M -.O_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O
M_D;_ .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_
M .U4 '_#1?\ TZ_^1O\ [50 ?\-%_P#3K_Y&_P#M5 !_PT7_ -.O_D;_ .U4
M '_#1?\ TZ_^1O\ [50!++^TEY@Q]D_\C?\ VJ@"+_AHO_IU_P#(W_VJ@ _X
M:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\
MR-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /
M^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_
M ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J
M#_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU
M_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ
M@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z
M=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]
MJH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_
M^G7_ ,C?_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?
M_:J #_AHO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AH
MO_IU_P#(W_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J #_AHO_IU_P#(
MW_VJ@ _X:+_Z=?\ R-_]JH /^&B_^G7_ ,C?_:J )$_:0V@C[)U_Z;?_ &J@
M"/\ X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _
MX:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_
M .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7
M_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C
M?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J
M #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_A
MHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\
MZ=?_ "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_
M "-_]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_
M]JH /^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH
M/^&B_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B
M_P#IU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#I
MU_\ (W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\
M(W_VJ@ _X:+_ .G7_P C?_:J #_AHO\ Z=?_ "-_]JH /^&B_P#IU_\ (W_V
MJ@!\7[1_EG/V3_R-_P#:J &M^T9N.?LO_D;_ .U4 )_PT7_TZ_\ D;_[50 ?
M\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_
M )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4
M'_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K
M_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5
M !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_T
MZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[
M50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_
M].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_
M^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1
M?_3K_P"1O_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1
MO_M5 !_PT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_P
MT7_TZ_\ D;_[50 ?\-%_].O_ )&_^U4 '_#1?_3K_P"1O_M5 !_PT7_TZ_\
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M'VI6ISA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'G/[1'_(#NO^
MV'_H^*I>Q<=SE/V&/^8C_P!NG_MQ61T'U50(* /SR_9W_P"0Y:_]M_\ T1+5
M+<F6Q]J5J<X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YS^T1_R
M [K_ +8?^CXJE[%QW.4_88_YB/\ VZ?^W%9'0?55 @H _/+]G?\ Y#EK_P!M
M_P#T1+5+<F6Q]J5J<X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MLZ/PG\1;#Q=D6,ZR,N<KRCX&,ML<*VWY@-V-N3C.:=[B:L='3)"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#BO^%S:5]J^P?:/](\[
MR=GES?ZS?LVYV;?O<9SCOG%*Y7*SM:9(4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ><_M$?\@.Z_P"V'_H^*I>Q<=SE/V&/
M^8C_ -NG_MQ61T'U50(* /SR_9W_ .0Y:_\ ;?\ ]$2U2W)EL?:E:G.% !0!
M\E?M,_$%M;O?[/0CR+5NJL6#R%5W%@#MRG* 8)4[\GYMHRDS>*.^^''[,%M;
M0K+JX,L[*<Q!RL:9P0,H0S.,')#;.2 #@.:427,TO#'[/"^$=4MKZRE+01K+
MYBRD&3+1NBE2B!2/F&0<8QD%LX!:PG*Z/0O&_P 0;/P5$)KU]N[=L0 L[D#)
M"@?@,G"@D!F&15-V)2N><?\ #66E_P#/*Z_[XB_^/5/,5R'JGACQ7;>*81<V
M4@EC+%<C(((Z@A@&4]#@@<$$<$&J(:L<OXY^-5EX)NH[.[$NZ1%?>JJR*K.R
M9/S!N-I)"J3CID\4F[%*-S.U_P#:,TO1+HV;F5F5RDCK'\B,'*,#N*L=N,DH
MK C[N3Q1<%$[GQ/XKMO"T)N;V011A@N3DDD]  H+,>IP > 2> 33)2N>5_\
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M,L!C=NZ\8YIIW)<;'<TR0H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M&16(;:Q;<'< MG:S%3@#H!B[&7,SY_\ V9=?ET_5DMT/[NX219%)./D1I%8
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M$/<X[]C_ /Y?O^W7_P!K5,2IA^V!_P N/_;U_P"T:)! ]'_9W_Y =K_VW_\
M1\M4MB);GR_\(OAU_P )[>BU9_+C5#)(1][8K*I"\$;B6 R> ,G!QM.:5S:3
ML>F?M#_"73_"=G%=6,9B<W C8;W=6#([9.]F.04XP1U.0>,4T1%W.C^ WB>:
MQ\.W4X(8VK71B##Y0%B68*=N"1O9B><\X!  PUL*2U/'OA)>:8]Y)=:\X9 N
MY1()I&>4N&WG8K!A@-N#G#;APW.)1;\C?^..I:!JT44VCE5N%<*R1Q/"AC(8
M[B#&J[@V ".2"0<@#:,4;GO?P'U&34-%M'E.6".@. /ECD>-!P!T50,]3C)R
M<FK6QG+<[ZJ(/BO]HC_D.77_ &P_]$15D]SHCL?:E:G.?.7[8'_+C_V]?^T:
MSD;0-+PYX5_X2?P>L"KF14GDCPGF-OCGD<!1UW, 4R.<,>#T+Z";M(YO]DWQ
M5]FN)]/=OEE021@O@;TX8*IZLRMDD<[8^00,A1'-'.?$Z:3XA^(C:1EMHF2V
M7Y Q14.)6PI^90WF/DG.WJ5 P$]64M$=K^UKIOV>*P\I-L,?GH-JX1<B+8G
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MI9E+GYI&!;G!<L1TZX  XK1&#=SY3\8"3X7>(&G@7Y4F\V-0@C5HI!EHUR&
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H \Y_:(_Y =U_VP_\ 1\52]BX[G*?L,?\
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MUXI)6*<KG=:EIT>IQ/!,-T<B,CC)&58%6&001D'J"#Z51!XS+^R7IQ*[9[@
M-\P+1$D;3P#Y8VG=@Y(;@$8R0PCE-.<[[P!\)['P*";1"9&7:TKG=(PW%L=
MJCIPH7.%+9(!JDK$MW.PIDA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!YS^T1_P @.Z_[8?\ H^*I>Q<=SE/V&/\
MF(_]NG_MQ61T'U50(* /SR_9W_Y#EK_VW_\ 1$M4MR9;'VI6ISA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!B^*?!=GXKC$5]"LJCH
M3D,O()VLI#+G:,[2,@8.1Q2L-.QY?_PR;I?_ #UNO^^XO_C-3RE\YVO@7X/:
M=X+PUM'NF'_+:3#R_P 0X. $X8J=@7<,;L]:I*Q+E<[6F2% !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /.?VB/\ D!W7_;#_ -'Q
M5+V+CN<I^PQ_S$?^W3_VXK(Z#ZJH$% 'YY?L[_\ (<M?^V__ *(EJEN3+8^U
M*U.<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \Y_:(_Y =U_P!L
M/_1\52]BX[G*?L,?\Q'_ +=/_;BLCH/JJ@04 ?GE^SO_ ,ARU_[;_P#HB6J6
MY,MC[4K4YPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SG]HC_D!
MW7_;#_T?%4O8N.YRG[#'_,1_[=/_ &XK(Z#ZJH$% 'YY?L[_ /(<M?\ MO\
M^B):I;DRV/M2M3G"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6#[!'_<7\A1<+!]@C_N+^0HN%C#\:VB1VDA"@'Y.0 /XUHN.QE_#_P#U#?\
M70_^@K2&=-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'EW[3?\ R+]W_P!N_P#Z414 >;_L,?\ ,1_[=/\ VXH
M^JJ!!0!\ ?LN?\C%9_\ ;Q_Z3RT#/O\ H$% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >:Z+_ ,A0_P#76;^3T#/2J!!0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_D
ME STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!0U_P#X]Y?^N4G_ *":!G)_"_\ Y;?]L_\ V>@#NZ!!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!@^.?\ CSD_X!_Z&M S&^'_ /J&_P"NA_\ 05H Z:@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/+OVF_\ D7[O_MW_ /2B*@#S?]AC_F(_]NG_ +<4 ?55 @H ^ /V7/\ D8K/
M_MX_])Y:!GW_ $""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/-=%_P"0H?\ KK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)=E^/^8?\-+ZC_SRM_\ OB3_ ..T?5EY_P!?(/KDNR_'_,/^&E]1_P">5O\
M]\2?_':/JR\_Z^0?7)=E^/\ F'_#2^H_\\K?_OB3_P".T?5EY_U\@^N2[+\?
M\P_X:7U'_GE;_P#?$G_QVCZLO/\ KY!]<EV7X_YA_P -+ZC_ ,\K?_OB3_X[
M1]67G_7R#ZY+LOQ_S#_AI?4?^>5O_P!\2?\ QVCZLO/^OD'UR79?C_F'_#2^
MH_\ /*W_ .^)/_CM'U9>?]?(/KDNR_'_ ##_ (:7U'_GE;_]\2?_ !VCZLO/
M^OD'UR79?C_F'_#2^H_\\K?_ +XD_P#CM'U9>?\ 7R#ZY+LOQ_S#_AI?4?\
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M_7R#ZY+LOQ_S#_AI?4?^>5O_ -\2?_':/JR\_P"OD'UR79?C_F'_  TOJ/\
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M_P#':/JR\_Z^0?7)=E^/^8?\-+ZC_P \K?\ [XD_^.T?5EY_U\@^N2[+\?\
M,/\ AI?4?^>5O_WQ)_\ ':/JR\_Z^0?7)=E^/^8?\-+ZC_SRM_\ OB3_ ..T
M?5EY_P!?(/KDNR_'_,/^&E]1_P">5O\ ]\2?_':/JR\_Z^0?7)=E^/\ F'_#
M2^H_\\K?_OB3_P".T?5EY_U\@^N2[+\?\P_X:7U'_GE;_P#?$G_QVCZLO/\
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M0 4 % !0 4 % !0 4 % 'FNB_P#(4/\ UUF_D] STJ@04 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNM?\A0?]=8?
MY)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 4-?\ ^/>7_KE)_P"@F@9R?PO_ .6W_;/_ -GH [N@04 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 >??'S_D"W/_;'_P!'1UT4?C7S_(Y,3_#?R_-'Q]7L'S@4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'T1\&/C/_:6W3]0;]]P(I2?O^B,?[_H?X^A^?!?S:U&VJ^:/;P^(YO=E
MOT?<]IKA/4"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H \N_:;_P"1?N_^W?\ ]*(J /-_V&/^8C_VZ?\ MQ0!]54""@#X _9<
M_P"1BL_^WC_TGEH&??\ 0(* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H \UT7_ )"A_P"NLW\GH&>E4""@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H \UUK_D*#_KK#_)*!GI5 @H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"AK_P#Q
M[R_]<I/_ $$T#.3^%_\ RV_[9_\ L] '=T""@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@#S[X^?\@6Y_[8_^CHZZ*/QKY_D<F)_AOY?FCX^KV#YP* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "%#_P!=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %#7_P#CWE_ZY2?^@F@9
MR?PO_P"6W_;/_P!GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >??'S_D"W/\
MVQ_]'1UT4?C7S_(Y,3_#?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?1'P8^,_\ :6W3]0;]
M]P(I2?O^B,?[_H?X^A^?!?S:U&VJ^:/;P^(YO=EOT?<]IKA/4"@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_^1?N_^W?_ -*(
MJ /-_P!AC_F(_P#;I_[<4 ?55 @H ^ /V7/^1BL_^WC_ -)Y:!GW_0(* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-_)Z!GI5
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /-=:_P"0H/\ KK#_ "2@9Z50(* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H H:__ ,>\O_7*3_T$T#.3^%__ "V_[9_^
MST =W0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * //OCY_R!;G_ +8_^CHZZ*/QKY_D
M<F)_AOY?FCX^KV#YP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M!P<$'&""09W5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@"AK_\ Q[R_]<I/_030,Y/X7_\ +;_MG_[/0!W= @H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \^^/G_(%N?\ MC_Z.CKHH_&OG^1R8G^&_E^:/CZO8/G H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#Z(^#'QG_M+;I^H-^^X$4I/W_1&/\ ?]#_ !]#\^"_FUJ-M5\T>WA\
M1S>[+?H^Y[37">H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'EW[3?_(OW?_;O_P"E$5 'F_[#'_,1_P"W3_VXH ^JJ!!0!\ ?LN?\C%9_
M]O'_ *3RT#/O^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MYKHO_(4/_76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5:@9 Y=B,.Q5@P,^FOV:_%X\3:);'(WP+]G<*& !B "#YNI,6QB02,DXQ]T
M'J% @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *&O\ _'O+
M_P!<I/\ T$T#.3^%_P#RV_[9_P#L] '=T""@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#S[X^?\ (%N?^V/_ *.CKHH_&OG^1R8G^&_E^:/CZO8/G H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H ^B/@Q\9_[2VZ?J#?ON!%*3]_T1C_?]#_'T/SX+^;6HVU7S1[>'Q'-[LM^
MC[GM-<)Z@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y=^TW_
M ,B_=_\ ;O\ ^E$5 'F_[#'_ #$?^W3_ -N* /JJ@04 ? '[+G_(Q6?_ &\?
M^D\M S[_ *!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNB
M_P#(4/\ UUF_D] STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'FNM?\A0?]=8?Y)0,]*H$% !0 4 % !0 4 %
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M^'WB"]\.2L1"[.T"N2[%DP\;93Y%+VYW.2 241?E(VD ^I:!!0 4 % !0 4
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M/_;'_P!'1UT4?C7S_(Y,3_#?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >U?!CX,?
MVEMU#4%_<\&*(C[_ *.P_N>@_CZGY,!^&M6MHOFSU</A^;WI;=%W/H>O-/:"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_\ D7[O_MW_
M /2B*@#S?]AC_F(_]NG_ +<4 ?55 @H ^ /V7/\ D8K/_MX_])Y:!GW_ $""
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-=%_P"0H?\ KK-_
M)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@ H * "@ H
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M/\CDQ/\ #?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![5\&/@Q_:6W4-07]SP8HB/O^
MCL/[GH/X^I^3 ?AK5K:+YL]7#X?F]Z6W1=SZ'KS3V@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H \N_:;_Y%^[_ .W?_P!*(J /-_V&/^8C
M_P!NG_MQ0!]54""@#X _9<_Y&*S_ .WC_P!)Y:!GW_0(* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-_)Z!GI5 @H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQ\_Y MS_ -L?_1T==%'XU\_R.3$_PW\OS1\?5[!\X% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![5\&/@
MQ_:6W4-07]SP8HB/O^CL/[GH/X^I^3 ?AK5K:+YL]7#X?F]Z6W1=SZ'KS3V@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_^1?N_
M^W?_ -*(J /-_P!AC_F(_P#;I_[<4 ?55 @H ^ /V7/^1BL_^WC_ -)Y:!GW
M_0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-
M_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /-=:_P"0H/\ KK#_ "2@9Z50(* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H H:__ ,>\O_7*3_T$T#.3^%__
M "V_[9_^ST =W0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * //OCY_R!;G_ +8_^CHZ
MZ*/QKY_D<F)_AOY?FCX^KV#YP* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /:O@Q\&/[2VZAJ"_N>#%$1]_T
M=A_<]!_'U/R8#\-:M;1?-GJX?#\WO2VZ+N?0]>:>T% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_\B_=_]N__ *414 >;_L,?
M\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V\?\ I/+0,^_Z!!0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'FNB_\A0_]=9OY/0,]*H$% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKK7_
M "%!_P!=8?Y)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 4-?_P"/>7_KE)_Z":!G)_"__EM_VS_]GH [N@04 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >??'S_D"W/_ &Q_]'1UT4?C7S_(Y,3_  W\OS1\
M?5[!\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 >U?!CX,?VEMU#4%_<\&*(C[_H[#^YZ#^/J?DP'X:U:VB^;
M/5P^'YO>EMT7<^AZ\T]H* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /+OVF_^1?N_P#MW_\ 2B*@#S?]AC_F(_\ ;I_[<4 ?55 @
MH ^ /V7/^1BL_P#MX_\ 2>6@9]_T""@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /-=%_Y"A_ZZS?R>@9Z50(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>E4""
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *&
MO_\ 'O+_ -<I/_030,Y/X7_\MO\ MG_[/0!W= @H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H \^^/G_(%N?^V/\ Z.CKHH_&OG^1R8G^&_E^:/CZO8/G H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/_76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U__CWE_P"N4G_H)H&<G\+_
M /EM_P!L_P#V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX_Y!_P ,T:C_ ,];?_ON3_XU1]97G_7S#ZG+NOQ_R#_AFC4?^>MO_P!]R?\
MQJCZRO/^OF'U.7=?C_D'_#-&H_\ /6W_ .^Y/_C5'UE>?]?,/J<NZ_'_ "#_
M (9HU'_GK;_]]R?_ !JCZRO/^OF'U.7=?C_D'_#-&H_\];?_ +[D_P#C5'UE
M>?\ 7S#ZG+NOQ_R#_AFC4?\ GK;_ /?<G_QJCZRO/^OF'U.7=?C_ )!_PS1J
M/_/6W_[[D_\ C5'UE>?]?,/J<NZ_'_(/^&:-1_YZV_\ WW)_\:H^LKS_ *^8
M?4Y=U^/^0?\ #-&H_P#/6W_[[D_^-4?65Y_U\P^IR[K\?\@_X9HU'_GK;_\
M?<G_ ,:H^LKS_KYA]3EW7X_Y!_PS1J/_ #UM_P#ON3_XU1]97G_7S#ZG+NOQ
M_P @_P"&:-1_YZV__?<G_P :H^LKS_KYA]3EW7X_Y!_PS1J/_/6W_P"^Y/\
MXU1]97G_ %\P^IR[K\?\@_X9HU'_ )ZV_P#WW)_\:H^LKS_KYA]3EW7X_P"0
M?\,T:C_SUM_^^Y/_ (U1]97G_7S#ZG+NOQ_R#_AFC4?^>MO_ -]R?_&J/K*\
M_P"OF'U.7=?C_D'_  S1J/\ SUM_^^Y/_C5'UE>?]?,/J<NZ_'_(/^&:-1_Y
MZV__ 'W)_P#&J/K*\_Z^8?4Y=U^/^0?\,T:C_P ];?\ [[D_^-4?65Y_U\P^
MIR[K\?\ (/\ AFC4?^>MO_WW)_\ &J/K*\_Z^8?4Y=U^/^0?\,T:C_SUM_\
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M'U.7=?C_ )!_PS1J/_/6W_[[D_\ C5'UE>?]?,/J<NZ_'_(/^&:-1_YZV_\
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MJ<NZ_'_(/^&:-1_YZV__ 'W)_P#&J/K*\_Z^8?4Y=U^/^0?\,T:C_P ];?\
M[[D_^-4?65Y_U\P^IR[K\?\ (/\ AFC4?^>MO_WW)_\ &J/K*\_Z^8?4Y=U^
M/^0?\,T:C_SUM_\ ON3_ .-4?65Y_P!?,/J<NZ_'_(/^&:-1_P">MO\ ]]R?
M_&J/K*\_Z^8?4Y=U^/\ D'_#-&H_\];?_ON3_P"-4?65Y_U\P^IR[K\?\@_X
M9HU'_GK;_P#?<G_QJCZRO/\ KYA]3EW7X_Y!_P ,T:C_ ,];?_ON3_XU1]97
MG_7S#ZG+NOQ_R#_AFC4?^>MO_P!]R?\ QJCZRO/^OF'U.7=?C_D'_#-&H_\
M/6W_ .^Y/_C5'UE>?]?,/J<NZ_'_ "#_ (9HU'_GK;_]]R?_ !JCZRO/^OF'
MU.7=?C_D'_#-&H_\];?_ +[D_P#C5'UE>?\ 7S#ZG+NOQ_R#_AFC4?\ GK;_
M /?<G_QJCZRO/^OF'U.7=?C_ )!_PS1J/_/6W_[[D_\ C5'UE>?]?,/J<NZ_
M'_(/^&:-1_YZV_\ WW)_\:H^LKS_ *^8?4Y=U^/^0?\ #-&H_P#/6W_[[D_^
M-4?65Y_U\P^IR[K\?\@_X9HU'_GK;_\ ?<G_ ,:H^LKS_KYA]3EW7X_Y!_PS
M1J/_ #UM_P#ON3_XU1]97G_7S#ZG+NOQ_P @_P"&:-1_YZV__?<G_P :H^LK
MS_KYA]3EW7X_Y!_PS1J/_/6W_P"^Y/\ XU1]97G_ %\P^IR[K\?\@_X9HU'_
M )ZV_P#WW)_\:H^LKS_KYA]3EW7X_P"0?\,T:C_SUM_^^Y/_ (U1]97G_7S#
MZG+NOQ_R#_AFC4?^>MO_ -]R?_&J/K*\_P"OF'U.7=?C_D'_  S1J/\ SUM_
M^^Y/_C5'UE>?]?,/J<NZ_'_(/^&:-1_YZV__ 'W)_P#&J/K*\_Z^8?4Y=U^/
M^0?\,T:C_P ];?\ [[D_^-4?65Y_U\P^IR[K\?\ (/\ AFC4?^>MO_WW)_\
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MQ_R#_AFC4?\ GK;_ /?<G_QJCZRO/^OF'U.7=?C_ )!_PS1J/_/6W_[[D_\
MC5'UE>?]?,/J<NZ_'_(/^&:-1_YZV_\ WW)_\:H^LKS_ *^8?4Y=U^/^1TW@
M']G8Z?/YVI-'(B8*1H696;_;W*ORC^[R&/WN 5;*>(NK(WI82SO*S\D>XUP'
MK!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'EW[3?\ R+]W_P!N_P#Z414 >;_L,?\ ,1_[=/\ VXH ^JJ!!0!\ ?LN?\C%
M9_\ ;Q_Z3RT#/O\ H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 >:Z+_ ,A0_P#76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@04 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U_P#X]Y?^
MN4G_ *":!G)_"_\ Y;?]L_\ V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!@^
M.?\ CSD_X!_Z&M S&^'_ /J&_P"NA_\ 05H Z:@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_\ D7[O_MW_
M /2B*@#S?]AC_F(_]NG_ +<4 ?55 @H ^ /V7/\ D8K/_MX_])Y:!GW_ $""
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-=%_P"0H?\ KK-_
M)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H H:_\ \>\O_7*3_P!!- SD_A?_ ,MO
M^V?_ +/0!W= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H P?'/_ !YR?\ _]#6@9C?#
M_P#U#?\ 70_^@K0!TU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 >7?M-_\ (OW?_;O_ .E$5 'F_P"PQ_S$?^W3
M_P!N* /JJ@04 ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 >:Z+_P A0_\ 76;^3T#/2J!!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7^)KD6NH
MF1LX5XF..N J&@9TG_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[
M)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4
M'_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\
MNR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5
M !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_
M +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\
M50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M
M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2_
M_%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"R
MK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?D
MO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_P
MLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LG
MY+_\50 ?\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?
M\+*M_P"[)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[
M)^2__%4 '_"RK?\ NR?DO_Q5 !_PLJW_ +LGY+_\50 ?\+*M_P"[)^2__%4
M'_"RK?\ NR?DO_Q5 %74_B#!=1/&JR99&49"XR01_>H Q/!OB6/1/,\P,=VW
M&T ]-V>I'K0!TO\ PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2
M_P#Q5 !_PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_
MPLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW_NR?
MDO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW_NR?DO\ \50
M?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW_NR?DO\ \50 ?\+*M_[L
MGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4
M '_"RK?^[)^2_P#Q5 !_PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^
M[)^2_P#Q5 !_PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q
M5 !_PLJW_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW
M_NR?DO\ \50 ?\+*M_[LGY+_ /%4 '_"RK?^[)^2_P#Q5 !_PLJW_NR?DO\
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M!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\
MXJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0
M?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?
M_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\
MA8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E
M_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X
M6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?
M\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@
M_P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_
M "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ
M#_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$'
M]U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#B
MJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_
M=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^
M*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%
M@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_
M .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8
M$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R
M7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_
M (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\
M)?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /
M^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W
M7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H
M /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U
M_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ
M@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!
M!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\
MXJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0
M?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?
M_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\
MA8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E
M_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X
M6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?
M\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@
M_P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_
M "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ
M#_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$'
M]U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#B
MJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_
M=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^
M*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%
M@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_
M .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8
M$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R
M7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_
M (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\
M)?\ XJ@ _P"%@0?W7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /
M^%@0?W7_ "7_ .*H /\ A8$']U_R7_XJ@ _X6!!_=?\ )?\ XJ@ _P"%@0?W
M7_)?_BJ #_A8$']U_P E_P#BJ #_ (6!!_=?\E_^*H /^%@0?W7_ "7_ .*H
M \X_:)\81:AH=U$@<%O(QD#'$\1[,?2@#D_V&/\ F(_]NG_MQ0!]54""@#X
M_9<_Y&*S_P"WC_TGEH&??] @H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@#S71?^0H?^NLW\GH&>E4""@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \Q\10"XU+8PRK20@CV(0'I0,[#_
M (0:S_YY_P#CS_\ Q5 !_P (-9_\\_\ QY__ (J@ _X0:S_YY_\ CS__ !5
M!_P@UG_SS_\ 'G_^*H /^$&L_P#GG_X\_P#\50 ?\(-9_P#//_QY_P#XJ@ _
MX0:S_P">?_CS_P#Q5 !_P@UG_P \_P#QY_\ XJ@ _P"$&L_^>?\ X\__ ,50
M ?\ "#6?_//_ ,>?_P"*H /^$&L_^>?_ (\__P 50 ?\(-9_\\__ !Y__BJ
M#_A!K/\ YY_^//\ _%4 '_"#6?\ SS_\>?\ ^*H /^$&L_\ GG_X\_\ \50
M?\(-9_\ //\ \>?_ .*H /\ A!K/_GG_ .//_P#%4 '_  @UG_SS_P#'G_\
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M_BJ #_A!K/\ YY_^//\ _%4 '_"#6?\ SS_\>?\ ^*H /^$&L_\ GG_X\_\
M\50 ?\(-9_\ //\ \>?_ .*H /\ A!K/_GG_ .//_P#%4 '_  @UG_SS_P#'
MG_\ BJ #_A!K/_GG_P"//_\ %4 '_"#6?_//_P >?_XJ@ _X0:S_ .>?_CS_
M /Q5 !_P@UG_ ,\__'G_ /BJ #_A!K/_ )Y_^//_ /%4 '_"#6?_ #S_ /'G
M_P#BJ #_ (0:S_YY_P#CS_\ Q5 !_P (-9_\\_\ QY__ (J@ _X0:S_YY_\
MCS__ !5 !_P@UG_SS_\ 'G_^*H J:OX-M;>&1UCPRQN0=S]0I(ZM0!SW@/0X
M=5\SSEW;=F.6'7=GH1Z4 =9_P@UG_P \_P#QY_\ XJ@ _P"$&L_^>?\ X\__
M ,50 ?\ "#6?_//_ ,>?_P"*H /^$&L_^>?_ (\__P 50 ?\(-9_\\__ !Y_
M_BJ #_A!K/\ YY_^//\ _%4 '_"#6?\ SS_\>?\ ^*H /^$&L_\ GG_X\_\
M\50 ?\(-9_\ //\ \>?_ .*H /\ A!K/_GG_ .//_P#%4 '_  @UG_SS_P#'
MG_\ BJ #_A!K/_GG_P"//_\ %4 '_"#6?_//_P >?_XJ@ _X0:S_ .>?_CS_
M /Q5 !_P@UG_ ,\__'G_ /BJ #_A!K/_ )Y_^//_ /%4 '_"#6?_ #S_ /'G
M_P#BJ #_ (0:S_YY_P#CS_\ Q5 !_P (-9_\\_\ QY__ (J@ _X0:S_YY_\
MCS__ !5 !_P@UG_SS_\ 'G_^*H /^$&L_P#GG_X\_P#\50 ?\(-9_P#//_QY
M_P#XJ@ _X0:S_P">?_CS_P#Q5 !_P@UG_P \_P#QY_\ XJ@ _P"$&L_^>?\
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M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS
M_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_
M ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\
M_P#\50 ?\(=:_P#//_QY_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#Q
MY_\ XJ@ _P"$.M?^>?\ X\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_
M (\__P 50 ?\(=:_\\__ !Y__BJ #_A#K7_GG_X\_P#\50 ?\(=:_P#//_QY
M_P#XJ@ _X0ZU_P">?_CS_P#Q5 !_PAUK_P \_P#QY_\ XJ@ _P"$.M?^>?\
MX\__ ,50 ?\ "'6O_//_ ,>?_P"*H /^$.M?^>?_ (\__P 50 ?\(=:_\\__
M !Y__BJ /-/VC_#5O9Z%=R1IAAY&#ECUGB'<T <5^PQ_S$?^W3_VXH ^JJ!!
M0!\ ?LN?\C%9_P#;Q_Z3RT#/O^@04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!YKHO_(4/_76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@04
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U_
M_CWE_P"N4G_H)H&<G\+_ /EM_P!L_P#V>@#NZ!!0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!@^.?^/.3_@'_H:T#,;X?_ZAO^NA_P#05H Z:@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_P#D7[O_
M +=__2B*@#S?]AC_ )B/_;I_[<4 ?55 @H ^ /V7/^1BL_\ MX_])Y:!GW_0
M(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-_)
MZ!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H H:_P#\>\O_ %RD_P#030,Y/X7_ /+;
M_MG_ .ST =W0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * ,'QS_ ,><G_ /_0UH&8WP
M_P#]0W_70_\ H*T =-0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'EW[3?\ R+]W_P!N_P#Z414 >;_L,?\ ,1_[
M=/\ VXH ^JJ!!0!\ ?LN?\C%9_\ ;Q_Z3RT#/O\ H$% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 >:Z+_ ,A0_P#76;^3T#/2J!!0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R
M%!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!0U_P#X]Y?^N4G_ *":!G)_"_\ Y;?]L_\ V>@#NZ!!0 4
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M_P#':/JR\_Z^0?7)=E^/^8?\-+ZC_P \K?\ [XD_^.T?5EY_U\@^N2[+\?\
M,/\ AI?4?^>5O_WQ)_\ ':/JR\_Z^0?7)=E^/^8?\-+ZC_SRM_\ OB3_ ..T
M?5EY_P!?(/KDNR_'_,/^&E]1_P">5O\ ]\2?_':/JR\_Z^0?7)=E^/\ F'_#
M2^H_\\K?_OB3_P".T?5EY_U\@^N2[+\?\P_X:7U'_GE;_P#?$G_QVCZLO/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_P#(OW?_ &[_ /I1%0!Y
MO^PQ_P Q'_MT_P#;B@#ZJH$% 'P!^RY_R,5G_P!O'_I/+0,^_P"@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO\ R%#_ -=9OY/0,]*H
M$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % %#7_ /CWE_ZY2?\ H)H&<G\+_P#EM_VS_P#9
MZ .[H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GWQ\_Y MS_VQ_\ 1T==%'XU\_R.
M3$_PW\OS1\?5[!\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!TW@'Q]/X,G\Z'YD; DC)PKK_1A_"W4'U!93E."FK'12JNF[KYH^M/"W
MBF#Q1 MS;-N1N"#PRMW1AV8?D1@@D$$^/*+B[,^CA-35T:]0:!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U__CWE_P"N4G_H)H&<
MG\+_ /EM_P!L_P#V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y]\?/\ D"W/
M_;'_ -'1UT4?C7S_ ".3$_PW\OS1\?5[!\X% !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =-X!\?3^#)_.A^9&P)(R<*Z_T8?PMU!]06
M4Y3@IJQT4JKINZ^:/K3PMXI@\40+<VS;D;@@\,K=T8=F'Y$8()!!/CRBXNS/
MHX34U=&O4&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!Y=^TW_R+]W_V[_\ I1%0!YO^PQ_S$?\ MT_]N* /
MJJ@04 ? '[+G_(Q6?_;Q_P"D\M S[_H$% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 >:Z+_R%#_UUF_D] STJ@04 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNM?\ (4'_ %UA_DE
MSTJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0!0U__ (]Y?^N4G_H)H&<G\+_^6W_;/_V>@#NZ!!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!Y]\?/^0+<_\ ;'_T='711^-?/\CDQ/\ #?R_-'Q]7L'S@4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =-X!\?3^#)_.A^
M9&P)(R<*Z_T8?PMU!]064Y3@IJQT4JKINZ^:/K3PMXI@\40+<VS;D;@@\,K=
MT8=F'Y$8()!!/CRBXNS/HX34U=&O4&@4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M%Y_W[A_^/T 6M)_;&T?49HX/+N8_,D1-\BPK&NX@;F;SSA1G+'L,F@#0U_\
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M1(C K)&6&0K*?Q&Y<H2&"L<&@#JZ!!0 4 % !0 4 % !0 4 % !0 4 % !0
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M&._6@9[50(* "@ H * "@ H * "@ H \UUK_ )"@_P"NL/\ )*!GI5 @H *
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M % !0 4 % !0 4 % %#7_P#CWE_ZY2?^@F@9R?PO_P"6W_;/_P!GH [N@04
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 >??'S_D"W/\ VQ_]'1UT4?C7S_(Y,3_#?R_-
M'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '3> ?'T_@R?SH?F1L"2,G"NO]&'\+=0?4%E.4X*:L=%*JZ;NOFCZT\+>*
M8/%$"W-LVY&X(/#*W=&'9A^1&""003X\HN+LSZ.$U-71KU!H% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?\
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M0<1$2R$?.2%7&&WE<9Y1@#S7]BK_ )#$_P#UX2?^CH* /M2@04 % !0 4 %
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M7<#(JCY5(.&//3(YH&?57A#XUV?BK3;C5X$F6"V\[>KJ@D/E1K*VT"1E/RL
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MM8R0PE0-*S ,X 4>:N6V(P.!LC9D=689 /<+N[2S1I96"(BEF9B%55 R6)/
M '))X H$>%7?[4<NHNQT;2KJ^MU8H9U#HI<'D )#+QM*L-Q5L-RB]P9Z5\+_
M (H6WQ'MFO+-9$1)FB(E"JVX*CDC8[C&''?.<\4 =A0(^5?VY_\ F'?]O?\
M[;T#/J6[M$O$:*50Z.I5E8!E92,%2#P01P0>"*!'R_\ M(_#%/ 1A\1:(#;2
MQS(DBPH!$N58++@#:@.!&ZD;)-X!&2V\&>X>%OB5'J>BIK<GS*+1II1&I'S1
MJ?.10Y'1T95R<' ^8CF@"+X-^.K#QC9&72H3;V\4SQ",QQQ -A9&(6-F4 ^9
MGL2<Y'<@&3\3/CQ!X/G&GVT,E[J#+N%O#R0.&^<@,RDIEP%5C@98*K*Q ,_P
M%^T+_;][%I=]87-E>3;VC2090HJ,^\EQ$XSL8#"$9 ^;K@ ]%\7^-+3P= ;N
M_E$4095W$$DL>BA5!9CU. "0 6/ ) (\5A_:T>_+3VFE74MA&W[RX&<HH56E
M)58WC!4$G!E (P25SP#/5?AG\5;+XC0&XL6.4;;)&X"RH>=NX L,,!E2"0>1
MG<K  &5\4/CSIWPX=8;PR/,ZJPBB3<VPEP')<HF-R$8W;LX^7'- 'G5Q^UM-
MH<D8U72;FTB?=ABS;SM'\*RQ0AN2H/S# .>> 0#WK0-?@\0P)=VCB2&1=R.O
M0CIWY!!R"#@J000""*!'E_CK]HJ/1KI].TNUFU&[BYE2'.Q ,A@61)&+*Q4,
M NT%L%PX*T#-#X7_ !T3QK<MITUI/:7L<+2RQ2@;54,@4 G8Y)616YC48)Y(
MP2 =+\0_B?8_#^$3W\FW=N$:*"TDA49*JH_ ;FP@)4,PR* /);;]K1V'VN32
MKI=-W-BZ7+#;N*(<&-8\E\*1YN%)(!8C! /9? OCJU\<6J7MD^Z-N"#PZ,,;
MHW&3AAGD<@@AE)4@D$=!0 4 % !0 4 % !0!0U__ (]Y?^N4G_H)H&<G\+_^
M6W_;/_V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y]\?/^0+<_\ ;'_T='71
M1^-?/\CDQ/\ #?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!TW@'Q]/X,G\Z'YD; DC)PKK_1A_"W4'U!93E.
M"FK'12JNF[KYH^M/"WBF#Q1 MS;-N1N"#PRMW1AV8?D1@@D$$^/*+B[,^CA-
M35T:]0:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'EW[3?_ "+]W_V[_P#I1%0!YO\ L,?\Q'_MT_\ ;B@#ZJH$% 'P
M!^RY_P C%9_]O'_I/+0,^_Z!!0!\0?M6>-O^$HU@6 D1;>TQ&'SO0.^UIG;R
MT9QMX1D&\@QG W$K0,[KXS_$OPYXFT0Z98W WP+$;56CNP 8@%"[C'R3%N0;
MR1D@L1]X $7[$OC7_CYTAE_Z>48#_<BD#'=_US*@+_?R?NB@#L/VQ_" U725
MO@!OM)E))+ ^7*1&Z@#Y22_EGG& IP>S &5^S)\3!:>'KH$!WTU9Y!&-R%HR
MKSIEB&7+.)%R!\H497NP!PG['?AMM?U2XU2X/F-;QD[F9S(99RP\S_:RBR!B
MQ/+ X)Y !]E4"/@#]J/_ )&*\_[=_P#TGBH&??\ 0(X_XM^*+3PWIES+?X:)
MH9(_*+%#*SHP$(*@L"W(R!E1ES@*2 9^<W]DS>3]J\M_(\SR_-VMY>_&[9NQ
MMW;>=N<XYQB@#]#_ ('^+(/$^D6LUL @2%(FC!SY;QJ$*<N[ < IO8L4*LW)
MH \D\6?ME?\ "/WEQ9?8-_D3RQ;_ +1MW;'*;L>0<9QG&3CU- &5XP^.?_"U
M/#NJ_P"C?9_L_P!A_P"6OF[O,N%_Z9IC&SWSGMCD /V&/^8C_P!NG_MQ0 ?M
MS_\ ,._[>_\ VWH \J^(G_(NZ%_W$_\ TH6@#ZJ_9<_Y%VS_ .WC_P!*): /
ME7]J/_D8KS_MW_\ 2>*@#[_H$?('[4/QG;Q5-_PC^G*[*DX64J'W2RJ2HA5!
M]Y0_J#OD"E0 H9P9Z_\ LY_!3_A7=J9;I4-]-R[#DQIP1 &R0<$;G*X!; RX
M1&H ]@H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z
M+_R%#_UUF_D] STJ@04 % !0 4 % !0 4 17=VEFC2RL$1%+,S$*JJ!DL2>
M .23P!0!\J_LY^,+2^U/4=>U*YCMWG8I$DUS$#L=_,9<.5<A%2)$;"KC*@'&
M%!D7[5>NV=Q-8ZSI5W;274$@0^7,DT@VGS8&V LNU6#[B1R74'<.@!]2>'M;
M37K:&\B!"3PQRJ&P&"NH< X)&<'G!(SW- CY%_8U\"VNNW5Q>W*;Y+3R#"#R
M@9_,_>$8Y9=@V$\*26QN"E09[5^UAI<=[H$\DBY:&2"2,Y(VL95B)X(S\DC#
M!R.<XR 0 :'[,MV]UX?LFD8L0LR@L23M6>1$7GL% 4#H  !P* /)?@%_R.&K
M?]O_ /Z61T >_P#Q8_Y ^H?]>%W_ .B7H \K_8J_Y \__7_)_P"B8* +_B']
MKO2M!N9K.6&Z+P321,52(J61BA(S,#C(XR <=A0!W?PM^+-K\289+BS29%CD
MV-YJ;<G ;AE9T/7D!MR\%@ RE@#PKX!?\CAJW_;_ /\ I9'0!]54"/E7]N?_
M )AW_;W_ .V] SU7]J/_ )%V\_[=_P#THBH B_95NTG\/VJHP8HUPK@$$JWG
MR/M..AVLK8/."#T(H A\>^&?%=[>RR:5?6T-F=GEQR*I=<(H?)-M)U<,1\QX
M(Z=  <+\//B7KVG>)5T'5[B.X!5P^V- H/V?[0K*RQQ-G@*=P(P6XSA@ 9_[
M<_\ S#O^WO\ ]MZ #_A07C#_ *"W_DY>_P#QN@#S_P"-?PQU[PK9I/J]]]I@
M:=45/M%Q-ARDA#;9451\JL,CGG'0F@#Z_P#A/_R!]/\ ^O"T_P#1*4 <K^U'
M_P B[>?]N_\ Z414 '[+G_(NV?\ V\?^E$M 'JM @H ^-?AGX%M?&'B[4([U
M/,CAGO9@A^XS+<A5#C'S+\^2O0D -E<J09]"_M">%T\1:)>(^ 8H6G1BH<JT
M(\SC)&TLJLFX<@,>HR" <?\ LC^!;73-*CU-$S=7/FAY#R0J2N@C7CY5^0,1
MU9N22%0* <_^T%X9ALO$6B7T8Q+<7<*28"@-Y4T&QC@ EL2;223\JH!C'(!]
M(7=VEFC2RL$1%+,S$*JJ!DL2>  .23P!0(^5?V<_&%I?:GJ.O:E<QV[SL4B2
M:YB!V._F,N'*N0BI$B-A5QE0#C"@R+]JO7;.XFL=9TJ[MI+J"0(?+F2:0;3Y
ML#; 67:K!]Q(Y+J#N'0 ^I/#VMIKUM#>1 A)X8Y5#8#!74. <$C.#S@D9[F@
M1\B_L:^!;77;JXO;E-\EIY!A!Y0,_F?O",<LNP;">%)+8W!2H,^BOCWX9A\0
M:+>).,^5!).A 7<KQ*9%()!QG!5L8)1F (SF@#BOV-M4DO=%:.1LK#=RQQC
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MG_HF"@#C]5U:?X,^)KO5=1BGGL[I75)U&<"0K(D8+,5)3RO*"%D.Q=X 7:I
M/>O OQ/TOXBJDEG(CRQ_/Y3@+/$=@5FVMR,"7873*'<5#G)H \%_;&\4))?V
M.G7/F"U11/-Y;#<RO(8SM5ALWJD;[&8D9<C@9R =5:?ME:)9HL45M=(B*%55
MB@554# 4 3X  X ' % ' ? OQ+!>^+))=&MS'97$,H9&3!B3RUD9L([*@,Z
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M 4-?_P"/>7_KE)_Z":!G)_"__EM_VS_]GH [N@04 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 <_X]\23>&K*6[MK=[N5-FV"/=O?<ZJ<;4<\ ECA3P#TZ
M@ \@_P"&C]8_Z%Z\_.;_ .1*!A_PT?K'_0O7GYS?_(E '7_"_P"+-_XPN6M[
MS2I[%%A9Q++YFTL&10@WP1C)#$]<X4\=P >H4""@ H * "@ H * "@ H * "
M@ H * "@ H * "@#S[X^?\@6Y_[8_P#HZ.NBC\:^?Y')B?X;^7YH^/J]@^<"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
MIO /CZ?P9/YT/S(V!)&3A77^C#^%NH/J"RG*<%-6.BE5=-W7S1]:>%O%,'BB
M!;FV;<C<$'AE;NC#LP_(C!!(()\>47%V9]'":FKHUZ@T"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \N_:;_Y%^[_[=_\
MTHBH \W_ &&/^8C_ -NG_MQ0!]54""@#X _9<_Y&*S_[>/\ TGEH&??] C/\
M0ZVF@VTUY*"4@ADE8+@L512Y R0,X'&2!GN* /A;X*?#8_&+4YVOWD";9)YY
M(U4%I'?A<[2B%F9F VG(1@JCJH,]Z_X8JT?_ )[WG_?R'_XQ0!\_Z7_Q9[Q.
MJR?+%;794M)^\/V>0%?,/E8RWD2;P .&P"O5: /N_P 0Z(FO6TUG*2$GADB8
MK@,%=2A(R",X/&01GL:!'YMG4;KPJ+S3'^7S<0W$9.0&AF5P1M;:65D*AOF&
MUG ^]F@9]M?LN>$#X;T2$N"'N6:X8$JP < 1D;>@,2HV"202<X^Z #UJ@1\
M?M1_\C%>?]N__I/%0,^_Z!'QA^UE\0'\5ZC'H]GF1+=@I5,MYEP^ 5 1F#%0
M0BC:'5S*O>@9[?\ \,_0_P#".?V%A//\OS/-^7'VK[V_=Y>[;N_=[MN_R?DS
MF@#P7]ESXF2^"M1.D78*Q7,PC97WAHIQE%^3!P6;$;@@'.PLP"$$ ^VJ!&5X
MLT+_ (2"SN++=L\^"6+?C=MWH4W8R,XSG&1GU% 'Q+\&_B/+\$=1N+;4H9 C
M+LGB4)YBNF6B<;L!AAB!APK*^\%L*"#)?C-\39/CA?6UIIEN^U-RPJV/.=I
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M_%C_ ) ^H?\ 7A=_^B7H Y7]ES_D7;/_ +>/_2B6@#E?VC_^0QX>_P"O\_\
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M\J_\U#_S_P! Z@9]54",KQ3XIM_"MN][>OY<$>W>^UFQN8(O"!F/S,!P/TH
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 >??'S_ ) MS_VQ_P#1T==%'XU\_P CDQ/\-_+\T?'U>P?.
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!W/PN^%TOC:7)RELA_>2=SWV)G@L1^"CDYRJMSU:O(O,ZZ%!U7Y=6?5NDZ3%
MI$2V]NH2-!A5'0?U))Y)/).222:\AN[NSZ*,5%66Q;I%!0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M 554# 4 <  < #@"@"6@#G]4^'NFZO(T]S9VTLK8W/)!$[G  &6923@  9[
M"@#H* .?_P"%>Z;YWVK[';>?YGF>;Y$7F;\[M^[;NW;N=V<YYSF@#H* .?\
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M(D<9!!PRJ",@D''8D4".@H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMKXHA-M?1)-$<_*XS@D%=RGJK ,0&4AAG@B@#S__ (9<\._\^?\ Y'N?_CM
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .Y^%WPNE\;2Y.4M
MD/[R3N>^Q,\%B/P4<G.55N>K5Y%YG70H.J_+JSZMTG28M(B6WMU"1H,*HZ#^
MI)/))Y)R2237D-W=V?11BHJRV+=(H* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H \N_:;_P"1?N_^W?\ ]*(J /-_V&/^
M8C_VZ?\ MQ0!]54""@#X _9<_P"1BL_^WC_TGEH&??\ 0(* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H \UT7_ )"A_P"NLW\GH&>E4""@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \U
MUK_D*#_KK#_)*!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@"AK_P#Q[R_]<I/_ $$T#.3^%_\ RV_[9_\ L] '=T""
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S[X^?\@6Y_[8_^CHZZ*/QKY_D<F)_AOY?F
MCX^KV#YP* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#N?A=\+I?&TN3E+9#^\D[GOL3/!8C\%')SE5;GJU>1>9UT*#JORZL^K=)
MTF+2(EM[=0D:#"J.@_J23R2>2<DDDUY#=W=GT48J*LMBW2*"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R[]IO_D7
M[O\ [=__ $HBH \W_88_YB/_ &Z?^W% 'U50(* /@#]ES_D8K/\ [>/_ $GE
MH&??] @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S71?^0H?
M^NLW\GH&>E4""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H \UUK_D*#_KK#_)*!GI5 @H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@"AK__ ![R_P#7*3_T$T#.3^%_
M_+;_ +9_^ST =W0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * //OCY_R!;G_MC_ .CH
MZZ*/QKY_D<F)_AOY?FCX^KV#YP* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * .Y^%WPNE\;2Y.4MD/[R3N>^Q,\%B/P4<G.55N>K5Y
M%YG70H.J_+JSZMTG28M(B6WMU"1H,*HZ#^I)/))Y)R2237D-W=V?11BHJRV+
M=(H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#R[]IO_ )%^[_[=_P#THBH \W_88_YB/_;I_P"W% 'U50(* /@#
M]ES_ )&*S_[>/_2>6@9]_P! @H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S71?\ D*'_ *ZS?R>@9Z50(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>E4""@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *&O_
M /'O+_URD_\ 030,Y/X7_P#+;_MG_P"ST =W0(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * //OCY_R!;G_MC_Z.CKHH_&OG^1R8G^&_E^:/CZO8/G H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#N?A=\+I?&TN3E+9#^\D[GO
ML3/!8C\%')SE5;GJU>1>9UT*#JORZL^K=)TF+2(EM[=0D:#"J.@_J23R2>2<
MDDDUY#=W=GT48J*LMBW2*"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /+OVF_^1?N_P#MW_\ 2B*@#S?]AC_F
M(_\ ;I_[<4 ?55 @H ^ /V7/^1BL_P#MX_\ 2>6@9]_T""@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /-=%_Y"A_ZZS?R>@9Z50(* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S76O^
M0H/^NL/\DH&>E4""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * *&O_\ 'O+_ -<I/_030,Y/X7_\MO\ MG_[/0!W= @H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H \^^/G_(%N?^V/\ Z.CKHH_&OG^1R8G^&_E^:/CZ
MO8/G H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .Y^%WPN
ME\;2Y.4MD/[R3N>^Q,\%B/P4<G.55N>K5Y%YG70H.J_+JSZMTG28M(B6WMU"
M1H,*HZ#^I)/))Y)R2237D-W=V?11BHJRV+=(H* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_\ D7[O
M_MW_ /2B*@#S?]AC_F(_]NG_ +<4 ?55 @H ^ /V7/\ D8K/_MX_])Y:!GW_
M $""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-=%_P"0H?\
MKK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-&H_\];?_ON3_P"-4?65Y_U\P^IR[K\?\@_X9HU'_GK;_P#?<G_QJCZRO/\
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MU'_GK;_]]R?_ !JCZRO/^OF'U.7=?C_D'_#-&H_\];?_ +[D_P#C5'UE>?\
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M .-4?65Y_P!?,/J<NZ_'_(/^&:-1_P">MO\ ]]R?_&J/K*\_Z^8?4Y=U^/\
MD7-)_9FNS*OVJ:(0Y^?RR[28]%#1@9/3)Z=<'&#+Q*MI<J."=]6K>7_#'T!I
M.DQ:1$MO;J$C0851T']22>23R3DDDFO.;N[L]F,5%66Q;I%!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M >7?M-_\B_=_]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V
M\?\ I/+0,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F
MNB_\A0_]=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!YKK7_ "%!_P!=8?Y)0,]*H$% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-?_P"/>7_KE)_Z
M":!G)_"__EM_VS_]GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8/CG_CSD_X!
M_P"AK0,QOA__ *AO^NA_]!6@#IJ "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \N_:;_Y%^[_ .W?_P!*(J /-_V&
M/^8C_P!NG_MQ0!]54""@#X _9<_Y&*S_ .WC_P!)Y:!GW_0(* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-_)Z!GI5 @H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+O
M%-U]DU R8SM>)L=,X53B@9K?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0!7
MO_B-]KC>/RL;D9<[\XR",_=H R?"_BC^PM_R;]^W^+;C&?8^M &]_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
MV% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?
M\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8
M_P#C_P#]A0 ?\+0_Z8_^/_\ V% !_P +0_Z8_P#C_P#]A0 ?\+0_Z8_^/_\
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M_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\
M]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &-
M!_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%
M_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE
M_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_
M /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V
M- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '
M_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_
M *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_
M (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\
M_P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T
M '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\
M+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\
MIE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\
MC_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_
M &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0
M?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL
M7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F
M7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/
M_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\
M8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_
MPL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?
M^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?
M^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__
M /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C
M0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"
MQ?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z
M9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X
M_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\
M]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &-
M!_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%
M_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE
M_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_
M /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V
M- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '
M_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_
M *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_
M (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\
M_P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T
M '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\
M+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\
MIE_X_P#_ &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\
MC_\ ]C0 ?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_
M &- !_PL7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0
M?\+%_P"F7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL
M7_IE_P"/_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F
M7_C_ /\ 8T '_"Q?^F7_ (__ /8T '_"Q?\ IE_X_P#_ &- !_PL7_IE_P"/
M_P#V- !_PL7_ *9?^/\ _P!C0 ?\+%_Z9?\ C_\ ]C0 ?\+%_P"F7_C_ /\
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M0 4 % !0 4 % 'FNB_\ (4/_ %UF_D] STJ@04 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F>O1B34PK $&6$$'D$8
M3B@9WO\ 8%O_ ,\H_P#OA?\ "@ _L"W_ .>4?_?"_P"% !_8%O\ \\H_^^%_
MPH /[ M_^>4?_?"_X4 ']@6__/*/_OA?\* #^P+?_GE'_P!\+_A0 ?V!;_\
M/*/_ +X7_"@ _L"W_P">4?\ WPO^% !_8%O_ ,\H_P#OA?\ "@ _L"W_ .>4
M?_?"_P"% !_8%O\ \\H_^^%_PH /[ M_^>4?_?"_X4 ']@6__/*/_OA?\* #
M^P+?_GE'_P!\+_A0 ?V!;_\ /*/_ +X7_"@ _L"W_P">4?\ WPO^% !_8%O_
M ,\H_P#OA?\ "@ _L"W_ .>4?_?"_P"% !_8%O\ \\H_^^%_PH /[ M_^>4?
M_?"_X4 ']@6__/*/_OA?\* #^P+?_GE'_P!\+_A0 ?V!;_\ /*/_ +X7_"@
M_L"W_P">4?\ WPO^% !_8%O_ ,\H_P#OA?\ "@ _L"W_ .>4?_?"_P"% !_8
M%O\ \\H_^^%_PH /[ M_^>4?_?"_X4 ']@6__/*/_OA?\* #^P+?_GE'_P!\
M+_A0 ?V!;_\ /*/_ +X7_"@ _L"W_P">4?\ WPO^% !_8%O_ ,\H_P#OA?\
M"@ _L"W_ .>4?_?"_P"% !_8%O\ \\H_^^%_PH /[ M_^>4?_?"_X4 ']@6_
M_/*/_OA?\* #^P+?_GE'_P!\+_A0 ?V!;_\ /*/_ +X7_"@ _L"W_P">4?\
MWPO^% !_8%O_ ,\H_P#OA?\ "@ _L"W_ .>4?_?"_P"% !_8%O\ \\H_^^%_
MPH /[ M_^>4?_?"_X4 ']@6__/*/_OA?\* #^P+?_GE'_P!\+_A0 ?V!;_\
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MV!;_ //*/_OA?\* #^P+?_GE'_WPO^% !_8%O_SRC_[X7_"@ _L"W_YY1_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKK7_ "%!_P!=
M8?Y)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 4-?_P"/>7_KE)_Z":!G)_"__EM_VS_]GH [N@04 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 8/CG_CSD_X!_P"AK0,QOA__ *AO^NA_]!6@#IJ "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \N_
M:;_Y%^[_ .W?_P!*(J /-_V&/^8C_P!NG_MQ0!]54""@#X _9<_Y&*S_ .WC
M_P!)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \UT
M7_D*'_KK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H H:__P >\O\ URD_]!-
MSD_A?_RV_P"V?_L] '=T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#!\<_\><G_ /_
M $-:!F-\/_\ 4-_UT/\ Z"M '34 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!Y=^TW_R+]W_ -N__I1%0!YO^PQ_
MS$?^W3_VXH ^JJ!!0!\ ?LN?\C%9_P#;Q_Z3RT#/O^@04 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!YKHO_(4/_76;^3T#/2J!!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%
M!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!0U__CWE_P"N4G_H)H&<G\+_ /EM_P!L_P#V>@#NZ!!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!Y]\?/\ D"W/_;'_ -'1UT4?C7S_ ".3$_PW\OS1
M\?5[!\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % '3> ?'T_@R?SH?F1L"2,G"NO\ 1A_"W4'U!93E."FK'12JNF[K
MYH^M/"WBF#Q1 MS;-N1N"#PRMW1AV8?D1@@D$$^/*+B[,^CA-35T:]0:!0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_\
MB_=_]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V\?\ I/+0
M,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNB_\A0_]
M=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!YKK7_ "%!_P!=8?Y)0,]*H$% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-?_P"/>7_KE)_Z":!G)_"_
M_EM_VS_]GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >??'S_D"W/_ &Q_]'1U
MT4?C7S_(Y,3_  W\OS1\?5[!\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!TW@'Q]/X,G\Z'YD; DC)PKK_ $8?
MPMU!]064Y3@IJQT4JKINZ^:/K3PMXI@\40+<VS;D;@@\,K=T8=F'Y$8()!!/
MCRBXNS/HX34U=&O4&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >7?M-_\ (OW?_;O_ .E$5 'F_P"PQ_S$?^W3_P!N* /JJ@04
M ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >:Z+_P A0_\ 76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0
MU_\ X]Y?^N4G_H)H&<G\+_\ EM_VS_\ 9Z .[H$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'GWQ\_Y MS_ -L?_1T==%'XU\_R.3$_PW\OS1\?5[!\X% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =-X
M!\?3^#)_.A^9&P)(R<*Z_P!&'\+=0?4%E.4X*:L=%*JZ;NOFCZT\+>*8/%$"
MW-LVY&X(/#*W=&'9A^1&""003X\HN+LSZ.$U-71KU!H% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_P#(OW?_ &[_ /I1%0!Y
MO^PQ_P Q'_MT_P#;B@#ZJH$% 'P!^RY_R,5G_P!O'_I/+0,^_P"@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO\ R%#_ -=9OY/0,]*H
M$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % %#7_ /CWE_ZY2?\ H)H&<G\+_P#EM_VS_P#9
MZ .[H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GWQ\_Y MS_VQ_\ 1T==%'XU\_R.
M3$_PW\OS1\?5[!\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % '3> ?'T_@R?SH?F1L"2,G"NO\ 1A_"W4'U
M!93E."FK'12JNF[KYH^M/"WBF#Q1 MS;-N1N"#PRMW1AV8?D1@@D$$^/*+B[
M,^CA-35T:]0:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 >7?M-_\B_=_P#;O_Z414 >;_L,?\Q'_MT_]N* /JJ@04 ? '[+G_(Q6?\
MV\?^D\M S[_H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!TW@'Q]/X,G\Z'YD; DC)PKK_ $8?PMU!
M]064Y3@IJQT4JKINZ^:/K3PMXI@\40+<VS;D;@@\,K=T8=F'Y$8()!!/CRBX
MNS/HX34U=&O4&@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M >7?M-_\B_=_]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V
M\?\ I/+0,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F
MNB_\A0_]=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!YKK7_ "%!_P!=8?Y)0,]*H$% !0 4 % !0 4
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MPNPVJ&<1C8>  7?:<<,#+?[3&FR^!-;L_$=NAV,T?F%6=2TD1PR,V"J"2#"
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ME=#@D'#*2#@@@X[@B@1-;6B6HVQJ%!9F(4 #<S%W;CN6)8GJ223R: ): "@
MH * "@ H * *&O\ _'O+_P!<I/\ T$T#.3^%_P#RV_[9_P#L] '=T""@ H *
M "@ H * "@#Y5_88_P"8C_VZ?^W% SZJH$>=?&#XR)\.1 @MY+FXN698(DP
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MF$3S_P#CWV[=OS_>QC^+'- 'T50(* /E7X^_\CAI/_;A_P"EDE SZJH$>/\
MQ5_:(C^'>I0:?/!NBECBD>?S"/+5I'C8[!&Y;:$+8!!/0#O0,YKPW^T5JOBF
M_M_L>ER?V7+,(S,8Y6;:9&0S>8@\I O!=<. 59?,YRH!V'Q6^.W_  A%U%IU
MM9S7EY+&)%CCX!3]X#@JLCEAY9)4)C;D[N,4 >?Z[\<O%/@G;<:OID/V7G>8
MBW'15S(DLZQ_,RXWK\W*KSR #WKP7XO@\8VD5_:$F*525W#:P()5E(]0P(."
M02,J2,$@CS#XK_M%-X7O3I&F6KWE]Y9)4;\(Q3>@"*C-+\OSN%*@+@!\[M@,
MY^3]H;6/ T@'B;3?+@?;MEMN0I(?Y<F62-V)7[OF(RJ"V&! H Y_]N?_ )AW
M_;W_ .V] 'T5XZ\=6O@>U>]O7VQKP .7=CG;&@R,L<<#@  LQ"@D C*^%'CF
MZ\;VHO;FT^R1O@P@R^8[K_ST(\M-JGC83DL,M@+M+ SM:!!0 4 % !0 4 %
M'GWQ\_Y MS_VQ_\ 1T==%'XU\_R.3$_PW\OS1\?5[!\X% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =
M-X!\?3^#)_.A^9&P)(R<*Z_T8?PMU!]064Y3@IJQT4JKINZ^:/K3PMXI@\40
M+<VS;D;@@\,K=T8=F'Y$8()!!/CRBXNS/HX34U=&O4&@4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ0HST% !XF\/ZC\&];NM?M+4WEC<+*9,-\Z>8?.ESM4E LD9.\HR",A2V\Y
M!ZK\*OVAM.^(96",F&[*DF"3J=J@OL<?*X&3@?*Y"LQ0*,T <A^VK_R!X/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#O/@QJE]9WRIIZ[]^/-0
MDB,H#RS'!V[<\-@D$X ;<4;GK)..OR.S#RDI>[\T?6M>.?1A0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?\ R+]W_P!N_P#Z414 >;_L
M,?\ ,1_[=/\ VXH ^JJ!!0!\ ?LN?\C%9_\ ;Q_Z3RT#/O\ H$% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_ ,A0_P#76;^3T#/2J!!0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 >:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 >-?M1_"Y_&VG":V0O=6K%
MXU4$LZ-@2H!N S@*XX9B4V*,O0,Y7X5?M56MI MAKWF6]U;J8WD9)) Y3"?.
M!NE68\[PRD$J6W L$ !H>-?VO+*WVV^BQO>W,F%3Y'2,,VY5&TJ)7;=M^15
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MLNX&=U\6_P!HG2[S3KFST]S=W$]M(@2-),*DD+,\K,4P D9+.HRRD;7"8<H
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M\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 :_A;PM/XHG6VMEW.W))X55[NQ[*/S)P "2 8E)15V:P
M@YNR/K3P#X!@\&0>3#\SM@R2$89V_HH_A7H!ZDLQ\><W-W/HZ5)4U9?-G35D
M;A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?_(OW?_;O
M_P"E$5 'F_[#'_,1_P"W3_VXH ^JJ!!0!\ ?LN?\C%9_]O'_ *3RT#/O^@04
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO_(4/_76;^3T#
M/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 >:ZU_P A0?\ 76'^24#/2J!!0 4 % !0 4 % !0 4 8FM^"+#7G$
MMY:P3N%"AI8HY&"@DA074G&23CIDGUH FT+PG9^']WV*WA@WXW^5&D6[&=N=
M@&<9.,],GUH U: ,36_!%AKSB6\M8)W"A0TL4<C!020H+J3C))QTR3ZT 1:7
M\/=-TB19[:SMHI5SM>.")'&00<,J@C()!QV)% '04 % &)K?@BPUYQ+>6L$[
MA0H:6*.1@H)(4%U)QDDXZ9)]: -N@"IJFDPZO&T%S&DL38W)(JNAP01E6!!P
M0",]P#0 :7I,.D1K!;1I%$N=J1JJ(,DDX50 ,DDG'<DT 8MW\,M*O':66QM7
M=V+,S6\3,S$Y+$E,DD\DGDF@"UHG@BPT%S+9VL$#E2I:**.-BI()4E%!QD X
MZ9 ]* -N@ H * ,K7?"=GX@V_;;>&?9G9YL:2[<XW8W@XS@9QUP/2@#)_P"%
M3Z/_ - ^S_\  :'_ .(H&:&B>"+#07,MG:P0.5*EHHHXV*D@E244'&0#CID#
MTH$&M^"+#7G$MY:P3N%"AI8HY&"@DA074G&23CIDGUH -$\$6&@N9;.U@@<J
M5+111QL5)!*DHH.,@''3('I0!MT % &5_P (G9_:/MWV>'[5_P ]_+3SON[/
MOXW?=^7K]WCI0!JT 17=HEXC12J'1U*LK ,K*1@J0>""."#P10!GZ?X3L].A
M>U@MX8X)-V^)(T6-MP"MN4 *<J #D<C@\4 2Z)X>MM!0Q6<,<"%BQ6)%C4L0
M 6(0 9P ,]< >E $NJ:3#J\;07,:2Q-C<DBJZ'!!&58$'! (SW - !I>DPZ1
M&L%M&D42YVI&JH@R23A5  R22<=R30!S_P#PJ?1_^@?9_P#@-#_\10,UM"\)
MV?A_=]BMX8-^-_E1I%NQG;G8!G&3C/3)]:!&K0!E:[X3L_$&W[;;PS[,[/-C
M27;G&[&\'&<#..N!Z4 5-+^'NFZ1(L]M9VT4JYVO'!$CC((.&501D$@X[$B@
M#H* "@ H * "@ H * "@"AK_ /Q[R_\ 7*3_ -!- SD_A?\ \MO^V?\ [/0!
MW= @H * "@ H * "@ H RM"\)V?A_=]BMX8-^-_E1I%NQG;G8!G&3C/3)]:
M-6@"IJFDPZO&T%S&DL38W)(JNAP01E6!!P0",]P#0!E:7\/=-TB19[:SMHI5
MSM>.")'&00<,J@C()!QV)% %O0O"=GX?W?8K>&#?C?Y4:1;L9VYV 9QDXSTR
M?6@"'6_!%AKSB6\M8)W"A0TL4<C!020H+J3C))QTR3ZT 3:%X3L_#^[[%;PP
M;\;_ "HTBW8SMSL SC)QGID^M &K0!S5I\,M*LW66*QM4=&#*RV\2LK Y# A
M,@@\@CD&@#I: "@#*U#PG9ZC,EU/;PR3Q[=DKQHTB[267:Q!888DC!X/(YH
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M >??'S_D"W/_ &Q_]'1UT4?C7S_(Y,3_  W\OS1\?5[!\X% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!K
M^%O"T_BB=;:V7<[<DGA57N['LH_,G  )(!B4E%79K"#F[(^M/ /@&#P9!Y,/
MS.V#)(1AG;^BC^%>@'J2S'QYS<W<^CI4E35E\V=-61N% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?_(OW?_;O_P"E$5 'F_[#'_,1
M_P"W3_VXH ^JJ!!0!\ ?LN?\C%9_]O'_ *3RT#/O^@04 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!YKHO_(4/_76;^3T#/2J!!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_P A
M0?\ 76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % %#7_\ CWE_ZY2?^@F@9R?PO_Y;?]L__9Z .[H$% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % 'GWQ\_Y MS_P!L?_1T==%'XU\_R.3$_P -_+\T?'U>
MP?.!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!K^%O"T_BB=;:V7<[<DGA57N['LH_,G  )(!B4E%79K"#F[
M(^M/ /@&#P9!Y,/S.V#)(1AG;^BC^%>@'J2S'QYS<W<^CI4E35E\V=-61N%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y=^TW_R+]W_V
M[_\ I1%0!YO^PQ_S$?\ MT_]N* /JJ@04 ? '[+G_(Q6?_;Q_P"D\M S[_H$
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_R%#_UUF_D]
M STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'FNM?\ (4'_ %UA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!0U__ (]Y?^N4G_H)H&<G\+_^6W_;
M/_V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y]\?/^0+<_\ ;'_T='711^-?
M/\CDQ/\ #?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0!K^%O"T_BB=;:V7<[<DGA57N['LH_,G
M )(!B4E%79K"#F[(^M/ /@&#P9!Y,/S.V#)(1AG;^BC^%>@'J2S'QYS<W<^C
MI4E35E\V=-61N% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 >7?M-_\B_=_]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,
M5G_V\?\ I/+0,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'FNB_\A0_]=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!YKK7_ "%!_P!=8?Y)0,]*H$% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-?_P"/>7_K
ME)_Z":!G)_"__EM_VS_]GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >??'S_D
M"W/_ &Q_]'1UT4?C7S_(Y,3_  W\OS1\?5[!\X% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MH ^JJ!!0!\ ?LN?\C%9_]O'_ *3RT#/O^@04 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!YKHO_(4/_76;^3T#/2J!!0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_P A0?\ 76'^
M24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % %#7_\ CWE_ZY2?^@F@9R?PO_Y;?]L__9Z .[H$% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'GWQ\_Y MS_P!L?_1T==%'XU\_R.3$_P -_+\T?'U>P?.!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!K
M^%O"T_BB=;:V7<[<DGA57N['LH_,G  )(!B4E%79K"#F[(^M/ /@&#P9!Y,/
MS.V#)(1AG;^BC^%>@'J2S'QYS<W<^CI4E35E\V=-61N% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y=^TW_R+]W_V[_\ I1%0
M!YO^PQ_S$?\ MT_]N* /JJ@04 ? '[+G_(Q6?_;Q_P"D\M S[_H$% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_R%#_UUF_D] STJ@04
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M 'FNM?\ (4'_ %UA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!0U__ (]Y?^N4G_H)H&<G\+_^6W_;/_V>@#NZ
M!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M<H]O+O\ @@^JP[?B_P#,/^%%Z/\ \^W_ )%F_P#CE'MY=_P0?58=OQ?^8?\
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M<H]O+O\ @@^JP[?B_P#,/^%%Z/\ \^W_ )%F_P#CE'MY=_P0?58=OQ?^8?\
M"B]'_P"?;_R+-_\ '*/;R[_@@^JP[?B_\P_X47H__/M_Y%F_^.4>WEW_  0?
M58=OQ?\ F'_"B]'_ .?;_P BS?\ QRCV\N_X(/JL.WXO_,/^%%Z/_P ^W_D6
M;_XY1[>7?\$'U6';\7_F'_"B]'_Y]O\ R+-_\<H]O+O^"#ZK#M^+_P P_P"%
M%Z/_ ,^W_D6;_P".4>WEW_!!]5AV_%_YA_PHO1_^?;_R+-_\<H]O+O\ @@^J
MP[?B_P#,/^%%Z/\ \^W_ )%F_P#CE'MY=_P0?58=OQ?^8?\ "B]'_P"?;_R+
M-_\ '*/;R[_@@^JP[?B_\P_X47H__/M_Y%F_^.4>WEW_  0?58=OQ?\ F'_"
MB]'_ .?;_P BS?\ QRCV\N_X(/JL.WXO_,/^%%Z/_P ^W_D6;_XY1[>7?\$'
MU6';\7_F'_"B]'_Y]O\ R+-_\<H]O+O^"#ZK#M^+_P P_P"%%Z/_ ,^W_D6;
M_P".4>WEW_!!]5AV_%_YA_PHO1_^?;_R+-_\<H]O+O\ @@^JP[?B_P#,/^%%
MZ/\ \^W_ )%F_P#CE'MY=_P0?58=OQ?^8?\ "B]'_P"?;_R+-_\ '*/;R[_@
M@^JP[?B_\P_X47H__/M_Y%F_^.4>WEW_  0?58=OQ?\ F'_"B]'_ .?;_P B
MS?\ QRCV\N_X(/JL.WXO_,/^%%Z/_P ^W_D6;_XY1[>7?\$'U6';\7_F'_"B
M]'_Y]O\ R+-_\<H]O+O^"#ZK#M^+_P P_P"%%Z/_ ,^W_D6;_P".4>WEW_!!
M]5AV_%_YA_PHO1_^?;_R+-_\<H]O+O\ @@^JP[?B_P#,/^%%Z/\ \^W_ )%F
M_P#CE'MY=_P0?58=OQ?^8?\ "B]'_P"?;_R+-_\ '*/;R[_@@^JP[?B_\P_X
M47H__/M_Y%F_^.4>WEW_  0?58=OQ?\ F'_"B]'_ .?;_P BS?\ QRCV\N_X
M(/JL.WXO_,/^%%Z/_P ^W_D6;_XY1[>7?\$'U6';\7_F'_"B]'_Y]O\ R+-_
M\<H]O+O^"#ZK#M^+_P P_P"%%Z/_ ,^W_D6;_P".4>WEW_!!]5AV_%_YA_PH
MO1_^?;_R+-_\<H]O+O\ @@^JP[?B_P#,/^%%Z/\ \^W_ )%F_P#CE'MY=_P0
M?58=OQ?^8?\ "B]'_P"?;_R+-_\ '*/;R[_@@^JP[?B_\P_X47H__/M_Y%F_
M^.4>WEW_  0?58=OQ?\ F'_"B]'_ .?;_P BS?\ QRCV\N_X(/JL.WXO_,/^
M%%Z/_P ^W_D6;_XY1[>7?\$'U6';\7_F'_"B]'_Y]O\ R+-_\<H]O+O^"#ZK
M#M^+_P P_P"%%Z/_ ,^W_D6;_P".4>WEW_!!]5AV_%_YA_PHO1_^?;_R+-_\
M<H]O+O\ @@^JP[?B_P#,/^%%Z/\ \^W_ )%F_P#CE'MY=_P0?58=OQ?^8?\
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MO^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO_(4/_76
M;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 >:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!0U__CWE_P"N4G_H)H&<G\+_ /EM
M_P!L_P#V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!@^.?^/.3_@'_H:T#,;X
M?_ZAO^NA_P#05H Z:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M5/23_OT/_B* #^VM4])/^_0_^(H /[:U3TD_[]#_ .(H /[:U3TD_P"_0_\
MB* #^VM4])/^_0_^(H /[:U3TD_[]#_XB@ _MK5/23_OT/\ XB@ _MK5/23_
M +]#_P"(H /[:U3TD_[]#_XB@ _MK5/23_OT/_B* #^VM4])/^_0_P#B* #^
MVM4])/\ OT/_ (B@ _MK5/23_OT/_B* #^VM4])/^_0_^(H /[:U3TD_[]#_
M .(H /[:U3TD_P"_0_\ B* #^VM4])/^_0_^(H /[:U3TD_[]#_XB@ _MK5/
M23_OT/\ XB@ _MK5/23_ +]#_P"(H /[:U3TD_[]#_XB@ _MK5/23_OT/_B*
M #^VM4])/^_0_P#B* #^VM4])/\ OT/_ (B@ _MK5/23_OT/_B* #^VM4])/
M^_0_^(H /[:U3TD_[]#_ .(H /[:U3TD_P"_0_\ B* #^VM4])/^_0_^(H /
M[:U3TD_[]#_XB@ _MK5/23_OT/\ XB@##M;J=)]Z;O/W,>%RV3G=\N/KVXH
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M@##NKJ=Y][[O/W*>5PV1C;\N/IVYH W/[:U3TD_[]#_XB@ _MK5/23_OT/\
MXB@ _MK5/23_ +]#_P"(H /[:U3TD_[]#_XB@ _MK5/23_OT/_B* #^VM4])
M/^_0_P#B* #^VM4])/\ OT/_ (B@ _MK5/23_OT/_B* #^VM4])/^_0_^(H
M/[:U3TD_[]#_ .(H /[:U3TD_P"_0_\ B* #^VM4])/^_0_^(H /[:U3TD_[
M]#_XB@ _MK5/23_OT/\ XB@ _MK5/23_ +]#_P"(H /[:U3TD_[]#_XB@ _M
MK5/23_OT/_B* #^VM4])/^_0_P#B* #^VM4])/\ OT/_ (B@ _MK5/23_OT/
M_B* #^VM4])/^_0_^(H /[:U3TD_[]#_ .(H /[:U3TD_P"_0_\ B* #^VM4
M])/^_0_^(H /[:U3TD_[]#_XB@ _MK5/23_OT/\ XB@ _MK5/23_ +]#_P"(
MH /[:U3TD_[]#_XB@ _MK5/23_OT/_B* #^VM4])/^_0_P#B* #^VM4])/\
MOT/_ (B@ _MK5/23_OT/_B* #^VM4])/^_0_^(H /[:U3TD_[]#_ .(H /[:
MU3TD_P"_0_\ B* #^VM4])/^_0_^(H /[:U3TD_[]#_XB@ _MK5/23_OT/\
MXB@ _MK5/23_ +]#_P"(H /[:U3TD_[]#_XB@ _MK5/23_OT/_B* #^VM4])
M/^_0_P#B* #^VM4])/\ OT/_ (B@ _MK5/23_OT/_B* #^VM4])/^_0_^(H
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MJ>DG_?H?_$4 ']M:IZ2?]^A_\10 ?VUJGI)_WZ'_ ,10 ?VUJGI)_P!^A_\
M$4 ']M:IZ2?]^A_\10 ?VUJGI)_WZ'_Q% !_;6J>DG_?H?\ Q% !_;6J>DG_
M 'Z'_P 10 ?VUJGI)_WZ'_Q% %35=4OYXV6</Y9QG,84=1CG:.^* *NCWUW
MA%N&V[N<)N&<#OM/;% %_P#M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF
M@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?
M_OT/_B: #^UM1]'_ ._0_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@
M_M;4?1_^_0_^)H /[6U'T?\ []#_ .)H /[6U'T?_OT/_B: #^UM1]'_ ._0
M_P#B: #^UM1]'_[]#_XF@ _M;4?1_P#OT/\ XF@ _M;4?1_^_0_^)H /[6U'
MT?\ []#_ .)H \^^/NHWLVBW*S!]A\G.4"C_ %T>.=H[T 8W[#'_ #$?^W3_
M -N* /JJ@04 ? '[+G_(Q6?_ &\?^D\M S[_ *!!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'FNB_P#(4/\ UUF_D] STJ@04 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNM?\A0?
M]=8?Y)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 4-?\ ^/>7_KE)_P"@F@9R?PO_ .6W_;/_ -GH [N@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 8/CG_ (\Y/^ ?^AK0,QOA_P#ZAO\ KH?_ $%: .FH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#R[]IO_ )%^[_[=_P#THBH \W_88_YB/_;I_P"W% 'U50(* /@#]ES_
M )&*S_[>/_2>6@9]_P! @H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#S71?\ D*'_ *ZS?R>@9Z50(* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>E4""@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *&O_ /'O
M+_URD_\ 030,Y/X7_P#+;_MG_P"ST =W0(* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M,'QS_P ><G_ /_0UH&8WP_\ ]0W_ %T/_H*T =-0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?_ "+]W_V[
M_P#I1%0!YO\ L,?\Q'_MT_\ ;B@#ZJH$% 'P!^RY_P C%9_]O'_I/+0,^_Z!
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNB_\ (4/_ %UF
M_D] STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?_(OW?\ V[_^E$5
M'F_[#'_,1_[=/_;B@#ZJH$% 'P!^RY_R,5G_ -O'_I/+0,^_Z!!0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNB_\A0_]=9OY/0,]*H$% !0
M 4 5-4U:'2(VGN9$BB7&YY&5$&2 ,LQ &20!GN0* .?_ .%L:/\ ]!"S_P#
MF'_XN@9T&EZM#J\:SVTB2Q-G:\;*Z'!(.&4D'!!!QW!% C/UOQO8:"XBO+J"
M!RH8+++'&Q4D@, [ XR",],@^E &?_PMC1_^@A9_^!,/_P 70,/^%L:/_P!!
M"S_\"8?_ (N@#;N?$-M:P?;))HUMRJL)F=1%M;&QMY.W!R,'.#D8ZT")=+U:
M'5XUGMI$EB;.UXV5T."0<,I(.""#CN"* += !0!B:)XWL-><Q6=U!.X4L5BE
MCD8*" 6(1B<9(&>F2/6@#;H * "@ H * "@ H * "@ H * "@ H * .:TGXD
M:?J][+IEO.'NH%+2(H<A0"JM\^W82&8 @,2#D$ @X .EH * "@ H * "@#P_
M7_VO]&TB=[=1/.$;;YD2QM$Q'7:6E4L >,XP<94E2"09ZWX5\21^)K6*]@#K
M'-&KJ)%*. ?4']",JPPREE()!&K0 4 % !0!GZ_K\'AZ![N[<1PQKN=VZ =.
MW)).  ,EB0 "2!0!%X6\4V_BJW2]LG\R"3=L?:RYVL4;APK#YE(Y'Z4 :M !
M0 4 % !0 4 % !0 4 % 'FNM?\A0?]=8?Y)0,]*H$% !0 4 % &5H7BRS\0;
MOL5Q#/LQO\J1)=N<[<["<9P<9ZX/I0!JT % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'G_PH^-=G\3?.^Q),GD>7
MO\U47._?MQLD?^X<YQVZT#/0*!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M %#7_P#CWE_ZY2?^@F@9R?PO_P"6W_;/_P!GH [N@04 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MW@3[%_9L/E>;]I\SYY'SL\G;_K';&-QZ8SGGM0![_P#\,N>'?^?/_P CW/\
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M!% $M !0 4 4-?\ ^/>7_KE)_P"@F@9R?PO_ .6W_;/_ -GH [N@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /+OVF_^1?N_P#M
MW_\ 2B*@#S?]AC_F(_\ ;I_[<4 ?55 @H ^ /V7/^1BL_P#MX_\ 2>6@9]_T
M""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MN\$*6SE!N8 &K^RIX<M;31XKZ"(1S7*D3%6D8.8998T;#NP4D9)VX!). !@
M \P\!^&X/COKU_J%\?.L;?"1(&EC#*2RP8!^95VHTC@,A\U@<8++0!Z_\1_V
M==+\46KQV]M#;W(C?R9(E$ #G!7>(UPRDJ =RL0I;9ACF@#C_P!C?QY/KUE/
M8W!+BT:+RW8Y(CD#!8NF<*8S@DGA@HPJ 4 >0:%\.'^(?B?4;$3&&'[3=O<%
M20SQ+=#Y /NDE]A&[Y5(WX8J%(![?\7?V>M(@T:=K2W2"6U@FECD&]G^7]ZZ
ML2^9-P4H#(6\L-E1QB@"W^R-XFFUO10DYW?9YW@0DL6V!4D4$DG[OF%5Q@!%
M4 <9(!Y_\ O^1PU;_M__ /2R.@ ^+NHQS>+[2'7=@TV.-3$'),1#(^)'&X@9
MN!L<L%4HB^8"@R0#V6/X2Z%XA-O?V<, ,,R2PS6NQ%+1R*Q!,7R2#='M.X,5
M&X*58YH X_\ :P\!65[ID^JR19O(8X(XY-SC:IN%!&T,$/\ K&Y*D\]>!@ Y
M_P" OP%T;Q5HUM>WMMYD\GG;W\V=<[9I$7A)%4?*H' _6@#Z5H$>:_'SP%9>
M)=-N+F[BWRVEI=R0-N==C>7NSA6 ;E%.&!''3DY!GBO[+_P9TKQOILMSJ%OY
MLJW;QAO,F3"B.)@,1NHZL3G&>>O2@"U^W/\ \P[_ +>__;>@#ZJH$?*O_-0_
M\_\ 0.H&6_VLM18:EI=O?\:49%>3!?YB)%6?<J-N^2(KM(4,/,<*220 #T^[
M^$OASQ];,MM#:L@8CSK3RD9'V_WX>"0&#;'W+G:64\4 1?M1_P#(NWG_ &[_
M /I1%0 ?LN?\B[9_]O'_ *42T >0> _#<'QWUZ_U"^/G6-OA(D#2QAE)98,
M_,J[4:1P&0^:P.,%EH ]?^(_[.NE^*+5X[>VAM[D1OY,D2B !S@KO$:X925
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M[,'<"0"VTJ3F@"I^S%J8\9^'C9W:ETC:>U?<[$O&5#8R,,H"2B, '@*,$<
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MY%6ER/R/HJ%=55Y]4=Q6!UA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_\
M(OW?_;O_ .E$5 'F_P"PQ_S$?^W3_P!N* /JJ@04 ? '[+G_ ",5G_V\?^D\
MM S[_H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_P A
M0_\ 76;^3T#/2J!!0 4 % 'E7[4?_(NWG_;O_P"E$5 P_9<_Y%VS_P"WC_TH
MEH \_P#VVM4M?L=M;%D-YY_F*N,R"+8ZN<X^52^P8)&\KP#L.T ]U^'OG?V;
M9_:M_G_9+?S?,W>9O\M=^[=\V[=G=GG.<\T"/G7]N?\ YAW_ &]_^V] SZJH
M$>5?M1_\B[>?]N__ *414##]ES_D7;/_ +>/_2B6@#TK5M4CTB&2YG;;%%&\
MCM@G"J"S' !)P 3@ GT% CY ^%?@#4/BY=7VN0WLUAOG95=&:1R&^<P[EEB;
M;&OE 9&TC&T#;@ ST6[_ &9=5O$:*77[IT=2K*RRLK*1@J0;K!!'!!X(H Q?
MV1-4DT"\U#P_.VYH9&D&T QAHW\B<[B%<[OW>T$8PI.%/4 ^GZ!'@'[7OQ'N
MO"MK;6UD[PO<R2%I8WV.%BV?("!N&YG4DJRG"E3D,10,U?#/[(^B:9"([J-[
MJ7@M(\DD?. "%6)T 7() .YAG!=L"@#R_P#9AMH+7Q/J$=G@VZPW:PE6WKY8
MNH@F&R=PVXP<G(YR: +?Q?LC\0_%2Z=]HCL3:0Q".=BHE>1MDB",CRW9]\JA
M$W_+M=T^9BI .EO/@;XC\:LL&OZFALQRR6XP7^=#M91%"A^[E6?S-C $(<F@
M#WK0- @\/0):6B".&-=J(O0#KWY))R23DL22222:!'RW^QWJ*^'-0O\ 2+KY
M+I]H"DIC=;M(LL8(;YF^?("[@55VS@<@SZIU;5(](ADN9VVQ11O([8)PJ@LQ
MP 2< $X )]!0(^:_V'=+DBAOKDK^Z>2"-6R.6C$C.,9R,"5#DC!SP3@X!E3X
M!?\ (X:M_P!O_P#Z61T >_\ Q8_Y ^H?]>%W_P"B7H \K_8J_P"0//\ ]?\
M)_Z)@H Y3X!?\CAJW_;_ /\ I9'0!]%>,? %CXSC$.H0),H^Z2"'7)4G:ZD.
MF=HSM(W 8.1Q0(^4/B9X5G_9VN[>ZTB[D:.X9R89!\I$00%9=A590?-;'RH4
M!^4[OFH&>]?M1_\ (NWG_;O_ .E$5 !^RY_R+MG_ -O'_I1+0!ZK0(Y3XL?\
M@?4/^O"[_P#1+T#/*_V*O^0//_U_R?\ HF"@#G_VXM+DDAL;D+^Z22>-FR.&
MD$;(,9R<B)SD# QR1D9 /I32=4CU>&.Y@;=%+&DB-@C*L RG! (R"#@@'U%
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MDDG)).2Q)))))H$?,O[&?_$DO-2TVX^2Z7RLQ_>_U+RQR_,N5^5I%'7G.5R
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'GWQ\_Y MS_P!L?_1T==%'XU\_R.3$_P -_+\T?'U>P?.!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 6])U:72)5N+=BDB'*L.H_H01P0>",@@@U+5U9E1D
MXNZW/J[X7?%&+QM%@X2Y0?O(^Q[;TSR5)_%3P<Y5F\BK2Y'Y'T5"NJJ\^J.X
MK ZPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H \N_:;_P"1?N_^W?\ ]*(J /-_V&/^
M8C_VZ?\ MQ0!]54""@#X _9<_P"1BL_^WC_TGEH&??\ 0(* .:^)7B\>#M.N
M;\D Q0L4W!F4R'Y8E(7G!D*@\C .20.0 ?&&D_M6:[;31R3W'FQ+(A>/RK=-
MZ@@LFX0Y7(R,CD9R*!GW?:7:7B++$P='4,K*0RLI&0P(X((Y!'!% CY*U_\
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M0@GW12QRQI!Y9'EJTB2*-YD<MM"!<D GJ3VH \PUW3(OCKXGGL+AC%;6,,J
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M(\Z\ _ S_A$M8N]9^T^9]J\_]UY6S9YLRR_?\QMV-N/NC.<\=*!GH'BS0O\
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MR_\ IHF,;/?.>V.0#U6@1S_CKP+:^.+5[*]3=&W((X=&&=LB'!PPSP>002K
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M ':1@!5YW &4G[)\NJSPR:OJD]]#$Q/E.'!(.,J':>0H"0-VT9(& 5.& !]
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@#S71?\ D*'_ *ZS?R>@9Z50(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /&OB!^S5!K]W_:>G7,FGWC-EY(AE22&#L K
M1LKMN^9@X!&<J69FH&8O_#-&I77[NZUZ\E@;Y98_WHWH>'3+7#J,KD<JPYY4
MCB@#U_P+X%M? ]JEE9)MC7DD\N['&Z1S@98XY/   50%  !'04 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M >:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 >-?$#]FJ#7[O^T].N9-/O&;+R1#*DD,'8
M!6C97;=\S!P",Y4LS-0,Q?\ AFC4KK]W=:]>2P-\LL?[T;T/#IEKAU&5R.58
M<\J1Q0!Z_P"!? MKX'M4LK)-L:\DGEW8XW2.<#+'')X  "J H  (Z"@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9E7(W%5,P9@.I +*">@+#/44 2_MS_\ ,._[>_\ VWH X7XH>$)[+POHMQ*
MH1KD%<Y8BY<SPL,9&#&F3D@@D#&<X /HK]E6[2?P_:JC!BC7"N 02K>?(^TX
MZ':RM@\X(/0B@#YE_:-TN35_%%Q;0+NEEDM(T7(&6:"%5&20!DD#)('J: /9
M?VN_BU<^&A!IUA,89)5:69DW)*$# 1!7&-H9E?=M.[Y0"0K$, 9/PQ_9-M-9
MT@3WDA-U=PQRPR(3M@5E#H-N0)"01YF[C'RH5(\Q@#SKX0^*KKX;^(!I4<KR
M6WV][62/.R-RTGD";8=X5@0K<?,0NS?M)H ^ZJ!!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % 'FNB_P#(4/\ UUF_D] STJ@04 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNM?
M\A0?]=8?Y)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 4-?\ ^/>7_KE)_P"@F@9R?PO_ .6W_;/_ -GH [N@04 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <?\4/!5SXPMEM[.\DL7697,L6[
M<5"NI0[)(S@E@>N,J..X!GF'_#.&L?\ 0PWGY3?_ "70 ?\ #.&L?]##>?E-
M_P#)= '?_"CX<7G@OSOMNH37_F^7L\W?^[V[]V-\LOWMPSC'W1U[ 'H% @H
M* "@ H * "@ H * "@ H * "@ H * "@ H \^^/G_(%N?^V/_HZ.NBC\:^?Y
M')B?X;^7YH^/J]@^<"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]$^
M#'@6ZUZZ6Y@=H8H7!:8=<_\ /-<@@L0<$$%0I^8'(5N:M-15M[]#MP])SE=:
M)=3ZMKR#Z(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M<I\2OB5:_#RU^VWN\H9%C58UW.S-DX&2JCY59B6(& 0"20"#-;PKXFA\46L5
M];',4T:NO*DC/56VE@&4Y5@"<,".U C5H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>E4""@ H * "@ H * "@ H
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M?C7S_(Y,3_#?R_-'Q]7L'S@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M=S\+OA=+XVER<I;(?WDG<]]B9X+$?@HY.<JK<]6KR+S.NA0=5^75GU;I.DQ:
M1$MO;J$C0851T']22>23R3DDDFO(;N[L^BC%15EL6Z104 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'EW[3?_(OW?_;O_P"E$5 'F_[#'_,1_P"W3_VXH ^JJ!!0!\ ?LN?\
MC%9_]O'_ *3RT#/O^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0!YKHO_(4/_76;^3T#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 5-6U2/2(9+F=ML44;R.V"<*H+,< $G !. "?04 <5'\?-$>U-_\ :T$
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M'HD,_D+Y[IN4>>L0$6#C+89EEPN>?DSP=H;C(,]5\(>-+3QC +NPE$L19EW
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MW=W9]%&*BK+8MTB@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R[]IO\ Y%^[_P"W?_TH
MBH \W_88_P"8C_VZ?^W% 'U50(* /@#]ES_D8K/_ +>/_2>6@9]_T""@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MF.7(7<Q7R5"9.%!88Y& #WKX>ZI)J^FV=S.VZ66TMY'; &6:-68X  &22<
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M[8_^CHZZ*/QKY_D<F)_AOY?FCX^KV#YP* "@ H * "@ H * "@ H * "@ H
M* "@#N?A=\+I?&TN3E+9#^\D[GOL3/!8C\%')SE5;GJU>1>9UT*#JORZL^K=
M)TF+2(EM[=0D:#"J.@_J23R2>2<DDDUY#=W=GT48J*LMBW2*"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#R[]IO_D7[O\ [=__ $HBH \W_88_YB/_ &Z?^W% 'U50
M(* /@#]ES_D8K/\ [>/_ $GEH&??] @H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#S71?^0H?^NLW\GH&>E4""@ H * "@ H * "@ H * "@
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M)GH ]4^$_P#R!]/_ .O"T_\ 1*4 =70(* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#S76O^0H/^NL/\DH&>E4""@ H * "@ H * "@ H * "@ H *
M"@ H X7XY^%W\3Z+>6L6=YAWJ%4NS-$RS! H()+%-HQD@G.#T(,\_P#V0?'D
M&J:6-,R%N+5I,IGYFC=S()0,#@,Y0@%L$ MC>HH YK]M'QU:S6\.D(^ZZ6=)
MG4<A%$<B@,<\,V\$+R=HW' *;@#TK_F3_P#N _\ MG0!RO[%7_('G_Z_Y/\
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M@#S[X^?\@6Y_[8_^CHZZ*/QKY_D<F)_AOY?FCX^KV#YP* "@ H * "@ H *
M"@ H * "@ H * .Y^%WPNE\;2Y.4MD/[R3N>^Q,\%B/P4<G.55N>K5Y%YG70
MH.J_+JSZMTG28M(B6WMU"1H,*HZ#^I)/))Y)R2237D-W=V?11BHJRV+=(H*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#R[]IO_D7[O\ [=__ $HBH \W_88_YB/_
M &Z?^W% 'U50(* /@#]ES_D8K/\ [>/_ $GEH&??] @H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#S71?^0H?^NLW\GH&>E4""@ H * "@ H
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MO_Y;?]L__9Z .[H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GWQ\_Y MS_P!L?_1T
M==%'XU\_R.3$_P -_+\T?'U>P?.!0 4 % !0 4 % !0 4 % !0 4 % '<_"[
MX72^-I<G*6R']Y)W/?8F>"Q'X*.3G*JW/5J\B\SKH4'5?EU9]6Z3I,6D1+;V
MZA(T&%4=!_4DGDD\DY)))KR&[N[/HHQ459;%ND4% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 >7?M-_P#(OW?_ &[_ /I1%0!YO^PQ_P Q'_MT_P#;B@#ZJH$%
M 'P!^RY_R,5G_P!O'_I/+0,^_P"@04 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!YKHO\ R%#_ -=9OY/0,]*H$% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!G^(=$37K::SE)"3PR1,5P&"NI0D9!&<'C((SV- '/\
MPO\ A?;?#BV:SLVD='F:4F4JS;BJ(0-B(,80=LYSS0,["@04 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % %#7_^/>7_ *Y2?^@F@9R?PO\ ^6W_ &S_ /9Z
M .[H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % '!_'2V:YT>Y2-2S'R<  DG]]&>@K>
MB[27]=#EQ";@TO+\T?*=OX*OKD92VG89QD12$?HM>K[1=U]YX/LI=G]S)/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_\B_=_]N__ *414 >;_L,?\Q'_
M +=/_;B@#ZJH$% 'P!^RY_R,5G_V\?\ I/+0,^_Z!!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % 'FNB_\A0_]=9OY/0,]*H$% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKK7_ "%!
M_P!=8?Y)0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 4-?_P"/>7_KE)_Z":!G)_"__EM_VS_]GH [N@04 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 8/CG_CSD_X!_P"AK0,QOA__ *AO^NA_]!6@#IJ "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M \N_:;_Y%^[_ .W?_P!*(J /-_V&/^8C_P!NG_MQ0!]54""@#X _9<_Y&*S_
M .WC_P!)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M \UT7_D*'_KK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H H:__P >\O\ URD_
M]!- SD_A?_RV_P"V?_L] '=T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#!\<_\><G
M_ /_ $-:!F-\/_\ 4-_UT/\ Z"M '34 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BD
MOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*',
M'_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/
M^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E
M]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"*2^J_F?\*.4.
M8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'*','_"*2^J_F
M?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5?S/^%'*','_"
M*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#_A%)?5?S/^%'
M*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\ "CE#F#_A%)?5
M?S/^%'*','_"*2^J_F?\*.4.8/\ A%)?5?S/^%'*','_  BDOJOYG_"CE#F#
M_A%)?5?S/^%'*','_"*2^J_F?\*.4.8/^$4E]5_,_P"%'*','_"*2^J_F?\
M"CE#F.!^._A^2TT>Y=BN!Y/0G/\ KHQZ46&I7*'[#'_,1_[=/_;BI*/JJ@04
M ?GI^SI_R';7_MO_ .B)::%+8^V*U,0H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#S?]HO\ Y 5U_P!L/_1\52RH[G(?L,?\Q'_MT_\ ;BLS8^JJ
M!!0!^>G[.G_(=M?^V_\ Z(EIH4MC[8K4Q"@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /-_VB_P#D!77_ &P_]'Q5+*CN<A^PQ_S$?^W3_P!N*S-C
MZJH$% 'YZ?LZ?\AVU_[;_P#HB6FA2V/MBM3$* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H \W_:+_ .0%=?\ ;#_T?%4LJ.YR'[#'_,1_[=/_ &XK
M,V/JJ@04 ?GI^SI_R';7_MO_ .B)::%+8^V*U,0H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#S?]HO\ Y 5U_P!L/_1\52RH[G(?L,?\Q'_MT_\
M;BLS8^JJ!!0!^>G[.G_(=M?^V_\ Z(EIH4MC[8K4Q"@ H \S^-'QH3X>(D<:
M"6YE5RJE@%0 8#L!\Q!;@ 8W8?YU*\RW8I*YXE;^*/%?Q$&;8S"(LTBF(+;1
MX#%=JR_(6 )QM+L3C)R5)$ZLO1!;?''7_ EPMOJ0,@10IBF0*S*&V[UD4!F)
MVD"0F13RQ#'FB]@LF?3W@[QC;>+[9;NT;<C<$'AD8=48<X89^A&""5()LS:L
M<!X@^/?]D:PNB_9MV9K>/S?-Q_K1&<[/+/3?TW<XZC-*Y5M+GK540?)?P_\
M^1Q?_K]U#_T&>LUN:O8^M*T,@H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /-_VB_^0%=?]L/_ $?%4LJ.YR'[#'_,1_[=/_;BLS8^JJ!!0!^>
MG[.G_(=M?^V__HB6FA2V/MBM3$* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \W_:+_Y 5U_VP_\ 1\52RH[G(?L,?\Q'_MT_]N*S-CZJH$% 'YZ?
MLZ?\AVU_[;_^B)::%+8^V*U,0H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#S?]HO_D!77_;#_P!'Q5+*CN<A^PQ_S$?^W3_VXK,V/JJ@04 ?GI^S
MI_R';7_MO_Z(EIH4MC[8K4Q"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /-_VB_^0%=?]L/_ $?%4LJ.YR'[#'_,1_[=/_;BLS8^JJ!!0!^>G[.G
M_(=M?^V__HB6FA2V/MBM3$* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^-','*']OOZ+^1_QHY@Y0_M]_1?R/^-','*']OOZ+^1_QHY@Y0_M]_1?R/\
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M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\
MA*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.
M8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B
M_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'
M_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#E#_A*I?1?R/^
M-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY'_&CF#E#_A*I
M?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"52^B_D?\ &CF#
ME#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-','*'_  E4OHOY
M'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(_P"-','*'_"5
M2^B_D?\ &CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/\ A*I?1?R/^-',
M'*'_  E4OHOY'_&CF#E#_A*I?1?R/^-','*'_"52^B_D?\:.8.4/^$JE]%_(
M_P"-','*'_"52^B_D?\ &CF#E.!^._B"2[T>Y1@N#Y/0'/\ KHSZT7&HV*'[
M#'_,1_[=/_;BI*/JJ@04 ? '[+G_ ",5G_V\?^D\M S[_H$% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_P A0_\ 76;^3T#/2J!!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >
M:ZU_R%!_UUA_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!0U_\ X]Y?^N4G_H)H&<G\+_\ EM_VS_\ 9Z .[H$%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % &#XY_X\Y/\ @'_H:T#,;X?_ .H;_KH?_05H
M Z:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /+OVF_^1?N_^W?_ -*(J /-_P!AC_F(_P#;I_[<4 ?55 @H ^ /
MV7/^1BL_^WC_ -)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \UT7_D*'_KK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /-=:_P"0H/\ KK#_ "2@9Z50(* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H H:__
M ,>\O_7*3_T$T#.3^%__ "V_[9_^ST =W0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M ,'QS_QYR?\  /\ T-:!F-\/_P#4-_UT/_H*T =-0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'EW[3?_(OW?_;O
M_P"E$5 'F_[#'_,1_P"W3_VXH ^JJ!!0!\ ?LN?\C%9_]O'_ *3RT#/O^@04
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO_(4/_76;^3T#
M/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 >:ZU_P A0?\ 76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % %#7_\ CWE_ZY2?^@F@9R?PO_Y;?]L_
M_9Z .[H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &#XY_X\Y/^ ?\ H:T#,;X?_P"H
M;_KH?_05H Z:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /+OVF_^1?N_P#MW_\ 2B*@#S?]AC_F(_\ ;I_[<4 ?
M55 @H ^ /V7/^1BL_P#MX_\ 2>6@9]_T""@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /-=%_Y"A_ZZS?R>@9Z50(* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>
ME4""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* *&O_\ 'O+_ -<I/_030,Y/X7_\MO\ MG_[/0!W= @H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H P?'/_'G)_P#_P!#6@9C?#__ %#?]=#_ .@K0!TU !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_
M\B_=_P#;O_Z414 >;_L,?\Q'_MT_]N* /JJ@04 ? '[+G_(Q6?\ V\?^D\M
MS[_H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z+_R%#_U
MUF_D] STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M^TJ-=NQI6KVQL;PK&%#E@KR$ E=KJK1%L@QJQ;<#MW;MN\ ]PH$% !0 4 %
M!0 4 % !0 4 % !0 4 % &#XY_X\Y/\ @'_H:T#,;X?_ .H;_KH?_05H Z:@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /+OVF_^1?N_^W?_ -*(J /-_P!AC_F(_P#;I_[<4 ?55 @H ^ /V7/^
M1BL_^WC_ -)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H \UT7_D*'_KK-_)Z!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /-=:_P"0H/\ KK#_ "2@9Z50(* "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!Y=^TW_R+]W_V[_\ I1%0!YO^PQ_S$?\ MT_]
MN* /JJ@04 ? '[+G_(Q6?_;Q_P"D\M S[_H$% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >:Z+_R%#_UUF_D] STJ@04 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FNM?\ (4'_ %UA
M_DE STJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4J2LS ,"#M:>1T;GL5(8'H001P: /4*!!0 4 % !0 4 % !0 4 % !0 4 %
M'/>/YU@LI6<A0-F23@??7N:!G*>!_%=G;0L'N(5/F$X,B _=7U- '0_\)K8_
M\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\
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M_P 50 ?\)K8_\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\
M?V/_ .*H /\ A-;'_GY@_P"_L?\ \50 ?\)K8_\ /S!_W]C_ /BJ #_A-;'_
M )^8/^_L?_Q5 !_PFMC_ ,_,'_?V/_XJ@ _X36Q_Y^8/^_L?_P 50 ?\)K8_
M\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\
MA-;'_GY@_P"_L?\ \50 ?\)K8_\ /S!_W]C_ /BJ #_A-;'_ )^8/^_L?_Q5
M !_PFMC_ ,_,'_?V/_XJ@ _X36Q_Y^8/^_L?_P 50 ?\)K8_\_,'_?V/_P"*
MH /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\ A-;'_GY@_P"_
ML?\ \50 ?\)K8_\ /S!_W]C_ /BJ #_A-;'_ )^8/^_L?_Q5 !_PFMC_ ,_,
M'_?V/_XJ@ _X36Q_Y^8/^_L?_P 50 ?\)K8_\_,'_?V/_P"*H /^$UL?^?F#
M_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\ A-;'_GY@_P"_L?\ \50 ?\)K
M8_\ /S!_W]C_ /BJ #_A-;'_ )^8/^_L?_Q5 !_PFMC_ ,_,'_?V/_XJ@ _X
M36Q_Y^8/^_L?_P 50 ?\)K8_\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_
M  FMC_S\P?\ ?V/_ .*H /\ A-;'_GY@_P"_L?\ \50 ?\)K8_\ /S!_W]C_
M /BJ #_A-;'_ )^8/^_L?_Q5 !_PFMC_ ,_,'_?V/_XJ@ _X36Q_Y^8/^_L?
M_P 50 ?\)K8_\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\
M?V/_ .*H /\ A-;'_GY@_P"_L?\ \50 ?\)K8_\ /S!_W]C_ /BJ #_A-;'_
M )^8/^_L?_Q5 !_PFMC_ ,_,'_?V/_XJ@ _X36Q_Y^8/^_L?_P 50 ?\)K8_
M\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\
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M_P 50 ?\)K8_\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\
M?V/_ .*H /\ A-;'_GY@_P"_L?\ \50 ?\)K8_\ /S!_W]C_ /BJ #_A-;'_
M )^8/^_L?_Q5 !_PFMC_ ,_,'_?V/_XJ@ _X36Q_Y^8/^_L?_P 50 ?\)K8_
M\_,'_?V/_P"*H /^$UL?^?F#_O['_P#%4 '_  FMC_S\P?\ ?V/_ .*H /\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!Y=^TW_ ,B_=_\ ;O\ ^E$5 'F_[#'_ #$?^W3_ -N* /JJ
M@04 ? '[+G_(Q6?_ &\?^D\M S[_ *!!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M*XAGV8W^5(DNW.=N=A.,X.,]<'TH$:M !0!4U35H=(C:>YD2*)<;GD9409(
MRS$ 9) &>Y H -+U:'5XUGMI$EB;.UXV5T."0<,I(.""#CN"* *NG^++/49G
MM8+B&2>/=OB21&D7:0K;E!+##$ Y'!X/- &K0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!0U__ (]Y?^N4G_H)H&<G\+_^6W_;/_V>@#NZ!!0
M4 % !0 4 % !0 4 % !0 4 % !0!\J_&CP+J'PSU3_A(]"1S%)O>Y4;I5#$L
M\WF(!GR' W$Y(1P2#'B*@9T&E_MM:;)&IN;:Y27G<L?E2H.3C#,\1/&"<J,'
M(YQD@'%>(8M8_:-ND\B-[;2$D^1Y!A,?,IF(R/.E^5E"H2L9(0LNYY& /K32
M=+CTB&.V@7;%%&D:+DG"J JC)))P !DDGU- CX@_9O\ C79_#+[7]M29_/\
M(V>4J-C9YN[.^1/[XQC/?I0,];U+]J"[\8![;PUI\\DC*B^>Z@B%W8@%D7?&
M!@95I)%4')92JD, =?\ L^?!B3P-')>Z@WF:A=8,I)#F,$EBF_EF9F.Z4YVL
MP4#.T.P!YK^W/_S#O^WO_P!MZ .EN_VU]*5&,5O=,X4[598D4MC@%A*Q4$]2
M%8@<X/2@#G]2\+ZW\>KN/^T8)-.TJ%LF-LB0L -Q =59W;=A7*".-=P&Y@PD
M /J"TM$LT6*)0B(H554!550,!0!P !P . *!$M !0 4 % !0 4 % !0 4 %
M!0 4 % '$?&K_D$W'_;+_P!'1T#/EF@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M^W?_ -*(J!A^RY_R+MG_ -O'_I1+0!Y5\ O^1PU;_M__ /2R.@#ZJH$% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-?_P"/>7_KE)_Z":!G)_"_
M_EM_VS_]GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <1\:O\ D$W'_;+_ -'1
MT#/EF@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M -/PYXCF\/3+<6[88<$'E6'=6'<'_ @@@$ 'TSX+\:0^*X?-BX88$D9.60_U
M!_A;O[$$  Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H \N_:;_P"1?N_^W?\ ]*(J /-_V&/^8C_VZ?\ MQ0!
M]54""@#X _9<_P"1BL_^WC_TGEH&??\ 0(* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#/UOQ#;:"@EO)HX$+!0TKK&I8@D*"Y S@
M$XZX!]* )=+U:'5XUGMI$EB;.UXV5T."0<,I(.""#CN"* += !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO\ R%#_ -=9OY/0,]*H$% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\J_ +_ )'#5O\ M_\ _2R.@9]54"/G#]KWQ0]\+3P_:9:XNIHW90Q0
M%=QCA0Y 1@\A)Y;"F,$CE2 9:M/V9=5LT6*+7[I$10JJJRJJJ!@* +K  '
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MT_#GB.;P],MQ;MAAP0>58=U8=P?\""" 0 ?3/@OQI#XKA\V+AA@21DY9#_4'
M^%N_L00 #H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /+OVF_P#D7[O_ +=__2B*@#S?]AC_ )B/_;I_[<4 ?55
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MJ)+@-EOF#%2Y;DD *. #I?@;^TS=S7O]E:_EI))A'')Y8C>.7(3R9$15X+<
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M@ H * "@ H * "@ H * "@#Y5^ 7_(X:M_V__P#I9'0,^JJ!!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'E7P,^.?\ PM3[3_HWV?[/Y/\ RU\W
M=YGF?],TQC9[YSVQR#/5:!!0 4 % 'FNM?\ (4'_ %UA_DE STJ@04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/6I?LK7+7]SJ-GJLEJ]Q-,
MY\J)E8+)(9"A9+A2P!QV ) .*!DW_#.&L?\ 0PWGY3?_ "70!U6H? S^T=?3
MQ!/<^8D>W9;/%N5=L11=KF0@8D)E&$X?D<_-0!ZK0(YKXD>!T\<Z?/ITCF,3
M*N'4 E65E=#@]1N49&02,@%2<@ YKP;\()/#^BSZ%)=>:LD=Q'')Y(3RUF4@
MC:'._#LSY+ G=MR !0,\ZT3]D^_T%#%9ZW/ A8L5BCDC4L0 6(2Y S@ 9ZX
M]* -71/V1K224W6L74]_,6.XLQC5EV!%#?,\I*XR")%& HQ@'(![K:6B6:+%
M$H1$4*JJ JJH& H X  X ' % B6@#E/BEX%_X3O3IM-\SRO-\O\ >;=^-DB2
M?=W+G.W'48SGVH&'PM\"_P#"":=#IOF>;Y7F?O-NS.^1Y/N[FQC=CJ<XS[4
M<KX!^!G_  B6L7>L_:?,^U>?^Z\K9L\V99?O^8V[&W'W1G.>.E 'JM @H *
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M2T % !0 4 % !0 4 % !0 4 % !0!Q'QJ_Y!-Q_VR_\ 1T= SY9H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * -/PYXCF\
M/3+<6[88<$'E6'=6'<'_  (((! !],^"_&D/BN'S8N&&!)&3ED/]0?X6[^Q!
M  .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M[97NF0:5'+F\ACGDDCVN-JFX8@[BH0_ZQ> Q//3@X /=:!!0 4 % !0 4 %
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M[20*UO'&S(&!W,AD%N8T3.5.X"1]K88 J%H ]5^#NH:[NN+3Q B%H?+,,Z*
M)@SS!FRA"<;%PNQ'"D%URP) /+[+XD:W\9KVXM=$GCL]/@8JTX!,K1N=BN-R
M[PY57= @BV_=>0,%:@"IXVT/Q-\'(FU&#4C>VJM#YPGRS#YRH&V5I"$)958Q
MR*Y+= %W  ]P\#_%>U\4Z7_;&?+B2.1IU)\QHC&"9 =F2< ;EX#,A5MHW8H
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M +"RNBB>1 S*1RRA,.Q5B"0NS<&(- 'G7AWX>^)/B5&NJ7FJO9)-&KPQ6^_
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M 4 % !0 4 % !0!Q'QJ_Y!-Q_P!LO_1T= SY9H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#3\.>(YO#TRW%NV&'!!Y
M5AW5AW!_P(((! !],^"_&D/BN'S8N&&!)&3ED/\ 4'^%N_L00 #H* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#R[]IO\
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MZ /5/A/_ ,@?3_\ KPM/_1*4 > ?'W_D<-)_[</_ $LDH /VY_\ F'?]O?\
M[;T ?55 CFOB;=O9Z5?2Q,4=+*Y964E65A$Y# CD$'D$<@T >2_L5?\ ('G_
M .O^3_T3!0,]4^+'_('U#_KPN_\ T2] 'DO[&MHEYHES%*H='O9E96 964P0
M J0>""."#P10!BW/PD\0_"'?+X=G^TV9D$CV[*ID^7<2-K#YLHJJS0LDLA(
M0;5( /1?@E\>!\0'EL;J$VU_ N9(_FVL%*I(PW %")#@QMDJ",,_S;0#P7PW
M;ZQK?BC4QH]RD5T)+L-)-\X\I+A$$8W1R],(%&!A5P"!P0#U7_A#?'/_ $$[
M/_OA/_D.@#:_9Q^"5S\,4N3>2QN\[186+<558P^"6=4)),AXVX  .3G  /9:
M!'RA^T1:)>>+=+BE4.CK8JRL RLINY05(/!!'!!X(H&?5] CX[^(8U'5/&K0
MZ9.([I518'E^:.-?L>]U *2  AGX"D;F)X))H&>B_P#"&^.?^@G9_P#?"?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@, X!QD$9Z9!]* #]KOP]<Z]I4,5G#).XO8V*Q(TC!1%,"Q" G&2!GIDCUH
M]+^&5H]GI5C%*I1TLK965@596$2 J0>00>"#R#0(^</">GZM\!M0O(+;3IK^
MTGV&-XQ(QVJS^42\<3*&"LPD0H#NPRD)@N#/I3P%XDF\2V45W<V[VDK[]T$F
M[>FUV49W(AY ##*C@CKU((Z"@ H * /-=:_Y"@_ZZP_R2@9Z50(* "@ H *
M"@ H * "@#R_]H'XNO\ #2R2:W6-[B68(B2$XV@%G?:I5F P%." "ZDG^%@9
MZ+I/G>3']JV>?Y:>;Y>[R]^!OV[OFV[L[<\XQGF@1PNO_M"Z'H$[VEQ=A98V
MVNJQS2 -W7='&RY'0@'(.5.""*!FAX.^-&D>,I#!8W2/+V0AXG;AC\JRJA?
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M H * "@"AK__ ![R_P#7*3_T$T#.3^%__+;_ +9_^ST =W0(* "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % &GX<\.3>(9EM[=<L>23PJCNS'L!_@ "2 0#Z9\%^"X?"D/E1<L<&2
M0C#.?Z ?PKV]R22 =!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 >7?M-_\B_=_P#;O_Z414 >;_L,?\Q'_MT_]N* /JJ@
M04 ? '[+G_(Q6?\ V\?^D\M S[_H$% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 >:Z+_R%#_UUF_D] STJ@04 % !0 4 % !0 4 % !0 4 %
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MXW8C &6R,DG ,^BJ!!0 4 % !0 4 % !0!0U_P#X]Y?^N4G_ *":!G)_"_\
MY;?]L_\ V>@#NZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q'QJ_Y!-Q_VR_]'1T#
M/EF@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H T_#GAR;Q#,MO;KECR2>%4=V8]@/\  20" ?3/@OP7#X4A\J+EC@R2$89
MS_0#^%>WN220#H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \N_:;_Y%^[_ .W?_P!*(J /-_V&/^8C_P!NG_MQ0!]5
M4""@#X _9<_Y&*S_ .WC_P!)Y:!GW_0(* "@ H * "@ H * "@ H * "@ H
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M"T6Y3-PCYW1E1%,!D[,*7#. J$C>09VOP?\ VGAXFN?[,U>(6MYN**?F6-Y
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M+0(^6O@!=NOBW6(@Q",UZS+D[2RW:A6(Z$@,P!Z@,<=30,^I:!!0 4 % !0
M4 % !0!0U_\ X]Y?^N4G_H)H&<G\+_\ EM_VS_\ 9Z .[H$% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '$?&K_D$W'_ &R_]'1T#/EF@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#3\.>')O$,RV]NN6/))X51W9CV
M _P !) (!],^"_!</A2'RHN6.#)(1AG/] /X5[>Y)) .@H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \N_:;_ .1?
MN_\ MW_]*(J /-_V&/\ F(_]NG_MQ0!]54""@#X _9<_Y&*S_P"WC_TGEH&?
M?] @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M=[[6;&Y@B\(&8_,P' _2@1:TO5H=7C6>VD26)L[7C970X)!PRD@X((..X(H
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M"3"[2!"PVDA)&CW8/(!*DC.#@C(!R  9_P 6/^0/J'_7A=_^B7H&>5_L5?\
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MH&?+- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M :?ASPY-XAF6WMURQY)/"J.[,>P'^  )(! /IGP7X+A\*0^5%RQP9)",,Y_H
M!_"O;W))(!T% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!Y=^TW_P B_=_]N_\ Z414 >;_ +#'_,1_[=/_ &XH
M ^JJ!!0!\ ?LN?\ (Q6?_;Q_Z3RT#/O^@04 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ML7R/E.XGY0%^Z  "/*M4_8VT6]D:2-KF%3C$<<BE%P .#+'(_.,G+'DG&!@
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M\_*;_P"2Z /?Z!!0 4 % !0 4 % 'RK^W/\ \P[_ +>__;>@9]54""@ H *
M"@ H * "@ H XCXU?\@FX_[9?^CHZ!GRS0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 :?ASPY-XAF6WMURQY)/"J.[,>P'^  )(!
M /IGP7X+A\*0^5%RQP9)",,Y_H!_"O;W))(!T% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >7?M-_P#(OW?_
M &[_ /I1%0!YO^PQ_P Q'_MT_P#;B@#ZJH$% 'P!^RY_R,5G_P!O'_I/+0,^
M_P"@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKHO\ R%#_
M -=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!YKK7_(4'_76'^24#/2J!!0 4 % !0 4 % !0 4 <U\0
M_A_;>/K1K&\R$9D8,NWS$93D,I=6"DC*DXSM9AWH U?#VB)H-M#9Q$E((8XE
M+8+%44("< #.!S@ 9["@#0H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H X_XH?"^V^(]LMG>-(B),LH,156
MW!70 [T<8PY[9SCF@9U=I:)9HL42A$10JJH"JJ@8"@#@ #@ < 4"): "@ H
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M/_2R2@9]54"/E#]J7XCW_A#6[5K.>1$2VAE,(DD6%V$\N0Z(RA@0H5NY7C-
MSI?"'[.NJ7-Y:ZYJFHO]L219'B"E]J[RS0"02JJJ59E947RQN95#+R0#M?BM
M\/\ 6O%UU$ECJ'V*Q$8,GEEA/YH\SYAL"%E(*@J90O!;:2!D \O\??LK)X-M
MI-4T6\GBFM8993O8;BJKE@DD*QLAV;QT8.2%)49- 'L'P!^(;^/=)BNIV#7"
ML\4Y52@WJ>#CIDQE&.WY<L0 N-H /&M;U;4/CKK%QIVGW;V^F6\;HTD>XQR
M_(V[RWVR^8V?+#.JF%2P&[>& -N__9JU#P*3=>%KZ1'V_/!,4(D(63N%$3'Y
M@$61,*27\Q>, &)^W/\ \P[_ +>__;>@#TKXS_&>31)%T;1E\_5I\!5 #"$$
M9WMGY=VWY@&^55_>280 . =7\*/ MQX1M0E[=37=T^#*\DLDB*>R1AR<*,]<
M!G/+8&U% .UH$% !0 4 % !0 4 <1\:O^03<?]LO_1T= SY9H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H T_#GAR;Q#,MO;KECR2>%
M4=V8]@/\  20" ?3/@OP7#X4A\J+EC@R2$89S_0#^%>WN220#H* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /+OVF_^1?N_P#MW_\ 2B*@#S?]AC_F(_\ ;I_[<4 ?55 @H ^ /V7/^1BL
M_P#MX_\ 2>6@9]_T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /-=%_Y"A_ZZS?R>@9Z50(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#S76O^0H/^NL/\DH&>E4""@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *&O_\ 'O+_ -<I
M/_030,Y/X7_\MO\ MG_[/0!W= @H * "@ H * "@ H ^0/V-?"=GX@^W_;;>
M&?9]EV>;&DNW/G[L;P<9P,XZX'I0,^FK3X9:59NLL5C:HZ,&5EMXE96!R&!"
M9!!Y!'(- CSKX_\ QGNO"<UMI6DJCWUWP"X^X'/E1%=VV,LTF<%F*KL^="&!
M ,M:7X \42QJ;G6T27G<L=E!*@Y.,,PB)XP3E1@Y'.,D \U_88_YB/\ VZ?^
MW% 'HOQ5_9W'B>Z;5M-N9+/4=H^=68(Q6,QCE2'C)7:I920%!_=LQ)(!Q7@G
MXNZUX"U.#0?$*B83,B13*5:7#OY,3[@1O0LASY@$WS%V)("$ V_VU?\ D#P?
M]?\ '_Z)GH ]4^$__('T_P#Z\+3_ -$I0!U= @H ^5?C[_R.&D_]N'_I9)0,
M^JJ!'RK\??\ D<-)_P"W#_TLDH&?55 CP7XN?&#47U:/PYH'EK<NJ^9,XR8V
M(\W #C9@1#<QQ(6#;4 =>08>-_ WB"#2KJ6\U@.%LIVFA6S@"L!$Q>,2?*V#
MRH?:#CG:#Q0!%^Q5_P @>?\ Z_Y/_1,% '*?L,?\Q'_MT_\ ;B@#ZJH$?*O[
M<_\ S#O^WO\ ]MZ!F?;%_P!GWQ#NNW,UC>JQ:Y>,R3[68DY? )=9-IE"%@Z$
M.4WE%4 ^M;2[2\198F#HZAE92&5E(R&!'!!'((X(H$2T % !0 4 % !0 4 <
M]X_@6>RE5P&!V9!&1]]>QH&<IX'\*6=S"Q>WA8^81DQH3]U?44 =#_PA5C_S
M[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$
M*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T
M'_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@
M _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1
M_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?
M]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^
M_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C
M_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"
MK'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\
M"%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\
M^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__
M !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^
MH_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\
MGV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S
M[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$
M*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T
M'_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@
M _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1
M_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?
M]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^
M_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C
M_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"
MK'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\
M"%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\
M^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__
M !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^
MH_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\
MGV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S
M[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$
M*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T
M'_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@
M _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1
M_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?
M]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^
M_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C
M_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"
MK'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\
M"%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\
M^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__
M !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^
MH_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\
MGV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S
M[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$
M*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T
M'_"%6/\ S[0?]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@
M _X0JQ_Y]H/^_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1
M_P#Q- !_PA5C_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?
M]^H__B: #_A"K'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^
M_4?_ ,30 ?\ "%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C
M_P ^T'_?J/\ ^)H /^$*L?\ GV@_[]1__$T '_"%6/\ S[0?]^H__B: #_A"
MK'_GV@_[]1__ !- !_PA5C_S[0?]^H__ (F@ _X0JQ_Y]H/^_4?_ ,30 ?\
M"%6/_/M!_P!^H_\ XF@ _P"$*L?^?:#_ +]1_P#Q- !_PA5C_P ^T'_?J/\
M^)H /^$*L?\ GV@_[]1__$T 7=.T2#3,_9XDCW8W;$5,XSC.T#.,G'UH NT
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % 'EW[3?\ R+]W_P!N_P#Z414 >;_L,?\ ,1_[=/\ VXH ^JJ!
M!0!\ ?LN?\C%9_\ ;Q_Z3RT#/O\ H$% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 >:Z+_ ,A0_P#76;^3T#/2J!!0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:ZU_R%!_UUA_DE ST
MJ@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!0U_P#X]Y?^N4G_ *":!G)_"_\ Y;?]L_\ V>@#NZ!!0 4 % !0 4 % !0!
MX!^RE\+=1\"?;?[2A\KS?LWE_/&^=GG;O]6[8QN'7&<\=Z!GO] CPK]H;X,7
MOB2XM]9TALWUMY86(E "$D,B.I?"[E9B2'.UEZ8*[7!D4VH>,O% 6RDMH+!)
M5VS7:.KN@W,6>-5G9E)3" 88[LL)(\@H 1?LI?"W4? GVW^TH?*\W[-Y?SQO
MG9YV[_5NV,;AUQG/'>@"_P"(=3\9:)<S)9P6MY;O-(\+L55HXRQ"0G][;Y*J
M 2</RW^L;H # T+X5ZUX]UF#6/$,4=H+-8O+2%E8R-'(TJ#B6;: QRY)!(PJ
MC)+J >J_&GX9CXC:<]D"%E#+)"[;MJR+D#.T]"I9"<-M#;@I*@4 >:?#.[\8
M:$+2PN+* VD30Q/*SQ&580P4G]W< $K'P,(2<#(9LD@'T+0(* / /B]\+=1\
M0>)-.U*UAWVL'V3S9-\:[=ER\C_*SACA2#P#GH,GB@9[_0(\ ^+WPMU'Q!XD
MT[4K6'?:P?9/-DWQKMV7+R/\K.&.%(/ .>@R>*!GO] CYZ^+GP?U2TUB/Q'H
M&);@LOF0N8P!B+RL@N4!1HQM89#J3N0\_NP9%XJM/%_CZWELI[>&Q@,#%C'(
MCRS,L?\ J 1,P599.N=H5,JSN 1( =5^R_X"O?!&FRVVH1>5*UV\@7<CY4QQ
M*#F-F'52,9SQTZ4 <5XZ^"NL>&=8?7?#>Q_-DW/ 7VDE\M,'$C!7B9AN.'#*
MS#8J[%< %N\L/&OCEEMKCR=,@ZR2PN-[#>G *2RR;@ 2 K1*PW*[X(% %O\
M:M^%NH^._L7]FP^;Y7VGS/GC3&_R=O\ K'7.=IZ9QCGM0!ZI\3_AY#\0+&2P
MG.W=ADD"JS1NIRK@'\5;!!*%E##.: . _9T\/ZWX.632=3@3['%YAMYUDC/)
MDR4VJ=Y5MQ=2ZJR\JW550 ]JH$% !0 4 % !0 4 8/CG_CSD_P" ?^AK0,QO
MA_\ ZAO^NA_]!6@#IJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H \N_:;_Y%^[_[=_\ THBH \W_ &&/^8C_ -NG
M_MQ0!]54""@#X _9<_Y&*S_[>/\ TGEH&??] @H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#S71?^0H?^NLW\GH&>E4""@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \UUK_ )"@_P"N
ML/\ )*!GI5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@"AK_\ Q[R_]<I/_030,Y/X7_\ +;_MG_[/0!W= @H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H P?'/_'G)_P  _P#0UH&8WP__ -0W_70_^@K0!TU !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M >7?M-_\B_=_]N__ *414 >;_L,?\Q'_ +=/_;B@#ZJH$% 'P!^RY_R,5G_V
M\?\ I/+0,^_Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F
MNB_\A0_]=9OY/0,]*H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!YKK7_ "%!_P!=8?Y)0,]*H$% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4-?_P"/>7_KE)_Z
M":!G)_"__EM_VS_]GH [N@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8/CG_CSD_X!
M_P"AK0,QOA__ *AO^NA_]!6@#IJ "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \N_:;_Y%^[_ .W?_P!*(J /-_V&
M/^8C_P!NG_MQ0!]54""@#X _9<_Y&*S_ .WC_P!)Y:!GW_0(* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \UT7_D*'_KK-_)Z!GI5 @H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-=
M:_Y"@_ZZP_R2@9Z50(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H H:__P >\O\ URD_]!- SD_A?_RV_P"V?_L] '=T""@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#!\<_\><G_ /_ $-:!F-\/_\ 4-_UT/\ Z"M
M'34 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!Y=^TW_R+]W_ -N__I1%0!YO^PQ_S$?^W3_VXH ^JJ!!0!^>W[.&
MK0Z1KMI/<R)%$OG[GD9409@E RS$ 9) &>Y H&?;W_"V-'_Z"%G_ .!,/_Q=
M !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,
M/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_
M .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z
M"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V
M-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T
M'_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P_
M_%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\
MX$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(
M6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T
M?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?
M\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\
M70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@
M3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9
M_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_
M^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_P
MMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q=
M 'G^D?$73(]1,AO+8)YLQW&>(+@A\'.[% 'H'_"V-'_Z"%G_ .!,/_Q= !_P
MMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q=
M !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,
M/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_
M .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z
M"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V
M-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T
M'_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P_
M_%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\
MX$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(
M6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T
M?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?
M\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\
M70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@
M3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9
M_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_
M^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_P
MMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q=
M !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,
M/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T >?ZO\1=,DU$2
M"\MBGFPG<)XBN $R<[L4 >@?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,
M/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_
M .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z
M"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V
M-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T
M'_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P_
M_%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\
MX$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(
M6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T
M?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?
M\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@3#_\
M70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9_P#@
M3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_^@A9
M_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_PMC1_
M^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q= !_P
MMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,/_Q=
M !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_ .!,
M/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T '_"V-'_Z"%G_
M .!,/_Q= !_PMC1_^@A9_P#@3#_\70 ?\+8T?_H(6?\ X$P__%T 4];^*FD2
M02JM_:$F)P +B$DG:>/OT <Q\.?B3I=IYOF7MJN=F-T\2YQNSU:@#L_^%L:/
M_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+
MH /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L_
M_ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&
MC_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\
MBZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+
M/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6
MQH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!"S_\"8?_
M (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^%L:/_P!!
M"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'_P"+H /^
M%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\ 00L__ F'
M_P"+H /^%L:/_P!!"S_\"8?_ (N@ _X6QH__ $$+/_P)A_\ BZ #_A;&C_\
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M /%T '_"U-(_Y_[3_P "(?\ XN@ _P"%J:1_S_VG_@1#_P#%T '_  M32/\
MG_M/_ B'_P"+H /^%J:1_P _]I_X$0__ != !_PM32/^?^T_\"(?_BZ #_A:
MFD?\_P#:?^!$/_Q= !_PM32/^?\ M/\ P(A_^+H /^%J:1_S_P!I_P"!$/\
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M_P#:?^!$/_Q= !_PM32/^?\ M/\ P(A_^+H /^%J:1_S_P!I_P"!$/\ \70
M?\+4TC_G_M/_  (A_P#BZ #_ (6II'_/_:?^!$/_ ,70 ?\ "U-(_P"?^T_\
M"(?_ (N@ _X6II'_ #_VG_@1#_\ %T '_"U-(_Y_[3_P(A_^+H /^%J:1_S_
M -I_X$0__%T '_"U-(_Y_P"T_P# B'_XN@ _X6II'_/_ &G_ ($0_P#Q= !_
MPM32/^?^T_\  B'_ .+H /\ A:FD?\_]I_X$0_\ Q= !_P +4TC_ )_[3_P(
MA_\ BZ #_A:FD?\ /_:?^!$/_P 70 ?\+4TC_G_M/_ B'_XN@ _X6II'_/\
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M/^?^T_\  B'_ .+H /\ A:FD?\_]I_X$0_\ Q= !_P +4TC_ )_[3_P(A_\
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MII'_ #_VG_@1#_\ %T '_"U-(_Y_[3_P(A_^+H /^%J:1_S_ -I_X$0__%T
M'_"U-(_Y_P"T_P# B'_XN@ _X6II'_/_ &G_ ($0_P#Q= !_PM32/^?^T_\
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M .+H /\ A:FD?\_]I_X$0_\ Q= !_P +4TC_ )_[3_P(A_\ BZ #_A:FD?\
M/_:?^!$/_P 70 ?\+4TC_G_M/_ B'_XN@ _X6II'_/\ VG_@1#_\70 ?\+4T
MC_G_ +3_ ,"(?_BZ #_A:FD?\_\ :?\ @1#_ /%T '_"U-(_Y_[3_P "(?\
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M +3_ ,"(?_BZ #_A:FD?\_\ :?\ @1#_ /%T '_"U-(_Y_[3_P "(?\ XN@
M_P"%J:1_S_VG_@1#_P#%T ><?M$>/].U;0[J&WN[>65O(VHDT;N<3QDX56).
M "3[#- '*_L,?\Q'_MT_]N* /JJ@04 ?*O\ PPQ_U$?_ "6_^Z*!A_PPQ_U$
M?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_
M -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#N
MB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_P
MPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_
M .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);
M_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4
M '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _
MX88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U
M$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W
M_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z
M* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_#
M#'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_
MZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\
MR6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T
M4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_
M (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_4
M1_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_
M )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^
MZ* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_
M  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88
M_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\
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MHH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=%
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MZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\
MR6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T
M4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_
M (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_4
M1_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_
M )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^
MZ* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_
M  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88
M_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\
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MHH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=%
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MZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\
MR6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T
M4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_
M (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_4
M1_\ );_[HH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_
M )+?_=% !_PPQ_U$?_);_P"Z* #_ (88_P"HC_Y+?_=% !_PPQ_U$?\ R6_^
MZ* #_AAC_J(_^2W_ -T4 '_##'_41_\ );_[HH /^&&/^HC_ .2W_P!T4 '_
M  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=% !_PPQ_U$?_);_P"Z* #_ (88
M_P"HC_Y+?_=% !_PPQ_U$?\ R6_^Z* #_AAC_J(_^2W_ -T4 '_##'_41_\
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MHH /^&&/^HC_ .2W_P!T4 '_  PQ_P!1'_R6_P#NB@ _X88_ZB/_ )+?_=%
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H S];\0VV@H);R:.!"P4-
M*ZQJ6()"@N0,X!..N ?2@"+0O%EGX@W?8KB&?9C?Y4B2[<YVYV$XS@XSUP?2
M@#5H * "@ H * "@#*\5>)H?"]K+?7)Q%#&SMRH)QT5=Q4%F.%4$C+$#O0!R
MGPH^-=G\3?.^Q),GD>7O\U47._?MQLD?^X<YQVZT#/0*!!0 4 % !0 4 % !
M0 4 % !0 4 % !0!%=W:6:-+*P1$4LS,0JJH&2Q)X  Y)/ % ''^"OC-I7C>
M9K;3[CS95C,A7RYDPH*J3F1%'5@,9SSTZT#.UH$% !0 4 % !0 4 % !0 4
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M& 2 2"PR"-#PMXIM_%5NE[9/YD$F[8^UESM8HW#A6'S*1R/TH U: "@ H *
M"@ H * "@#FOB'\0+;P#:-?7F2BLBA5V^8[,<!5#LH8@98C.=JL>U %3X7_%
M"V^(]LUY9K(B),T1$H56W!4<D;'<8PX[YSGB@9V% @H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#SKXJ?':P^&CQ17@D=Y59@L0C9E4$ ,P>1" Q
M)"GD$JWI0,[7P]K::];0WD0(2>&.50V P5U#@'!(S@\X)&>YH$:% !0 4 %
M!0 4 % !0!GZ_K\'AZ![N[<1PQKN=VZ =.W)).  ,EB0 "2!0!XK=_MGZ- [
M(L=TX5B ZQQA6 . PWS*V#U&X XZ@'B@9[5X>UM->MH;R($)/#'*H; 8*ZAP
M#@D9P><$C/<T"-"@ H XKXI?%NS^&L,<][O;S9-B)'L,AP"6;:[IE1P&(S@L
MH[T#-7P%XUA\;V46H6RNL4N_:) H<;7:,Y"LPZJ<8)XQ]*!'04 % !0 4 %
M%35-6ATB-I[F1(HEQN>1E1!D@#+,0!DD 9[D"@#G_P#A;&C_ /00L_\ P)A_
M^+H&;>B>(;;7D,MG-'.@8J6B=9%#  E24)&<$''7!'K0(B\5>)H?"]K+?7)Q
M%#&SMRH)QT5=Q4%F.%4$C+$#O0!RGPH^-=G\3?.^Q),GD>7O\U47._?MQLD?
M^X<YQVZT#/0*!!0 4 % !0 4 % !0 4 % !0!E:[XLL_#^W[;<0P;\[/-D2+
M=C&[&\C.,C..F1ZT <_X9^-.C>)<"UO(2S2"-4=O)D9CC 5)0CMG( (!!/ .
M010,[6@04 96N^++/P_M^VW$,&_.SS9$BW8QNQO(SC(SCID>M &3_P +8T?_
M *"%G_X$P_\ Q= SIK2[2\198F#HZAE92&5E(R&!'!!'((X(H$9^N^++/P_M
M^VW$,&_.SS9$BW8QNQO(SC(SCID>M &3_P +8T?_ *"%G_X$P_\ Q= S0T3Q
MO8:\YBL[J"=PI8K%+'(P4$ L0C$XR0,],D>M C;H YJ[^)NE6;M%+?6J.C%6
M5KB)65@<%2"^00>"#R#0!TM %35-6ATB-I[F1(HEQN>1E1!D@#+,0!DD 9[D
M"@"KH7BRS\0;OL5Q#/LQO\J1)=N<[<["<9P<9ZX/I0 :[XLL_#^W[;<0P;\[
M/-D2+=C&[&\C.,C..F1ZT 6M+U:'5XUGMI$EB;.UXV5T."0<,I(.""#CN"*
M+= !0 4 % !0!PMS\<='MKW^S&N@;HS+%L5)7'F,0H3>J%,[C@_-\IR&P0<
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ML#C)Q@$@$@L,@&AX6\4V_BJW2]LG\R"3=L?:RYVL4;APK#YE(Y'Z4 :M !0
M4 % !0 4 % '"_$SXTZ=\.0!>N3*R[DAC&^5EW!=V"0JCK@NRAMK!=Q!% SF
M? 7[4&F^-[V+3[:*Y667?M,B1!!M1I#DK*QZ*<8!YQ]: /8*!!0 4 % !0 4
M % '-?$/X@6W@&T:^O,E%9%"KM\QV8X"J'90Q RQ&<[58]J *GPO^*%M\1[9
MKRS61$29HB)0JMN"HY(V.XQAQWSG/% RKH/QQT?7[L:=:70DN&9U5524J2@9
MFP^SRR,*2"&P1]TG(H [J@04 % !0 4 % !0!%=W:6:-+*P1$4LS,0JJH&2Q
M)X  Y)/ % 'A^J?MDZ+92-'&MS,HQB2.-0C9 / EDC?C.#E1R#C(P2#/5? 7
MC6'QO91:A;*ZQ2[]HD"AQM=HSD*S#JIQ@GC'TH$=!0 4 % !0 4 9^OZ_!X>
M@>[NW$<,:[G=N@'3MR23@ #)8D  D@4 8G@7XI:=X[\S^S9O-\K9YGR2)C?N
MV_ZQ%SG:>F<8Y[4#.KH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 8GB_QI:>#H#=W\HBB#*NX@DECT4*H+
M,>IP 2 "QX!( (O!7CVR\;PM<Z?+YL2R&,MM=,, K$8D53T8'.,<]>M '04
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M),GD>7O\U47._?MQLD?^X<YQVZT#/0*!!0 4 % !0 4 % !0 4 % !0 4 %
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M':B@N^-PSM!V@Y.!S0(Y72_VD= U.188[U S9P9$EA3@$\O*B(.G&2,G ')
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MCA6!!!4D,.XY% S5\%?%/3/&^X:?<)*RYRGS)( -N6V2!7V_,!NQMR<9SD4
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MG8X51RS!47HM $5M\7M)N;+^TUNHQ:AF7>Q*'>H+&/8P#[]HR$V[F&"H((R
M5?"'QQT?QA.+2QN@\Q5F"%)8R0.3CS$4,0.<#)P"<8!( .ZH$>?^)OCYHGAJ
M8VUU=H)5SN5%DFVD$J58Q(X5@005)##N.10,U?!7Q3TSQON&GW"2LN<I\R2
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M"-V-PY&<&@8>#OC1I'C*0P6-TCR]D(>)VX8_*LJH7P%).W.T<G&10!VM @H
M^2X/V4]4\=S3:CK-PEK//(7\M0;EADL-I/FA555"B,!Y,)@':5Q0,\*^*7@7
M_A!-1FTWS/-\KR_WFW9G?&DGW=S8QNQU.<9]J /N_P"!FMW.MZ+9W%Z")FAP
M2V[<RJS)'(=Y+$N@5RV<,6W#@B@#NJ!'Q+^V7KXO]72W1RPM[9%9/FVI([-(
M< \9,9C)*]0 "<K@ SIO^&'9O)W?;D\_R\[/);R]^/N[_,W;=W&[9G'.S/RT
M <?^R3XQN=.UB*Q1R;>X6</&6;8&$1D\P*&"A_W2KN()VDCT( +7[9>OB_U=
M+='+"WMD5D^;:DCLTAP#QDQF,DKU  )RN  =7:?L-.R*9=0"N5&Y5MRZAL<@
M,9E+ 'H2JDCG Z4 >M?!#X!P_"[SI/-^T3S;5\PQK'M0<[%&YV&6Y;YL-A/E
M!7) )?VAOBJ?AYIQD@8"[F;RX 0K8/5Y-I(R%7OA@'9 RE2: /A;4_"$^F6E
MM?R@"*Z:<1<Y8B$JKL0.@W-@9.25)P!M+ 'Z$_!V[2ZT:P:-@P%E;J2I!&Y8
MU1UX[A@5(Z@@@\B@#RK]M/7Q::9!:!RKSW(8H-P#QQHQ?./E(#M&<'J<$ [<
M@ J_L[Z_!\-_#+:EJ#A8IKF:2-5YD8X6$1A3C+EH6( . OS,R@,5 /&K?2]0
M_:(UB2=5\J/Y=[$L\5O$.%49(RQP2%&W>Y=L(NXJ ?;_ (5\,P^%[6*QMAB*
M&-47A03CJS;0H+,<LQ &6)/>@0>*?%-OX5MWO;U_+@CV[WVLV-S!%X0,Q^9@
M.!^E 'QAKGQ]FU'Q"+N.[GBTT7L&466;RC#&R*[^6,<.JERFW/S%2">H,^O_
M  /\2-/\<H\FG3B81L%<8=&4D9&5=5;!YP<8)! )*G (S]'^-.C:PTRPWD)^
MSX\UF;RT +[ P=PJNNX@;D++EEY^9<@RUX%^*6G>._,_LV;S?*V>9\DB8W[M
MO^L1<YVGIG&.>U 'D'@OP%X8\3:Y)=V5W-<7D<\MTT>2( PESN5A"@95D=2N
MV1@W&=RYR >Z^)O%5KX7A-S?2I#$,_,YQD@%MJCJS$*2%4%CC@&@1RGAGX^:
M)XEF%M:W:&5L;5=9(=Q)"A5,J(&8D@!02Q[#@T#-70/BEIWB"\FTVUFWW4'F
M>;'LD7;L<1O\S(%.&('!.>HR.: /FO\ ;>UWSKRSLMN/*@DEWYZ^:^S;C'&/
M)SG)SNZ#'(!]'_!_0!H&D65N$,96VB9T;<&$CKYDN0W(/F,Q(['@  8H ["@
M1\Z^*? 7ACQUK[QSW<SZ@\BA[="?))AB&Z,N(3CY(R' D#!MR@JPP 9[?XO\
M:6G@Z W=_*(H@RKN())8]%"J"S'J< $@ L> 2 1E:E\7M)TVTCU&6ZC6WF7=
M$V26<9"MM0 R,5+ . N4.=X7!P##P/\ %W2_'+O%IUP)7C4,R[9(VVDXW 2*
MI8 \$C(!(SC<,@'84"*FK:I'I$,ES.VV**-Y';!.%4%F. "3@ G !/H* /S!
MN?.O]]U)O?,@\R5MS9=]S#<QS\S;6/)RV&/.#0,^[_V7/%Y\2:)"')+VS-;L
M2%4$( 8P-O4")D7) )(.<_>(!\]?M*^=XN\3C3UV*P^R6T1.X#]X%D!<_-_'
M,<D#[H'!/) /H7]J;7QI&@W"[RCSM%$FW<"Q+AG3*] 8E?.< C*G.<$ ^:O@
ME^SB_P 3K:6\-R($2;RE'EF5F8*KL3\\848=<<DDYR!@9 /6O"O[%D.DW45Q
M<WGGQ1R*[1?9U4/MY"L6DD&TD#<"IW+E>,Y !](7=VEFC2RL$1%+,S$*JJ!D
ML2>  .23P!0(^ /&^MW?QIU&ZO(@!%;VT\JAL)LMH=S@'!8LY+<X+?._58Q\
MH,]5_8:NT5]0B+ .RVS*N1N*J9@S =2 64$] 6&>HH ^KZ!!0 4 <UXX^)&G
M^!D2349Q")&*H,.[,0,G"HK-@<9., D D%AD VM)U2/5X8[F!MT4L:2(V",J
MP#*<$ C((." ?44 <K_PNC2/MW]E?:D^U^9Y>S#[=^/N;]OE[L_+MW9W_)C?
M\M SI=?U^#P] ]W=N(X8UW.[= .G;DDG  &2Q( !) H$8G@7XI:=X[\S^S9O
M-\K9YGR2)C?NV_ZQ%SG:>F<8Y[4#/C;X/W$?B[Q.-0N(]L'GW5Y)ECLA"B29
M'=QM 59-F6;"DX!&#B@#ZJ_X:1T#SOL_VU-_F;,[)?+SG;GS-GE[<_Q[MF/F
MW8YH ]*H$?.O@OP%X8\3:Y)=V5W-<7D<\MTT>2( PESN5A"@95D=2NV1@W&=
MRYR#.*_;>UWSKRSLMN/*@DEWYZ^:^S;C'&/)SG)SNZ#'(!]'_!_0!H&D65N$
M,96VB9T;<&$CKYDN0W(/F,Q(['@  8H B\8_&C2/!L@@OKI$E[H \KKPI^98
ME<ID,"-V-PY&<&@ \'?&C2/&4A@L;I'E[(0\3MPQ^5950O@*2=N=HY.,B@#M
M:!!0!Q7C'XT:1X-D$%]=(DO= 'E=>%/S+$KE,A@1NQN'(S@T#"W^-&D7-E)J
M4=TC6T6WS& <NFY_+3=&%\U<MTRHR/F'R\T =!X6\4V_BJW2]LG\R"3=L?:R
MYVL4;APK#YE(Y'Z4"/B7X*(/'7BI+MX3L>YN+IE!9A&?GEC)90O"RE!DX#'
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MZ'KS@G!R#R"*!FKXE^-&D>&HX9[FZ3RKCS/*>,/.C^60'PT*N."0#GOD=C@
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M6(*]2 "#0!VM CA?C8-.FTN6'6)S!:R-$K.O^LW!U=54;)"QRG("D[0QX )
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M@<G'F(H8@<X&3@$XP"0 =5K^OP>'H'N[MQ'#&NYW;H!T[<DDX  R6)  )(%
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M02KG<J+)-M()4JQB1PK @@J2&'<<B@9;U#XT:186::D]TAM7D6,2('DP[(9
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MR03DDC V\@'O6@:):>'/#"6U^3:VYT[%P6R'1IH_WW#AB',DC83!.XA57HM
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M::3*PW=S;!]I&YBLL$9VC=C<Y ZD+GDX!- 'NO[:O_('@_Z_X_\ T3/0!?\
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MD8(39N!.UMS88CS,[6 !X?\ LC^)IM,UN.UC/[JZCE2126Q\D;RHP (&X%,
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MA!&PMG89#G<H^4#KP0#SK]GC]GBS^(]G+>WLLR[9S$B1%%^ZB.S$NCYSO
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ME3F.@#BOV</V<+7Q;:C5-4#M&TCB&$-L1U7*,[%#O^_D  H04R=RL!0!Y_\
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M96E9T.0: .%^ G[,:^.[<ZAJ$CQVS[A"L13S'*L59R65PJ@@J!C<QR?E4#>
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M!D<84@Y /HJ@1\=_MN:V\U_:V9 V1VS2J>=VZ61D8'G&,0KC@').2>, S:\
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MAHV(;<[.9-JA?D"(,A02 ??_ (%\"VO@>U2RLDVQKR2>7=CC=(YP,L<<G@
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MO% 8S]HF"[D5?OHK#>@;=(BX7.<C> 0A( -O]HKX3V7PVN8+>RFDD,D)=TE
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M(!]*:-^SGX?NY;74M,RHAF65&@G,T4C(X(#&0RY 9"#L*GE@3D# !Y5^V/\
M%%[B==$MW(CC57N0"0'=L/&ARHR%7#\,5)<9&Z,8 .U\!_L@Z=#9#^TQ))=R
MPKO/F;!"Y!R(Q&2K%=P!+F16*[@ I*T >"_#"YF^'_B:.U@?=MOS9N2&59$:
M7R6)4-]'4$D!PI.<4 ??] CC_C!KXT#2+VX+F,K;2JCKN#"1U\N+!7D'S&4
M]CR2 ,T#/B;X(?#2Z^(LTUC!+Y%N8U:XE\O?PI_=QY&W.Y\-L+JK;-Y#-$H
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MFKX$_"N[^)Z&SEEDATN"8RL54%6F81H4&2/G\H<,0XB'\(\SY@#FOCGX!M?
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M[E@ 'VE-RYH \/\ &6FO\'M>=+&0L;2:-XV;*DJR+)L?85R"K['QM#C/"AL
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MG:H  /:K3]G/POXYMEFTW*H6!\V"=W;[N?+83&4*<,"5*JX.,XY! />J!!0
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MIRI/(SC((5V7#$ ^G_VT]?%IID%H'*O/<AB@W /'&C%\X^4@.T9P>IP0#MR
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M8$$*,;1]XEB50 \5N?A^(=9_L59PX^VK;><J,!DR",ML;:<J3R,XR"%=EPQ
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M$$,,*A ;( R 9]B_&+XJP?#FR>XD8>>ZNMO&1N+R8XR 5.Q207.1@< [F4$
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M5&"!0!]4_';XRP?#ZTD1) +^2$_9X^K9)">:?D=0%R6 ? D*%1WP > ?L6:
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M@LQRS$ 98D]Z #3[.3]H/Q&Y=G2V.YCC&Z.VCPJ *SL S$J&V[@))&?:5R*
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M32RL>=VZ)510.<8Q,V>"<@8(YR >B_LQ>%O^$?T*WW)LDGW3O\V[=O/[MNI
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M6B6:+%$H1$4*JJ JJH& H X  X ' % B6@ H * "@ H * "@ H * "@ H *
M"@ H * .:^)'A!_&.GSZ?',;<S*JF506(7<I=<!DR&4%",@$,<Y'! .*^"7[
M/,'PP>6X\XW%Q(NP/M\I5CRK%0F]\DLH)8D\ !0OS;@9ZU0(\ ^*7[*7_"=Z
MC-J7VWRO-\O]WY&_&R-(_O><N<[<]!C./>@9[5XLT+_A(+.XLMVSSX)8M^-V
MW>A3=C(SC.<9&?44"/GK0/V(X+2=)+N\,\*MEXEA\HN!_#O$S%03C.!DC(!4
MD, 9]-4"/"OC7^R_'X_N&U"UG\BY:/#JREXY&50L9SN!CX 5B PP 0FX-N!F
M5X4_8UM=(6<W-Q]HDD@DCA)AVI$SHR^:4\QM[+D%,E0IR?O;60 [KX'? Y/A
M8DX$YG>=H]S;!&H5 VT!=SG.7;)W8(P !@D@'*VW[*B+K/\ ;4EV6'VUKH0K
M$%.[S#*B[S(W ;&3MRP! VDY ![5K^@0>(8'M+M!)#(NUT;H1U[<@@X((P5(
M!!! - CY@UO]A]PX-G>@H9AE98B&2(DY(9&(D<#'&V-6.3E.E SO_A5^RI9>
M"9UO+B4W<\;$Q[D$<2'C:VS+DNI!(8M@9!"AE#4 >X4""@#YEU_]B."[G>2T
MO#!"S92)H?-* _P[S,I8 YQD9 P"6(+$&=5\'_V78/A]=_;Y;@W,J*1%\GDJ
MA8%78@2/N)4X&2  2<$[2H!H?&?]FZU^)$BW22?9KH8#R!/,$B@8 9=R98<
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MY7E!B!M#$#D@;03Z4"//_@E^SBGPQN9;PW)G=X?*4>6(E52RNQ/SR%CE%QR
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M .FB8QL]\Y[8Y -O0_A6FC:(=!CE)#6T\1E903NF#EWV@C@,Y(7.<8!8GYB
M<I\$OV<4^&-S+>&Y,[O#Y2CRQ$JJ65V)^>0L<HN.0 ,Y!R, &5\1_P!E1/'.
MJ2:G+=F-)6BW1+$"VU$2,@2&3 )"Y!*$ GHV.0#VKQ#IKZI;36\4AA>2&1%E
M7.Z-F4J'&"IRI.1@@Y'4=:!'E7P2_9Q3X8W,MX;DSN\/E*/+$2JI978GYY"Q
MRBXY  SD'(P#-#XS_L^6OQ-9;AI'@NDC$:R ;T*[]V&0D9QEL%60Y;+%@ *
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M0J!MH"[G.<NV3NP1@ #!) /)=4_8=^9C;7WRF0;5DAY"%QG++)\S!,D850[
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M!5&223@ #))/J:!'/_%+P+_PG>G3:;YGE>;Y?[S;OQLD23[NY<YVXZC&<^U
MSE?@9\#/^%5_:?\ 2?M'VCR?^67E;?+\S_IH^<[_ &QCOG@ Y7PM^RE_9VJ)
MJ][>_:76=IW3R/)W2DEU;*3$#$A#X"[3C;C!H ]?\?\ @Z/QG8SZ?,<+-&0&
MY.U@0T;X#+G:X#8R V,'@F@1YK\%/V;_ /A65X][]K\_? T6SR?*QEXWW9\U
M_P"YC&._7B@9[50(Y_Q_X.C\9V,^GS'"S1D!N3M8$-&^ RYVN V,@-C!X)H
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M\W=YGE_]-$QC9[YSVQR =A\-_ Z>!M/@TZ-S((5;+L "S,S.YP.@W,<#)(&
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MQ(  &.<E  =JG[*-K;ZO%JD$WE6\,D#I;)%C!A1 N9"YSET#.2I9LMD[COH
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MHW)1@64. SMQM /L_P""WAG_ (1K1K.U(=6$"NZR##J\F99%(P,8=R ",@
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MB55+*[$_/(6.47'( &<@Y& #*^(_[*B>.=4DU.6[,:2M%NB6(%MJ(D9 D,F
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M1<<@ 9R#D8!EOXV_L\P?$]XKCSC;W$:["^WS5:/+,%*;TP0S$A@1P2&#?+M
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M2@ .U3]E&UM]7BU2";RK>&2!TMDBQ@PH@7,A<YRZ!G)4LV6R=QWT >ZT""@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $5W;"Z1HVR RE259D;!&#AD(9
M3Z%2"#R"#0!Q7PS^"VG?#D$V2$RLNUYI#OE9=Q;;D *HZ9"*H;:I;<0#0,[J
M@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MNIXY%>(X,,:%2C(VU69F8,IZN4(."F1F@#W6@1XK\:_V;_\ A9MXE[]K\C9
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@#A?BI\9++X9I$]Z)&,S,$2)0S$* 68[F10!N4=<DL,
M@$@&;7@+QK#XWLHM0ME=8I=^T2!0XVNT9R%9AU4XP3QCZ4".@H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S_C7Q[9>"(5N=0E\J)I!
M&&VN^6(9@,1JQZ*3G&..O2@#BO\ AJ/P[_S^?^0+G_XU0,Z7PA\7M)\8$)8W
M4;N691&28Y20NXXCD"NP"\Y (X//!P =A0(* "@ H * "@ H * "@#S7XW_&
MN/X6PPR&+SY9I&"Q[S'\JC+ON\MQP2@P<$[LCH:!F_\ "WQU_P )WIT.I>7Y
M7F^9^[W;\;)'C^]M7.=N>@QG'O0!U= @H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#BOB]\3H_AO8F^D3S&\Q(XX]Q3>S')&X(^W"!FR1
M@[<9R10,J?!3XK_\+-LWO?)\C9.T6SS/-SA(WW9V)_?QC';KS0!Z!0(* "@
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M, @$D@$&1?"_XH6WQ'MFO+-9$1)FB(E"JVX*CDC8[C&''?.<\4 =A0(* "@
MH Y3XE?$JU^'EK]MO=Y0R+&JQKN=F;)P,E5'RJS$L0, @$D@$&1?"_XH6WQ'
MMFO+-9$1)FB(E"JVX*CDC8[C&''?.<\4 =A0(* "@ H * "@ H * "@ H *
M,3QIXO@\'6DM_=DB*)06VC<Q)(55 ]2Q &2 "<L0,D '-?"CXUV?Q-\[[$DR
M>1Y>_P U47._?MQLD?\ N'.<=NM SBM3_:ECM]:&B0VWF+]KBMC/YI3#,RQR
M'88OX')7[V&VY!P0: .K^-_QKC^%L,,AB\^6:1@L>\Q_*HR[[O+<<$H,'!.[
M(Z&@#?\ A;XZ_P"$[TZ'4O+\KS?,_=[M^-DCQ_>VKG.W/08SCWH ZN@1X_\
M&_\ :(C^&$T-L(/M$LD;2,OF&+8N=J'/EN&W$., @C;R.10,]+\)Z[_PD%G;
MWNW9Y\$4NS.[;O0/MS@9QG&<#/H*!&K0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % &5XF\56OA>$W-]*D,0S\SG&2 6VJ.K,0I(
M506.. : /&KO]L_1H'9%CNG"L0'6.,*P!P&&^96P>HW ''4 \4#/3_AY\3['
MX@0F>PDW;=HD1@5DC+#(5E/XC<N4)#!6.#0!0^*GQDLOAFD3WHD8S,P1(E#,
M0H!9CN9% &Y1UR2PP" 2 #JO#VMIKUM#>1 A)X8Y5#8#!74. <$C.#S@D9[F
M@1PNF?'_ $_4]7.A0K,UP))8R^Q1#NC1FD&2X?C85SLP6'!*X:@9Y)^U-\=K
M:Z@N- M06E$T2S2$*8MJXE9499,[Q(%5@RX&'7J : .:_9O^/^G_  _LVL;Y
M9MTEV9/,1%:-59(DRWSA^-A)"JQQT!/% 'V50(* /AO]J":?Q/XD-C&H+HMM
M;P@?*6,BB102S;<[YB,_* ,9Z$D&?3_QGU;2?#.DF+58BUDS11+!$"I)4AT1
M=C1A0HCW?>487 R2%( ? K3-)73UO-%MS;PW+,Q#DM*2C-'\Q+R' *DJ-Q R
M2 "S4 2_$;XZ:7X REU+OG&/W$6))OX3R,A4^5@PWLNY<[=QXH YKP=^U=I'
MB>Y2S43PO(RK&98UVL[,J*@\IY""2W5@% !RPXR >B^,?']CX,C$VH3I"I^Z
M"27;!4':B@N^-PSM!V@Y.!S0(\@_X;5T?_GA>?\ ?N'_ ./T#/9/"'C2T\8P
M"[L)1+$69=P!!##JI5@&4]#@@$@AAP02".:U#XW6-EJZ:"1,UTVT$I&6C4LA
MD"L0=WW<$L%**#EF #E09ROB;]KG1=$F,"&:XVY!>!%:/()!4-(\>[IG<NY"
M""&/. #TKP+XZM?'%JE[9/NC;@@\.C#&Z-QDX89Y'(((925()!'*_$K]H32_
MA_)]GN7>2X^4M%"H=U# D,Q9D0=!\I;?AE;;M.:!F?\ #S]IK3/'=VMA;I/'
M*ZN4\U$"L5&XJ"DCX.T$\@# (SD@$ /VBO$^BZ5;00Z[%).DDQ:**+<&W(I#
M.2)(A@"3&"V26&%."5 .E\"Q:9X5TE+JRC^S6)@^U$$,SA602LS\NS,%X/+'
M "KD "@#$\.?M&Z3K-E)J3M);P13+$3-&06=@" GEF0.<<E5)90-S*JX8@'/
MZ!^U_HVKSI;L)X [;?,E6-8E)Z;BLK%03QG&!G+$*"0 >X4"/)?'G[3VD>#9
MS:.TD\J,RR+ JL(V&/E9G=%)YP0I8J596VD8H&0V_P"U5HMQ927JR/NCV[K8
MA5N3N?8-JLX1_P"\=CMM7EL'B@#T#P%XUA\;V46H6RNL4N_:) H<;7:,Y"LP
MZJ<8)XQ]*!'04 % &?K^OP>'H'N[MQ'#&NYW;H!T[<DDX  R6)  )(% 'BMW
M^V?HT#LBQW3A6(#K'&%8 X##?,K8/4;@#CJ >*!G=:A\;]/LM(37B7-M)M"(
M HF9BY1HPKLH+*0VX!B-J,REE&2 ?&&N?%!-9\0C7)%(B6]@E"J '\J%D"#!
M<C>8T&?FV[LX('0 ^U?A7\9++XF)*]D)%,+*'250K ,"58;6=2#M8=<@J<@
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M6*E65MI&*!D-O^U5HMQ927JR/NCV[K8A5N3N?8-JLX1_[QV.VU>6P>* /0/
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MEI6!=62+=@ 8P#YA5E;DX165E^<$ S:_93^%R>&-.6_E0?:KM=^[ ++"<&-
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MNQ(!GV5XQ\?V/@R,3:A.D*G[H))=L%0=J*"[XW#.T':#DX'- CR#_AM71_\
MGA>?]^X?_C] SV3PAXTM/&, N["42Q%F7< 00PZJ58!E/0X(!((8<$$@C;H
MRO$WBJU\+PFYOI4AB&?F<XR0"VU1U9B%)"J"QQP#0!XU=_MGZ- [(L=TX5B
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MS!0^ N]@ 2U 'RUKGQ036?$(UR12(EO8)0J@!_*A9 @P7(WF-!GYMN[."!T
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M% CX@_:,^-</Q-FM_LB.D$$;X\Q560NY&_[LCKMVHFWH<[LY&*!GO_P$^/\
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MD*_>'525)SQ@D=10![+^VYK:0V%K9D'?)<M*IXV[8HV1@><YS,N.", Y(XR
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MXYSP <@<XR" >-?MB_$J34KT:,G$%MY<CY49:5D+ ALD[5CD  POS%\A@$(
M-;PSXE\&>%]+%O.J7MP8QYQ%O(TS.X"R>7)-'#L5>=F&C(4;AF0DL <_^QUX
M.NKW4SJ*%TM8(Y%=APDC,H A/S#.,B0\,%*)D LAH Y3Q9K$>C>*;BXUB%[B
M%+^4O$^=S1[CY) ?[RA-C(APCH%3(0T ?57A7PKX8\<-%?Z;%;,]M(LB&$&W
M=&#Y4R1IY;?>CRHE4@@$J,$Y /0/%7B:'PO:RWUR<10QL[<J"<=%7<5!9CA5
M!(RQ [T"/C#X<>&W^.WB":\O5/V;<99@"1A!\D$&]$ S@*N?D9D1V!#C- SZ
MY^*?C7_A"-,N-0"[FBC^08R"[,(X]PW+\N]ANP0=N<<X% 'R-^S5\+(OB;>W
M-SJ9,T4*AI%,CAY)92VUF8?,1\KLQW*Q;;]X%A0!]%1_LNZ+:7-O>6L<D#V\
MR2@)*S*[*RNH?SO,. 5_A*D@G)Z8 /F_X]^)IOB5X@&GQ':D4ZV<(<L%#F01
MR2, 7 S)_$H!,:IE<C% 'TU#^S7HD-DU@+88=<&<X:YW84;Q(02IRH.U0(\Y
M&S:S @'RW^R?JDEEK\$<;86:.>.08!W*(FE Y!Q\\:G(P>,9P2" :'[8>MIJ
M.M^4@(-O;0Q/G&"Q+39&"<C;*HYP<@\8P2 >W_M*^3X1\,#3UWLI^R6T1.TG
M]V5D!<_+_!"<D#[Q' '( ,7]B/1$AL+J\!.^2Y6)AQMVQ1JZD<9SF9L\D8 P
M!SD \/U&YF^._B'8K^6L\C+$7#$1PQJS ;=S?-L4L5#!6E8\J&R #V7XV?L[
M:+X4T66[MTDCF@6+$H=I&D8LL8#J[A &9@6*!2I^900/+8 Y_P#8?T1)KF]O
M"3OCABB4<;=LK,[$\9SF%<<@8)R#Q@ \U^.,Q\8>)+J.T4EWN8[=%;:I,B*E
MOC);: 74X)(X()QR  >]:[^RWI'A71[N5U>XNHK2>03.[IAUA)&U(V50NY=P
M5MYYP688H \Z_8HNW75;B(,0C63,RY.TLLL05B.A(#, >H#''4T <K-=O\=/
M$BJ[%(IYMJ DJR6\:L^T9\T*YC5FP,H96)X!- 'T?\4O@-HUIHMRL%JD36\$
MTT<B?Z[<BO( TC;G=3R"K$C:?EP54J >/_L2ZI)%J5S;!OW3VGF,N!RT<B*A
MSC(P)7& <'/(.!@ Q?VP];34=;\I 0;>VAB?.,%B6FR,$Y&V51S@Y!XQ@D ]
ME\&?LF6,MNLVL&:>^F\N2<M*1M?=YDB H3NW9V2.S.6P7C,9.0 >*?'OQ--\
M2O$ T^([4BG6SA#E@H<R".21@"X&9/XE )C5,KD8H ]E\0_LLZ+H.D3-*)#/
M!;22-=*6,A9%,A81&018XVA#@[>/,#?O* /(/V/-$34=;\UR0;>VFE3&,%B5
MAP<@Y&V5CQ@Y YQD$ M?M>^'-/T"_B2SB,=Q,LMQ</N=E<RR$*1N=L$,DA(
M4888ST ![5\'?V?M'ALK#46@+W7DV]QYK2R@^80LH.U65,*QP!MZ ;MQR2 ?
M/?Q0\GQOXMD@.]8I;^WMG/RAQM,=M(5^\.JDJ3GC!(ZB@#WK]L#X@/X>TY+&
M'(>]9E9AD8BCVF1<A@06+*N,,K(7!QD4 <U^RW\"['4;%=6U")+B2623RE?+
MQJBEHCNC("EBP8_-O  0KM;- 'E7[4O@6U\'ZL([)/+CF@68H/N*S/(K!!CY
M5^3(7H"2%PN% ![?\=/%YF\'P271+S7L-@"P"@>80EP[$#: "(V^Z.I P!R
M#R7]F_X(_P#"Q-T]^7_L^"0A463;NF/E%UVX)"F,*)&&QC\@5CM.T Y7]H?P
MM8^%=7DLM-1XXXXXMZ,Q90[('.PL68KM92=QSOW8^7;0!]*?MD^=_8J^5OV?
M:XO-V[MNS;)C?CC;YFS&[C?M[XH \U_9P\5^&S:BQU6"V2[$CGSKE$D24'+
M^9(I6+:JA=A*J3@J6=V  /I_P5X"LO!$+6VGQ>5$TAD*[G?+$*I.9&8]% QG
M''3K0(Z"@#X&FNW^.GB15=BD4\VU 259+>-6?:,^:%<QJS8&4,K$\ F@9]'_
M !2^ VC6FBW*P6J1-;P331R)_KMR*\@#2-N=U/(*L2-I^7!52H!X_P#L2ZI)
M%J5S;!OW3VGF,N!RT<B*ASC(P)7& <'/(.!@ XKXS:C)XC\3W!T_>LYNXH8N
M1&_FQ!( 5;=A?WB95LC P3M/0 ^FO!/[*ND^&3!,WF37,$R2^:SE075>%V+\
MH0/^\ Y;("L[)E2 >RT"/F#]N+SO)L=N_P CS)]^-WE[\1^7N_AW;?,VYYQO
MQQNH&'P+U;PMXHL8M-N;:VCO/+\MQ*B^9*Q(4O'.P#;G9_E0,)$.50;45J .
MZ^,VL1?!_P /FWTQ#$'8P089V\MI=\CON+[P0N\H020^WC;G !XA^S'\!+?Q
MVLFH:@=]M'(T2P@LI=]BL69E((4!Q@*<LW4A5PX!S_[3GPYL? FH1P:>'19(
M%D:,Y9$^9D&UV8N<["2K?=/(8AMJ 'O_ .Y\&^"/XV1],_V2V^['_ 1M$D_U
M"#^(CD \Z_8?T1)KF]O"3OCABB4<;=LK,[$\9SF%<<@8)R#Q@ \P\:^/8_BA
MK2W.H2^19>8(PVTAH[969@,1K*3*02<X8>8W41@;0#O_ (U>,O"ESIGV/1X$
M:Y^3RI8X&B*;&4'S))!'(^Z,L.?,RWS-A@K4 >E_L<^#KK1-/EN;DNL=U(C0
MQ-P-JJ?WP&[CS-P'*@E8U;+*5P >_P! CX5^/?B:;XE>(!I\1VI%.MG"'+!0
MYD$<DC %P,R?Q* 3&J97(Q0,^FH?V:]$ALFL!;##K@SG#7.["C>)""5.5!VJ
M!'G(V;68$ ^6_P!D_5)++7X(XVPLT<\<@P#N41-*!R#CYXU.1@\8S@D$ Z#]
MK_PMIWA^\A^QILNI_/GN?FD;=O<;&^<E1EA+PF,=P!MH ]D^!?P%TO3K*QU*
M2$2WAACG$K&3 :0>8G[LN8\H&"AMN<J'&&Z 'N% CY%_;@UM)KFRLP#OCAEE
M8\;=LK*B@<YSF%L\ 8(P3S@&>H:#X"TS_A%;5=1B>>U@M!>LNYE?<8WG?:4:
M/./,<*"<8QDDC=0!\X?LR_#RT\=ZF]O?J7BCMI)=@8H&8/&@!*X; WD\$'(&
M21D$ ^C_ (M^ H/!'AJ_MM&B>)6VR,J-*[$%XEF)+,S;?*4AQG;L#9&,T >%
M?LU>*]!T_P VUUN"$RR2(8[B=!+'CA1$0RL(L$EM_"L"=[+L7(!]:>!? 6F>
M&O,N=*B1%N]DC-&S-&X^9D*C<45?G)4( N",# & #JZ!'QA^V/\ $!]4U!=*
M3(BM55G'(#2R*'W<,0P6-E"D@,"T@Y!% SV7PK^R?HUE:Q1WL'G7(C7S9/.G
M 9SRVT(T8V@G"_*#M W9;)(!E>/]/A^ /A^>#37F9[F<I&[LI9'EC 9@T8B*
MXCB)0C)$FTG(S@ \Z_90^"UIXL2;4M003)',L<49)V[U"R.SJ  PPR!025(+
MAT/RF@"I^U_\.K+PM/:W%C$(3<+,)(T 6+,7E!65  %)#X;'!P#C<6+ 'I6A
M^+S#X$-Q=$N?L4]N-H4'!D>TA&/E&%!0$]< GYFZ@'A?[//PC/Q+GF@GDDCL
MHE1YO+906D^=81ALC.#(0VUL ,OREP: /?\ XB6-I^S_ *9<W6C1F.>\FAB0
ML3*B,$;!Q(W0*)&&=Y,C ,#'A5 /!?V?)M TR22[U^1"RX6"%XI9DY!WR.JQ
M.AZ@("QP=Q*Y"-0!G_%#[%X^U=8O#5L0)%6,1J@B5Y%9P9%3.$0QA220F &9
MU4[B0#[T\/::^EVT-O+(9GCAC1I6SND95"ESDL<L1DY).3U/6@1B?%/QK_PA
M&F7&H!=S11_(,9!=F$<>X;E^7>PW8(.W..<"@9\=_L\_",?%2]FN+^0M# R/
M."S&69Y"Y +=0"58NV=W9<%MZ@&W^U3\)=,\!_99-/5XFF\T&/+21D)M)?=(
MY=6^<#'*L.?D*G> >O\ [-7D^$?#!U!M[*?M=S*!M)_=EHR$'R_P0C )^\3R
M!@  ^6_@SX G\>WXL(6*Q,H:Z(?9^X61"_8[CNV[!M8;]K$ *6 !Z5^T]\)]
M)^'MM9I8QR+<2,X+ERZNB*H=GW'A]S*5V!5P7R!A0 #U#X7^-?\ A"/!<>H!
M=S11W&P8R"[74D<>X;E^7>PW8(.W..<"@#P_]GGX1CXJ7LUQ?R%H8&1YP68R
MS/(7(!;J 2K%VSN[+@MO4 V_VJ?A+IG@/[+)IZO$TWF@QY:2,A-I+[I'+JWS
M@8Y5AS\A4[P#V_\ 9)T1-.T&*5"2;B:>5\XP&#F' P!@;8E/.3DGG&  #V6@
M1\ ?&;49/$?B>X.G[UG-W%#%R(W\V() "K;L+^\3*MD8&"=IZ SUKQO^SEI/
M@3P_/=72R27B0H3*LA.V9O+0*JX1##YAYW*9-A;!W!< $7[#'_,1_P"W3_VX
MH \PFNW^.GB15=BD4\VU 259+>-6?:,^:%<QJS8&4,K$\ F@#Z/^*7P&T:TT
M6Y6"U2)K>"::.1/]=N17D :1MSNIY!5B1M/RX*J5 /'_ -B75)(M2N;8-^Z>
MT\QEP.6CD14.<9&!*XP#@YY!P, &+^V'K::CK?E("#;VT,3YQ@L2TV1@G(VR
MJ.<'(/&,$@'I^C?LT6.DZ7/J'B%9IKPP33SE9BS1D"20E"-JO+M(W>89$,@X
M)4DD X#]BK_D,3_]>$G_ *.@H ]J\5?M::3X<NI;)TN9'AD:-VCCCV;EX8#?
M*C'#94G&"02"1@D VO!7[0MAXPMKR\MXYU2QA\V4.L88KMD?";9&!.(SU*C.
M.>N #Y;^$WAMOC1KSRZB=R-YEQ.H9U)4%56)"=S!0S(H&X$1 A6!"T ?1^M_
MLDZ#J*!(HI+<A@=\4SEB,$;3YQE7'.> #D#G&00#Q7]L?X@/JFH+I29$5JJL
MXY :610^[AB&"QLH4D!@6D'((H ]U\!_LUZ3H-D+>ZMHYYY(56>1\R$O@[O+
M)"F, L0I0(V I8EAF@#Y5\%PGP=XIBM[1B!%JIMU9MK,8S,8&!^7&3&2"0!@
MG*X., 'I7[<&MI-<V5F =\<,LK'C;ME944#G.<PMG@#!&">< &W\'_V8+7Q'
MI\=_K#323W$ \M?,P(HRJK RD%BS"-05#'8JL$:+*T <5^U?XU\N>+P[:KLL
M[&.'Y2,DOY7R88LS%5B< 9P2Q?=NPI !T'AGQ+X,\+Z6+>=4O;@QCSB+>1IF
M=P%D\N2:.'8J\[,-&0HW#,A)8 Y_]CKP==7NIG44+I:P1R*[#A)&90!"?F&<
M9$AX8*43(!9#0!]J4"/D7]N#6TFN;*S .^.&65CQMVRLJ*!SG.86SP!@C!/.
M 9T'P4_9FM-<LH=2UKS)Y9X5*1-(51(L*(.8VWD^6HQ\P558(4!3- 'BN@6P
M\/>*T@M,QI'K'E(%9LB/[3Y>S).X@IE3DG<"0<Y- 'I7[<&MI-<V5F =\<,L
MK'C;ME944#G.<PMG@#!&">< &W\'_P!F"U\1Z?'?ZPTTD]Q /+7S,"*,JJP,
MI!8LPC4%0QV*K!&BRM '"?M8^+ MU#H-J"EK80QJ$RV"YC4IU=MP6(JJE@&!
M:3D@YH ^@/ ?[->DZ#9"WNK:.>>2%5GD?,A+X.[RR0IC +$*4"-@*6)89H ^
M5?!<)\'>*8K>T8@1:J;=6;:S&,S&!@?EQDQD@D 8)RN#C !VO[8_Q ?5-072
MDR(K559QR TLBA]W#$,%C90I(# M(.010!ZKX0_9!TNSLA#J(,UVRMOF221
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MZB,#: =_\:O&7A2YTS['H\"-<_)Y4L<#1%-C*#YDD@CD?=&6'/F9;YFPP5J
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M,B,@Y!H&;?P:_9DTJ]TNWN=2A\^XGC$Q82S*JK( T: (T?1""V03O+88KMP
M=+<>$++X!:?J.IV D8R*A$;D2(K[F2%1]Q]@>8;LNS;1P2W4 \ _9J^%D7Q-
MO;FYU,F:*%0TBF1P\DLI;:S,/F(^5V8[E8MM^\"PH [K]KWX7Z?H=G!J%G D
M$OGK"RQ*L<;*R2/DHH W IPPP2"0V["[0#I?V5_%YT[PY<7%R2T5E-<E54+N
M$:Q).RC[N26=R-QZG&0 , 'SA\$/A])X_P!0%@KO' T9:Y9" ?*1E;&"0#F0
M(!PVUB'*D+0!]B>'OA/I/PB2?5;:.3,5DPD.\NS)&#)(P#%5WOM7/W5RH"A
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M\*P)WLNQ<@'UIX%\!:9X:\RYTJ)$6[V2,T;,T;CYF0J-Q15^<E0@"X(P, 8
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M@S\VT*P!Z7^TY\$=(\%Z?'>6,;P2^>L84,\J/N5F^;S9"5P$)#+GGY2IR&0
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M&(C1@6!7 !X_^SYXKT;0+J0:Y DD<D8"2R)YR1$98@Q[6SNX < LI &-KN0
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M)(5?:PY9M^]LL3M(4 '"_L46CMJMQ*%)1;)E9L':&:6(JI/0$A6('4A3CH:
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M/&XXSCS",*59R&4,#D ]5H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX$@C)*XP2 3AL$ E_8Z\,_V9HQNF";KJ>1PP'S[$Q$JL<#HZ.0,D -D8+$4
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M'!&=Q4, ?36C_&#3]>OO[,L9/M,HC>21XMK0QJH3!+E@&R7"@1>80V0P7!(
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M8;=3\TCX*CJS.06/S,(U9OER >E?MJZHMC#8:9 R)$/,D,*A!M"!8X#@#*J
MTBJ!A3@C!V\ 'L'[.7AG_A']"M$(0/+&9V*#[WFDR(6. 2PC**<YQMP"0 :
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M@BVC@A^-QY+4 ?57[0^MOHV@WLL8!+0B([LD;9G6%SP1R%<D=LXR"." >/\
M[#^@%4O;YD&&:**.3Y2V5#/*@_B ^:,GH&..I7@ ]0_X9<\._P#/G_Y'N?\
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M!;<Y8@$Y+-R30(^0/V7X9_$_B07TC NBW-Q,3\I8R*8V("KMSOF!Q\H SCH
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M8EU4 M>$?AG/HW@N\D0B.XNX3<LWW6\A=KB,NA8L&A5B%.!F4HP&6) .5_9
M^(MEX6GNK>^E$)N%A,<CD+%F+S2RLY("DA\KG@X(SN*A@#H/VJOCM;:M!_8V
MFR"4,R/<2H5>(J/G6)6P=QW;69E("[0F6)=5 .J^%7A>7X5>&+N\GQ;WDD,T
MP+JBNC>7LMHVW$[CNPRHP!#2%"F[.0#SK]BGPS]MU"XOF"%;> (,C+J\K?*R
M\''R1NI.0<-@9!. #L/VX-;>&VLK, ;))I96/.[=$JHH'.,8F;/!.0,$<Y -
M#P[X9N-+\#2) $AGDM)YW)"G?$[-(Q) ;+-:X5<_,/E!*E<J >=?L>>,;#P]
M<W:WSQPO)#&8YI6CC4*K'S(P[L""Q9&VCA@A)^Z* ,3]I7XWQ_$2:*WL2_V.
M#>?F!3S)"2OF;=QRH0#RRRJXW."!G% 'T!X#ED\"^#EF,B)*EA/-&^1M#3;Y
M8!\X +9D1=I!!?Y1NR,@'DO[$>B/-?W5X"-D=LL3#G=NED5U(XQC$+9Y!R1@
M'G !S/[0LLGC7Q.UE%(C?O+:UA.1L0L%W*Q0$_+-(^[.64Y7L  #[*\6:A_P
MBNFW$]JB+]FM)7B3;B,>5&2B[5*X7Y0,#'' Q0(^4/V+- -WJ<]V4#)!;%0Y
MVDI)(ZA,9^8$HL@R.@R"1NP09ROQ'UN70?%DEYJ ),&HQ2D+L+&%'1X0,$+G
MR F,D'/WR&S0![_\=OVD;+1;22TTV<37<T)"20L'CB#$*6,B.-K[=Q3;N*L%
M+ *1N /-?V(]$>:_NKP$;([98F'.[=+(KJ1QC&(6SR#DC /. #[$H$?+7[<&
MOE4LK%7&&:662/Y2V5"I$Y_B ^:0#H&.>I7@&>M_LY>&?^$?T*T0A \L9G8H
M/O>:3(A8X!+",HISG&W ) !H ^7]+ED\<^,UD21)/^)F71\C8T5LQ9=I0$']
MS$ I_B."3R6H ^D/VIM?&D:#<+O*/.T42;=P+$N&=,KT!B5\YP",J<YP0#A/
MV(="\FSO+W=GS9XXMF.GE)OW9SSGSL8P,;>ISP >5:7+)XY\9K(DB2?\3,NC
MY&QHK9BR[2@(/[F(!3_$<$GDM0!Z+^W!KY5+*Q5QAFEEDC^4ME0J1.?X@/FD
M Z!CGJ5X /1?A?X;NK#PE';6Y_TJ2PN'A,;;2&G$DL.&.W:P\Q03D!6S@X&:
M /E;X :9I&IZ@T.NE!;M ^PR2/"GFAD(RZLF/D#XW$*3@?>*B@#Z?TYO!G@:
M/SX6L?W<BR!@ZW<ZME0I3F6;@@$!.%Y; Y- 'I7BSQ_8^$/*^WSI#YTFR/<3
MR>YX!PHR-SMA%R-S#(R"/FO]I30?#=Y;RZG97$)U!Y%PEO,DBRLS+O9T7?MP
M@=MPV N<N69@"#-K]A^VG6VO9&S]G::)8QNROF*K&7"YX.UH\G W# R=O !Y
M!KVOF?Q>;B[< 1ZPBL[;458X;A8UR>  L: $GL,L2<F@#[.N];C\:V-W'I-P
MC2>7+"DT;G8DK0AE(D3/W?,4EDSM.1]X$  ^-OV6O'5KX/U8R7K^7'- T(<_
M<5F>-E+G/RK\F"W0$@MA<L #VK]I']H&SMK%].TV9)Y[F,JSQ,DD<<1.'!8;
ME+,N5"CYE!+DJ0FX B_9$\!GPQ93ZQ? 1"=5\MI JE8$!=I=Y.51R<D$*"(U
M?YE*D 'DG[-&G2>,O$:WEQLD9//NI=X'S,?E#*H7:&$LJN/NA<97! % 'O7[
M8>MOIVB>4@!%Q<PQ/G.0H#39&",'=$HYR,$\9P0 <U^S7X6N(O#-[);)MNKK
M[5]GD5E21ML7EQ?.""NV8/MW$;22PP#D@'A?P TS2-3U!H==*"W:!]ADD>%/
M-#(1EU9,?('QN(4G ^\5% 'T_IS>#/ T?GPM8_NY%D#!UNYU;*A2G,LW! ("
M<+RV!R: /:J!!0!\%_M8:I)>Z_/'(V5AC@CC& -JF)92. ,_/(QR<GG&<
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M30&69X%QEQ+AE=%)Y3@G.,E1@-@ ^E?#=WX3\)O;QV#67G-,(H6B*7-QOE+
M NOF2@'<5W,0H!"D@8% 'K5 @H * "@ H * "@ H * "@ H * "@ H * "@
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MDVA5 &X*?EV!L '8?M/>.)?'VH1>'-,0RF*;YPI1@\VWH",[1$I<.2R@$OO
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M?Q.U<("6*J,F@#A=?_91TC7;U[^4S@RS>;)$LBB)F)W..4,@#').'!&3M*C
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MY+ $.CC@EB" #\QR3@8 ./T']C32+!P]P\\X#/\ (SJD94EM@/EJKY52,D.
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MDDG'<DT"+= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@* .  . !P!0(EH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M . *!$M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q7Q.^$-C\2(TCO@^Z/=Y<D;E7
M3<4+X!RASL .Y6P,XP>:!GFO_#%6C_\ />\_[^0__&* /7_!W@"Q\&1F'3X$
MA4_>(!+M@L1N=B7?&XXW$[0<# XH$=!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\U?'/]J"\\$:F^GV,4++%''YAF1R2[+YGRE)5^78R]0#NW
M=L&@9]*T""@ H J:IJT.D1M/<R)%$N-SR,J(,D 99B ,D@#/<@4 1:)XAMM>
M0RV<T<Z!BI:)UD4, "5)0D9P0<=<$>M &A0 4 % !0 4 ?-7PO\ VH+SQOK<
M>GB*%;.62XV'8XG"+'))'N/FLF[Y1NP".N.QH&?2M @H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YJ^%_[4%YXWUN/
M3Q%"MG+)<;#L<3A%CDDCW'S63=\HW8!'7'8T#/I6@04 % &)K?C>PT%Q%>74
M$#E0P666.-BI) 8!V!QD$9Z9!]* -N@#P7XL?M5IX"U"33DM#,8ECWN91$-S
MJ'P (Y,C:R\D@YR,8 )!GO5 @H * "@ H * "@ H * "@ H ^</C3^U>_A.[
M?3]-ACD>%E$DLC%X]V"7C58V4Y4D L6!#!T*<!J!G2_!#XH:YXNO)K?5K-+:
M**!7_P!5+#)N=]L?RRR$E2$DY"XRN"1T(![50(Q+;QO874_V..Z@:X#,IA66
M,R[ESO78&W9&#D8R,'/2@#;H ^:OA?\ M07GC?6X]/$4*V<LEQL.QQ.$6.22
M/<?-9-WRC=@$=<=C0,^E:!!0 4 % !0 4 8ESXWL+6?[')=0+<%E40M+&)=S
M8V+L+;LG(P,9.1CK0!MT % !0 4 % !0 4 ?-6I_M07G_"0#2+>*'[+]OBMB
MSH_G?ZQ8I2"LNW[VXH=OW=NX9R*!GK?QD^*B?#.R%Z\1F+3)$B!@@+,&;)8A
ML *C=%8DX& "2 "'X*?%?_A9MF][Y/D;)VBV>9YN<)&^[.Q/[^,8[=>: /0*
M!!0 4 % !0 4 % !0!RGQ3\:_P#"$:9<:@%W-%'\@QD%V81Q[AN7Y=[#=@@[
M<XYP*!G ?LW_ !KO/B;]K^VI"GD>1L\I77._S=V=\C_W!C&._6@#VJ@04 %
M&)<^-["UG^QR74"W!95$+2QB7<V-B["V[)R,#&3D8ZT ;= !0 4 % !0 4 %
M !0 4 % !0 4 % !0!X_^T9\:YOAE#;_ &1$>>>1\>8K-&$0#?\ =D1MVYTV
M]1C=G!Q0,ZOX,^-9O&^E6^H7*HLLOF[A&&"#;*\8P&9CT49R3SGZ4 =K0(*
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M0\)Z[_PD%G;WNW9Y\$4NS.[;O0/MS@9QG&<#/H*!&K0 4 % !0 4 % !0 4
M<+\9/BHGPSLA>O$9BTR1(@8("S!FR6(; "HW16).!@ D@&0_!3XK_P#"S;-[
MWR?(V3M%L\SS<X2-]V=B?W\8QVZ\T >8?&G]J]_"=V^GZ;#'(\+*))9&+Q[L
M$O&JQLIRI(!8L"&#H4X#4 =+\$/BAKGBZ\FM]6LTMHHH%?\ U4L,FYWVQ_++
M(25(23D+C*X)'0@'M5 @H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMPC106DD*C)55'X#<V$!*AF&10!X+=_MRHKL(M/+(&.UFN C%<\$J(6"DCJ
MS 'C)ZT >R_"#XSVOQ.A>2W5XY8?+$L;C.TN"058<,I*L ?E;Y<LBY&0#%^,
M'[1UE\.7^R[3<7>T,8D8*J D8\Q_FVDJ2R@*Q( W!596(!YU%^VE#J=O<QO
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MC?*R[@N[!(51UP790VU@NX@B@#P__AN?_J'?^3/_ -ST >P6GQ[L=0T:?78
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M%\X^8$HL9P>@P0!NR0#ZDT>6/P!I,(U"1$2TM(4EDR2F414.W@,<L,*,;F)
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M,;M^[.W;MYW9QCG.*!'BOA/]K*SUB.\NKB!X+:VV;'+H[RER_EQA/E(E8(2
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M\)Z[_P )!9V][MV>?!%+LSNV[T#[<X&<9QG SZ"@1JT % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ?#?[6.I/KWB VL49+PPV\"A<NTC/\
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M0RQ^7(H5650-Q*EPY=0VW H ^<+2T2S\6K%$H1$UP*JJ JJHN\!0!P !P .
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M,>>" 0P;*B@#BOV._A;!<P2:O=Q!W,P2W\R/(41X8RH6.TDOA0P&4,; -RP
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M/0L!E<@ ]T_:/U"+X>:%+#IT$< NYA PB1(U D1C(Q4)ABT<9CSP0"&#944
M>=_LG_!*UUR%M7U"/S1YCQPQ2)F$@ ;I<-D2<DHO&U65CRV"@!Q_[6_A>R\.
M:G%'8P" O;+)($PL1)=T7;&% 0X3YB#AL@[0P9G /K3X/Z - TBRMPAC*VT3
M.C;@PD=?,ER&Y!\QF)'8\  #% &WXLUW_A'[.XO=N_R()9=F=N[8A?;G!QG&
M,X./0T"/B#X$_#S_ (6WJTLNHEVB7?<7#*NT2.S@B,LN!'O)9OEP2JL$V_>4
M&>M?M;^ =,T+3(KBWM(X9OM*QJT*I",,CLV]53$@Q'@ X*DY#8W*X!J_L6:
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M2,T4,1V!7"NH5MH "JPRC%00"K^TYI\_A[Q$U_+"&BD:WDB\Q=\,HBCB5T8
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MDYW=!CD [#XE:D_PZ\&VUK!&8GN(88) V0R--&TUSE9 QRQ#J5^4H7RN-H%
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M [L+GD@4 >%?L<^ [/Q'->3WL23>3'"B)(B21_O"Y9MKJ?F'E *1C 9ASG@
M^Q;2T2S18HE"(BA550%55 P% '  '  X H$>2?M5>,9/#6BR+"/FNI%MBW'R
MJZNTAP5.<HA3L1NW @J*!GE?[)_P2M=<A;5]0C\T>8\<,4B9A( &Z7#9$G)*
M+QM5E8\M@H <?^UOX7LO#FIQ1V, @+VRR2!,+$27=%VQA0$.$^8@X;(.T,&9
MP#W37D'@3P64$)4_V<B/&Q9662YVI*3N!((DF9BO'(VC:.@!X!^S+\'XOB%=
MR27F&M;95\R++JTC2!Q& 4*E0"I8G.<@+@AB5 -7]K_1K+0[^WM[*UCMS]FW
MNT0$:N&D=5!10%!78QW=6# 'A!0![AXET+^V_!:Q;MFW2;:7.-W^IBCGVXR/
MO>7MSVSG!Q@@'FO[#NJ1Q37UL6_>O'!(JX/*QF17.<8&#*@P3DYX!P< '"7<
M,OQT\3,BL6MVF(#KO 2UB. PWJ_EEEY&X!3-)R%W8H ^[Z!!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ML>BDYQCCKTH&?17[0OCJ.;PPUU$[Q?;8[80CD.1*5E:-MA(&80X8$[2,KDY
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M)(487)R2 ._>@1\;?LOPS^)_$@OI&!=%N;B8GY2QD4QL0%7;G?,#CY0!G'0
M@R']KS3YK777>5]R2P0O$-S'8@!C*X(PO[Q';"Y'S9ZDB@#UOQQ^V':16"'3
M@7O9H3N7D+;.8^I:2+;*5<\ +M8*22HP& /)/V0]"_M+74EW;?L\$TN,9W9
M@VYR,?ZW=GG[N,<Y !]"_&W]HY/AC<Q68MC.[P^:Q\P1*JEF10/DD+'*-G@
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MW(. #W#PGKO_  D%G;WNW9Y\$4NS.[;O0/MS@9QG&<#/H*!&K0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVN/LY<%HV2-Y'>)"GH"<N&/+"0R ]  N10!ZK:6B6:+%$H1$4*JJ JJH& H
MX  X ' % CA/''P(TCQM-]JO(,SGRPTB.\;,$(.U@I"G*C86(W[.%92JE09-
M8? [1["TFTZ*U"V]PR-*N^7<Y0ADRY?S, C( 8 $GCYFR ;_ (0\%VG@Z 6E
MA$(H@S-M!))8]6+,2S'H,DD@ *.   1S7CCX$:1XVF^U7D&9SY8:1'>-F"$'
M:P4A3E1L+$;]G"LI52H,FL/@=H]A:3:=%:A;>X9&E7?+N<H0R9<OYF 1D ,
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M_%5N]E>IYD$FW>FYESM8.O*%6'S*#P?TH$9_@?X;Z?X&1X].@$(D8,YR[LQ
MP,L[,V!S@9P"20 6.0#/\:_!G2O&\RW.H6_FRK&(PWF3)A068#$;J.K$YQGG
MKTH&=A:6B6:+%$H1$4*JJ JJH& H X  X ' % CC_!7P9TKP1,USI]OY4K1F
M,MYDSY4E6(Q([#JH.<9XZ]:!GRA^U!-/XG\2&QC4%T6VMX0/E+&11(H)9MN=
M\Q&?E &,]"2 ?1_B3]F+0M=D$QM_);S$9A"QB1PHQY90?(JGC<4".3R&!))
M.U\'> +'P9&8=/@2%3]X@$NV"Q&YV)=\;CC<3M!P,#B@1E>-?@SI7C>9;G4+
M?S95C$8;S)DPH+,!B-U'5B<XSSUZ4#.PM+1+-%BB4(B*%55 554# 4 <  <
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MPP0 \$%FX 5P#FOV1/@Z=.3^W+Q"LDBE;9&5>(V"DSC.6!;E5^[\FX_,L@(
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M6[MMCD5<GJ2!DG+'))- S5\#_"+2_ SO+IUN(GD4*S;I)&V@YV@R,Q4$\D#
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &5XI\+6_B
MJW>RO4\R"3;O3<RYVL'7E"K#YE!X/Z4 9/@7X6Z=X$\S^S8?*\W9YGSR/G9N
MV_ZQVQC<>F,YY[4#.KH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 5-6TN/5X9+:==T4L;QNN2,JP*L,@@C()&00?0T <KX*^#.E>")FN=/M_*E
M:,QEO,F?*DJQ&)'8=5!SC/'7K0,[6@04 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!Y__ ,*%T;[9_:7V;_2O/\_S/-G_ -;O\S=M\S;][G&-O;&.
M*!GH% @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#*\4^%K?Q5;O
M97J>9!)MWIN9<[6#KRA5A\R@\']* .:\(? [1_!\XN[&U"3!64.7ED(!X./,
M=@I(XR,'!(S@D$&=U0(* "@ H * "@ H * "@ H * "@ H * "@ H \_\4_
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M-(9"NYWRQ"J3F1F/10,9QQTZT =!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH& H X  X ' % $M !0!E>*?"UOXJMWLKU/,@DV[TW,N=K!UY0JP^90>#^E
M'->$/@=H_@^<7=C:A)@K*'+RR$ \''F.P4D<9&#@D9P2"#.ZH$% !0 4 % !
M0 4 % ''^./A)IOCETDU&$S&-2J#S9D503DX5)%7)XR<9( !)"C ,V_"WA:W
M\*VZ65DGEP1[MB;F;&YB[<N68_,Q/)_2@1JT % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=H!#DL%H ]@H$% !0!POQ4^,EE\,TB>]$C&9F")$H9B% +,=S(H W*.N26&
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MT7X1?'*R^)B,(,Q7$:J9('(W $#+(0?G0,=N[ (.-RKN7(!Z+0(* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y_1_']CK-U-86
M\Z/<V^/-C!.5['!QAL'Y7VD[&(5\,0* .@H * "@ H * "@ H * "@#Q7]I/
MXC:CX9^PV6D';=7D[*K_ +ML[=B"/$JLOS-*IW$C;M]"< SVJ@04 >5>&_C#
M=:[KMQI$=DXMK?B2=CL9" Y#E2"&60[1$ 0Q3,O*DJ@,]5H$% !0!S^L>/['
M1KJ&PN)T2YN,^5&2<MV&3C"Y/RIN(WL"J988H Z"@ H * "@ H * "@ H *
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MHBDD(RVUBRH <8W!@:!E1/VL)=*GACU?2Y[&&5B/-<N2 ,98(T$9< D;MIR
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M4M-TK3+K[/+<R 3'RDEPLLD<43_O%(.").%8'CYL94T#/=:!!0 4 % !0 4
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M967_ %2N<L,<<'=B@9O_  JO+B_TNTGO9?.GF@25Y-BQY\P>8J[4PORJP7(
MW8W8!.* .KH$% !0 4 % '/^$_']CXO\W[!.DWDR;)-I/!['D#*G!VNN4;!V
ML<' !T% !0 4 % !0 4 % !0!XU\1OB'?>%?$.FV[,1IMVOE%%6)BTQ9TSD_
MO%"F2$G! QG 8[A0,]EH$% !0 4 >?\ QG^+\/PQM5N)$\Z620)'$'5"W=V)
M(8A5'4A6^9D4XW9 ,F^#?Q43XF61O4B,)69XG0L' 90K9# +D%77JJD'(P0
M2 :OQ(\7OX.T^?4(X3<&%58Q*2I*[E#MD*^ JDN3@@!3G Y (A^%OCK_ (3O
M3H=2\ORO-\S]WNWXV2/'][:N<[<]!C./>@9U= CPH_M+S:I<7D6E:<]Y%9XS
M(DK$R?O%B^18H90<DLZ?-\T2,_&"H!F5JG[4NI:1&T]SH5S%$N-SR/*B#) &
M6:U &20!GN0* );3]IK5;Q%EBT"Z='4,K*TK*RD9# BUP01R"."* .K\3_&^
MY\.Z+%K4VG2*[S;);=G9&B7=(JNS&'(!*KC*J,R*,],@'=> /&,?C.Q@U"$8
M6:,$KR=K E9$R57.UP5S@!L9'!% CBOC%\>X_A[-!916[W=Y/M*PJ2GRL2BG
M(1]S,XVJB@DX))'RA@9ZA:,[(IE 5RHW*K%U#8Y 8JI8 ]"54D<X'2@1+0!Y
M5\5?V@[7P+,MC%&]W?/MVP1GH6*A5=@&(9@<HJJ['C(4,K$&<5J'[5MYHFR3
M4-%N;>!I%4R.SKUR2%$EO&K-M!(7<N<=0,D 'O6@:_!XA@2[M'$D,B[D=>A'
M3OR"#D$'!4@@@$$4"/.OB-^T%;^%;@Z;:P37NH#'^CQ*PQ\JR<MM8G]VQ8;%
MD^Z0VWK0,Y6V_:N;3)DCUK3+FPBDR$D;>W(*ACM>*(E5#98IN8< (<T >Z:M
MJD>D0R7,[;8HHWD=L$X5068X ). "< $^@H$>%_\-4S:Q^\TC2+R[@'RM)AE
MP_4IB*.=>%*GE@>?N@8)!G2_!+]H:#XGO+;^2;>XC7>$W>:K1Y52P?8F"&8
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M&P656CW,A81.$DQ@N,O,P!(V$PJ.5=10,^JK2T2S18HE"(BA550%55 P% '
M '  X H$?-_[;7AF%[.VU#&)TG\C("_,CH\F&.-QVLGR\X&Y^,MD SV#2?&,
MEMH,>JSCS95TQ+EQPF]A )6'"X7)ST7 SP.U 'DOAS]JFY\0VL5O969NM6D5
MBZ1JR6T69'1&8LS-@?NR^2J8?F5",  VOAK\?+Z]U7^P-;M$AO#N(:%@47$0
MF567?)U0,=RN>2J[!RP /=:!!0!XU^UMK::=H,L3@DW$T$28Q@,'$V3DC VQ
M,.,G)'&,D SH/@9IJ>&/#]GYL@V"V\]G;"*JR[K@Y)) "A\%B0"!NXZ  J?
M/XJ7/Q*MI[RXBCB1+EHX@C,6VA5?:^X8) 8?." Q)_=IM&X J_M#?&U_AA!#
M]GB$EQ<,^POGRE6/9O+!65B3O 4 @<EB?EVL :O[0^MOHV@WLL8!+0B([LD;
M9G6%SP1R%<D=LXR"." <+X%UB3X6>#4OUA3SQ'YNTX <SSA8I'*<M^[="1D-
MM4(2I'R@'K7PU\7CQCIUM?@@F6%2^T,JB0?+*H#<X$@8#DY R"1R01Q7B[XS
M3Z=X@L]"LXHYA*H:X._$B!MQXY 4I&OFD,&,BD*H4D,09ZU0(* *FEZ3#I$:
MP6T:11+G:D:JB#)).%4 #)))QW)- 'RAXLTT>,/'$:V"#-O-;/<2!FD0F (\
MC':"(R %@V]/,4!B&8X!GH'[8'Q ?P]IR6,.0]ZS*S#(Q%'M,BY# @L65<89
M60N#C(H ]*^$OP_3P#IT-BN"ZKNF88^>5N7;.U2P!^5"PW;%4'I0!X+\??\
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M<$=4SO\ F"T =UXV\4)X5LI[^3!$,+N%9@@9@/D3<0<%FPHX)R0 ">*!'-?
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MJ'<JQ&\9FA &, A=X#!AYC$$ &=7\$OCP/B \MC=0FVOX%S)'\VU@I5)&&X
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M#QKXA^+X+/Q@UWJ)C%OIMLA52-TDA,6^-44Y#3":X#+]P*J;R1L+4 :OB/\
M:4UWPR8[V]TH0V$K,J(Y=9]RJ1M9S]PE@64/"I9 =N<%Z /HKP]K::];0WD0
M(2>&.50V P5U#@'!(S@\X)&>YH$>-:[\?+[Q%=2V/A6T2\,&TRW#L!!_$"J_
M/$#SC:V_YMK[490'H&1>#OVA;VRU%-&\1V@MKB9E$4D63&2^T1*1NDR&;<OF
M*Y ;"LJ[78 'O5 @H \ ;]J3[#=:A;SV^]H+M+:T@A.Z>5_WRDMEN5+Q*,HA
M*>8JX<D$@S/U+]HG6_"#QW6M:8(K"=L1[&/G("0P#DNPWB//R.L)=@?N;6
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M@LR  @ 'K7PJ^)D'Q&LEOK<%#N*21MR4D !9<X 888$,.H(R%;*@ \P_:/\
M^0QX>_Z_S_Z.M* /?Z!!0 4 % 'S5X.W_&[7CJS\:;ILFVW7][B5P69)!G8
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M4,8PKXP67(R." #C_P!C;5)+W16CD;*PW<L<8P!M4K'*1P!GYY&.3D\XS@
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M / 8,J@'">*/CCJ.K7L^F>&;(7,EJV)YI3LB# LK1@%XN=PP&+Y;:^U&4;Z
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MD4#$M@J"7D4$D*3G.=O ,]5^.>I)X8\/WGE1C8+;R%1<(JK+MMQ@ $ *'R%
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M0$X( ;!P6!H ]*^%7A;_ (172[2R*>6\<">8F[=B5AOFYRP/[QF/!V_W>,4
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M7>667R7'RLK*%5G# @AQ&RDC- STK]KS7?[-T)XMN[[1/#%G.-N"9]V,'/\
MJMN./O9SQ@@':^$]0_X170;>>Z1U^S:9$\J;<2#RH 77:Q7#?*1@XYX.* /#
M_P!BSP'!+%/J\@#S+,8(LCF,!%:1@<XRPD"YP"H4@-AV% '0?MKW:+I5O$6
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M,[?]<1!NS@_=\S=COC&1G( ,7]EG0!I&@V[;"CSM+*^[<"Q+E4?#= 8E3&,
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M#M<W,[)YL@R61<,S*S#<=TK,)#N(9D&?F4T =K^U'_R+MY_V[_\ I1%0!4^
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M!P !P . *!'S?\ _^*A\3:OJ</DB!-\0\K[K[Y1Y<HQE6W+ 7=L_,[;@,,<
MRKX[\GQ5XYLK4[U^S1Q;B-HR\2RWB8^]E?F0-D _> QPU $O[46KG7]5TSP\
M^5MY9H))64KN)EE:!<90[2BA\')!+\K\HH ^E;2T2S18HE"(BA550%55 P%
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MZ^!NOVNDDP7,-RL2"001PS[)YMN3(%,A*R*3M9W5D 'RG;L /KJ@04 % !0
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M&#NB8\9&".<Y  .0_:I\GQ'K&D:1)O&Z0>8R[1\EQ-'$-I.?F'E,>5P,KUY
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MWF!@P+!P=V<$$@'V3I.H?VC#'/L>/S(T?9(NV1=P!VLN3AAG##L<B@1;H \
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M"@1MT % 'QW:>/#\*/%.H7FL1SL)EG$6T*[-&\R-"P+NH*"./:,$[2-F 5(
M,^A-8^)2W>@S:S;[[;-I-)#YZHCAL,L)VDLIW-M*#)#AEP#NQ0!Q_P"QYHCZ
M=HGFN01<7,TJ8SD* L.#D#!W1,>,C!'.<@ '(?M4^3XCUC2-(DWC=(/,9=H^
M2XFCB&TG/S#RF/*X&5Z\@ '=?M7>#KGQ/I 6S0R/#<Q2F-59Y&7:\1"JBL20
M9 QZ *&.>,$ Q= _;)TN6U\R[69;E(XM\:QC$CGB3RCYC *IR?WC(=N,;FR*
M /1?A7\4#\1$ENHK:2&T5E6"64J&F.#YN$7.T(PVY#,&.>0RLH .ZH$>7_M+
MZ^=%T&[9'"/(J1+G;EA(ZK(@#=28M_3D %AC&0#/&_A'^T&OPOL8M,UBUF4"
M-9K9X@C>9%.6E#'?(HZL<%2>Z,JLC;@"UH4]Q^T-K$5Y+#LT>QD;:KA<N?E;
M8V58.SE4,B#Y$B^7=N8-( =7^UIX9OIH[/5M/&3I\DDCD ,Z9,3+*%((95,>
M7ZX!!(*ABH!4_P"&VM-\G=]FN?/\O.S]UY>_'W=^_=MW<;MF<<[,_+0!+\!_
MAU>ZUJ$WB?78C'=.Q%O&08BHVF)F,>-P 3$<>\DD;F8$E'(!G_MM:7=7-K:3
M1*YM8I)?/P?D5F\M869<_P"^H8C +;<@N 0#TOX6_'JS^)4TD%E#<KY4>]WD
M1!&,D!5W)(^&/)4'&0K'M0!XU8>.G^!^NZFVI0R-:WTSRQR1QD[FWF5 K2-&
MA"I.5DQN(?: <9) ._N?VKK+4)_L6D6\]]<NRK$% AB<G!;YG.] JY)+1X&T
MDD)\] '0?M+Z^=%T&[9'"/(J1+G;EA(ZK(@#=28M_3D %AC&0 6_V>-$?1M!
MLHI""6A,HVY(VS.TR#D#D*X![9S@D<D \E\=^3XJ\<V5J=Z_9HXMQ&T9>)9;
MQ,?>ROS(&R ?O 8X:@#M?VN=+NM0T4_9%=E2=))PA_Y9*KY+ 'YE#[&(P=N-
MY "D@ J? 3X]6?B!+/18(;DSQ6D:.Y1/)7RH@&8L)"P4L JDJ,LR@X)H Y_X
MORR>)?%^E:?%(A6W\N8J2/D97:>4$J"P9HH4VJW'*G@,6(!TO[7^@3ZOHP:W
M0N(+E)9-O)6,1RJSXZD L,XS@98X4$@ YK2?VNUOK..VM+:YNM5,"#'E)Y;R
MA!YCXB<N5&&?"HN0,?(.5 .:_9ST2YU3Q-=7.IDSW-O#(9)?F*QSL4B,9("I
ME4,L849CPA,6456H Z7XORR>)?%^E:?%(A6W\N8J2/D97:>4$J"P9HH4VJW'
M*G@,6(!]*T",_P 0ZD^EVTUQ%&9GCAD=8ESND95+!!@,<L1@8!.3T/2@#QJW
M_; TN..3[7%<P7,6U7MS&"Y?.V1%.X#Y"#GS/*)'1=V5 ,Q?@/I#^+];O/$\
M4!M[&572$%BC2/E%=RJ85P=C,^[<HE;@NZ%E .?\?^*I?A9XO?5;J.06=S"%
MRBHQE001H57<0 5F1"PRK  '[K#< 1?%SX[77Q#L95TB*:WTY(V^UW,J[=QR
MJBV!C,@&XN@(!+-O&_9")&8 ]:_99T :1H-NVPH\[2RONW L2Y5'PW0&)4QC
M (PPSG) .$^ <LGB7Q-J^J>8DD2;X592/F5I0("NT;6416^-V<GY3\V2: *O
MCW7YOA/XIEUJYA=[&[@2-GC1F(_=J @9C'&)?,MPQ4L?W1)QD\ '5:A^V!I?
MR1V<5S<SR1J4C2,+^];(6!B6W;MV 3&LB\_*7/% 'M6DW$ES#')/'Y4K1H7C
MW!]C$ LFX<-@Y&1P<9% BW0!\U?M)6U]X1U:S\3VR;[>WC2*3!&1\\FY6RK;
M5D24H' .UCV8IN!EO5/VS+.ZC:/3+6YDO'PL*2(FPNQ"J#Y<KN>O"J,L<*"N
M=P -K]F[X53Z()M:U52-1O&=B"=I6-V60[D4*JNSC<PYV@*H"-O6@# ^*SGQ
M/XPTK3Q, ENJSE0%8K(I>=U."&!=(8Q@GY00X7GY@#Z/H$% 'RUX9F'Q[\0O
M=3*'TO3U(CC.YDD)9A$S(S*09"#(WR8VQK%(#U(,]Z_X5/H__0/L_P#P&A_^
M(H ^=OVC/#EG\/=8TK4X(DB@$B,\,$21_P#'O,DC.,%59F60+SC&T9;!X /K
M2@1\=_M#ZN?AYXF74[7)FDLBXR5PDCQ36B, 4((4*K[6!W$$9 / ,]O_ &;O
MAI_P@VEIYJ[;JXQ+-D89<C]W$<HK#:O56SMD:3!P: /5:!'S!X[\GQ5XYLK4
M[U^S1Q;B-HR\2RWB8^]E?F0-D _> QPU SZ?H$?*OC77;CX_ZHNCV2XTNTG#
M3S@J=VTLAD#@.HRN]8%&=^3(_P H/E@SW_5OAQ:W.ER:- B16[0/$@V;U0D'
M;)@GYF#X?).XN-Q;=S0!XK^Q_P")IK%KS0+PXEMI&=(R68KAS'<*&!:,*LFT
M@+C+.[#=DD 'TK0(X7XX^$)_&&CW5C: &9UC*!CM!*2I)MR> 2%(&<#)&2!D
M@&>%?!3]I&R\!Z>FD:E#/'-;-< D(&!.YY-I!971]Y,>T@@'!9E!;: 'Q'\7
M7?[0R0V&B6<@M8YA)+<3@1J' V;=RLR85)=S*"TC Y5 %.X ]E^*'PUDU+P]
M)HVG_,Z06\<7F, 6$+1L 6P%W,L> <*NXC)4<@ \:^$_[45MX(T^/2]5ANC<
M6S21D@*YVACM4B1XV0IGR]F"%"C!'W5 -#0M&N/CYJT6KW4+Q:/;;A;J^UA*
M4=259&8CYR?WC*I3;'Y.XLN^@#V7XJ?&2R^&:1/>B1C,S!$B4,Q"@%F.YD4
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M.6&0<C=R 6_VCM0N/!GB#3M=".+6...-I%56SB24S188X#-"YVYVYY*G*DJ
M2^,?VD9_'5L]OX>AGAPK&ZNY4VK;Q!69F!B:7:2JL=WW\*1$K2,I4 U?V+-
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MS%(H)&P"ZK\\@R!@X;@E> #Z5H$?,'[*WD^(]8U?5X]XW2'RU;:/DN)I)3N
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M^,&M1>(-3B>VLX=CVX 4;A&RRPQC=AV4[R[2[2K_ #*I3*A #ZJH$% !0 4
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MF?>NA6<C; FY5G<$!=Q.UMS*2QP,Q1G8-CR>8P,^GZ!!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!B
M>-M6GTBRGN+2(SSI"[1QJ-Q9P/EXW*6 /)"G<0"$!8@$ \5MOVS["W&R^M+J
M&X5F62)1&X1E8C;EWB;/'(**0<CG&2#(OA5H&J>.M=;Q%J\#VD=O&T5M"RF-
MN0P"X= SJ%D<LYVYD8;/E5D4 ^BJ!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!S_CWQK#X(LI=0N5=HHMFX1A2YW.L8P&91U89R1QGZ4 ?.LVM2?M!Z
MQ9/!:NFEV4C,\LL88.?W;R1O\QC^8JB! 68*QD8%<JH,^JJ!!0 4 % !0 4
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M]RSKMR6W1J(P@4 EBQGXP<Y&,'/ ,^BK2T2S18HE"(BA550%55 P% '  '
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MBJVZ.5C&[IN&3U9SYC,PV!(\@SVJ@04 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!POQS\+OXGT6\M8L[S#O4*I=F:)EF"!0026
M*;1C)!.<'H08? R6Y;1;-;V(PS1P^48V1HV"Q,T49*O\P)158]B3D  @4 =U
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \%
M_:(MK_QS/;>'[&*=8'F5KNY\J00*O!4;RR1R!1EV7."XC56\P%0#/;])TN/2
M(8[:!=L44:1HN2<*H"J,DDG  &22?4T"+= !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % &5_PEEG]H^P_:(?M7_/#S$\[[N_[F=WW?FZ?=YZ4 :M !0 4 %
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MA(S@@XZX(]: (M"\66?B#=]BN(9]F-_E2)+MSG;G83C.#C/7!]* -6@ H *
M"@ H * "@ H * "@ H * "@#*_X2RS^T?8?M$/VK_GAYB>=]W?\ <SN^[\W3
M[O/2@#5H * "@ H * "@ H * ,K0O%EGX@W?8KB&?9C?Y4B2[<YVYV$XS@XS
MUP?2@#5H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * ,^'Q#;3SM9I-&UPB[GA#J957Y?F* [@/F7DC'(]10!H4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 96A>++/Q!N^Q7$,^S&_RI$EVYSMSL)QG!QGK@^E &K0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &5KOBRS\/[?MMQ#!OSL\V
M1(MV,;L;R,XR,XZ9'K0!JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $5W=I9HTLK!
M$12S,Q"JJ@9+$G@ #DD\ 4 5-$\0VVO(9;.:.= Q4M$ZR*& !*DH2,X(..N"
M/6@#0H J:IJT.D1M/<R)%$N-SR,J(,D 99B ,D@#/<@4 36EVEXBRQ,'1U#*
MRD,K*1D,"."".01P10!+0 4 % !0 4 % &5J'BRSTZ9+6>XACGDV[(GD19&W
M$JNU20QRP(&!R>!S0!+K?B&VT%!+>31P(6"AI76-2Q!(4%R!G )QUP#Z4 6[
M2[2\198F#HZAE92&5E(R&!'!!'((X(H EH * "@#*UWQ99^']OVVXA@WYV>;
M(D6[&-V-Y&<9&<=,CUH U: "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@"IJFK0Z1&T]S(D42XW/(RH@R0!EF( R2 ,]R!0 :7JT.KQK/;2)+$V=KQ
MLKH<$@X920<$$''<$4 6Z "@ H * "@ H * "@ H * "@ H * "@"*[NTLT:
M65@B(I9F8A550,EB3P !R2> * ,G1/&]AKSF*SNH)W"EBL4L<C!00"Q",3C)
M STR1ZT ;= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S^E_
M$+3=7D6"VO+:65L[4CGB=S@$G"JQ)P 2<=@30!T% !0 4 % !0 4 % !0 4
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M:"5,8P6+B'!R#D;96/&#D#G&009Z+\/=4DU?3;.YG;=++:6\CM@#+-&K,<
M#)).  /04".@H * /F"XO%^.OB2.-5W:9IFXL3L>.5@_4$(ZE9&50$9B'AC=
ME*L2 #/I^@04 % !0 4 >=?M#ZV^C:#>RQ@$M"(CNR1MF=87/!'(5R1VSC((
MX(,YKX/Q2>!_"0NEC19UM+JZP0"')$DL3/L()S&$!Y#!0%.",  S_P!C30#8
M:0]PZ!3<7+LK_+N>-%6,9(YP)!( &Q@DD##9(![U0(* "@ H * /*OA-\7YO
M'VH:C J0_8[214BD1V9WRSJ&S@HZOY98$%=HPO[S.X STK5K>2YADC@D\J5H
MW"2;0^QB"%?:>&P<'!X.,&@1P'P-^&=YX&MY%U"Z>YGED+%=[O#'\SL2GF -
MN=G+R-@;F(&,J68&>E4""@ H * "@#YJ^$$4GB7Q?JNH2QH5M_,A# #Y&5U@
MB(#$L&:*%]S+QRPX#!2#/I6@04 % !0 4 % 'E7PF^+\WC[4-1@5(?L=I(J1
M2([,[Y9U#9P4=7\LL""NT87]YG< 9W7C?6WT&PNKR( O!;3RJ&R5+)&S@'!!
MQD<X(..XH$>0?L:: ;#2'N'0*;BY=E?Y=SQHJQC)'.!()  V,$D@8;)!GO5
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M55VG"@L.01@&?15 @H * /+_ -H'XNO\-+))K=8WN)9@B)(3C: 6=]JE68#
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M/<&!DW1RARNUSY60LDLR,0SCAE  RP(90" >]?"SQK_PF^F6^H%=K2Q_.,8
M=6,<FT;F^7>IVY).W&><B@#JZ!'G7QR^+J?#.R\\*)+B5BD$9( +8)+L,ABB
M\;MO))5<KNW &>:Z'\&?$?BJ);Z_UF>VEE5&\F,2J%4HN R*]NL;CD.H3&1D
ML230!Z+\&?"^L>&_M-OJ]S]JA611:NQW2,OS,[L2"_.]5P[,5*,%^0*S 'I5
M @H * "@#G_'^CW6LV,]O83?9[EXR(Y?[IR,C(Y7(RN]<LF=Z@L * ,KX/\
M@.;P/I\=G<W#W$HP69F9D3Y5411[N1$H4!0<9.6PN=H!G:T""@ H * "@ H
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MGI?A#X':/X/G%W8VH28*RAR\LA /!QYCL%)'&1@X)&<$@@'=4""@ H * "@
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M+\WC[4-1@5(?L=I(J12([,[Y9U#9P4=7\LL""NT87]YG< 9ZK0(* "@ H *
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MIH%JD+K)&7N&9VWK\KN%&T':P1-^&!WAE'[L'?0,]5H$% !0 4 % !0 4 %
M!0!\U?M33R>+-0TWPY"7'FR"60B,. &8Q)(,'<?+59F<95=I!)XRH,^D+2T2
MS18HE"(BA550%55 P% '  '  X H$?-_P#ED\2^)M7U3S$DB3?"K*1\RM*!
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MK*L;><$\M0\9*YVY9QCY&.&+@ ]5_9U^)D_Q"TS[1=@":*9H79>!(51&\S:
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M-B3P<NQ.0 >GVGPHN_C2BZGKES)!:S*'MK&!AM1",Q2,S!D9RC,3\F[##YD
M\I0 _9/>?2I=4TB28RPV-RJ19& "7G60@9)4,8PVW) .2.68D Y7XU>.+MO%
M<,.F))+<VUL\,4>1M$T\,A\Y0VY,*DJ,Y8 $1D.0@#4 :OC;]G.=+*?6=0U&
M>75((7G213B)#&/.\M ?G #[]C(8PN01&,%2 >@?LP^/)_&6D*]V2\L$SP-(
MQW-(%5'5CP.0KA23N+%=S,2QH \ZOK^^^.NL7%G9W3P:/:?NY6B<*95;*M]Q
MF$OF%&",V8UB&XKN)60 J?$?X9WWP2M7O="NIC9-&\=S%*XRC2XC6=-@C&X$
MH R@2(RKR\9<* >J_!G_ (HCPQ;SW/S+%:2W+"/DE&+W( W;?FV, 0<#=D9Q
MS0!X!\!;#7O'$,UG:73VMFT\DUQ=@%IGE<1G8'W!V;Y S;63"LQD9MR*0#H-
M8^'\GP5US3$TNYF%K>SQ1R([ABY654D#JJ(A79,-A(+*Q8@J0IH ZK]K_4;K
M0_[,U"#F*WNV<JQ_=F5=CP;D# MPDG(Z L,C=R >_P"K:I'I$,ES.VV**-Y'
M;!.%4%F. "3@ G !/H*!'@'[+*S>*+K4O$,KN%N)S&L/F,X&,2?-E1NV(R)$
MP(PN\;0"*!GT50(\_P#C]I\U_H5\EN^QQ 7)W,N40B25<J"?FC5EQT;.&P"3
M0,S_ -F6[>Z\/V32,6(6906))VK/(B+SV"@*!T   X% '@'ACXJRZIXNCU-F
MD:TGN9+2$H'6-H\>7$N'(X#/'-(O9FW[ Q H ]__ &C_ (@/X)TB66'(FG80
M1,,C8SJQ9\AE92$5BA&2'V\$9H S_AAM^$?AJ.?4MZ^7&99%'F,P,KY2((^-
MC?,JLN%02;F8\LY /-?!?PZU/X]1C4]<NW2Q:1O)MX=J@[3(NX#E4VL2H9UD
ME90P) VL0#*\8VEU^S5?6\FGSO/I]QYA-M*W4J(Q+G:H0,<J4E50PQM92H/F
M 'K7[6?BA]"T1TCR#<S1P%E8H54AI'Z#Y@RQE"O (8YR." =U\*-+;2M)LH'
M5U=;2#>LA<NK%%+*=Y+##$@+P$ "@    'D$<MUX@\=&-I,P:? SHA. JR6R
M*VT 8+&28$D\E1C.%5: (OVW-;2&PM;,@[Y+EI5/&W;%&R,#SG.9EQP1@')'
M&0#TKQ_XO@^#VC*5)8PPI;VP8;R\BQD1!]NP8PFYSE> =OS%5(!Y5X.^ ]U\
M5K9-3\2WD[/*JO;QQ-&JI&RK\Q&QHU+@*=J*N  7)=B$ .5N/#VKIXATO1-2
MG%Q]FN3<V]PY8O)#N$K;CEFS_H[!5;)5LKO,>Q@ ?8E @H ^8-7OI/C=X@N=
M$EN)H-.M(Y0T4>$:5HI(T8ODNI_>G<A8, B#"*[,U SNO '[-Z> -02\L+V<
M6X4^;;O@B5MLBJ69#&N%W@J"C$$$@\\ &?\ &?XKW5[>KX8T([;^; EF)V"%
M2GF$*>N[R_F+KDJO$8:4C8 <KX__ &8;/PO8SZM]NN1?01F?SW= K3*0V1P'
M#._"?O"P=E.7(PP!Z+^S#XOO?%.D+-J!+.DSQQR,"&DC54PY)^^0Q9"XZE?F
MRX8D \Z_96\GQ'K&KZO'O&Z0^6K;1\EQ-)*=P&?F'E*.&P,MUX( #QWY/BKQ
MS96IWK]FCBW$;1EXEEO$Q][*_,@;(!^\!CAJ /I^@04 ?'?[6_A6]M+N'_2Y
M[F.]F<Q6I!*QN@C1514.UB?,(7"!L<,79F8@SV3X8? N\\&W$<T^JW-S!%&5
M2V.](?N[%!4S2*552=J@##!2#A<$ \5OM8NM<\7WLFCP[[OYX8I).$MV1([:
M6Y8+N5E"JX4-D$NAV,^(R :'Q@^ MSX$M/[>AU&>6]A8>?,[,DC*Y$*&-@S.
MI"L$8,[!ER05 ", ?1_A/Q3_ ,2>WU*^?_EPBGGDV_\ 3$22-M0?4X4>P':@
M#Q#28KO]H^>6:662UT2%C$L,;@2S.-K@N/F7(^1SN#*GRI&&8O( #C_B+X7D
M^ VH6G_"/W,TDEQR]JY$A<JVQ Z1A-ZOO94&W<&5BC[ON@'V50(* /"OVM?A
MNWBJQBNXG19+60\22QPQE)2JM\TFU0VY4V[G48W#EBHH&<5<?MASZU:QVUE
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M (R-P 9BHH&4/A#^U##J6-/US_1KZ/>KRR!8H6*=0VXKY4O7<I 3<IP066,
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MD 'G7PX^%^K?%.P@_M>YDMM,2&*."UB 1I8TC55D8G/!9$=3()-QW%%C0H2
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M0\D>000 P+84YH&>J_L<>$!I6DM?$#?=S,006)\N(F-%(/R@A_,/&<AAD]E
M.E_:C_Y%V\_[=_\ THBH \O?7G\*^ HU8F*6X5XHPR'++-<2.PY4@!K?>P8X
M&""IR5H ]5_9K\(#PSHEL,#?.OVARI8@F4 H?FZ$1;%(  R#C/WB <A^VK_R
M!X/^O^/_ -$ST >M?#*T>STJQBE4HZ65LK*P*LK") 5(/((/!!Y!H$=+0 4
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M1$9@ :'QD^%L_P &4M]8TV]G-Q)-LN97?YI)& E!VA?F1FC<NLC/D[ =W)H
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ME@#%^.?C6^E\4P0:.KO=6T'E1H0&02S1N7E52VT8BE4EFPH,>7!1>0#5\?\
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M,T4*;5;CE3P&+$ /VOY9-<FTS1H)$#7$[$HQ'#,4B@D; +JOSR#(&#AN"5X
M-O\ ;/NW@T:-48J'O8E< D!E\N9]IQU&Y5;!XR >H% &AX9_9PFTV$0SZQJ+
M;,*@@F:WC5  %0(3+TP>A Q@!1C) .J^'/P+TOP!A[6+?.,_OY<23?Q#@X"I
M\K%3L5=RXW;CS0!Y590?VEX^E,LVW[/ #$C'.[-JBF),L,?ZUY2%!^ZQQR6
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MJ1E7R-RR2! #]Y@!MR=M &5^QUX9_LS1C=,$W74\CA@/GV)B)58X'1T<@9(
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MT='(&2 &R,%B* .5_:I\GQ'K&D:1)O&Z0>8R[1\EQ-'$-I.?F'E,>5P,KUY
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M4#)8D\  <DG@"@#YZ_8WMY-0AU#59Y-\MU=@.-H7YD!E9^,#YC.> H"[>.N
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M#Q%?ZKK30E#--^[;+%5$LDDTL0;"JQ&(\G&0,'Y0V"#"&$^,O';$M'+#80Y
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M2AC=V@62W:,,-OWO.!?8&=59E1=V">@&X@ T#/I^@1\U:A%)XH\>(CQH\5C
MI.0.%\DR)(0Q.6$\Z[2HR/E./E+4#/I6@04 >"_MEZG!;Z0D,JAI9+E/*&_:
MR%58O*%'WP%/ED'@&0-U"Y!FUIVA3:%X/>WN6=I5TFX+>8&5TW0NXB(8DCRP
MPC .,!1PO0 &?^QY#!'HF8&+.US,9P>BR84!1\HX\H1MU;ECS_" "+]L'QC'
MI&D?82,RWDBA1R,+$Z2N_P!T@X(1<$@_/D9VD4 >B_"'P@?!^DVMBX(=(09
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M,J<94]Q@T"/G6XUVW^)GC6V:W7SK:TCQYB%F0F$22K+E0,*)W5 <E'(!!97
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M>5O+W;%RJ(%!8 MP@))5>21@XR0#S_Q5^SYJUAK$NL>'KJ&W\[<S"0R9#/\
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M[#O8?NVWE@K< $ &5<>&?&\L<<:WUBK)NW2!3ODR<C<&MF0;>@V*G'WMQYH
M]:\%^'G\.VD5I+/)<NBG=-*2TCL26))))QDX4$DJH"Y.,D$>"_#:'_A;OB.?
M7I!NL;'$5KE?E9AG8WS1#.,M,02)(W>(9(% SZ5H$% '@'[:O_('@_Z_X_\
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M@#/^*'P?O_%FMV&I0RQBUM&@9HW>0-N2<R2,BA&3+(%&<@DJ > #0![+0(*
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M8;$ !ZW\;/!ESXUTN73K/RP\S19:5V155'60D;(Y"QR@&.!@DYXP0#5^&OA
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M1D57^4[%?/SE6 (QE0>H% SS_2?ASXUTB&.V@U&S6**-(T7:#A5 51DV9)P
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M+@G W9QD"@#S70/ OC/0[7[%%>6.Q8XHXF(8O$L? "_Z,%.5 4F0.<#((/-
M'HOPK\(ZCHB2S:Q>&ZNIV7<%.+>-4!51&NU "P.7(503C@E2S '=4""@#R7X
MV_ <?$!XKZUF-M?P+B.3YMK!2SQJ=I!0B0Y$BY*@G*O\NT&<?_PKKQOY/V?^
MU+;9Y>S.3YF,;<^9]E\S=C^/=OS\V[/- 'HOPZ^"T'A2RN+.XD-T]XTINIG&
MQY0X*E20Q?&TGJ['<SL"-V  >7Z/\!/$?@22:+0-0A2SDD#*LWS/TQDJ;>5
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MB,?-DK@8H \0\)_ 3Q3X$\V'2=0MD@>3=AMQSC@/L>WE5&*XW;2<X +,%!H
M]/\ A7\+[W1;F75=:N1=7\L*Q J"L<4:L247[BD-A&/[M-K!L9W,S &?\'_@
M[<>%M2U#5;[R?-NY&,0BDD?8LDCRRH=T<0//EX.,_*?NY((!M_'GP'>^.].-
MA821QEYHS+YI(5HURVT%4<@^8$/ ' (S@D$ VM)\%?\ $GCTBZ;_ )<$MI6C
M/_3$1.5++]2I*^F1VH \0\*_ [Q5X&22UTJ_M4MVF9QN7+,2 H8A[:7:2JKE
M0Q /0GJ0"73?V3[C3=2L[P7*2K%.+BXGD\S[1+()/,VA,LFWY5&XOOW/([%A
ML0 'K?QL\&7/C72Y=.L_+#S-%EI79%54=9"1LCD+'* 8X&"3GC! -7X:^$!X
M.TZVL  #%"H?:693(?FE8%N<&0L1P, X  X (X2]^%.H7OBB+79)839PQF.-
M,L)E4P.I&!&%/[V1FR7)VGKP% ,F_:&^"3_$^"'[/*([BW9]@?/E,LFS>&*J
MS C8"I (X*D?-N4 X_5/A#XA\3QM#XCU6%=/7$DODJJDA"&(9O)A55"Y;<Q=
M58*Q0X! !4_8AT+R;.\O=V?-GCBV8Z>4F_=G/.?.QC QMZG/ !VOQM^"$WC2
MXM]3TZ9(+ZUV[#(&9&VR+)'D_,%V'>P_=MO+!6X ( ,JX\,^-Y8XXUOK%63=
MND"G?)DY&X-;,@V]!L5./O;CS0!ZUX+\//X=M(K26>2Y=%.Z:4EI'8DL2223
MC)PH))50%R<9((VZ //_ (_:[_8FA7TNW?N@,6,[?]<1!NS@_=\S=COC&1G(
M!F?^S1H!T70;170(\BO*V-N6$CLT;DKU)BV=>0 %.,8 !G_';X$MX^:*^L9?
M(U"#8$<LZH5#E@"5!9&5B61U&<Y!!RK( <KJGPM\8^(HVL[W4[;[-+A9?+7#
M["1N V6T1/'5=ZAAE6.TF@#UKX5?#.#X<V2V-N2YW%Y)&X+R$ ,V,D*,* %'
M0 9+-EB <?H?P=N%\2S^(+OR?*:,B!4DD:16"1PAV!C1>8@^1E@I; W8#4 >
MP4""@#/\0Z(FO6TUG*2$GADB8K@,%=2A(R",X/&01GL: /G7PK\#O%7@9)+7
M2K^U2W:9G&Y<LQ("AB'MI=I*JN5#$ ]">I!DNF_LGW&FZE9W@N4E6*<7%Q/)
MYGVB602>9M"99-ORJ-Q??N>1V+#8@ /6_C9X,N?&NERZ=9^6'F:++2NR*JHZ
MR$C9'(6.4 QP,$G/&" :OPU\(#P=IUM8  &*%0^TLRF0_-*P+<X,A8C@8!P
M!P 1PE[\*=0O?%$6NR2PFSAC,<:983*I@=2,",*?WLC-DN3M/7@* 9[!0(*
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M'()'*G#8;&U@#FOA+X#\2>'988M1OH'L((=BPQ(K,P5-D:EC!&P"\-NW,25
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M6W1AL/.6< Y !#$T >]>!? MKX'M4LK)-L:\DGEW8XW2.<#+'')X  "J H
M(X7XAZ!XJU&[9](O+6WM J!$9<R$XRS-NMY>=Q(&T@;0O&[)(,\OT#]GOQ3X
M?O)M2M;VS2ZG\SS9/F;=O<2/\K6I498 \ 8Z# XH ]ZT/0=1GTDV>HW(^WO#
M.C7,0P%9RXC=0JP\JI7H%.1U[T >56G@3QQ:HL:ZG:D*H4%@'; &!EGM"S'U
M+$DGDDF@";PS^S?=:U?#5/%%REY*F L*#]R0H&S=E8QM!+$Q*@5F^9F;<ZD
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MAF64L5W.<N1^[E#*Q^8HXPC@,I^Z$ ,_4O@%X@\>/'%XAU&-K6-MX6!1N+9
M(QY,* [-P5VWE">$(9J /9/%7A)I=)ETO3U1=UHUM$)'=452GE EMLC':IR.
M"6( )&=P ,KX&?#5OAYIB64NPSF2229HV=D9F;"D;PI'[M44@ #()P222 <_
M\4OA3J'B[6-.OHI819V4D4AC<L)-PF#RE=L9SE$0 ,P&1T&22 =W\2/ Z>.=
M/GTZ1S&)E7#J 2K*RNAP>HW*,C()&0"I.0"/)?A9\*/$_A!K>U>_MET^&3+Q
M1H)'*ES(R O;JWS,2"=X*@DC. I!F_\ &WX.W'Q'O+!OW/V.VD)G#R2+)(KO
M'YB*$C./DCX.\$EL?+MR0#IOC9X,N?&NERZ=9^6'F:++2NR*JHZR$C9'(6.4
M QP,$G/&" :OPU\(#P=IUM8  &*%0^TLRF0_-*P+<X,A8C@8!P !P 1PE[\*
M=0O?%$6NR2PFSAC,<:983*I@=2,",*?WLC-DN3M/7@* 9-^T-\$G^)\$/V>4
M1W%NS[ ^?*99-F\,55F!&P%2 1P5(^;<H!Q^J?"'Q#XGC:'Q'JL*Z>N))?)5
M5)"$,0S>3"JJ%RVYBZJP5BAP" "I^Q#H7DV=Y>[L^;/'%LQT\I-^[.><^=C&
M!C;U.> #M?C;\$)O&EQ;ZGITR07UKMV&0,R-MD62/)^8+L.]A^[;>6"MP 0
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MJTM$LT6*)0B(H554!550,!0!P !P . *!$M !0 4 % !0 4 % !0 4 % !0
M4 <U\1?"\_BFREL;><6YF4I)(8O./EL"'4 N@!8'&XYP,X ;#* 0_##X>0_#
M^QCL(#NVY9Y"JJTCL<LY _!5R20@52QQF@9U= @H X_XL?#I/B%I\FGNPC+-
M&R2E!(496!W %EY*[DR"#ACU!((,V_">A?\ "/V=O9;M_D011;\;=VQ F[&3
MC.,XR<>IH$:M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M$% !0 4 % 'C7C;X)7/CK6XKZ_EC.FVRIY4"[G=V!#,)$=3& SY#D9+1JB$
M_,H,]EH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'BOQ2^'/B/Q?<36
M]O?0PZ7-Y:F/'[X)M02C*PACE@QV^: RG:Q"D@ SO_AA\/(?A_8QV$!W;<L\
MA55:1V.6<@?@JY)(0*I8XS0!U= @H Q/%_@VU\80&TOD+PEE8H))(P2.1GRV
M4L ><'(R <9 ( -N@ H * "@ H * "@ H * "@#BM'^$EGIVIS:TV^:\FP \
MFPB(;=FV,(B8^0!-QW/M&-WS/N!G:T""@ H * "@ H * "@"*[A,Z,BL4+*0
M'7:64D8##>K+D=1N!&>H(XH Y3X9_"JR^',!M[%3EVW22.0TKGG;N("C"@X4
M  #DXW,Q(,["@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >7_&#X::CXFE@O=)OC:W%NK!4/$3[GC9MS*"V#L&Y&61'VJ-
MJ_,6!G"ZI\%/$_C:-K/6=4A%J<-B&,,692-H8+%;Y7JW+$;@IVD@%0#V_P %
M^$(/!UI%86@(BB4A=QW,2269B?4L23@  G"@#  (VZ "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@"*[NTLT:65@B(I9F8A550,EB3P !R2> * .4^
M'GQ8T_X@B4Z?(7,+ .&1T(!9PC?, "&"%A@Y QO"M\H!F+9?%^2]U^7P_':Y
M6&,227'G ;5,2.#Y909^>14P&)YW8P#@ ]*H$% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!Q7Q7^*]K\-[4W-R=TC9$,(.'D8=AUPHR"[D$*"."Q56!G/_
M  U^+^H>++K[-=:1<V<?ELWG2%M@(Q@'S(HNN<#:6;./EV[F4 ]5H$% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y5\4OCW'X.N(].L[
M=[Z^?EK>(G<B[2V2520[B!N"!<[,NQ4;=P,Z#X6^/+KQC#)+>6$UBR2;564_
M?& <C<L;\9P<IMZ;68[@H!VM CBO'7QETOP0K_;+A/-3CR$(DG)*%U78IRN1
MT9]J<C+#(H&<5^RYXX_X2.Q<W5[]IOI)YI9(G;$D2Y10JJ3_ *KHP* 1J7V
M J: /:J!&?K^OP>'H'N[MQ'#&NYW;H!T[<DDX  R6)  )(% &)X%^*6G>._,
M_LV;S?*V>9\DB8W[MO\ K$7.=IZ9QCGM0,M^-?'MEX(A6YU"7RHFD$8;:[Y8
MAF Q&K'HI.<8XZ]*!'%?\-1^'?\ G\_\@7/_ ,:H&=KX*\>V7C>%KG3Y?-B6
M0QEMKIA@%8C$BJ>C YQCGKUH$=!0 4 >:ZI^TCH&F2-#)>H67&3&DLR<@'AX
MD=#UYP3@Y!Y!% SM?#/BJU\40BYL94FB./F0YP2 VUAU5@&!*L PSR!0(T+N
M[2S1I96"(BEF9B%55 R6)/  '))X H \TN_VFO#]J[1M>@E6*DK%.ZY!P<,D
M95AZ%201R"10,]%TO5H=7C6>VD26)L[7C970X)!PRD@X((..X(H$5?$WBJU\
M+PFYOI4AB&?F<XR0"VU1U9B%)"J"QQP#0!Q6E_M(Z!J<BPQWJ!FS@R)+"G )
MY>5$0=.,D9. .2!0,]*H$% $5W=I9HTLK!$12S,Q"JJ@9+$G@ #DD\ 4 >:7
M?[37A^U=HVO02K%25BG=<@X.&2,JP]"I((Y!(H&>BZ7JT.KQK/;2)+$V=KQL
MKH<$@X920<$$''<$4"*OB;Q5:^%X3<WTJ0Q#/S.<9(!;:HZLQ"DA5!8XX!H
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M*^U)]K\SR]F'V[\?<W[?+W9^7;NSO^3&_P"6@9VM @H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /-;+XOR7NOR^'X[7*PQB22X\X#:IB1P?
M+*#/SR*F Q/.[& < STJ@04 % !0 4 % !0 4 >:_#SXOR>,M2OM/%KY<5E)
M)&T_G!MS"1HT&S8I&X([9!8+MP3R#0,]*H$% !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 <UXO^)6G>#@3?W,<1"JVPMF4J6VAA&N9&&<\A2!@D\
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M0!YK\7?B_)X"FL[:"U^U2WLCQHOG"'# Q*HR48?,9 ,DJ!CD^@,]*H$% !0
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M+$@*"2!0(^5?$OQPL-=\4VEZ\SKIMI&0L@,X!8QNQ<(JJZY=EC<8(=4&_*'
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M(V<_P%L$$-M(Q0,Z;X9_&G3OB,"+)R)57<\,@V2JNXKNP"58=,E&8+N4-M)
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MR_ZO[W^S\U SNM'^*MEK.HOI-LQDE2V6X:10##L;85 ?/S$K(C J"NT_>R"
M :'C'Q_8^#(Q-J$Z0J?N@DEVP5!VHH+OC<,[0=H.3@<T".%\!_M/:1XRG%HC
M202NRK&LZJHD8Y^561W4'C #%2Q957<3B@9U_P .OB5:_$"&2YL=_E1SO#N=
M=NXJ%;>HR3M(<$;@K>JB@"AJ?QIT[2[VXT^=RCVML)YY&&(E4E $SG<SGS$(
M"J0=P4$O\M &?\.OC_I_Q O)+&Q6;='&\GF.BK&RJZIE?G+\[P0&53CJ >*
M-#XF?&G3OAR +UR967<D,8WRLNX+NP2%4=<%V4-M8+N((H Y_P !_M/:1XRG
M%HC202NRK&LZJHD8Y^561W4'C #%2Q957<3B@#U6[NTLT:65@B(I9F8A550,
MEB3P !R2> *!'C^M_M9Z)I=R+4/)*-P5IHD#0J=Q4Y)968#&[,:N"I&PL>*!
MG5VOQITZ_N[.QMG,SWL+RQ,@_=A%#G+EBI!)C==H!964APO% &_XO\:6G@Z
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MO/SN@P8CMH [#]I7X9Z9IVAW%Q;VD$4L30,CQ1)$P)F2,Y*!<@JY&#D9P<9
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MBYW9W,: .E\=?$.;X7:3:QR#[5J4D<-O&@9G,LP0*\ASB5UW=<#<S,BG:7W
M /@A\+;CPWYVIZM)YVIWFTRL=K>6HY$2L!]-P4B/Y45!MC#, >JT""@#Q_QC
M^U5HOAJ00K(]TW\1M@LB+PI'SLZ(V<_P%L$$-M(Q0,Z;X9_&G3OB,"+)R)57
M<\,@V2JNXKNP"58=,E&8+N4-M) H M?$7XL:?\/45]0D*F19#$BH[LY0*648
M&T'YE WE1D]0 2 #Y[_9;^*6F>'(;C[?,_\ :%W=C/R7$\DHPOE_<1P6,CR?
M[;$\Y^6@#ZTH$17=VEFC2RL$1%+,S$*JJ!DL2>  .23P!0!XUXF_:YT71)C
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MH<\$@,,E2RYZ,:!'2T % %35M4CTB&2YG;;%%&\CM@G"J"S' !)P 3@ GT%
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M#0!;\8^/['P9&)M0G2%3]T$DNV"H.U%!=\;AG:#M!R<#F@1YKX9_:YT76YA
MYFM]V 'G15CR2 %+1O)MZYW-M0 $EAQD&>RW=VEFC2RL$1%+,S$*JJ!DL2>
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M$))8 &?37@?XCV/CE'ETZ0RI&P5F\N6-=Q&=H,B*&(') R0",XW#((Z6@ H
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M=BI&\\KM;RP'=]J@&K\3= @^%WA>[M].0!!"(V+<LYF=(9)&(VY<JY(/0$*
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M8"'/5/E/'% &A\>+Y_B+KUGX6CD"VZLDL^ 5</L>1@&*L,BWY3 V[GPY./D
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M@ *M &?^S/\ #6[L=1O-:N;8V44ZR+!;LH4A9)MY7;\K($\L* R*&#!EP!R
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M.U  #U#]H&[3P=X;G@M6$0$,-M$I()*%EC:,;\ECY._U8 %LY&0 :'P#T_\
MX1KP]:?:715$#3L^["*DC/."Q8#&$<;L\ @\D<T ?/\ ^S9\*%^)-U/K>JCS
M8TG)VD)LFG;]XY=1CY5W*Q3:%<L!G:K(0#J_VU8K6QL["W2/;*LD@AVC;&D2
MHJR1[00!DF+:-IP%(!7HP!]/T""@#XU?4-4UKQ7?ZAHUDD\]M(\>)&/EIL46
MN_=YD"[G5&VH2>"V Q3< 9ZKI/BKQK<S1QSV%G%$TB!Y,A]BD@,^T7N6P,G
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M(S&L;=<AG*[PK  U?VR] LFTY+Z9#]K69(H9$P.&W.R29ZIM5BO4J^,85GR
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M595&%'"X^5@4)! /+_V+- %IID]V4*O/<E0YW /'&BA,9^4@.T@R.IR"3MP
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M9U_T#Q5JUK#\D ^V8B7Y8QLND6/Y1A?E5B%X^4$@8!- &A\37'BKQIIUBDQ
MMEB=EPQ59$WW1 !(&7C6,%ESQC.2FV@#Z*\0ZVF@VTUY*"4@ADE8+@L512Y
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M;>JY$LA&5CV \L&" '=?M!:(F@^%)K.(DI!#9Q*6P6*I- @)P ,X'. !GL*
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M+1RS!91A0&4*D#,6!X!)^7;D@'TK=W:6:-+*P1$4LS,0JJH&2Q)X  Y)/ %
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M<65').P!O+^9G(0 ]?\ @#H7]B:%8Q;M^Z 2YQM_UQ,^W&3]WS-N>^,X&<
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MJE,;6$FP[_E7<:!AXH_:$T3PZF][R.4E7*I 1.S%0#M_=[E4G("[RH)[X!(
M//\ ]D#P==Z9!=:C=H(TO6A:)0HC)5?-)<(JJJ(?,&P  $#(4(4+ $U_^S#>
M?;+J]LM7FM?M4\DKI%&Z?>=G524N$W;=Y ) ZG@9H \?_:,\ WG@F&WCO=4N
M;[SI'9(Y _EKY8 9\O/)\W[P!<+T+?,,88 ^BOAM\.'^%<,]Q?ZA-=010#:'
M\T1P11@L^V/S95/RA<87<H7:O#$4 =+:?&+1KI%D6_M0&4, T\:-@C(RKL&4
M^H8 @\$ T >%?M(_$Y/'IA\.Z(3<RR3(\C0N#$V%8K%D':X&1([$[(]@).0V
MP ]UM%MOA;I"B4@0V=L-S*JQ[V5>2%+!=\C] 6RSMC))S0!+\-?B5:_$.U^V
MV6\()&C99%VNK+@X."RGY65@5)&" 2""  > ?";QU'X+\3:O:Z@Z6\5S/.X>
M;,?S+*[Q?,Q"JK12,P+<-\FT\@, =U\=OV@;+1-.DCTZZCFNYU,<9AD$GE@X
M#R%HW&PA2=ASG?M(4JK8 .F_9[^&LGP_TM+:X_X^))&FE4,&568*H0$ =$10
MW+#?NVL5Q0!XU^R3\18/"Z7FE:G+':E)A(HF/DMOQY<R,7(4%=B80X;)8\@'
M: =+^T7\88=8MX]$T69+BZO9(XV,+JRA&;;L\Q7"AG;"E22/++[PH920#0^(
M_P /W\)^#)--3,CPPQ,^W+_-]H2:9AA5.Q26() (09;H30!H? ;XS:?<:-:Q
MWEW;0SPQ^2R/(L) C^6,XD8$YC"DLN5+$@8(*@ \_P#B3JW_  O?6H-&T^3=
M86N9+B16VJV&"RNA)97VJ0D3;#\[N<F([J /=?BE\6[/X:PQSWN]O-DV(D>P
MR' )9MKNF5' 8C."RCO0!U6DZI'J\,=S VZ*6-)$;!&58!E." 1D$'! /J*!
M'RW^R3\18/"Z7FE:G+':E)A(HF/DMOQY<R,7(4%=B80X;)8\@':#.E_:+^,,
M.L6\>B:+,EQ=7LD<;&%U90C-MV>8KA0SMA2I)'EE]X4,I(!H?$?X?OX3\&2:
M:F9'AAB9]N7^;[0DTS#"J=BDL02 0@RW0F@#0^ WQFT^XT:UCO+NVAGAC\ED
M>182!'\L9Q(P)S&%)9<J6) P05 !Y_\ $G5O^%[ZU!HVGR;K"US)<2*VU6PP
M65T)+*^U2$B;8?G=SDQ'=0!J_MB:A-HDVDZA"F[[//*X+*QCW@P21JQ!'WO+
M/&02%;'0D 'L'_"Z]%\G[1]OMMGE[\>:OF8QNQY>?,W8_@V[\_+MSQ0!XU\%
M+:?XH:]/XHERMK TD5LI;#9V;%0H3)@"*0N^&4&5\KD;P #Z:H$>/_M87$D6
M@3K''O5I(!(VX+Y:^:K!\'[V754P.?GW=%- RK\/OC+HOA?0;9S<0@PVD8>"
M,J)S* !(HBRK%FER2Q 4Y,A;:2] 'E_P;UNY^)'BPZG=@PF*V>6.$[F B:-8
MHD!8C *SB7<!M<DL% ?@ Z7]M[7?)L[.RVY\V>27?GIY2;-N,<Y\[.<C&WH<
M\ 'I?A7XS:#!I\4D%W##!' H6&20"=%C7;Y9C+-(S +@ ;B_!4L""0#R_P"#
M;/\ %3Q%<>)")$M;9?+MU=B?F,9CV_=*8V%Y'16!1Y$Y8$D@%34?$T'@WQS-
M/J"!(IX8TCFD&U8RT$2B525/!9&B+ J%#/N8!6% 'K?CK]H/2?"]J]S'<0W,
M@X2&&6.1V8YP#M+;%XRSD8 Z!F*JP!Q_[*O@:>WBGUV_(:XU!MZYCVR!-[LS
M9PN!*Q#[5&TJJ,"<@* <_P#LEH/$5_JNM-"4,TW[MLL542R232Q!L*K$8CR<
M9 P?E#8(!T'[9>OFPTA+='"FXN45D^7<\:*TAP#S@2",DKC!(!.&P0#U_P $
M:(^@V%K9RD%X+:")BN2I9(U0D9 .,CC(!QV% C;H ^5?A-XQM?!OB;5X-2"0
M-//.8YIOW>T"5Y F67A9$8."656V)C<66@9[A>_&O3(Y[>TMYA=S7,PC5+9D
MG*CJTC[6PB*.6)YQDA2%8@ \?^.$MMIWBS3;C4X@]D]L(F,B*T)8O.F6\S"8
M1I$=\G*+AL9QD ]U3QOI6DP0L+JUBMV4K ?-B2(K'A"L?S!2%X4A>%Z<4"-#
MPMXIM_%5NE[9/YD$F[8^UESM8HW#A6'S*1R/TH ^>OV2T'B*_P!5UIH2AFF_
M=MEBJB622:6(-A58C$>3C(&#\H;!!GTU0(^2_P!ECQY9_;-4U#4I;:WGN)(W
M4NZ1?ZQYI)50R-NV[MN1D]%W9(!H&>M?M,7:7GAJZEB8.CK;,K*0RLIN(2&!
M'!!'((X(H R?@=\5-(T;0;42W$%L8H9/,A:=7EW*[[WV$^82Y!D"!2?F"J",
M9 /)8?&LWQ@\4Z=(RO;VJ2>9;*P8[DA9Y6?&[;ND:$HS)PNT*2YCR0#N_P!M
M/4GFMK'3HHR[SW+.NW);=&HC"!0"6+&?C!SD8P<\ 'HOQHN(_!OARZC@C_=)
M:"V1-Q^59-MNIR=Q.T.#SRV,$C.: ,_]EG0!I&@V[;"CSM+*^[<"Q+E4?#=
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M3M)# @'G !Z!0(\5_:\UW^S=">+;N^T3PQ9SC;@F?=C!S_JMN./O9SQ@@P^
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M#;OS\NW/% 'C7P4MI_BAKT_BB7*VL#216REL-G9L5"A,F (I"[X9097RN1O
M />O'7CJU\#VKWMZ^V-> !R[L<[8T&1ECC@<  %F(4$@$>:_##PS-\1)H_$V
MLCU-A:$-Y<"9XF.X#?*V ROC&-KC_EFL0,RKW_B;>.8O-_<_9; ^5N_Y>-RO
MG9G;T\]\[=_^I;ISM (?&5VGQ#\66-C P>'35>>9HR R2AP2A+95@'2%6" L
M"S@D$'8 ?0M CYJ_;$G_ +.FTF]DA\Z"&>4R(P_=MS XB8E64;U1A@@Y ;@@
M&@9[!_PNO1?)^T?;[;9Y>_'FKYF,;L>7GS-V/X-N_/R[<\4 >*_#%9/C-XA?
MQ"Z[+&RVQP)(@8L=K[ " %W*S&9CEFC9D4$C:X -7]LBXDU"'3]*@CWRW5V2
MAW!?F0")4YP/F,XY+ +MYZY !]"VEHEFBQ1*$1%"JJ@*JJ!@* .  . !P!0(
MEH ^8/CSK<?A7Q5INHWD6ZU6! 6924!$DP9Q\K;FB\Q9,*"V0N,$@T#/9=?^
M..C:+ ]PU[!($7/EQ2QRRL>@545LDD\=@.K$*"0 >:?M<ROK&@6]RD4B@W,$
MKJZ$/&K0RC$@&=A#.J')P&(7.2* /2_ WC'1$LC<V#VMO;[8I955H(A$TH 4
M2A&VHYP$Y.25V@G% &UX:\?V/BB2:&QG2=H/+\PQDL@\P$IAP-C9VG.TG!!!
MP>*!'@OB5!XL\=V\#PEDLH4W$%B,I&]S'*=H&T"65%P202 #G=MH&?35 CY5
M\8^)H9?'4/\ :!A2WM(U17D*J@_T9YT9BYVAA++\IXP0F/F&2#/</'WB&VU[
M1-1ELYHYT%E=J6B=9%#"!B5)0D9P0<=<$>M 'E7[*/Q TS1](,-Q-!;2BYEW
MB6=%:0E4(E"NPVC;B/ X)0MU)H \Z^,OQ*;XQZA9Z?:[XM/-V(8YBKXED9HT
M>4J2JG8KC8IPX5R6*^9M4 ^E/C]KO]B:%?2[=^Z Q8SM_P!<1!NS@_=\S=CO
MC&1G( ,7]EG0!I&@V[;"CSM+*^[<"Q+E4?#= 8E3&, C##.<D \__9+0>(K_
M %76FA*&:;]VV6*J)9))I8@V%5B,1Y.,@8/RAL$ Z#]LO7S8:0ENCA3<7**R
M?+N>-%:0X!YP)!&25Q@D G#8(!Z_X(T1]!L+6SE(+P6T$3%<E2R1JA(R <9'
M&0#CL*!&W0!\@:+\0[&W\:W5[J(\I1)+;Q.6)1)4"VPD<_+A61'!R"J%QGA=
MX!GJOQM_:#T_0M/DCLKA)[J>.2.+[/*K&,E<&5G0G9MSE?XF; 7 #,H!G^"/
MA^_@GPA=Q39$T]E>3RJ<C8SVY"I@JK*0BJ'!R0^[DC% &5^RC\0-,T?2##<3
M06THN9=XEG16D)5")0KL-HVXCP."4+=2: /.OC+\2F^,>H6>GVN^+3S=B&.8
MJ^)9&:-'E*DJIV*XV*<.%<EBOF;5 /L^[M$O$:*50Z.I5E8!E92,%2#P01P0
M>"*!'P7X,^(]WHVF3^&+6$K>7=[Y9+@ [94$$L)#[?+?<BKELC#/]QE5B#/L
MGX2_#]/ .G0V*X+JNZ9ACYY6Y=L[5+ 'Y4+#=L50>E 'BOPR0>*O&FHWSPD"
MV65%;+%5D39:@D@ 9>-9"%;/&<9*;J /0/VIM?&D:#<+O*/.T42;=P+$N&=,
MKT!B5\YP",J<YP0#:^ .A?V)H5C%NW[H!+G&W_7$S[<9/W?,VY[XS@9P #RK
M4(I/%'CQ$>-'BL8%)R!PODF1)"&)RPGG7:5&1\IQ\I:@"+XX2VVG>+--N-3B
M#V3VPB8R(K0EB\Z9;S,)A&D1WR<HN&QG&0#W5/&^E:3!"PNK6*W92L!\V)(B
ML>$*Q_,%(7A2%X7IQ0(T/"WBFW\56Z7MD_F02;MC[67.UBC<.%8?,I'(_2@#
MYZ_9+0>(K_5=::$H9IOW;98JHEDDFEB#856(Q'DXR!@_*&P09T'[9>OFPTA+
M='"FXN45D^7<\:*TAP#S@2",DKC!(!.&P0#U_P $:(^@V%K9RD%X+:")BN2I
M9(U0D9 .,CC(!QV% CYF_98\>6?VS5-0U*6VMY[B2-U+ND7^L>:254,C;MN[
M;D9/1=V2 :!GT3J'Q5TO3IDMY[N&-Y(%G0NX6-HF)5660XC.2#@!MQ'S 8YH
M \5_:XT_19K625GA754DB"K&R^>^[8"LJJ"Q41#<K/C;A0K -M< ];\/>(W\
M*Z%#>ZNQWPV4;S%@4E+;!A")7R9B<(=S O)V7=M !?\ AK\2K7XAVOVVRWA!
M(T;+(NUU9<'!P64_*RL"I(P0"000 #JZ!'SA^VGJ3S6UCIT49=Y[EG7;DMNC
M41A H!+%C/Q@YR,8.> 9[?JUQ'X(TV22"/,5G:.4CW$96&,E4W'<>B@9.3W.
M:!'DO[&F@&PTA[AT"FXN797^7<\:*L8R1S@2"0 -C!)(&&R09[U0(\J_:C_Y
M%V\_[=__ $HBH&8GP.^*FD:-H-J);B"V,4,GF0M.KR[E=][["?,)<@R! I/S
M!5!&,@'DL/C6;XP>*=.D97M[5)/,ME8,=R0L\K/C=MW2-"49DX7:%)<QY(!W
M?[:>I/-;6.G11EWGN6==N2VZ-1&$"@$L6,_&#G(Q@YX /H32=+CTB&.V@7;%
M%&D:+DG"J JC)))P !DDGU- CYU^ <LGB7Q-J^J>8DD2;X592/F5I0("NT;6
M416^-V<GY3\V2:!GH'[4&D_VCH%UB/S'C\J1<+N9=LJ;W'!(Q&7W,.B;LG&:
M / -&UVX^./]F>'H5\JTM((6NCE0Q\K]RTBL0Q/[ME"*%XDD8/N10X /KG7]
M;MO!=D]S(!';VT.0J[5 51A(T!*KD\(BY )(4=:!&?\ #7XE6OQ#M?MMEO""
M1HV61=KJRX.#@LI^5E8%21@@$@@@ SJZ!'SA^VGJ3S6UCIT49=Y[EG7;DMNC
M41A H!+%C/Q@YR,8.> 9]":3I<>D0QVT"[8HHTC1<DX50%49)).  ,DD^IH$
M?.'QPEMM.\6:;<:G$'LGMA$QD16A+%YTRWF83"-(CODY1<-C.,@SW5/&^E:3
M!"PNK6*W92L!\V)(BL>$*Q_,%(7A2%X7IQ0(T/"WBFW\56Z7MD_F02;MC[67
M.UBC<.%8?,I'(_2@#YE_9)\>67A5+S3M1,=I<"8.7F(A9@!Y;1,7"X,;#(4M
MG,C84;6- SWJS^,&GZE?1:99R?:99(WD9X-LL,2J.LCJV%R?E &3N*A@NY20
M#P_5I;#3O&MT-:BC-O<6R")KA(_(#"&$B3,V% _=/&&&3O.SUP ?0&M_$S3-
M#027-W @:$2J#*A9XR"0Z*"6<'!V[ =QX7)H$2ZMXQCMM-DU6 >;$MH]R@Y3
M>HC,JCE<KD8ZKD9Y':@#QK]BS0!::9/=E"KSW)4.=P#QQHH3&?E(#M(,CJ<@
MD[< &97[3T,&A:WHVJS,5 F42GJJQP3QR;@%4L3^];/7(  &<Y +?PHT>7XM
M:N_B>^0K:P-Y=@C1H RJTFUCDL28R=Q89'G'Y' BV4 '[7$J6%SH]Y<Q&2UA
MN9#,-@=2NZ!S&=V$)9$?"L0& /8' ![)I?BS1](M5>VN+.*S60QJ8Y(4@#G,
MA0%2$#')8J.>2<=Z -#PKXTM/%B22V,HF2.9HF90=N]0"0"0 PPP(9<J0>":
M!'SA\(M?M?"OBC6!J.RW=Y+@QS32>2 IN ^P!]JMYBLCJ>NU,KD,30,T/VEO
MCM%>VDFF:/()RZ_Z5-$798HLQX =!L82,X1B&*@9C8;G& #UKX Z%_8FA6,6
M[?N@$N<;?]<3/MQD_=\S;GOC.!G  /0*!'R+\7O'%I:^,K>744(M[)8$9E)8
M[MK3QRX7:<))*I*C<2$/#9V4#/</'7[0>D^%[5[F.XAN9!PD,,L<CLQS@':6
MV+QEG(P!T#,55@#C_P!D3PA/IUE/J5X)!-?3*X,AR7C4$I+S\^6>1R2Q^8;6
M P=S '*?'7Q"GP]\56.L/ 6B^S?O"@"EV_?0N0Q&'=(W0X)S@(I*@@@ V_V;
M/#-QXKNI_%FIA#+<92WVA< +^[=@N"5P$$2'=O*B3?G<&8 ^BJ!&)XWUM]!L
M+J\B +P6T\JALE2R1LX!P0<9'."#CN* /GO]D+Q9IOA_39_M=Q;03O=MGS)(
MHI&01Q[/O$,5#%]O8$MCDF@9VO[7FN_V;H3Q;=WVB>&+.<;<$S[L8.?]5MQQ
M][.>,$ [KX/Z - TBRMPAC*VT3.C;@PD=?,ER&Y!\QF)'8\  #% 'C6GRR>*
M/'CNDB/%8P,!@CA?)$;Q@J#EA/.VX,<CYAGY0M $7QPEMM.\6:;<:G$'LGMA
M$QD16A+%YTRWF83"-(CODY1<-C.,@'NJ>-]*TF"%A=6L5NRE8#YL21%8\(5C
M^8*0O"D+PO3B@1H>%O%-OXJMTO;)_,@DW;'VLN=K%&X<*P^92.1^E &K0!\B
M_%[QQ:6OC*WEU%"+>R6!&926.[:T\<N%VG"22J2HW$A#PV=E SW#QU^T'I/A
M>U>YCN(;F0<)##+'([,<X!VEMB\99R, = S%58 X_P#9$\(3Z=93ZE>"037T
MRN#(<EXU!*2\_/EGD<DL?F&U@,'<P!RF@^*+;2O&U]/JOEVQ\DI"TK*5#!(0
MCA\;4+P*S<D$!S&26." 3?M*?'V._MY=)TAO.#1J;JXB8M&D991L#(<'<65'
M).P!O+^9G(0 ]?\ @#H7]B:%8Q;M^Z 2YQM_UQ,^W&3]WS-N>^,X&<  \ \;
M^//^%2^*=0NUM^)[0B+Y=J%WCB<2X^7>IGC(D(8')<Y++@@'I_[,/P_ETZ"7
M6K_#7FHMYN[Y"1$_[P'Y5&PNS%V4$K@1Y"LI  .5^.$MMIWBS3;C4X@]D]L(
MF,B*T)8O.F6\S"81I$=\G*+AL9QD ]U3QOI6DP0L+JUBMV4K ?-B2(K'A"L?
MS!2%X4A>%Z<4"-#PMXIM_%5NE[9/YD$F[8^UESM8HW#A6'S*1R/TH ^>OV2T
M'B*_U76FA*&:;]VV6*J)9))I8@V%5B,1Y.,@8/RAL$&?35 @H ^6M!\46VE>
M-KZ?5?+MCY)2%I64J&"0A'#XVH7@5FY((#F,DL<$&3?M*?'V._MY=)TAO.#1
MJ;JXB8M&D991L#(<'<65').P!O+^9G(0 ]?^ .A?V)H5C%NW[H!+G&W_ %Q,
M^W&3]WS-N>^,X&<  ^>_V</B=IT6LW][?D6TMXTCPN[XB17D:66)G)5<GY-K
M,H!V$ J6"L =U^T?\;;6\LCH^E2?:;J\V)FV?>%4N,IF/=N:3!C\L<E6); *
MAP#0^(_P_?PGX,DTU,R/##$S[<O\WVA)IF&%4[%)8@D A!ENA- &A\!OB[I/
M]C6L4D]M:R0Q^4\3RQQ'<O63#;,[_P#6$@$;F(+%@U 'G_Q;\4_\+RU.#P]I
M3_Z-%(\D]QMWQ$JI!==HSM0%D5MRI*\@&0NQR :O[9$_DV>GZ3:PY\V<F)8Q
MT\I!$D2QJO.?. 4#&-H !SP ?16DZ7'I$,=M NV**-(T7).%4!5&223@ #))
M/J:!'SK\ Y9/$OB;5]4\Q)(DWPJRD?,K2@0%=HVLHBM\;LY/RGYLDT#/I6@1
MX!^VK_R!X/\ K_C_ /1,] SJM'^-^BZ%I,,_GPHL=I"1:QS+/.GR*%@"[M[,
M.%)8#&"SE0"0 >-?!O6[GXD>+#J=V#"8K9Y8X3N8")HUBB0%B, K.)=P&UR2
MP4!^ #H/VDD'B?7](TAX3(FY7DVEB6CEF"RC"@,H5(&8L#P"3\NW) /I6[NT
MLT:65@B(I9F8A550,EB3P !R2> *!'SK^QK#/J*:CJMPP8W-R@8]&,BAY)&(
M"A0#YXQCOD8  R#-#]M'2?M.DPSK'N:*[3+A<E$9) V6Q\JE]@/0%M@/.* .
M/\/:E+^T3K4-Q+&$TS3UC=HFV$[W4,4.0WF!Y8\'(53"G1';# 'U?0(RO%/B
MFW\*V[WMZ_EP1[=[[6;&Y@B\(&8_,P' _2@#G_$VL:'XHLR;Z:SFLS(8][RQ
M&,2%#PK[OEE",2"I#@'((ZT#/'_V0+=H9M36TD=]-6=1 75_G.7PX)V*&\H)
MY@V;CNC)V!0& ,7X,>*K+0/$^L&]:.$O-=;)Y91$H NOFB 8A6+Y5LYR!&<<
M,: -#]I3X^QW]O+I.D-YP:-3=7$3%HTC+*-@9#@[BRHY)V -Y?S,Y" 'I7PM
M_P"*$\+0S_ZWRK"2ZQ]S.]7N?+S\V,;MN[!SC=CM0!Q_[%F@"TTR>[*%7GN2
MH<[@'CC10F,_*0':09'4Y!)VX !S7PMU#3=%\1:Q'K"0QR_:VGMY;E8D";9I
M&!1I2"K,)$=-OWE7=G@9 /?_ !3\5=+\*[Q>W<,;Q[=\>\-,-V-O[I-TAX8'
MA?N_-TYH ZN@04 ?*OPF\8VO@WQ-J\&I!(&GGG,<TW[O:!*\@3++PLB,'!+*
MK;$QN++0,]%^,7[1EAX8LG^P7$=Q=RJZ0B%XY1&V/]:Y&]0%R"%()<_*!MW,
MH!;_ &:/AB_@73!]H %Q<L)G&PHZ*479"Q8!B5Y)! "LSJ ?O, <5^R6AUZY
MU76FA""YN?W;95F4LTDTL0; ; WQY.%#$ ]5P #Z/H$% !0 4 % !0 4 % $
M5W;"Z1HVR RE259D;!&#AD(93Z%2"#R"#0!B>"O 5EX(A:VT^+RHFD,A7<[Y
M8A5)S(S'HH&,XXZ=: (O%_PWT_QB\,FH0"8V[,T08OM!8J6RH8*X.Q<APP(&
M,8)R =+0!RG@7X6Z=X$\S^S8?*\W9YGSR/G9NV_ZQVQC<>F,YY[4#)IOAQ8S
MZ@NKO&6O$7:DADE(5=K)M"%_+ PS<!<9);[Q)H$'CCX<6/CE$BU&,RI&Q95\
MR6-=Q&-Q$;J&(' )R0"<8W'(!TM 'FNJ?LW:!J<C3262!FQD1O+"G  X2)T0
M=.< 9.2>230,VO _PBTOP,[RZ=;B)Y%"LVZ21MH.=H,C,5!/) P"0,YVC !%
MXQ^"^D>,I!/?6J/+W<%XG;A1\S1,A? 4 ;L[1P,9- $7A#X':/X/G%W8VH28
M*RAR\LA /!QYCL%)'&1@X)&<$@@':W=HEXC12J'1U*LK ,K*1@J0>""."#P1
M0(\_T#]GK0] G2[M[0++&VY&:2:0!NS;9)&7(Z@D9!PPP0#0,ZKQ?X+M/&,!
MM+^(2Q%E;:200PZ,&4AE/49!!()4\$@@CBK3]F7P_:NLBV0)5@P#2SNN0<C*
MO(58>H8$$<$$4#/2[2T2S18HE"(BA550%55 P% '  '  X H$<_I/PXL=)O9
M=4AC(NYE*R2M)*Y*DJ=N'=E &Q0   H 5<+Q0!H>*?"UOXJMWLKU/,@DV[TW
M,N=K!UY0JP^90>#^E !X6\+6_A6W2RLD\N"/=L3<S8W,7;ERS'YF)Y/Z4 <I
MXF^ >B>)9C<W5HAE;.YD:2'<22Q9A$Z!F)))8@L>YX% R;PA\#M'\'SB[L;4
M),%90Y>60@'@X\QV"DCC(P<$C."00#NJ!'DO[4VOC2-!N%WE'G:*)-NX%B7#
M.F5Z Q*^<X!&5.<X(,S_  %\"-(\0:-IWVV#SF6T1PY=T?\ ??OW4F(IE0[M
ML#9V@G')8D [KP/\(M+\#.\NG6XB>10K-NDD;:#G:#(S%03R0, D#.=HP =7
M=VB7B-%*H='4JRL RLI&"I!X((X(/!% CS2T_9E\/VKK(MD"58, TL[KD'(R
MKR%6'J&!!'!!% SI=.^%FF:;>_VG#;HMUY:QAQNPJJBQJ$3.Q,(H4%%!VY&<
M$Y ,#XZ?&>/X8VJN%\RZFWB!"#LRN-SN1CY5W#(!W,2 ,#<Z@&3^SG\%/^%=
MVIENE0WTW+L.3&G!$ ;)!P1N<K@%L#+A$:@#UN[MA=(T;9 92I*LR-@C!PR$
M,I]"I!!Y!!H$8G@KP%9>"(6MM/B\J)I#(5W.^6(52<R,QZ*!C...G6@"+Q?\
M-]/\8O#)J$ F-NS-$&+[06*ELJ&"N#L7(<,"!C&"<@'2T <IX%^%NG>!/,_L
MV'RO-V>9\\CYV;MO^L=L8W'IC.>>U P\:_"S3/&^TZA;I*RXP_S)( -V%WQE
M7V_,3MSMR<XS@T <U:?LR^'[5UD6R!*L& :6=UR#D95Y"K#U# @C@@B@#T#7
M]!BU^![2X!:*1=KJKO&2O==T;*V#T(!P1E3D$B@1%X6\+6_A6W2RLD\N"/=L
M3<S8W,7;ERS'YF)Y/Z4 9.O_  MT[Q!>0ZE=0[[J#R_*DWR+MV.9$^57"G#$
MGD'/0Y'% SJZ!'FO_#-V@>=]H^Q)O\S?C?+Y><[L>7O\O;G^#;LQ\NW'% S5
M\8_!?2/&4@GOK5'E[N"\3MPH^9HF0O@* -V=HX&,F@"+PA\#M'\'SB[L;4),
M%90Y>60@'@X\QV"DCC(P<$C."00#NJ!!0!POB_X':/XPG-W?6H>8JJEP\L9(
M' SY;J&('&3DX &<   R7P=\%](\&R&>QM427LY+RNO##Y6E9RF0Q!VXW#@Y
MP* /-?VE/C-I_P#9$MG97:2W%SM1?L\BR84.K2;V1OE4IE,'E]V,%=Y4 ]/^
M$/A ^#])M;%P0Z0@R!BK$2.3)*N5^4@.S 8SP!R>I .PH$17=HEXC12J'1U*
MLK ,K*1@J0>""."#P10!YI:?LR^'[5UD6R!*L& :6=UR#D95Y"K#U# @C@@B
M@9U=I\-]/M+M=12 "X2$11MERL<8&T)&A8QQC&1\BKP6_O-D$>'_ !$EC\4>
M-=.LC(Y2VC5V0$@+*@DNA@,"OS*L6\KU7"Y!7Y09Z+=_LR^'[IVD:R +,6(6
M6=%R3DX5) JCT"@ #@ "@#T#0- @\/0):6B".&-=J(O0#KWY))R23DL22222
M:!&A0!%=VB7B-%*H='4JRL RLI&"I!X((X(/!% 'G^@?L]:'H$Z7=O:!98VW
M(S232 -V;;)(RY'4$C(.&&" :!G:Z_H$'B&![2[020R+M=&Z$=>W((."",%2
M 000#0(\Z_X9<\._\^?_ )'N?_CM STK2])ATB-8+:-(HESM2-51!DDG"J !
MDDDX[DF@1;H S]?T"#Q# ]I=H)(9%VNC=".O;D$'!!&"I (((!H X72_V;M
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M.=HZYQCCO0,ZN@04 <+XO^!VC^,)S=WUJ'F*JI</+&2!P,^6ZAB!QDY. !G
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M:NLBV0)5@P#2SNN0<C*O(58>H8$$<$$4#.KM/AOI]I=KJ*0 7"0B*-LN5CC
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M)C92P!Y .0"3C&XY!FKX0\%VG@Z 6EA$(H@S-M!))8]6+,2S'H,DD@ *.
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M  "<* ,  C;H YKQ#\.+'Q%<P7MW&7FMF5H3YDJJC!@X8(KA,[@,DJ2P #9
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MDC;A),)&&5"AE90_E87H44,[$,5C ,^H+2T2S18HE"(BA550%55 P% '  '
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M>'?^?/\ \CW/_P =H&>E?V7&L/V9%V1>7Y86,F+:N-H"F,J4P.%*D%>,$8%
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M+@A[EFN&!*L ' $9&WH#$J-@DD$G./N@ ]:H$% !0 4 % !0 4 % !0 4 %
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MVKB ?;77:9278XVJG"EBBG8H7*@'&1G#-D Z6@ H * "@ H * "@ H * "@
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MG#-D Z6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H J:MI<>KPR6TZ[HI8WC=<D95@5
M89!!&02,@@^AH S_  AX+M/!T M+"(11!F;:"22QZL68EF/09))  4<   &W
M0!S_ (U\!67C>%;;4(O-B602!=SIA@&4',;*>C$8SCGITH V[2T2S18HE"(B
MA550%55 P% '  '  X H EH * "@ H * "@ H * "@ H * "@ H * "@ H *
M .:U;X;Z?J][%J=Q 'NH%"QNQ<A0"S+\F[82&8D$J2#@@@@8 .EH * "@ H
M* "@ H * "@ H * "@#FO%_PWT_QB\,FH0"8V[,T08OM!8J6RH8*X.Q<APP(
M&,8)R =+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S
M_C7P%9>-X5MM0B\V)9!(%W.F& 90<QLIZ,1C..>G2@ \'> +'P9&8=/@2%3]
MX@$NV"Q&YV)=\;CC<3M!P,#B@#H* "@ H * "@ H * "@ H * "@ H * "@
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M>@4""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /*M;
MT?Q#?:]%)!,D.DQQJ3C:Q<94R1,C9;S69<!QA8XN5;>75P9ZK0(* "@ H *
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M3(FEKQ%$NUUE7#^6 #\\;+NW2N<%G 10T878 >JT""@ H * "@ H * "@ H
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M /*OA%H_B&*ZN[C79D\EI&$4";63/R 2HWWDB"KM1&.YB6>10_S.#/5:!!0
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MZVF@VTUY*"4@ADE8+@L512Y R0,X'&2!GN* .?\ A/\ $ ^/]/CU$P& 2-(
MI=9 0K%=P88.,@CYE4Y!X*[68&<+^UYKO]FZ$\6W=]HGABSG&W!,^[&#G_5;
M<<?>SGC! .Z^#^@#0-(LK<(8RMM$SHVX,)'7S)<AN0?,9B1V/   Q0!V% @H
M * "@ H * / /B/^T-=7=T^C>&K=Y[Q)'CEE,>4CQB,LHR!\LC8,DH$2E>0Z
ML& ,J+HWCRRC6Y^TVTS#RV-MMA#MDC=&Q\F-.,G<5E' .QB<9 /6OA/XSG\8
M:?'=W<!MYMTB2(>!OC8QN0"2ZC>I&U\,I!!W !V .PH$% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '/^/_ +=]AG_LG9]L\L^5OQMS
MD9QGY=VW.S=\F_;O^7- &5\']'U/2=/CCUF;SKHX/\),:[5"Q,Z_ZQA@EG.2
M68C<P 8@SQK]DM!XBO\ 5=::$H9IOW;98JHEDDFEB#856(Q'DXR!@_*&P0 \
M2H/%GCNW@>$LEE"FX@L1E(WN8Y3M V@2RHN"2"0 <[MM 'TU0(* /F7]I)!X
MGU_2-(>$R)N5Y-I8EHY9@LHPH#*%2!F+ \ D_+MR09]-4""@ H * "@ H *
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M M>"?$9\364%\T9A,\*2>6S*Q 89'*G!!'(/!P1N56RH -N@ H * "@ H *
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MSPP*Y\ME^8%@ #UKX5>*?^$JTNTO2_F/) GF/MVYE4;)N,*!^\5AP-O]WC%
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MG1B3D,=@  ?M2>/+WP8^FW%L9!;K<L\ZH3&LA0QLD3N <!E\P;3D, 25;8,
M'NMW=I9HTLK!$12S,Q"JJ@9+$G@ #DD\ 4"/!?V?O&=[XKNM3UJYN7&F>8RQ
M1RE B!?G!^]B+RX=H?'RR%]S,S)F@94E\9:I\;KJ2WT29['2H<J]V%(EE<88
M!.4<=!A59"$):4Y=(J .5\:ZWK7P!NK:22_?4;:XW%XYMV3Y> R@NTICXD!5
MD;EA\Z%5 8 ]D_:2\:/X3T6:6"4PSR-'%$R@[MS,"X! .T^4KD-P01\I#;:
M/&_#C>*OBY9Q/97'V.UACAC5VEECDGDC0I)+YB(TKY;.[)"9P/G=':@#Z?\
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MC5R!DDXR>,DG'<T"-N@#FOB'8:C?6C)H\T<%T63:\J[UVY^8#A@I([E'&,C
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MPV#\BGGY%49.,T =K0(^4/V=[1+/Q;JD42A$1;Y550%55%W$ H X  X ' %
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M"$):4Y=(J .5\:ZWK7P!NK:22_?4;:XW%XYMV3Y> R@NTICXD!5D;EA\Z%5
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MG:XOI0@A2/.Z/"K&5#MS'C8WRJ6 .6:( +NTUGX1ZSIL4NI27T%],(668R$
M&2-'^1Y) "!(K(ZMG.01MR' />OBKXI_X172[N]#^6\<#^6^W=B5ALAXPP/[
MQE'(V_WN,T ?/?PK\4>(?B/8Q6%A.88HE9;N_FW/,SO+*3'&Y9BQ$+H1@(R,
MH'F("FX T-$\5ZI\)]>M]%U"\>^M;O859P6E!F/E(V7<LN)4P5WNFPE@N]L
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MD#<0/6@#Q7]GOXHIX2\,3W=XX*6US-' A(4NQC25800I)+2.QR0Q4$L?D7@
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M^8R@'L>20!F@#A?V0]"_LW0DEW;OM$\TN,8VX(@VYR<_ZK=GC[V,<9(!X_\
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MNBB&Q> 2!B0RCH&/?(VT#*G[:.H>=9V>GQH[SSW>^,*N[.Q#&5P#N+%IEV@
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M%4!5&223@ #))/J:!'SA^S:X\3Z_J^KI,9$W,D>X,2T<LQ:(Y8AE"I JA2.
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MEE9)Y<$>[8FYFQN8NW+EF/S,3R?TH$:M $5W=I9HTLK!$12S,Q"JJ@9+$G@
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M&]'Q@[=I.: +7QHTN/P%X7NK;35\F)(Q&JY,F%FG591F0L?F$C#.<C/RD8&
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MAI6,FX2HCR+"!Y97<SIO D7 16=@<D*P,^Y;2T2S18HE"(BA550%55 P% '
M '  X H$2T % 'Q+\.M(U;Q)?W_B/P_D.MZS+%( BS1S2.[Q,Q<1DJ-A=-W
M8,KJZIN!G=^+/"_B_P"*/E:?J,,-E9F3,KQNA4@<@NHGD=\8^1!A2Y!8C 9
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MRK(6)D=!C"8XR<D<8R0 :OPA\('P?I-K8N"'2$&0,58B1R9)5RORD!V8#&>
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MAD.I.Y#S^[!F?XFM/&OCV$Z=/;VUG#+D22I(!E<',;%9IWVMP"%7)Z,=A8$
M]J^&'P\A^']C'80'=MRSR%55I'8Y9R!^"KDDA JECC- 'B'B3X::]X.\07&K
M^'[>.6*X4DAI$VDR;6E5A))&X/FKY@V' !4 XW( #*^(?P<\1?$*)K_4U!N0
MJ):V4#QK'%E_WKN9)-@!1<_(\CLS)DJD>T 'T)I/@K_B3QZ1=-_RX);2M&?^
MF(B<J67ZE25],CM0!\]_#CPKXP^%Z36=E9P3PM,6!>2(KN V%T_?Q/AE5>'&
M0 /E4EL@'K_PKT;6[FYEU/7G$9>%8XK.)R88P&)=V0%U+G:I5Q(YVLRG VJH
M!S7P0^%MWH^L:GJ]]"\'VB23R%9X7RDLS2ON$3R88;8Q]['+?>Z@ Z7]HWPY
MJ'B;26L=,B$SS31"0%D0B-29-P+NBYWH@[\$\=P =7\,] /A[3+2T=!&\=M"
MLB+MP)-@,OW?E)+[B2,[B2<G.:!'A7A#P#XD^$-S-!I5O'>V$LRN \RJRH&8
M ?.\(29H]N]@CKD)C.W;0,[70-3\6:_>HMW!!I]DLWF.RF.>5XU/_'OD2N"6
M! +A8\8+ @X1@ _:B\$7WC6PAL].@,SBY$K'?$BJJQNF#YDB$DF3C (P#DCC
M(!ZKX>T1-!MH;.(DI!#'$I;!8JBA 3@ 9P.< #/84"-"@ H \/\ VHO@_=_$
M&"WEL,/+;-)^Z)"EUD\L$AF(4%=@.#@$$X.0%8&8NJ:9XQ^(<;:=>QVVGVTF
M/-EC;<[)D!HP$GE)R#DCY P4JT@5B& ,_P#8?T1X;:]O"1LDFBB4<[MT2L[$
M\8QB9<<DY!R!QD Z70_A;=W7BZ?6[B%XK58SY#EX3O<11V_*J[L%*[V7(4\+
MNP<K0![K0(^8+OX8^(? 6N7>J:-!#=I=>:<R,J!1+*)60JTT3;E90 02I4@\
M$E5!F5\2O@]XE^(,?V_4$1K@;4@LX98T2$9)DD8R,4.=@X61G8NI+*L0C(!]
M*>$]+D\-:;;VSKYDMO:11E8R/G:.,*0ID*#DC"EBHY&2.< CR_\ 98^$]UX"
MMKE[^,Q7$TR#9OC=?+C7*,/++8):1P<GH!P.I!A^U/X(U3QK;6UGID F03/+
M*=\:,K*NR,#S)$!!$CYP"<@<CN >J^(?"Z:I83:=%B%)+:2!=JC;&K1F,84%
M1A0>%! P,<4"/G7X7^%?%WPX1M.L[.U>%[EF,TL@9>0D9<;)T?9M0-CR]^,_
M+GY:!GHO[1GPFNO'4-O<:<^V\M)'>/Y_+R" QVL%.)=\:;"611\Q)'! !E?\
M)MXS\G;_ &5;>?YF=_G1^7LQ]W9]IW;MW.[?C'&S/S4 >E?#6WU..UWZS(C7
M4DC2;(U54A5L;8 5SOVX.6))R2-S@!V /$-5^&FO>!-=N]5T*WCN8[I7.99$
M^4RNLDBD&2 Y$B_+C<-A )+9P 97Q,^$_B;XAP"[U&.-IE;;!:0O%&(0V/-D
M=W)# B)<()7.9-VY AC8 ^E/!&B/H-A:V<I!>"V@B8KDJ62-4)&0#C(XR <=
MA0(VZ "@#Y0\$?#CQ1\(I[J+2K:"[BE:/$KLBAE3>4(4W$;*?G(8'(R/E)'S
M$&>_^,O [^.=)?3KYQ'+-#'YCQ E%E4J^5#\E/,7H2&*\94G( /$/ ^G^,_A
M[;_V;:V=M/!%))Y;N\?0L6.W%Q$VTL2PWKO&[!P % !T'PY^#&IZSJ@\0^)&
M3SDR8;92LBQD%@@/WD54^_&$9F+D.SAPVX ]_H$% 'E_[17PSG^(6F?9[0@3
M13+,BMP)"J.OE[B0%)#D@GC( .T$LH,Q?@U+XGLFM['4K2V@L8(!&9 P:9A'
M&$C V3R#<2 6)4+M#8(.T$ J>._A;=^*O%-EJ!A=;&VCBW3!X1EXFEG3"[V<
MKO9$;*@_>Q@8>@#V7Q#-/!;3/9J'N%AD,*-PK2!244_,O!; /(X[CK0(\J_9
M=^&]UX&L)H[^ 0W$ER6SF-V:,1H$RT;-P&WX!/!).!NY!G*ZK\./$'@'5[O4
MM CCN8;UG9HY) -K,RR%F4O N0[.(R"Y5"P;!.2 ;]SK?C#Q#/Y$=I!IUN[+
MF=GBNI8E&"YXD*N3@@#R@/F )7'F  ]PH$% 'G7[0/ARZ\3://8V,1FFF:$
M!HT "RK(6)D=!C"8XR<D<8R0#/)?!GA?Q?\ #&%;2PAAN[=XXY LKI^XD89E
MB'[^/HY.=I9&X==K,XH VO ?P/U'Q%J8U_Q,X\U&5H;9&R(V1R8P2I*JB8#*
MJLQ<G=(V=X< Z#]I[X3S^/[*(V,8DNH)LJ"^PF-QB11N(3.X(WS$<*=IR=K
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M$Y(!OW.M^,/$,_D1VD&G6[LN9V>*ZEB48+GB0JY." /* ^8 E<>8 #W"@04
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M*2OS$+MPK '8?M1>"+[QK80V>G0&9Q<B5COB1558W3!\R1"23)Q@$8!R1QD
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M  "X!D^//AQXH^)L!EU2..,0*WDV4$B(9)3A5E9F>2,!0Y)W/N(1D14,ADH
M]K^!WA"?P?H]K8W8 F19"X4[@"\KR;<C@D!@#C(R#@D8) /*OB9\*]:TOQ /
M$.BQ1W)9?N.RH$80"W(8-+'N!7YE*MD'(8  %P#V3X:WNJ7MKYFMQ0PW)D;$
M<))"H,!=QWR#<2&/RL1M*]&R  =70(* /E#P1\./%'PBGNHM*MH+N*5H\2NR
M*&5-Y0A3<1LI^<A@<C(^4D?,09Z_\:_#FH>)M!>QCB$U[,MN'$3(D0=7221@
M9G0[,H0O5N5R,9( .@^$/A ^#])M;%P0Z0@R!BK$2.3)*N5^4@.S 8SP!R>I
M /.M<^'NHZWXN@U*>V1M/MXPB2%HSTBD=6*%R^Y9Y#M(48VJPZ;B :O[1GPF
MNO'4-O<:<^V\M)'>/Y_+R" QVL%.)=\:;"611\Q)'! !E?\ ";>,_)V_V5;>
M?YF=_G1^7LQ]W9]IW;MW.[?C'&S/S4 >E?#6WU..UWZS(C74DC2;(U54A5L;
M8 5SOVX.6))R2-S@!V .KH$% 'R7\/\ PWXR\$375S#8PRRWDBR3-+) <L#(
MV0([B,#)D)(QCI@"@9Z?X+\1^+K^[BCU&RM8+4L?-E4AV"@$X 6[8Y8@*#@A
M2=Q! (H V_CI\&(_B=:J@;R[J'>8').S+8W(X&?E;:,D#<I (R-R, >=:!KG
MCO2($MVLH)RB[?,EDC:5@.FXK=*&('&<9.,L2Q)(!#;?!76/BC?)?>*=D-M#
MD+:1/G. IP-C.%5S]]]YE.W: J[&0 ]Z\0VDMG831::H29+:1;95"*JN(R(E
M ;Y  V  ?E Z\4". _9E^'EWX$TQ[>_4)+)<R2[ P<JI2- "5RN3L)X)&",D
M'( ,]:H$% 'A6A_"V[NO%T^MW$+Q6JQGR'+PG>XBCM^55W8*5WLN0IX7=@Y6
M@9M^,K_Q1HNH/+IT,%[82-'MB9DBEB5542#<QBY=BQ!/G!<#A?NL <5XC\$>
M(OB]/'::S!'8:;',TI\MXY96QE43<)),OM8@-M1.68JQ")0!]'T""@#QK]J+
MP1?>-;"&STZ S.+D2L=\2*JK&Z8/F2(229., C .2.,@SU7P]HB:#;0V<1)2
M"&.)2V"Q5%" G  S@<X &>PH$>->!/A[J/\ PE-[K.H6R+ T<J6\@:-ONM%%
M$P4.[JS0H=QP.K#@';0,U?VD?@Q)\2+6-[5L75MYAC0D!) ^W>A)^ZWR#82=
MN<AL!MZ@'*_\)-X\\GROL-MO\O;YNZ'S,XQYF/M/E[L_-C9LS_#CB@#L/@/\
M$G^'XFNKZ43W]RQ\R098*NXM@.ZB1BY.Z0G 8A1CY-S &)H?PMN[KQ=/K=Q"
M\5JL9\AR\)WN(H[?E5=V"E=[+D*>%W8.5H ]%^+UC=ZCI-U;Z=&);B6$Q*C$
M*"LA"2'+,@!$;,1DXR!P>A ,K]G[P7+X.T>"TNHA%<!IFE4%"2QE;:Q9"0Q\
MO8,Y)  7M@ 'HM CSK]H'PY=>)M'GL;&(S33-"  T: !95D+$R.@QA,<9.2.
M,9(!GDO@SPOXO^&,*VEA##=V[QQR!973]Q(PS+$/W\?1R<[2R-PZ[69Q0!M>
M _@?J/B+4QK_ (F<>:C*T-LC9$;(Y,8)4E51,!E568N3ND;.\. :'[17PMN_
MB'>:=%#"[6L4C_:95>%-J2O$&VAWW%E5"WW".5QN.0 #L/V@?#EUXFT>>QL8
MC--,T( #1H %E60L3(Z#&$QQDY(XQD@ U?A#X0/@_2;6Q<$.D(,@8JQ$CDR2
MKE?E(#LP&,\ <GJ0#SK7/A[J.M^+H-2GMD;3[>,(DA:,](I'5BA<ON6>0[2%
M&-JL.FX@'5_M"?#63X@:6]M;_P#'Q'(LT2E@JLRAE*$D'JCL%Y4;]NY@N: /
M.O#R^-H[:'3(K>UM$CACB6Y9D=E6-0 2!+,"6"[3B(C+9PO4 $O[/GP,O? 6
MK75Q,FVU$#0Q.SHSRDO&3*%3.Q3Y9;:^&0.J9<AFH U?'?PMN_%7BFRU PNM
MC;1Q;I@\(R\32SIA=[.5WLB-E0?O8P,/0!H?M1>"+[QK80V>G0&9Q<B5COB1
M558W3!\R1"23)Q@$8!R1QD ]5\/:(F@VT-G$24@ACB4M@L510@)P ,X'. !G
ML*!'C7@3X>ZC_P )3>ZSJ%LBP-'*EO(&C;[K111,%#NZLT*'<<#JPX!VT#*O
M[0/PEU/6=2L];TE4GEM_*!A8JF#%(TR/EG0,I)VL 58<8SDE0#F?B/HOBKQQ
M83_VNL%C:6T,L[I$VYIS'&TBJ0LLN0&0<,R %@^V1D  !VO['FB/IVB>:Y!%
MQ<S2IC.0H"PX.0,'=$QXR,$<YR  8"^*-3\:>+C#I\\B6%BRI/LW^20@;S%D
M1V",[R%XE8#(51(@/E[J /H^@04 >7_M%?#.?XA:9]GM"!-%,LR*W D*HZ^7
MN) 4D.2">,@ [02R@S%^#4OB>R:WL=2M+:"Q@@$9D#!IF$<82,#9/(-Q(!8E
M0NT-@@[00"IX[^%MWXJ\4V6H&%UL;:.+=,'A&7B:6=,+O9RN]D1LJ#][&!AZ
M /9?$,T\%M,]FH>X6&0PHW"M(%)13\R\%L \CCN.M CRK]EWX;W7@:PFCOX!
M#<27);.8W9HQ&@3+1LW ;?@$\$DX&[D&<KJOPX\0> =7N]2T"..YAO6=FCDD
M VLS+(692\"Y#LXC(+E4+!L$Y(!OW.M^,/$,_D1VD&G6[LN9V>*ZEB48+GB0
MJY." /* ^8 E<>8 #J_V@?#EUXFT>>QL8C--,T( #1H %E60L3(Z#&$QQDY(
MXQD@ U?A#X0/@_2;6Q<$.D(,@8JQ$CDR2KE?E(#LP&,\ <GJ0#*^//PO?XCZ
M<;.%@DR31RQ%B5CW#*,&PCMC8[8P,[MO.,T <+H'B?QGIEK]GDTV&65(XDCE
M:XCS\O#M*#<$R,P'4-'ALL=V<4 >B_"M=:G26YUTQH\C+Y5M$J[854$,2X9R
MQ<_-@LX4 8(W%% .ZH$% 'SA\7/A/K%GKT?B#08Q,Y52ZN\0"NJ>2RE9#'\C
MQ8'RL6!WG*?(:!F@L/C'QJRVE['#IUMYD;2S02[)R@<;HT9)9RK$'(.U0=N&
M;:2K %_]J+X/W?Q!@MY;##RVS2?NB0I=9/+!(9B%!78#@X!!.#D!6 ,75-,\
M8_$.-M.O8[;3[:3'FRQMN=DR T8"3RDY!R1\@8*5:0*Q# &K^R_\*;WP+]MD
MO8O(6>2(11M*DT@6/S#EFC 0_P"L R,$E6.Q1C( >._A;=^*O%-EJ!A=;&VC
MBW3!X1EXFEG3"[V<KO9$;*@_>Q@8>@#V7Q#-/!;3/9J'N%AD,*-PK2!244_,
MO!; /(X[CK0(\J_9=^&]UX&L)H[^ 0W$ER6SF-V:,1H$RT;-P&WX!/!).!NY
M!GLM @H ^2['X1>(]+U*\U[3X_)F-VSQV\DD)\^*:1V=&*3,@V_)N5F&<ED<
M.BY!FUXF\(^+OBJ$L-2C@L+0,&D9&!#X9< JDTS.5Y95)1"1EFW!" #V_3/A
MK:Z9I9T2'>ML8)82=V9,2!O,?)!&XERW3:">%"X% 'BOPUT3Q7\+5_L^.SAO
MK-9&<,+A4/SH#MC:5UV*'Y(,7+%R/O!J .[^'EUXHUF[636$@L[6)7W11!)&
MG9AA03YLQ0(1NR"I)PN&!)0 ]:H$% 'A7[17PMN_B'>:=%#"[6L4C_:95>%-
MJ2O$&VAWW%E5"WW".5QN.0 9[K0(\*_9U^'NHZ)>:CJ&L6R0SW4B.A5HW^^\
MLDRJ4>1E7<4X)YPO4KD S/\ BY\']4M-8C\1Z!B6X++YD+F, 8B\K(+E 4:,
M;6&0ZD[D//[L S_$UIXU\>PG3I[>VLX9<B25) ,K@YC8K-.^UN 0JY/1CL+
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M;C0!#=ZAXX\2(UFUM:V0E4J;A7 9!C)P4GF8$XV@JA()R"I&X 'J'CWX=?\
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M?N@\OM5G84 >@4""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \O\ C!IOB#S8+S0)
M(R(5826SX!EW/&>2Y\LC"^L3H-^QV,F #. U_3O&GQ!@?3[B&UL8G7YY%DP7
M7H8LQRW# -G)PJ@@%2V"58 ]D^&'P\A^']C'80'=MRSR%55I'8Y9R!^"KDDA
M JECC- '5T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#PKXH_#+4_B5K$,%POEZ+;[
M';,BD3L,%\(C+(K$-Y0+<(JNZ'+;6!GN%I:)9HL42A$10JJH"JJ@8"@#@ #@
M < 4"): "@ H * "@ H * "@ H * /!?AQ\)]0UO5YM?\11A75B+2W9TF\H;
MMT; QGRP$!(7C+.6E(5P&8&>]4""@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /'_B=9^)]/OA?:(T,]L8XT-H^%Y D)=O,=1U;[T;QL
MWR*R,J%B#.*\2>"_%OQ6C%GJ8MK"U61#($8L91GKA))MVS&X(S1J6())(!0
M]J_X07^S=+_LG39/L^V#RHY=NYER,-+B-HOWIR6W K^\.\@\@@$7PJ^&<'PY
MLEL;<ESN+R2-P7D( 9L9(484 *.@ R6;+$ ["@04 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'A\WP\U3
M4?%ZZO*H%A;P[8G+1Y*F!E*!5RY/FRNV7 & <-]P$&>X4""@ H * "@ H *
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MP_$UU?2B>_N6/F2#+!5W%L!W42,7)W2$X#$*,?)N8 ]:H$% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H XK0_BW9ZWJD^BP;VGMXR[N-AA
MX,890P<MN5I K J,,K \CD&=K0(* "@#/\0ZVF@VTUY*"4@ADE8+@L512Y R
M0,X'&2!GN* ,3X:_$6'X@6OVZVCFCB\QD7SE5"VW&67:S@KDE<@_>5AVH&=7
M0(* "@ H * "@ H * "@ H Y_P >^-8?!%E+J%RKM%%LW",*7.YUC& S*.K#
M.2.,_2@"7P7XJ3Q9:17T4<D:3*6595"2;<D!B 6&& W*02"I![T ;= !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%=W:6:-+*P1$4
MLS,0JJH&2Q)X  Y)/ % &?X9\56OBB$7-C*DT1Q\R'."0&VL.JL P)5@&&>0
M* -6@ H * "@ H * "@ H * "@ H * "@ H * .%^)GQ@MOA\]O%<13S/=,Z
MQ+ BR,64H-N&="23( H&23^&09W5 @H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MR6 W(P#IG:<;@-P&1D<T"-N[NTLT:65@B(I9F8A550,EB3P !R2> * /.O\
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MO-$C[MF%\O=P&^5F^ZI(#$$B@1:\7^-+3P= ;N_E$4095W$$DL>BA5!9CU.
M"0 6/ ) !G^-?BGIG@C:-0N$B9L83YGD(.[#;(PS[?E(W8VY&,YP*!FMX9\5
M6OBB$7-C*DT1Q\R'."0&VL.JL P)5@&&>0*!!XF\56OA>$W-]*D,0S\SG&2
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MND27N@#RNO"GYEB5RF0P(W8W#D9P:!FKX.\?V/C.,S:?.DRC[P!(=<E@-R,
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M3*C)(&T'YE.TG=@AL;2#0(+_ ,:6EA=PZ=)*!=3J[118)8J@+,QP"%&%."Q
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MN=RHLDVT@E2K&)'"L"""I(8=QR*!G5^&?%5KXHA%S8RI-$<?,AS@D!MK#JK
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!\P?$YI/C-XA3P\C;+&RW23O&X8L=J;R02%W*S"%1AFC9G8@C<@!GHOQ
M%^ ^B3Z9+&88[18(2XN(XP94$:$[F(&^4;0=ZL27ZY#[6 !Q7[',20V%]JMS
M*=\ER1-)(XV[8HQ*9&9N<YF<NS$C !XY) .4\#^([3XNZB^K>([B"&VMF"VM
ME)-$L9)Y.Y7=68#"ER5 E8@9V1F*@"K^T4^B:Z(+#P]!'+?B8D_8H05,?EEF
M7,("R'[I&T/L"."4Y# 'NGQ \&QW'A[R]5074ME9>:2TDVUYX;=@7+(T<C G
M=G)!(.3@] #RK]G+]G[3?$VDK?:G )GFFE,9$LR$1J1'M(1D7.]'/?@CGL #
M0^/D4GB7Q-I&E^6DD2;)F5@/F5I29PVX[6416^=N,GYA\V0* .E_;#UM].T3
MRD (N+F&)\YR% :;(P1@[HE'.1@GC." "A\$OV;K>TMX[_6D^TWDD<96.8,R
M0H(]B1%'^\P3 (<$(554 V;F .?^">G6NF^,-3AL/]0L$X QM"MYUOYL:@*H
M"K)N10!C:!@D<D T/VRII]133M*MU#&YN7*CHQD4)'&H)8* ?/.<]\'( .0#
MO_CQX+TZ\T:9KJ*-1:6TIMCGRA&_EE(E7:5X+;%$?W6(0;20M 'E7[.7[/VF
M^)M)6^U. 3/--*8R)9D(C4B/:0C(N=Z.>_!'/8 '8?M;ZA_86@K:VZ(L4L\$
M&T+@(BAI5"!2 N#$H'! 7( Z$ %OQYX%DM_!S:>$2*6&P@>1> H:'9//R@(+
M$H_(R&<Y)Y+4 ;7[,MV]UX?LFD8L0LR@L23M6>1$7GL% 4#H  !P* /,/AU
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MDG;C'((!VOPU_9NL?#\?G:FB7U])N::68&5-SD,P59,@X(_UC#S&)8DJ&V
MX7]CF&""YU=+-B]NLT A=N&:,-<A&/RKR5P3P.>PZ4 ?35 CYP_:,UR?QIJ-
MKX3LV"B9HY+AU?+ ?.VQDW(,)&OG%&.7/EE=I W STK1/V>]$TFV-H+..0,I
M#22@23$E0I82'YD)QG]WL"L24"F@#QK]E^63P_KVI:-%(YLXOM)5&(/S13I$
MLG &&*'#%0 W&1\JX ,KXO:%>?$;Q<=-MV\KRH$B,JA_EA:+S)6?:><^<T8'
MRJVY48C<20#T7XF_!31/!WA^["PA"D(9;@J)+@RC8L?SE6*AY JN$"H S8"
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MEL9.XF@#%^+VA7GQ&\7'3;=O*\J!(C*H?Y86B\R5GVGG/G-&!\JMN5&(W$D
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@F?=C!S_ *K;CC[V<\8(!VOP4TN/3-%L(X5VJ;2&0C)/S2*)9#R3U=R<=!G
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M;,@[Y+EI5/&W;%&R,#SG.9EQP1@')'&09[_X>T1-!MH;.(DI!#'$I;!8JBA
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M=L0OMS@XSC&<''H: /"OV)=+CBTVYN0O[U[ORV;)Y6.-&08S@8,KG(&3GDG
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M+RAW/7C).!@#@ 4 =+HEW;2H8K-HRD#&$K$5*QL@ ,1"<(5&!MX*C' H$:%
M'S!;:C:V/CZ<W?WFCC2!B=JK*UK"!G++G<F]%'S9=U &<$ SW_QUXZM? ]J]
M[>OMC7@ <N['.V-!D98XX'  !9B%!(!'BO[*/A::_>\\27:(KWTC^459N 97
M:?Y<D!3(%"[B7^0] <L#,KP)Y/BKQS>W0WK]FCEV@[1EXEBLWS][*_,Y7!!^
MZ3CE: /I^@04 ?,%EY/_  L&7S=^_P L>5MV[=_V),[\\[?+WXV\[]O;- ST
MKX^_&N'X=6K1QMF^FC80(-I*9RHG;<& 53T!!WL-H& [* 8G['FB/IVB>:Y!
M%Q<S2IC.0H"PX.0,'=$QXR,$<YR  <A^RMY/B/6-7U>/>-TA\M6VCY+B:24[
M@,_,/*4<-@9;KP0 =?\ MAZV^G:)Y2 $7%S#$^<Y"@--D8(P=T2CG(P3QG!
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 >2_$/]F73/'=VU_<//'*ZH'\IT"L5&T,0
M\;X.T <$# !QDDD&5%_91TB*T-E&9T+LIEF61?.D52S+&Q*%-FX@E510S)&S
M99 : /6M)TN/2(8[:!=L44:1HN2<*H"J,DDG  &22?4T"/(/^&3-+M;C[793
M7EHX^X()PNSY=K;6='D&1G.7/4C@<4#-KX9_LZZ9\/9S=V_F2S%=JO,R.8P<
MAMFU$ + X).3C@$!F# 'G7[45Y_PF-]IWAVUER[S[KA$3S&CW!5CD;&#\L;2
MN5W#Y/F; *M0!]*T".*^'_PIM_!$UU<PRS2RWDBR3-*8SE@9&R!''&!DR$D8
MQTP!0,+WX4V][J\6NR2S&XAC,<:9C$*J4=2,",.?]8S9+D[CUV@* #I?$.B)
MKUM-9RDA)X9(F*X#!74H2,@C.#QD$9[&@1S_ ,+_ (7VWPXMFL[-I'1YFE)E
M*LVXJB$#8B#&$';.<\T#(M#^%-OI&J3ZV)9GN;B,QN',?EA<Q[0H2-3\HC50
M22<#YB6.: -7QUX%M?'%J]E>INC;D$<.C#.V1#@X89X/(()5@5)!!'"_#S]F
M73/ EVM_;O/)*BN$\UT*J6&TL D:9.TD<DC!)QD @&=+>_"FWO=7BUV268W$
M,9CC3,8A52CJ1@1AS_K&;)<G<>NT!0 =K0(\J\#_ +-FE^"[[^TK7SC(OF>6
MCN&CCW@J=N%#'"DJ-[-P<G+88 SU6@1X_P")OV7-+UN\.H(]S;SM(9"8)0O[
MTN9#*#(DC*VX_P )51@8 .209-X0_9ETSPW>C4B\]S.&9P;ATD D)SYO$:EG
M!R06)P3NQN"L #UJ@1GZ_H$'B&![2[020R+M=&Z$=>W((."",%2 000#0!XK
M:?L8:- ZNTETX5@2C21A6 .2IV0JV#T.T@XZ$'F@9VN@? ;3M!U!-3@$@>&'
MRH(B_P"XB7;L)1<;LG+LVYF#/([D%SN !H?%O3]+U2S^RZTZ1P32;$D=@FR4
M([JRN1M1@JM@M\I^X=P;:P!Y?=_LK>'O"*-?W\L[6\*EG$LJB,C&!GRHTD)R
M1M"MEFPH#9VD S_V3=&AU&\U368(?+@DG:.V^ZNU&=I7BV(Q484P]L#HAQNH
M ]@O?A3;WNKQ:[)+,;B&,QQIF,0JI1U(P(PY_P!8S9+D[CUV@* #M:!'G7Q0
M^ VG?$=UFO!(DR*JB6)]K; 7(0APZ8W.3G;NSCYL<4#.4E_9&TRZ>)[FXO9Q
M$J(J2S(R^6AR(AB(,J=1A"N 3M(/- 'M=I:)9HL42A$10JJH"JJ@8"@#@ #@
M < 4"/&O^&3-+M;C[7937EHX^X()PNSY=K;6='D&1G.7/4C@<4#-KX9_LZZ9
M\/9S=V_F2S%=JO,R.8P<AMFU$ + X).3C@$!F# &WXS^%-OXNO+2^N)9@UE(
MLD4:&,1[@ZN2V8RYSL4$;@,#Y0"22 =K0(X7X5_!NR^&:2I9&1C,REWE8,Q"
M@A5&U44 ;F/3)+')(  !A\5/@_;?$M(HKR6=$B9F"Q.JJS$ !F#HX)4 A3P0
M&;UH [J@1XK_ ,,F:7:W'VNRFO+1Q]P03A=GR[6VLZ/(,C.<N>I' XH&;7PS
M_9UTSX>SF[M_,EF*[5>9D<Q@Y#;-J( 6!P2<G' (#,& -OQG\*;?Q=>6E]<2
MS!K*19(HT,8CW!U<ELQESG8H(W 8'R@$DD [6@1Y_P#"CX*6?PR\[[$\S^?Y
M>_S61L;-^W&R-/[YSG/;I0,/BE\$-/\ B3Y;7@=)8^%EB*K(5Y_=DLK@KDY
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M;+9WC2(B3+*#$55MP5T .]'&,.>V<XYH Z#P]HB:#;0V<1)2"&.)2V"Q5%"
MG  S@<X &>PH$>2^*OV2])\1W4MZ[W,;S2-(ZQR1[-S<L1OB=AELL1G )(
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MT"#P%X*A\$646GVS.T46_:9"I<[G:0Y*JHZL<8 XQ]: .@H \_\ BE\$-/\
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MQF8J7<*OR[AN9QD<,L7S%HW=%H&?4MI:)9HL42A$10JJH"JJ@8"@#@ #@ <
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y_Q[X*A\;V4N
MGW+.L4NS<8RH<;7608+*PZJ,Y!XS]: .5^&O[/>E_#^3[1;(\EQ\P669@[J&
M !50JH@Z'Y@N_#,N[:<4#/2J!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 <I\0_AA8_$"$07\>[;N,;J2LD988+*P_ [6RA(4LIP*!GFNE_L;:+92
M+)(US,HSF.210C9!')BCC?C.1AAR!G(R" >RZ!H$'AZ!+2T01PQKM1%Z =>_
M)).22<EB222230(T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#$\:>%4\66DMC+))&DRA6:)@DFW(
M)4$AAA@-K @@J2.] $7@7P+:^![5+*R3;&O))Y=V.-TCG RQQR>   J@*
M=!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
00 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840974432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVALO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0705648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">540 Gaither Road, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">522-8707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,249,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450844274128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,307<span></span>
</td>
<td class="nump">$ 13,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current portion</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,519<span></span>
</td>
<td class="nump">16,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,409<span></span>
</td>
<td class="nump">14,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,235<span></span>
</td>
<td class="nump">33,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,588<span></span>
</td>
<td class="nump">13,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current</a></td>
<td class="nump">14,115<span></span>
</td>
<td class="nump">5,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,454<span></span>
</td>
<td class="nump">22,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">31,204<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;$0.001 par value; 200,000,000 shares authorized at June 30, 2023 and December 31, 2022; 14,036,940 and 9,430,535 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">314,755<span></span>
</td>
<td class="nump">292,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(321,738)<span></span>
</td>
<td class="num">(303,824)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(6,969)<span></span>
</td>
<td class="num">(10,915)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 24,235<span></span>
</td>
<td class="nump">$ 33,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment and Operating Lease Right-of-use Asset, After Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840862384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,036,940<span></span>
</td>
<td class="nump">9,430,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,036,940<span></span>
</td>
<td class="nump">9,430,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450838157872">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">708<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">10,667<span></span>
</td>
<td class="nump">18,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">5,134<span></span>
</td>
<td class="nump">14,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">12,861<span></span>
</td>
<td class="nump">17,060<span></span>
</td>
<td class="nump">34,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,150)<span></span>
</td>
<td class="num">(11,828)<span></span>
</td>
<td class="num">(15,943)<span></span>
</td>
<td class="num">(32,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(996)<span></span>
</td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(1,945)<span></span>
</td>
<td class="num">(2,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,036)<span></span>
</td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(2,190)<span></span>
</td>
<td class="num">(2,343)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,186)<span></span>
</td>
<td class="num">(12,982)<span></span>
</td>
<td class="num">(18,133)<span></span>
</td>
<td class="num">(35,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,193)<span></span>
</td>
<td class="num">$ (12,987)<span></span>
</td>
<td class="num">(18,148)<span></span>
</td>
<td class="num">$ (35,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (3.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (3.73)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,193)<span></span>
</td>
<td class="num">$ (12,987)<span></span>
</td>
<td class="num">$ (18,148)<span></span>
</td>
<td class="num">$ (35,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,038)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841782096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jul. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.0833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837735184">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th" colspan="2"><div>Common&#160;stock</div></th>
<th class="th" colspan="2"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,517<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23,082,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 285,239,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (262,166,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested during period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased through employee stock purchase plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased through employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,980,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35,038,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35,038,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,405,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,951,000)<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">291,244,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(297,204,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,517<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,342,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">290,550,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(284,217,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested during period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased through employee stock purchase plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased through employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">669,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,987,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12,987,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,405,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,951,000)<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">291,244,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(297,204,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,430,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,915,000)<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">292,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(303,824,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare', window );">Issuance of shares of common stock and warrants in underwritten public offering, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue', window );">Issuance of shares of common stock and warrants in underwritten public offering, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,748,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,744,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to ATM Program, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044,672<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to ATM Program, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,531,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,529,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common shares in exchange for pre-funded warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common shares in exchange for pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,640,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,873,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants in exchange for retirement of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants for common shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased through employee stock purchase plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased through employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,748,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,148,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,148,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,036,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,969,000)<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">314,755,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(321,738,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,267,000)<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">307,499,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(313,779,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to ATM Program, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044,672<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to ATM Program, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,531,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,529,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common shares in exchange for pre-funded warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common shares in exchange for pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,640,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,873,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants in exchange for retirement of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants for common shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased through employee stock purchase plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares purchased through employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">893,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,193,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,193,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,036,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,969,000)<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 314,755,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (321,738,000)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Exercise Of Prefunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841963184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jul. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.0833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837787728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,148)<span></span>
</td>
<td class="num">$ (35,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,748<span></span>
</td>
<td class="nump">5,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal', window );">Allowance for other long-term asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in fair value of derivative liability</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_IncreaseDecreaseInLeaseIncentives', window );">Lease incentive</a></td>
<td class="nump">158<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,131)<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(5,627)<span></span>
</td>
<td class="num">(3,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_IncreaseDecreaseInLeaseLiability', window );">Lease liability, net</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,078)<span></span>
</td>
<td class="num">(28,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Leasehold improvements</a></td>
<td class="num">(158)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Disposal of property and equipment</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Prepayment on Notes</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(14,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants in underwritten public offering, net</a></td>
<td class="nump">13,748<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram', window );">Proceeds from sale of common stock pursuant to ATM Program, net</a></td>
<td class="nump">6,531<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,346<span></span>
</td>
<td class="num">(14,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(6,865)<span></span>
</td>
<td class="num">(43,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">13,318<span></span>
</td>
<td class="nump">54,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">6,453<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants', window );">Fair value of common stock retired in exchange for issuance of prefunded warrants</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">11,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 6,453<span></span>
</td>
<td class="nump">$ 11,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Common Stock Retired in Exchange for Issuance of Prefunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_IncreaseDecreaseInLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Lease Incentives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_IncreaseDecreaseInLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock Through ATM Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450845748048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text">Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Avalo&#8221; or &#8220;we&#8221;) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (&#8220;HVEM&#8221;), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin &#946; receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (&#8220;BTLA&#8221;), and CD160 (collectively, the &#8220;LIGHT-signaling network&#8221; or the &#8220;LIGHT network&#8221;). Accumulating evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo was incorporated in Delaware and commenced operation in 2011 and completed its initial public offering in October 2015. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, Avalo generated a net loss of $18.1 million and negative cash flows from operations of $21.1 million. As of June 30, 2023, Avalo had $6.3 million in cash and cash equivalents. The future principal payments inclusive of the final payment fee under the Company&#8217;s Loan Agreement (as defined in Note 9) were $15.2&#160;million as of June&#160;30, 2023, which gives effect of the $6.0&#160;million partial prepayment in June of 2023, as collectively agreed upon with the Lenders (as defined in Note 9). On July 20, 2023, the Company entered into a forbearance agreement (the &#8220;Forbearance Agreement&#8221;) with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#8217;s business (the &#8220;Existing Default&#8221;) and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $15.2&#160;million, plus interest, fees, and other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $3.0&#160;million plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by the Company as a result of any future sale of the Company&#8217;s equity securities while the Forbearance Agreement is in effect. The Company closely monitors its cash and cash equivalents and intends to raise money through all means available to raise capital to meet its projected operating requirements, including but not limited to sale of equity securities under its &#8220;at-the-market&#8221; (or &#8220;ATM&#8221;) program or otherwise, out-licensing transactions, strategic alliances/collaborations, sale of its core and non-core programs, and/or mergers and acquisitions. If the Company is able to negotiate extensions to the Forbearance Agreement and absent future cash raises or modifications to the originally planned principal and interest payments, the Company has approximately 60 days of cash on hand as of the filing date of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future success and ability to fund its operations within one year following the date on which this Quarterly Report on Form 10-Q is issued depend on its ability to obtain additional capital. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be, or that any amount that the Company is able to raise will be adequate. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, the Loan Agreement prohibits the Company from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without the prior consent of the Lenders. If the Company requires but is unable to obtain additional funding, the Company may be forced to make further reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued.</span></div>The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company&#8217;s ability to continue as a going concern is dependent upon its ability to obtain additional capital as described above. The unaudited financial statements as of June 30, 2023 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements and less than the amount of its outstanding debt, leaving no proceeds for stockholders.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450954106656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2022 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2022 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2022, Avalo effected a 1-for-12 reverse stock split of the outstanding shares of the Company&#8217;s common stock. The Company retroactively applied the reverse stock split to common share and per share amounts for periods prior to July&#160;7, 2022, including the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July&#160;7, 2022, including the three and six months ended June&#160;30, 2022. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2023</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This guidance eliminates the requirement to calculate the implied fair value of goodwill of a reporting unit to measure a goodwill impairment charge. Instead, a company will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. This new standard was adopted effective January 1, 2023 and will be applied upon any recognition of any future goodwill impairment charge. This ASU has not had a material impact on our financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div>During the six months ended June&#160;30, 2023, there were no significant changes to the Company&#8217;s summary of significant accounting policies contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March 29, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450843075408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Avalo generates its product revenue from sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors. Wholesale distributors account for substantially all of the Company&#8217;s net product revenues and trade </span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">receivables. For the three months ended June&#160;30, 2023, the Company&#8217;s two largest customers accounted for approximately 65% and 35% of the Company&#8217;s total net product revenues. For the six months ended June&#160;30, 2023, the Company&#8217;s two largest customers accounted for approximately 63% and 37% of the Company&#8217;s total net product revenues. Net revenue from sales of prescription drugs was $0.6 million and $1.0 million for the three months ended June&#160;30, 2023 and 2022, respectively, and $1.1 million and $2.2 million for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license and supply agreement for the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;), which expires on September 30, 2023. Avalo is required to pay Teva fifty percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which commenced on July 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu BioScience, Inc. (&#8220;Aytu&#8221;), to which the Company sold its rights, title, and interests in assets relating to certain commercialized products in 2019 (the &#8220;Aytu Transaction&#8221;), managed Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations until August 31, 2021 pursuant to transition service agreements, which included managing the third-party logistics provider and providing accounting reporting services. Aytu collected cash on behalf of Avalo for revenue generated by sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the second quarter of 2020 through the third quarter of 2021 and is obligated to transfer cash generated by such sales to Avalo. In the third quarter of 2021, Avalo finalized its trade and distribution channel to allow it to control the third-party distribution and began managing Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations at that time. The transition services agreement allowed Aytu to withhold cash of $2.0&#160;million until September 30, 2022, and allows withholding of  $1.0&#160;million until December 2024. As of June&#160;30, 2023, the total receivable balance, which represents revenue generated by sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the time Aytu was managing its commercial operations partially offset by minimal operational liabilities Aytu paid on our behalf, was estimated to be approximately $1.0&#160;million, all of which is due in December 2024. In the second quarter of 2022, Avalo fully reserved the $1.0&#160;million due in December 2024 as a result of Aytu&#8217;s conclusion within its Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, that substantial doubt existed with respect to its ability to continue as a going concern within one year after the date of financial statements were issued. This conclusion has remained unchanged within Aytu&#8217;s most recent publicly disclosed financial statements. We will continue to re-assess collectability each reporting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841062032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS is provided below for common stock for the three and six months ended June 30, 2023 and June 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS for common stock is computed by dividing the sum of distributed earnings and undistributed earnings by the weighted average number of shares outstanding for the period. The weighted average number of common shares outstanding as of June&#160;30, 2023 and 2022 include the weighted average effect of pre-funded warrants, the exercise of which requires nominal consideration for the delivery of the shares of common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#8220;treasury stock method&#8221; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#8220;treasury stock method&#8221; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#8217;s losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of common stock for the three and six months ended June&#160;30, 2023 and June&#160;30, 2022 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,193)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,987)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,971,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,400,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,038)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,853,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,400,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June&#160;30, 2023 and 2022, as they could have been anti-dilutive:&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"><tr><td style="width:1.0%"></td><td style="width:59.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849,229</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379,570</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price is nominal. The weighted average shares outstanding for the three and six months ended June&#160;30, 2023 include the weighted average effect of 525,909 and 321,096 pre-funded warrants, respectively. The weighted average shares outstanding for the three and six months ended June 30, 2022 included the weighted average effect of 114,007 pre-funded warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841837824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC No. 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#8209;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#8209;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></div><div style="text-align:justify;text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-413">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying unaudited condensed consolidated balance sheets.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023 and December&#160;31, 2022, the Company&#8217;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities, derivative liability and debt. The carrying amounts reported in the accompanying unaudited condensed consolidated financial statements for cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The estimated fair value of the Company&#8217;s debt was approximately $10 million as of June&#160;30, 2023 and is in Level Two of the fair value hierarchy (refer to Note 9 for more information). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Valuation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the derivative liability for the six months ended June&#160;30, 2023: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.444%"><tr><td style="width:1.0%"></td><td style="width:82.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, Avalo sold its economic rights to future milestone and royalty payments for previously out-licensed assets AVTX-501, AVTX-007, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and AVTX-611 to ES Therapeutics, LLC (&#8220;ES&#8221;), an affiliate of Armistice, in exchange for $5.0&#160;million (the &#8220;ES Transaction&#8221;). At the time of the transaction, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Armistice was a significant stockholder of the Company and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#8217;s Board until August 8, 2022. The ES Transaction was approved in accordance with Avalo&#8217;s related party transaction policy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The economic rights sold include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (a) rights to a milestone payment of $20.0&#160;million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., (the &#8220;AVTX-501 Milestone&#8221;) and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited, including up to $6.25&#160;million of development milestones, up to $67.5&#160;million in sales-based milestones, and royalty payments of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the &#8220;AVTX-007 Milestones and Royalties&#8221;). In addition, Avalo waived all its rights to AVTX-611 sales-based payments of up to $20.0&#160;million that were payable by ES. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exchange of the economic rights of the AVTX-501 Milestone and AVTX-007 Milestones and Royalties for cash meets the definition of a derivative instrument. The fair value of the derivative liability is determined using a combination of a scenario-based method and an option pricing method (implemented using a Monte Carlo simulation). The significant inputs including probabilities of success, expected timing, and forecasted sales as well as market-based inputs for volatility, risk-adjusted discount rates and allowance for counterparty credit risk are unobservable and based on the best information available to Avalo. Certain information used in the valuation is inherently limited in nature and could differ from Janssen and Apollo&#8217;s internal estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the derivative liability as of the transaction date was approximately $4.8&#160;million, of which $3.5&#160;million was attributable to the AVTX-501 Milestone and $1.3&#160;million was attributable to the AVX-007 Milestones and Royalties. Subsequent to the transaction date, at each reporting period, the derivative liability is remeasured at fair value. As of June&#160;30, 2023, the fair value of the derivative liability was $5.1&#160;million, of which $3.7 million was attributable to the AVTX-501 Milestone and $1.3 million was </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">attributable to the AVTX-007 Milestones and Royalties. For the six months ended June&#160;30, 2023, the $0.2&#160;million change in fair value was recognized in other expense, net in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the AVTX-501 Milestone was primarily driven by an approximate 23% probability of success to reach the milestone in approximately 4.3 years. The fair value of AVTX-007 Milestones and Royalties were primarily driven by an approximate 17% probability of success, time to commercialization of approximately 5.3 years, and sales forecasts with peak annual net sales reaching $300&#160;million. As discussed above, these unobservable inputs were estimated by Avalo based on limited publicly available information and therefore could differ from Janssen and Apollo&#8217;s internal development plans. Any changes to these inputs may result in significant changes to the fair value measurement. Notably, the probability of success is the largest driver of the fair value and therefore changes to such input would likely result in significant changes to such fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that Janssen and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those customers for that amount when it is no longer probable there would be a significant revenue reversal with any differences between the fair value of the derivative liability related to that payment immediately prior to the revenue recognition and revenue recognized to be recorded as other expense. However, given Avalo is no longer entitled to collect these payments, the potential ultimate settlement of the payments in the future from Janssen and/or Apollo to ES Therapeutics (and the future mark-to-market activity each reporting period) will not impact Avalo&#8217;s future cash flows. </span></div>No changes in valuation techniques or inputs occurred during the six months ended June&#160;30, 2023 and 2022. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the six months ended June&#160;30, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841766256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo currently occupies two leased properties, both of which serve as administrative office space. The Company determined that both of these leases are operating leases based on the lease classification test performed at lease commencement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent for the Company&#8217;s office located in Rockville, Maryland is $0.2 million, subject to annual 2.5% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of 12 months following the Company&#8217;s date of occupancy. The lease has an initial term of 10 years from the date the Company made its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease two&#160;times, each for a period of five years, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent for the Company&#8217;s office located in Chesterbrook, Pennsylvania is $0.2&#160;million and the annual operating expenses are approximately $0.1&#160;million. The annual base rent is subject to periodic increases of approximately 2.4% over the term of the lease. The lease has an initial term of 5.25 years from the lease commencement on December 1, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining term of the operating leases at June&#160;30, 2023 was 5.1 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased properties include (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453"><span style="-sec-ix-hidden:f-454">Property and equipment, net</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-457"><span style="-sec-ix-hidden:f-458">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-461"><span style="-sec-ix-hidden:f-462">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease right-of-use (ROU) assets are included in property and equipment, net and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our unaudited condensed consolidated balance sheets. The Company utilized a weighted average discount rate of 9.1% to determine the present value of the lease payments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three and six months ended June&#160;30, 2023 and 2022 were as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Includes short-term leases, which are immaterial. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of June&#160;30, 2023 (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2023 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841798144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities  <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June&#160;30, 2023 and December 31, 2022 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841819936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cost Reduction Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Cost Reduction Plan</a></td>
<td class="text">Cost Reduction Plan<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first quarter of 2022, the Board approved a cost reduction plan to enable the Company to execute its strategy of prioritizing the development of its most promising programs (the &#8220;Plan&#8221;). A reduction in workforce plan was approved to reduce headcount and related expenses. The reduction in workforce plan was considered a one-time termination benefit as defined by ASC No. 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The one-time termination benefits mainly relate to severance payments to separated employees. As a result, the Company recognized $1.5&#160;million of expense during the first quarter of 2022, of which $0.7&#160;million was recognized in research and development expense, and $0.8&#160;million was recognized in selling, general and administrative expense. $1.4&#160;million of severance payments were paid in the year ended December 31, 2022 and the remaining $0.1&#160;million was paid in the six months ended June&#160;30, 2023. Additionally, $0.4&#160;million of stock-based compensation expense was recognized in the first quarter of 2022 related to the Plan, which was mainly related to accelerated vesting of certain separated employees&#8217; stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, previously and separately, during the first quarter of 2022, the Company separated certain section 16 executive officers. Each of the former executives are entitled to the benefits provided in their respective separation agreements, which include severance payments to be paid over <span style="-sec-ix-hidden:f-509">twelve</span> to eighteen months. As a result, the Company recognized $1.7&#160;million expense during the first quarter of 2022 within selling, general and administrative expenses. Additionally, the Company accelerated the vesting of certain outstanding stock options and extended the exercisability periods, which resulted in $3.9&#160;million of compensation cost recognized in first quarter of 2022. Refer to Note 11 for information regarding stock compensation expense related to separations entered into the first quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840958080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">Notes Payable <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 4, 2021, the Company entered into a $35.0&#160;million venture loan and security agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;) and Powerscourt Investments XXV, LP (&#8220;Powerscourt&#8221;, and together with Horizon, the &#8220;Lenders&#8221;). In accordance with the Loan Agreement, $20.0&#160;million was funded on the closing date (the &#8220;Initial Note&#8221;), with the remaining $15.0&#160;million fundable upon the Company achieving certain predetermined milestones, which the Company met in the third quarter of 2021. On July 30, 2021, after achieving a predetermined milestone, the Company borrowed an additional $10.0&#160;million, which was evidenced by a second note payable (the &#8220;Second Note&#8221;). On September 29, 2021, after achieving a second predetermined milestone, the Company borrowed the remaining $5.0&#160;million, which was evidenced by a third note payable (the &#8220;Third Note&#8221;, and collectively with the Initial and Second Notes, the &#8220;Notes&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June of 2023, the Company, as collectively agreed upon with the Lenders, prepaid $6.0&#160;million of principal. Additionally, in the second quarter of 2022, the Company, as collectively agreed upon with the Lenders, prepaid $15.0&#160;million, of which $14.8&#160;million was applied to principal and the remainder applied to accrued interest. As of June&#160;30, 2023, the outstanding notes payable balance was $15.2&#160;million, inclusive of the final payment fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Each advance under the Loan Agreement will mature 42 months from the first day of the month following the funding of the advance. Each advance accrues interest at a per annum rate of interest equal to 6.25% plus the prime rate, as reported in the Wall Street Journal (subject to a floor of 3.25%). The Loan Agreement provides for interest-only payments for each advance for the first 18 months, however the interest-only period was extended to 24 months as a result of the Company satisfying the Interest Only Extension Milestone (as defined in the Loan Agreement) in the third quarter of 2021. Thereafter, amortization payments will be payable in monthly installments of principal and interest through each advance&#8217;s maturity date. Upon ten business days&#8217; prior written notice, the Company may prepay all of the outstanding advances by paying the entire principal balance and all accrued and unpaid interest, subject to prepayment charges of up to 3% of the then outstanding principal balance. Upon the earlier of (i) payment in full of the principal balance, (ii) an event of default (see below), or (iii) the maturity date, the Company will pay an additional final payment of 3% of the principal loan amount to the Lenders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Each advance of the loan is secured by a lien on substantially all of the assets of the Company, other than Intellectual Property and Excluded Collateral (in each case as defined in the Loan Agreement), and contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 20, 2023, the Company entered into a Forbearance Agreement with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#8217;s business and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $15.2&#160;million, plus interest, fees, other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $3.0&#160;million plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by Company as a result of the any future sale of the Company&#8217;s equity securities while the Forbearance Agreement is in effect. As of June 30, 2023, the carrying value of the notes payable was $14.1&#160;million and is classified as a current liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On June 4, 2021, pursuant to the Loan Agreement, the Company issued warrants to the Lenders to purchase 33,656 shares of the Company&#8217;s common stock with an exercise price of $31.20 per share (the &#8220;Warrants&#8221;). The Warrants are exercisable for ten years from the date of issuance. Debt issuance costs and the amount allocated to the warrants were recognized as a debt discount on the date of issuance and are amortized to interest expense using the effective interest method over the term of the loan. The $1.1&#160;million final payment fee is included in the contractual cash flows and is accreted to interest expense using the effective interest method over the term of the loan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The effective interest rate of the Notes was 17.1% as of June&#160;30, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Balance sheet information related to the note payable for the Notes is as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:56.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,139&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,244&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,115&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,416&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $1.1&#160;million final payment fee for the Notes, which represents 3% of the original principal loan amount.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of June&#160;30, 2023, the contractual future principal payments, excluding the Lender&#8217;s right to accelerate the maturity of the obligations on the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement, were as follows (in thousands): </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:70.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="14" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $1.1&#160;million final payment fee, which represents 3% of the original principal loan amount.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the Company is unable to reach an agreement with its Lenders to waive the Existing Default or extend the forbearance period prior to the expiration of the Forbearance Agreement on August 15, 2023, the Forbearance Agreement will terminate automatically and without further notice or action, the effect of which shall permit the Lenders to immediately exercise any and all rights and remedies available under the Loan Agreement, including acceleration of the outstanding principal payments and final payment fees, plus interest, fees, and other amounts accrued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841765024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Structure</a></td>
<td class="text">Capital Structure <div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s amended and restated certificate of incorporation, the Company is authorized to issue two classes of stock, common stock and preferred stock. At June&#160;30, 2023, the total number of shares of capital stock the Company was authorized to issue was 205,000,000, of which 200,000,000 was common stock and 5,000,000 was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock. All shares of common and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock have a par value of $0.001 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with entities affiliated with Venrock Healthcare Capital Partners (&#8220;Venrock&#8221;), pursuant to which the Company exchanged an aggregate of 1.3&#160;million shares of the Company&#8217;s common stock, par value $0.001 per share, owned by Venrock for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 1.3&#160;million shares of common stock (subject to adjustment in the event of stock splits, recapitlizations and other similar events affecting common stock), with an exercise price of $0.001 per share. The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercisable by Venrock if, upon giving effect or immediately prior thereto, Venrock would beneficially own more than 9.99% of the total number of issued and outstanding common stock, which percentage may change at the holders&#8217; election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extend required by Delaware law. In accordance with ASC No. 505</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares outstanding and a corresponding impact to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June 30, 2023, none of the Exchange Warrants have been exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into an &#8220;at-the-market&#8221; sales agreement with Oppenheimer &amp; Co. Inc. (&#8220;Oppenheimer&#8221;), pursuant to which the Company may sell from time to time, shares of its common stock having an aggregate offering price of up to $9,032,567 through Oppenheimer. In the second quarter of 2023, the Company sold approximately 2.0&#160;million shares under the ATM program for net proceeds of approximately $6.5&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2023 and as of the filing date of this Quarterly Report on Form 10-Q, the Company sold an additional 6.2&#160;million shares under the ATM program for gross proceeds of approximately $1.3&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Q1 2023 Financing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, the Company closed an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to 3,770,000 shares of common stock, at a combined price to the public of $3.98 per share and warrant, resulting in net proceeds of approximately $13.7&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by us. The warrants were immediately exercisable at an exercise price of $5.00 per share and are exercisable for one year from the issuance date. Armistice, who was a significant stockholder of the Company at the time of the financing, participated in the offering by purchasing 0.5&#160;million shares of common stock and 0.5&#160;million warrants, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC and Point72 Asset Management, L.P., which each beneficially owned greater than 5% of the Company&#8217;s outstanding common stock at the time of the offering, participated in the offering on the same terms as all other investors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants were classified as a component of permanent stockholders&#8217; deficit within additional paid-in capital. The warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,701</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,770,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,691</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841819936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, our board of directors adopted the 2016 Equity Incentive Plan, which was approved by our stockholders in May 2016 and which was subsequently amended and restated in May 2018 and August 2019 with the approval of our board of directors and our stockholders (the &#8220;2016 Third Amended Plan&#8221;). During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year ending on (and including) January 1, 2026, by an amount equal to 4% of the total number of outstanding shares of common stock of the Company on the last trading day in December of the prior calendar year. On January 1, 2023, pursuant to the terms of the 2016 Third Amended and Restated Plan, an additional 377,221 shares were </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made available for issuance. As of June&#160;30, 2023, there were 41,183 shares available for future issuance under the 2016 Third Amended Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants expire after ten years. Employee options typically vest over four years. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. In addition, in the first and fourth quarters of 2022 and second quarter of 2023, employees were also granted options that vest on the first anniversary of the grant date. Options granted to directors typically vest either immediately or over a period of <span style="-sec-ix-hidden:f-613">one</span> or three years. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#8217;s stock-based awards is amortized ratably over the individuals&#8217; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options and employee stock purchase plan shares. The amount of stock-based compensation expense recognized for the three and six months ended June&#160;30, 2023 and 2022 was as follows (in thousands):&#160;</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of separation agreements that the Company entered into in the first quarter of 2022 and in accordance with the terms of the pre-existing employment agreements, the Company accelerated the vesting of certain separated employees&#8217; stock options and modified certain awards to extend the exercisability periods. The Company recognized $4.3&#160;million of compensation cost in the first quarter of 2022, all of which was recognized in selling, general and administrative expense. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with service-based vesting conditions</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. A summary of option activity for the six months ended June 30, 2023 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:39.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,532&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company granted 0.3&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award that vest over four years. In May 2023, the Company granted 0.3&#160;million options with service-based vesting conditions to its employees that vest over one year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. As of June&#160;30, 2023, the aggregate intrinsic value of options outstanding was zero. There were 0.2 million&#160;options that vested during the six months ended June 30, 2023 with a weighted average exercise price of&#160;$11.13 per share. The total grant date fair value of shares which vested during the six months ended June 30, 2023&#160;was&#160;$1.7 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense of $0.9 million and $1.7 million related to stock options with service-based vesting conditions for the three and six months ended June&#160;30, 2023, respectively. At June&#160;30, 2023, there was $4.5 million of total unrecognized compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8% - 146.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43% - 4.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with market-based vesting conditions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, there were 0.1 million exercisable stock options that contained market-based vesting conditions (that had been previously satisfied). The options have a weighted average share price per share of $39.53 and a weighted average remaining contractual term of 1.0 years. There were no stock options with market-based vesting conditions granted, exercised, or forfeited for the six months ended June&#160;30, 2023.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;ESPP Effective Date&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#8217;s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company&#8217;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of their earnings during the offering period. The Company&#8217;s board of directors may establish a maximum number of shares of the Company&#8217;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company&#8217;s common stock for each calendar year in which such right is outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially reserved and authorized up to 41,667 shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP automatically increases by a number equal to the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 41,667 shares of the Company&#8217;s common stock, or (iii) a number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors or compensation committee. The number of shares were increased by 41,667 on January 1, 2023. As of June&#160;30, 2023, 192,079 shares remained available for issuance. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 718-50,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Employee Share Purchase Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $41&#160;thousand and $0.1 million for the three and six months ended June&#160;30, 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841774432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company recognized minimal income tax expense for the three and six months ended June&#160;30, 2023 and 2022 due to the significant valuation allowance against the Company&#8217;s deferred tax assets and the current and prior period losses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450845600176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation - General</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Payments for In-Licensed Compounds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo is a party to license and development agreements with various third parties, which contain future payment obligations such as royalties and milestone payments. The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-002 KKC License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) for exclusive worldwide rights to develop, manufacture and commercialize AVTX-002, KKC&#8217;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#8220;KKC License Agreement&#8221;). The KKC License Agreement replaced the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the KKC License Agreement, the Company paid KKC an upfront license fee of $10.0&#160;million, which we recognized within research and development expenses in 2021. The Company is also required to pay KKC up to an aggregate of $112.5&#160;million based on the achievement of specified development and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization, the Company is required to pay KKC sales-based milestones aggregating up to $75.0&#160;million tied to the achievement of annual net sales targets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is required to pay KKC royalties during a country-by-country royalty term equal to a mid-teen percentage of annual net sales. The Company is required to pay KKC a double-digit percentage (less than 30%) of the payments that the Company receives from any sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Avalo is responsible for the development and commercialization of AVTX-002 in all indications worldwide (other than the option in the KKC License Agreement that, upon exercise by KKC, allows KKC to develop, manufacture and commercialize AVTX-002 in Japan). In addition to the KKC License Agreement, Avalo is subject to additional royalties upon commercialization of up to an amount of less than 10% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense related to the KKC License Agreement was recognized in the six months ended June&#160;30, 2023. There has been no cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-006 Astellas License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#8220;Astellas&#8221;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (AVTX-006). Under the terms of the license agreement, there was an upfront license fee of $0.5&#160;million. The Company is required to pay Astellas up to an aggregate of $5.5&#160;million based on the achievement of specified development and regulatory milestones. The Company is also required to pay Astellas a tiered mid-to-high single digit percentage of the payments that Avalo receives from any sublicensing of its rights under the Astellas license agreement, subject to certain exclusions. Upon commercialization, the Company is required to pay Astellas royalties during a country-by-country royalty term equal to a tiered mid-to-high single digit percentage of annual net sales. Avalo is fully responsible for the development and commercialization of the program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense related to this license agreement was recognized in the six months ended June&#160;30, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been $0.5&#160;million of cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement, which was recognized in 2021. The Company will continue to monitor the remaining milestones at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-008 Sanford Burnham Prebys License Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an Exclusive Patent License Agreement with Sanford Burnham Prebys Medical Discovery Institute (the &#8220;Sanford Burnham Prebys License Agreement&#8221;) under which the Company obtained an exclusive license to a portfolio of issued patents and patent applications covering an immune checkpoint program (AVTX-008). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Sanford Burnham Prebys License Agreement, the Company incurred an upfront license fee of $0.4&#160;million, as well as patent costs of $0.5&#160;million, which we recognized within research and development expenses and within selling, general and administrative expenses, respectively, in 2021. The Company is required to pay Sanford Burnham Prebys up to an aggregate of $24.2&#160;million based on achievement of specified development and regulatory milestones. Upon commercialization, the Company is required to pay Sanford Burnham Prebys sales-based milestone payments aggregating up to $50.0&#160;million tied to annual net sales targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is required to pay Sanford Burnham Prebys royalties during a country-by-country royalty term equal to a low-to-mid single digit percentage of annual net sales. The Company is also required to pay Sanford Burnham Prebys a tiered low-double digit percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the payments that Avalo receives from sublicensing of its rights under the Sanford Burnham Prebys License Agreement, subject to certain exclusions. Avalo is fully responsible for the development and commercialization of the program.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense related to the Sanford Burnham Prebys License Agreement was recognized in the six months ended June&#160;30, 2023. There has been no cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Proceeds for Out-Licensed Compounds </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-301 Out-License</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 28, 2021, the Company out-licensed its rights in respect of its non-core asset, AVTX-301, to Alto Neuroscience, Inc. (&#8220;Alto&#8221;). The Company initially in-licensed the compound from an affiliate of Merck &amp; Co., Inc. in 2013.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the out-license agreement, the Company received a mid-six digit upfront payment from Alto, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $18.6&#160;million based on the achievement of specified development, regulatory and commercial sales milestones. Additionally, the Company is entitled to a less than single digit percentage royalty based on annual net sales. Alto is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has not recognized any milestones as of June&#160;30, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-406 License Assignment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 9, 2021, the Company assigned its rights, title, interest, and obligations under an in-license covering its non-core asset, AVTX-406, to ES, a wholly owned subsidiary of Armistice, who was a significant stockholder of the Company at the time of the financing and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#8217;s Board until August 8, 2022. The transaction with ES was approved in accordance with Avalo&#8217;s related party transaction policy. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the assignment agreement, the Company received a low-six digit upfront payment from ES, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $6.0&#160;million based on the achievement of specified development and regulatory milestones. Upon commercialization, the Company is eligible to receive sales-based milestone payments aggregating up to $20.0&#160;million tied to annual net sales targets. ES is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has not recognized any milestones as of June&#160;30, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition Related and Other Contingent Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger Possible Future Milestone Payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#8220;Aevi&#8221;), in which Avalo acquired the rights to AVTX-002, AVTX-006 and AVTX-007 (the &#8220;Merger&#8221; or the &#8220;Aevi Merger&#8221;). A portion of the consideration for the Aevi Merger included two future contingent development milestones worth up to an additional $6.5 million, payable in either shares of Avalo&#8217;s common stock or cash, at the election of Avalo. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first milestone was the enrollment of a patient in a Phase 2 study related to AVTX-002 (for treatment of pediatric onset Crohn&#8217;s disease), AVTX-006 (for treatment of any indication) or AVTX-007 (for treatment of any indication) prior to February 3, 2022, which would have resulted in a milestone payment of $2.0 million. The Company did not meet the first milestone prior to February 3, 2022. Therefore, no contingent consideration related to this milestone was recognized as of June&#160;30, 2023 and no future contingent consideration will be recognized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second milestone is the receipt of an NDA approval for either AVTX-006 or AVTX-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. The contingent consideration related to the second development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. No contingent consideration related to the second development milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the second milestone at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ichorion Asset Acquisition Possible Future Milestone Payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company acquired Ichorion Therapeutics, Inc., including acquiring three compounds for inherited metabolic disorders known as CDGs (AVTX-801, AVTX-802 and AVTX-803) and one other preclinical compound. Consideration for the transaction included shares of Avalo common stock and three future contingent development milestones for the acquired compounds worth up to an additional&#160;$15.0 million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of Avalo.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first and second milestones were marketing approval of the first and second product, respectively, by the FDA on or prior to December 31, 2021, which would have resulted in milestone payments of $6.0&#160;million and $5.0&#160;million, respectively. The Company did not meet the first or second milestone as of December 31, 2021. As a result, no contingent consideration related to these milestones was recognized as of June&#160;30, 2023 and no future contingent consideration will be recognized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third milestone is marketing approval of a protide molecule by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $4.0&#160;million. The contingent consideration related to the third development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. No contingent consideration related to the third milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the third development milestone at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AVTX-006 Royalty Agreement with Certain Related Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Aevi entered into a royalty agreement, and liabilities thereunder were assumed by Avalo upon close of the Aevi Merger in February 2020. The royalty agreement provided certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil, the Company&#8217;s Chief Executive Officer and Chairman of the Board, and Mike Cola, the Company&#8217;s former Chief Executive Officer (collectively, the &#8220;Investors&#8221;), a royalty stream, in exchange for a one-time aggregate payment of $2.0&#160;million (the &#8220;Royalty Agreement&#8221;). Pursuant to the Royalty Agreement, the Investors will be entitled collectively to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of the Company&#8217;s second generation mTORC1/2 inhibitor, AVTX-006. At any time beginning three years after the date of the first public launch of AVTX-006, Avalo may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments. A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company's accompanying unaudited condensed consolidated balance sheet as of June&#160;30, 2023 and December 31, 2022. Because there is a significant related party relationship between the Company and the Investors, the Company has treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which will result in a corresponding increase in the liability balance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Karbinal Royalty Make-Whole Provision </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, in connection with the acquisition of certain commercialized products, the Company entered into a supply and distribution agreement (the &#8220;Karbinal Agreement&#8221;) with TRIS Pharma Inc. (&#8220;TRIS&#8221;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;70,000&#160;units </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2025. The Company was required to pay TRIS a royalty make whole payment (&#8220;Make-Whole Payments&#8221;) of&#160;$30&#160;for each unit under the&#160;70,000&#160;units annual minimum sales commitment through 2025.&#160; </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the Aytu transaction, the Company assigned all its payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#8220;TRIS Obligations&#8221;) to Aytu.&#160;However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841786720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2022 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2022 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2022, Avalo effected a 1-for-12 reverse stock split of the outstanding shares of the Company&#8217;s common stock. The Company retroactively applied the reverse stock split to common share and per share amounts for periods prior to July&#160;7, 2022, including the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July&#160;7, 2022, including the three and six months ended June&#160;30, 2022. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Adopted in 2023</a></td>
<td class="text">Accounting Pronouncements Adopted in 2023<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment.</span> This guidance eliminates the requirement to calculate the implied fair value of goodwill of a reporting unit to measure a goodwill impairment charge. Instead, a company will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value. This new standard was adopted effective January 1, 2023 and will be applied upon any recognition of any future goodwill impairment charge. This ASU has not had a material impact on our financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840973520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of common stock for the three and six months ended June&#160;30, 2023 and June&#160;30, 2022 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,193)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,987)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,971,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,400,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.38)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,148)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,038)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,853,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,400,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June&#160;30, 2023 and 2022, as they could have been anti-dilutive:&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"><tr><td style="width:1.0%"></td><td style="width:59.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849,229</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379,570</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price is nominal. The weighted average shares outstanding for the three and six months ended June&#160;30, 2023 include the weighted average effect of 525,909 and 321,096 pre-funded warrants, respectively. The weighted average shares outstanding for the three and six months ended June 30, 2022 included the weighted average effect of 114,007 pre-funded warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841703472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-413">Derivative liability</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying unaudited condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Fair Value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the derivative liability for the six months ended June&#160;30, 2023: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.444%"><tr><td style="width:1.0%"></td><td style="width:82.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450838074912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Assets and Liabilities Lessee</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased properties include (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453"><span style="-sec-ix-hidden:f-454">Property and equipment, net</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-457"><span style="-sec-ix-hidden:f-458">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-461"><span style="-sec-ix-hidden:f-462">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text">The components of lease expense for the three and six months ended June&#160;30, 2023 and 2022 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>*Includes short-term leases, which are immaterial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of June&#160;30, 2023 (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2023 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841849744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June&#160;30, 2023 and December 31, 2022 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450835245712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text">Balance sheet information related to the note payable for the Notes is as follows (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:56.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,139&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,244&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,115&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,416&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of notes payable, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $1.1&#160;million final payment fee for the Notes, which represents 3% of the original principal loan amount.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Contractual Future Principal Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of June&#160;30, 2023, the contractual future principal payments, excluding the Lender&#8217;s right to accelerate the maturity of the obligations on the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement, were as follows (in thousands): </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:70.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="14" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="14" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="13" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"> Balance includes $1.1&#160;million final payment fee, which represents 3% of the original principal loan amount.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841768256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Common Stock Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,701</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,770,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,691</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450842658288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">The amount of stock-based compensation expense recognized for the three and six months ended June&#160;30, 2023 and 2022 was as follows (in thousands):&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:42.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text">A summary of option activity for the six months ended June 30, 2023 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:39.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,532&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions for Options</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8% - 146.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43% - 4.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837916848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,193<span></span>
</td>
<td class="nump">$ 12,987<span></span>
</td>
<td class="nump">$ 18,148<span></span>
</td>
<td class="nump">$ 35,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,078)<span></span>
</td>
<td class="num">(28,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,307<span></span>
</td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">11,249<span></span>
</td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">11,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Partial prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">$ 14,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Notes Payable | Horizon &amp; Powerscourt Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, outstanding</a></td>
<td class="nump">15,244<span></span>
</td>
<td class="nump">$ 15,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Partial prepayment</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Notes Payable | Horizon &amp; Powerscourt Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash in deposit account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage', window );">Additional resticted cash, percentage of aggregate cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450835710224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal', window );">Allowance for other long-term asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Pediatric Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss', window );">Total receivable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal', window );">Allowance for other long-term asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_MillipredMember', window );">Millipred | Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment', window );">Percent of net profit for installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LicenseAgreementInstallmentPayment', window );">Installment payment</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avtx_MajorCustomerNumberOneMember', window );">Major Customer Number One | Sales Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avtx_MajorCustomerNumberTwoMember', window );">Major Customer Number Two | Sales Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LicenseAgreementInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LicenseAgreementInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent of Net Profit for Installment Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=avtx_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=avtx_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_MillipredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_MillipredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avtx_TevaPharmaceuticalIndustriesLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avtx_TevaPharmaceuticalIndustriesLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avtx_MajorCustomerNumberOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avtx_MajorCustomerNumberOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avtx_MajorCustomerNumberTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avtx_MajorCustomerNumberTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837762912">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,193)<span></span>
</td>
<td class="num">$ (12,987)<span></span>
</td>
<td class="num">$ (18,148)<span></span>
</td>
<td class="num">$ (35,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,971,968<span></span>
</td>
<td class="nump">9,400,902<span></span>
</td>
<td class="nump">12,853,579<span></span>
</td>
<td class="nump">9,400,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,971,968<span></span>
</td>
<td class="nump">9,400,902<span></span>
</td>
<td class="nump">12,853,579<span></span>
</td>
<td class="nump">9,400,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (3.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="num">$ (3.73)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450834277040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">1,849,229<span></span>
</td>
<td class="nump">1,379,570<span></span>
</td>
<td class="nump">1,849,229<span></span>
</td>
<td class="nump">1,379,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_WarrantCommonStockMember', window );">Warrants on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">4,136,990<span></span>
</td>
<td class="nump">366,990<span></span>
</td>
<td class="nump">4,136,990<span></span>
</td>
<td class="nump">366,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised', window );">Pre-funded warrants exercised (in shares)</a></td>
<td class="nump">525,909<span></span>
</td>
<td class="nump">114,007<span></span>
</td>
<td class="nump">321,096<span></span>
</td>
<td class="nump">114,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_WarrantCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_WarrantCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avtx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840987008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Derivative liability<span></span>
</td>
<td class="text">Derivative liability<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical&#160;assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">$ 5,042<span></span>
</td>
<td class="nump">$ 12,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant&#160;other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant unobservable inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 5,050<span></span>
</td>
<td class="nump">$ 4,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837722576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in the Fair Value (Details) - Derivative liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 4,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of derivative liability</a></td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 5,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450844332672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral', window );">Change in fair value was recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant&#160;other observable inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Estimated fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX501Member', window );">AVTX-501</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX611Member', window );">AVTX-611</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneOneMember', window );">Milestone One | AVTX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneTwoMember', window );">Milestone Two | AVTX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-501 And AVTX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial valuation of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-501</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial valuation of derivative liability</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-501 | Measurement Input, Probability Of Success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-501 | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DerivativeLiabilityMeasurementInputTerm', window );">Derivative liability, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial valuation of derivative liability</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-007 | Measurement Input, Probability Of Success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-007 | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DerivativeLiabilityMeasurementInputTerm', window );">Derivative liability, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative liability | AVTX-007 | Measurement Input, Sales Forecast Peak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_ESTherapeuticsMember', window );">ES | Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial valuation of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DerivativeLiabilityMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DerivativeLiabilityMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX501Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX501Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX611Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX611Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_MilestoneAxis=avtx_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_MilestoneAxis=avtx_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_MilestoneAxis=avtx_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_MilestoneAxis=avtx_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX501AndAVTX007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX501AndAVTX007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=avtx_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=avtx_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=avtx_MeasurementInputSalesForecastPeakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=avtx_MeasurementInputSalesForecastPeakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_ESTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_ESTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450834278944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>property </div>
<div>renewal_option</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseNumberOfLeasedProperties', window );">Number of leased properties | property</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseRemainingLeaseTeam', window );">Remaining lease team</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent', window );">Annual rent increase (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseRentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term of contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent', window );">Annual rent increase (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term of contract</a></td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_LesseeOperatingLeaseAnnualBaseRent', window );">Lessee, operating lease, annual base rent</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseNumberOfLeasedProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leased Properties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseNumberOfLeasedProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Number of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseRemainingLeaseTeam">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Remaining Lease Team</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseRemainingLeaseTeam</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_LesseeOperatingLeaseRentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_LesseeOperatingLeaseRentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_OperatingLeasesRentExpenseAnnualIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Rent Expense, Annual Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_OperatingLeasesRentExpenseAnnualIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450834555392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Assets and Liabilities Lessee (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450841014832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450844232784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">July 1, 2023 through December 31, 2023</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less implied interest</a></td>
<td class="num">(512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450844231824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AccruedResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">$ 3,339<span></span>
</td>
<td class="nump">$ 6,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AccruedSellingGeneralAndAdministrativeExpenses', window );">Selling, general and administrative</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CommercialOperationsCurrent', window );">Commercial operations</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalty payment</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,588<span></span>
</td>
<td class="nump">$ 13,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_AccruedSellingGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Selling, General And Administrative Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_AccruedSellingGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CommercialOperationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Operations, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CommercialOperationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450835680096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cost Reduction Plan (Details) - Employee Severance - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Restructuring Plan, One-Time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, accelerated cost</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Restructuring Plan, One-Time Termination Benefits | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Restructuring Plan, One-Time Termination Benefits | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Separation From Certain Section 16 Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, accelerated cost</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Separation From Certain Section 16 Officers | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RestructuringAndRelatedActivitiesPaymentTerm', window );">Payment term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Separation From Certain Section 16 Officers | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RestructuringAndRelatedActivitiesPaymentTerm', window );">Payment term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RestructuringAndRelatedActivitiesPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RestructuringAndRelatedActivitiesPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=avtx_RestructuringPlanOneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=avtx_RestructuringPlanOneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=avtx_SeparationFromCertainSection16OfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=avtx_SeparationFromCertainSection16OfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450835353888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 04, 2021 </div>
<div>USD ($) </div>
<div>business_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Prepayment on Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 14,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm', window );">Warrants or rights exercisable term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember', window );">Horizon &amp; Powerscourt Notes | Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Prepayment on Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RepaymentOfDebtPrincipal', window );">Repayment of debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,244,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentInterestOnlyPaymentPeriod', window );">Interest-only payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod', window );">Interest-only payment extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment', window );">Number of business days required for prepayment | business_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage', window );">Prepayment charges percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage', window );">Additional final payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,416,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentFinalPaymentFee', window );">Final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember', window );">Horizon &amp; Powerscourt Notes | Notes Payable | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash in deposit account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage', window );">Additional resticted cash, percentage of aggregate cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember', window );">Horizon &amp; Powerscourt Notes | Notes Payable | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm', window );">Warrants or rights exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember', window );">Horizon &amp; Powerscourt Notes | Notes Payable | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentInterestRateFloor', window );">Floor interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants or Rights Exercisable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued And Unpaid Interest, Subject to Prepayment Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Final Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentAdditionalFinalPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Only Payment Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentInterestOnlyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Only Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentInterestOnlyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Business Days Required for Prepayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RepaymentOfDebtPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Debt, Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RepaymentOfDebtPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450834548448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of Debt (Details) - Horizon &amp; Powerscourt Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">$ 15,244<span></span>
</td>
<td class="nump">$ 21,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of notes payable, current</a></td>
<td class="nump">14,115<span></span>
</td>
<td class="nump">19,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion</a></td>
<td class="nump">14,115<span></span>
</td>
<td class="nump">5,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Carrying value of notes payable, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentFinalPaymentFee', window );">Final payment fee</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage', window );">Additional final payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=avtx_InitialNoteMember', window );">Initial Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">$ 8,711<span></span>
</td>
<td class="nump">12,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=avtx_SecondNoteMember', window );">Second Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=avtx_ThirdNoteMember', window );">Third Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">$ 2,178<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Final Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentAdditionalFinalPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=avtx_InitialNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=avtx_InitialNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=avtx_SecondNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=avtx_SecondNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=avtx_ThirdNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=avtx_ThirdNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450843350960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of Contractual Future Principal Payments (Details) - Horizon &amp; Powerscourt Notes - Notes Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 4,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">9,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">15,244<span></span>
</td>
<td class="nump">$ 21,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentFinalPaymentFee', window );">Final payment fee</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage', window );">Additional final payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentAdditionalFinalPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Final Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentAdditionalFinalPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avtx_HorizonPowerscourtNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450834380176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>class_of_stock </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_NumberOfClassOfStockAuthorized', window );">Number of classes of stock authorized to issue | class_of_stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CapitalStockSharesAuthorized', window );">Number of shares of capital stock authorized to issue (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold', window );">Class of warrant or right, ownership, exercise threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold', window );">Class of warrant or right, ownership percentage, exercise threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold', window );">Class of warrant or right, ownership percentage, exercise threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avtx_NantahalaCapitalManagementLLCMember', window );">Nantahala Capital Management LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Percentage of ownership</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm', window );">Warrants or rights exercisable term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">3,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Armistice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ATMAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_SaleOfStockMaximumAmountOfSharesToBeSold', window );">Sale of stock, maximum amount of shares to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,032,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ATMAgreementMember', window );">ATM Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ExchangeAgreementMember', window );">Exchange Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ExchangeAgreementMember', window );">Exchange Agreement | Venrock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ExchangeAgreementMember', window );">Exchange Agreement | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Ownership, Exercise Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Ownership Percentage, Exercise Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants or Rights Exercisable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_NumberOfClassOfStockAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of classes of stock permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_NumberOfClassOfStockAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_SaleOfStockMaximumAmountOfSharesToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Amount Of Shares To Be Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_SaleOfStockMaximumAmountOfSharesToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avtx_NantahalaCapitalManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avtx_NantahalaCapitalManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avtx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_ArmisticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_ArmisticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avtx_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avtx_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_VenrockHealthcareCapitalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_VenrockHealthcareCapitalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840993392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure - Schedule of Outstanding Common Stock Warrants (Details) - Common Stock<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">5,478,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationDateOfJune2024Member', window );">Common Stock Warrants Expiration Date Of June 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">333,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 150.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpirationMember', window );">Common Stock Warrants No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">41,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationJune2031Member', window );">Common Stock Warrants Expiration June 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">33,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 31.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationFebruary2024Member', window );">Common Stock Warrants Expiration February 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">3,770,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpiration2Member', window );">Common Stock Warrants No Expiration 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationDateOfJune2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationDateOfJune2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationJune2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationJune2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationFebruary2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsExpirationFebruary2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpiration2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avtx_CommonStockWarrantsNoExpiration2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450837116192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Apr. 05, 2016</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">$ 5,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_EmployeeStockPurchasePlanESPPMember', window );">Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remaining for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum portion of earning an employee may contribute to the ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum', window );">Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear', window );">Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increase in shares available (in shares)</a></td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember', window );">Service-based options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Exercisable stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,345,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember', window );">Service-based options | Special Advisor To The Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember', window );">Service-based options | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Exercisable stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_EmployeeStockPurchasePlanESPPMember', window );">Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent', window );">Annual share reserve increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease', window );">Increase in number of shares reserved for issuance (in shares)</a></td>
<td class="nump">377,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remaining for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember', window );">2016 Plan | Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember', window );">2016 Plan | Equity Option | Maximum | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember', window );">2016 Plan | Equity Option | Maximum | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember', window );">2016 Plan | Equity Option | Minimum | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Automatic Increase to Shares Authorized as Percentage of Outstanding Stock at End of Preceding Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase in the number of shares reserved for issuance under the incentive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avtx_EmployeeStockPurchasePlanESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avtx_EmployeeStockPurchasePlanESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avtx_SpecialAdvisorToTheBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avtx_SpecialAdvisorToTheBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avtx_StockOptionsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avtx_StockOptionsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avtx_EmployeeStockPurchasePlanESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avtx_EmployeeStockPurchasePlanESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avtx_The2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avtx_The2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840980720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">$ 5,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
<td class="nump">$ 5,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450835233408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Option Activity (Details) - Service-based options - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, beginning of period (in shares)</a></td>
<td class="nump">1,345,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">760,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(339,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, ending of period (in shares)</a></td>
<td class="nump">1,765,894<span></span>
</td>
<td class="nump">1,345,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">563,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 28.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">42.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, ending of period (in dollars per share)</a></td>
<td class="nump">14.42<span></span>
</td>
<td class="nump">$ 28.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">31.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, beginning of period (in dollars per share)</a></td>
<td class="nump">17.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue', window );">Expired (in dollars per share)</a></td>
<td class="nump">27.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, ending of period (in dollars per share)</a></td>
<td class="nump">8.98<span></span>
</td>
<td class="nump">$ 17.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 18.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450840993136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details) - Service-based options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term of option (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">89.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.43%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term of option (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">146.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.13%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avtx_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140450832689936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">64 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>therapy</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>unit </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RoyaltyAgreementPaymentReceived', window );">Payment received</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement', window );">Period after public launch to terminate agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments', window );">Percentage of net present value of royalty payments</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avtx_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=avtx_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=avtx_IchorionMember', window );">Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneOneMember', window );">Milestone One | Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneOneMember', window );">Milestone One | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneTwoMember', window );">Milestone Two | Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneTwoMember', window );">Milestone Two | Ichorion | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneThreeMember', window );">Milestone Three | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_MilestoneAxis=avtx_MilestoneThreeMember', window );">Milestone Three | Ichorion | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember', window );">Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing', window );">Percent of payments received from sublicensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate', window );">Cumulative expense recognized to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember', window );">Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember', window );">Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember', window );">Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate', window );">Cumulative expense recognized to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember', window );">Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate', window );">Cumulative expense recognized to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts', window );">Patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember', window );">Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember', window );">Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avtx_TRISPharmaMember', window );">TRIS Pharma | Karbinal Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired', window );">Minimum quantity required | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit', window );">Make whole payment per unit (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember', window );">AVTX-301 Out-License | Alto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Maximum proceeds from milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments', window );">Revenue recognized from milestones to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember', window );">AVTX-406 License Assignment | ES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments', window );">Revenue recognized from milestones to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember', window );">AVTX-406 License Assignment | ES | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Maximum proceeds from milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember', window );">AVTX-406 License Assignment | ES | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Maximum proceeds from milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX801AVTX802AndAVTX803Member', window );">AVTX-801, AVTX-802, And AVTX-803 | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AssetAcquisitionNumberOfPreclinicalTherapies', window );">Number of preclinical therapies | therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avtx_AVTX913Member', window );">AVTX-913 | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avtx_AssetAcquisitionNumberOfPreclinicalTherapies', window );">Number of preclinical therapies | therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_AssetAcquisitionContingentValueRightNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Value Right, Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_AssetAcquisitionContingentValueRightNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_AssetAcquisitionNumberOfPreclinicalTherapies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Number of Preclinical Therapies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_AssetAcquisitionNumberOfPreclinicalTherapies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Patent Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Revenue Recognized to Date From Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Asset Acquisition Contingent Consideration Liability Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RoyaltyAgreementPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RoyaltyAgreementPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Period After Public Launch to Terminate Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avtx_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avtx_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=avtx_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=avtx_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=avtx_IchorionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=avtx_IchorionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_MilestoneAxis=avtx_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_MilestoneAxis=avtx_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_MilestoneAxis=avtx_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_MilestoneAxis=avtx_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avtx_MilestoneAxis=avtx_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avtx_MilestoneAxis=avtx_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avtx_AVTX002KKCLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avtx_AVTX002KKCLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avtx_AVTX006AstellasLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avtx_AVTX006AstellasLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_TRISPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_TRISPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avtx_KarbinalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avtx_KarbinalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_AltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_AltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avtx_ESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avtx_ESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX801AVTX802AndAVTX803Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX801AVTX802AndAVTX803Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avtx_AVTX913Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avtx_AVTX913Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>avtx-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avtx="http://www.avalotherapeutics.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avtx-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2022-07-07</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avtx:MajorCustomerNumberTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:MillipredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avtx:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:MillipredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avtx:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">avtx:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avtx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX611Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501AndAVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501AndAVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX501Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">avtx:MeasurementInputSalesForecastPeakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:RestructuringPlanOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">avtx:SeparationFromCertainSection16OfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2021-06-04</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-29</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2021-06-04</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:InitialNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:InitialNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:SecondNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:SecondNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:ThirdNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avtx:ThirdNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avtx:HorizonPowerscourtNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:VenrockHealthcareCapitalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:VenrockHealthcareCapitalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-08-03</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ArmisticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avtx:NantahalaCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationDateOfJune2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsNoExpirationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationJune2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsExpirationFebruary2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avtx:CommonStockWarrantsNoExpiration2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avtx:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avtx:SpecialAdvisorToTheBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-05</startDate>
            <endDate>2016-04-05</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-05</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avtx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:KyowaKirinCoLtdKKCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AstellasPharmaIncAstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX006AstellasLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AstellasPharmaIncAstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX006AstellasLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:SanfordBurnhamPrebysMedicalDiscoveryInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:AVTX008SanfordBurnhamPrebysLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX301OutLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-28</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:AltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX301OutLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:ESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX406LicenseAssignmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX801AVTX802AndAVTX803Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avtx:AVTX913Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">avtx:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="avtx:MilestoneAxis">avtx:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avtx:TRISPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avtx:KarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="property">
        <measure>avtx:property</measure>
    </unit>
    <unit id="renewal_option">
        <measure>avtx:renewal_option</measure>
    </unit>
    <unit id="business_day">
        <measure>avtx:business_day</measure>
    </unit>
    <unit id="class_of_stock">
        <measure>avtx:class_of_stock</measure>
    </unit>
    <unit id="milestone">
        <measure>avtx:milestone</measure>
    </unit>
    <unit id="therapy">
        <measure>avtx:therapy</measure>
    </unit>
    <unit id="unit">
        <measure>avtx:unit</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001534120</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-14" decimals="4" id="f-164" unitRef="number">0.0833</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-14" decimals="4" id="f-263" unitRef="number">0.0833</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-14" decimals="4" id="f-346" unitRef="number">0.0833</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-3" id="f-406">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-413">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-453">http://www.avalotherapeutics.com/20230630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-454">http://www.avalotherapeutics.com/20230630#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-457">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-458">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-461">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-462">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <avtx:RestructuringAndRelatedActivitiesPaymentTerm contextRef="c-111" id="f-509">P12M</avtx:RestructuringAndRelatedActivitiesPaymentTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-158" id="f-613">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37590</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">AVALO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">45-0705648</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">540 Gaither Road, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">522-8707</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">AVTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">20249447</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">6307000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">13172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">38000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">6000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">1919000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">18000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">20000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">1135000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">1290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">15000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">15000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">7519000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">16416000</us-gaap:AssetsCurrent>
    <avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">2176000</avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">2411000</avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">14409000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">14409000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">131000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">131000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">24235000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">33367000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">751000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">2882000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">88000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">7588000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">13214000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:NotesPayableCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">14115000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">5930000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">22454000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">22114000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">13486000</us-gaap:LongTermNotesPayable>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">156000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">141000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">5050000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">4830000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">1544000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">1711000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">31204000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">44282000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-75"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-77" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">14036940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">14036940</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">9430535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">9430535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">314755000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">292900000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">-321738000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">-303824000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">-6969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">-10915000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">24235000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">33367000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">1033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">1117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-95" unitRef="usd">2206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-96" unitRef="usd">643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-97" unitRef="usd">1033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">1117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-99" unitRef="usd">2206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-9" decimals="-3" id="f-100" unitRef="usd">708000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-10" decimals="-3" id="f-101" unitRef="usd">1567000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">1259000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-11" decimals="-3" id="f-103" unitRef="usd">2286000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-9" decimals="-3" id="f-104" unitRef="usd">4658000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-10" decimals="-3" id="f-105" unitRef="usd">8510000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">10667000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-11" decimals="-3" id="f-107" unitRef="usd">18094000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-108" unitRef="usd">2427000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-109" unitRef="usd">2784000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">5134000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-111" unitRef="usd">14468000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-9" decimals="-3" id="f-112" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-10" decimals="-3" id="f-113" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="-3" id="f-115" unitRef="usd">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses contextRef="c-9" decimals="-3" id="f-116" unitRef="usd">7793000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-10" decimals="-3" id="f-117" unitRef="usd">12861000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">17060000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-11" decimals="-3" id="f-119" unitRef="usd">34886000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-120" unitRef="usd">-7150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-121" unitRef="usd">-11828000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-15943000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-123" unitRef="usd">-32680000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-9" decimals="-3" id="f-124" unitRef="usd">-996000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-10" decimals="-3" id="f-125" unitRef="usd">-1154000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">-1945000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">-2323000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-9" decimals="-3" id="f-128" unitRef="usd">-40000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-10" decimals="-3" id="f-129" unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-220000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-11" decimals="-3" id="f-131" unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-25000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-135" unitRef="usd">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">-1036000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-137" unitRef="usd">-1154000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-2190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">-2343000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-140" unitRef="usd">-8186000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-141" unitRef="usd">-12982000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-18133000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-143" unitRef="usd">-35023000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-9" decimals="-3" id="f-144" unitRef="usd">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-145" unitRef="usd">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-147" unitRef="usd">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-148" unitRef="usd">-8193000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-149" unitRef="usd">-8193000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-150" unitRef="usd">-12987000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">-12987000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-18148000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">-18148000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-154" unitRef="usd">-35038000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-155" unitRef="usd">-35038000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-3.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-165"
      unitRef="shares">13200535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-166" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-167" unitRef="usd">307499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-168" unitRef="usd">-313779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-169" unitRef="usd">-6267000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-19"
      decimals="INF"
      id="f-170"
      unitRef="shares">2044672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-171" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">6529000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-9" decimals="-3" id="f-173" unitRef="usd">6531000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-19"
      decimals="INF"
      id="f-174"
      unitRef="shares">1300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-19" decimals="-3" id="f-175" unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-20" decimals="-3" id="f-176" unitRef="usd">3873000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-21" decimals="-3" id="f-177" unitRef="usd">-234000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-9" decimals="-3" id="f-178" unitRef="usd">3640000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-20" decimals="-3" id="f-179" unitRef="usd">3640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-9" decimals="-3" id="f-180" unitRef="usd">3640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants contextRef="c-19" decimals="INF" id="f-181" unitRef="usd">72110</avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-19"
      decimals="INF"
      id="f-182"
      unitRef="shares">19623</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-183" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-9" decimals="-3" id="f-184" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-20" decimals="-3" id="f-185" unitRef="usd">893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-9" decimals="-3" id="f-186" unitRef="usd">893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-187" unitRef="usd">-8193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-188" unitRef="usd">-8193000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-189"
      unitRef="shares">14036940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-190" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-191" unitRef="usd">314755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-192" unitRef="usd">-321738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-193" unitRef="usd">-6969000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-194"
      unitRef="shares">9430535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-195" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-196" unitRef="usd">292900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-197" unitRef="usd">-303824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-198" unitRef="usd">-10915000</us-gaap:StockholdersEquity>
    <avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare
      contextRef="c-28"
      decimals="INF"
      id="f-199"
      unitRef="shares">3770000</avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare>
    <avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue contextRef="c-28" decimals="-3" id="f-200" unitRef="usd">4000</avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue>
    <avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue contextRef="c-29" decimals="-3" id="f-201" unitRef="usd">13744000</avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue>
    <avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">13748000</avtx:IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-28"
      decimals="INF"
      id="f-203"
      unitRef="shares">2044672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-204" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-205" unitRef="usd">6529000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">6531000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-28"
      decimals="INF"
      id="f-207"
      unitRef="shares">1300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-28" decimals="-3" id="f-208" unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-29" decimals="-3" id="f-209" unitRef="usd">3873000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-30" decimals="-3" id="f-210" unitRef="usd">-234000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">3640000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-29" decimals="-3" id="f-212" unitRef="usd">3640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">3640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants contextRef="c-28" decimals="INF" id="f-214" unitRef="usd">72110</avtx:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-28"
      decimals="INF"
      id="f-215"
      unitRef="shares">19623</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-29" decimals="-3" id="f-216" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-29" decimals="-3" id="f-218" unitRef="usd">1748000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">1748000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-220" unitRef="usd">-18148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-18148000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-222"
      unitRef="shares">14036940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-223" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-224" unitRef="usd">314755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-225" unitRef="usd">-321738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-226" unitRef="usd">-6969000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-227"
      unitRef="shares">9399517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-228" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-229" unitRef="usd">290550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-230" unitRef="usd">-284217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-231" unitRef="usd">6342000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-35"
      decimals="INF"
      id="f-232"
      unitRef="shares">938</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-35"
      decimals="INF"
      id="f-233"
      unitRef="shares">5269</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-36" decimals="-3" id="f-234" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-10" decimals="-3" id="f-235" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-36" decimals="-3" id="f-236" unitRef="usd">669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-10" decimals="-3" id="f-237" unitRef="usd">669000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-238" unitRef="usd">-12987000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-239" unitRef="usd">-12987000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-240"
      unitRef="shares">9405724</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-241" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-242" unitRef="usd">291244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-243" unitRef="usd">-297204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-244" unitRef="usd">-5951000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-41"
      decimals="INF"
      id="f-245"
      unitRef="shares">9399517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-246" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-247" unitRef="usd">285239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-248" unitRef="usd">-262166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-249" unitRef="usd">23082000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-45"
      decimals="INF"
      id="f-250"
      unitRef="shares">938</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-45"
      decimals="INF"
      id="f-251"
      unitRef="shares">5269</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-46" decimals="-3" id="f-252" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-11" decimals="-3" id="f-253" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-46" decimals="-3" id="f-254" unitRef="usd">5980000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-11" decimals="-3" id="f-255" unitRef="usd">5980000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-256" unitRef="usd">-35038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-257" unitRef="usd">-35038000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-258"
      unitRef="shares">9405724</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-259" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-260" unitRef="usd">291244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-261" unitRef="usd">-297204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-262" unitRef="usd">-5951000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-18148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-265" unitRef="usd">-35038000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">74000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-267" unitRef="usd">97000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">1748000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="-3" id="f-269" unitRef="usd">5980000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">699000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-11" decimals="-3" id="f-271" unitRef="usd">686000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">0</us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal>
    <us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal contextRef="c-11" decimals="-3" id="f-273" unitRef="usd">1000000</us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-275" unitRef="usd">15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-220000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-11" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">38000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-11" decimals="-3" id="f-279" unitRef="usd">-516000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">-1913000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-11" decimals="-3" id="f-281" unitRef="usd">-2433000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-2000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-11" decimals="-3" id="f-283" unitRef="usd">-15000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">-155000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-11" decimals="-3" id="f-285" unitRef="usd">-487000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <avtx:IncreaseDecreaseInLeaseIncentives contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-158000</avtx:IncreaseDecreaseInLeaseIncentives>
    <avtx:IncreaseDecreaseInLeaseIncentives contextRef="c-11" id="f-287" unitRef="usd" xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-2131000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-11" decimals="-3" id="f-289" unitRef="usd">-1205000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">-88000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-11" decimals="-3" id="f-291" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-5627000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="-3" id="f-293" unitRef="usd">-3537000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <avtx:IncreaseDecreaseInLeaseLiability contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">-30000</avtx:IncreaseDecreaseInLeaseLiability>
    <avtx:IncreaseDecreaseInLeaseLiability contextRef="c-11" decimals="-3" id="f-295" unitRef="usd">14000</avtx:IncreaseDecreaseInLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">-21078000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="-3" id="f-297" unitRef="usd">-28537000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">158000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-11" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">25000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-303" unitRef="usd">56000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="-3" id="f-305" unitRef="usd">-56000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebt contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">6000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-11" decimals="-3" id="f-307" unitRef="usd">14806000</us-gaap:RepaymentsOfDebt>
    <avtx:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">13748000</avtx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <avtx:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-11" decimals="-3" id="f-309" unitRef="usd">0</avtx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">6531000</avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram>
    <avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram contextRef="c-11" decimals="-3" id="f-311" unitRef="usd">0</avtx:ProceedsFromIssuanceOfCommonStockThroughATMProgram>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">67000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-11" decimals="-3" id="f-313" unitRef="usd">25000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">14346000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="-3" id="f-315" unitRef="usd">-14781000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-6865000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="-3" id="f-317" unitRef="usd">-43374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">13318000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-319" unitRef="usd">54864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-320" unitRef="usd">6453000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-321" unitRef="usd">11490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">1439000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-11" decimals="-3" id="f-323" unitRef="usd">1657000</us-gaap:InterestPaidNet>
    <avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">3640000</avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants>
    <avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants contextRef="c-11" decimals="-3" id="f-325" unitRef="usd">0</avtx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-326" unitRef="usd">6307000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-40" decimals="-3" id="f-327" unitRef="usd">11249000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-328" unitRef="usd">15000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-40" decimals="-3" id="f-329" unitRef="usd">14000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-330" unitRef="usd">131000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-40" decimals="-3" id="f-331" unitRef="usd">227000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-332" unitRef="usd">6453000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-333" unitRef="usd">11490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-334">Business &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avalo Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Avalo&#x201d; or &#x201c;we&#x201d;) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (&#x201c;HVEM&#x201d;), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin &#x3b2; receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (&#x201c;BTLA&#x201d;), and CD160 (collectively, the &#x201c;LIGHT-signaling network&#x201d; or the &#x201c;LIGHT network&#x201d;). Accumulating evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avalo was incorporated in Delaware and commenced operation in 2011 and completed its initial public offering in October 2015. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2023, Avalo generated a net loss of $18.1 million and negative cash flows from operations of $21.1 million. As of June 30, 2023, Avalo had $6.3 million in cash and cash equivalents. The future principal payments inclusive of the final payment fee under the Company&#x2019;s Loan Agreement (as defined in Note 9) were $15.2&#160;million as of June&#160;30, 2023, which gives effect of the $6.0&#160;million partial prepayment in June of 2023, as collectively agreed upon with the Lenders (as defined in Note 9). On July 20, 2023, the Company entered into a forbearance agreement (the &#x201c;Forbearance Agreement&#x201d;) with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#x2019;s business (the &#x201c;Existing Default&#x201d;) and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $15.2&#160;million, plus interest, fees, and other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $3.0&#160;million plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by the Company as a result of any future sale of the Company&#x2019;s equity securities while the Forbearance Agreement is in effect. The Company closely monitors its cash and cash equivalents and intends to raise money through all means available to raise capital to meet its projected operating requirements, including but not limited to sale of equity securities under its &#x201c;at-the-market&#x201d; (or &#x201c;ATM&#x201d;) program or otherwise, out-licensing transactions, strategic alliances/collaborations, sale of its core and non-core programs, and/or mergers and acquisitions. If the Company is able to negotiate extensions to the Forbearance Agreement and absent future cash raises or modifications to the originally planned principal and interest payments, the Company has approximately 60 days of cash on hand as of the filing date of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future success and ability to fund its operations within one year following the date on which this Quarterly Report on Form 10-Q is issued depend on its ability to obtain additional capital. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be, or that any amount that the Company is able to raise will be adequate. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, the Loan Agreement prohibits the Company from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without the prior consent of the Lenders. If the Company requires but is unable to obtain additional funding, the Company may be forced to make further reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise funds, management has concluded that substantial doubt exists with respect to the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report on Form 10-Q were issued.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company&#x2019;s ability to continue as a going concern is dependent upon its ability to obtain additional capital as described above. The unaudited financial statements as of June 30, 2023 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements and less than the amount of its outstanding debt, leaving no proceeds for stockholders.</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-335" unitRef="usd">-18100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-336" unitRef="usd">-21100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-337" unitRef="usd">6300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-47" decimals="-5" id="f-338" unitRef="usd">15200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-48" decimals="-5" id="f-339" unitRef="usd">6000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-49" decimals="-5" id="f-340" unitRef="usd">15200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-49" decimals="-5" id="f-341" unitRef="usd">3000000</us-gaap:RestrictedCashAndCashEquivalents>
    <avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage
      contextRef="c-49"
      decimals="INF"
      id="f-342"
      unitRef="number">1</avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-343">Basis of Presentation and Significant Accounting Policies&lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2022 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2022 audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 7, 2022, Avalo effected a 1-for-12 reverse stock split of the outstanding shares of the Company&#x2019;s common stock. The Company retroactively applied the reverse stock split to common share and per share amounts for periods prior to July&#160;7, 2022, including the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#x2019;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#x2019;s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July&#160;7, 2022, including the three and six months ended June&#160;30, 2022. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted in 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This guidance eliminates the requirement to calculate the implied fair value of goodwill of a reporting unit to measure a goodwill impairment charge. Instead, a company will record an impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value. This new standard was adopted effective January 1, 2023 and will be applied upon any recognition of any future goodwill impairment charge. This ASU has not had a material impact on our financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;During the six months ended June&#160;30, 2023, there were no significant changes to the Company&#x2019;s summary of significant accounting policies contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March 29, 2023.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-344">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2022 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2022 audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 7, 2022, Avalo effected a 1-for-12 reverse stock split of the outstanding shares of the Company&#x2019;s common stock. The Company retroactively applied the reverse stock split to common share and per share amounts for periods prior to July&#160;7, 2022, including the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#x2019;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#x2019;s equity incentive plans have been reduced proportionately. Avalo retroactively applied such adjustments in the notes to the unaudited condensed consolidated financial statements for periods presented prior to July&#160;7, 2022, including the three and six months ended June&#160;30, 2022. The reverse stock split did not reduce the number of authorized shares of common and preferred stock and did not alter the par value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-345">Accounting Pronouncements Adopted in 2023&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment.&lt;/span&gt; This guidance eliminates the requirement to calculate the implied fair value of goodwill of a reporting unit to measure a goodwill impairment charge. Instead, a company will record an impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value. This new standard was adopted effective January 1, 2023 and will be applied upon any recognition of any future goodwill impairment charge. This ASU has not had a material impact on our financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-347">Revenue&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Avalo generates its product revenue from sales of Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors. Wholesale distributors account for substantially all of the Company&#x2019;s net product revenues and trade &lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;receivables. For the three months ended June&#160;30, 2023, the Company&#x2019;s two largest customers accounted for approximately 65% and 35% of the Company&#x2019;s total net product revenues. For the six months ended June&#160;30, 2023, the Company&#x2019;s two largest customers accounted for approximately 63% and 37% of the Company&#x2019;s total net product revenues. Net revenue from sales of prescription drugs was $0.6 million and $1.0 million for the three months ended June&#160;30, 2023 and 2022, respectively, and $1.1 million and $2.2 million for the six months ended June&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license and supply agreement for the Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#x201c;Teva&#x201d;), which expires on September 30, 2023. Avalo is required to pay Teva fifty percent of the net profit of the Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which commenced on July 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aytu BioScience, Inc. (&#x201c;Aytu&#x201d;), to which the Company sold its rights, title, and interests in assets relating to certain commercialized products in 2019 (the &#x201c;Aytu Transaction&#x201d;), managed Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial operations until August 31, 2021 pursuant to transition service agreements, which included managing the third-party logistics provider and providing accounting reporting services. Aytu collected cash on behalf of Avalo for revenue generated by sales of Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the second quarter of 2020 through the third quarter of 2021 and is obligated to transfer cash generated by such sales to Avalo. In the third quarter of 2021, Avalo finalized its trade and distribution channel to allow it to control the third-party distribution and began managing Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial operations at that time. The transition services agreement allowed Aytu to withhold cash of $2.0&#160;million until September 30, 2022, and allows withholding of  $1.0&#160;million until December 2024. As of June&#160;30, 2023, the total receivable balance, which represents revenue generated by sales of Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the time Aytu was managing its commercial operations partially offset by minimal operational liabilities Aytu paid on our behalf, was estimated to be approximately $1.0&#160;million, all of which is due in December 2024. In the second quarter of 2022, Avalo fully reserved the $1.0&#160;million due in December 2024 as a result of Aytu&#x2019;s conclusion within its Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, that substantial doubt existed with respect to its ability to continue as a going concern within one year after the date of financial statements were issued. This conclusion has remained unchanged within Aytu&#x2019;s most recent publicly disclosed financial statements. We will continue to re-assess collectability each reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-50" decimals="2" id="f-348" unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-51" decimals="2" id="f-349" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-52" decimals="2" id="f-350" unitRef="number">0.63</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-53" decimals="2" id="f-351" unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-5" id="f-352" unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-5" id="f-353" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-354" unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-355" unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <avtx:LicenseAgreementPercentOfNetProfitForInstallmentPayment contextRef="c-54" decimals="2" id="f-356" unitRef="number">0.50</avtx:LicenseAgreementPercentOfNetProfitForInstallmentPayment>
    <avtx:LicenseAgreementInstallmentPayment contextRef="c-55" decimals="-5" id="f-357" unitRef="usd">500000</avtx:LicenseAgreementInstallmentPayment>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-56" decimals="-5" id="f-358" unitRef="usd">2000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-57" decimals="-5" id="f-359" unitRef="usd">1000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ContractWithCustomerReceivableBeforeAllowanceForCreditLoss contextRef="c-58" decimals="-5" id="f-360" unitRef="usd">1000000</us-gaap:ContractWithCustomerReceivableBeforeAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal contextRef="c-59" decimals="-5" id="f-361" unitRef="usd">1000000</us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-362">Net Loss Per Share  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS is provided below for common stock for the three and six months ended June 30, 2023 and June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EPS for common stock is computed by dividing the sum of distributed earnings and undistributed earnings by the weighted average number of shares outstanding for the period. The weighted average number of common shares outstanding as of June&#160;30, 2023 and 2022 include the weighted average effect of pre-funded warrants, the exercise of which requires nominal consideration for the delivery of the shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#x201c;treasury stock method&#x201d; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#x201c;treasury stock method&#x201d; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of common stock for the three and six months ended June&#160;30, 2023 and June&#160;30, 2022 (in thousands, except share and per share amounts):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,971,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,400,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,853,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,400,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June&#160;30, 2023 and 2022, as they could have been anti-dilutive:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.064%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.065%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849,229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379,570&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants on common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price is nominal. The weighted average shares outstanding for the three and six months ended June&#160;30, 2023 include the weighted average effect of 525,909 and 321,096 pre-funded warrants, respectively. The weighted average shares outstanding for the three and six months ended June 30, 2022 included the weighted average effect of 114,007 pre-funded warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-363">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of common stock for the three and six months ended June&#160;30, 2023 and June&#160;30, 2022 (in thousands, except share and per share amounts):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,971,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,400,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,853,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,400,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-364" unitRef="usd">-8193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-365" unitRef="usd">-12987000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-366" unitRef="shares">13971968</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-367" unitRef="shares">13971968</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-368" unitRef="shares">9400902</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-369" unitRef="shares">9400902</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-371"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-372"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-373"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">-18148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-375" unitRef="usd">-35038000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-376" unitRef="shares">12853579</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-377" unitRef="shares">12853579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-378" unitRef="shares">9400214</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-379" unitRef="shares">9400214</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-380"
      unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-381"
      unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-382"
      unitRef="usdPerShare">-3.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-383"
      unitRef="usdPerShare">-3.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-384">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June&#160;30, 2023 and 2022, as they could have been anti-dilutive:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.064%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.065%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849,229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379,570&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants on common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price is nominal. The weighted average shares outstanding for the three and six months ended June&#160;30, 2023 include the weighted average effect of 525,909 and 321,096 pre-funded warrants, respectively. The weighted average shares outstanding for the three and six months ended June 30, 2022 included the weighted average effect of 114,007 pre-funded warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-385" unitRef="shares">1849229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-386" unitRef="shares">1849229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-387" unitRef="shares">1379570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="0" id="f-388" unitRef="shares">1379570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-389" unitRef="shares">4136990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="0" id="f-390" unitRef="shares">4136990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="0" id="f-391" unitRef="shares">366990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-392" unitRef="shares">366990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-393" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-69" decimals="0" id="f-394" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-70" decimals="0" id="f-395" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-71" decimals="0" id="f-396" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised contextRef="c-72" decimals="0" id="f-397" unitRef="shares">525909</avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised contextRef="c-73" decimals="0" id="f-398" unitRef="shares">321096</avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised contextRef="c-74" decimals="0" id="f-399" unitRef="shares">114007</avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised contextRef="c-75" decimals="0" id="f-400" unitRef="shares">114007</avtx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-401">Fair Value Measurements &lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC No. 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#x2011;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1&#x2014;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2&#x2014;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#x2011;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3&#x2014;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:99pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-406"&gt;Derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-413"&gt;Derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;*Investments in money market funds are reflected in cash and cash equivalents on the accompanying unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023 and December&#160;31, 2022, the Company&#x2019;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities, derivative liability and debt. The carrying amounts reported in the accompanying unaudited condensed consolidated financial statements for cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The estimated fair value of the Company&#x2019;s debt was approximately $10 million as of June&#160;30, 2023 and is in Level Two of the fair value hierarchy (refer to Note 9 for more information). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Level 3 Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the derivative liability for the six months ended June&#160;30, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2022, Avalo sold its economic rights to future milestone and royalty payments for previously out-licensed assets AVTX-501, AVTX-007, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and AVTX-611 to ES Therapeutics, LLC (&#x201c;ES&#x201d;), an affiliate of Armistice, in exchange for $5.0&#160;million (the &#x201c;ES Transaction&#x201d;). At the time of the transaction, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Armistice was a significant stockholder of the Company and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#x2019;s Board until August 8, 2022. The ES Transaction was approved in accordance with Avalo&#x2019;s related party transaction policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The economic rights sold include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (a) rights to a milestone payment of $20.0&#160;million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., (the &#x201c;AVTX-501 Milestone&#x201d;) and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited, including up to $6.25&#160;million of development milestones, up to $67.5&#160;million in sales-based milestones, and royalty payments of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the &#x201c;AVTX-007 Milestones and Royalties&#x201d;). In addition, Avalo waived all its rights to AVTX-611 sales-based payments of up to $20.0&#160;million that were payable by ES. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The exchange of the economic rights of the AVTX-501 Milestone and AVTX-007 Milestones and Royalties for cash meets the definition of a derivative instrument. The fair value of the derivative liability is determined using a combination of a scenario-based method and an option pricing method (implemented using a Monte Carlo simulation). The significant inputs including probabilities of success, expected timing, and forecasted sales as well as market-based inputs for volatility, risk-adjusted discount rates and allowance for counterparty credit risk are unobservable and based on the best information available to Avalo. Certain information used in the valuation is inherently limited in nature and could differ from Janssen and Apollo&#x2019;s internal estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the derivative liability as of the transaction date was approximately $4.8&#160;million, of which $3.5&#160;million was attributable to the AVTX-501 Milestone and $1.3&#160;million was attributable to the AVX-007 Milestones and Royalties. Subsequent to the transaction date, at each reporting period, the derivative liability is remeasured at fair value. As of June&#160;30, 2023, the fair value of the derivative liability was $5.1&#160;million, of which $3.7 million was attributable to the AVTX-501 Milestone and $1.3 million was &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;attributable to the AVTX-007 Milestones and Royalties. For the six months ended June&#160;30, 2023, the $0.2&#160;million change in fair value was recognized in other expense, net in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the AVTX-501 Milestone was primarily driven by an approximate 23% probability of success to reach the milestone in approximately 4.3 years. The fair value of AVTX-007 Milestones and Royalties were primarily driven by an approximate 17% probability of success, time to commercialization of approximately 5.3 years, and sales forecasts with peak annual net sales reaching $300&#160;million. As discussed above, these unobservable inputs were estimated by Avalo based on limited publicly available information and therefore could differ from Janssen and Apollo&#x2019;s internal development plans. Any changes to these inputs may result in significant changes to the fair value measurement. Notably, the probability of success is the largest driver of the fair value and therefore changes to such input would likely result in significant changes to such fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the event that Janssen and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those customers for that amount when it is no longer probable there would be a significant revenue reversal with any differences between the fair value of the derivative liability related to that payment immediately prior to the revenue recognition and revenue recognized to be recorded as other expense. However, given Avalo is no longer entitled to collect these payments, the potential ultimate settlement of the payments in the future from Janssen and/or Apollo to ES Therapeutics (and the future mark-to-market activity each reporting period) will not impact Avalo&#x2019;s future cash flows. &lt;/span&gt;&lt;/div&gt;No changes in valuation techniques or inputs occurred during the six months ended June&#160;30, 2023 and 2022. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the six months ended June&#160;30, 2023 and 2022.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-402">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-406"&gt;Derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-413"&gt;Derivative liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;*Investments in money market funds are reflected in cash and cash equivalents on the accompanying unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-403" unitRef="usd">5042000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-76" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-77" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-78" decimals="-3" id="f-409" unitRef="usd">5050000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-410" unitRef="usd">12133000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-79" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-80" decimals="-3" id="f-415" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-81" decimals="-3" id="f-416" unitRef="usd">4830000</us-gaap:DerivativeLiabilities>
    <us-gaap:LongTermDebtFairValue contextRef="c-82" decimals="-6" id="f-417" unitRef="usd">10000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-418">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the derivative liability for the six months ended June&#160;30, 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-83" decimals="-3" id="f-419" unitRef="usd">4830000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-84" decimals="-3" id="f-420" unitRef="usd">220000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-85" decimals="-3" id="f-421" unitRef="usd">5050000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-86" decimals="-5" id="f-422" unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-87" decimals="-5" id="f-423" unitRef="usd">20000000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-88" decimals="-4" id="f-424" unitRef="usd">6250000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-89" decimals="-5" id="f-425" unitRef="usd">67500000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-90" decimals="-5" id="f-426" unitRef="usd">20000000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-91" decimals="-5" id="f-427" unitRef="usd">4800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-92" decimals="-5" id="f-428" unitRef="usd">3500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-93" decimals="-5" id="f-429" unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-94" decimals="-5" id="f-430" unitRef="usd">5100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-95" decimals="-5" id="f-431" unitRef="usd">3700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-96" decimals="-5" id="f-432" unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral contextRef="c-3" decimals="-5" id="f-433" unitRef="usd">200000</us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-97" decimals="2" id="f-434" unitRef="number">0.23</us-gaap:DerivativeLiabilityMeasurementInput>
    <avtx:DerivativeLiabilityMeasurementInputTerm contextRef="c-98" id="f-435">P4Y3M18D</avtx:DerivativeLiabilityMeasurementInputTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-99" decimals="2" id="f-436" unitRef="number">0.17</us-gaap:DerivativeLiabilityMeasurementInput>
    <avtx:DerivativeLiabilityMeasurementInputTerm contextRef="c-100" id="f-437">P5Y3M18D</avtx:DerivativeLiabilityMeasurementInputTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-101" decimals="-6" id="f-438" unitRef="usd">300000000</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-439">Leases &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avalo currently occupies two leased properties, both of which serve as administrative office space. The Company determined that both of these leases are operating leases based on the lease classification test performed at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual base rent for the Company&#x2019;s office located in Rockville, Maryland is $0.2 million, subject to annual 2.5% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of 12 months following the Company&#x2019;s date of occupancy. The lease has an initial term of 10 years from the date the Company made its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease two&#160;times, each for a period of five years, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial annual base rent for the Company&#x2019;s office located in Chesterbrook, Pennsylvania is $0.2&#160;million and the annual operating expenses are approximately $0.1&#160;million. The annual base rent is subject to periodic increases of approximately 2.4% over the term of the lease. The lease has an initial term of 5.25 years from the lease commencement on December 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining term of the operating leases at June&#160;30, 2023 was 5.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leased properties include (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-453"&gt;&lt;span style="-sec-ix-hidden:f-454"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-457"&gt;&lt;span style="-sec-ix-hidden:f-458"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-461"&gt;&lt;span style="-sec-ix-hidden:f-462"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease right-of-use (ROU) assets are included in property and equipment, net and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our unaudited condensed consolidated balance sheets. The Company utilized a weighted average discount rate of 9.1% to determine the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three and six months ended June&#160;30, 2023 and 2022 were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;*Includes short-term leases, which are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a maturity analysis of the operating lease liabilities as of June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 1, 2023 through December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less implied interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <avtx:LesseeOperatingLeaseNumberOfLeasedProperties
      contextRef="c-3"
      decimals="INF"
      id="f-440"
      unitRef="property">2</avtx:LesseeOperatingLeaseNumberOfLeasedProperties>
    <avtx:LesseeOperatingLeaseLiabilityAnnualBaseRent contextRef="c-102" decimals="-5" id="f-441" unitRef="usd">200000</avtx:LesseeOperatingLeaseLiabilityAnnualBaseRent>
    <avtx:OperatingLeasesRentExpenseAnnualIncreasePercent contextRef="c-103" decimals="3" id="f-442" unitRef="number">0.025</avtx:OperatingLeasesRentExpenseAnnualIncreasePercent>
    <avtx:LesseeOperatingLeaseRentAbatementPeriod contextRef="c-103" id="f-443">P12M</avtx:LesseeOperatingLeaseRentAbatementPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-102" id="f-444">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <avtx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-103"
      decimals="INF"
      id="f-445"
      unitRef="renewal_option">2</avtx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-102" id="f-446">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <avtx:LesseeOperatingLeaseAnnualBaseRent contextRef="c-104" decimals="-5" id="f-447" unitRef="usd">200000</avtx:LesseeOperatingLeaseAnnualBaseRent>
    <us-gaap:OperatingLeaseExpense contextRef="c-105" decimals="-5" id="f-448" unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <avtx:OperatingLeasesRentExpenseAnnualIncreasePercent contextRef="c-105" decimals="3" id="f-449" unitRef="number">0.024</avtx:OperatingLeasesRentExpenseAnnualIncreasePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-104" id="f-450">P5Y3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <avtx:LesseeOperatingLeaseRemainingLeaseTeam contextRef="c-1" id="f-451">P5Y1M6D</avtx:LesseeOperatingLeaseRemainingLeaseTeam>
    <avtx:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-452">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leased properties include (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-453"&gt;&lt;span style="-sec-ix-hidden:f-454"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-457"&gt;&lt;span style="-sec-ix-hidden:f-458"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-461"&gt;&lt;span style="-sec-ix-hidden:f-462"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avtx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-455" unitRef="usd">1457000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">1750000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-459" unitRef="usd">535000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-460" unitRef="usd">532000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-463" unitRef="usd">1544000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-464" unitRef="usd">1711000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-465" unitRef="usd">2079000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-466" unitRef="usd">2243000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-3" decimals="3" id="f-467" unitRef="number">0.091</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-468">The components of lease expense for the three and six months ended June&#160;30, 2023 and 2022 were as follows (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;*Includes short-term leases, which are immaterial.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-9" decimals="-3" id="f-469" unitRef="usd">132000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-10" decimals="-3" id="f-470" unitRef="usd">122000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">253000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-11" decimals="-3" id="f-472" unitRef="usd">239000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-473">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a maturity analysis of the operating lease liabilities as of June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 1, 2023 through December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less implied interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-474" unitRef="usd">267000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-475" unitRef="usd">537000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-476" unitRef="usd">547000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-477" unitRef="usd">557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-478" unitRef="usd">258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-3" decimals="-3" id="f-479" unitRef="usd">201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-3" decimals="-3" id="f-480" unitRef="usd">224000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-481" unitRef="usd">2591000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-482" unitRef="usd">512000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-483" unitRef="usd">2079000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-484">Accrued Expenses and Other Current Liabilities  &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of June&#160;30, 2023 and December 31, 2022 consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-485">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of June&#160;30, 2023 and December 31, 2022 consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <avtx:AccruedResearchAndDevelopment contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">3339000</avtx:AccruedResearchAndDevelopment>
    <avtx:AccruedResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-487" unitRef="usd">6293000</avtx:AccruedResearchAndDevelopment>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">527000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-489" unitRef="usd">2699000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <avtx:AccruedSellingGeneralAndAdministrativeExpenses contextRef="c-3" decimals="-3" id="f-490" unitRef="usd">717000</avtx:AccruedSellingGeneralAndAdministrativeExpenses>
    <avtx:AccruedSellingGeneralAndAdministrativeExpenses contextRef="c-4" decimals="-3" id="f-491" unitRef="usd">1008000</avtx:AccruedSellingGeneralAndAdministrativeExpenses>
    <avtx:CommercialOperationsCurrent contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">1863000</avtx:CommercialOperationsCurrent>
    <avtx:CommercialOperationsCurrent contextRef="c-4" decimals="-3" id="f-493" unitRef="usd">1694000</avtx:CommercialOperationsCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">607000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">508000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">535000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">532000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">480000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">7588000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">13214000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-502">Cost Reduction Plan&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the first quarter of 2022, the Board approved a cost reduction plan to enable the Company to execute its strategy of prioritizing the development of its most promising programs (the &#x201c;Plan&#x201d;). A reduction in workforce plan was approved to reduce headcount and related expenses. The reduction in workforce plan was considered a one-time termination benefit as defined by ASC No. 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;. The one-time termination benefits mainly relate to severance payments to separated employees. As a result, the Company recognized $1.5&#160;million of expense during the first quarter of 2022, of which $0.7&#160;million was recognized in research and development expense, and $0.8&#160;million was recognized in selling, general and administrative expense. $1.4&#160;million of severance payments were paid in the year ended December 31, 2022 and the remaining $0.1&#160;million was paid in the six months ended June&#160;30, 2023. Additionally, $0.4&#160;million of stock-based compensation expense was recognized in the first quarter of 2022 related to the Plan, which was mainly related to accelerated vesting of certain separated employees&#x2019; stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In addition, previously and separately, during the first quarter of 2022, the Company separated certain section 16 executive officers. Each of the former executives are entitled to the benefits provided in their respective separation agreements, which include severance payments to be paid over &lt;span style="-sec-ix-hidden:f-509"&gt;twelve&lt;/span&gt; to eighteen months. As a result, the Company recognized $1.7&#160;million expense during the first quarter of 2022 within selling, general and administrative expenses. Additionally, the Company accelerated the vesting of certain outstanding stock options and extended the exercisability periods, which resulted in $3.9&#160;million of compensation cost recognized in first quarter of 2022. Refer to Note 11 for information regarding stock compensation expense related to separations entered into the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-106" decimals="-5" id="f-503" unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-107" decimals="-5" id="f-504" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-108" decimals="-5" id="f-505" unitRef="usd">800000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-109" decimals="-5" id="f-506" unitRef="usd">1400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-110" decimals="-5" id="f-507" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-106" decimals="-5" id="f-508" unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <avtx:RestructuringAndRelatedActivitiesPaymentTerm contextRef="c-112" id="f-510">P18M</avtx:RestructuringAndRelatedActivitiesPaymentTerm>
    <us-gaap:RestructuringCharges contextRef="c-113" decimals="-5" id="f-511" unitRef="usd">1700000</us-gaap:RestructuringCharges>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-113" decimals="-5" id="f-512" unitRef="usd">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-513">Notes Payable &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On June 4, 2021, the Company entered into a $35.0&#160;million venture loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Horizon Technology Finance Corporation (&#x201c;Horizon&#x201d;) and Powerscourt Investments XXV, LP (&#x201c;Powerscourt&#x201d;, and together with Horizon, the &#x201c;Lenders&#x201d;). In accordance with the Loan Agreement, $20.0&#160;million was funded on the closing date (the &#x201c;Initial Note&#x201d;), with the remaining $15.0&#160;million fundable upon the Company achieving certain predetermined milestones, which the Company met in the third quarter of 2021. On July 30, 2021, after achieving a predetermined milestone, the Company borrowed an additional $10.0&#160;million, which was evidenced by a second note payable (the &#x201c;Second Note&#x201d;). On September 29, 2021, after achieving a second predetermined milestone, the Company borrowed the remaining $5.0&#160;million, which was evidenced by a third note payable (the &#x201c;Third Note&#x201d;, and collectively with the Initial and Second Notes, the &#x201c;Notes&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June of 2023, the Company, as collectively agreed upon with the Lenders, prepaid $6.0&#160;million of principal. Additionally, in the second quarter of 2022, the Company, as collectively agreed upon with the Lenders, prepaid $15.0&#160;million, of which $14.8&#160;million was applied to principal and the remainder applied to accrued interest. As of June&#160;30, 2023, the outstanding notes payable balance was $15.2&#160;million, inclusive of the final payment fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Each advance under the Loan Agreement will mature 42 months from the first day of the month following the funding of the advance. Each advance accrues interest at a per annum rate of interest equal to 6.25% plus the prime rate, as reported in the Wall Street Journal (subject to a floor of 3.25%). The Loan Agreement provides for interest-only payments for each advance for the first 18 months, however the interest-only period was extended to 24 months as a result of the Company satisfying the Interest Only Extension Milestone (as defined in the Loan Agreement) in the third quarter of 2021. Thereafter, amortization payments will be payable in monthly installments of principal and interest through each advance&#x2019;s maturity date. Upon ten business days&#x2019; prior written notice, the Company may prepay all of the outstanding advances by paying the entire principal balance and all accrued and unpaid interest, subject to prepayment charges of up to 3% of the then outstanding principal balance. Upon the earlier of (i) payment in full of the principal balance, (ii) an event of default (see below), or (iii) the maturity date, the Company will pay an additional final payment of 3% of the principal loan amount to the Lenders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Each advance of the loan is secured by a lien on substantially all of the assets of the Company, other than Intellectual Property and Excluded Collateral (in each case as defined in the Loan Agreement), and contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 20, 2023, the Company entered into a Forbearance Agreement with the Lenders, pursuant to which the Company and the Lenders agreed that an event of default had occurred due to a material adverse change in the Company&#x2019;s business and the Lenders agreed to forbear from enforcing its full remedies related to the Existing Default, including acceleration of the outstanding principal payments and final payment fees of $15.2&#160;million, plus interest, fees, other amounts accrued, until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Lenders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Loan Agreement) in an amount not less than the sum of (a) $3.0&#160;million plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by Company as a result of the any future sale of the Company&#x2019;s equity securities while the Forbearance Agreement is in effect. As of June 30, 2023, the carrying value of the notes payable was $14.1&#160;million and is classified as a current liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On June 4, 2021, pursuant to the Loan Agreement, the Company issued warrants to the Lenders to purchase 33,656 shares of the Company&#x2019;s common stock with an exercise price of $31.20 per share (the &#x201c;Warrants&#x201d;). The Warrants are exercisable for ten years from the date of issuance. Debt issuance costs and the amount allocated to the warrants were recognized as a debt discount on the date of issuance and are amortized to interest expense using the effective interest method over the term of the loan. The $1.1&#160;million final payment fee is included in the contractual cash flows and is accreted to interest expense using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The effective interest rate of the Notes was 17.1% as of June&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Balance sheet information related to the note payable for the Notes is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of notes payable, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of notes payable, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt; Balance includes $1.1&#160;million final payment fee for the Notes, which represents 3% of the original principal loan amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of June&#160;30, 2023, the contractual future principal payments, excluding the Lender&#x2019;s right to accelerate the maturity of the obligations on the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement, were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.510%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="13" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="13" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt; Balance includes $1.1&#160;million final payment fee, which represents 3% of the original principal loan amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;If the Company is unable to reach an agreement with its Lenders to waive the Existing Default or extend the forbearance period prior to the expiration of the Forbearance Agreement on August 15, 2023, the Forbearance Agreement will terminate automatically and without further notice or action, the effect of which shall permit the Lenders to immediately exercise any and all rights and remedies available under the Loan Agreement, including acceleration of the outstanding principal payments and final payment fees, plus interest, fees, and other amounts accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-114" decimals="INF" id="f-514" unitRef="usd">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-115" decimals="-5" id="f-515" unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-116" decimals="-5" id="f-516" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-117" decimals="-5" id="f-517" unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-118" decimals="-5" id="f-518" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-119" decimals="-5" id="f-519" unitRef="usd">6000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-120" decimals="-5" id="f-520" unitRef="usd">15000000</us-gaap:RepaymentsOfDebt>
    <avtx:RepaymentOfDebtPrincipal contextRef="c-120" decimals="-5" id="f-521" unitRef="usd">14800000</avtx:RepaymentOfDebtPrincipal>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-47" decimals="-5" id="f-522" unitRef="usd">15200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c-115" id="f-523">P42M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-114" decimals="4" id="f-524" unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <avtx:DebtInstrumentInterestRateFloor contextRef="c-121" decimals="4" id="f-525" unitRef="number">0.0325</avtx:DebtInstrumentInterestRateFloor>
    <avtx:DebtInstrumentInterestOnlyPaymentPeriod contextRef="c-115" id="f-526">P18M</avtx:DebtInstrumentInterestOnlyPaymentPeriod>
    <avtx:DebtInstrumentInterestOnlyPaymentExtensionPeriod contextRef="c-115" id="f-527">P24M</avtx:DebtInstrumentInterestOnlyPaymentExtensionPeriod>
    <avtx:DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment
      contextRef="c-115"
      decimals="INF"
      id="f-528"
      unitRef="business_day">10</avtx:DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment>
    <avtx:DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage contextRef="c-114" decimals="2" id="f-529" unitRef="number">0.03</avtx:DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage>
    <avtx:DebtInstrumentAdditionalFinalPaymentPercentage contextRef="c-114" decimals="2" id="f-530" unitRef="number">0.03</avtx:DebtInstrumentAdditionalFinalPaymentPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-49" decimals="-5" id="f-531" unitRef="usd">15200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-49" decimals="-5" id="f-532" unitRef="usd">3000000</us-gaap:RestrictedCashAndCashEquivalents>
    <avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage
      contextRef="c-49"
      decimals="INF"
      id="f-533"
      unitRef="number">1</avtx:RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage>
    <us-gaap:LongTermDebt contextRef="c-47" decimals="-5" id="f-534" unitRef="usd">14100000</us-gaap:LongTermDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-122"
      decimals="INF"
      id="f-535"
      unitRef="shares">33656</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-123"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">31.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm contextRef="c-122" id="f-537">P10Y</avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm>
    <avtx:DebtInstrumentFinalPaymentFee contextRef="c-47" decimals="-5" id="f-538" unitRef="usd">1100000</avtx:DebtInstrumentFinalPaymentFee>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-47" decimals="3" id="f-539" unitRef="number">0.171</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-540">Balance sheet information related to the note payable for the Notes is as follows (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Initial Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of notes payable, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of notes payable, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt; Balance includes $1.1&#160;million final payment fee for the Notes, which represents 3% of the original principal loan amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-124" decimals="-3" id="f-541" unitRef="usd">8711000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-125" decimals="-3" id="f-542" unitRef="usd">12139000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-126" decimals="-3" id="f-543" unitRef="usd">4355000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-127" decimals="-3" id="f-544" unitRef="usd">6070000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-128" decimals="-3" id="f-545" unitRef="usd">2178000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-129" decimals="-3" id="f-546" unitRef="usd">3035000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-47" decimals="-3" id="f-547" unitRef="usd">15244000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-130" decimals="-3" id="f-548" unitRef="usd">21244000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-47" decimals="-3" id="f-549" unitRef="usd">1129000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-130" decimals="-3" id="f-550" unitRef="usd">1828000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-47" decimals="-3" id="f-551" unitRef="usd">14115000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-130" decimals="-3" id="f-552" unitRef="usd">19416000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-47" decimals="-3" id="f-553" unitRef="usd">14115000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-130" decimals="-3" id="f-554" unitRef="usd">5930000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-47" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-130" decimals="-3" id="f-556" unitRef="usd">13486000</us-gaap:LongTermDebtNoncurrent>
    <avtx:DebtInstrumentFinalPaymentFee contextRef="c-47" decimals="-5" id="f-557" unitRef="usd">1100000</avtx:DebtInstrumentFinalPaymentFee>
    <avtx:DebtInstrumentAdditionalFinalPaymentPercentage contextRef="c-47" decimals="2" id="f-558" unitRef="number">0.03</avtx:DebtInstrumentAdditionalFinalPaymentPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-559">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of June&#160;30, 2023, the contractual future principal payments, excluding the Lender&#x2019;s right to accelerate the maturity of the obligations on the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Loan Agreement, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement, were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.510%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="13" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="14" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="13" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt; Balance includes $1.1&#160;million final payment fee, which represents 3% of the original principal loan amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-47" decimals="-3" id="f-560" unitRef="usd">4168000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-47" decimals="-3" id="f-561" unitRef="usd">9463000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-47" decimals="-3" id="f-562" unitRef="usd">1613000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-47" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-47" decimals="-3" id="f-564" unitRef="usd">15244000</us-gaap:DebtInstrumentCarryingAmount>
    <avtx:DebtInstrumentFinalPaymentFee contextRef="c-47" decimals="-5" id="f-565" unitRef="usd">1100000</avtx:DebtInstrumentFinalPaymentFee>
    <avtx:DebtInstrumentAdditionalFinalPaymentPercentage contextRef="c-47" decimals="2" id="f-566" unitRef="number">0.03</avtx:DebtInstrumentAdditionalFinalPaymentPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-567">Capital Structure &lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Company&#x2019;s amended and restated certificate of incorporation, the Company is authorized to issue two classes of stock, common stock and preferred stock. At June&#160;30, 2023, the total number of shares of capital stock the Company was authorized to issue was 205,000,000, of which 200,000,000 was common stock and 5,000,000 was&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preferred stock. All shares of common and&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preferred stock have a par value of $0.001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company entered into an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with entities affiliated with Venrock Healthcare Capital Partners (&#x201c;Venrock&#x201d;), pursuant to which the Company exchanged an aggregate of 1.3&#160;million shares of the Company&#x2019;s common stock, par value $0.001 per share, owned by Venrock for pre-funded warrants (the &#x201c;Exchange Warrants&#x201d;) to purchase an aggregate of 1.3&#160;million shares of common stock (subject to adjustment in the event of stock splits, recapitlizations and other similar events affecting common stock), with an exercise price of $0.001 per share. The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercisable by Venrock if, upon giving effect or immediately prior thereto, Venrock would beneficially own more than 9.99% of the total number of issued and outstanding common stock, which percentage may change at the holders&#x2019; election to any other number less than or equal to 19.99% upon 61 days&#x2019; notice to the Company. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extend required by Delaware law. In accordance with ASC No. 505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded the retirement of the common stock exchanged as a reduction of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common shares outstanding and a corresponding impact to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June 30, 2023, none of the Exchange Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company entered into an &#x201c;at-the-market&#x201d; sales agreement with Oppenheimer &amp;amp; Co. Inc. (&#x201c;Oppenheimer&#x201d;), pursuant to which the Company may sell from time to time, shares of its common stock having an aggregate offering price of up to $9,032,567 through Oppenheimer. In the second quarter of 2023, the Company sold approximately 2.0&#160;million shares under the ATM program for net proceeds of approximately $6.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to June 30, 2023 and as of the filing date of this Quarterly Report on Form 10-Q, the Company sold an additional 6.2&#160;million shares under the ATM program for gross proceeds of approximately $1.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Q1 2023 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2023, the Company closed an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to 3,770,000 shares of common stock, at a combined price to the public of $3.98 per share and warrant, resulting in net proceeds of approximately $13.7&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by us. The warrants were immediately exercisable at an exercise price of $5.00 per share and are exercisable for one year from the issuance date. Armistice, who was a significant stockholder of the Company at the time of the financing, participated in the offering by purchasing 0.5&#160;million shares of common stock and 0.5&#160;million warrants, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC and Point72 Asset Management, L.P., which each beneficially owned greater than 5% of the Company&#x2019;s outstanding common stock at the time of the offering, participated in the offering on the same terms as all other investors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants were classified as a component of permanent stockholders&#x2019; deficit within additional paid-in capital. The warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2023, the following common stock warrants were outstanding:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;underlying&#160;warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;per&#160;share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,770,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,478,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <avtx:NumberOfClassOfStockAuthorized
      contextRef="c-3"
      decimals="INF"
      id="f-568"
      unitRef="class_of_stock">2</avtx:NumberOfClassOfStockAuthorized>
    <avtx:CapitalStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-569" unitRef="shares">205000000</avtx:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-570" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-571" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-572"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-573"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-131"
      decimals="-5"
      id="f-574"
      unitRef="shares">1300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-132"
      decimals="3"
      id="f-575"
      unitRef="usdPerShare">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-133"
      decimals="-5"
      id="f-576"
      unitRef="shares">1300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-134"
      decimals="3"
      id="f-577"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold contextRef="c-135" decimals="4" id="f-578" unitRef="number">0.0999</avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold>
    <avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold contextRef="c-136" decimals="4" id="f-579" unitRef="number">0.1999</avtx:ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold>
    <avtx:ClassOfWarrantOrRightOwnershipExerciseThreshold contextRef="c-137" id="f-580">P61D</avtx:ClassOfWarrantOrRightOwnershipExerciseThreshold>
    <avtx:SaleOfStockMaximumAmountOfSharesToBeSold contextRef="c-138" decimals="0" id="f-581" unitRef="usd">9032567</avtx:SaleOfStockMaximumAmountOfSharesToBeSold>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-139"
      decimals="-5"
      id="f-582"
      unitRef="shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-139" decimals="-5" id="f-583" unitRef="usd">6500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-140"
      decimals="-5"
      id="f-584"
      unitRef="shares">6200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-140" decimals="-5" id="f-585" unitRef="usd">1300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-141"
      decimals="INF"
      id="f-586"
      unitRef="shares">3770000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-141"
      decimals="INF"
      id="f-587"
      unitRef="shares">3770000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-142"
      decimals="2"
      id="f-588"
      unitRef="usdPerShare">3.98</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-141" decimals="-5" id="f-589" unitRef="usd">13700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-143"
      decimals="INF"
      id="f-590"
      unitRef="usdPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm contextRef="c-144" id="f-591">P1Y</avtx:ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-145"
      decimals="-5"
      id="f-592"
      unitRef="shares">500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-143"
      decimals="-5"
      id="f-593"
      unitRef="shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction contextRef="c-146" decimals="2" id="f-594" unitRef="number">0.05</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-595">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2023, the following common stock warrants were outstanding:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;underlying&#160;warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;per&#160;share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,770,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,478,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-147"
      decimals="INF"
      id="f-596"
      unitRef="shares">333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-147"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">150.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-148"
      decimals="INF"
      id="f-598"
      unitRef="shares">41701</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-148"
      decimals="3"
      id="f-599"
      unitRef="usdPerShare">0.012</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-149"
      decimals="INF"
      id="f-600"
      unitRef="shares">33656</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-149"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">31.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-150"
      decimals="INF"
      id="f-602"
      unitRef="shares">3770000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-150"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-151"
      decimals="INF"
      id="f-604"
      unitRef="shares">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-151"
      decimals="3"
      id="f-605"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-152"
      decimals="INF"
      id="f-606"
      unitRef="shares">5478691</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-607">Stock-Based Compensation &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2016, our board of directors adopted the 2016 Equity Incentive Plan, which was approved by our stockholders in May 2016 and which was subsequently amended and restated in May 2018 and August 2019 with the approval of our board of directors and our stockholders (the &#x201c;2016 Third Amended Plan&#x201d;). During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year ending on (and including) January 1, 2026, by an amount equal to 4% of the total number of outstanding shares of common stock of the Company on the last trading day in December of the prior calendar year. On January 1, 2023, pursuant to the terms of the 2016 Third Amended and Restated Plan, an additional 377,221 shares were &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;made available for issuance. As of June&#160;30, 2023, there were 41,183 shares available for future issuance under the 2016 Third Amended Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants expire after ten years. Employee options typically vest over four years. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. In addition, in the first and fourth quarters of 2022 and second quarter of 2023, employees were also granted options that vest on the first anniversary of the grant date. Options granted to directors typically vest either immediately or over a period of &lt;span style="-sec-ix-hidden:f-613"&gt;one&lt;/span&gt; or three years. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#x2019;s stock-based awards is amortized ratably over the individuals&#x2019; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options and employee stock purchase plan shares. The amount of stock-based compensation expense recognized for the three and six months ended June&#160;30, 2023 and 2022 was as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As a result of separation agreements that the Company entered into in the first quarter of 2022 and in accordance with the terms of the pre-existing employment agreements, the Company accelerated the vesting of certain separated employees&#x2019; stock options and modified certain awards to extend the exercisability periods. The Company recognized $4.3&#160;million of compensation cost in the first quarter of 2022, all of which was recognized in selling, general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options with service-based vesting conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted options that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. A summary of option activity for the six months ended June 30, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, the Company granted 0.3&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award that vest over four years. In May 2023, the Company granted 0.3&#160;million options with service-based vesting conditions to its employees that vest over one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. As of June&#160;30, 2023, the aggregate intrinsic value of options outstanding was zero. There were 0.2 million&#160;options that vested during the six months ended June 30, 2023 with a weighted average exercise price of&#160;$11.13 per share. The total grant date fair value of shares which vested during the six months ended June 30, 2023&#160;was&#160;$1.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense of $0.9 million and $1.7 million related to stock options with service-based vesting conditions for the three and six months ended June&#160;30, 2023, respectively. At June&#160;30, 2023, there was $4.5 million of total unrecognized compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the six months ended June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Service-based options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of option (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.8% - 146.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43% - 4.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options with market-based vesting conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, there were 0.1 million exercisable stock options that contained market-based vesting conditions (that had been previously satisfied). The options have a weighted average share price per share of $39.53 and a weighted average remaining contractual term of 1.0 years. There were no stock options with market-based vesting conditions granted, exercised, or forfeited for the six months ended June&#160;30, 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2016, the Company&#x2019;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was approved by the Company&#x2019;s stockholders and became effective on May 18, 2016 (the &#x201c;ESPP Effective Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#x2019;s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company&#x2019;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of their earnings during the offering period. The Company&#x2019;s board of directors may establish a maximum number of shares of the Company&#x2019;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company&#x2019;s common stock for each calendar year in which such right is outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially reserved and authorized up to 41,667 shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP automatically increases by a number equal to the lesser of (i) 1% of the total number of shares of the Company&#x2019;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 41,667 shares of the Company&#x2019;s common stock, or (iii) a number of shares of the Company&#x2019;s common stock as determined by the Company&#x2019;s board of directors or compensation committee. The number of shares were increased by 41,667 on January 1, 2023. As of June&#160;30, 2023, 192,079 shares remained available for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 718-50,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Employee Share Purchase Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the ability to purchase shares of the Company&#x2019;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#x2019;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $41&#160;thousand and $0.1 million for the three and six months ended June&#160;30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent contextRef="c-153" decimals="2" id="f-608" unitRef="number">0.04</avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent>
    <avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease
      contextRef="c-154"
      decimals="INF"
      id="f-609"
      unitRef="shares">377221</avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-155"
      decimals="INF"
      id="f-610"
      unitRef="shares">41183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-156" id="f-611">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-157" id="f-612">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-614">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-615">The amount of stock-based compensation expense recognized for the three and six months ended June&#160;30, 2023 and 2022 was as follows (in thousands):&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-160" decimals="-3" id="f-616" unitRef="usd">331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-161" decimals="-3" id="f-617" unitRef="usd">365000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-162" decimals="-3" id="f-618" unitRef="usd">658000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-163" decimals="-3" id="f-619" unitRef="usd">653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-164" decimals="-3" id="f-620" unitRef="usd">562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-165" decimals="-3" id="f-621" unitRef="usd">304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-166" decimals="-3" id="f-622" unitRef="usd">1090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="-3" id="f-623" unitRef="usd">5327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-9" decimals="-3" id="f-624" unitRef="usd">893000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-625" unitRef="usd">669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-626" unitRef="usd">1748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-627" unitRef="usd">5980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-168" decimals="-5" id="f-628" unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-629">A summary of option activity for the six months ended June 30, 2023 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-169"
      decimals="INF"
      id="f-630"
      unitRef="shares">1345532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-169"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">28.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-632"
      unitRef="usdPerShare">17.48</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-170" id="f-633">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-171"
      decimals="INF"
      id="f-634"
      unitRef="shares">760272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-171"
      decimals="2"
      id="f-635"
      unitRef="usdPerShare">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-171"
      decimals="2"
      id="f-636"
      unitRef="usdPerShare">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-171"
      decimals="INF"
      id="f-637"
      unitRef="shares">339910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-171"
      decimals="2"
      id="f-638"
      unitRef="usdPerShare">42.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="c-171"
      decimals="2"
      id="f-639"
      unitRef="usdPerShare">27.13</avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-172"
      decimals="INF"
      id="f-640"
      unitRef="shares">1765894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-172"
      decimals="2"
      id="f-641"
      unitRef="usdPerShare">14.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-172"
      decimals="2"
      id="f-642"
      unitRef="usdPerShare">8.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-171" id="f-643">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-172"
      decimals="INF"
      id="f-644"
      unitRef="shares">563963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-172"
      decimals="2"
      id="f-645"
      unitRef="usdPerShare">31.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="c-172"
      decimals="2"
      id="f-646"
      unitRef="usdPerShare">18.54</avtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-171" id="f-647">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-173"
      decimals="-5"
      id="f-648"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-173" id="f-649">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-174"
      decimals="-5"
      id="f-650"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-174" id="f-651">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-172" decimals="-5" id="f-652" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c-171"
      decimals="INF"
      id="f-653"
      unitRef="shares">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-172"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-171" decimals="-5" id="f-655" unitRef="usd">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-5" id="f-656" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-5" id="f-657" unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-172" decimals="-5" id="f-658" unitRef="usd">4500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-171" id="f-659">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-660">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the six months ended June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Service-based options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of option (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.8% - 146.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43% - 4.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-176" id="f-661">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-177" id="f-662">P6Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-178" decimals="3" id="f-663" unitRef="number">0.898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-179" decimals="3" id="f-664" unitRef="number">1.460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-178" decimals="4" id="f-665" unitRef="number">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-179" decimals="4" id="f-666" unitRef="number">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-171"
      decimals="INF"
      id="f-667"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-180"
      decimals="-5"
      id="f-668"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-180"
      decimals="2"
      id="f-669"
      unitRef="usdPerShare">39.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-181" id="f-670">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-181"
      decimals="INF"
      id="f-671"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-181"
      decimals="INF"
      id="f-672"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-181"
      decimals="INF"
      id="f-673"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-182" decimals="2" id="f-674" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-183" decimals="2" id="f-675" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <avtx:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum contextRef="c-182" decimals="-3" id="f-676" unitRef="usd">25000</avtx:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-183"
      decimals="INF"
      id="f-677"
      unitRef="shares">41667</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear contextRef="c-183" decimals="2" id="f-678" unitRef="number">0.01</avtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-183"
      decimals="INF"
      id="f-679"
      unitRef="shares">41667</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-184"
      decimals="INF"
      id="f-680"
      unitRef="shares">41667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-185"
      decimals="INF"
      id="f-681"
      unitRef="shares">192079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-3" id="f-682" unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-5" id="f-683" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-684">Income TaxesThe Company recognized minimal income tax expense for the three and six months ended June&#160;30, 2023 and 2022 due to the significant valuation allowance against the Company&#x2019;s deferred tax assets and the current and prior period losses.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-685">Commitments and Contingencies &lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation - General&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Possible Future Milestone Payments for In-Licensed Compounds&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avalo is a party to license and development agreements with various third parties, which contain future payment obligations such as royalties and milestone payments. The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-002 KKC License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#x201c;KKC&#x201d;) for exclusive worldwide rights to develop, manufacture and commercialize AVTX-002, KKC&#x2019;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#x201c;KKC License Agreement&#x201d;). The KKC License Agreement replaced the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the KKC License Agreement, the Company paid KKC an upfront license fee of $10.0&#160;million, which we recognized within research and development expenses in 2021. The Company is also required to pay KKC up to an aggregate of $112.5&#160;million based on the achievement of specified development and regulatory milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization, the Company is required to pay KKC sales-based milestones aggregating up to $75.0&#160;million tied to the achievement of annual net sales targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company is required to pay KKC royalties during a country-by-country royalty term equal to a mid-teen percentage of annual net sales. The Company is required to pay KKC a double-digit percentage (less than 30%) of the payments that the Company receives from any sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Avalo is responsible for the development and commercialization of AVTX-002 in all indications worldwide (other than the option in the KKC License Agreement that, upon exercise by KKC, allows KKC to develop, manufacture and commercialize AVTX-002 in Japan). In addition to the KKC License Agreement, Avalo is subject to additional royalties upon commercialization of up to an amount of less than 10% of net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense related to the KKC License Agreement was recognized in the six months ended June&#160;30, 2023. There has been no cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-006 Astellas License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#x201c;Astellas&#x201d;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (AVTX-006). Under the terms of the license agreement, there was an upfront license fee of $0.5&#160;million. The Company is required to pay Astellas up to an aggregate of $5.5&#160;million based on the achievement of specified development and regulatory milestones. The Company is also required to pay Astellas a tiered mid-to-high single digit percentage of the payments that Avalo receives from any sublicensing of its rights under the Astellas license agreement, subject to certain exclusions. Upon commercialization, the Company is required to pay Astellas royalties during a country-by-country royalty term equal to a tiered mid-to-high single digit percentage of annual net sales. Avalo is fully responsible for the development and commercialization of the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense related to this license agreement was recognized in the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There has been $0.5&#160;million of cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement, which was recognized in 2021. The Company will continue to monitor the remaining milestones at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-008 Sanford Burnham Prebys License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, the Company entered into an Exclusive Patent License Agreement with Sanford Burnham Prebys Medical Discovery Institute (the &#x201c;Sanford Burnham Prebys License Agreement&#x201d;) under which the Company obtained an exclusive license to a portfolio of issued patents and patent applications covering an immune checkpoint program (AVTX-008). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Sanford Burnham Prebys License Agreement, the Company incurred an upfront license fee of $0.4&#160;million, as well as patent costs of $0.5&#160;million, which we recognized within research and development expenses and within selling, general and administrative expenses, respectively, in 2021. The Company is required to pay Sanford Burnham Prebys up to an aggregate of $24.2&#160;million based on achievement of specified development and regulatory milestones. Upon commercialization, the Company is required to pay Sanford Burnham Prebys sales-based milestone payments aggregating up to $50.0&#160;million tied to annual net sales targets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company is required to pay Sanford Burnham Prebys royalties during a country-by-country royalty term equal to a low-to-mid single digit percentage of annual net sales. The Company is also required to pay Sanford Burnham Prebys a tiered low-double digit percentage&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the payments that Avalo receives from sublicensing of its rights under the Sanford Burnham Prebys License Agreement, subject to certain exclusions. Avalo is fully responsible for the development and commercialization of the program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense related to the Sanford Burnham Prebys License Agreement was recognized in the six months ended June&#160;30, 2023. There has been no cumulative expense recognized as of June&#160;30, 2023 related to the milestones under this license agreement. The Company will continue to monitor the milestones at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Possible Future Milestone Proceeds for Out-Licensed Compounds &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-301 Out-License&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 28, 2021, the Company out-licensed its rights in respect of its non-core asset, AVTX-301, to Alto Neuroscience, Inc. (&#x201c;Alto&#x201d;). The Company initially in-licensed the compound from an affiliate of Merck &amp;amp; Co., Inc. in 2013.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the out-license agreement, the Company received a mid-six digit upfront payment from Alto, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $18.6&#160;million based on the achievement of specified development, regulatory and commercial sales milestones. Additionally, the Company is entitled to a less than single digit percentage royalty based on annual net sales. Alto is fully responsible for the development and commercialization of the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has not recognized any milestones as of June&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-406 License Assignment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 9, 2021, the Company assigned its rights, title, interest, and obligations under an in-license covering its non-core asset, AVTX-406, to ES, a wholly owned subsidiary of Armistice, who was a significant stockholder of the Company at the time of the financing and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo&#x2019;s Board until August 8, 2022. The transaction with ES was approved in accordance with Avalo&#x2019;s related party transaction policy. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the assignment agreement, the Company received a low-six digit upfront payment from ES, which we recognized as license revenue in 2021. The Company is also eligible to receive up to an aggregate of $6.0&#160;million based on the achievement of specified development and regulatory milestones. Upon commercialization, the Company is eligible to receive sales-based milestone payments aggregating up to $20.0&#160;million tied to annual net sales targets. ES is fully responsible for the development and commercialization of the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has not recognized any milestones as of June&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition Related and Other Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aevi Merger Possible Future Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#x201c;Aevi&#x201d;), in which Avalo acquired the rights to AVTX-002, AVTX-006 and AVTX-007 (the &#x201c;Merger&#x201d; or the &#x201c;Aevi Merger&#x201d;). A portion of the consideration for the Aevi Merger included two future contingent development milestones worth up to an additional $6.5 million, payable in either shares of Avalo&#x2019;s common stock or cash, at the election of Avalo. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first milestone was the enrollment of a patient in a Phase 2 study related to AVTX-002 (for treatment of pediatric onset Crohn&#x2019;s disease), AVTX-006 (for treatment of any indication) or AVTX-007 (for treatment of any indication) prior to February 3, 2022, which would have resulted in a milestone payment of $2.0 million. The Company did not meet the first milestone prior to February 3, 2022. Therefore, no contingent consideration related to this milestone was recognized as of June&#160;30, 2023 and no future contingent consideration will be recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The second milestone is the receipt of an NDA approval for either AVTX-006 or AVTX-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. The contingent consideration related to the second development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. No contingent consideration related to the second development milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the second milestone at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ichorion Asset Acquisition Possible Future Milestone Payments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company acquired Ichorion Therapeutics, Inc., including acquiring three compounds for inherited metabolic disorders known as CDGs (AVTX-801, AVTX-802 and AVTX-803) and one other preclinical compound. Consideration for the transaction included shares of Avalo common stock and three future contingent development milestones for the acquired compounds worth up to an additional&#160;$15.0 million. All milestones are payable in either shares of the Company&#x2019;s common stock or cash, at the election of Avalo.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first and second milestones were marketing approval of the first and second product, respectively, by the FDA on or prior to December 31, 2021, which would have resulted in milestone payments of $6.0&#160;million and $5.0&#160;million, respectively. The Company did not meet the first or second milestone as of December 31, 2021. As a result, no contingent consideration related to these milestones was recognized as of June&#160;30, 2023 and no future contingent consideration will be recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The third milestone is marketing approval of a protide molecule by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $4.0&#160;million. The contingent consideration related to the third development milestone will be recognized if and when such milestone is probable and can be reasonably estimated. No contingent consideration related to the third milestone has been recognized as of June&#160;30, 2023. The Company will continue to monitor the third development milestone at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AVTX-006 Royalty Agreement with Certain Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, Aevi entered into a royalty agreement, and liabilities thereunder were assumed by Avalo upon close of the Aevi Merger in February 2020. The royalty agreement provided certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil, the Company&#x2019;s Chief Executive Officer and Chairman of the Board, and Mike Cola, the Company&#x2019;s former Chief Executive Officer (collectively, the &#x201c;Investors&#x201d;), a royalty stream, in exchange for a one-time aggregate payment of $2.0&#160;million (the &#x201c;Royalty Agreement&#x201d;). Pursuant to the Royalty Agreement, the Investors will be entitled collectively to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of the Company&#x2019;s second generation mTORC1/2 inhibitor, AVTX-006. At any time beginning three years after the date of the first public launch of AVTX-006, Avalo may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments. A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avalo assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company's accompanying unaudited condensed consolidated balance sheet as of June&#160;30, 2023 and December 31, 2022. Because there is a significant related party relationship between the Company and the Investors, the Company has treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which will result in a corresponding increase in the liability balance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Karbinal Royalty Make-Whole Provision &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, in connection with the acquisition of certain commercialized products, the Company entered into a supply and distribution agreement (the &#x201c;Karbinal Agreement&#x201d;) with TRIS Pharma Inc. (&#x201c;TRIS&#x201d;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;70,000&#160;units &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through 2025. The Company was required to pay TRIS a royalty make whole payment (&#x201c;Make-Whole Payments&#x201d;) of&#160;$30&#160;for each unit under the&#160;70,000&#160;units annual minimum sales commitment through 2025.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a part of the Aytu transaction, the Company assigned all its payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#x201c;TRIS Obligations&#x201d;) to Aytu.&#160;However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee contextRef="c-188" decimals="-5" id="f-686" unitRef="usd">10000000</avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-189" decimals="-5" id="f-687" unitRef="usd">112500000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-190" decimals="-5" id="f-688" unitRef="usd">75000000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing contextRef="c-188" decimals="2" id="f-689" unitRef="number">0.30</avtx:CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-191" decimals="-5" id="f-690" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate contextRef="c-192" decimals="-5" id="f-691" unitRef="usd">0</avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate>
    <avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee contextRef="c-193" decimals="-5" id="f-692" unitRef="usd">500000</avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-193" decimals="-5" id="f-693" unitRef="usd">5500000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-194" decimals="-5" id="f-694" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate contextRef="c-193" decimals="-5" id="f-695" unitRef="usd">500000</avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate>
    <avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee contextRef="c-195" decimals="-5" id="f-696" unitRef="usd">400000</avtx:CollaborativeArrangementRightsAndObligationsUpfrontFee>
    <avtx:CollaborativeArrangementRightsAndObligationsPatentCosts contextRef="c-195" decimals="-5" id="f-697" unitRef="usd">500000</avtx:CollaborativeArrangementRightsAndObligationsPatentCosts>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-196" decimals="-5" id="f-698" unitRef="usd">24200000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-197" decimals="-5" id="f-699" unitRef="usd">50000000</avtx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-198" decimals="INF" id="f-700" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate contextRef="c-199" decimals="INF" id="f-701" unitRef="usd">0</avtx:CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate>
    <avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-200" decimals="-5" id="f-702" unitRef="usd">18600000</avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments contextRef="c-201" decimals="-5" id="f-703" unitRef="usd">0</avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments>
    <avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-202" decimals="-5" id="f-704" unitRef="usd">6000000</avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-203" decimals="-5" id="f-705" unitRef="usd">20000000</avtx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments contextRef="c-204" decimals="-5" id="f-706" unitRef="usd">0</avtx:ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments>
    <avtx:AssetAcquisitionContingentValueRightNumberOfMilestones
      contextRef="c-205"
      decimals="INF"
      id="f-707"
      unitRef="milestone">2</avtx:AssetAcquisitionContingentValueRightNumberOfMilestones>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-205" decimals="-5" id="f-708" unitRef="usd">6500000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability contextRef="c-206" decimals="-5" id="f-709" unitRef="usd">2000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-207" decimals="-5" id="f-710" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-207" decimals="-5" id="f-711" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability contextRef="c-208" decimals="-5" id="f-712" unitRef="usd">4500000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-207" decimals="-5" id="f-713" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:AssetAcquisitionNumberOfPreclinicalTherapies
      contextRef="c-209"
      decimals="INF"
      id="f-714"
      unitRef="therapy">3</avtx:AssetAcquisitionNumberOfPreclinicalTherapies>
    <avtx:AssetAcquisitionNumberOfPreclinicalTherapies
      contextRef="c-210"
      decimals="INF"
      id="f-715"
      unitRef="therapy">1</avtx:AssetAcquisitionNumberOfPreclinicalTherapies>
    <avtx:AssetAcquisitionContingentValueRightNumberOfMilestones
      contextRef="c-211"
      decimals="INF"
      id="f-716"
      unitRef="milestone">3</avtx:AssetAcquisitionContingentValueRightNumberOfMilestones>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability contextRef="c-212" decimals="-5" id="f-717" unitRef="usd">15000000.0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-213" decimals="-5" id="f-718" unitRef="usd">6000000</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-214" decimals="-5" id="f-719" unitRef="usd">5000000</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-215" decimals="-5" id="f-720" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-215" decimals="-5" id="f-721" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-216" decimals="-5" id="f-722" unitRef="usd">4000000</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities contextRef="c-217" decimals="-5" id="f-723" unitRef="usd">0</avtx:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <avtx:RoyaltyAgreementPaymentReceived contextRef="c-218" decimals="-5" id="f-724" unitRef="usd">2000000</avtx:RoyaltyAgreementPaymentReceived>
    <avtx:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement contextRef="c-218" id="f-725">P3Y</avtx:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement>
    <avtx:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments contextRef="c-218" decimals="2" id="f-726" unitRef="number">0.75</avtx:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments>
    <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired contextRef="c-219" decimals="INF" id="f-727" unitRef="unit">70000</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
    <avtx:CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit
      contextRef="c-219"
      decimals="0"
      id="f-728"
      unitRef="usdPerShare">30</avtx:CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit>
    <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired contextRef="c-219" decimals="INF" id="f-729" unitRef="unit">70000</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-158"
          xlink:label="f-158"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-159"
          xlink:label="f-159"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-161"
          xlink:label="f-161"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-157"
          xlink:label="f-157"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-163"
          xlink:label="f-163"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-162"
          xlink:label="f-162"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-156"
          xlink:label="f-156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-160"
          xlink:label="f-160"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-158"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-159"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-161"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-157"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-163"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-162"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-156"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-160"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-240"
          xlink:label="f-240"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-236"
          xlink:label="f-236"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-234"
          xlink:label="f-234"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-251"
          xlink:label="f-251"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-233"
          xlink:label="f-233"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-258"
          xlink:label="f-258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-229"
          xlink:label="f-229"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-232"
          xlink:label="f-232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-247"
          xlink:label="f-247"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-252"
          xlink:label="f-252"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-228"
          xlink:label="f-228"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-245"
          xlink:label="f-245"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-260"
          xlink:label="f-260"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-250"
          xlink:label="f-250"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-242"
          xlink:label="f-242"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-227"
          xlink:label="f-227"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-246"
          xlink:label="f-246"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-259"
          xlink:label="f-259"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-254"
          xlink:label="f-254"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-241"
          xlink:label="f-241"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on July 7, 2022. See Note 2 for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-240"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-236"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-234"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-251"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-233"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-258"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-229"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-232"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-247"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-252"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-228"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-245"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-260"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-250"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-242"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-227"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-246"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-259"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-254"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-241"
          xlink:to="fn-2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MGY/>PT7C 'O K&[I%I<U9:SRCX.GE=>,N\7J>DK<[A,U,IXB^SA5]G'PI#(
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M@K(!^'XEI;F?V*[;7[+9/U!+ P04    " !X. -7_H;=I"X'  #C)0  &
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U:77/;-A;]*QBULY/,Q!8!?HCR
MVIIQ;'$VF6V;B9OV86<?8!&RV)"$EH#D9']] 9(61> 2DEN^2")U[@'N!X #
M$M?/O/HJ-HQ)]*W(2W$SV4BYO9I.Q6K#"BHN^9:5ZI\UKPHJU67U-!7;BM&T
M-BKR*?&\:%K0K)PLKNM[GZK%-=_)/"O9IPJ)75'0ZOM[EO/GFPF>O-SXG#UM
MI+XQ75QOZ1-[8/++]E.EKJ8'EC0K6"DR7J**K6\FM_@J\6N#&O%;QI[%T6^D
M77GD_*N^^)#>3#S=(Y:SE=045'WMV1W+<\VD^O&_EG1R:%,;'O]^84]JYY4S
MCU2P.Y[_GJ5R<S.))RAE:[K+Y6?^_"_6.A1JOA7/1?V)GENL-T&KG9"\:(U5
M#XJL;+[IMS801P;8'S @K0$Q#<(! [\U\$V#8, @: V"<UL(6X/PW!:BUB"J
M8]\$JX[T/95T<5WQ9U1IM&+3/^ITU=8JP%FI*^M!5NK?3-G)Q1TO4U4G+$7J
ME^!YEE*I+AZD^E(%) 7B:_3+EE54%X) M-3(0E7Q1I?7GJ%_<R'0FR\EW:69
M,GV++M"7AWOTYL>WZ$>4E>C7#=\)92:NIU)U6#<[7;6=NVLZ1P8ZYZ.?>"DW
M BU5)U/ ?NFVCQSV4Q6H0[3(2[3NB)/PXZZ\1+[W#A&/^$!_[L\W)Y [?Z_U
MY"^WW@N&?R@=O^;S!_@^LSTK=TQ<08EM3 /85$^75V)+5^QFHBI)L&K/)HM_
M_( C[Y]05,<D6XY)EHQ$UHM_<(A_X&)?_,HES=7LWF3A'2J9A#+1D$0UB5YG
M]HLH4-6S/PZPC<&>;X"6  CC61^4V"!"O.@ ZCD:'AP-G8763C_E$V+?MGJR
M@DLN'+/DQB1;CDF6C$36RT1TR$3D++D[+J1>$+853W<KB03-&3BO-S3A41G,
MO-@H.AN#P\BHIR4 (N'<*#H;1$@\4'2S@ZLSIZN?5?!HM=K4*UZJ!EG.MWI!
MA+R=6>T'46BZ:X/B$'N&NS8(>Y$9E 1 Q=X\@!V.#P['3H<?E+I38^P=>F*E
M&F]Y[3A-E>;(A-3C;\\@WV,[]@$Q.GP/@&9Q8/AN@T+L&Z#$!N$@B&+8]?G!
M];G3]=N"5S+[?RUQ7N88R->YU;B1O_N3B.5)1&(C_ '_L->I/.^,M8);$RFH
MR3Q[\,[FYI(!H+ :=-AP%X+-O,CT&8#Y03PTAO&1NL6O\CLK5[Q@Z$VN1.M;
MT'EL=>1BAD,SSQ ,XYC$IOL0+IR;"W "X7P2Q=Y  $@7 .)>.^6&52_I!I?-
MEF"D=7-4MN6H;,E8;/U4='(9.]7@XD,IF>*5+]D85&PM3Z\8YO/(+$$ A7%H
MSJH@;!Z$9@$",.(3?Z#^.HV*W2+U;D/+)Z;W@6N:56A/\QW3"B)E5;:O%Q64
M9_0QRS/Y'8Q%8/<KL$:C#3*G78A'*5,S"BZB?@0Z\8J=BJP_ H=S'IY<6TY#
ME@#D@EBIAD!#;G;*$+NE83O3GN>L+=@NU(;#JG (!E0X "-X;N46@OG!4(5W
M.A&[A6+]_..1K7G%D*3?!M946[)=Q#BV/ 9@F,QC8KH,X6)L;MD2".>'WN"P
M[K0B=HO%#\TZJOQUZ25LJS53&0*0T'06T'Q633LQ?2<[58C=LO!G)I$6"J!K
MMDI3";55TMS:#]<)-;<Y$)U*:!";?@)\*J%# I%T I&X!6+_F=Z0URU)=,)K
M=UNO%0%0HU!LQFJU'\%.:A*WU'RI%J3$)A(;6M7KG!HFA=I4",E77]_I9^#9
M"KU1JV'*\YQ61V!(C;X_T>1_\'_!+#56\7' O$MSUWP/P?"E;TI8&!9@,_H
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MNQO.;-? G8.F#4VS,D@M&,R:9AZL#Z#SRA@\.+X/A[](_A=02P,$%     @
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MH)U2 *@V?2PTE<LZ"T!_4!J =LL#F)O3.RYVRP2T^*#IV76)7 "MDP$4+QM
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MWRPFOCX4_))P<$<Q\TXVQNQ\\KV8\]@+ @4Y>@9!RQZ6H)0G(AE//2<?KO3
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M/)I><6:[MNX2-$UHI8U!:LP05O0E .L+Z+PT!E\3WYW#MR7[!U!+ P04
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MZW>]6;DHT??T'0DZUW;$5WO1&+,W75K4R)V2<@?^\(M[[L:[25E16PE]+I&
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M?#;R6U'_857CKGU+97&)=*\%;NU"TP+,KQ0.<MT'*1A^![CX&U!+ P04
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M-TH5]<)26J])'EEMPA%YZPF12J_&XB,^[5CH//PC;2IDYHQ0>+O(-%(4?H,
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MH*"D1MW;(AF/>EAIY+VO%:WQPGH<+'KF(-KWTJ9)E39_J!:P+WFP,$U>Q/F
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MX/NE@>OC&SJ@^1'3Q;\!4$L#!!0    ( '@X U?/#UE"#@8   4/   9
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MP/>9Q:&V>2 %W1]%KO\'4$L#!!0    ( '@X U?I[,N,]@L  -<C   9
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M>=ITE53M%IT2^=_*&K9\U9OVNH,]1]<>@YVC9JPYD[@8'A)43^<B"/>BWZ=
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M#/MIN47/.G3^!OH4[JSQ-<%'4V'U+SYE);V<?"=GEA\D_-*: 8RR#Y!G^>@
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MO93:4X+:ZG)F 9_1\C/%J>R'P_'^F+PPXX3H<7:I6D1,V3,T5<-.L8.M0W@
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M-L0%0C@*B72YR-"@W##@_0E+%[((4(GM4GKQ%FJ5"T!E;Q)*SQ08=Q'B*5G
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M>0I,9)#QHC:8@2#SPO*HB(=V!20[<BO)@\2:WEDTAV5RA>B<-7^ LA$&6F$
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MBP;(QFGWL-@#+8TM(A3IDI0=__N=H1Z14=7M84][L4EJ'M\WG!G.Y*#-L\T
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M)OCO5(X!8G0:PAGCVC2LP%E$.]^@_H[1_/??DO'PSQZ"HX[@J ]]OB2CE:U
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M+PBU,Z#SE5)VOW .NI_:["=02P,$%     @ >#@#5]ZD9%I@!   / H  !D
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M;%V@_CCS#/&MEY?N6,N.%;[#&L&M%";7<"TRS/Z/]TA7+R[<BUN&)X'?:C&
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MVF5.@QB5=:#SC91FO[$)^M&>_ -02P,$%     @ >#@#5X$!$2^J!   ) L
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M<QQD1/>0B!XRHH^$!2!82R6FT137C%-,Z_748S4#I3DU32\(%QK3@])\*"U
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M.P.Z+Y2RVXUST/\'I+\!4$L#!!0    ( '@X U>^;.5=' <  $9    9
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MP>,2/*X%_^88N13370,J>XDR?D+0C%NM1Y@51IUFLYJS77*V:SDOI:&<V,-
M#1-3PFT9O$3;?K+38= Y>$1;812VHFK:3DG;J<]JR>G*M4'<)VA73G:OD-KU
ML 89&FK 'F?;U\Z8H")E&.- :N8^(]>G=\9^DT;8^4Y%GCE)*2H+OA[G=574
M?R.QC<SMEYG;?UWF'KK\?8/TBTIZV\S5X_QS7??_G_Y&?@_*_![\=7Z_2I'^
MCQ2_0/2J#M1_([$B>?[:[<3>#+]0-65"8W>9H'RPU\$FIHK;5C$Q<NXN+"-I
M\/KCAC.\H(*R!OA\(J5YF-@[4'GE37X!4$L#!!0    ( '@X U<DG]NBCP(
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MHC4W5W+['MIX3BU?)KEV7[)M=(=G'LEJ;639@M&#DHGF3V_;/.P!D*<?$+:
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MRBD@MD3?,^!8DG2%BMOHEN YH41NT>D-2$RH.%.*Q]D-.CTY0R>(I.@A9KG
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MAV>$EJ!X,;,3S@?"^>6CR4^T5"?2T--+)W(^V3;VSLV;QD0O>9<,9,E%L@^
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M]3QZ6L_\Z5I.J7!"*C2;FU;F\/]!Y]0^+ 4VZ)WO\T:J=*C0;-Y:K</=8N>
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MZG^(C0'Z8,\ HQY@'#N@7P_H;P\8[ADPJ <,CIUA6 \8'CO#J!XP.G:&\WK
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M [E"OO,>>8[G:^Q9O1SNZ=SY?]KC_ZR]%PR_K1R_XO.?JYP,,]"5Q UCF.Q
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M*UL,HW(3[/>%E&;7<0LTY77Z U!+ P04    " !X. -7?8J 'T,4  "%90$
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M3Q?W_T__V/Q%/#F@UWOE@-[F@-ZS P:OC=#?'-!_=D#_M1$&FP,&N]ZEX>:
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MG<L&-"B(:B&J"52+4"U&-8EJ"M425-.H9C;:TV7#2>ON2I8:UZWU)@0X\(<
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MT!_[^_YS@6BJ#]5"5!,;S5OF:%0/U22J*51+4$VCFD$U2VE.F8^:J-YHRS:
M=177+]N3O*S*MFKV'[YO-:-:B&H"U2)4BU%-HIK::-O>$4G0436J&52SE.:6
M=!.V&_G#=O\W9_9WV4?(?T?W;AYHG@_5!*I%J!:CFD0UA6H)JFE4,ZAF*<UM
M,4WJ;W282P:/T-@?JH6H)E M0K48U22J*51+4$VCFD$U2VEN0VBR@:,MEPS^
MOABP7]V['Z#Q0%03J!:A6HQJ$M74Z&6LLC?HM:XOT)0@JAE4LY3FUGJ3$AQY
MDTG_'^N+5S8<\M_1O=L'J86H)E M0K48U22J*51+4$VCFD$U2VENBVG"B:/#
M7)QXA$8+42U$-8%J$:K%J"913:%:@FH:U0RJ64IS&T(3+1QMN3CQ=ZXOT&0A
MJH6H)E M0K48U22JJ='+BQ\/6Z_7E:#C:E0SJ&8IS:WU)C4X\J<&?_FBOFXV
M&ZH7 3HMODT7];K"^YD"/[EWH:,10E03J!:A6HQJ$M44JB6HIE'-H)JE-+<9
M-$'#T6&N23Q"PX:H%J*:0+4(U6)4DZBF4"U!-8UJ!M4LI;D-H<DECORY1#M=
MK%<"OR_3136M[H(B^WTY+>K.\&>P7$S;9P=H)!'50E03J!:-7@8<3U[.C&-T
M4(EJ"M425-.H9E#-4II3Y2=-+/'$'TNTZ6]9<'N5SQZ7]T$]$5@7>/#C=!&<
MY[-96I3K&\MZJ9"MMB'](3B^_Z8UR>@?<=\F@&HAJ@E4BS;:TQ5R_WD'0$>4
MJ*90+4$UC6H&U2REN1V@23&>^%.,ZS<,^YUN\/.R^OO#NX-_!A]G5>M;@7YM
M[^I&HX:H)E M0K48U22J*51+4$VCFD$U2VEN'VBBAB>'B1J>H%%#5 M13:!:
MA&HQJDE44ZB6H)I&-8-JEM+<AM!$#4]VBQI>%_DDR\[+X*+(Y\W;@>US?S1G
MB&HAJ@E4BU M1C6):@K5$E33&\VYPN!XU/(>I4''M93F%GJ3,SSQAHQ.OV0W
MV6+I?.SX6:G[/H;LQ_<N>5(+44UL--_'D-$!8U23J*90+4$UC6H&U2REN;7>
M!/Y._+L1KE?[@\ZHR0&7Y?1RL0D"BZ^M%8Z&_5 M1#6!:A&JQ:@F44VA6H)J
M&M4,JEE*<YM!$_8[.<P^@B=HV@_50E03J!:A6HQJ$M44JB6HIE'-H)JE-+<A
M-(G $W\B\"^N!-!L(*J%J"9.7FZ3]V(E@ ;^4$VBFD*U!-4TJAE4LY3FUGH3
M^#OQ[RRX;26PR[XC_B'VKG@T_(=J M4B5(M13:*:0K4$U32J&52SE.8VAR;\
M=_+V,"L#- "(:B&J"52+4"U&-8EJ"M425-.H9E#-4IK3$,9-3G"\+2>X_YN!
M?G+?9H!J(:H)5(M0+48UB6H*U9+QRP#EJ.T3AAH=UJ":I32WSILTX'B'-."N
MJX)7=@OQ#[%WW:,10503J!:A6HQJ$M44JB6HIE'-H)JE-+<Y-!'!\6$B@F,T
M(HAJ(:H)5(M0+48UB6H*U1)4TZAF4,U2FML0FHC@F(\(^LF]FP$:$40U@6H1
MJL6H)E%-H5HR?AGJZ[5N/*+1<0VJ64IS"[V)"(Z]L:3[9<&XT_TIV'S5J[]:
MG#]\UZ^7!6IRE1?3?-%:\V2$Z@S50E03J!:A6HQJ$M44JB6HIE'-H)JE-+<O
M-''"\6'V#QRCD4)4"U%-H%J$:C&J2513J):@FD8U@VJ6TMR&T$0*Q_[] _^Q
MG'_+BB"_J-<$V:3^T_56Q=55W2:NIUE9SQ/NO[YK[0IHKG"C/8WK]]T97X@.
M*% M0K48U22J*51+4$VCFD$U2VENJ3=AP;$_++B>^[_M;IW[HZE 5 M13:!:
MA&HQJDE44ZB6H)I&-8-JEM+<^F\"A./#[!@X1D.#J!:BFD"U"-5B5).HIE M
M036-:@;5+*6Y#:$)#8[].P;^M;D_FAP<O]Q0K_M\[H_& 5$M0K48U22J*51+
M4$VCFD$U2VGWI7Y<7F59%:95>OI^GA67V5DVFY7!)%\N:GZ5#WB\-2BRB[H5
M=-]][!T=O[C]4_?=67=U^W'#G+Z_3B\SFQ:7TT49S+*+FNR\67WTL9A>7CU^
M4^77'XZZ1\&WO*KR^?K+JRP]SXK5#]1_?I'GU<,WJP%N\^*W]=T^_5]02P,$
M%     @ >#@#5SJBOXM2 P  KA4   T   !X;"]S='EL97,N>&ULW5C1;MHP
M%/V5*%VG5IH:0D8@*R!M2)4F;5.E]F%OE2$.6'*<S#$=[.OG:X<0J&]%^[#"
M@FCL>W+./;9O$I=AI=:<WBTH5=XJYZ(:^0NERD]!4,T6-"?555%2H9&LD#E1
MNBOG055*2M(*2#D/NIU.'.2$"7\\%,O\)E>5-RN60HW\01/R[.EK.O+#^*/O
M6;E)D=*1_W#Q_M>R4-?O/'L^^W!VUGFXO-Z/7QC@T@^<HKT#1*\Z'5P80$P\
M/DS\.6U,NK\KW5@!L:TQE#YPT,\;ZCE&2]Q9S]M),7*_<]!L/#,9F'#H=-7R
M9(A!767C85:(;;%%O@UH99)3[Y'PD3\AG$TE U9&<L;7-MR%P*S@A?24KG*=
M*H1(]<?"H>W!#5#KY$P4TN2V&>S?:7WY'K#I@4'&>6.PZ]O >%@2I:@4-[IC
M+C;!)Y!7M^_7I78XEV0==GO^EF!..LFTD"F539K0WX3&0TXSL"/9? %G590!
M@$H5N6ZDC,P+08R'#:-N:-D9Y?P.G@X_LQWM5=9:,U,*HFEJ0W73RM@.Z+?5
MK'9;MO<J7:]DCX7ZLM3#$:8/149O)<W8RO1766, 4P]Q=5*6?/V9L[G(J1W\
MP0G'0[+A>8M"LC\Z&Y3*3 >H]+U'*A6;M2._)2GOZ4IMRFF5X9Z[)^CYW\[S
MG HJ"6^;UK5_S+/\:L=1_ZTLFZ?*OF&GQ_J5?^PF>Z=@,CX%DR=1DX/C-QDE
MQ^^QWDP>N<G^FSW97V(R/$J30;U=:^T)=W:$3=2#G??(_P%[>+Y-ZDV7C"LF
MZMZ"I2D53S:&6EZ1J?YG=$=?7Y_2C"RYNF_ D;]M?Z<I6^9)<]4M3$1]U;;]
M#887QLVV7^=B(J4KFD[JKIQ/3=/3#9VU/H"PC]R8PXU@'(NY$<"P/)@#C&-9
M6)[_:3P#=#P6P[P-G,@ Y0Q0CF6YD(GY8'G<G$0?[I$F213%,3:CDXG3P02;
MMSB&KUL-\P8,+ ]D>ME<XZN-5\CS=8"MZ7,5@HT4KT1LI/A< ^*>-V DB7NU
ML3S P%8!JQW([\X#->7F1!&L*N8-NX-Q)$DP!&K17:-QC,Q.#!_W^F!W210E
MB1L!S.T@BC $[D8<P1R !PR)(O,>W'L?!9OW5+#]A7;\%U!+ P04    " !X
M. -7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    ( '@X U?]\ZQ*( 0  ' B   /    >&PO=V]R:V)O;VLN>&ULQ9I-
M;]LX$$#_"J%3]]#:^DK;H"[0)NUN@#0QXB#7!2V-8R(2:9!4DO;7=R39#;5V
M!GL9ZV2+DJFGL68>2>G3D[$/2V,>Q'-=:3>+UMYO3B<35ZRAENZ=V8#&/2MC
M:^EQT]Y/W,:"+-T:P-?5))E.3R:U5#KZ_&G7U]Q.P@WCH?#*:&QL&^X4/+F7
M_>VF>%1.+56E_,]9U'VO(!*UTJI6OZ"<1=-(N+5Y^L=8]<MH+ZM%84U5S:*X
MWW$'UJMBKWG10M[*I>M:O%S>2 2912=3['"EK//=$5W_$AD? 0_NMQIOOJO*
M@SV7'OZVIMDH?=]V@U<Q"2ZCB\/NLP_BJ?T_832KE2K@W!1-#=KW<;10M8#:
MK=7&14++&F;1F7D$VUX/GN"B[*_-(U00*7NJ<(>]*#L\3A1=@G90"OSF3*5*
MY"C%5UE)78 ((!,",AD1\M\D@$P)R'04R$6+@S\-(#,",AL1<A#)G(#,QX1,
M \@3 O)D3,@L@'Q/0+X?$S(/(#\0D!]X(;\V3FEP+J#Y2-!\9*:13CEA5F)N
MP>&AW1%":HR:NM<JK-I3JFQ/>3%OX!%T R$.:1%FC5QAOY?&.3$'*Q9K:0=D
ME#IB9G=\E\J*.UDU('Z =(UMB[$/;[:8DD;,;(U+9((!#66'F%D/7XK"-E@@
MOCUOVK+ANOO^VJ_Q3SUK[&#(0ODA9A>$\^(&RJ8;A(HY#@-"-,H*,;,6KG!H
MC%D@?\KNO"]0E 5B;@W(C<(1-M9]BR%KALE)5?Z8N?0OO"D>WF+)[0Q5MS==
M=U#(1[D@9I;!A2Y,#>)6/@]R-*$J?\)<^3%.M?)=$>O2$\WN<2(#NE!#2,H'
M";,/2(L.QID).:]@EL.^ML2;VS9SW5\A(B6(A%D0K_AKQQEB4N9(F,W1>^Q@
M]"A3),RF((4VO \I:R3'M,;!(%+Z2(ZMCX.$E$>2D3RR!0TQ*9TDW'.+[4Q'
MO#D'+U4U"&!*224]SG3B,!@EDO3H$POQ5BRPX[+!3#$A)B62]/@B><$<KE"1
M2U0CR63+&F)2,DF994)B#J-)R25EELOKF%?26AEB4G))F>6R5?.6JET2/YSF
ME&)29L7\87Q)[97XXAST@]P0D_),RNR9@YA=HVCGI"$FY9F4V3,',:\WT/[[
M^CY<U,\HZ63,TJ$'9^$Z;T8I*&-_1+*WVG P@3)*0!FW@ 8CR+U<#S$I 67,
M OHO9GB#GL,RQ"2?DC +B,(\&RQ/9)2 ,NYUL+V!^>"/#S$I 67<CTH.8 81
M#3$I!V7,#GIU$M$'-<2D')2--=?I@QIB4@[*F!U$8@Z?-%(.RID=1&.&#LHI
M!^7L#B(6_0:9GE,6RCL+379O.)2PPOEH>86G<-A>R*J86]%^](]MLKQ=?5TU
M576&;=?ZTLAR]\+$[F6/S[\!4$L#!!0    ( '@X U>*,79?SP$  #,?   :
M    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V<MJPD 8AN%;D5R XW^(
M/:!===-M\0:"'0]X2,A,J=Y]11?V"UUT4^9;A4G(GQ<"#V$R>X_[)F_;8]IL
MNS0Z'?;'-*\V.7?/(:3E)AZ:-&Z[>+Q<6;7]H<F79;\.7;/<->L8=#*9AO[G
MC.IE]G/F:''NXE\FMJO5=AE?V^7G(1[S+X/#5]OOTB;&7(T63;^.>5Z%T_Y^
M.H7K0<:7R=7H[6->]6\?4H7200I!6C[((,C*!SD$>?F@&H+J\D%3")J6#WJ
MH(?R08\0]%@^Z F"GLH'R01EG! D#; FT%J0:R'P6A!L(1!;D&PA,%L0;2%0
M6Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706P<?VP1Z*^JM!'HKZJT$
M>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;8+.$
M0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=
M0&]'O9U ;Q]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z%VCWC6!WC7J
M71/H7:/>]7_JG?)Y'].]Y[;&Y_\GU?ER;[P__KJ\G1R\ERO. ?Z1OWP#4$L#
M!!0    ( '@X U<RX8'AQP$  !(?   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W9R6[",!0%T%]!V5;$>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&HB$J]
MFT2)[7=?;.EL,G[;6?*];576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$MF-79
M2B^(B<%@Q#)3!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2:&O+
M(M,ACK--G7]+Z1\2TKBRG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OPHJLX
MBVU+YL.N))]VESC3HYG/BXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^RJ_.
M;\MT!<:9,V>LCR?FZ/*XXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RXO1_&
MK=KS\*R]7;_'7\_X5/_"/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@<?H#2"
M(BI'(96CF,I14.4HJG(45CF*JQP%5HXBJT"15:#(*E!D%2BR"A19!8JL D56
M@2*K0)%5H,@J4625*+)*%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K I%
M5H4BJT*15:'(JE!D52BR*A19%8JL0Q19ARBR#O]3UG=C5G_]E[:YIY4NZF,^
M:W^%3S\!4$L! A0#%     @ >#@#5P=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !X. -7=0Q)K.T
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ >#@#5SA*WL2J @
M< <  !@              ("!-Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( '@X U?^AMVD+@<  .,E   8              " @1<7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !X. -746R?
MAB0"  !1!   &               @(%['@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ >#@#5\]$V"V5"@  &%0  !@
M ("!U2   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '@X
M U=^_IRP, (  &<$   8              " @: K  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !X. -7:O0ESL,'  "Z(@  &
M        @($&+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( '@X U>]66<WB P  - D   9              "
M@<!5  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ >#@#
M5\\/64(.!@  !0\  !D              ("!?V(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !X. -7;>@=AOH"  #Z!@  &0
M        @('$:   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( '@X U>LQN\D=@0  &\*   9              " @?5K  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ >#@#5P^<4Q9["P  G"
M !D              ("!HG   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !X. -7O^":JW8)   @&0  &0              @(%4?
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '@X U?I[,N,
M]@L  -<C   9              " @0&&  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ >#@#5UFV\PA_ @  A@4  !D
M ("!+I(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !X
M. -7O,G%HNT2  !O00  &0              @('DE   >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '@X U<A[Z5CF@8  /P0   9
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M970R-BYX;6Q02P$"% ,4    " !X. -7WJ1D6F $   \"@  &0
M    @(&=O@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M '@X U<A$W^TQ (  .8%   9              " @33#  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ >#@#5X$!$2^J!   ) L  !D
M             ("!+\8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !X. -7=[=[:E0%   \)@  &0              @($0RP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '@X U=!T,*SM@8
M +%    9              " @9O0  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ >#@#5YHX@]@"!   [0T  !D              ("!
MB-<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !X. -7
M.(F(@0$$  "L%@  &0              @('!VP  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( '@X U<&4@I@V@,  #\1   9
M      " @?G?  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ >#@#5_Z!EQV; @  #P8  !D              ("!"N0  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !X. -7OFSE71P'  !&0
M&0              @('<Y@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( '@X U<\%,R^U0,  $ .   9              " @2_N  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ >#@#5^,;4ALW
M P  _@H  !D              ("!._(  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !X. -7))_;HH\"  "Z!P  &0
M@(&I]0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '@X
M U<%=83H'@,  ,X+   9              " @6_X  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ >#@#5PK(-:E+ P  ^0D  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( '@X U<!;"5C' D  $-@   9
M  " @7$7 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M>#@#5X!2N$.C P  NQ$  !D              ("!Q" ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " !X. -7,L?).T,/   5SP  &0
M            @(&>) $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( '@X U>0+]MME ,  ,D0   9              " @1@T 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ >#@#5Q;U= N6!
MWQ8  !D              ("!XS<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " !X. -7LB!C8D4#  !J"P  &0              @(&P
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( '@X U=]
MBH ?0Q0  (5E 0 9              " @2Q  0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ >#@#5SJBOXM2 P  KA4   T
M     ( !IE0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !X. -7EXJ[',
M   3 @  "P              @ $C6 $ 7W)E;',O+G)E;'-02P$"% ,4
M" !X. -7_?.L2B $  !P(@  #P              @ $,60$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ >#@#5XHQ=E_/ 0  ,Q\  !H
M ( !65T! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M>#@#5S+A@>'' 0  $A\  !,              ( !8%\! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     #P / !;$   6&$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>89</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders??? Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Deficit (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders??? Deficit (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Cost Reduction Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CostReductionPlan</Role>
      <ShortName>Cost Reduction Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Capital Structure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CapitalStructure</Role>
      <ShortName>Capital Structure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/NotesPayable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - Capital Structure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CapitalStructureTables</Role>
      <ShortName>Capital Structure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/CapitalStructure</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/Business</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/Revenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in the Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - Leases - Schedule of Assets and Liabilities Lessee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails</Role>
      <ShortName>Leases - Schedule of Assets and Liabilities Lessee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - Leases - Schedule of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - Cost Reduction Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CostReductionPlanDetails</Role>
      <ShortName>Cost Reduction Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/CostReductionPlan</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - Notes Payable - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails</Role>
      <ShortName>Notes Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - Notes Payable - Schedule of Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails</Role>
      <ShortName>Notes Payable - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - Notes Payable - Schedule of Contractual Future Principal Payments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails</Role>
      <ShortName>Notes Payable - Schedule of Contractual Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - Capital Structure - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails</Role>
      <ShortName>Capital Structure - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - Capital Structure - Schedule of Outstanding Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails</Role>
      <ShortName>Capital Structure - Schedule of Outstanding Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954728 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954729 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954730 - Disclosure - Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="avtx-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954731 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalotherapeutics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: avtx:RestructuringAndRelatedActivitiesPaymentTerm, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  avtx-20230630.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="avtx-20230630.htm">avtx-20230630.htm</File>
    <File>avtx-20230630.xsd</File>
    <File>avtx-20230630_cal.xml</File>
    <File>avtx-20230630_def.xml</File>
    <File>avtx-20230630_lab.xml</File>
    <File>avtx-20230630_pre.xml</File>
    <File>ex-3112q2023.htm</File>
    <File>ex-3122q2023.htm</File>
    <File>ex-3212q2023.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>avtx-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="589">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "avtx-20230630.htm": {
   "axisCustom": 1,
   "axisStandard": 35,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 589,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 219,
   "dts": {
    "calculationLink": {
     "local": [
      "avtx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avtx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "avtx-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avtx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avtx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avtx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 521,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 12,
    "http://www.avalotherapeutics.com/20230630": 1,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 18
   },
   "keyCustom": 61,
   "keyStandard": 239,
   "memberCustom": 56,
   "memberStandard": 31,
   "nsprefix": "avtx",
   "nsuri": "http://www.avalotherapeutics.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.avalotherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.avalotherapeutics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.avalotherapeutics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.avalotherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.avalotherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Cost Reduction Plan",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.avalotherapeutics.com/role/CostReductionPlan",
     "shortName": "Cost Reduction Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Notes Payable",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.avalotherapeutics.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Capital Structure",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.avalotherapeutics.com/role/CapitalStructure",
     "shortName": "Capital Structure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.avalotherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.avalotherapeutics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.avalotherapeutics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.avalotherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avtx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.avalotherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avtx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - Notes Payable (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.avalotherapeutics.com/role/NotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - Capital Structure (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.avalotherapeutics.com/role/CapitalStructureTables",
     "shortName": "Capital Structure (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - Business (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.avalotherapeutics.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - Revenue (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.avalotherapeutics.com/role/RevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-56",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-60",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-60",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-76",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-76",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-83",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails",
     "shortName": "Fair Value Measurements - Schedule of Changes in the Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-83",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "avtx:LesseeOperatingLeaseNumberOfLeasedProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "property",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "avtx:LesseeOperatingLeaseNumberOfLeasedProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "property",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avtx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - Leases - Schedule of Assets and Liabilities Lessee (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails",
     "shortName": "Leases - Schedule of Assets and Liabilities Lessee (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avtx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - Leases - Schedule of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails",
     "shortName": "Leases - Schedule of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails",
     "shortName": "Leases - Schedule of Operating Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "avtx:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avtx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "avtx:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-106",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - Cost Reduction Plan (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
     "shortName": "Cost Reduction Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-106",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - Notes Payable - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
     "shortName": "Notes Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-114",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-47",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - Notes Payable - Schedule of Debt (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails",
     "shortName": "Notes Payable - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-47",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-47",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - Notes Payable - Schedule of Contractual Future Principal Payments (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
     "shortName": "Notes Payable - Schedule of Contractual Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-47",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "avtx:NumberOfClassOfStockAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - Capital Structure - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
     "shortName": "Capital Structure - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "avtx:NumberOfClassOfStockAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-152",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - Capital Structure - Schedule of Outstanding Common Stock Warrants (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails",
     "shortName": "Capital Structure - Schedule of Outstanding Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-152",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-182",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-9",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954728 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-160",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-169",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954729 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-171",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-171",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954730 - Disclosure - Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value Assumptions for Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-171",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-218",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "avtx:RoyaltyAgreementPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954731 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-218",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "avtx:RoyaltyAgreementPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-41",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Deficit (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Deficit (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-41",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Deficit (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Deficit (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.avalotherapeutics.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "avtx-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 89,
   "tag": {
    "avtx_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Agreement [Member]",
        "label": "ATM Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX002KKCLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-002 KKC License Agreement",
        "label": "AVTX-002 KKC License Agreement [Member]",
        "terseLabel": "AVTX-002 KKC License Agreement"
       }
      }
     },
     "localname": "AVTX002KKCLicenseAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX006AstellasLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-006 Astellas License Agreement",
        "label": "AVTX-006 Astellas License Agreement [Member]",
        "terseLabel": "AVTX-006 Astellas License Agreement"
       }
      }
     },
     "localname": "AVTX006AstellasLicenseAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-007",
        "label": "AVTX-007 [Member]",
        "terseLabel": "AVTX-007"
       }
      }
     },
     "localname": "AVTX007Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-008 Sanford Burnham Prebys License Agreement",
        "label": "AVTX-008 Sanford Burnham Prebys License Agreement [Member]",
        "terseLabel": "AVTX-008 Sanford Burnham Prebys License Agreement"
       }
      }
     },
     "localname": "AVTX008SanfordBurnhamPrebysLicenseAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX301OutLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-301 Out-License",
        "label": "AVTX-301 Out-License [Member]",
        "terseLabel": "AVTX-301 Out-License"
       }
      }
     },
     "localname": "AVTX301OutLicenseMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX406LicenseAssignmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-406 License Assignment",
        "label": "AVTX-406 License Assignment [Member]",
        "terseLabel": "AVTX-406 License Assignment"
       }
      }
     },
     "localname": "AVTX406LicenseAssignmentMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX501AndAVTX007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-501 And AVTX-007",
        "label": "AVTX-501 And AVTX-007 [Member]",
        "terseLabel": "AVTX-501 And AVTX-007"
       }
      }
     },
     "localname": "AVTX501AndAVTX007Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX501Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-501",
        "label": "AVTX-501 [Member]",
        "terseLabel": "AVTX-501"
       }
      }
     },
     "localname": "AVTX501Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX611Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-611",
        "label": "AVTX-611 [Member]",
        "terseLabel": "AVTX-611"
       }
      }
     },
     "localname": "AVTX611Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX801AVTX802AndAVTX803Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-801, AVTX-802, And AVTX-803",
        "label": "AVTX-801, AVTX-802, And AVTX-803 [Member]",
        "terseLabel": "AVTX-801, AVTX-802, And AVTX-803"
       }
      }
     },
     "localname": "AVTX801AVTX802AndAVTX803Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AVTX913Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVTX-913",
        "label": "AVTX-913 [Member]",
        "terseLabel": "AVTX-913"
       }
      }
     },
     "localname": "AVTX913Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.",
        "label": "Accrued Research and Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_AccruedSellingGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Selling, General And Administrative Expenses",
        "label": "Accrued Selling, General And Administrative Expenses",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "AccruedSellingGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_AeviGenomicMedicineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aevi Genomic Medicine Inc [Member]",
        "label": "Aevi Genomic Medicine Inc [Member]",
        "terseLabel": "Aevi"
       }
      }
     },
     "localname": "AeviGenomicMedicineIncMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alto [Member]",
        "label": "Alto [Member]",
        "terseLabel": "Alto"
       }
      }
     },
     "localname": "AltoMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ArmisticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Armistice [Member]",
        "label": "Armistice [Member]",
        "terseLabel": "Armistice"
       }
      }
     },
     "localname": "ArmisticeMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_AssetAcquisitionContingentValueRightNumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Value Right, Number of Milestones",
        "label": "Asset Acquisition, Contingent Value Right, Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "AssetAcquisitionContingentValueRightNumberOfMilestones",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_AssetAcquisitionNumberOfPreclinicalTherapies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Number of Preclinical Therapies",
        "label": "Asset Acquisition, Number of Preclinical Therapies",
        "terseLabel": "Number of preclinical therapies"
       }
      }
     },
     "localname": "AssetAcquisitionNumberOfPreclinicalTherapies",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities Lessee [Table Text Block]",
        "label": "Assets and Liabilities Lessee [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avtx_AstellasPharmaIncAstellasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas Pharma, Inc. (Astellas) [Member]",
        "label": "Astellas Pharma, Inc. (Astellas) [Member]",
        "terseLabel": "Astellas Pharma, Inc. (Astellas)"
       }
      }
     },
     "localname": "AstellasPharmaIncAstellasMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_CapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Capital Stock Shares Authorized",
        "terseLabel": "Number of shares of capital stock authorized to issue (in shares)"
       }
      }
     },
     "localname": "CapitalStockSharesAuthorized",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avtx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Exercised",
        "label": "Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Exercised",
        "terseLabel": "Pre-funded warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avtx_ClassOfWarrantOrRightOwnershipExerciseThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Ownership, Exercise Threshold",
        "label": "Class of Warrant or Right, Ownership, Exercise Threshold",
        "terseLabel": "Class of warrant or right, ownership, exercise threshold"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOwnershipExerciseThreshold",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Ownership Percentage, Exercise Threshold",
        "label": "Class of Warrant or Right, Ownership Percentage, Exercise Threshold",
        "terseLabel": "Class of warrant or right, ownership percentage, exercise threshold"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOwnershipPercentageExerciseThreshold",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Warrants or Rights Exercisable, Term",
        "label": "Class of Warrant or Right, Warrants or Rights Exercisable, Term",
        "terseLabel": "Warrants or rights exercisable term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsOrRightsExercisableTerm",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date",
        "label": "Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date",
        "terseLabel": "Cumulative expense recognized to date"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit",
        "label": "Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit",
        "terseLabel": "Make whole payment per unit (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMakeWholePaymentPerUnit",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments",
        "terseLabel": "Maximum aggregate milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsPatentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Patent Costs",
        "label": "Collaborative Arrangement, Rights and Obligations, Patent Costs",
        "terseLabel": "Patent costs"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPatentCosts",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing",
        "label": "Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing",
        "terseLabel": "Percent of payments received from sublicensing"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Fee",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Fee",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontFee",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_CommercialOperationsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Operations, Current",
        "label": "Commercial Operations, Current",
        "terseLabel": "Commercial operations"
       }
      }
     },
     "localname": "CommercialOperationsCurrent",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_CommonStockWarrantsExpirationDateOfJune2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Expiration Date of June 2024 [Member]",
        "label": "Common Stock Warrants Expiration Date of June 2024 [Member]",
        "terseLabel": "Common Stock Warrants Expiration Date Of June 2024"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDateOfJune2024Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_CommonStockWarrantsExpirationFebruary2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Expiration February 2024",
        "label": "Common Stock Warrants Expiration February 2024 [Member]",
        "terseLabel": "Common Stock Warrants Expiration February 2024"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationFebruary2024Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_CommonStockWarrantsExpirationJune2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Expiration June 2031 [Member]",
        "label": "Common Stock Warrants Expiration June 2031 [Member]",
        "terseLabel": "Common Stock Warrants Expiration June 2031"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationJune2031Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_CommonStockWarrantsNoExpiration2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants No Expiration 2",
        "label": "Common Stock Warrants No Expiration 2 [Member]",
        "terseLabel": "Common Stock Warrants No Expiration 2"
       }
      }
     },
     "localname": "CommonStockWarrantsNoExpiration2Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_CommonStockWarrantsNoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants No Expiration [Member]",
        "label": "Common Stock Warrants No Expiration [Member]",
        "terseLabel": "Common Stock Warrants No Expiration"
       }
      }
     },
     "localname": "CommonStockWarrantsNoExpirationMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Revenue Recognized to Date From Milestone Payments",
        "label": "Contract With Customer, Revenue Recognized to Date From Milestone Payments",
        "terseLabel": "Revenue recognized from milestones to date"
       }
      }
     },
     "localname": "ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued And Unpaid Interest, Subject to Prepayment Charges, Percentage",
        "label": "Debt Instrument, Accrued And Unpaid Interest, Subject to Prepayment Charges, Percentage",
        "terseLabel": "Prepayment charges percentage"
       }
      }
     },
     "localname": "DebtInstrumentAccruedAndUnpaidInterestSubjectToPrepaymentChargesPercentage",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_DebtInstrumentAdditionalFinalPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Final Payment, Percentage",
        "label": "Debt Instrument, Additional Final Payment, Percentage",
        "terseLabel": "Additional final payment percentage"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalFinalPaymentPercentage",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_DebtInstrumentFinalPaymentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Final Payment Fee",
        "label": "Debt Instrument, Final Payment Fee",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFee",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_DebtInstrumentInterestOnlyPaymentExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Only Payment Extension Period",
        "label": "Debt Instrument, Interest Only Payment Extension Period",
        "terseLabel": "Interest-only payment extension period"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentExtensionPeriod",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_DebtInstrumentInterestOnlyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Only Payment Period",
        "label": "Debt Instrument, Interest Only Payment Period",
        "terseLabel": "Interest-only payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentPeriod",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_DebtInstrumentInterestRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Floor",
        "label": "Debt Instrument, Interest Rate, Floor",
        "terseLabel": "Floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloor",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Business Days Required for Prepayment",
        "label": "Debt Instrument, Number of Business Days Required for Prepayment",
        "terseLabel": "Number of business days required for prepayment"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfBusinessDaysRequiredForPrepayment",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_DerivativeLiabilityMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Liability, Measurement Input, Term",
        "label": "Derivative Liability, Measurement Input, Term",
        "terseLabel": "Derivative liability, measurement input, term"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInputTerm",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_ESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ES [Member]",
        "label": "ES [Member]",
        "terseLabel": "ES"
       }
      }
     },
     "localname": "ESMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ESTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ES Therapeutics",
        "label": "ES Therapeutics [Member]",
        "terseLabel": "ES"
       }
      }
     },
     "localname": "ESTherapeuticsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants and Directors Stock Options [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_EmployeeStockPurchasePlanESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan (ESPP) [Member]",
        "label": "Employee Stock Purchase Plan (ESPP) [Member]",
        "terseLabel": "Employee Stock Purchase Plan (ESPP)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanESPPMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement",
        "label": "Exchange Agreement [Member]",
        "terseLabel": "Exchange Agreement"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Common Stock Retired in Exchange for Issuance of Prefunded Warrants",
        "label": "Fair Value of Common Stock Retired in Exchange for Issuance of Prefunded Warrants",
        "terseLabel": "Fair value of common stock retired in exchange for issuance of prefunded warrants"
       }
      }
     },
     "localname": "FairValueOfCommonStockRetiredInExchangeForIssuanceOfPrefundedWarrants",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_HorizonPowerscourtNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon &amp; Powerscourt Notes [Member]",
        "label": "Horizon &amp; Powerscourt Notes [Member]",
        "terseLabel": "Horizon &amp; Powerscourt Notes"
       }
      }
     },
     "localname": "HorizonPowerscourtNotesMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_IchorionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ichorion [Member]",
        "label": "Ichorion [Member]",
        "terseLabel": "Ichorion"
       }
      }
     },
     "localname": "IchorionMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_IncreaseDecreaseInLeaseIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Lease Incentives",
        "label": "Increase (Decrease) in Lease Incentives",
        "negatedTerseLabel": "Lease incentive"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseIncentives",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Lease Liability",
        "label": "Increase (Decrease) in Lease Liability",
        "terseLabel": "Lease liability, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_InitialNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Note",
        "label": "Initial Note [Member]",
        "terseLabel": "Initial Note"
       }
      }
     },
     "localname": "InitialNoteMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Share",
        "label": "Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Share",
        "terseLabel": "Issuance of shares of common stock and warrants in underwritten public offering, net (in shares)"
       }
      }
     },
     "localname": "IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetShare",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "avtx_IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Value",
        "label": "Issuance of Shares of Common Stock and Warrants in Underwritten Public Offering, Net, Value",
        "terseLabel": "Issuance of shares of common stock and warrants in underwritten public offering, net"
       }
      }
     },
     "localname": "IssuanceOfSharesOfCommonStockAndWarrantsInUnderwrittenPublicOfferingNetValue",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_KarbinalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Karbinal Agreement [Member]",
        "label": "Karbinal Agreement [Member]",
        "terseLabel": "Karbinal Agreement"
       }
      }
     },
     "localname": "KarbinalAgreementMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_KyowaKirinCoLtdKKCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin Co., Ltd. (KKC) [Member]",
        "label": "Kyowa Kirin Co., Ltd. (KKC) [Member]",
        "terseLabel": "Kyowa Kirin Co., Ltd. (KKC)"
       }
      }
     },
     "localname": "KyowaKirinCoLtdKKCMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_LesseeOperatingLeaseAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Base Rent",
        "label": "Lessee, Operating Lease, Annual Base Rent",
        "terseLabel": "Lessee, operating lease, annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualBaseRent",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_LesseeOperatingLeaseLiabilityAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Annual Base Rent",
        "label": "Lessee, Operating Lease, Liability, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityAnnualBaseRent",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_LesseeOperatingLeaseNumberOfLeasedProperties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Leased Properties",
        "label": "Lessee, Operating Lease, Number Of Leased Properties",
        "terseLabel": "Number of leased properties"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfLeasedProperties",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Number of Renewal Options",
        "label": "Lessee Operating Lease Number of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_LesseeOperatingLeaseRemainingLeaseTeam": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Remaining Lease Team",
        "label": "Lessee Operating Lease Remaining Lease Team",
        "terseLabel": "Remaining lease team"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTeam",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_LesseeOperatingLeaseRentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Abatement Period",
        "label": "Lessee, Operating Lease, Rent Abatement Period",
        "terseLabel": "Rent abatement period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentAbatementPeriod",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_LicenseAgreementInstallmentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Installment Payment",
        "label": "License Agreement, Installment Payment",
        "terseLabel": "Installment payment"
       }
      }
     },
     "localname": "LicenseAgreementInstallmentPayment",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_LicenseAgreementPercentOfNetProfitForInstallmentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percent of Net Profit for Installment Payment",
        "label": "License Agreement, Percent of Net Profit for Installment Payment",
        "terseLabel": "Percent of net profit for installment payments"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfNetProfitForInstallmentPayment",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_MajorCustomerNumberOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Number One [Member]",
        "label": "Major Customer Number One [Member]",
        "terseLabel": "Major Customer Number One"
       }
      }
     },
     "localname": "MajorCustomerNumberOneMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MajorCustomerNumberTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Number Two [Member]",
        "label": "Major Customer Number Two [Member]",
        "terseLabel": "Major Customer Number Two"
       }
      }
     },
     "localname": "MajorCustomerNumberTwoMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MeasurementInputProbabilityOfSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Success",
        "label": "Measurement Input, Probability Of Success [Member]",
        "terseLabel": "Measurement Input, Probability Of Success"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MeasurementInputSalesForecastPeakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Sales Forecast Peak",
        "label": "Measurement Input, Sales Forecast Peak [Member]",
        "terseLabel": "Measurement Input, Sales Forecast Peak"
       }
      }
     },
     "localname": "MeasurementInputSalesForecastPeakMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "avtx_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three [Member]",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two [Member]",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_MillipredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Millipred [Member]",
        "label": "Millipred [Member]",
        "terseLabel": "Millipred"
       }
      }
     },
     "localname": "MillipredMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_NantahalaCapitalManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nantahala Capital Management LLC [Member]",
        "label": "Nantahala Capital Management LLC [Member]",
        "terseLabel": "Nantahala Capital Management LLC"
       }
      }
     },
     "localname": "NantahalaCapitalManagementLLCMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_NumberOfClassOfStockAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of classes of stock permitted to be issued by an entity's charter and bylaws.",
        "label": "Number of Class of Stock Authorized",
        "terseLabel": "Number of classes of stock authorized to issue"
       }
      }
     },
     "localname": "NumberOfClassOfStockAuthorized",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "avtx_OperatingLeasesRentExpenseAnnualIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Rent Expense, Annual Increase, Percent",
        "label": "Operating Leases, Rent Expense, Annual Increase, Percent",
        "terseLabel": "Annual rent increase (as a percent)"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseAnnualIncreasePercent",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Asset Acquisition Contingent Consideration Liability Operating Activities",
        "label": "Payment for Asset Acquisition Contingent Consideration Liability Operating Activities",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_PediatricPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Portfolio [Member]",
        "label": "Pediatric Portfolio [Member]",
        "terseLabel": "Pediatric Portfolio"
       }
      }
     },
     "localname": "PediatricPortfolioMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock and Warrants",
        "label": "Proceeds From Issuance of Common Stock and Warrants",
        "terseLabel": "Proceeds from issuance of common stock and warrants in underwritten public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_ProceedsFromIssuanceOfCommonStockThroughATMProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock Through ATM Program",
        "label": "Proceeds From Issuance of Common Stock Through ATM Program",
        "terseLabel": "Proceeds from sale of common stock pursuant to ATM Program, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockThroughATMProgram",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment and Operating Lease Right-of-use Asset, After Accumulated Depreciation and Amortization",
        "label": "Property, Plant and Equipment and Operating Lease Right-of-use Asset, After Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_RepaymentOfDebtPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Debt, Principal",
        "label": "Repayment Of Debt, Principal",
        "terseLabel": "Repayment of debt, principal"
       }
      }
     },
     "localname": "RepaymentOfDebtPrincipal",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage",
        "label": "Restricted Cash and Cash Equivalents, Additional Cash Proceeds Adjustment, Percentage",
        "terseLabel": "Additional resticted cash, percentage of aggregate cash proceeds"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAdditionalCashProceedsAdjustmentPercentage",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_RestructuringAndRelatedActivitiesPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities, Payment Term",
        "label": "Restructuring And Related Activities, Payment Term",
        "terseLabel": "Payment term"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesPaymentTerm",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_RestructuringPlanOneTimeTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan, One-Time Termination Benefits",
        "label": "Restructuring Plan, One-Time Termination Benefits [Member]",
        "terseLabel": "Restructuring Plan, One-Time Termination Benefits"
       }
      }
     },
     "localname": "RestructuringPlanOneTimeTerminationBenefitsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Maximum proceeds from milestones"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments",
        "label": "Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments",
        "terseLabel": "Percentage of net present value of royalty payments"
       }
      }
     },
     "localname": "RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_RoyaltyAgreementPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Payment Received",
        "label": "Royalty Agreement, Payment Received",
        "terseLabel": "Payment received"
       }
      }
     },
     "localname": "RoyaltyAgreementPaymentReceived",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Period After Public Launch to Terminate Agreement",
        "label": "Royalty Agreement, Period After Public Launch to Terminate Agreement",
        "terseLabel": "Period after public launch to terminate agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "avtx_SaleOfStockMaximumAmountOfSharesToBeSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Maximum Amount Of Shares To Be Sold",
        "label": "Sale of Stock, Maximum Amount Of Shares To Be Sold",
        "terseLabel": "Sale of stock, maximum amount of shares to be sold"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountOfSharesToBeSold",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanford Burnham Prebys Medical Discovery Institute [Member]",
        "label": "Sanford Burnham Prebys Medical Discovery Institute [Member]",
        "terseLabel": "Sanford Burnham Prebys Medical Discovery Institute"
       }
      }
     },
     "localname": "SanfordBurnhamPrebysMedicalDiscoveryInstituteMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued expenses and other current liabilities.",
        "label": "Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avtx_SecondNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Note",
        "label": "Second Note [Member]",
        "terseLabel": "Second Note"
       }
      }
     },
     "localname": "SecondNoteMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_SeparationFromCertainSection16OfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation From Certain Section 16 Officers",
        "label": "Separation From Certain Section 16 Officers [Member]",
        "terseLabel": "Separation From Certain Section 16 Officers"
       }
      }
     },
     "localname": "SeparationFromCertainSection16OfficersMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ServiceBasedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Options [Member]",
        "label": "Service Based Options [Member]",
        "terseLabel": "Service-based options"
       }
      }
     },
     "localname": "ServiceBasedOptionsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Automatic Increase to Shares Authorized as Percentage of Outstanding Stock at End of Preceding Year",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Automatic Increase to Shares Authorized as Percentage of Outstanding Stock at End of Preceding Year",
        "terseLabel": "Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase in the number of shares reserved for issuance under the incentive plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized Increase",
        "terseLabel": "Increase in number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Share Reserve Increase as Percent",
        "terseLabel": "Annual share reserve increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "avtx_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum",
        "terseLabel": "Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avtx_SpecialAdvisorToTheBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Advisor to the Board [Member]",
        "label": "Special Advisor to the Board [Member]",
        "terseLabel": "Special Advisor To The Board"
       }
      }
     },
     "localname": "SpecialAdvisorToTheBoardMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Exercise Of Prefunded Warrants",
        "label": "Stock Issued During Period Value Exercise Of Prefunded Warrants",
        "terseLabel": "Exercise of pre-funded warrants for common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avtx_StockOptionsWithMarketBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options With Market Based Vesting Conditions [Member]",
        "label": "Stock Options With Market Based Vesting Conditions [Member]",
        "terseLabel": "Market Based Options"
       }
      }
     },
     "localname": "StockOptionsWithMarketBasedVestingConditionsMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_TRISPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRIS Pharma [Member]",
        "label": "TRIS Pharma [Member]",
        "terseLabel": "TRIS Pharma"
       }
      }
     },
     "localname": "TRISPharmaMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_TevaPharmaceuticalIndustriesLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva Pharmaceutical Industries Ltd. [Member]",
        "label": "Teva Pharmaceutical Industries Ltd. [Member]",
        "terseLabel": "Teva"
       }
      }
     },
     "localname": "TevaPharmaceuticalIndustriesLtd.Member",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_The2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2016 Plan [Member]",
        "label": "The 2016 Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "The2016PlanMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_ThirdNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Note",
        "label": "Third Note [Member]",
        "terseLabel": "Third Note"
       }
      }
     },
     "localname": "ThirdNoteMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_VenrockHealthcareCapitalPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Venrock Healthcare Capital Partners",
        "label": "Venrock Healthcare Capital Partners [Member]",
        "terseLabel": "Venrock"
       }
      }
     },
     "localname": "VenrockHealthcareCapitalPartnersMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avtx_WarrantCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant common stock.",
        "label": "Warrant Common Stock [Member]",
        "terseLabel": "Warrants on common stock"
       }
      }
     },
     "localname": "WarrantCommonStockMember",
     "nsuri": "http://www.avalotherapeutics.com/20230630",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r236",
      "r266",
      "r409",
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r654",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r197",
      "r596",
      "r667",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r305",
      "r415",
      "r451",
      "r485",
      "r486",
      "r539",
      "r541",
      "r543",
      "r544",
      "r553",
      "r573",
      "r574",
      "r586",
      "r593",
      "r606",
      "r613",
      "r665",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r305",
      "r415",
      "r451",
      "r485",
      "r486",
      "r539",
      "r541",
      "r543",
      "r544",
      "r553",
      "r573",
      "r574",
      "r586",
      "r593",
      "r606",
      "r613",
      "r665",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r197",
      "r596",
      "r667",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r194",
      "r417",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r575",
      "r594",
      "r612",
      "r637",
      "r661",
      "r662",
      "r667",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r194",
      "r417",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r575",
      "r594",
      "r612",
      "r637",
      "r661",
      "r662",
      "r667",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r297",
      "r305",
      "r333",
      "r334",
      "r335",
      "r414",
      "r415",
      "r451",
      "r485",
      "r486",
      "r539",
      "r541",
      "r543",
      "r544",
      "r553",
      "r573",
      "r574",
      "r586",
      "r593",
      "r606",
      "r613",
      "r616",
      "r658",
      "r665",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r297",
      "r305",
      "r333",
      "r334",
      "r335",
      "r414",
      "r415",
      "r451",
      "r485",
      "r486",
      "r539",
      "r541",
      "r543",
      "r544",
      "r553",
      "r573",
      "r574",
      "r586",
      "r593",
      "r606",
      "r613",
      "r616",
      "r658",
      "r665",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r236",
      "r266",
      "r409",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r306",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r164",
      "r306",
      "r632",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r479",
      "r481",
      "r483",
      "r540",
      "r542",
      "r545",
      "r554",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r595",
      "r616",
      "r667",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r479",
      "r481",
      "r483",
      "r540",
      "r542",
      "r545",
      "r554",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r595",
      "r616",
      "r667",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r164",
      "r306",
      "r632",
      "r633",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r654",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND",
        "terseLabel": "Maryland"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r611"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r21",
      "r579"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalty payment"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalty obligation"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r66",
      "r611",
      "r725"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r465",
      "r648",
      "r649",
      "r650",
      "r700",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r8",
      "r38",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants in exchange for retirement of common shares"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r337",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r5",
      "r55",
      "r77",
      "r254"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r5",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r697",
      "r698",
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r98",
      "r119",
      "r146",
      "r181",
      "r188",
      "r192",
      "r200",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r364",
      "r366",
      "r390",
      "r434",
      "r506",
      "r611",
      "r624",
      "r663",
      "r664",
      "r710"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r115",
      "r126",
      "r146",
      "r200",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r364",
      "r366",
      "r390",
      "r611",
      "r663",
      "r664",
      "r710"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r30",
      "r117",
      "r577"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Investments in money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r81",
      "r142"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r81"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r122",
      "r123",
      "r124",
      "r146",
      "r168",
      "r169",
      "r171",
      "r173",
      "r179",
      "r180",
      "r200",
      "r223",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r264",
      "r265",
      "r268",
      "r271",
      "r278",
      "r390",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r494",
      "r515",
      "r533",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r631",
      "r643",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r179",
      "r264",
      "r265",
      "r266",
      "r268",
      "r271",
      "r276",
      "r278",
      "r459",
      "r460",
      "r461",
      "r462",
      "r593",
      "r631",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails",
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares available under warrant (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r217",
      "r218",
      "r563",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r648",
      "r649",
      "r700",
      "r722",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r65",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r65",
      "r494",
      "r512",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r65",
      "r437",
      "r611"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014$0.001 par value; 200,000,000 shares authorized at June 30, 2023 and December 31, 2022; 14,036,940 and 9,430,535 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r130",
      "r132",
      "r136",
      "r431",
      "r442"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r32",
      "r34",
      "r53",
      "r54",
      "r197",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r53",
      "r54",
      "r197",
      "r457",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r53",
      "r54",
      "r197",
      "r562",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r32",
      "r34",
      "r53",
      "r54",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r32",
      "r34",
      "r53",
      "r54",
      "r197",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r281",
      "r282",
      "r295"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerReceivableBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r634",
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.",
        "label": "Contract with Customer, Receivable, before Allowance for Credit Loss",
        "terseLabel": "Total receivable balance"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerReceivableCreditLossExpenseReversal": {
     "auth_ref": [
      "r283",
      "r293"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.",
        "label": "Contract with Customer, Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for other long-term asset"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableCreditLossExpenseReversal",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r417"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r33",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r144",
      "r232",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r248",
      "r255",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "netLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r62",
      "r63",
      "r99",
      "r100",
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r398",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r100",
      "r259"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Notes payable, outstanding",
        "totalLabel": "Total principal payments",
        "verboseLabel": "Notes payable, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r56",
      "r58",
      "r233",
      "r398",
      "r589",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r23",
      "r56",
      "r262",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r23",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r398",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r24",
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r398",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r24",
      "r42",
      "r45",
      "r55",
      "r56",
      "r58",
      "r60",
      "r90",
      "r91",
      "r150",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r398",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r57",
      "r244",
      "r260",
      "r589",
      "r590"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Less: Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r5",
      "r95",
      "r107",
      "r358",
      "r359",
      "r646"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r348",
      "r349",
      "r435"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r5",
      "r184"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral",
        "terseLabel": "Change in fair value was recognized"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r127",
      "r128",
      "r389",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r507",
      "r509",
      "r510",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r582",
      "r723"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [
      "r294",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r294",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r307",
      "r310",
      "r338",
      "r339",
      "r341",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r137",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r166",
      "r168",
      "r171",
      "r172",
      "r173",
      "r177",
      "r377",
      "r378",
      "r432",
      "r443",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r137",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r168",
      "r171",
      "r172",
      "r173",
      "r177",
      "r377",
      "r378",
      "r432",
      "r443",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r694"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r112",
      "r133",
      "r134",
      "r135",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r178",
      "r201",
      "r202",
      "r280",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r406",
      "r452",
      "r453",
      "r454",
      "r465",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r380",
      "r381",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r380",
      "r381",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r381",
      "r411",
      "r412",
      "r413",
      "r589",
      "r590",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r52",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r380",
      "r381",
      "r383",
      "r384",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r298",
      "r303",
      "r381",
      "r411",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0prices\u00a0in active\u00a0markets\u00a0for identical\u00a0assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r298",
      "r303",
      "r381",
      "r412",
      "r589",
      "r590",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0other observable inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r381",
      "r413",
      "r589",
      "r590",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r9",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial valuation of derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofChangesintheFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r411",
      "r412",
      "r413",
      "r589",
      "r590",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r379",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesThatAreMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r385",
      "r387"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value of derivative liability",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r118",
      "r203",
      "r430",
      "r587",
      "r611",
      "r656",
      "r657"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r71",
      "r102",
      "r181",
      "r187",
      "r191",
      "r193",
      "r433",
      "r440",
      "r585"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204",
      "r209",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r347",
      "r351",
      "r352",
      "r353",
      "r356",
      "r360",
      "r361",
      "r362",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r108",
      "r162",
      "r163",
      "r185",
      "r350",
      "r357",
      "r444"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r416",
      "r642"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r138",
      "r140",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r125",
      "r578",
      "r611"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r707"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "July 1, 2023 through December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less implied interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r146",
      "r200",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r365",
      "r366",
      "r367",
      "r390",
      "r493",
      "r584",
      "r624",
      "r663",
      "r710",
      "r711"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r70",
      "r101",
      "r439",
      "r611",
      "r645",
      "r655",
      "r703"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r116",
      "r146",
      "r200",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r365",
      "r366",
      "r367",
      "r390",
      "r611",
      "r663",
      "r710",
      "r711"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r18",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r100",
      "r245",
      "r261",
      "r589",
      "r590",
      "r719"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Outstanding balance",
        "totalLabel": "Carrying value of notes payable, current"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.",
        "label": "Long-Term Debt, Current Maturities",
        "verboseLabel": "Less: Current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Estimated fair value of debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r7",
      "r150",
      "r250"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r7",
      "r150",
      "r250"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r7",
      "r150",
      "r250"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r647"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Carrying value of notes payable, non-current"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable, non-current"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.",
        "label": "Long-Term Purchase Commitment, Minimum Quantity Required",
        "terseLabel": "Minimum quantity required"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentMinimumQuantityRequired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r24",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofContractualFuturePrincipalPaymentsDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableScheduleofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r72",
      "r83",
      "r103",
      "r114",
      "r129",
      "r131",
      "r135",
      "r146",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r170",
      "r181",
      "r187",
      "r191",
      "r193",
      "r200",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r378",
      "r390",
      "r441",
      "r514",
      "r531",
      "r532",
      "r585",
      "r622",
      "r663"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Adopted in 2023"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r181",
      "r187",
      "r191",
      "r193",
      "r585"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Total operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r404",
      "r610"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r704"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.avalotherapeutics.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "verboseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.",
        "label": "Payments for Capital Improvements",
        "negatedLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "PaymentsForCapitalImprovements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r208",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r64",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r64",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r639"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r304",
      "r407",
      "r408",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r511",
      "r513",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r304",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r511",
      "r513",
      "r538",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Prepayment on Notes",
        "terseLabel": "Prepayment on Notes",
        "verboseLabel": "Partial prepayment"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r61",
      "r346",
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r695"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r30",
      "r97",
      "r117",
      "r142",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash in deposit account"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r30",
      "r117",
      "r142"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "periodEndLabel": "Restricted cash, current",
        "terseLabel": "Restricted cash, current portion"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r30",
      "r105",
      "r142"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "periodEndLabel": "Restricted cash, non-current",
        "terseLabel": "Restricted cash, net of current portion"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r208",
      "r211",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Cost Reduction Plan"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r5",
      "r212",
      "r213",
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r67",
      "r92",
      "r438",
      "r455",
      "r456",
      "r463",
      "r495",
      "r611"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r112",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r201",
      "r202",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r369",
      "r371",
      "r372",
      "r374",
      "r376",
      "r452",
      "r454",
      "r465",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r186",
      "r189",
      "r190",
      "r194",
      "r195",
      "r197",
      "r292",
      "r294",
      "r417"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Total revenues, net",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r110",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r197",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Contractual Future Principal Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r10",
      "r11",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions for Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r90",
      "r91",
      "r92",
      "r122",
      "r123",
      "r124",
      "r179",
      "r264",
      "r265",
      "r266",
      "r268",
      "r271",
      "r276",
      "r278",
      "r459",
      "r460",
      "r461",
      "r462",
      "r593",
      "r631",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Common Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Share-based payment arrangement, accelerated cost"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum portion of earning an employee may contribute to the ESPP Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock remaining for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance, ending of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)",
        "terseLabel": "Exercisable stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance, ending of period (in dollars per share)",
        "periodStartLabel": "Balance, beginning of period (in dollars per share)",
        "terseLabel": "Weighted average share price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "terseLabel": "Increase in shares available (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Balance, ending of period (in dollars per share)",
        "periodStartLabel": "Balance, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value per share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r111",
      "r122",
      "r123",
      "r124",
      "r146",
      "r168",
      "r169",
      "r171",
      "r173",
      "r179",
      "r180",
      "r200",
      "r223",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r264",
      "r265",
      "r268",
      "r271",
      "r278",
      "r390",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r494",
      "r515",
      "r533",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r631",
      "r643",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureScheduleofOutstandingCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r27",
      "r112",
      "r133",
      "r134",
      "r135",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163",
      "r178",
      "r201",
      "r202",
      "r280",
      "r342",
      "r343",
      "r344",
      "r354",
      "r355",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r406",
      "r452",
      "r453",
      "r454",
      "r465",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r178",
      "r417",
      "r458",
      "r476",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r178",
      "r417",
      "r458",
      "r476",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares purchased through employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92",
      "r459",
      "r533",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares pursuant to ATM Program, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested during period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares purchased through employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92",
      "r465",
      "r533",
      "r556",
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares pursuant to ATM Program, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common shares in exchange for pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Retirement of common shares in exchange for pre-funded warrants"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r85",
      "r496",
      "r512",
      "r534",
      "r535",
      "r611",
      "r624",
      "r645",
      "r655",
      "r703",
      "r726"
     ],
     "calculation": {
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r145",
      "r263",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r280",
      "r375",
      "r536",
      "r537",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Capital Structure"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersDeficitUnauditedParenthetical",
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r397",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r397",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r397",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/BusinessDetails",
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CostReductionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r614",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/CapitalStructureNarrativeDetails",
      "http://www.avalotherapeutics.com/role/NotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Expected term of option (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/StockBasedCompensationScheduleofFairValueAssumptionsforOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r166",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.avalotherapeutics.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org//420/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001628280-23-026990-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-026990-xbrl.zip
M4$L#!!0    ( '@X U?2TY^)M",! -$8#P 1    879T>"TR,#(S,#8S,"YH
M=&WLO6ESXSBR+OS]_@J^FKGG5D=(,E<MKFK=4-FN;L^X;!_;U3/G_3(!D9"%
M*8I4<[&M^?4W 9+:%U*B1%#"1(_+EK@ F4\F,A.)S"__]V-H2V_8\XGK_%I1
MZG)%^K^=+_]?K?;/KT]WTK5KAD/L!-*5AU& +>F=! ,I&&#I'Z[WD[PAZ=%&
M0=_UAK4:N^O*'8T]\CH()%56M>2J^$OOLJ<:N-EJ-6M]I=6OZ8:!:[V6K->T
MIBJWVX:B-=NH^GK9;LF:W-113=-4K:;W3*.&](92:\I8[_?4MH6::M6Z;#?Z
M6D\Q5 VU>GI3;2!-,XV^KC3;+<N034Q?.PA@?C!'Q[]$;\''KY5!$(PN+R[>
MW]_KZ W9+DS&0R,<!L3TZZ8[O* #EQL:$"*ZC7P$-1^;<W?"W_57]^V".#9Q
M,"751> AQZ>40 &0$IZB&#6Y5=.4Y#EPY<^YAWST/+ON>J]PK:Q=T*][R,?)
MY:%?>T5H-+FCC_P>NSK^@HUS.L9U3U:TF4$FEUN83*YGUR;S@2_FGNL'(V_U
ME?2;N4OIMV3#_(CC!\@Q)_,COJNK2G/3'=$5DQ<L$?!=8Q<K[7;[@GT[P[+5
MS]W$+U6NR6I-46<G9"W0*1Y;XR+Z<G*I3U8-#*Y4+O[Y_>[9'. AJBU2P/>"
M9>["A[-D73]?"FQVT:6-G-=?*]BI_7BN . QLCI?ACA $KVUAO\,R=NOE2O7
M"4"0:R_C$0S C/[ZM1+@C^""/>JB\[_^U__Z$I# QATJ*;5$#KY<1!]^N8@>
MW7.M<>>+1=XD/QC;^->*1?R1C<:7CNM@& #YN*078B_ZE5@6=MBO\/T]:!./
MF-'[/X(GW/^U8M9 1!PTI$_"Y/+&@=>-KV!T'K)O'0M__!V/*Q*Q?JWT:ZI1
MZ<A 54/3%15&-O?4#"^Y"CT/WO"-^":R_P<C[\:QKD'!5:0($;]6 $*7%GQ2
M&\)3!C4+3<?0J'04]4)3=G]]HE:G[_\&G_B3-S0K'4K]O%[P")>[UOPK6I7.
M?ZN[OZ +3[?8&VST.D^U/OG 5JV/;*K+XK>U*YUOW;OGFS4O_.8ADTJA%#HD
M>IT3#GO8JRP.0:](%C;)$![^:T5/!A1KQ,OGP#5_#EP;L.?? .R#\;T;8/;I
M\\@F <A O-(]4:&'"5'JP /D9*!*0P> U>66-B%^,C;NQJHVM-*,5=,;V\:Z
M&G3:XEBNX:(W>,L;OB.H1^#MX^< Y)1B\:'_C3B@80E WO4)??K-!^@YG_1L
M?./0%S!EGXQ*EV%4FY;7ORR_C6#_WG7,2']DDI\ELN8Z%44K<BH/(S8>Y_4.
M@PGS1 W A_X/'W=]'P?I)G5'_& R&V,ZF^V&VE\>/1?>'XS!%G6"KF-1C([H
M"^'WC2/K]@/L=4W0E:%-S=MK//) #!AEX=[NT/4"\A_V9R;Z+*$V=_KHITR?
MB3C$R_0N!&IN$0>8E1=B:T86*#$H#6<^RE,H\IA4Z^B32LNIJ2+985X-9<N\
M%J=P&+65TV34XTQ&428&&377+Y^P'WBA&80>S ?8_H29R'9AD7UC[WE$8SJ3
M%^P-D\$:,AAFCXKZ/=N; 8>+%L( >?@KT-"Z<H<C($ND(CSPL5X9_;Z.IY?$
M ^F^(\]B/_Z H<.@(S-520;7H$O:H_(_2V.[F'<K/-S'0#T3^RN\(>H57OK,
M_X+12\Q+O S !_JUXI/AR*;.&/MLX-')S3D^]0_?@D=<S#\C>O_TI?$8?#?T
MV%_,#[Z,*<:F0DWGY'/,O)OD+V+1O_L$>Q)[/EX99+BZ_?N\U[-X<R?Y:/[I
M(T;/Y"_P/;V ^CC,M:C)"OR7W#?];C),:^;21DV3IZ^(ODG^3EYR,3?OU610
M.2!#Y(0'\<Q:X/)/'A1_DVYFU*)FT_(IKOW)S(:@24(/=V+"LB^31R3?)7_3
M9ZRFE,8=I68QL".E0B9.\Z2(8SR7/YZOLU-)YXM*-'A4TY3]J02*D&G+R?0L
M4.$6GKWT/O( 7&]'@B[=3S^\QHX[A&5NQ6/3PGGN$1?SH]_*3^/0_(QG@5_I
M^A/]:<'+/L")-4GP'5/?6++(D*[K-!SN>\$E&,\6+*L/WC/VWHB)NQ\$I#U9
M^.)OHUN_7*Q\XF3FDQ?OH*[UXZOKAF#':G:HZ=FAYL>.IF '3\9,2[!CK72D
M94>.TM'FP!;@0&<K,F]T*$99*MRY7,6(A7)PGRNKFIIN*L2AE6A'@<8-7 ?^
M].=UUA,.$'&P=8,\ASBO_DDN[<K!_;V3XU(1LL2#O[E(AR;\EY(.LY=FH\/$
M.8VW#U=[AR/X-;L3KW#G]67$/GP^=!VV&YH_[.>#,-K.X84%FG/GVF6D>=>R
M6 P>V8^(6+?.%1J1 -FEH3]WOAQW^OY A#^XUU;<U [N 959CW+@FJD'=\U.
M1>GRP*R#^X^EU] \<*GLWNT1;<?=-_ 6:%YV7[4@VS$W^A_<"RV]9CH0X86C
M>H1]\ 6:"T>U6/H+1[4@PG.WO<B3LN%@^U<MN[M=F#=7 +.TLKO>Q_?FBN!2
MV7WNXQE8N44-M;)[T,486/G1O^S>])$-K/P(S\-F[H&F)AQ5OM,]-.'5EHA9
M97>!CVB5Y!5JT\KN_19DE>1&_[([M\>V2O(BO,Y#^NZ!IB:\NW0T5_*+(NK"
MNRN6_L*[*XCPG'EW>4Y->'=\IXGKPKLK$;.X]>[N7.<UP-[P&O<"6K1OGD=W
M+G)H10_4L_$6QJ1^(WW3K4.KB-"A1N]CI45^=SWR']=Y=-^QYYMNZ 6T_E=I
M$C=T;KW)<^0Q!QM-.K?N[?$!\1SV?/QG2!>%-_BQ_-*%"TX'B//*IEE3<U$V
M!G=;S?1<^'?T;]>["OW '0)59Z@]]\4].]WUX.0&KBO7,3$MY$K-B2?B__PZ
M_HH=<S!$WL\%E"$;^T\8$!;B>YP;RE8,8!GAR?27+C[)G&F#VSA,86C)*B$O
M[ZX Z.$ REW02FA0?@%:@/EH<!O5$QI4 )0"E-LC(G%1TD<@P_B%-F"(:H#[
M7\>SW\Q@YP6_H<<!\H;(9)6-64L 8*9'L'\76/4\@+NZ:%($76+;9.1AZ\ X
M45AUAK3!KW9>..$VE"QPLC=.%B[="R?<1K1O'1/4^B2N_179M,'*\P!C6MM\
M&LB^)KYIN[0B"4 (_ABY/K)_\]QPY,,C[- BSBN]!J9-8$5,JJ(#XF:8_(@M
M@@!1YJ/K!7W7)KFM87,CNK*1[P-=S*B&\MPZMGJ,T>WP2?_KF"[L_( P3V7%
M7:2>ZH0)])[!KD PFXA?[*OXDV^NATWDYV:1"\P7@'FUIL@I,:_/[_7NA7EN
M=RX$"(\#PL/LB!G<;H (7!6BW(I(K&YPMU,R28" )UC$#FFSI&=LAA[KGW'S
M07&%K6^>.Z2I$V' F/703Y*CDK+M7\>K'S"#O)OAR';'&%\!LT.;RC'MU')-
MP%((7,]GR3$/(X:%DXSQ-KC=A#@SWA<0G6IP%]\_1]X7DV[5X#9T?F:\+V*]
MYS8J?7C>_P/15EC!J9<X;' ;4#Y-%A>Q>G,;"SY!%A>DJ+F+M)XVBXNPP[@-
M+!Z4Q=/M1;HS: ;88BS^X9# ?WK^<9IK,K>QOM-F=0%K<_,\(VK%LKH8!=X\
MSP!:X:PNHN_?&<?+'CW\+73@8;%==IK1\.891\4*X' 1*_,9Q[Z.S>&"M/09
MA[X*X' 1)A>WD:]OB'A_(#L$7GV/^J[1!WSSV+%-<SQO.DTNGKG4?Z)L]8#M
M>25 S QI\NOO,$GDF8/Q'7[#]II1W3H 19]=H90EG:;);<#L1)&AE@89W,;9
M3A096FF0P6U8[D21<=C5),?6#RUNHW@GBHS#KB9Y(H/;H-^)(N.PJTF>R. V
M1LB_@.:XJ+>X#>3-L.&.H!ZQ:?TWFI>^D(X.DWU#U-'_1ASDF(2>HTR*]/C)
MG>3 Y7CR% QN V_\<X2#N&F+VZ@:_^P[D(HK0Q3L&!S9.BYZ!O3*#8%XWHB>
M5K]'P]DCXS?/+P-8!D?LN/KA(Z:ICR^J^1U?;'$7%]MRC+_[Q\L_#;D\GB)W
MT:44])7EYKZ2E91<P'[@.@ME&*+/ME=@XH>)W 6"MI,WA_(]N2"%&R:VN8O9
MI*!O0RF-IFN7(?+!C=6Q?86C9ZD/)6$<&![M,H1#2@07KGQ++2^0B& -YVLU
M#R 1\:-R+CS%Q*O:(EYUN@M/;B 1(;3377AR PEWL3->09*\<&8WF>T=3JL
M1\&+A:\!5[UX] _]Y] TL5]:I7:84'^;N_#B=E:ON^+F8X3I<:$7[ T/D&'
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M+@D.'(@#+]VO=S?T5//5P_W+S?W+<T9#L^N!][+?F>(UE#JZ*:" *=#>Q10
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M>HGL=S3V*Q=S@QL2)YF'UH")+I+YZ+*D<B1+F\>27I::E<X+%176! )>N*;
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M=26OG9!#(^\<TIH?/7<$PQFS< O-LAS1D[7Y!K:%&95!Q:.WX.,RX<JCC9P
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M\HS/Y:3(]J1Y,;&OYF=VUAJ53K/:;.=5MH:70V$"?,=*'=T+?73G2JVV&HJ
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M&4="78.)TFI)W!K,FQ':Z>@U&*#EACT;SP\^Q5.._L*RF/NGSXD#OI A_R)
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M#+PV;W>(=! >%@ ?V+*D_$>A1_D<2($K=5^^2W#+JX>&XG@;WWK^90 $>QT
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M+F"Z\M S']+OSW](O]ECTQUYP"KB2-?LY.KOV!MA_XUXH2_=.($WEKYCBZ
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M@1L3FS'5Z=MH.(Q(#DJ!1=A8G^H>\CR"/1C^*TA-G6DQ#.P"Q+^#EL$V ?4
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M^POV;WVOX0P)\UB#TA5)M)D"S( N4+U;2W=SSFR7W9* @I5'4OVR]DSH&B5
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MP<I A<S)A_IPEE_HBA+DTDW*E.5*YE$"B.JX\B(R]5BFYJ>1HWN9UIEM:"C
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MG2TFV_Z>RVG^C*F.\'4 C 3H$)=?G7FK3LYFAFUA<BT*:[X('A#%F1*MER"
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M\0,'>H:?(M]3;D6^"(%]'^!R$"P#.,/HCTOF(I;!1:X741:8 G0HSPEX0_!
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MW?S^-JFU9C1G7LS\P^* 57,Z09I77]&S*D]AG1S;N6]K37+JJ+4.V]ME%7)
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M!>M:>VB"(=%)+W:>FW0FO=@Y&]+Q[FNE#@X/&_7MF)X7![[/><BIM+67/>=
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M&L,A?_9%/;,7 O#^7+,P!K4WF%$=U8"^^CE@H:NPU2H,[D%+9C3E6PE3.*\
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MG]11T%GA&"2ZY#47"<\(+3*X+$$=S#,(>>Y$$IV&PL&+K-0-_U[[,C-('-A
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MGN@S0Q\Q>U+.2O]9>N>C.:<\P7SQ3L%'4$BV2LPY@40>A99$<#@B?QU0UQI
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MO1C9N^;NT_)D6NF#1AVV#F&<:!>'$T\5RJF$"6GBISH:MHS9KN3]X-3R>;!
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M$DD)-^Z9EDFP4)65E5L]F2DH?T3A@4-X.GL\)3LFH[2-C]6;0Z:J.T:H5;)
MX%7MO>D]C0'_Q?KISI-YBEA.QI$=NJ24EP4A3C&!9/G.P$Z F8J&;Z1GWA3(
MR =G R&-U$M/(>SIG"=L,)VTE)]-MIG<,QQQG&T<G53,",&4:==VX=<QF146
MR ?ML\AP_7Q^8$NM3U@@-](%!F%YL<4S;.DCTXS\($8)%0+O4ND(2L)-F6L>
MA(+S'>ME%>2/]$FO7))C%=.,UX:PYD'BQ\%$\X+H7$NNJEN0ZA1[6PU:H$O*
MYN*JD[Y1@BEM$K[1=RQ.(,<-Y40Q$OQ$=A3C6F[G"]:I>C*4BZD$P.^8%H60
M3@J.P_\E\2P(*4EBC=1:YIOTUO@FFBZXL!9HZ+);<B6G 4[CIR1.0H'^"U9%
MK\U2IV]^[9NMX; BFR@3'"5F<>7K--PJ'MRV <;F?UL^U:TP\9=EKBHF$9<$
ME2Z$7'++"F]!NL/^4NS<P\VQ0P%',")!I<83?U/8(V!E***(WX&*;$NZ93,9
ML31S7ZWA4D[_)N"M/4^9ZCR2^M^:@EE0E"'G\4??^3;Y#HI X(?_CR(D%>IH
M!.IHN9W Z4<;:PMF0N6<:DG>0,</,!,:IF>JWR_4[(H\0";" 1Z7LTV.RSIY
MVY)&$I# >IBB!O/;$1C3H[#K$D^JPEJ ]U8;W&QOE.9"031UP.A%M?>L_V1E
M'C&J1%^I(P0,2/^MNZNCSO)=#32!IB(CRZ\):E-G\%34R2?ZG]]:KH?Q>S@!
M%'VK32(LXG[6;75.*_)G);-PY)E"T?)M.5U1JZX(7Y>Z(/=]3L\Z,.OATD=K
M-0@=TI(4O<,C.DU<_@1,J_/K"^/4')T,.BVUGN<.DRU)SLO"/.0@YL(\T1//
M=>7,I.TP)DA:S@&H(SOCLH.<.B14,D%6F C+#JS\*A0+- 1]*AZ5EHSR'7E/
M"%PO6IFY@I&/3.P&($D6&"]31@U\K=@"1 LQ#<S$NV^MSSIR\VJ LRS8"^-)
MI12@T/!)L2 $&K%N5$KVQ=^'8$"YD8NY3YS$H>7[9N/GW%29-;4VAPG?^J3E
M!4;#:J_N*;+R>YF([*(665)G"FRZ)"*?H7:-@='I+FH,C'IK+H6W421@@]3J
MU6*?4D37)J&>]=_L'$MA=MMK+E^+^PI633 7-];/#VYD>T$$9FLY\Q+-*TDS
M<!AP=SNCOC-RG(YP'+-_.AZ?]>VQ:5I G*%]ZG1*F9K\&@/>(TH5XUZD=]\Y
ME7BG<K+Q6MHM*Y&"<6TX1V@J(S%CZV<N,[3V.:'GX(^NX21">;$1D,V=@-?K
MQYI,M3"?E1NB3<'\BN)*#>@(4' 8=L>I6> -QUDU,CN!;V!,_#?H-YBO%/7
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MOLXPOKB>B&*LZ"QCP%S$[](_^>S:Z(8XM+&8IK*ELD.'85<\V)38HR6OSE@
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MKVF!+($]I7TERD3(-N0&O00N*9\1)_=$;1MDA-9A&0&E&DZTT/:2A>0,=)R
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M#\(%<AO(:0P$NSY*=6 U^!N#G2AX,1X"/[FS0N?$"X(?J$*C&'ZB%=IW_=O
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M^I^1:< %>P(2M(UO:14*M<85F4I@O(R%%5(Z8W5VTB?MB24)2MJ26L9"*PG
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MW&+QPJ_*=4CA )V$$/D.X<E:&-\#SSQSJ%/K@P*M-.*)N@7@M*9V-B]'S$&
MQ^I6<&+=@AF,HB.R)B*6ER0!W@I(40GG#3-#M"&T IW>O;1IG#QN3 6ON7FS
MDX0*+,;X(E0$#* 7_E1:#_""5!0C0@]O9'XN/#32$4"69@"ALVMY-'DV.F\)
MS,])=1DI,*!;10K:&.XSG14#)6,D71]9,7-67 C 8B919H:5LVG@[Y-%L-!0
M?>G@-*@ @L@RJ1'?]NMT:E?5>CS DUPMMKXEH7'-T9(7?"V/JY0QH7O95I"J
MBW).8JJ>I.*4ED#TR_;W?8&FC#\]\<1$5IA;4Y+IQ!SM,"L19.?P_>Y@UN]S
MY#+[[0'2XIR*]%* 4T/244P\;=*G H.Z0\924\<_JZ8Z*RIF-1OV^ W[D,O0
M G/W) [D%5-V*F%GP,ZU?\BRJ'P3QQ )?K0EZ\ZW\F53!5>$DSFG.@=8<6H>
M5^UYL^5/N.7?M@!GYMH3S38]I2A-6P?G;D>RW6$+$(UR/%D>&8%6>)\6C:!K
M5"?7BI9NQ?/)GNFI?,%QF7,"VJM@A+Q95PDI"O@HO1%*ZO EX$-'"$ALQJV@
MY!PLG"Q"2B2AO(QUX12D/%ZGR2 #8_L%>_F8%R!%[8O8A.J4L,KJ7@>]W*7%
MO:H)0"YXZ$895NR&>KU\82SJQQ2+:N2:/E =@I=)I^K3^EW>LU[QK6P+WA1O
M7##AD.BRD@I?J64,4T+=3V,IXK>=]C"% Z<MQ(F1UH*:=:_\K=GN;#J.8L@N
M!UH<(=L_X'P0$X=V8<PFGQ)P5O:4Z^M500^;E5=NV;^$5M"*>SFGREHF>0F]
M_/Z"V@+85-:!D,FRF_07W!4LMO8D)LD0S8L-;)(2XB .%K^<]-H5F1(J-D.5
M0T[[.S2EWOR:MC 1:2?*%*+6-M*"&'05DI;KQ?I-LNU#"M3 ,]'LQ&/@'.+G
M@NZ,0<!<BT4L6Q?IW3RU/%HN%E@2>5@!4@F28MD>AAV76N@>M("IJ2LO H9X
M*YUYC27(#YH &RU7<0E77.?$D4[[M*X^*ZO$81X\G8;A+>S@1-W^4)UM1Q52
MODE6/E!>E+[<S6MD[Y[+7KOR=-67P ?-PC4%\)4.,=(NF(V/0%,?@;%;I\;K
MA(:.&FAH PT]"&AHOO $FP%:X0E9W[P:F"B4U-C4@LE"1$<4H P2F+H3'2\O
M7B'SWE&/#?*!^?3TR#DKJ8'QS1."\2\B\8OZXSVB5CWK_A<P>I &]*.'9-6?
MG;:[9ST\07$(_^>H%\O#U:;#]2YVRM^=FNVSX?*O.VWS@=\->MT'_7+59$VP
M+GNGAS39LXV&?4>[QCL'O(%<]U]O>F\RV4IW&[]T%S\-,\]O>-U1,J*(,[9]
M<D=KD5,594_EPE>LJ8,K>E/QZ-DFR^?CMAL"E $G++F6QJ-S5&FV?-6C4F"B
M@.V@GV 0W-? M;P_*'9 _;(!:399[RLC6[?.<1E;]@\$2_K.B9RA;0L!5MI>
MG*,-4*=\:9/=,BLC9A/>6;?V(N.L^]VF7-0Q#H&J;XLDW-KR]673+<5>K;MK
MFM62>5OKAXTW:M*AX>*&B^NM>S \VT\NKJV0)O3_#DHA76Q%&Q46OM2,Z=8C
M7N6YW3\&-EO#L].:+%S-*D\J;%_W)O5:W?YH=YOT&HS;BR\73VK4;L2A%70[
M$ X%,3(:/$P3[I'-]L(WJ=LZ&]:5]5O<I#5B1,6:_8"N-5;LZ_X]^1JLK4L,
MPOB:M?7+DYI;AS[&EI0F2Y9NNSO8<_:XMCPKI(I+8^&+B5OHRH; @T:QUB?K
M\/2!#F:C5I_/]NF>/3"6M4>>_N$(&DP8/N&.P]1=RX\XL5SJI28(4-^_[-7E
MWR8$\-Q;-*SK7NU? .!@1,PWK.O5&"OUH^%-"&#/=^BT<_"&REY+CHW!)K7U
MV[K?R0LEB<KKP1YQ'2=#+?JU7CANG3[[?<+[K>'@@7<%6R/1CDW!YJ@T1V43
MPHQ: [.N/MR7HT+*]!T!LI<!Y67=E6%OAV57'I; _]SSO%J+U5?I40ZV7SFK
MSB!<A^.7_4&K\@FQ>ZWPL5BA59&BJ.<6EA!XW$,!?Y6U$,O]8";F6*SIGLH0
M)Q/+CI.0*B]S>W(JO!BEO8$OOEQD-1OE*PIYD)6SP,5P&487UY-/ZW6XWC-F
MJI5:B:BB*S*M7J5@JBY/^EOQCK;R/41]EXKG!I/\,HTPP8+;V4RP3O8MMU]1
M&Y=6-:2ZE5QCTL)&,URMR@(2HD3 ,HU<AB=6+>$*Q34M!RMOJYYCLN$8%G*5
M?0.8"OA:^<K39:O/M]V1Q6Y/5$*E_$C5]>$W<F?$[HM.+\U5OXPVN''0#ZY>
M5:/$0JI$YPPVD=LX\5C\*;WJ/C_T2R;T)]4T8YU<Q'+&6(S*M9%5J16S<%P[
MIHY]Q-KW],P,!D=BI^6F@^I6<!L5G]8[Q:1BA.JQIT6'UK1D2LNX1ZJ14:X^
M6E4'DT*G)*S8M5FOI->2*TOU3*^%YQ$!?Z>VFER.[-P!T>P22;$:X(9ILWMK
MONQMRF&DB#_5B&_EB;^][,,UQEV3@]CD(#8YB$T.8I.#V.0@-CF(>Y"#N'^H
MR2?$5QX@ GU7 +IUOWNMP?"7E:C6KPWQ:=(M&R[>.RX^&^XG%[\&;,-G,;6\
M%I5<3;RXT ,Q#"8BBCA.UZ1C/@)+W#EML)A[OTF#0?_@T9A[+6N>!.3]NJ%_
M@V&W06?N]Q;U.G7%2@//K$7@<X=F$RGCA5M;X;^:Y)$'0XH;<V6_-\AL;)4F
M6V0/^;(W>* SWQ@DSQ9O,7>X1:_!(&GR1?8N8OK*0/#=5K_[0!-NYR#XYJ@T
M1^59C\KIZ(&V],Z/R@;Y(CE$::YU[_YA,/<),6UV=>#K)MC+'"B]_[!6C[FV
M5OBK1>C"[SF!H*)S599B@@^[\%L[YJ;M$;8!NB4P-,P66PK#DY%AV6$01897
M]]:GXMTP3QB6VE!/)I&(<1:NG^:&K(GU&@YG<M B.3]"@2+DTH,%8[*GH>7+
MC\5\X07W0J3Y)9& )3C&S/(FN&Q"M.)*)FX(!- ^/O#F1BNY5.+Z:P&%&XA_
M _'7>8C"'0K$3YU[#WKUCP7=LR04BAR^B!\/K5^>&?$Z&X.=-8W!FL9@I9U<
MPP;/G%TR;(^&PP=FEXSZ#TW*6)VP,7B2A(VS_B%-=K-AFU2#)KNDV?(7FB;1
M9)<TV26O/;N$JG>+*,YY*KN^M'Y4W'S_XL-'9V?#XWU#IC?;^NAM-5OFH+]W
M&_L:KL<O9I8_I=H_$\L-C5O+2\@U!,*ZMQRG]%P94&R@>_4YN]_9G*T;W-ZS
M8T-&7;/[O@'O/3EX;Z^,HE?#J0V:[[5MTV--EJ=H]-. ?QKPSX9>0*=7P[W;
M%^!/<TR:8[+'SO*^').Z^+@# S*4S5R]_#"BKD(7\5<(=2E$"HM@J\\!3/]\
M&@I!I4"/$%LF)O!&JD/[-8B%<::>37PK<5PN7X.@((9X^;1W-*9$Z5@>$ 0^
MP!&CXYI .(6B:!N7LO*NQ'>U=/P1K-41AJ6P:(AB6ECWM 1X_*TY:'?R59?I
M^II&N(6'$#;EX<KQ;9&PDQ Q3%9*AKN9:\\,)PQN!?WF;:?=K:S'7"+O:AQ?
M?DF]_))H#2X62]8Q5&^'Q:7 CV%4H/,"OJZUKI=<Y/9?#'*SX_*>:+6KE^,'
M>U5EFC6V<HM;!WN%^WSGQC,NO(U%JHD5U=[(GT;&6$Q=WT?0D7Q]/'-#Q_@[
M >Z%W5-(18): CTE%^<+9D>PU3_\X,[/D'JYUZ:K1AP</AZ[.2Z<"_KFM8#;
MNGQ- L=1&#?63X5P.^C5+P7R#22X34F2$+A[ZL./'0-1H'-B#R)%#*10QP+E
M,JC-V4.$\T'3<2D7E2Y/B;)$55"H+'J16-?NSVI(0@$(^#*I5'W6OH>!DX#T
MO1(@G1*&DC+WE/_WH.FRD@JP:,01$R5"I@299F_-MEG*#(B C=:<N%;.H'C;
MU<R0S4?I5H#XI:UHQ7'HCA-&U\$;K)RF3'Q$2H-]Y[QPRT$V; ""S"PP^<C#
MB C3CD0*?++KYB(DVW8QL\*Y98N$_ ^UW2WC"VX,PNG5DK>ZF"'Z2>MAFV4,
M,3I9)[UV!>X1DS0870KL<MI__R3SWG 36M+FOB.K)G+1JE7(_+9Q?FMY09IS
MH!IGD)&;+!:>;KKCL6AVXC$ ;; /P+*-,./C6BS C1O#7NAM;\#.!"J#B+]+
M;>ZBS---;B6H[H45HHA"._B#L.6XIAKWH 5,365Y@6E:8$PHI7EM>5J!O4,D
MP$;+55R">3@1< ]XJ[E.1X]1C!6C6/,TQ0R4V78480O=1,>-["2B_D/CX%8<
M..^N;M+32-[]EKQVY=FJ+W\/FH5KBM]<A[@/6B>D#9O9[#DU'IL$M[Y15 U!
MO30MKNDULX_M6YI>,Z\B->1 LX&6!MZ:7*!7F=32Y (]?2[0BP"&?@]%J<MM
MTWZE:5SQP.+;IX/];%S1<''#Q74:'PQ'^\G'KR(;:BOZZ'4GU?1;_=.Z?1":
MS*=GWJ1AJ]-KBI8_K2SY<O&D9NT+3Z7IMLY.'Z@)]\AJ>^&;-&B99F]OLYWV
MKP[&$U;,.$!KBRIFZ(5-?WE2<^O0Q]B2TF3)TFUW!WO.'KMJU_O"9;;9&IWN
M4&8WF[29$S48G.VM8JWE&QR$J'F*9HBOW,,<U+7>FR# LV]173VP?R& @Q$Q
M30^S!YHK9MUNS8VQ\MQ;-*S;WFC_3)6]EAU-#[.]NW9\944GS$YK6/N4[TOE
MB>:L-&?E.<_*J-4Y>YE=S%YE<Y1>IVF.TC1'*>UDD0V:3GZ;SO-J;2Z+UK[O
MM-W/E]JIE><2K6WBYT:5N8=9,S\+,QE/\W-(?P%\$FUP36$XG'\;P6)#;(2F
ME7Y*RX+(.C3<+B]?AZ9K3,)@;LR$Y=B@-3"G%Q/+J(=:/+- 2[@.M6<+Q4)8
M<;X0CA?<B9"G>2^GDWM5KN!.OHDAO0;&25_\HM,JTP)/WGW+0/@&[F,)HJPS
M9[=MYAD#?_'6; ]SG[8P>PL3 X&TWGU[HZ$EPU#OQ;2K'O';^5\W_S[I=$ZY
M^A%U?)2UN/1-ST:*L%L@IB^6FNK)#-Q>(0,7/BW/;'V3R5(BFIQHU_C^\?Q/
MXR;$.@V5]9Q@-MSCDCY2S[FQ82W@2\N>R:B\)V)%8[!_< ,-QXIQ/ NLI%(Y
MJ,-.GUS)JK++Y/JDP*:U9--:4ODFIWH3W=^UOJ3G^;ZD&R;<[JV]L[<YO+6:
MPFXCG7>-0=@D]39)O4U2;Y/4VR3U-DF]35)OD]1[R*#-=;][K7<O+RT]TAP-
M]S,]LN'CAH_KP'O/'HB9:=)\'T_^SV)J>2TJ:IIX,?KK%)VB#@Z+,)AP-+))
M WY<_EYWE_#29I,VV:1>Z[2V'-H_#/!>RYHG22UXY7C35N>LTX""]WN3!JU>
MMX$%/RF)SQV:3:0,F+D5_A!DSC1I2P\V6^H*EL9F>6[!TA@L3:+2/O+EZ($%
MZ!J;Y+FV:+A+L_$U6"1-HM+>!4Y?6?+%H&4^M+#9SG,OFJ/2')7G#*/T6_W:
MQ4;WY:RLSE/: -FV9SC.I7U$NSIJ<Q/@H 9//VOW'IX[44I9H 9#RZ*9C\YC
M6 9?SYXER#QVUHFL6X(&P_)CEU:_(J.AC0VS@4WNJ4&/-LVW_2)U,)ECV?J6
MC=^M@K1;8#9Z$NK,D9G <2? R[%\C0VLC>#I2"RLD( 18K[P@GLA(@FUYID8
MP6)IDD?;R"<L;):'DC%'KYA8(S?\;;?X!=)EX\25'&WV)FNE]HV?3BFS/:BD
MU#)F?*%),B2*9.9!+2ASDX30)"'H/'0^#T"S_R]+PY?<!'S3Q !+)XC>"OS)
M^GEM@:J[RA$8MD?#X0-S!$;]AT+K5\/N!T\"NS_K'])D-QNV@8PW.0*O?L-?
M)MB]R1%X^AR!_2M4OOF3K^'R-&?:HM7OQY8_==% LJ)(-+D/#6;\X7=KX/YV
MW^\G:KSAY(:3-T<=[W.'LZ5W"@<?B#B_M;P@"Z+9?R<4;46]-(<E.\9=$/Z8
M!*'-A9 F"59ZD:&)-6']%GR51!2&I2"'7DYF;0VF@P[];![ZZJ;@*A7S:L%[
MXH->_6,#7QR %XH<OHBW$O9:SE*OLX"AV10P; H8EG:R">LV8=TFK-N$=9NP
M;A/6;<*Z35BW">LNE1'4J5)$<<Y5V76.S*."8?L7%3HR6V?]P?&^!86:C7WT
MQG9;O6YO[S;V->3C7,PL?TH5G2>6&QJWEI>0:PB$=6\9I>>Y$D[7) L_@+.[
MG<WYNLD4/H@;LR9=N'ZZ\%[910?(J4?=^H;/@1HW![D[-:3\'F4,/T47^W6_
M:Y(+GXL^^WYF6N99?>-HYWF%S3%ICLDS^\;]&K[QOAR3%PZ5*1NU>F\PA+.$
M+J8&,L(S%QI,$RXEUN5S -,_GX9"4&>>(PM3"R?P1D+4? UB89RI9Q/?2AR7
MLS4Q XZS4'W:.QI3IJ19'A $/L 1H^,'02;:QJ7LEJ3P.VF>'2S3$8:EVCUA
MMM["NJ?9PWK?FH-V)Y\.21?5-,(M/(3I@1XNFO*%A9V$F*MGI12XF[GVS'#"
MX%;D@4*N7R;F:N309;[A4WX5-&W@>2N7'OAV6)P]_!A&!:HNX.M:2SEPZ-+*
M$_ OSM^TX_*>P%;H>T:<)Y!A\SFYE:V^4DYRBUNGY_["8'%HV7%"W*?V1OXT
M,L9BZOH^@HKDZ^.9&SH%3)KL:@;TE(R;Y[4(MOJ'']SY61)J[K7IJC'%$Q^/
MW1P7S@5]\UKR-KM\"P+'41@WUL\7G;5I#B1X34D2+=4=$YSGQ!Y$BAA(H>=K
M@I*<U1?%+X&*I7M0HN)G]^_$=4AHPF(O9&KVE8B")+2ULMJ/7?CSGY#2>NF$
M_!/3W4'6I.M>,M/]V[_E$$YU"A)<FVU%,\[@=Q''"<80)=E3FTI_&J!,UOL0
M BD0YKFT3^'"70CJX\C),6F)CP@_",#0B95*P/3Y()Q:ODRNH3,X":TH#A,;
M%77;D*4)9'X_S(0F._&"NZ8$P;.6(-B7TWB!^_\)][_I9+A=W+9VLE8Z'T;3
MHE#'J38M"IL6A?L'6VQPJJ]LPU\FX++!J38XU:WB5 \0[_55Q&R;'241!9B/
MT;R_=5$\CN]_>1 R8XN7R@\\-WM'YJ<K<]U0\_4 I](XA67'[JT;NP_L,_?(
MF@I[=)M\]C1E$_;A/GBSI1UUS5;G='3(6+"&W0Z)W4:M0>_T(,%MAR#B+_U;
M$6U#Q+]0'/>&7&KVZB-D]@@+]L)W9S#<R>:\!A/QD[K^>6(3\5#QVYMQJ-EO
M]?H/[!J_1X;5R]ZD(]BETY'9F")/&!G245L4):+K=OQ#_)VXMY;'U6*V;Y\\
M"LYZ*%#H;7L3VZ7-?A_^86LTK)$!M572''*F0',V7O[9Z/=:O=/^@1V.#?(#
M7A_JIB;<-KW,D7<Y&K(M<P?*$/3#0AANMDA,OGC;-=MFC79F>>P1IE&X$<+J
M,NAB,#$LRNWP@BCBW(91\14I5([L)0>)Q2#T."!<,+AG<*;20>!3?Z,59;"_
MI2W':$+M4T-.I=CORZ;:#M05BUXOZSBX^=Y5@_:HT+LJ;96EGJ(A+-L.$^Q#
MEC9M2OMCZ2-3FR>;FFI%",A7M0;A/<,RX=YV"^1L(104LPI@#K@&F6)">S&)
M8!4P+0M7?5:8M&:Y\J2 ]@),5GC]2VVW5?MXC-H#H];)Z+9J'(W>H-TQ]N14
M# M3(9;I&57<LOR4E/&N&['&ZZP@V]WDJ#059)L*LCM-W-$:%#99 +O. M@%
M9VQN85-Z4DF[NJLN[ Z1(/6,BZKE<^*S3'NKFVF\VOPX2%[K/M2;4Y/>.>O3
M=-36:_! #30X677Q=$";5?,<Z,2H(D$M_L_,:A"Z:'O"Z+80CO0T>^W3@C.+
MO9(MF4U_%[HQJ%YCD8QA/]$[@J6A,@-[FL_J)S$.$^R-G!ZVTCN&ND. H]/4
MI1H HQI6P'8VO":,$LN/58)S2='%)_#Q"3@'/_@EJ"L*R=^%].MJYPZ?+Z?@
M:SG>689XEHK_]"447I4+69^S4XF=9VK:3+-?C#!4U(VP%@M/YL]7U5HXJ U^
M]DQJSF4$@8#15N.<HR^X?=]AS39U?/\(\Y[#8B/VZ,^C*)G+SO$''A^\F;F1
M\<7RP4?$G4PET@<WLA-JVLXK!HO['C@3V?)3R@#@O[ Y3L]<42T*>N1;:GIC
M:0>.,F!L(0D?QE_2?E==DF#,?[ T!.%W)19!2"[$IR"<&V;GY!\M601E9MT*
M8RQ0SN-9"?GW&%\+';3B.?7Y]_/S[VT^8I?J2=5E:<ED<,9PHN?HG*1C%(N\
M_(!=$HIQ.(ZB\4T\LV*>(&RZ"[^Q:0V<J-W2 RD8U /W*6&/(@T@AK1NX5 =
MCDAHK[*QHHH7!88%:@V&C1(0#S1WSNJ&B7.LQX%-9H4WQOQSW4W2'P,_!YPF
MK-X!WPB?CT3H1C_X-&0TLA4_4.F8!^]V2R<;^$XD6&$ZK0KG+2..K"(14Q@4
MD]RY\DS@)$@"T,I1:VG4JZ77[YT+*P(75TZ%:M7 YVETK**V+Q%$\X.5)IB7
MSQ7G\&,$3X2\VU&$#[2TDA<XVC0(G#L0^#*$" >7I%,<(JDHF P[S"58%,>-
M!>B 6_HQN=MV$H8H[B? 6C+UWPWM9 Z$AK?3TH %<9>6<RF2'V-]X'&//0&3
M<68BI!(UR/'\>"A2M>7'V-*,E1'R #[,Q6B0C+[%H8,)LKQZ)[K.V1NI$@R>
M.SP.-#]9+R:4PF5NW5.( 30;F5PB+YFSE>"#MVB_@;+S058NH0),WXU$V_@&
M9)@CT]A*$5B9(EA-'UTV(37/?3^A*AQ%N?1G:@7<"RN4^O^#L,5\#,OIF=(&
MF+B>JLJ SUY_O,!!OF"!!Y92W;-65H$'PRFIF/,# ^=)3*(BLQ@\P93RBG4M
MI((SG"25>!N8W@?I5VYF!GR;3$Y^LSQ2#M<S :;=>1@B'><Y[,[Z^;]_ZCO8
MM;?;JZY@]\X,^9<PG(!$NU2)Y-2 I.:MB&@K+&TK6H9FQ(ZET+$IL(H')DP\
M>5I#,4T\MD56&*FO\]:AM_5;!QS"=?[KS?HXN-D9OMG"745OV%Q4[,5%Q6')
M^4LP-0U0H/_ J(P;LSF'X@(^\-2_/[!Y##9+9)R3#?R% S178/O648)/K@S6
M5C@X*&5PCI4-H[GE>01$0#.*C6:R<\&Y$V1WH;8(A>RR2Y$/BBZ2%:.[+^DS
M%!\# Q,W?]GM])Y@I#86HF=O]F,G5QRS?IOD1QAXK)&_8PS5P5/5G*$GH_S'
MG,^:2;)E6_'$MR<;T+3\OP<>6CN/<J+G"DQ27I?9LT[,P='XF/])L;/LRX&C
M?RG#P-=<'!=]M8\_V;,SSFT*<9AGO3Y9P]:<'+:6(9U,_<$6^8!9/$(/]> W
M6=18_(17D?H+\"(?)##=I>>>R8(V\ID6A7<2&V,RZ-MGS&=%*I(M_#2HS?6%
MX3>W0I?+RV)ZDC"=DW^D8U%@"Z,<(DI?X(@(-CU_]:\J)#K9 ;#U [#(9!&&
MK'@("MUC,$$N0])H_1A%*F>5366\#_V:I;]EYQVO>&;!'2@YSY/S(:*J1>$&
M8X!/:;L *V9G(1J*3H3D-&&<Q9ZY0FL9'Q$SRAD8P?@_3$58_&\J1DOSS#:P
MM1%[K& -BG5Q?"2--ZVG)"P_U+;9L&):0>4Z/2QXN15&H^#QBXAN5$ND#^OI
M+H-9+8H_H<E+H59+156K?Y2R*5AAPJ?Q::\KK3!X9BR*H6<5(F1K#[>?PF"$
MJTG&, /M-BLG &$W+=M.Y@D7A6>\Y7R>8+A4PGL>)_E62CV4N@L@!#R$H4QX
MF85U'8T8=HT 3K8;49PP%%,KI'>F=,@.P8O@N"77:AD\E'I\^GQK1.+G&QQ*
M[3+I2AGZ+X$:2RM_PM$@T0;"7H/.(B.ZBCZI>$;Z9$R7.4(NVL#NQ%UZR:#I
M7QUY<$5!,6E].,=XN*2U@?^8E ^7%A9^B"1E(: "TG@S0/)<FBBYJX5[D#,_
M\,C$0?D'K7KT>1SP>-!_/?&__B[C?V:WB?^]H/C?[KB[6O-\/[^Z,2XO#1**
MYGOCV\T?'Z^,RZ^?OEU].;^Y_/9U*[Q?A]\';YXQVK0B'F.VC<]@CGCL_0NT
M2NHF:^P(:17XHFW41=QLNCVC_8^DF>=MBCT;GRP[#L(7G9EUF8']%32-,]-T
MIP)1C_ O[%^P&2[H/DB,"/P:#PLS@"1,/.HWY4>N\BXF3%HRSY-( CF^PZ#&
M98N$2;?SOG(SZ#L0--M! ;0VAP$HM)--RRI93S2;<1*Y&"MI5:%UR!R;<%Z'
MQ%DPL@0Q/N3=V:$[7@.^(H,/':9LG4!?Q'_8Z)>-L1V5BMIS.PN,6] +@.3*
M&Y-8%CT74SZ$0R>(FL$\$ J$X4@2XP)#<;,AX)0DX@ 8F)[@168/. (VC9U/
M=YZB)! F0E@IG6X.6):1>!P%*?*4P> LV<4C#BUR \%CY! -83,TK' ;37"Q
M(+X&WQ>;>F2DR*&RY(A('LFUVGD8"_!#Z:I$PH*X44CV;*1%3!S"X4PV,>GI
M>IXH3VY"CM\D!AJ\^B+/B!5<\3*$6+74OB+6O<HZUB',*'-YOTN?(=>]YROA
MRP^:)DMS)<I=C#"E['*20TY.+->3F:X6];31F]LI<?A94#SH*=K]P:_O+ P#
MP< 6'N46=SGC%#,X7F.0VQ1YE$XQ'3P;S[[ED8]*0:04!MZ"WY&<P6,#TH>,
M:G@) RH3+9?N91R%ZKS!2P+-^AC/!89/>PX!R<-[].T#)292ZJX&K)N/V^4\
M6->-]&"_=0L<2+N4_53;V77IA"H#! -]\;WJ:X@:BV.8N&QI2.3R/I0!<03\
M)+\_O_DB/SU.LT(P/1$-H3L76V?F,A51N_B19<NDQW+:8E3(6VQMF+784HF1
M<Q%.1:CJ%, "68"1,J$;"_AO),0/(F.FM^@\A:@[L_TE-4UW5FEJ.S<)O!5
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MSD-[AN&)=\*96N$[L-FM=^:@UP>E^PZF:PZ[H^ZHT^UUNIVA:;X3/T_ZYO^
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M'O=]?;7@3K<>F'HW#IQ[^,\LGGN__O]02P,$%     @ >#@#5^=>H9>.%
M,N   !$   !A=G1X+3(P,C,P-C,P+GAS9.U=6W/;N))^GU_!]59M9:N.8DFV
MX\N.<TJ^S?'&%Y6E)+-/4Q )29A0A 8 9?O\^M, +Z)X TE),?;(>8E%HKL!
M? V@N]$ ?_W[R\RU%IAQ0KWSO<[']IZ%/9LZQ)N<[WT=WK1.]O[^^9=??OV/
M5NOWBZ<[ZXK:_@Q[PKID& GL6,]$3"TQQ=9WRGZ0!;+Z+A)CRF:MUF=%=DGG
MKXQ,IL+JMKL'4;'H+3L;=8_P\<G)<6O<.1FW#H^.<&MTTCYL'1QWVZ>G1YV#
MXU/TM\G9Z4G[H'U\B%H'!]V#UN'(/FJAPT^=UG$;'XY'W5,''7<5TQ=^QNTI
MGB$+FN;QLQ=^OC<58GZVO__\_/SQ^> C99/];KO=V?_]_FZ@BNZ%95WB_5@I
M_3)B;E3^8%^^'B&.H^)H(5Y6BJ,%<BET!D-S[ MB\X\VG>W+=K<_';0C,LF4
ME(@A'A?(LV,QCF M\3K'O)-/!._WY7LIJ-UJ=UK=3H943]EMM0]:!YUD)1T1
MDR5K>+0?O-RSD!",C'R!;P#P*SQ&O@LDOO>7CUPR)M@!;7*QU)>5 HG7 K$)
M%@]HAOD<V;A.;W[^Q;(DVF0VITQ87H;'&/&1JC-G0I'M68%FW%$;":7PLB2/
MFI<IOX]=P>6OEOSU\84[>_O5I?J\-4%H7DMRDB:0'CZI4X.$FG=.3T_W7Z3>
MYM<@5_]4^9;\L]7I@DK4$%NDR-5EPZ]61+>).BS';+TZ1'1KUB%W;!;I@HY2
M_>;K5B,>Z+6K$5+6JD;^Q%$1BXA @G!41R#']L<)7>P[F%09?^GB\H\Z(VZ%
M"1=S5D=H7%[]E2,6>1X5BH-\$CZ;SXDWIL$#>"35]2S2V2<\CF;QS(J6,S&H
M_\X0LQEU-;/(_IS1.6:"8)Y<#16#*</C\SVY)K:B.?H/%XT^0DVB(AD!JP-/
MOMX'$NS>+5L2T4JE.]_C@(&+@[XQN>%SANLV'$@XK)0*Z/_W[;>16[?]0&+[
M[K]'\QT\KMM\("$>:=!Z23V$]Q9QSO<N*1CS>Y9\]O7IMH(YI60'5!';B/&R
M1I_;ZE_':BT=@):EJ'[=3Y=-<?$Y=AZ]S^KOM(J'Q&&1$L*4;E2F6^W47++P
M8=2+I7WK.=@#8OB#4Y<XT@&Z0*XT5093C 5OT/%:EEI4N@#% /H4Q["$/*TD
M4ROD:@5LWV%+]'$?,6C>% ,VR-T"AJO\M8 >- '4^K BY;]W'>"X SD=/\+4
MK>K(D0>%9M#<*1"0!;ZCG'_UD.\0(;W132#?1+!6)0ZKJ<12MD7'UE*Z!>*M
M%?F6K(#U(:["N[[4AVT+T\;:M=!JTM'6->E])BK&]'**O GFQ!L(:O^84M?!
MC%]!%6PBMC@/51.KU9U/370GE&T1STI*_Z__/.EVCO_'"FOQ/A6M@=R6)Z(&
M=="JTO'/4:7WN:@$5L2G-RY]WJ8!E"-#JQHGC50#!%E*TH[.)!<^#%#,Z[N@
M,:$6F%/I_A-NNY3[#,./B'27NAEQ GK=3S0"+*(!F7@$)A_DB9YM4]\3Q)OT
M055M@AL@TD"&#KQ..P.>E"*'3E*.,N\2DJRE*"N2M4-H/^$%]GQ<&\&(3HM*
M)XU*2+E#??R A?0@^I@-IK!6U^[K-+VVS[OI/@<.@1,#/"S%9(>Z_P81]@VY
M/K['2/:'6E%K@Y#/10O%01H*R<=2C*PDIQW"XPZ:W6#-",FT/7Z8[O& <(<Z
M&%8TYF/G^F4NC4H96WF477KI,^DHW!$T(BX13=;MZIRU,!VE80IY6Q%SM5 K
M]E;(WTH(V"$X+RD73]CQ;<FO[R*O@1.3YJ"%YU,:'LG#BIG('#AOAS!XH +S
M/GI%([?!^ITDUO;\<6;QEN162+]#?7Z)YD0@=R 8Z)S?P&[*,-#V_4E&ZP,6
M5LQCA_I?!:# A\(J- ]SLJI/;10*V&BQR/CBBE%+<;*2K'8(DEL/NA4/T4N#
MM3M)J^O\;L:7#J@M1;Y#'0YZ-B-"6>AJBTK%";#7*.A1QDL+2,:-3G +=ZP2
M_'8(H0:AI)\9MJH2OCH]/3H\;F<0;AR^LCY$?^U2>#@5)1E*:ZD^Q/E<M.!5
MB+A8'P)FNX1);M"D(3)EO+3X5 W#[")(07RD(2HKQ%H8"F(SN]CKE4,I#8&I
MRU^+W9H!FUW$..GX-UV/LBRT2&5B-RL1A%T$(AT): A& 1LM()F03B:LL(N@
MY <&&D)3RDP+4";N4Q1KV$6<HAR(*RP0<9NG7T3T6C0*LS"L#R&/7>K^<+^\
M:>^GR'6=G\VB"!GL9-^GO$%YE-[Q74S'J1=-P:G+7XM>)HB0XX?"[!;*D<&%
M/$?U'>DE$CU/$(>X -P"#[#M,V7-;ASP<C%:W*O$'U9QEP);D41K*7(GT<^-
M+23 X1RKH&W2;9HBT6,1@8-$S(-ZZ$EV)R/>1,7PFBK+SZF55K<JQTY2"J:J
MIYS"I!LH:VA!%2-2QX+?"8XRQ&G%-0V#H.\ZF4$_3ED'W8F+;DG32F5I]2<3
M]*FF/XE4>'GY3H+H71O"'GM 3!Y:6FP6]PQ7+<*9T% QPC'SG40Q"'>N#5L!
M&RU.F<!0&'Y]AT5V0_G*>@?^)UX3L3H2M&!F@DHQF!56X4#6.]@ A?HML]LV
MA6V&H1;*3/@I%TKU,,C#>\<M/CSL3=2+2+E?-X6BAKT6TTP0*Q?36$J(;BSG
M'6(M!G]TM@PR"'B'^2VW/A/K9562IL/_9]1)ITS9K+N:6ZRII;_F_NP.:F(F
M,;ZI^A0RTF*>D]B72;3?26R2.]]K>TRES+089:.K*QOJN^X^)3MW.3U>X5%C
MDUK/48M9)FJ9QBPY54K.[]#E=70#(ZL*SW?XM@B?3 5GR!8^<F]\F5W29\2S
MR1RY4%0%XC8[+JO+T\*>B167P9Z0:P6"K5BR%8G>2;U()RJMO7YJ&6J1S<2(
MLSE0N[Z.ICLYX:?Z0MX7+K]9(,]]T.">HN^RM]88S>O*TV*>/42:@_F*G[R4
M:P6"@TPL*Q*]DWJ1G]NV]IBNR%:+<B8079@\M^L#/+_'E\-.O1^EWX?^^V9A
MKBE4JP35,RA71WQ0;)0M%E;@74]R('N<R]\]&P;2&A'O9E*TFE#YW&XF1JH>
M1O+>@<^!)-ZO[W'NSU2'\3%E0=<UM@,V(U6G& >9Z&9%Q4@D$R0J8$$-0IW9
M3:N@Y#AQ\RBFEJ46Y7H'E?_=D?MU?_5+)L'OE:^=R&^=A)^04KC*SRS\T7,%
MO<>SD?S2 1IQY>:>[X'5C/?4QUG.]Y(E/.*ZTC^.2JC/;YW-,2/4&:KO*C@^
M"V]OX#ZP(\*7OWYCU)^?[P7%B<"S/2OX#,/R>UQG#ITAXMW"2\EI^<F6;)6_
M#7\_[1QH:KU:R(B*1V&$[T1,+WTNZ RS,.G]"=MTXI%_8F=(KY# -XS.[HF+
MH9"'HPA#LJUCY/*XL>LSUO=/\"$I$;T:!3?FG^_9##M$5.RUX EX6S 6V6N%
M+ON&/09S]S\P<L741@R'CET?,>%AQLN5H"KU]K2CNG*HU.F,==R3WNA$%1V]
M+HN$P/6>$7/"I>GZ!3.;<-F,[UA^(Q [O07,O1/\FW1H%?;1\EJH2#^W$C64
MKNZ8G(=Y[Q4Z_GI0KD3+]T9,(M>SN4M?,987^/JN[!W>\YPKPK M*./*U G1
MR+9K!>P&G(SH@2?Z"N/YM3=A6+T)]1!F.@S^OE/87BU=G=:E9D$'C[8W">9$
MQL!I)4%5;O"(^<"GV^X>EBMR;39&H!TF%SR!'8:8/94:"BN;2^>R6"'6&BI3
MESL%SBWX'MBY\N6QA+ZJDIHOP[D5/\IK8<:^YV G@K%X/F_*;XVAL-T>Z@<?
M#WN5V0H"8+W^RR<*5/A[-<GJ2:X_C^.O'*O4U-Y88 9JX<^D60[]@<&VMTFP
MP'E.;T:9(/\,FU30G3]'>'/EW.HL%$Z7-Y0%3;*A\5QY*K&C)>120ISP R=Q
M[EG<-6'(1=V(5-3%FY5BK![+G>1;@)&I+\#=$"_>P[S!Q?:9ALK4:>W6 _Y(
M!GF#_V^]N^ _&XK!VENL#A4HC858NJ!'[8X<W_!7NWVL]UASBYNQ#$.=/G4Z
M^B8D"AE1\=C9'3YK AUY)8UHP@"YL$JKM?P>O9"9/X,%P_=@?5$^#A_2"SR@
M;K'E6YV!J2;PEU?ZC+X0,&$NZ9UPOGRY+,>RN+P9B&*;>HY,.2EO1K:<$=6_
M'@P385V=^YQ7UHAF!&>35@VWGN?YR+U0GXPM\2^JD)JZ&D=;'H]18GDB.;M7
M?GO7$+^("Q>FD>*I9B/,MZD>(A)3VTKK.8ZR1)&;M+S I9+&")I4-=OT;+8;
M&)-BJ@8D,YMUV5C@13H6N-S%4XO,2I)/<@TJCT)N5[*IZ]P3YF'&DG360>(C
MF"-D!F.#S4!9I+ +[.$Q$9IIMP$C(^;D!]!J-(6^#D/U]\A# >AW=YHUOQ*I
M$8V\([9,.8DCD7)N0*Z;"$H6+SP52$U5;C $NNW.)ZF-Y4CF%#0"MW!)&V#7
MA5'U&XP?AESIL#DPIHALB?1)HV-0NN!D93:F&A+Q=/LX3L26G[ @(/;6NWZQ
MU<T:-Y3)$*2L49W8Y8:XFSH85FV"!U^J^>,XOL(.O?(G_)<OVPHMA';--1-#
M8WX;'UGA$T_@"6850POM=A=\M/3DIH\VE-,9,6G$887>"^':V$-0: ,5=\29
M ^N]Q^'Q;08=J -,/55JO[Q5Y=:;^Z+/Z"@*N(X'OFV#<FG"*C4XF 78E:+0
M0A85,Z+R3]' ?E0'H>)C*L6[HH4$Q@96EX&Z*0SXJD&]9%DCH/J"V$@Z@!6G
MN\+B1C1F=?FYA<F?0;\_R80/E]+B) 0MG1&^\"65E:"!899P1-4VGXIKC%PR
M47W,+X--/BB8SK,*+;IT2E9)6M=6I1JZSYC>]XM,&;!9;+"7Y;?'@XABV39B
M/29O;@)%J3C*Q.W[#$Q;CJ7[<SWH]S7QU2JD1DP1T/<W*\9Y><,*BQO1F#IC
MLP_#3>Y:\](4SH;\#!W%!1NW\6Y]W1W?!*&I'EUQPH)R8Q62T3P43]+5I["J
M[-Y\,KL"40NEQS%H:1] 1B%+3(**]%MJ:414Q1)%?U(695P'8.BWF4MIC)C<
M^F"](_ 0[3YE8DQ=HFE2<7DCFE-G;KU'/_#W*77Q<EOFJT>*PRX;X;W-7JJ1
M"5VG+5_G8T;+DY6:LC-T1<O;\I4;O;T1+,<AG%##6EO&N?1O/ZW%Y_7!I PR
M1'J^F%(FO8=BN$N)-NW&A6$L):?*VHP7Y#?LT1FQ[V&RLHDG<\@T\<52&B-F
MMM T3L3'-3G_Q01&M"<(Z7[J<8&A-KQ)/%A+;$1#2W/QI7O^./Y?W\-K)O7G
M,S*B Y9[-L%<L;+) VM#U)A;[ROX@.R9$0%.3]^')<-^'(^Q#%\_8%%^G&FS
M0HR-AP[Q O6A@3-DJRPKY-YZCB]#_)C?">>C9K.U(K41:@..CDOFT)O:J.]J
M,2,J/YP25B'I+U/,B,H/YO+ @MMS%H13-J3#*;Z@B&F T%$9T;1;>> :N7ID
M<@J:T8#-S'.*>-N3:2AD2T9N98/P$BP$:$)8Z4<6'-AYEJ>"IV0>G8V2FT9\
M6I9:79N/ =9]F<D0& L'FD3_6BR,&")1I"S$*U!:O5.C(]N.6U,C=R(T=H,%
M'-R3Z('&5-:1&8%9[MB*$%E^2.P2N2YV+EXC30P+1H?1RUS6C0EXZ^FL\@DC
MT\X5]1FU,7:XO)=BN<+DKRQEYS)K,#%U_T"E[!);8.<2<7ED6?XGCY@ND(OE
MX?PX;UR^B-K<<_X$8[UB(OHF16QM8[[&OGPJL3[(JX1F??7FB#A1-L' '_V)
M;3&DR[2W2QA8$\SKY^ZO)<*(7(9U[_AXH-X"6HR7=W[,95;AVUTZTKQ"AL3=
MHU36BG&NPN(F7&/38S,"C&V-)Y4I9L1B] ]IUE&O3Y_!?+>ISX2Z%;J\*1HB
M(QJVNNO GY9I0<&AM6C3/9RL"H=J;3Y;'F&;.LIT47"@*+8%4_L943N;'V%J
M+O&M3<U<H[G - Z.]97L]3=C]O8^] "S!<Q>"K["VY963_(6$A@Q0P2?[^OE
M?">PXL'/Z@Q,.=RY<D0.*OZ$U=TLR^M#PG%9JL#UF+R]XA;'YLKU5T]GAAJ#
MBWO0[CSZ(MS^TWO$N<6-:$Q>QD"T/J@?3G@A45DF;#TF;QW/*JLM6!OX&;GA
M[-FHP6D6;YXKE[Z3[L)_I;X(ZK?T'!_'#UCT@ZMHPR-Q(:'V:M#-"3##E*N7
M;Q7<=3*!QL.C3&;\9K)Q*T@Q]0!G3BKBHZ<[4%-*8\2\&=ZD5.FZ):,JGG\8
MYM%S7^.S'"(XT:?)-:O/Z.TMD^'3[2#8C]!LCV?*&8%=^4;@<JK=U-9B*4<3
M8K/Q!=2R X.K)\<44).Q^7CV_(88D15=N=(ON+VCQ.1>E[&I\_&M+;U]JKD=
M(5W*#/7/[@@_T.6><+?V?G(NM0D1S@&>H_#.7$9GEV Y ]T JX^H=CZ!5P2>
MA.YB\GH\C  X-FOT%D).22.:D+S16EZ5?X_8#RQ42.8;U%A]@\P+-L!T^#7@
M9$87-(U+]GPP^*"P'04BAS0=HNSQI$.1OGJI)Z[!;%8',+%\^'\8%:<IFU9-
M(S;N,O>7*_'J:N$@(G.'?,^>#FETQ]-RAZCZG>AU>+Z]S2B-^)-V)_BO&UZ=
M>M*N\&V0,BHC1JJLTV'[4Y3%SCF9>-5RX,NHC&A:7H0F/NJWQ@6,A3Q,M??2
MQQKE/:W\AL+<@S@,191SFJ/L9I5"<B-0;SRGJZ?R)G^VP-&T'D_BFU]"-.),
M"8.5&LQK6=M&:4V0LW8R0![X>,Z%S[PIFL'J/'HM/.!3EOQ6BY$1': -Y:P;
M"C(G M0;WE<%,Z>D$6CEJ9<Z/(A<^:TZNL"P,'B!;-W=STU8&=$)Z?$4SIWA
M)@,=$_EYAS7NO*S,SYRY6D;HY+Y3&(CBX17()1L0)32FFC/:--SA%&1-IC!Z
MH>B$H>)M]2:L3,WKS3_X'08OU:\A+NF*JN1O/W_7NL,F&L/1+IE$>J!<3KDQ
MX4TV<U..7LK/=>W59SFY/07\/O_R+U!+ P04    " !X. -750^ZH 4:  "O
M_   %0   &%V='@M,C R,S V,S!?8V%L+GAM;.5=67-;MY)^SZ_0>%ZG8^Q+
M*LDMQ\LM5SFQRW'FWGEB86E8K$N1NH>4E_GUTZ!(F]HI$H<Z]L0IV:0.B4;W
MA][0:/S\MT\GDZ,/V,W'L^DOC_B/[-$13M,LCZ?O?WGTU[L7X![][=<??OCY
M/P#^^=O;5T?/9NGL!*>+HZ<=A@7FHX_CQ?'1XAB/_C'K_C7^$([>3,*BS+H3
M@%^7'WLZ._W<C=\?+XX$$W+]V/JWW4]1:+3.62C<%5!:(T3'%$@KF/>:2^O#
M?[W_R3LFF54!I!025$P:@C(<+$-5HO Y6+'\TLEX^J^?ZH\8YGA$TYO.ER]_
M>72\6)S^]/CQQX\??_P4N\F/L^[]8\&8?+Q^^M'J\4]7GO\HET]S[_WCY6^_
M/#H?7_<@?2U__,_?7_V9CO$DP'@Z7X1IJ@/,QS_-EV^^FJ6P6'+]3KJ.;GRB
MOH+U8U#? BY \A\_S?.C7W\X.CIG1S>;X%LL1_7OO]Z^O#!D^! F,Q)@%T[Q
M;#%.\Q_3[.1Q??+QT]DTXW2.F?XQGTW&N4K\MS"I4_GS&'$QIPDM!UA\/L5?
M'LW')Z<37+]WW&'YY5'XL/@$5?+,2%;)^L\MOO7Q5])3F*2SR9)3K^CUZKLK
M>7W- C\MD#YQSK\U&9-9NO#0I$IOUJT_.0D1)\MW1V=S>!_"Z>C5.,3Q9+P8
MX_S)-/^YF*5_'<\FF9;:\W^?C1>?1\0/YG,48'7(H!)JB#)(*)X+K442R:J+
MO*SSG=.$EQ@H81Z70%@-^+@R^3%.%O/U.TNV+UF^+4WGC&\RYQ$7DLO"-/B
M')3@!KQV&;*VF)32V5K9W_0NSF0#1$^Z=#3K:,JD[1X=?<2JF5:*[YR6T*4K
MZ+JXZ%9//)Z?G9PLOQ/&"SQ9?[YTLY,>D;"8M6'YN4AI*OO*_)KY:,4B!EM
M*FE!%:O VU"(&*N,M=XHDQJ+_BXL7X\ \3T@8$\!- /"QB2?GG4=.0DCP55F
M6!3$+ 4HY0*$P")$QIW@-MM@2G\Z8$7%OO,BL['H0EK\@SR=IV?SQ>P$N_4H
MG]<S11>4L)830=8#<=U!R$R 48+%3$LQ<MYXIMO0-5 UN L^+L.^N5B:+80G
M*75GF"\N^M?5.=E4UM()IH51P*0BTA0OX'S.($)VWO'@0S:-$;,580/5FRT@
MTUXPS3#SQVR!\S?A<X@37$_5442$CAD*=#QI<4P4&=4?.0?A"Q?<*=T8(=>0
ML0T>Y+>)AWV9WE)CS,ZFB\NT6"]Y0.U)9SD'*G .GM&_R)M+J1A4KK1VH:^G
M9!L,J&\3 PU8WX<'-<*L-"(-R[F7H'B,X#--3"27G71H.89#A4]-?$$RP#0!
M\DF%B F45Y+D@Q:R"3X)X9W3^<"^X&#\H7M)^Y8(<!=>-T/O,RQ(P^>7TT2^
MV+OP:8.P/Y T*TW%&_10,-952I2%H!4D+S5Z+TF]MHX*[R!IH*[.7FAH*85V
MBFTV??\.NY--@SM*CLO$H@2>C0'%?(%8I ''A/6%3' TMK5"N(:.@?HW^ZF$
M??G=3/*7O>L_9M.TCLV066ZT@(RYD(D-#&J.'S#(*&Q(-8G16/XW4S-0#V<O
M%#3B?4,#T8T_$ ,^X/5$I>Q0,B)%%T^!EW$"?$@<)&-""Y^,:)Y#N8.D;5"A
MOS%4M)1"ZY3)V]GG,-EP9"@\WZ",DYMOA(T@N2<%)H6"4+V:Z$-DWGD=T?>3
M,;F5KFU 8KXQD#271SNDS.>XH,EQSEE"\ENX0 K3"X(+*4(B_R47$VU!UQH+
MRY'WI?\MSA?=."TP/PWS8V)H_:NF[3^$"3%U<R4RDV(V/(/.@H'*TI'!-@F,
MQNB4TJ'DU@[2]M0-*9+: 1.7 =^36)K!_N^S6?XXGDQ&KFB7)"TZCYG\]X("
MG$H9I%$R9!229=88%.NQAQ0N-1#Y3BS=6Z"U'F+TIIN=8K?X_&82EDJU NWT
MY%S!OJ;?$ >F[U]AF./;RLO7Y:\Y+F?\I"RP(^5\=E)9C_D9GG:8QN=2F.8G
M)[-N,?[?Y<M1$J1_+>EC7RSA5+ $/@4+F+,// 7"["7U<;56XV#4#BD*VP-;
MPY1N8^.[SC+)8I@A;0?9TN)1.EH(O$3B4DS**F:4:YVBO$# D&*V!OIH=^;V
M)%^MLG,R:@A8-%!$6,#;;(')8!4W/F7;?(?R9OGNL'%_K25_LG@:NNXS+<'_
M#I,S')FLO78&H?!DB=&J0%1)D5,KI#29FQ*P\2RW(FQX#M8NN+BR:]]<)FU3
M56\Q(5$5)\MLZ9?=(,Y+45%"3#[3L@X:(GE[D+0NUEB:=6F=F;B9FN&Y82V
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MPC*./JFQP+E65%$'49LPUGL[0%DOZAE_!T)))RUF%YOW!;^>DFW08K\OG=-
M)-_Z"9BD+!<E!W!6UA.V7-:JF@(LHA+>NMI<L3'\AGL"QGUGRO ;P%2/AOJ\
MG=)%)Z+ZI%>N11L9G6)!2YZI):="T6('Q\E'38F3F<BUW4KK1; 'N=L@V7]?
MBOI0PFU8<'(UI/[J@#RE]39>U-6SR@K6DQ3=/$Q&0=20.EB@J%J#XJ(N(E?
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M][U-Y#YR/=C5-)OW-0L9G64%*'APH) B6V])BVFK"BN&(^K6]_FUO4_X8%T
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MH5>;=9_9-3)8YR;QAH'7=4C/SI!\)\=+S )L$:;6&&6(C&E(+GFA,GD\S?O
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M)9 ]Z2)GW@5BLXXBA: L-+\\?1#0-[R5MQ=X#[>/=S MR=X%U#;[^C8.W#I
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M<H3:\FT4];#Z=Y#R@9MRO$'">8E[A,#>>4++"-B'P-T)@ 4N=98()G+04EB
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M&!:KB6)-3L)9'[3N5('UD="'M8.?C*761KSW]>WWTO<2Q^_CV4=,Y$UA7N6
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M$7/>1H5',;Z:B'F-WG:041^OWM<)\9!BB&2RQ!1H_" \BR(5)D"BP)K9>K=
MV /:.L)KUI^V=I-1ZQ[Q%8D5*]Z07RU=+IZADXHFE 4+A3:!6C$V!JM ;+$\
M7C_V)!;%W834PUW!O:!@^KO%#IYBRA[II9>9ZWH\30Y<@MI/4Z829 );6M>]
MW83E^W1ZFFJHA]#M=;B6KT879#W=_6]&=9Q+^S;:ZT")/41_H&5EA3 I:WT&
M%BR2:X"\$,*06=;>!!<2(F_=+.;0I'CD:OO@G-A"XLU/JN_ HOTT+B]#S\K;
MRT3[Z>J24@67L]2&*5<-%^]KZI*K24R"]M(HP[W.L)L.0SN/>?A[Y59JFO0O
MXQ[B%^\B??GY(Z8YYIJ*M$2873 FU2-Y&PO3$3B#@I',U^22<);^TSJ YG%4
MWSQ/>E) WZO%6QCA[)<)F50PFY\C_//:QW'2UKH<W%A9@WIS;2-96-0.+4\F
M!B5V6BHV#/C-Z[\WZ?89F_IPXS2IN7'>U-U1<^(I>N8E[9C&Y)"M=H[ ]A?M
M?-H]--N$/;?2WGV.V</V-^P"]L\>FBTUOE>CPUW4=?0>FAZE !":&1XB@3;
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M 5I/QO\#L(YC]3=28!=:["']/C(:'H!(*YB'6 N%.ZP]56FG\IS>B!(3Q!!
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MSOEX[0>_^IO9V%">T>_-8 A'6LM;;22.22#")*F$\U'XVMDQ]]<_@D'+^T3
ML)(F.N@ZM*!EWK.Q#34=-:Y]2,EAFM8^7S-K5+R#6+M7-@V1F<PR$0[_*%$"
MXG.D) ?N2YN [*Q[@4K>T)NV*QUO(\W:TRNNO@"G3!>*YMU2A;5&&#2L)*/%
M6^"Q]'_ XTH:IA30:&-HY8L^^NC]V[V["'I834H=#-J<W2>+4=Y6AYAL-"1&
M6D(IB1(K$8LY49,A&*=-[1>+!P2<]Z7\?%UTU1[M68*X8V.0EO9-&YXZNMN[
MX.<P%L(.,-G6G=Z7C@_1R_(YO%'+$X282>!!XV$-N>SN3%C(SDB35?;J;'&[
MP>@Y<MANH]HNX'J7-3<W# R5@2HAB:'&D%GK%9",^."5B<QJ%^K/<5DBX@@#
MC)WK=E6NX[,54[W)]*STL&%^GD2V&%OHHP2K%1&^3"1@3I, %'>5 :JRE?E1
M%<6ZEY]U2YPQ&"K*OK;?=3_=]H_^Y,O?_>B?,&F(G+=Y?#4<I/Y]<I%;YQ"G
M)):>NU)373S.2'22A@=&!=,M.^%OO?;98ZA;;=6>07B;Q=3DZRTR^5 6;SY]
M_+B@+WGAE+ (^=+8Q6@@EDI/4!2*.QI3@'89/RT6.W?XU-9'Q;;$X]&D=UF$
MTIAW.8 (BJ+?RTIWQ&@R<<Y%(C+SF=)L?*)MC!?\U'N&"WYU9[0\6/ \ P?/
MEWD7BI_CKPT9V_CX;2!0_W38[([O(/QE]>T@N8KFQ#(YSML@DHF$XY*%'+QX
MM%,DI< XB"RL;>7L'EJ!:_S2^OK;1F"5]39/PES,*3,\6FLY7B@*/10#DC@N
M\'Z1EG(G>$RFAN8>++J_JWDGL0]KR*RB5]<0@J*Z(R08[V-.E@#H0*1->'^#
M*4\#AD)*V079RN_?I+S[B[Y Y3U;9AT$;YHZVV*5^<ETW!PGP2?.O,&3Q'F.
M:**<(+8$,5PGX*4!"M3N=/.(B/.TB>KHI(,Q!P\(FCL";4CJZ#UD!3F'><[8
M45%/J7T'*7=]2LQ),\D'#3034"D3F;PA/J1(DF4B9,FU9K7KV_>F^ WO =WK
M?1OA=OH"M3C9[@Z^A2._N 69XDGAM<>Y*[4SJHPGYXF(E(Q(0;M$:X]I;D_=
M_H,N.RMS[8-154U4-@.O^I-R:;X;I/ZW?IKZZV93,,:M"TH1I5RICH4RW)):
M$E4PEC+&5&R5U+O!'%RY^'E:$'5T47&BS4J"2O3X$JX;>8R_]+]>#=\,)OW)
M]_EV:4-JQ2C,EN3M/U)30:%/P:,#;52.$&Q+,@W!T1@3\=3A99Q":=+(FLD?
MU)I@DW"MBB-? G">B! =%C?;**$R7E[W1Q#QQPL/&YQ/*DGBHA9$:N3=2L6(
M%2RS+%@,[0JF-L#AX:K[#4MTJIQA%<E63R?X"K&/F$[?^N/AZ&IX]07^-BQ-
M#.9/228B5P+O;%V"H@8YM%%">80TR6;%8'FPZ;J'XB?7.3TUUQ9N%][)-(S[
MJ>]'WS_YQM)JZC^;A'3(U$CTP'3,"$@F*)K @(#,21;K&*VH5F]WVS@CZX@Y
M3PNTKHZZF#YW1TYYUOZ0KU <8Q^+:!;U)BTH["K5=R-UAXET55+G,DBZT447
M1\YF2K,S2N&]1]"K-T1:F?$>3)K$G$+@6C EJ@\?/!!:-H3'#@:6;510.YFM
M37X+I\BEPRN3N5R&(4A';$FV<Z7?!P /-/I61LEQYAM55M"VV4/;2'>M-?H?
M/RW)ZSU^V?R@^7Z1QR7DOY3__W;Y[E9V?_[YYU_]-W\]+,7Z_BM,)_TX_FL<
MWOS42+ A^]%-O+BIAS.A/6I1-Y]&_!HFOG\]?DCZN(\2@4U@J;+N3W?L/Q3+
M?/$'(-J[(.!_)S!(D/[]+_WTG__>!X_*9\$Y4;HV 5BOA%2:"H18C)3UJE!P
MH*X@[V\+^65(BANCB3!-Z9WUQ'E7[#.AN$(C'$_3?5=S;*1Z3]/68W11L10(
MYPG-5@<H%L\%B=&HR%(6RK+*LCGA:>O;(.V9T]:W45@'=:3U'"8>E*11.^)U
M0+_8JD"\E(*(2 T#*Q-CM4O"S[&+R2Z0/(RRCZ6+R;L!WL3-XV3SN>_+/RA,
M-[8Y33J#S40[Y4N(2!)G8R  BF:C@,7J+5^?(.?E1T^VPL>P&SUUX FO(6WA
MKK<@KJ/0R9.$'29J4DV-[>"Q@P[V#A1+.>=()?'9H[,6FIQ5[DOB:BDJL0%X
M[4CM 0"R(5!R&'QL(_H.<%&ZH>('?KD8I-?P#:Z'7YM<EIDMN'A@<#ID)QA)
MSI0XD;'$@<[$JA)V=H*'ZLT\6I"U?_N]HB*'W6JA"[L<KO%'GW^& 8S\-1)Z
MD6Y0XN/)"(7P#>:TCN^B/Y8UM0^B5.4G$<N4%D$R3T'C]E'&5)]8N V!IP2>
M[C2S]KPY3%QN5NYZ$9&K\JK:72!N]4+[C+RU8'4IU*:%C%X!6K922P_)4E!2
M,<=4\N"4W!AJ6[WDP6-K2BL7 @4BO2PE\9D22]%[$$*RP*35C$'MD^3@L;7G
MMZ=]-/+P<GA]_78X*C_L^>@%]VC 9%8ZU"H\8"SZ0\2;C+=']"SQZD/0.N'D
M1<;NMD%RAV-CGPN(+FR*>ES-)T)3FX/G:!]EXS.1*&EBD[)$<-!*,.J,ZB[_
M_?P&@U=$5^?#PK>!QB':B&U@Z.$(SI]'P_&XYPRWVF5&8I-'1E6QZB(M?1_+
M-$3@4>V]B]CV;/S ^Q' XQ"-'S>PA(Y+?S1+IKP=:QA *!N#(1(L.L%6<V(Y
M\L6MT"P9%[7K9,1W739^(/X(X%&Q<TEWEY8QV97@#O&A3'IC,9$@E2%":X7.
M7<2=?<06^RI[YA#G2#,[N#P#S:6:@Q.(3D]X*K5Y7B3B)!5X.O*L4P2=H79.
M0G4F7M 9<APNT&XP.$*+\-Y&^P/ZG[],(%U\@Y'_#(MIV<VHU')>Y_EY;<"4
MS$Y#6(+2F\0KXH6CI4Y:IJA*UM^Q 7][+G_LC.,"TA&:EBTY[@FIRE!Y3X0I
M]HTO$WJB<<0:[Y73 #+4[KZR)]9>T";9$TH/LZFV@MA1=3=?Z7@^R6KB+H<B
M?Q,5E$PQ06R&B'Z#X#9ER1WL?59>/?9^[*A==]2!H'94,R_6.[=/\NM4\"$H
M3:*-BLC -)XBK+1 ,Q9M6N8C5._QOF<>?^ROKO=7EZ [[FC+DVPRHZ2DKDR8
MX'B":%M,<T"N>391:ZLH?:%.TZ$U<,\E?U(#U !'7UT1R,+C&4X#<4P[ CI)
M%US(U-9.0-L3:R_H4#L.7[4+R'1U-CVJ6WO,9EC#YJ_#P3<8(W-+3#8FT&L_
M@;>^/_K=7T_A(I1$KSCI,1U<MCD3DW,YC0TG+@A.:$S)JI0]=YU8UWOE\CSW
MR_$"J8/VIOOCN,<E0S_ )L(XST1"TR?2<@*2&\.9C:9=>^NCW#('VBI'C-6#
M;:VM@':$+PU/.MXKV!4.[6+N-5'":8*.2T3'(%C\DIF0A7 \'DT]]/-8_+&Y
MVFRN(X5<[>%&&U436JKFOA_>YEBAPEBM32!1E6A!4))X\(RD\E\$JWE<NK_6
MM54[$ <_MM&:;?1R</6BG:>>IU& 0-:$-"4Z; 2Q"AS)6D&.U#M%J_<(.) %
MN.=#;;VCOD(-*AN5?%+E_<L2Z:0B-BI%\) 26O R*%/NY2#;ANJS\46/&P\5
M^V/7,EXNTFSRHK]^W1^7CA+3$8QO[P.O@263$U%&4B(Y".(E)&)<CE*"!YNK
MM\7LDJ&SV0?'!X\N.G+N>#VM?WJXA*+<V632AM6IO[Z"T0WO!096J! )];08
M[Z&TZ0!)F+# I 850R?^XG[9?$'[I#Y0*\=>ND995T&8'5A>?X&N8YGU8M29
M0[0D.!%+ABM%KSAF(JD&YY@127=2/+M?-G]LK)>#LBZ2;2HVB;*0';I_B<=
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M38V7CP^Z&+<@MZ.6^UN2>IAN^A64O%PEM0<-== P?UNR/7>*>ZU)Y!%MD9B
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M;XU5-?]V^2/@+OFO?_M_4$L#!!0    ( '@X U>8[^9V_C@& "8-"@ 4
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M%W-MI[\1_3["@&/P6P %V/9;'$A0X/B. QQ'D=G!=[Y>Q@&4'PY\.=(YI"$
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M'Y:3Y,%-@]AOFN]+14KG4 K;KSL*JFDENWJ(6_B8%&9HXKJ"V07W%0.&#'"
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M:K#K'>0GDKDOZUNA2>S@5$0T2[) M+IZ$2T?/%Z#0E59M%]/;'=&I4Y OG)
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MV%1$WLO.*S<:GS 9$KI8^GE9J$(@@=./$);6B@Q:,)OGED%34M06_8?%_%7
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MVVFS*^#]'_0*J., <AD'=$QW$3A0.PPYKAY7?V=5>.2^]"K\L*+P4!P?/M1
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MKKQ0#;S:9[>)B[$/[:G<KCB<2NVXHU9W?X=>%2&6UP<N#VGPR#>"A)S'EG9
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M@XJ\%P?2E?X>;70)WK/\Z-?E68IN8072SYGVP$7W-%K%$5!YP@B4R87 /^!
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M".AH(* ._YP1I 6.H+:EIXC [U?T>-S_)'PWZ>._O^DW5( T/3!W^FQ6V>,
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MC?JR6T $<B>-*,K&O[>_RKOC<<<#*ED8S=T[*,C48N).BMP7G=HVU$TRP3W
MX]UD7#!!F</^=*_NTS$IM?K)7@X+<PS_>*Z;WQ@["+->)?5)A1S\J4G)SYW
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M'O'5P_WKUXW SZI=+AM$-YDDI;3>-"E"G&3]HRPI(S;2BCM+5GUJ95X&WO/
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MV9GM,%46FK@T"@2E]7K-5I?1%GP"7GUK^^U,U?K> G)]QQ=5ZH-1.EF_UO4
M:-VZUKIQ]1+68#6QM?;]U'1]4O\C?*5$Z\GW2WN3RAAM_RX%T+O_Z3RK<>XZ
MXM1+_*2OI"X8A?1&ON(&^R? S'M.@4)]U)EWHCT1D)A ^CM/TZ*NFD2=^!R\
MV=.?;7]^*>;629\T>LP(1LX3XY=[\OEN#(Y%*0Y?VL>4XQREJ'U-"-G!?L]4
M18Q-UD:.69&D.BU7$#S>+_SN=EV_4501>JZM(OG*LD6:J0H;$ZL<'3B,+\@(
ML )D0-]0S('40_,W:#ZW24M,6UPX.1++E7_3*J&T]D/>(W(F0,A$<7A'% *9
MDSZ!Z],JYU!@T*&3Z#3S%H2YZ&^DM>N<4>ZQBX_AG?3A"FVA'%K?V[(TVCI=
MYBG9C_HZK36LH_B5@)K1OE(K7B6U9#RJ?N[44Z!TP3ID_$7!?/(G_I#[N8V5
MWB)/&/;LS,]G%;1CJ['1F9[9HG^[COY?P\@ S<[42+=SG^^"VA$&(P:VFX:;
M5V)DFWLG"!6DU/:!8Z%Z$?@S'O1"+__;Y]2=$Y6=SFZQ#1"ZBI+R;D$NQH],
MZJ+@!VB8$[:,I /&6/T["1IOWM\84R'I ++B)=_@ASG<N!_FLO(0,VC-FEM-
MUG,^AF=Y<$"M)W_;Y_62U<93);4&4ZA84L^A$SCS,#.0VPIG;9#=9Q)Z)G59
M6[8BUM1I7#1^Y>ZY>)]RWMU5&2=PCYKTEG='#MU92/V'N=@YS>I;8\_,%V/*
MVT4_/"\F/\/+&&Y%:7_0PA+(BS^!%7D\=9\SGVFR]P-EF'VD&=7'N#,:SHJS
M2X],)=%*JJP^+9 W2+?R+SGK.W[^6VO+^3WI338$"[,)I<W!#Z&.WV-&;[*7
M@Q9YU''N\V5126UG:?TD/PAYY.NQ11IX]?OT*.37?KH) H.#=IA &],B."5(
MI(+?O;L1*L&B9BK)-I'\<7T6BFZMY(ZB>K/Q;(IL@%]=,%)\ 1Y!!+Y^3A"L
M'>[A,Y\V\ FK2DB1Y-<O,1QD9EY)M4HE!]?AKA7X50;@-L\6:XYC7K]BE[F-
M6/4,(HO7?Y/7Q\++Q!P_2 5Y8P1)0Y+2P-"00RB!<6;_+LDR=C4?RI/BFB]$
MH(7P?6$<#4-^;*+WJS)NXL@O=VMDTIXWE.M'#H=1^4108X8Q,IZ#_KGTN022
MD6[3("00 6K60[EM^,(,X:E_SBI\%AJP]1W!\_R_71$<C/LV]SB.V>F7HH_S
M\B61I!I?L167X8:EWJ(]DVS#-00;O H>Y*[&6FC@7J2SI/_%;<Y78.FBIZB*
M]JU/AD?%Y6OW_@+U;&V^C0H9+PS^R>YVEDJMZ.GP>Z4GIY:B$V38=.R&#96[
MF$'7%D1:7*_4H#8>LC#^ZDX"7HCV&[^828]D$]^\U:RV]!AR,PS-CPN:I6=!
M7HQ\2A"=8Q!+=WWNM]LG /OL\B23K,A\TV<6*&KP50!]A;%M77[U#'=#0K+9
ML_A"PWOWR\^^]K-Z2$1X>0;[<$]8TU@"/ _GI\0QV>+EYURGJEVB6]X&;:1>
MHYGX=%EX%% -7"W>T];K<P-^6H>@(!FM^R9O' X$9YP2[40UYQ2['S,B9L2Y
M2A8SSY#/WIM$J 4UT>#BYMXM%K:_MJ]+T(;>KQ?RTKVF]\AX;9#[&CE7<.,3
M@/+G0%WLV_.PS]OK"[?-]J[/]&JFW^I]\H+OB3]4QK73W-\>#?J1 O@;;@C-
M'A"!T]]*[[XH]E62K7[$;4<ID\CC6QD,7E=>B3^IW$V*UBF0Y[!QP5<61O(8
MJ=GD,T<;9<%@B?6!H$%*#VI!NJ1X>LTM*%YXQBWDX+SC&+)UQ?U >"I=M6(Q
M<,<'MJP\4^?;\P8-"_DO00L\A3O'D008<Y;MM0).;31UF*'N"=.MT,0*-M^K
MPQ'*)/?RXQW)D.WH!#>1/(![E+5)ZHG:\,V?'=GV.DL)MTG*+CTXAY&3'U3)
M/;FSF[XEN1*C\/75#QQ^S&R#ZV\ >E*]Y\H75);10KB'6[U7YVJ&[Y,S]F*M
MGE-2RVC[VSO-+-GFOS;%</(&=0N@Z7EQWEN_.E%TPCGKBA7ZB;<LD0EL$[=4
M!:UG+O#.UH*Z3NQ((5I CEO0FQSO4@O]8.\WU*M_&?LGT$M$5@[/UDO6GK6N
M;Z3T$=8,1J@G+=P/)R6TCAGM0Q'69X4O=NY MGMKQYI]?)(%X$BWMJT!TO]A
MO[>C6) FV8Q%EJUN">)A_+H=^I:I=K5Z!4*U)5M4;%STZ?'TIKC(+1KX:6>S
MSV07K<80D>0=+)JFC&SG@D>OC:JPV_,RUE.: 3N&U,X$Y:T.LL^B(1T5; M,
MZJ7I.[\L+ ?H]'\8+<6?5&0  )Z8+3M]+/^DGG=9K]ISUM3R9?Z)E)14!-\-
M]*TLO4GV6*4S-*%   6 W,.*MTZ+C-3H??]Q1OX$9A(C&$=C)FHG,3QIJ]Y1
M2->8X=0J=I(*0C%?%CXMA_V>0IG?^,Q"3EZH1#L?7S!V2\6%C@C0RE $QZ4'
M@WX8MM-';"&E1P8JXAE>"59=G&DT#FB@6V<0$PL9E&F,I58 [<#;*%%1@:+G
M8EK8M ,2PQZ)56SH,C.;3EZ)1L:#*80J]<B/3O+VGN^F'\4*(U>B%@Q#!B)=
M&6G]$X39],09(^ZKLWE'>Q^%8R $5,%/?':W^ 6NX*>>S823VW<KO66M0(O3
M-A%.7OA-+CL!M86GP(_F<<XY?)/RAW%:!VE/KHH>)DHMNI9D&X-9&X&*U9.(
ME0K2F@@F E6QA2]6XV_<\9E7]6/KUDMA2[MRD$M^N8MOMT[9F#G8D(:4!V/C
M0G.Q]_-K61'I!48G1VJ"R.7*87EH =Y@;2H!7C2R(A_)B;W67EH<'K.C/6I]
M]N:D8)2*L5U6+)LC5[!)*DWG97/P>5T<^+7?=R/+(48& >VX?KJO_=C7AFD<
M$UE%)V6ZS@0O898'@(!?G=\!5%O BS[;@M-FX\.JKV=?OZ2"E28D2\AI5LPU
M?0.VW$-O4F =@Y?#IP2V7U[?5*J_\=D]1>CTU<1^(N#YX,P0ES>"<Z:ZL.7N
MT.DIG2+G1XDJ,7:I,L9*0KXLR565I<A\OIY)LM=*=.M WKP[-:YQGKMYM(8Y
MELHN<C+9J<Y*-TJMVB:QO$\90K#HR$_C3;F02Z]Q^ 1/ZS_[[ISE0TVXF%FC
M[]^0*7OE3Y;X#9*B,_I_%.+])K;_8=FN#/+V8=I/:<[5.HZPZMH^YB:S88%>
M+M=( 17:4R=+/(/]NCX$Y1B2$@?Z[+?6!^K6:S#!&UXJO*?7O!W/F#F3-]XR
M#XFFZEU<5]ZK&!'TH7Q(BXB#XK ',!VLO$._L;]2@O85BR"G*>UE$QOZO@B7
M[T:Z%)5EVQN4?E-UZQ/S&5<.L[AG+<_3.KI^;)M8MN61EI!:STR%-XYJJ+B2
M/-$:$0"C'-E@W-":29GL'T6@W3E^"L3].+7$RQKQLRFS8F1S:#7P_*LHI#'V
MJH4YQM8GW;)W_?QI)Z_*H>IR0,*YC9(B&-S> (!SL77K;@3NRNQ=U3F^8-;D
MYP@[NB(EY4DA)'?NPE*K,CG:"U"U'CLU_^I[9.@NZX#@/(N%0%:0%UCV!&?W
M93V1]%;R65TE5U. [$LHW+'TD+,CYK6>(.74:W<AFE=\:2Y]HAHA;%8Q"W#%
M<[/9LU#-]P*+-]QW-3_BX5Y2"@85Z'8[5C\I!E5FN!P9FX1KFHU)^>1IM3ES
M=O<.5&5JU?R]NZ4'H\O-SN@;0WQAM]JK .3+D&69\:A2#JEU1P\:T'=K2B2+
M4K!"Z4/84D+!XX%).PFCS91%-HF2!S*#B!7X=8 4YHRM[3YHQGFBA)86X\^I
M5W607Q)07!!THY[AH+M%CUSA,H+</=#$2S?@XFYQ9V5HQZ:=.2.7:CHND$#%
MR3CHM5 KF^T$'&8WL4[BE<L3!['/?0/2DMD>RVW(8M#<7R-4SD^PD7S+,I2]
MV>'0 +/_"I/G*EG9*9U2K;L=P6FK.ZC9T5Z2:9,M^R.7OO#K7P>IRG/V0 <)
M;<:EI@Z;]W$(7A+7K7P;];*#-P:MY:&/7A AIU1>=6(?17+A_(D #1&X&-X:
MI5#:4'#O1EY6>@7L55 HG8=^T9R?$>@#+D+KTH/QNRIZU&IR6IT>;.+%FMH:
M[*T+O-&["E1[7V9SUC^5X" F4?O.LS(EO94OC0T:/B4$%U,*F8%V:ZDQ)CRY
M1C*XS@-!@WG5+TT?"F+(U[\K>,NC!44DNDVYXCL231:<#_*+:=#L>@=B=P/Y
MLZ$;KQ"7W*)]H>?\ETR5)P5.:;,8N *9LP_G.9V,03]0<7AN:/2ZX\BRLL5S
M7B61NV0<2BT.@U] %?&<;&JG$'$I]TA"!=\<J=MC-1O>2ZAVK[P;-AD3TST:
MZG"9TF0K((KR002&"*!]">=J1UYMK,1,#[+J.63EFR5$M3423),7TWM<,A=_
MJCT]VD\E=XK+';T^UJOA)YD;&;58;!]CE!!_4DZY&\(=1@;SP,:MNWM2O&]X
MOVDLN*/T3/^#0)OVAT9!Q/JH2[RNF1%KFLH=2@<+0M\T+S8N>7]@^2,GP<(A
M<=5IIXLV"=IOZAT)Z0OVYW0ZVGP@PYW^TK);[&"?87=33ZVQ O.-:]8A5D4-
M $Q!"(!QP;KJR_I/U-8\P:"OA_=>@.,CJJ?:KAC=R5--"FQM/'N#RKF.?X&B
MKC+_#ZIK3V'V!=8^LYIY,O $.,\;C]&P+]B3SYZ*SO:@[K)#\(@?J <.72,"
M)Z47W[Y-A.C4^J$C\V]/VL>TJBYH1/-]SUR(HH162Y/>$LM#4.U3X=4RL'\4
M>?V":YL>5T*E$EM[[![)PM/G_88]GC.&,M[2+G4OLNIS&;ZPO,GXMF#P:[8L
M>EATM5U%(/I0E'VUF1M&IX,]]\E(*>W^R1UPHH]#10,7'?Y5M7U0@RZYO9LV
ML$<$+ARF(!'( 9A!<GA'#R=L+-_)8?##8 6@).<*72/WMVDT#ZH'[M7"*X4&
M0TI;_1T4;O?29C@C4D8G6;1UXKGC0P=G)_S!;#T0!= 4X0.40AHF?)BT;DCC
MSQ-(!,YF>9.RC)B$YE\GO6.GG, C>,9GL)!;=QW/4,S6!@N+)Q8DGM741BAW
M+_!R^3!3[95U$H&*@4G6%PM:V<IY=&5L"4MZMA[>8?8Z@F> YTQL]U3$WP4]
M;:(^3/]YM;BU:,WWF:=;]ZJ9Q>WD:O<FA?YNQ1?K2='9N8"E%]H)Z7V8NHQ]
MM[9JID15V;<4*9 NHU&CZ';M@MWPM24Q_\F)?4G ^]N!DE](9WS)W6L'SW6Y
MGST:$'PIS-=OJVE4UON!81LLX,)SG;M1'_T LCZS9;PSES9.&-]JSEETV7XR
MP:DV-3;#@4+:L7__@%8A G&H*NZNV++PO,(>.E?!.\(6%Q^G(EBL6"S.Y=)H
M,Y] XSMC <4F,CS[)R2]MQ"FP$?8L$J0L2/1@#_,;#)GC8R"2HX1P4L-Y?2G
M Z7,T8^M$@%MK,#=1#U0W=V,'LU278<)N5X&&PRK@-_00&R]2#TD%^F,DX1T
M4@G$ZM'):W9TBG*VG*CK-\Y(EN'3\=  0F)Z6WA +P@#36>VY@SNBK=R&<M7
M52M=O< D<V7G7)BV4#DS\S4UY(3V">"!=*OAV'4X97_=?E)!9Z\WARCLH@MU
MQQ,75A>;8K$\3D%*F]>YW*@-VJVFE7GU4!\?5XYS5OGYO1;7G&*U>%UT5/IB
M1S'^N2>:0V T&:T<IDTY7MT?.I<W95-%??6WZ4Z;JK,Y\GKGO +\RC#N),7%
M-I5Z%ED:N%08++DRJ>5A1A/EXRMD5@O91*(?BH*__:F&<7Z0#?H#M9M(G;=1
MN[WFUUS(1/0,RJ9\[]M<@:I,:Y#3V7AY;X>HE1+82LV)0/8NZM>V.T$6P9.R
MM;"K4C,L:)!UV;KFW+J[H-2H$N!+.6E1<&-4X%%KUV"^K!'HARD9S/3/V#93
M][%?G>/)KES[:=W3MG)Z_O=:TX3\0>SZE=N@%6<06L4(M$&0Q9GM#T40@?)G
MR1#+NWZI9L8L3Z$2P0C!(CN>DTHL$&47&[1?V/?U@_FUMQ,]Q>Y1NI.PM;X7
M<5QG8E*21#SL,!_JS>BT360@KY 4.)H<.F,]A_A+]^5R;U.1/0M*XCBU$V^=
M:E>M;++'7,;+5?@G @V>NP?F,X51]^OOK>D:CB^8SSI*  D%8EL8D*J)='J@
MK890-USL#"\WQ<RZPFJT[4>P\M6:ZY//4KN \B=1P0_B7R)6( 6 R6$"3&QZ
MP/<P055/O5'SNIQ&4K=L&'A99#&T:"(6X16DN>F"]FF2/LPN^YG#)-7 %4][
MOZ$JN50A^$;Y2PT,N8.7#Q=R]%NB*A!P+>:'SI>74B_G>=5V1SH**IGE,=W4
M+2+L:K.G8C%!?\IP>A,!YF8'SHF,L?LW^&=9_?/KMR?3"RRHF4!<48J)UJH&
M_@$P(_/M%C))N]T;7]2N<C:5!B89<GF^*GDBY!34*Q'6=R'E<-R[QD 7Y^L2
M4@_^W.Q8%O8+?E)"L.JMT]3TTA(E?W_C1<]<R .^0:-=C.P X-',0P1NJ\9Q
M6Y\X;YC(-J[[\6+E$U8)M%B]6.5]!'.T*"=H[S$7X$H2FGP)CF?9($9__6+.
M;5V!2,'4"S2O&N"?R6D8[/G1"":8XC8;6+P-6O6)$#.O_44P$>SV12DQS"R^
MK]8AF;<U6DH;FY/![6'H08_ C6Q=IX]BT.%*9+L=%AEEI(3F=$\O4!*UT8R=
M#09!.%-(D>VEPPSDU;FVU,_7@I7S'1V=W%Y$"=H\7[Y/$VU@(RKZVF^O-IH#
M^&$=G%-9'7CBB?M/$8/'R<L*1LCTT5.1<J-2HZW&IIJ*NG2M-Q!G4<[TP6DY
MIP)[=D7"U.+@J*>##3-+KICNF8,(E2ZW:M W M4P5*.\IBHY>,M2XQ1+CW$/
M1YX +Y>]9_Q)51IRY"\B0-=<C')'W=VKG=;9S1GW^9[6/[:R5]^54N<S+=O(
M_OWH3.[O3NH'<V_]91#$OPVG-_<#%4#&?RW0K<3Y7X8+^"*R=W_EDU( EYR_
M;.52+:X&OD!S_IEOL,'4MA:SA2NR>\\@PY_*A5\*OBC.P.4JY-T@U] MH,(5
MA."J:W4/D<7+AMLS[7T8X$]-NA6W="7T4N.DAT%F]*E&2&XNO<Z?>>6_#!X9
M=@>7=B T4#2M6)!_P]^[1_5BWQF'\?4-/K_%2 ,ZV1LEUP12=^2#$/V6.6.E
M'?O=!^J[13Q38\C.NX^+P]^WK-@]*V6,1NNR@Q,^ @&H-OJ0T\UTM_PVQA93
MW27Z!#+=1*E )AXEM++@9?<,NHT@-#WB_Y7]$?]O'2!HI-MA*A&84ZE/,JZL
M'[LO/(#ME:=U-5^PDI-:;"L6X;\T$+1-6IA=4X1!@N1;[:@;1N?.I3C<;<28
M&<N8A)RF$@BF)S<BN2.VPQS)0'9Y*XDX]1&,G3/5:)#O9ENN"'O;8I5*[Y)^
M\ 7@P:L_4X7S[]?S_P\&BL:FG!C Y"];\+^COC <CN"(@!A0]M<*Y=3U^WA1
M,I5S.<6YE.__PFD +<U4S^ ?_T+]K0\L).-_2;/>_]\-E/?!?ZG_^4?HU?]-
M??E'<,__O8'L[N7F,$!'Y.I/!6#\KYR%?U/WOX,:M2/8PH_@L^J803]-2:8'
MOX03F'?':=\/"!C(=DQ;QC?6KMR3D[92A.T^,))?;<8YN^_?(P+=,X<E:/IC
MXI@X)HZ)8^*8.":.B6/B_R.$.!%HOT $1LH(VD1@PP1 '5/'U/]I"B317)V6
M+KMKB(\A N-%9-(XI^;]^_^LKL?$,?'?(P0-Q\\[":QGH;[5$8$[N51$8.X9
M$?CVA0@(H'9+ /@Q=4S]'Z"0UM6H5.]_,F^@5P?:;BH'TG^SA#E;PZ@?:T0@
MH?G %( >$\?$GR<\H1Q-"J@VO?S)ZP]S;A,!\>4=)3N7X;I+(>JRG]&"_[;5
M\F!<T .K!R\J7.G:O92R$A+/G>?C"J:_<HGF<O?^%P)+> X14$-A]^"X-Q\P
M:OWP.7-G(K#3102@243@\;/6_O8_\$AP';,<LQRS'+,<LQRS'+,<LQRS'+,<
MLQRS'+,<LQRS'+,<LQRS'+,<LQRS'+,<LQRS'+/\+V"9)9SS8QHR&-Z\':[^
MNNGRR17UV]$\M(SO/S@5]=1>_;M#(XN,WT^-AJ3'9@CG4YMW9XB EH%)G; E
M](Y9H?+_CAL$Q\/Q\'<#C_>!%JK[Y!IA%/455W*SL\L[^>\UFAORR81*%+S3
MM^M+!.*7R@[KB, PTR?)GM2N\93BP?\%+W \' ]_'""9A&'H-O@-$:B%[L/$
MTBH\)Y?@_X(C;*:C\?N%GNW#+"*PJ'*7"+@2@1]:-09>#A6[!7>\P_Z??X7C
MX7CXXP!:@5?KX-&;S1L1A+BH@G4K7Q7#?[FCQI+P_K>;TW"U9D?4WLGK)$U'
M'3)*&D\^<7E8?#USCO0+.MY>M24?=%NOF%3),S #<GHB:& QZ0-:;<'L\-D/
M5Y5@ZOZ(@='IZZIBT?'VDP@SC=@B\\S@O+!+?4N.5^;@CVIYI+HKLNP=!J\E
M(^D<:I7-)G9 C9Q>GIDC[SH^Q<8^X?O#,U,:1N*ON<XY71I8#Q9MI^CI$<Q&
M4U"D_U0&MJC5R)Q/B&>B\ K:$40 ;KU'B2*<U5_RJGJ^E=-A2<]J;SY8*;<B
MW@NCE)O@$G?=0T_%-"@/.D_/W^G2N1C_YR[T*9?AK,:OC3>U[L;]B%/M&5L:
M(%0%#C2,U7WWS%QH\CSZMYH7NO]PUCT)(KAW!;B;=JZ^'DQ&N2G4 O'T%]?_
M+_;>,RRJ;%L;75!(SH)0DI/D5*B 9) B*3D*2,Z2D:!($00!B47.63*2@]"2
M<T9%HF0*@2(J&>HKNT_J<_;=>]^[>Y_3Y[O^&@\/B\D<,[SO.\8<<RTHL)).
M2TOJ&HBGQPE=5_N]'RMK-F9+NS=FO".]IH=IL[GBJ@*L""'-2;N<(N(".(&"
M,7;P3Y'VYO_/G2?F7A[MBC[1.RI^NN8S^T;_:/=@/]YSQ+/U6##":TNIF2)A
MF/^5GP *>-G3PXT"^ <.O2[2&E:>1&1X5K@W2. 8J==AEWEX]/_6F'OO>XF&
M/8G6F9UC2KZBDB!W(=ITPA@< *X$ GT&WFQKZ@GYT5P8U)T$K%\FL)FP#\ZO
M8QGMSD<X>ETMC;C.O-PATD?:P?^Q>37L7*"^_9:T(<GY*?C%0(Z)QX/N* J.
M>";W3($F9&8>W[*K[38GW$<*C<]VCL(RC8GC$UZVZ7D09L>Y%@&:5:WV/G9J
M5M?80)OD<2BB3 ?\>WRFU>O."F/8>XO4W!HX;'A0A5Q86^% IB-A.Q;4NY-Q
MGIS<KSJ<T0]4\C[>&CCP'!I'+JS;X$:F(]5V5ZB1D__%PY_F_PKS!X@ C ,]
MI-#^M;KFA>UO+'UU3B7=07TZ7C< Y(";OVF"V(&?8QZGD'?>^Q/7<P%#0]GJ
MS<5!,<XAF8&>E'80AYQ0!&W,K"@CR'\]7LG]=HO@N3C_RZ<J#EN<*C(W!]=Y
M\L&0\7><FJ$4T<F6M!;@:S7^CSK<WDD0]*  TB<7E*2IWX]VYJL GAWI?GR<
M18A+=@PX1%[+DXT[TQ4%$%D5H(!1[K?GR_Q7$EI#>DR;F=3[Q@WA9E1W-?$L
M>/18& /O!5)C:XTM!K1CN<B4,)72MD;YW3'POK4I)E;%]Y7,Y%E)-5=-M>5%
M>^.,$G[^RALUBK0J96&A.A0P(Z0RSA>9EF*0,*"XQ= 709L':BRE:^SG*,,]
M;Q+7<-$0R[I^4C';,9:6-HVE$4(0!U>2 / )!#==,!;)O;$^H'NH]U]Z:/*W
M>WCS8Y?W6Z05"F!L;-TZD+JDO',_DJD)T8HEB6MP<C"\4Y%I];31MBTRA@\3
M.GV:9Y%>M?NUF[7"J, BZB1AL5^2:E,Y1JG9J7_1#<,*8V2^+;(@B E9%T*,
MK?SR4[CJQAE,YZ2&ZM7M9F/54^K+',:!+HS.?K*81;$(?IPFB7O?2YLB*[9M
M[%% K772&QFB=DA3!JC,@6&$RCV'W55[:<6*45!TU4IUDX^VT&%I@=IP:]*N
MJ&O6U-*&!P7<&LM_-9^)/9%_'=YB22Z 1OAHD8\P^Q>W)F1#:P;RJ#TB93,Q
M5H8\G.[1%JVB@4Q/T#=BX^+:?K/J?FWF?<+QX4-S3FUN 74\+NWJS,+(V4IJ
MY(R0K-?UR*C-]35'G?S8P-QB:VM&#L 2K@9@]+,7:.#$VDO52<;9,=TW6-.(
MN ?-40/VU^\)TQ%KNXGTM0L-V?7U(5OMY[FL=6QW2&\ -:Q6VM>/HZ8-*N^E
M8[[ $-=<)X9Z7(F>?+):3"O:WNEJSI=_L5G25S+2'W>(O6+'RA47E2*NY=2A
MT93Q]FH\]7&8QY.Y@:$*307]J_NF:]1TW?K('B5Y4X7Y_N77@6%3WLV]B8])
M=)Y_O2\S%;R4$@9BQP]( S7U8$NSLUI]Z2IP'Y9:*JMM/5U[B@)\Y5% ;XG/
MZU4)K4YZ[OK]!\SK S(\5N&KEJ0*ZG+ P#-:4A'&*-P[]^]8)'V4O&-@=Y8\
MOD8>]KHGX*CXM4=X61#3:_=&/L_%ZR-4MQ(&UB;6^5K/']K=N_^&$C(:L;:L
MPQFCR$CE,?]!U*@8B[0GRJQ(J*C^I.G-L/F[O ?D<Y5:C>2;B"N#>./AEJ>,
M-FNG[9R'6DUW-]R>\2-ET+N>%>OAC:/>%*Z>JF)D8UF$]"BX!]NMBS"F*7S5
MILQHKKRD%BZ@K<,SU'4-((0K+0*BK-]*A,1?:UP6?TM3PF<>Y8HPF[B#[XT3
M+3C>N.&6%]L#Q<NT4(5ZMI*\9T>OXKO/(;-YL^LLQ;K&W8$(L%9&?F29R[W%
M_8=B\$]!W5F4'@NX XSOTP9C8T1HV&#Q\.PULE<ZXC;B&L\Q]>Z]=DAXIP._
M2QB1DQ ?F$\6(T-+JL 85=O/FDT2C@+6;5% X^C5O*ZQ:E06R^9"*(QT<8^6
MX*E'->1VK@ +OB&;0<TA),),#:;*#=TV3Q@BTEJY2BI\).\]TCOZ<+^K-"64
MI*H:#[_1M),ML'YRRI"B0E)3#?!U_W#A+%@?-!1EW*03SY4$$JM'>F+Y0Q1P
M:/VES;%VB.]"T),ZXZ TP290G.AKPT]>_"!0!FA^LY,RL*;(&'+;G4@FXSCH
MPLQY>>MI<ZUCWQRIMZ79)VKW$/ 962">)M[SF$]1SNKHE5BX::$0KWR+_R;.
MS!O>":YJPA#>D<6F67\U$:-4/>XDE60TE"/OY'\E3]8>E!1*"M-^(\/H;_S!
MZ\&:6SZIW$W1D.R1W-GE];0[X9N1 BIN[:J+*J59I]8:7G?W/P9D)2&P"H=5
M5V=S^C=:Z[ 3BH=BR&X;SM);EM[L*:Q?KA8$B=M0@P=)(;+KW+&9617V@WDR
MO!_]X\/9?WQW#[<@%,QH XJ(_5["N';U5^02W(M&E^TD<E_S0QL!C7$8]< 0
MF87Z<##(W7>H!.BC<W,3P,4*:,;4N]O"N>SMJ^5(AZRZ):H=V^AH*L,UH%!D
M*M.C ,:*N(GU*8J[H[7V5LHRF9"UXGTRGRAK=0SC=B4:\($7)++5YS60$^52
MH149D75B_X)]^*!^M,%O07C0.'E$>,7OLA&QL].[AP@7?=4W:ES?9%A@P&+:
M-P V4.22 6/]^E6P+6UKE_<2)_.%WK?4F#WM;IVZ4RB#XP58;_#H*,CT(*>X
M/)&BQ4[=17/=8U)VY>QZ\;(]^D(1XB4Y$$6 /.K\&8(W&"#7UQ@2QG[6K9&L
MCM,-0X<FK_A^A":AX=7/,\BFCMZ>6,[S7SV;ARVXPO93*[0DW;N>.A#L!LXD
M'\PYZ\Q%2*Y6";(0-_5A%1/FKPH,-.!_%[OIJWCVZ'S%ZDW&&\/-@_P0T6FM
M)Z9"W$O'_",6?;I0X_D]7&K1TJ8DOOI[4J"3&1+P+.]:A:<0),&Q^6-Q#S6W
M  ZUJ="QHL370K='5:_W:58HL_P?B>R\C#K@%M /%.+ (JRTT<1@#19'.#Q3
MGP_)<W]TN$R4F65%7^AVI4V>_Z"YG?>\F["T3IA\2I3)W1]O R]WR6+DOR!7
M^*H$'P.MH;%^?3$!F'>2TW*@F/#^\P: P6Y$.R#=YC/M)Z/7'B*78D<1$[N\
M5BVWM/4SU/,4#FL@8MDT!/S#5?YL_M?\'+,#=0;6A*]H+[1K]\_Z)@/E!2&O
M#"BXS0)F%K@A,2X*1A&T_KALA:YW+*[WF*!7PI)=9$W*K5C]TE!M 5G!=IZ^
M_,,(SB>D<J81FD_LA4FPK\92;<*M;_19AD!-BVZIY_2/ J7W@GH$NMT4">"N
MLJ8K%N,[3KJ?'BE1<W$E6IMC^F,KL>X!M/!G.J0^-_+.M;[>A5/(9^I0=^;;
M4^R1T%ODN8ZM*;!$1%P7[TF/B)H]*I]X8Z4;M81A2@"!ZLA(>2,3TD#%;>QC
MU[OY3%=MS/99EH??=J( ;J02M\\7ZP4>%@OK.81[X7&/8.;WAU/Q%4]OTI>]
M&R(SAN(JF2M1W 4!F]2@0*B+3[O4(W,1YQ.39UY'T4=ZN[X+8OV'=TFXAT;F
MF^9;=R]29B,.,UKO/$0#/4+XW #6Q\=_=A&- N0?*LN%()3.Q5! '_'GJUD4
ML'%J5Q[,.R#)=%G@$4E7S]+O(B?@S ;)+N[]XBEO^IR"AU@HG2PNF<+ IOW7
MG9427 UFBDWFPHOG<'-OXQK)WH\0-()CKJ:K)XM,28KYR@5U'#D[0/I&O9S=
M::TP$W!,C>H-%,$Q'CBM]'EFE.X=DJ ?.  [RJIC+4?XB/E61D9F6KLW?3A?
MH1Y]]G+;@<U]@^3Z2;3ROFK$4YJ/D&E*DMI2/!#.%(4C8^GN@*7 8U5#LUME
M_;=2&-J^UC8/&EB/+]JR"%' A)*LM35%(8J>_A>$B^13(-98K$AGA@O]JCT.
M3&1_;));5Y!'A/"U4?62>P?=[B$$<-PW\R\31KC^VARI"1I%?(^D>O3**)C/
M,5V)XG6"V5CT.JXXJ8L,%BDN<UE0U-^BVC=K;E_=J4PNW]1F,&OAI]CTN.US
MQ?>QDA*\<_J:7J$=B&NA(/ 1O. MU7/CBJ_!L!DZ%]F.$P*ETW@E8I:50\V8
MP)C41*0_\X:E&^; ?WJM&P68Q*(GK;B$U8YH5.*$:4]VM#?1^:G'(7=Y)Q3K
M28 +^=W181K:M6B8*B>;VQHWF:_-999"4#;5)-^$="-Y&/ZNYG"=$:4.87Y,
MOH6+B'B@)Y$^"W=F]+FHKT%2M\8OP2M.F12$<-I$N#A2+$JP24FC,;W15)%5
MZ$8*N2ZW=U.+,'9U?<.-2+;M&KFF>&$X:TS%_*:5SI-5H27JNRO-[C<H[%Q+
MI[XO_#6I^PE<X#Z  OZ"M+'I?,\<U.7"]JET-_C8\0D$X4 I+H &WE4=TD]1
M*KVM-+6[6/VKJL.L"WSF87*0$*S [O"B#9'YYFNJ\X6W?RAQT6&QH\()IU7<
M+7%E]R3OCT6+F;X-GHCLCDPU$3#C.@.+A.?,FE."9600"X>5%6,Q%EH^89'U
ML91KI*QGTEWFW?[%SMK-*MA,WA.BD%[\-)IE .)AHR[3?AH Q@A-2URVO;B'
MYMR5Z<<$9ER*8:WD7!$5LG!\H2@\,%907X^+"[N+:Y7*WT >]2F.N4.2*-@-
M'M^G!5!>VK ;.W=MTQUCH?V?)90KOPXD]FC?Q<,L:$ZBM/9DJ':^"%Q# 6_[
MI;YIWUY^<"SV]J^NZ1(GM&R,^M"*%M$[TE$U786B7I'*47B(02^G9X2<JX<!
M<*H?:WKV+VJB.JA-JK<7&H"_%Z3T)U(&4T[UT[L53(I'<_2/9\C@X*QC66(S
M.QF&Y>UMK>@D15MY\[XL9KYUH5@":<)7Y!@18;4D)V$!M[=EM/?T_$UY"5M"
M]!@RT O).ZSSE!1$N-VBL>427E.Y!6FS\-QIL4BUFTNBH1N&R/ZQ[XW\:?XG
M#&@$9AM]BC$/FR6Y9*!4F6K<<<NJ[+WH@B$_H  G;I;L7S\7Z^?C-X("#FC1
MP70]"CAC?E30!)DZUZP3[4"W<9*Y/NW4HCS>EQ-;YU96AJ%)-(++N(=>M\\F
M?U7NR/"/"/13'WKHG:/%H9,?G+B<)4=?]G-3N#TQS]Z9#2;<=JT5M&X#ES78
MR(XSW-]BP/A6.BMG1]GB2OIV;0 $I@QU+#-T\0+J/6LH14#9U,U@=R$$"IA.
M,DE2^P2?)]G9(9>/51(Y)<O7!4B%,1NQ@H*M017VS YL.7D_"%:3_^P03;#0
M8579D-Z<$_XCTZJ0:>)LUN<A^C,RK?8Y..[09F)<EE5S%1N:F!SQ.^2TH_R7
M^7>*[SA:E5NYQ$I7,5]O-7\E'[MJ*DR[UL35Q%4BH+ANX#JU6_'T+?;#)Y,.
M:[D)C(J5JC::JL@.W; LQF_]+ R<U_P>E>-]1..#93E4<7>'$>?8V?&7$!P>
M.'/.B%!;;",.CC@"A,_VX"RW5D!<[Z@:!<08F7P_9;@*3\V%QLP=P%XNT$LM
MF<S\\G:Z!?GA=EK+ C_XOI'%(&S'1G1WHD#LILA<?ZNQW,K=_ ]R9*<I>J74
MI@_H<M(#*4R%Z+&/YG3</,<;?3F.&&8,E8QI[M?51<!CC61N)K:;D^-I7_?'
M=A%M8U N?G+?2Q3FCP(PD!</G>[0W1=B$</-):HST.,R#L]  3!&0#TP12S!
M/S]FC9L*9MOLNCA\=U"A9F"V1MF0IWLJ1_<T2IJQ);BO1_@:%P4'A03FO>8,
M]C:3E[J\A=W/O9Q8&U.,LD2]BC1/'A9UVE[3%GAR0RR*Q@XS]?[ HTR)_<'V
M<6\2+9VJ6[=M<U,%"AJ@,E9+KX6NOY-87+40H1/2_!3)O!.M?W)8JE9VXCFY
M@2D^60=W20L$]H5,#_S4!"J$KQ\Z(D1*GI/1=2YZ!=]^H04E<J=K[KMAW60S
M91E!]513/V.<A!>23]E#$.5F*W-KQ\>D78IP]N2UP<%+R:>YIV_#HH>*"H\?
MM!OHI'EV6W4R$2[PB9(W\*GVS5R6M:YR4EWZ]** /.M")CF+L0NJ<P']SB>O
MU,DE.GD<&1?JU(.:\HQ?89$="++51/:I9]X,([9QWV=I>^85>E&:H5/?Z;C^
MXBN6!H.0_06RG39X-N2QM^@(5RJ;&+W9BB.L(W!@>63>]# 13'Y+T<0K.=RW
M^A;>H6^;U>N8E5WR_'7CUTKI"]L)1?UTEUW %1+94-FV!K^O+=KC32X,+"+2
M%\WN%R<ST-Q.G/15X"VSQ$DTU/]8+QNX?S\['=,U;@3C3/-YE!A]SO+"]&>U
M\=JP% QA]=G:+%NV@VXI[TY3%W^!:S@XMHSP(8A]%Z>]]W';*""W\D*NKXE]
M(.I60KR+$3?S]HB,NHJ;@@@6(3FULAZ?:J_"N<+%W>H]AT=UX=1=I1Q6<R--
MLLEF+3687HN'4=B **M]Q^NF>7NJZJTO!$0-/)4]C=)J_=<ZWFR[>2L>"VZ(
MBA,GC&7D^_2V,U!OS'# Z1[/&V>T&WP1O%<2+,6D2?U6 A]3OV'8W__C&Z,X
MR;0]J6"/>58E]P(>,SX:GG%1[ZE2X?G3% K,(8%DT!L1P#;"4(0AD@'$OH]<
M%58?OLG<5:5(>W<15.-DA$F]-#J@[,$@+,53YY;'35^\5,YP3CY)8#S;DFP1
M[7EW9RK /2+=!MRC*F$?:ATIR$") H;&48!KUN6[LG<9=)(*=7Z3)@<$KZ]:
M65# N):.X@A->E8;S/\H]3+[XU.R];+FEQK8'OB4 TGF!4KFVOX8,U1Q<.G[
ML9H)T>PGY4NV%]S%<P8=,,\H?&)O/9U8+7@7DJB!=76%'=RMPBN6]^5"Y5S,
M+O56G)BC=5/(C)+XY79!!D7KW)PZ)XN3@*+)\ORASM2PBE;T)?R.=?C!^D>,
M:A57)O&=(2=*:01U5WFF&"'9B+:"4-K)='Y]S;*HHP6C>/5,3T$U!54XVV_?
M5""9B)LKVG[VZC7,QE@*.G'+$FM>SFGB17;2(,7E"E% !]!&04N7':@BT%]*
M6E"\L@ 2QR")_$["O)K%)9*JJ]'N4O:Z1O2:#&\_[2*I@*(9IU&3&!T#DF%O
M9K"]W'Z2PX*\+"?)_=X:OEG(P1#>0M"("#6P&EN*SX<H.['0==3K>,CBC_NA
M(F^%T9P-SB8>-_(1ZQP!$'.=D1Z+[$ZA@"N35N1G%."@W57\"AF  OBDCKZC
M@%K;&.EOL.F%*VG/7PN-% :UZYD-L_@OF$_06A0/N5%G<["B#5%4^#)55B*[
M!UW6)\P$^MM[/J3JW8VK^II5*]5A+-7AZ6JLWV/N[L)B]LN\/D3,<M=:])I(
M.YVJS K%.)G7/2G_+^RIO9T-6H'4,W7CH0*GTOJ)IH5.>#3380CQ15*@TQ!?
M1:OW/?ECNV@?MLF6I1B^-7*\?)OX1D>$>:69_VQ0^MVE3O<P^586V$I40;;]
MN/S=*!TGRHYJA>L=(1#J'<:>TL:[  L<#X>1*(_"Z?E"VPOH0SGY6A]5?99L
M$=!:E$(D#N"A Y)0A;BYV4_VN,WMEH1*<E_F2JV*HKU\(O7MOD[<W$;4K\4H
MOFOGIK#!Z,M?8,B;(]"QVRVB2R8G2A?TE5SK\DJKT7CK=T\0L6T:G]T!+99T
MP<5O_-EIM5'.1P_W]:8KV#_,OS=05Z+F#_A%Q+3D60VW9>S(U"D683#9,"VB
MZVO^R:ME%CNP8ZYEO4F,H+Q<F"&^GQ71NJ32R)<"Z38U7<UQNK=(AS>7F=PD
MG'<[&3*#[)>HF'G#VMJ65,<W"NF(1*]C\@?[<>Y]*;:C"T:V"(PP3^U"*FAC
M9N=4_:S8P:?ACCSD$!<.7>R4K?<<>]OTM.-\2$<M2TZ;IW5NPY']+/3Z<!_6
M _LS<*&G;_N>PI+B28 K\]!0XEXV7W^#JW7??9J:B*7DC#*!QL7*.[].\"X]
M9*^\M>,7KBN$LA8%O$P:OC,K8Q7Z1*P!4[BFN)]IE+5(Y\8W(=7M?;5 JD>W
MTJVR'@G6A&C@B[LK S/M4R5Y4)FYNSO]UY0Z]AZP*)GDF*R\F(R$W=;:R/<=
MZ+!4_,+1;IQ#S<WLK\CN^452W06/+82L5>N3I(B]\,VLD')VMI3\<Y81;5/2
ML42V0/^<!\'>C'S(1@2EFCE+$WO;+K[MV9N(F^MB7C$\PVZCE?W4?)OY56*Y
M](^L%+DCJ&A7QP(?SAVT!OJ!&_9OU*SA^F[)'YI<9TC14-M)":PNO8L,'PR1
M!;\W<F-S,LJ(7?";8CA800'.)N?0]+  I D1;)7*"@4\]EPXX[0?3YL[%;NR
MCCZ/0 '(3S8?9PO[CM[.#%[)N,(^K\+.N.R+P9WN^;^> N'\RRF0;^UD1R)"
M& 7@9@6_I_5M@+(G^T8B&&H'#WT7:Y6I^:D[<3]'$%XL0,:)D9G@_5+U#W<(
MQOFB*&3-'BZ1Y9H("(&"K8Q\<]QK 34I[SC-88OU%P0K),3M*W388N??#IV8
M/]RT]*TVAP88I^'JJ!K(M&.Y^@OJO8.H#ATX3[<NS4='^'T^.FE9X.Z;/NQ+
MGE_?.8]H&AG_+"%2K+S6CPY*(V=X[C&\LJFOEZ'5*,/0]@"-1N^S9BJ)LL*5
M6..TCX2BUM6VTU  8Q-LZT#MDI*((^IY)O<>"E"5NOZ]\G-[AI4/6YK9DVLZ
M;'JL5?J']8(CLC$E;8L?RPWRQNGW]PT7>U)G+$>=L5SZ'9UV:7)CIJ2I0SI)
M!*K?S(\V1B2N(NZ.IR869OKU/[HH?NIJD=XQ=MK(NK>YD0(2 9,<NL;5^2R_
M87M(V]HSS%:713;H ,982YR\PQN3W:+!P0ZD6Q[Z^\5GKBE8?!+_V\"N'\RK
MRGVD_-$RZFH9@'D>S4Z9NO4S<]&NB./1^+NXC[@(Y&J/EG#+@?Y"6J'SZ.$/
MF=CZ_93]*CPD].6Q!,.RWD7@+FQK!"V(Y>]HL3GYKIS?0@%]FB9GAW%HS=NI
M<=U@FUX2!<2V2VT=JJ& ,=.<'0*+HLNWR)3$ >E"\[J.Q/89 MSPP&>8LE6@
M]\3W;KK=NN;\MS<V)S?1F^?&:^F/01]NW>"@Y"U'P&^;CS1AK+:S-9 :OI78
MPRV=&O7T;=VC:=OW/E9/J+L&UY]@CQU9Q\BW!G!<#RW7DGW;JHQ6_=O6$X;S
MT4R%)-E[T_-9[?FYOD6@_B.>4X<J Y7MV3KE;-&8N\B"]^J_W-.Z+[^I<,ZZ
M=3 _.S<C.N32XDBOQ.J3=LS1WV;T9A%@$!(4'<62M=TG>7D%2-Y[KR*KW$/1
M4M;LQ<4G%-E;;%XB(C+?6 R$OZRPG8\N1+ZG,?"%!"(T/HR=[D_U8<2F? KG
MC*D"T]9P[?3@#-S%&K11T>\YEH2=4"WJ[!_E(GUOZFO0*RE]\6JFY;#1U:1.
MY$^'S^*VKX8JKU=[*FB<RUW05^_%DSV>"B*%A*:*UQ2S&7<&;NLS)&&YD6 Y
M,NXX7@<;[< L%TZO#:*G% [;*++K2MGQ5@AY6FI"OOGFT-B%T3-V#6=4E$U1
M\</@W"(G=RTY(-_S#(3]5CYGP==LLN5.N<'U-Z=V7C2<$?*@#NH;ZIL+[W18
MG/1ML,C:5T,*S5G<QUJM(J$JO[#%CNARIY!A QT)2KB+[H=BM.F9KF, %^NH
M.\+YKP_.,'=J@\57AZS R<>4-2TO)$4)#^P^R$I:QR9OFRN:[#8[]H$8.'!+
M$T<2!=>;#A?:LRB^IF+M7I8[W5*BI*2+5ZZZ6! 4;, B"]3'W&K +W0M@E;K
M2>;ML;_R\&%UU%)2;% , .>R<F"Q/!$,JJ,)9G74Q7G+BKAO/COULV+A_P[S
M#U??XO0PU%(%&G8^2H>[F3=9IU"O'O1"^#P#8E;3"9? $#>'6U&AS7FS+0SG
M#^W>!;_[Y?PR<]%E@UQ/4V&_6-XY_DQPCEB!$=MA7<CU[C=8](V;W[_=>Q%F
MEVK<U5_;$WY#E#8Z'9OW ",RQV5Z/K;^]>O$WI&9]7+^@!8EWH_^;Y-\#P2,
MRWHX]:M [$Z/V%=8R3)+%,AJ[LPSJ#B8W+P]2*#0'+4.5GS][#XKI@*K;UBM
MU4>XM*A)'+P-<%!)/LB2\!NBIW=4T*$",?'FQO;/*,,WS;79_?-#K.G<*_WO
MQ:8_M/[&=X4.+BA>7[6@"7Z\1BM&SF+KYEC;R<I16(VCE%&B@3I$L5*QI OY
M%+=(9JK=GR>B,,$)@MMWYU=56&+WA73/*8<ZX290*$+RE.=A.TL"7,?L0T1
M;-]BD$X.E8W%WB!T;-LZW397B)G'@3M/B0.C>@#49,6XLH[[K(AH(.*V2JO6
M6$GH7T@Z]%\F7[#8E'V=Z'_J3%C!-R^G1"Z&L=;EFJCI"E>5&":C_5+88C?S
MY)&E.3691:3[2WG</-8X_VP,N)(DXHZU0M35?XR:M!4G:#+8MW?1K"UF<NZ,
M#J37WM13-(@PS!RKPA7+$*!CVT,6VBAP!X301CQT-D9 < 0"R=<F0@$!,*HG
MB _F#2V-49S(SX/,NHH!ZFKQVG 0X,]YQ0C5=P._[.;8]![M;:7H77EH>$-N
M6%MQ438%)M@@1)=-[&?#)=AX5YB3*5CEXP17WW>U&3*KO9Y@Q\(>E5L;3/ '
M'+ID4$6L&SP%*2"BIIX) D+_CT?,]VKZ:J4(;:EB#/M=BU0(Y])"AXA10/>Q
M>F[E8Z$0ML.8;KWX8K[M,ZK%R/HP"]K8C0\^%5.'*C5XR4RL@E"\8'KKL8$
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M7?/NQ+AHSL1;]Q#)EJ))T_6R$@4DJN  Y))61$TR".H9 0H,%?/'Z\[;,!3
MOW"TA4:8XOON$E(K/1FW<G+G\^5XR&@C @YZF141\'M<<5&%U&"17R/6PX9V
M N/K&I#V<MQ/@YS!7Y1RL1S--PV,+0!'&B]3>)=5(R99V=NQ[P\5.NB)/JQ
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MCPF:@+\3H0!CDJO VA"/CW^&I.+_8D-O?/X0'5FV>J&E.5J&:U "/JW_4=<
MOXIU7XQS/EA?MPT*<&8X4^,%2:( M-CY8SOBD(ONASH*^&S0&C<F-%%$^L]T
M'"=UR^2 @N'[),-J/.$W=(C]SQI?BCLHX.0XZ:I)"3UDJ=AN, (4L-9P68,"
MIC= S?_X(%)+BJ* :%&I18:SFV-"-$OH.0Q! 16O4(#,(^!KT9]!.O\O-N+-
M1VDH(-9O]VH>!7S+Y0(.8?_^\G,*C%]?Y7L".C)"/Q,^>O5%ZEOF(^P7*$ Z
M\ _NQF=Y%!"3@Y[7&AA[MDV!.N,_TVV2.Y.MJQQ26V52_1S@K]JX_[31Y7!
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M188V4(0Y@'SL;V.Y'#H0BO:!;<5GG>%EV[#OM5X9PF:E+C/]Q=[]PW(8 ['
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MC$E@*VCC/3FU@N8-0<?^-&%<9V9YPQ=W^<T(DV:AJ/J@N:FGM#12M[4]6U*
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M>F*J4:O'L78G?MWI%_+N1VJ7_PO@_^:E:,L)YP3GG#M<<L8W8T^.B>RG\<[
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M]" D0'L\@[!" DT9)!"%A1*9G%&;LR00AR(!=C2,P/\1LT+^)B_F^ZZJY)'
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MPNR?HL[OR5*)_N_)TF1M-&\NV<U2#/JZ]JCGBJO$@CVK^EJ0P^4V7D&'*>8
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M(>W&!HWP!>_+#UN+!-HG!5W$GK64>D)YL_B#/4B@$!7BXOU61$F']82QLD,
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MTQ05R(XE9I.7'#_&=LF4XR-#%Q1Y0%'!#34F.Q=LHC9OGNE-.R4:+4' Y@Y
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MN_RY,]?[P6'Q@X=*2O02L+4Y<ZBG@LM:4_<3M8Y/G?#SO<YV.3.O6+Q'^ _
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M!] 2O\KMPIF,X$<HN,X]WU!FC[EFS6MC%E>* VZGQP[V%)'0],1+1UL_ IG
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MQC']MH.IW\63^(-';'H[8=K6CZW;[^ZR-.3(E5\Z'](P!(G9&,0!HM^.@G'
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M='B+\JBEB_JTR,A C#%$>-6.+L4O/SY&MV ]O8K[(V6N0MD^/PY(Q6O;=QS
MBXV+0,GJHVQW9&[.[I\R&#]-&R(>MA';(DI)7*3^0@WO45KCB+F:R>OZ@C)G
M0J(JJ=ENR0N1<E?I7( I<GQB<^:K5D-:X1NG<S#BGHLJ( L_!@N572MV?GKB
M9?FFFY#@T0W-4[+DU=_L\9=,$N'Q7S))[NHBV(H1R5<6.H_#OU,=;N%_,2R"
M&!0XB4<O42F?(/'.\['=*>_ZPLA2.C-S*KI>FS?I 7=TJD:76&YN;.X2%.JM
MH8%0NCOBJ_4]P+XNO%9=T(5+BJ3G-?0Y(8$XB0P'NR%^II*L813(SG<+PVUI
M$G+%9?PZYE5ND5/N1B 6FIYT$DGH87;;#$/U]L5S$X?P^]SYF1V>6@)U^B9V
M3*@>->B6.H&2"69TZP&6OJG?Z6+]?=;=$AM3GZ09AS>S:?6<RT4[2V8#XGW3
M?#!\K,%\H7:TD6TT'<46[$IJ+JP:'6CG#=&6Z5Z$Y_I+@FI/T\ ;?DT#-Q0"
M HG7_8O*8BZ0GW!]7:H/+3A_/NG3!E<O$V?3C8,=@DTBDTD9%E3HE>*;:6O4
M^$C=+9YO1O,6792!13( GR/P!"E%A+-?P+;67TU3"_4V^Z$/IREV\!Z.@W5(
MI(7SLZ1%YI&V-(L_;Q8Y8+G@<83$ 2-=G\&S6$%D%[L!#B@C1Y_0[H&6D>5F
MQ^'XJ+KL0'GO$CWHVV\'30JCEG@-*< !KU[C /CODF;!R[:_/U=64L+CP?DG
M^-6,P69IGQY?<3<K.U$=0 -BL.A.;')#@9/)_X49=WEQP!0Q#KCU&9SYQZ4&
M[W\\54QVO%ZR8^/R4(K8<#;0W.P!FZ_RX=9I,DYE@9/RD9>+MS9%4I?M-#RC
MHS^M58O;@6E [Z*>-P0BR\W-P:[C(O<DJ%%LJGGR<99D&C.AHSGD2@0(1LA"
M3554H-ESEA(-02_.>SDO:.4\-!G-Y!&TE&K9E#X/)),L:Q.>A3C_&9#& ^!+
M(?(+K!(F.=JUZJAEORQ[HE9M+I2Y-\,HK!F^J,""AR4N?MFQ%6TMPQ_$*U)[
M>C34"&0XDE58:! I64TBR':5Q<MRY+9Y6DK=*RD-M0YEWL<UH#:X-.'J9B+^
MA2J[(P]BD).SV,DAXE.&.[7]U\-<,5;O/42ZCN@36(Q2\OVZGL^*R4/6;]VS
M=Q%*]01UJ.05NQQ)8&YNGS$O52LL<G1\\\;1D9LSG,XN0I;04QVXS4:-82W$
M*'GYV]^DM2MYU-O+"6QYK<@3P;W2(B,T/+4XV!BVP[J.U;:-UF:=D]LFU*B3
M_?AY ID=8KFY>_U"=XHNSNYL^.OGQ*=29NW.><0>W^R%H%\\JF2IL$ID/!C:
M<*11C=E<MCCN3P21>#N#9ZHH"*BH$%E9L=S1%R9BWP)?9].UN^%+Y?!T[7/A
M[.+8#N0VO/%#U61*^EI(2></](?&\MY=8;-E%WK?5=FK*"U(D,B&8UG+M4?]
M'@)16?./S3,PN4^&NS#@UX;I>@ <NGR7FH+JC[D"/>AK*0>Q>#5\CITR($0S
M7B#%<@?<5X96C:@XO'RLKK&@MASZXEXB*)=(?;J1TWK.(9.#5;J-?7P4L=64
MX>/)V?9Z0LO(@O<N'9\J]W6%]L1*[40^@Z>Q!HWA".)U$QS @5??KUC]$[K3
M[,]=O/T,GH"+P)_+8BVOWF]Z$.A&L)EEI1L[[ VQ*'0T3$? X-!TXA<%FE%A
M;4WGHM8W;Q\OW,X?;!'8Y7ZLF0F;\JL(F;)SU_,> P;M,*,O-9\YU^Y<FC2>
MN,PDP[N2=LDP&?1E$Q($74H5=P;C\:"]F["N$,.3-,]*ZUZX$\>F07F;/N'B
M:E(T)16L@P0.CO]7)\C<*U1G]-#DC?8,N^S"@P8IM*^3:$5MESRM8VUXM%8R
M6TQ!=<3*,N*VXP,2B_T>AMLL!7>A]JA&'1)*SS?7=HH["?A%KZ;#E^L.4$KW
M?XM;_J)%LW]>8/S7-O_Q+SIDR^)L1-@HW[_RZ ;:R>FG8'>[PLSO1JU"5 MV
M1"FUP:F@[>B,(U/7FO>:\!]LMW2Y&%-Z:B]_(1%\<$?V:F)BLH8W'^Q'Z-,)
M&ZY>.F)-@YX>-8'S,"C)W"];'(&2SB@.<&:U;\%R!NNN-5?H3DFZT5\B:J@Q
MK*0]N!-K+K-4@X"2]J0ZC>*WU-;]YYCQT+GB!ZZ*XE?([]E8Z&?3%0M(=37O
M,G1Q=!PT@PF]@\%B2MP!HQU!QMOJ'O23ZD_+;T1/R*-&[MT=Z.ME><G</]-@
M=G.#3'4NVH[JPD=EYUEZ%UI)1FDJ^N*D;IXJDD4.FDQG%1@A35[;66 CA'>;
MKJ.6,6M-P>S<N3R.!5TQJ*,NJN7)F;;'B_*Y!,8.X>V %69TVZD-2?%=0U_9
M]T'WBM5F!+O08I?]F65K'' NI.;@8U?K<<.'(>*1^[;)I;ZLBKZ^(9;WH'VS
M 2]?9GFVD(?T1L TM.S,TOEH=FW?L2=.?&M+<E9A[<QV6E$8T5R>;.IBJ.":
M,F2MS$SP/(C>P,P-27S5P0.A'>)8M/.&?T=]I&6 EQ=MUSME84[N>G=C"P<)
M3I*Z51Y[$G9*/0E$5ZFRLSYUB/P'4RH:,#Q8 U.#*"VOUV5N>UFB0=*Q\"1:
MK3IZ"3AT:E>F*=T3$OJ>ZM_,86%_U(L.8-,Y&>E]FZ.A<US7"X *J.XI*&[[
M=-A2+P7>+H_M-&01%20SYN.'OZ'(.HAD$+9*1Y#) &MA$.Q[:1\;'.#H>N "
MOZ?)DF>>M)C-J9!#PQ @U"PSE=2ZK&</[%,EVS)>F7^8G4>O[25 'R&.('JM
M[0>#&@9,UZ;KO#+SFP/--3%O=R8K>,":\.!O<7K)\XVNS)#=SHO5I/7"S>A>
M;Q)!\PO ;71E[8:0_\*#JI'J"[0*\5CCSX^8O6/2[L2+WAL3?4J0:DS [.4(
M'-[\]V'$OX'\>D*,MD2.>8-N3WCD+ <VV7Z3^M;13:O?4.?S\,T7L=PC XDN
M2?2XJ]$(M[E0]>2]QU<WM$:,5=*UWY4.@>'I7E,9"&8;NI-,-R$GZ?K&G9MF
M1.$4PJHA#5+N1IL#&E/7<A]=J7H.*Z#R+-#,#/'!P'  ^97UV35EIR/EASA
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M1X':*<@<&'J$D"N+1U=&H9->,1K4Y*Q_NQ/?+[Z9X==NHE;;=SFQ@=&5T^8
MJL4/ZOG"7I&Y4ENAJ&99]R;<P52LON%V%\^E;%K^FA&$6VGB'C<'*OA3>('*
M_&?:D6%"SXX&0\8"UN =;5EX;A8^ (,/<0\T@K<DL#1"U[]9'.GG[)<I_[ Q
M[<^[U2LRN\OL)[6XF;BJ<+O J2"@$H]3[T0,+/3Z#2J17I]-FO1_='FL:T B
MU\'I@P'W7<SYK4(L0^:#\<"9L(,):ZQM9N(3EUKFV:.<@>"]A? <&]"I%I)D
ME?N7G#SO.S++/RH3N#$HY9C][2"I@=GKAX9/GIP!D3[;,<$#Z[?9!N^_"SR
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MMCD:P/JRYHW>^"S2W[\!0L=26^PW\ YY)1[[#?AC !XK[$<062U1>J FD/U
M'5(PQ#F(9O+EQH[V\I[ZV[V&^>K!U?7=?1^89$FUQ+37\8PU\>A+2?!5_XO>
M=&BJM]<<1/MV&^:O'#SV6K((OS [4SLPXT$_X)</8.] A^;" !-SUJ@:O]3^
M:0QPT[=$R&JKRW'+_B"7I"0PATAF04_O;6K6VE;6\_F5(]U>Q<<N;S% ;>9:
MDQHW<#B.G1-:APP]GSG%G@_8.7F<R15>S3B*/!IXZ+X*E\()8($]\^5&]X\[
M>FQ)>$VQZ3;D7&%T9F>LWA+' %JC-LA9[V6&ZAVRA9/JV-=G._?8&>*#+L\+
M,*C)7_0PR8MZ)3;PP70N@.7J<W2O3LJ=UT\^%/MW]390%'9&1:G$ TAYMMG$
MS&<D"3>JV8)$&NB0EUL0&_J7-$8084\U:/%O]:G 6_LL]JZEG!L@!]3& '.
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M 68&W.9?4H.2=R(17##R%X'[O*$5#4$V>DET1YJI=^"?*I,'5CS8HN)DCV[
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MY^-2) C%-@#2'H>,.YK>3@IC&PP1=:V6\$[Z&RSJ51T'%MP$JY0"(0QFHN8
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M1*,Z(5$[/_[M-M9)D5&]$=R#!"H/+Q+7-@ZJ*CQ+TB!':%R<4GI]E&^^9JP
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MC7/$W+R90Y"^1JI#RZ7;H6B'QK1Z,UM!SQZ;G5)6[GAMS]YE\ZR"=CP2:74
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ML]GP#YJ>WZC>)J0(T..\A+O,>Q&EN-)+2<_+=!8X(,.]UV*W\$7O"K_#^(V
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M;^$$XC,O.P/72J89VS]YN9D_ZV$/H6SUF3?QT+(2X(*3945P)R73DQ!\=JD
M5PY+BWK+?Y^*D<[O4R'@X*S5HA[J;RK1HPZFZS$]",\EXS^D6N2]1-<A.&6S
MOFM[X%+7E>(!%)GY)GN03#,8"<^(XIEYB4K .4Y>"RN--\A;6U. UJJJPU4M
MN*UKTD%BN$L7,G%<)H8@PVB:0Z&\0RNQ9X$CM-Z>R1G*2S[OP/5]@C2S]5YL
M47@(;G4 8*'9\;J+ 1[=[MC/2"D6U3VR6WX3ZPVE&,])<K3(:A@-W"SHULDJ
M *3&5<:$G2*(F?O.G!D.5(AGI,^@I<2_&TBKNSL,#J16+NRV_ R:^F4C\*.F
M!Y&N+7BU?O)UN*RF,4FVQ;7Y</WFMFYLB](%<2W'!Y4^=.GC<D$%J+KRS[,7
M5"*5PQTVWG/9\!=<(_NL(IG@<X$KX9;/F=G9G.OT^867(MTC?@#K_8/#C]Q
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M.LD]!]SZP1)$_[R8_^;ZAE\+>&=@:*D5#%"L ?MX/B S!_M01P[8KPH;Y#T
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M!Y8UU?;\B*#>-YM%$D%H7'(H&_A3#M[A""M-VVI'&PDAYP6^T.,@U*7YB4
M\D_Y53Y>&Z(8@.-D_J0>*Q8*FJ!5#/!7.P>G2:Q8\"W<)D8KG3% SV. KV77
M\/VTH#%VBSJ174$57Q[O0@7D.D3Q+0594\ZQ^[3$Y4M&@1.@RX /;#UTH:IJ
ME.O]JL1:8]9L'M_Z>GY?D/^FJ$^V':6@LHEN8C.^B_&9IL61PV(_)M\JK[3=
M _2&HF8/_@>_/J3NVYJV,YNNKLV7@(?8&"#V"/R9]=L"5L\\-8)+ENSS8!6@
M) ;XA@$NH,,#X5+H %9N_X']<.O%60WN) Z.>9X">$'!Y46L+PA  %(@UWKL
M*\%NR50L^OKTX)\L!?WW!(++DS\E$"2I0EFT_NHI?_;@_]5^VZ\'4+OO?>Q#
MWNHZ*<, P\-#0BL9/X)E_T%@='LM;'7[ZSL7QPG3%DBRZ:RN%P1%P :'0D:E
MB7?RI'E#^R-#Z"D5U?3(OD$.#9I*<0'2?\(F2];O/\8 \?Y;Z%FL4#SE ?9@
M$^9H,YG]3UB[0OVS$3D$[]_#7A,QB)Z3^9JMC^^' 7ZU^0?+&.R<J0H,-.AY
M%D",=X:WZ+YNH%S@,@F"*J8&,@(_]_?BCMD_?'#(RH/"P<Y<FS9V,C' "5],
M0(Z6.N<:V=1!!YGO)4D9VY2:N@Q12Q)UFAGS8%*H(AG[A936M!;.9#:&^Z/[
MEF/VPV:1QG4*UXD*"GD*\NF)@+IFK,..P#IC9#$RA)5DH:Q6'RS>&^UJ9E&P
M:#D)BAB.=,0*K)+D%E(2 DS.TS& =,9.8U7&06AQ"0<NU['F;KX]/M'^.H*)
M4BAH@)!ATP8\T&16<@0>Q #&N["/:=S@<93'4J$Q>.KMQI>-:&_ =;-+PEPV
M/D4,X0S@I07CPI4"T=U&5#GJ*5OM.A:I-;:<\M%/WHDE^ B\N2P:K,7M3!!_
M8YN;X>L8CF3A_C/LHWON_4FP\+]O.496_;3E^)QR")+L^]<S\W/.T]]_!;]S
MS8 +Z]FF92H7#&#?]-7=G>3(ZG]="?Q(\/]%(9%=/GF! 9:-L<Y*->R$.P(N
M.;]/CP'28D_J8!L= -8N!\*E@>^.K]G/CN^%E( <V!!;+ND_-->^IGGHL8R-
MBN$>J:['E-W!2[NO1Q\$$I]?(-7AY.2,SXS ]YNW]4P-*VMO&7XO6!;7VZLH
MCR/&%B/+1 &-3:C$ %,0W6U8F-'(L3-?PL$9QNM4(,>-)/OV1E,.6E+Q2W%@
M'-<\AF]C.-+.)Z_0(L;>/*M3@S>36E?I4NZNM'_N[2_CE^QP)1!H= 9:F+*;
M^VZ'S5W=R4Z6O&/0(3)L:Z_WI"H&(?SBG%"Y8!=/R)Y7\=A4O5Q<#7L:N-_C
M]I1HQUF%:+S^M@Z>)5<5!QRQ;EQ+?7)%65SK4GRXA#$A2F'G=<=*W6V:GO"7
M86()??(,&@A^6[Q2[IJ!-2"9@<T%2HN^BM+;86WSNY,X.&NUZY."S U]Y[U+
MWU&K ^O)N=3HX<J/ 2Y_$P9]?9&Z5&BH=-O0T)CV!5A(=(ZGX'DFO]R\("+D
M3@(]S7($KN_X=NB22/T.ISZYDLO*Y%&L</R1YU89GGU8-;62_8K9C+1IO;^8
M,,GQ2 "%X>SS#.&R-PK7^?K:>0H"$MJS 7#";:PB[:YNJC!JVJ$]G#KTE+F(
MOW^=D$I9';37.^H8+<YD;H/7ZNA6$6=Y2WYI/D+Z[!R7_I"*EV*QJ0O02\?I
M^O;-D<&R)6,U*#-)4ATRJG_0WBV<Q?;E$2OW-%=W=!L5QZL(H0KID;[>/%2+
M2@_""BYMN7W0,<C@*Q^_,M+)R:S@W/SFHGIN?@)"Q&"51+/6407@1H"?'S(B
M;\[V/SQ)+EG)2S!E<O4Q$XVY]VC70D$+40TLN8J2)8M'@<?\)7UU:@]AN#*F
M54(S]_HXHY*MP@UBDQZQI\^+18/PWO3G)-H!WE?")7V68L_H1R([O3<&!M/:
MK&YL(>O'U.L>,"\XMU]L(^<&C\&L2F+=?.7V[$M:B?/-E72@[U;96B7X6]1;
M(A(#GU2C\G$R@#4,<%_FT;Q-=<.'M;IT5%/Y2<:\6,BE?FK![8[R^I C!6^G
MMW5PJ9_ML^=/]OFI/O!-_Q];IE\PG+Y/S)<P )5WET'C2,7TQ"+MGB$-91?M
M,)/;D:DLN7([JJU$G?""E&Q6*(J]41P#Y&;EG&SGH$*A++_>)_AO _6_[RFN
M&(.EL6RM[Y&WCT4GT8/+&."=L:A7^BIL5+A3Y.&:5&FWT)@-^9]"C?]I-@AH
M[\-S).^]RI.!9]8%/?</J&ZN]88G!_:PQSVQJ-%H9O($XDBY&4110B&E&$#^
MS-H*-J(Z-P31RO<E00^/C[93S1R%L\RF#-*N&)92&Q9;L)G)6=*KL<8/]D-9
M"K\'$DH!HUW7?(_=8\RI>!;>XV@E)P\AOC$F65A0"H(T7 'Q$GP46V+;,=\Q
M=:K1_1[F=I>>Y4>['RS9HI\,H"2$EM]<\)R!XX$EORB<)&Y]I1;0^^+6'!Q)
M$R'.J=$.Z#ZJ!8L!UL7 U]PSAE3[BA4)=SV*#&_#!,QKRNG'4DVNG]F3S"L6
M)(A7Q(DR88(_?/W\J=[3#LI'"NH%!3@_^10(0 QPQL,YETMZ=S$U +8@,?IB
MU'>0MW\7 _A4^XLH)_C-OLO<Z+H3M385$-HZCS7;K80OY5\<93LEK_KO.?9M
MQ2\CZQ_3S\:\%!NL!%P;08<,&( @I=2KZ.1E'U(G!UG":S4H8IFZ=11=S^AR
MH.B6?4T=4C#TCU9TN.TPP,[6E1/71 P@*TRRC*;#OG0GI#4&*!^">/WWPD86
M)TWMO=8Q3^6[56K<FJV4VM0?03-P@G0IPP9!-6Z9GE^@_:^=%ILBI"EZ&0V4
MMQPL3 HYUJ-5<2]5&HF]?]*SK,K 1]'0"+H/'-NIC'&.+<2LXL]2E^:%37#R
M- MFDA-TLR'@?M=QI U*L6Y,>(/YZWE;?8=U%V*?XHAP\TB;&''4F]PP+C-_
MT_%\W,3LW'XR2N_1#@Q -&%TWXKQBTR<\AUUCDW_=.7%>$;B"@E>!6*XO
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M.US/*',BN\4D](Q^QZ43YH9_5Y^'0L+4K,2/XM"F*[I0J>:HI\'D1O9\WJ,
MZVOBU%9QP#)6%Z<U@1#&K/!^MOPNN^+U%?Q +W+7W"B-0F,&";*U1\%#[IND
MU?5>-,8SN= L/XZ#P9X<Z/F<OZ!GUX3E;M+XFKF,]K62W>2^7BF=" )JOUR
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MU_$7[1:Y/_(7U&6(P\Z<^A^*Z<]Y?'!HTD<4<.-32\<IDQ-A=*V_:TY_.0R
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M5\ND@Y-I= >NQ;$ /70BB++ZW0.&AS>R9Q53V$>F8I/'EA-<!E3$F4/BEJ.
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M[&LCOHF0[ORC-6:,7I8-EM0,BD@:F?=IO^\SHIZTSG6WK5:>DLC+QPPT(H@
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M7+\,Q^-,Q[7]0PO/L^G9>B?IZBBW= VHW/_Q-84O@.#*W M@[/;H!4#PZ,]
M)+@D&_//\248OLSDX$->YZ9TDXCW(;<!K3"0P'69U% 69Z6W@.W_;9O0PZPM
M]C=3CX,49\5&;"*N?.&P56C4#/QLZY20]N2T49=<6#G;YD_1D8)^8R4FUL'W
M+'D2/0]/%(C -1S @DG>:;SQ8F9+6Y.Z$D@!PIW^Y8. ]=I-;H3V'FH^IL=_
MIVT^#"<(93+.E2(=NEG42[+"=A?B_M]3DE6GZ'R<T2&D4-RX6F;=._MSX+47
MT@DP@?608X.ZML$$LRY(!-'3MW]?LT+QI(^-1OP" '.H%(ZPTXAHP[RL$99+
MF@85J(%>$(*&C!QKZVW8(W'.6Z\ZRWV >.G9-S.84:K9X%PJ:\49_UN#Z.U_
M7ZI!MB>VHI:QNPIZNHH?;&2/<DI(<C:>0O+&- CBF9X0SEW"P+H?X8F&7:OD
MNTCUNH@UJR3_"8X[5 Z8N-72TJ?7>T$;; ^!P_^./] ;>Y3+A/58!\;?!UQT
M\;?+%D2F8P@*/36ZR2OA(Q\M9K"\?D)'.0Y[K-/E_)_NW$EYS:%1/!N8BY.0
MCGK4Y[<AHR%:%G09QY/;O1EV[L@&:P\=[5=%// TRNI!3E)E]@JE>6X.K/1_
M7_P(T?.RLX[F+Z6F5A43(2W.MJSDQ@*K+]MI04N_"[9>OIY6?M];+\;3BXRY
M03P-['+A)%=04IK]J/X.Q*C.+D/TH[UWKQX&5S7U")Z]1N?T3MJ.W*ZF*'8)
M].X;#_C?!^#9?/]]RLH:L+T]IT3^I'&^"311CWR)!0;,T0".$##W9EA.S%AI
M$SN1<)+$3Z_[X:Y);L^>5S)(S3RU@6W4@F_^?]N[1,0=>6IGM_CEROSI:YX@
MWFT$3O^'1C&9R#=G$(*@#ZL,1':8W*K::Q%P*QA<[ZZ"#3JX=P&E&*3.+1CS
M"O//[^C__0 ^DSWJ,9_8KK#RE$-B]DN$]5_8X[.Q\*#^%T3(8)E G7<\\)FC
MO['H'^:/.,K?<QQ=*A49]7W7,BW!H531[TQB/;.=HMEN+A:(E[Z$[HZV2_VA
M4_"FA-6\WBH^/.DQG?YT_'3%4/:5%QNH/FY:XM%=O5X'OMZ#&W59+NOXRA32
M8[=KM'1:;AP\W]HMI#8*'A)YUORWC3S$9=OCPXP&^AP<B=;F=#KH 7-U #3
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MF-L7?4T>1V00!D9BQ>8"T*Q/_H]+)>1_&_NV5WHXCJR4\&RQ+PN%!(5HR7=
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MVIGC>.!M%P"9JMKY^_/>@[:)MHW$ ;F-K+1?A_8GZ6<[CBT:1/7__WJ0.>A
M[%^A\I'3970T5KW4BOG*."/0:@&L3;@=VS4)MSY>:[+"* W)FMB"L_\1Y3#<
MH:U_*,]GI;8I>KBJ^JZKC@YMW#B1<W&_R&"1%1"H!G<E[[D 0N+'9':JSVHE
MC]/$JDR%I&:SQ&R2ZN7ZFJUE':;6L;=X YCUHOS%[5BOQ,D_<P\7<@>M>2RI
M#U7RO>HWPVPZ,D<MCHGAVVS;(A-EV7</,F2U&PPV J]UT7GO#O-88S169.4!
M8:.@!AHH@N;\;S./8S7_<":F3-+ARZ-B&9("<1<1P^9\[T6$)%Y6DS_M5=EX
M\0([5!J?D:]@!N_T[S6E\.]P$JSF.=X8TCBY\_:D=RGL.,_HT2O18Q\H)9I5
M?M?QLQR1=QF?71Z^R\O-GLV.*;FT N-Y^>97*?($?5"0,6C3^4S;/C3HO&WE
M G@O-D9X 4P=&#Y3NK.?#@AL6X>+I">P6P\,2$GG/^HE E:DD."-=S>O'<TN
M/Q=72N;*,%%D_T!F&U@^HM&H:SMVG1U[H ]H4V,IOA_V';W^=;4LW'%5B;%D
M#JM,L14:3:%MR;MT9)[7T#\/:R<J?R%GWE_&'_3XP0#+]Q*JRE>VN4B_B/8B
M42J?9Z799Q]13%/@'G\B;^?'F8CJ>@,0B=LZ"9U^";'D/6%F3N"S"<B,&,KE
M*C$&K?"?8SRRJ:K4D]))-. \#ER*R%-[_B(K$7TS ?Z%*8Y2?9>HB*V+C53>
M2\PGDB4[F9QN;J(R$=5 &9NIR;I)?7H'% ?(.A])[BZ;1L]$]XSDBP?3>8WR
MOCJ +_#17)DF%<Z+8M?1GB)84P:^70"/A0(>/@]TR&F;>-7-^(BLIW%5ZVYS
M.%A:C$"""J/,"7% ; ,_RZ>9NB>>/.51&=FI'MEEYXJT)\7Q(%_^\NLLB0(B
MLBE$T;>* ]B(O5=,LU8*PFC&YT>G9RSH&KX5T1P@.PP'!ZP4KC\(Y:1>W7I(
MY"M8=$+SM0K3.;.^QK7R1&7M;E!\>G'>G;TXX2XH--T,ZS.Y);FB]'ZY=O==
M2WYN35V HSY!H)*VNL#=^#$>&C/IZX)B!Y@KP%,][ 5@R7*3B?WL#1*WK:_G
M<R!!;!04#XM*,&_&<@U%]'@!M G9E(1'C]PDNR[%JM(3\/:LO_U<'+Z*4W6U
MDI?IRS<2!$K++0+X53ZK;DJ?:DD?@&_YQ1YQI5W&)9=A1%8+7&,#+>H MOJ!
M \I .8B@[/79OFOYXN_M#F?'IVEY%M[E^=RE[X?%18]H_KH 2LAEVEZ!8RMW
M5UGA>_?H=7%P\U"=.D5/X[?QHD0/V@=T\?0 $5\C&D(*_#*=I6SWU'IX*4+4
MD9'N)5=:B(GWDX^CV2'V ADA"AEX68V;NVB9[X?>9YG\YYS3@[Z^_(-U;C1(
M18;MU](B@K'I.P! ).PC=8R6+I]Y Y.!YQA\.2S5@,=!F'WBNZ,L;::*7Z2P
M2MJON&4L6M( -TVGK3_+D7D[+ZAS;V>JIB5)J_=7GG\-98IT(7$D\FF'PA%L
M J="$QYL# NU^>DXIQ9=U2*ED4[Z>%8;3W,*49!3,IQD?]]K"\%2O@7>Y1U<
MBJXMZ7)!)M%4\^46SG1H,\1+!%00(>S-5T-A3O'AP.^KAZX?.<=EA)S<I!TB
M>+97/3M0.IG6%E@2%) .J&=G4V9>?KRM&S]WJ,B*++F60I8]!?XU$.'JVKTA
ME>9B@5/N\\-2FOZMST;<"GH<?WIS-R^U=/C=0Y5UDL VB24G9@/0^4&OK$.#
M\6G4=22X6Y99?]9/[>-ZZ^2V10A-KP%XJ-+)? %);/G2&]UBY46K2)+ 7PI0
MSC!AQMR+ENZ#NJC*N+6]4A'^F.B$N0IS!6&'LG8'(-A^%;SP<W!+J:.5E!(9
M(MV_E:V!EY"Q/>#@,"M.\ @.O!J-;X_K"?D&[)5/EW2QLNX)I3F4DG\6#U\M
MP8_UXIUS-'+??%5-IS-78?*K[!J#?F@C/[\R[2?E&UHA:KX65R5-I$UL5%R
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MM"^15O">8EVSH,\MPUJ4+)-F2JO8,S278NC1=RRM# 8Y _6I;D<YL'DG<FF
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M;GY[,>]1F@6T=R@PU!9ZPV*I7T9L.9G_+5*TAZ+$/F*SV9##DKP@ /?V%3]
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M>):C6?!3?PKX^J)EB149 *:;RR8@!'PGMY[M&=?P>;S?&N%JBJHI)2M!&E8
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M=OOO#,DG*P^LH7->WT&0P!S.5\0DT$@L9>(YJ9]XTU$"LLE=ZU@BUW*BW^(
ML*1!(MR/8U./M+Z1[C@E9]."?N2>BM8><>9]FY28O$IYDYQ3<@%#_+X3C,G>
M%KNKMDO+P]<^,]+.^N2$ZHN)Q]K:]J:/AA+]D,>!J?_F1I0/JI?"RP.V"HXX
M"EWF*X]Y^*6VRN$]G%%:QWJ6L3=72(@WSY'8TK[([Y&L0S$/N.FH\H37P%M2
M!7?.5R3SA5YT'4VNID*LHRLN&)P1,E0=\$L?>R\"Q+"ID.,SF9347+DFSVPH
M,CG\[*0Z4V1U!28U_\$BCD+N[R6#D]8 NAL.6K<XX((V#I6*3/U;@<[%9"+M
MD'1 #> >TX!V+U1YIO[^%4;XH8IFM\M%FOY?7>)&*7.W].&&R@&D12M:K/:L
MX<;NJ)5YF6L)?Y72 6$7G7+Z!4 BQX_UX!4;DT30R=*>CU2=WJV+U9SDSJ"Z
M'6]X)X>Z)?DC1(V,B/2%8^<F8>R.%\NQ&07#H6M]S&P/_5X'=QK-@"?-_7S)
MPD"S\IK]1AA*)FIQ#/KY%?%!^0R;X3,F^7>)PB2V=Y0\E6?%2@6].>/*E+?2
M+:D[B/R6=I665C]S[*Y7O<_ZV7JWM[AT7VQF??'-^]BV=YK.*@/<3H PI*TR
M-+(WI7#8;!7D0<S712^JT!@8B (/VI',2?$"B-UV6!9T.;:/58!!E:GFBI>'
M1R Q#PBGGW)(0X3DH>12I2I +&*?AFYUO&V1^*1K=@5WG[_49[Z)2UM#JE=$
MS";0E8AX \'Z?+>D[_).%'&S7YL,<'#8X/J-VKF0VXN/]LNN,A$$U !HZ/]B
M[BW#FHS?]^%[;#!B=,C( :.1EA"$T:6"2$K' *5!"25&2@P8(U524 GI%J1C
M-&+0708@H834@__GU?/B__7[XG?\CN?]CN/>[IV?ZSK/\XH/7N>O-J7:+:]9
MKLVY]6#L7J3+%]JU?@J)+KAD=;,,M#\"0X8DTI8#EMM<V^(*5&O/"6$QC4T&
MXS3,[A$BU$.D:U-^*^O$LM%@81Q9F_-"1"YZY_0'UY12,7AMM]E1GQ7)!IU>
M$'ZF'-4:G# P!DTZ[YTN]+OW48O'[G5MNEPOV6Q'06HBJ*^?E2V+2B(+1PJ=
M^?6W,D2=%NH1>OPT=&;A?&9,ZM61ZRY($;Q(\'Q!_-F#B5'N>,TU-EQ45M"6
M>FCI]E9<]\,\ZF<A;('C/^X%';(.W@IUYSN<O?FL"93K&[SYKO+JZ! I/V(,
M.LY9'YI$E7V?*HT6WF2_ARVV8T/K$A72@74(MJ:9<7L4MD2<T8^OG HGD5YJ
MEWFC0P,=(4(!G5AFN(+& MQ)60IZMR_=49Y<C078H8[@A'FT<LU=>]7<8L \
M.LU'T<08\D>8\BOKPYA&RPV>  @7 NQY$'>DC]Z97J=X(EB(ZR?SUT&)%'@;
MVWXO*I1A=N\URD<N10-*N8T3O6%+D$91!^&"SJ(?C>+)6U_D*DUQ0;T&U []
M"-@8-"&D^_J5[,# )\T<1K0]->Q!$PO-\BL<MR4BLN<TY8&5\VN-NQ-Q.1_X
M%#C6YS^;1=O!C[EQQ/8M(J]&2,!LN! W''7!!7"_(FYK\8;R8(/<N^8%-F?1
M5PQB/WD-&X\S?**.4Z-MN[P,2:'AYZ,+5-)7;T-;)LIMB3,+37[ZX' %\+3Z
M@6K'K))2=X!HTI9@!(YK_+#<O$NDMO14)'J=J<[/U#UAK\F>G6(SX="QNHJT
MR7T6#_K#B4I2/OJVRWI.0REJ42B7?0$\@IX]\O*:+14;R,^%R=3/-0V2DP25
M[O OWLQE+$S_\\?4PCBYJ]'VXZ @*(8XPH$U0J%2G@#0F>/ 5P["CO2A71:?
M&NHS"7A5)/G*89&DZ;IM"99"4,@48AM])\H9^'-7Q7M1G_BI%*/RU,@W[F@3
M<U%_190[,ASYS$B6+:'/Y2MHG;.**FK#VMIZNR\-XNW69W/M<'LDH"\%:[OA
M?R<1)6<#=]UQM>9_5K>1O+GR_CG?S&?[1"VS,>)5A-Q"S0:B6=11'L&IZ[)0
MD_MT>ZWN4^U0430ZC85LZ(,V81'3JR:*<D1L"@7:WD:U0]-")B_EL/7RHP]7
M9V-6C)_@R$!SE;OY ]@H2V6840:<M8 9V J"GB"^C4U1;TD@,WPZFT>?5:JN
MLL5T.Y8RSH)$'4V$&X'",B! K(OB62OGT7,%,TZ_F7VGU6CC9!8;WEB#!2T#
M'5!G2I8!=.$7Z<JYN.L*:ES,@R)S8$;W_^!H8C">.! ZA 8.%/' ,%B)[XAK
M9_S'LLA'LPZQ9 \'D\:,P87.W+F^Y :%7,K*=Z5N\VK2N@#)!;#%M6,XNI0Q
MI=2]KYR[\7/?G)55L:QQBB4T:$-^:QQSHZMC7OJ),N2L.E#WNKFE!EL<>75E
MX-4MS%ZO"M0^^COU4%^I 33[/Z-V[!]AF_T\?*4]AX+*22BT)GM< _:VVG([
M #.M ]&1+/*09TW\, 9>]PS/I11MY=41S69HO54T);W'?-H.A\22LBLYK+<R
MO MOGED7( :>7 !Q(7"Q#G9ZHZ;Q;3ZZ6P>V;V=D7\8R28*%DC*/J]D7!0U,
M76#-D^"!-J<*6,"3[E;W^DJI@'%^?(6P&JM@9Y1JXHM7HE[&L4CWO3YJ%*?A
MJ=21+'IG;9NCO3\^796P"3?@\BG)%7"C7 WJB04<-Y"8H+3_0@?_,3UX/=&;
MG#<KNI>DH$'G/DM!MY0M^1X4:R/?SB/DFT5#1?_7I'NA,#@WM>^<>#7SVQK?
MV=2H_'X5%N;^W;<=BC]U]5ZI8+SQ\J;?C>'W)56P3JD]#01Y3X"Y7A:,1!YQ
M>JG!/I_<_['\\6;XF+QISJJ$2B,T4=K^N&\ Y8==_"V'8&\"..QVM!:C^GH4
M E8_O7Y^56GFL05W%.MA;9*@ZA28CK9I0.D"^&WW-&,/XWV@Q!;1I208/C"N
M)F+PO9Y0/EA7S8<:"( +3:FV SW^ D 8BN/'B7W0G6 6TE_QSL*\G1E9Q8AC
MQ3S]9H(?5,&,C<N$V 9'=7?QYV;RE9A-_(EQNKI4B:)$)X$4BRV5=_32(R*]
MDU#PDZZ[! @H&^W:I:HYBZMYRNENX2E_!]./T[1P<)<W#(3WJI!O-MJ#_NB@
M$H67%[I*E=FGCEDBDQAH=38R--5[N[WTI.,&&(3I'CO 1Z10H[$AX" Q_9@_
M,37/XE1Q_2*OM,UEL-Q1 ]<WGI3[2#3XR_< 3Z!;C$L6^M$L#"PWL'CPC6]I
M71)7A5ZRK\5%W11F1EF"<&]!ML,HCOC_@4K)/_]WZN>MD%/AYJ.<Z!%SQZ=Z
MX0["C ;&K^U8&. \&WM/86HQ3W>2I-:!]5;Y(Y*)]L<O)LUU]UYJP3W%@[X.
M-=<S@8S/#<O),8#MFS0D)MCFY,[IG5#(MTY69\%'#WMXT$A)[L6!Q2T>.:&(
M-%N;QUFO@/]!_[)MY6,2),!T4\F;BJNN3LN X"A<*7>L,\TBL(#(HDU#;D#
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M[.A.RAX!:EAP ^SSMS('/!3;O$7>>W7F$,4[(G,!E/,%-_:?M#K-'O9Z26%
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M9C.I-!.S,-S0E&(DU,[W4&6JN0[PXJSU[X4<)3QN0X].7?V,YVXGVNP[Q*^
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MGU7^;OA8JR\(<"^O,^?*$PQ8W+"T$>]XV59M<Z3"09EM54DIZ,)1A4U-UPM
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M1_]2QE_O\4??.^>H4WF'0)%BRLIP@7[R+LFD= -:4U^)-,LJ ]_HH+1! ^@
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MW'776%,M)=Y[*=Q<4SQK<9^ ,(!63]_C?2YR1T!=@[PD3Z@D#)-WR:HQ4,"
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M^2+0'V#7$*:Z-JT9N@ 3@(\X33,XXJ46 /CO"R#&B8-B_/63:X#YE+:=YNP
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M&VG77'5.J!;*8FO3!?XHM[<2U^W<*#$WYYN<P.N+;GJ_TY*#.R3J P CR@"
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M3HD7M[A0J(\197$ F'VE -B\N6_0T/1AZ0/BR7!3E":'"%[8NCN&59)5;J3
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M-P:"(=9Y7M"XA7W%TX5WFU7U1R]J1UT\D6J2J]2O*A11RNGZ;*N623YR'C[
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M8C/)X;T$@K8"9EL;J.A!WS@)]LM5Y6M?&#:8F1=_K=>E5YC=9NDUM9N\(V'
M_(\A;T$!E7C#5= ?R+4\I0G!262^/F2Y"SND9W]CT;$1=- S<*A*@*?6E7Z_
M__;%TM[CHL;?CK&O#2U=YSLQ#,941IT@#, O<A5$$ZC^-B1&Y')F]*]NMUR6
MDOO[S#6,FK2';L5[/V-:Z\]^F@"(?TT1S NC/KN[OYYR+38]J]Q/SRF@8<W.
M4*O<B@0=>L.PB' ^U$?5" 1'(D3/2,=E4L>_'&HWRNW-UTE2ZM^\*7WCD/:
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MW#$S:_H0/Q8,&=[)>/P<_9[7R; EW<=T,1CGS%Q =?T\7FSAL65L)'6BX^!
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MN.2A5H"Z\LL0$&RVK;]D:0/=_*0$/UC-(LPH.(T?/!"&,)^8X7L?(#%,9%$
MY]?]\:YU;RB.;U1<=DL.J":%9FA8*5'+(8D3V[YM(K#L2"J^\^P+XDO@4^>"
MRDG8UC&<^Z[CW >'-2;K)KA@@@ ZNEL-9JITYS.EV5',WOODJ,?!(O430:M)
M"HV%DDZ4O>Q;(A;QVT[\OL/GTR<!GZ%C^0T&N>?Q;:;G^>XOAN9:O(9J'4(5
MYM8]NG?DMW?C@4.;F8ZN4#:YUSTF$3-BG4DA/U[JT1KZ84\P@N8-I5'3-]\I
M"%DL((%_PG /"&KWM$0]WW:M:8VQD.X$#E"7WG%T5J$G=V%_].//&@Q5HJSM
MB^M!:)/IHGM#[T%\%J*KIL\*55W-),ODB S[._=("ERNX!M]&]CU2Y9H/^XA
M6K:5[C9[W$6+GW O6'<N=^* M(;7[<3'Y"8RZ!+8TB_58RSV]V#[;>"V+K7D
M-]H;'Z/0BTWM!N%&8$NVX/CCH9*^%36Z>0ZU)\->*]%B6M[KG;2 2:-=6%"F
M:2\6IV2 H'K32G<J]%V51>+6HN.4Q"W,2?F:^N,'3/9GK\ 7>Y26,&&E:\9_
M4,X5-VIJW;W6XW4)\ [FA\H'/]WG2F\Y#O0\E-O(\>YA*V$.(9ML%5UYP5P_
ME^WNNJO<+MI9TN98KFNT/XR5VW Y,91 4YH039@64/Y8E:MAPET"5-G/),G5
MIW%$+',#;H&]NTUM>QJ[ NIPU46Y*V;,?2IY!FG<G^TK>0A]5N\GHT\L4OS5
MOL;9"18%ZB;(J7O,;48)&KD8SZ?T""$IN4&4Q\&HRZB3L(96=59_/_,B9PM>
M]FR\UY[M(?#T$M@)85M*7G5\)GV.F=OI.8-XTAK\(E:+34(H_SCB&J5USY[[
M=.=X.9Z/W?.*#-<HNRA&^?8R\\/VD502^U7)#L>O*D2'7XFCG=:).SRY"QM,
MG<$TY47]ZOP*=NOR=YG9$$J70.(#J;WBX<PC%4Z(>WY*?YH"*T\VB_HA''6#
M=R>A>F-P(&0HFG0"]#VL9B2RLOZVJF4VY@?'1.SGSGF*TK>_L5ZK@_-0(1+S
MR=I^,X#S$OBSV/U_KG13<%YU)OHV*/2 J^;-P+NSDYU0-[: WVQL&WPZYOJ?
M'#BP;*[@&57",\*QGS^$.6[J:C5&,V_0UJ2 BCCM0[>:DP68!3R;^V.8O9"<
MRXCDOXUX/8F.7!*5OJ"Q-)FP#]ZVK6<J;\FT\4W<>%;,JKPZZ%.0X\ "3YP
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M6.-=,GEQTM)/T$H;]^<'(Y99 [<).619>!I(URS,[QC!.+)AD0F2'I%]*M_
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MI3=3\B1T-P7 XY> IUHL%1"I\T*(0^N0$^$TWT?K,Y_8/XA+9Z%!^5$ C\,
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MG<'1II-,TL0NAE _8QA9A(0$$:#*.%Z./TZLNFXNW74TUQ+!AOQ!7SQKA%6
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MC!1-NNFMD/#]IBA^\"X#/>CG1<XB^9Y,:(BHPVDS(P+W9>>Q1XE1SH \A(#
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M^OOSW7[I]A4HCM"&_':OGPKBX"A=\0@F#C0:Z2^9&]R99C%*JQ8.+.!!6W\
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M>S)H3A_&:-*H=;&A="H59TBSB+H7$'\HM0M[7R'PT1E\18P!$2F&2'CCR\:
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M$#+$]JN-U9TU:8 /OA:)Q!D,2FGKJ^6G7UC?_QZL/EBM(ID]6OFX777KON<
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MT2^URYTE_1CQ6<^?1(MC4B)$2G4:-5):Z9>MR'.!)6%5(2J2<=G"79[MKN)
M>1__>.1^D:CV^YHWB5$ASB::QD$#8FRO3)UGM=W +7O?PY_MO4UK>3QTM5=B
MI$_F6=^4)1FU*$V9+"YP[%/8?] ^0CAZ=G+-(EBGV6J((*BC:P;G<_OH'Q4
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M5A\KVH1N4<YS9*V.!&,Y]:3RB(X[10.+@^1S73<MZK012>,-Z^Y+) 1!.3T
MG!H_V(GS8Z+XR]WU_[@0NCL5>D"05'FWO(_PG>=P2_8GD16V7HST?E71ED=W
MA6CU!W;+-;@,R OX!]SFXW>:]$O70KK&TWJ'-TOD",*^_?=]HV/?3=S(+PC(
M6=UF&Z'N'1RG*+ HV1C<6!_2ID#6:?"BP53RO9)BT-/>*=$8\>S.SQR>JC>_
MC:W0JS''(V;?<]SQIL<(!;1"*J=N\S]!Z0NJ:U 5Y0D5A>'R: $P#@+H\=W^
M#PV3CG_'8^.CS:*%RF73];?IB[<U+YHA/(?X*A5D^(R1VP+RPX'R>8ZE>O!_
M]!=YW1@KVF?$,)<#CLR+"6(2%DWIAB)U<L8S;ZA6(MMX @T/\NRLJ$]9IX/E
M:ET49)+'UIRU'Q7++!4^I(D.9U.9EA^1!DW\X]__^\0YIGJ]$S*]=%N#>:7J
MN?I@F^T](P<X,,C%R9A'_PH/EBT%RS21+10&,]BSY+H.CVFT.">]]FF84DLI
MRB_FM*:5^)FGI?(/M16T;"EQ\L@W\<+,NV788B#LB0I37$UV9G;6X6M>TO0O
M!8* C98\N<9B[B2'QMC%"_5/EMTIM&=O*^(I;"L*@MYB7=Q5*<ETV8"#?W+8
M_[^H6QS]_]8'_!_Q?\3_6H+G<K#/2:&8(L/KYEPL$ZI"B^>Q@Q:R42QS[U%:
MB 7A'5JASJ\MSW'\7THU4SUY64J;S*'KPZ?!N.S3VQ\MB88YP*$IP(@W&:#Q
M/"!RVE)-)&ML."PV/>:3!A3@UU;5]%3I,6?XCF;_K\YEWZ3]3^K._>[?,_<#
M8IFKTG7BH[ Q[2AO;>[EM4KW0\T-DBO+%?]WD_]O'*/2W?,8I6<9,'\G49=!
MM=:[SZM\PTM.(T$;,1/\Z<:\X"Q.R]Q/&OK[7VK+@&)*B7,=*E[,JQ_HY?7:
M[-/E)EXCR4$3G'8,.9F0<9S,%W!;""KDH_."B.H->1%H-W]B4*:ZFD]A,(!(
M1;B((<.S"-8D*CD__XT'98<=R[J;EJ<7&A\HWXB4YV;11U9*!/RRSH@WEKF5
MAB3I"H-R47FRAV6+M='%LJ_'E5VL^U@R/B689W(&&*$DW?VG>090#]-XD2NB
MDO5(7SCW1S1!QX-CPD+W0&XKSP4W^)(Y74IT=?CG!(>?)JVFI+C/OW1WK2SB
M#*@A6X__6?]CETG8$97!0=MSX:'I2LK5GB&[V;WX"=)[/5CTR(O_AE+)^4?B
M-T0<CS@S]$3:[/6I==@R?+"V&R*- @@P3)[M.YK#]U_IRMW0\_\?(\&8NEB>
MRI-F8=OAQ/70$M,7\)+&D(.E*(_9Z7I'OK"<NMW4I>?!4I6L90R/J_L8X=:X
M*G+7=-YRDGQ?8^2"-0D&B%IXU15*-*OU"%HYY!!PJ@W,<?=,;M[8T-U>9MO\
M_ 3X047ZWVLIYZLN9?8SH)WAI?E=D+^T_G$XC&SRH=<61\;J7(<?A8)/@J<@
MK#5DZ Q@WU:Z>%*V^9HJD%MSY)*%3\O0;/:>\G]A+%.%?T;.EJ$D6UZ3N^%M
M@:XC2U,70=E:#,7'E==N9!&@=BO84L!M]!]!..4CS6"7IXN/9,X ._7 ]>3=
M-6%I&WJ:,\!/W6TZ6^8GVVS6.8PK)DHMFS5YO+CSC54H#M7LOLAF'>Y:QM;J
M@!W3]-:5_ZT'<?G+*T2I8[72E^%N__)"%<9O78\R8FH (Z$+7BGD0;' 3MGD
M]X.(%F)B*'_VBB<??U4_5(>O=A'I!)I'_)?=+JDOMTG_;:/_4T6@VK&[H1FF
MYG&@KI43R,-M6Z7) ,S_LM.<;7COH1\_V=8%OM(2KG3Y:?=OH^9GWH65 VM;
M#)$4,OV[!'*'JTR.R/W<%X#?N7F2"#=65VFF&U-$O\A\'&&D)VF:V@IX:R]0
M 2.C36:.2S3SMO61#Q[/KV)2-H?]UFWDAFFE/I_;EM0I,F!1D>;52&%OI K5
M&P8,66:F/KFN2D/D34HPDAQ!"DXDPG9'3EE>386.-8\<A J<WCYL;!J1.LU\
M*5$U+[^9H))3_/^8PG-D=@;0+Q)#L?S'RWXS0IHPHP(_.4/24]0$Z4-HVTT)
M],B3A9/2FLT[PT_ZNUGQJ*IDYLYF@^"NZPDI0HEI-TTC(*0+M #DXRGWD\#-
M9T%=E)ZCW0X:J\:J>6\3,^MIDN05_:\Z,<3L*B]Q*M-MV+5DN4]'8#J$JA-Z
MJ'"Y74^!I+#'E[H%8?OF/#6U[XH#WYN9MN]HI'OSU6?TZSY^G3RNH;_W>H ^
M;R'K' ;];NEXKWNU6BS@F2@[VV!O4U&O(:O^OBRH$B*0L%Y*(OT?\&L;2C*G
M8WT[W6O"$JZ._E%#V#6*-,,JOK ]C.DJAR) +G[S)G!5K?W^]C&2Q>]7HU_@
MCH;HX-;T._#F,+E7EB-8"1_&7OVOE,6S!:8D)-"AP'M_%Q9W/9F/G():W*'/
ME@,0DM6PO4D.('%VRF1*PN>&.505-"_0.ZF@436X[_,P_I>C;6@H6X][TRCD
M<;#S2?%\N[_'JZ_E/8CV?F2ZIACW!N-N47>_=P'.M)PW_-E-\#G;W%%;BFQ8
M^MY7^M-%NC96D/D,^*@#?9I]T+,WP,N/T9:G)KRAY** U/R/0N?_(P3_U+D_
M#HY:]$_E23N(69N9,TW&3H7';_@U0NNH]Q;+SP!Q83ST!QWE]Y:=)+/IN<W)
M]3:F1JE&]Q]T=7*P;J\LZ&\JTD"32&7GQ\$ZI?$L4S1CL(L:#?N&D7O+_JC"
M0A4#O0C>0P..Q$;TD%7\&<##2[18Z5E]\#RP3C8=:7J0MQS$]:9#I/VXWE5Y
MD&H!YV.I?/)FHTG:F", F?.@<%RS4Y4/55!]TXMW/VGA"AFOMI"5=]J?+.H9
MFS20SE_I\WTROQC>[#QM^NBT5V2JU-D&;66&>ZH8S,N,TA8O.7;=$8L2IXY;
MD_>;YG0"7UN/GU81$L];C8'3DOM+XD%+[%:;7= 4P88*W[CL(<X!X01:\5).
M]#[.NP,LD&6-"PP)"S[W(\?6&0P83IG\M>X-*C!-PUPX2 72%PU*HI2;44&.
M0CZ? 1>4A":#Y7'F5A(#M1/+:'831?<I2OT("$H;\)1J>$1/1S]^!K@+VB5K
M#,45F&\YK9F9>WI%."U!LL#I;##%95)PS4[=IKS'4JF]=)Q@<"]RMO)[D*A?
MN[W'K.*UCC6#K+HC"[D\.J&35R'*9X#K2;Y*S74MSF^50XT*Q\V65^/9A&NM
ME:QG-I:%/H!&3D?FJWF.X?3QLAN)7NL6V[,<I_OK##TUV G_NH&]^('ZI*9[
M>72E2KS'NA7$4(J<TQN-=11C*LY((4DCPQ"PCPU("!:I 02(S&_VQV[PO1^
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MX9=#;@.EX3U2NQ(2*F $I!KK'O(FE&-Z!9I9Z+R\&E887U.2<M-)V8?W&ID
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M*6KD&%>)R8=V %RZGV$UPVHYPF.5(6H X!C>_KGR(ZF'0@0Q-=P\?V!1R&_
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MSH,T%HNVA[0SN'^N5D'7NK!..K[;<3K-;Y7K5AO.!<+-T*/<K.FJ"#?AM55
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M+&3ZOJR7/O78R6P4:T-TEFE(YP+E0"ZW:6.Y1N95D!F*9C7T(W=A.#3 OP0
M8E>VPN:4VC'^K"T&O-T2DI(*15JHTJ;K)^8L^N2"X4K;LI=A! \"_<Z%2T9R
M<ND.-G!S=*<A#82N$QK.3[>F<[:<P;*AU3C*$HH-O5I:LPS.UL749&HM%H-:
M<&.E9-'TR5G2R?68->ZE44"X##[&X?T5==X4A;K;<'VM ^UDS2$5MG^.IU+X
M:GV<6ZL8$M#26'M.**%IUOZQF$6+>^)5R]S",)Q//S(5-6H-/N*9/()MB>1X
M\ 0Q"DI]1KKG;SA+2#)!=E$=2-B&<P=91=S1>1<\R[FB(U6S.$%W9#B+G\V0
MVJ4O$N1(^N)P%4C0N_;-O/RK2-QEZJ%#3)]CIGT@B[QV==/BVRVGC6\$-GW)
M=WZO+[+S7 F?NQS+._8VP9C6'N=5"L"1J8FKCR$^%WYV$#BM6^02%DMPRX_@
MCW(-"_.-+9^? D+Q_!"F3LY ML=D_G_49W)4P#*FRC\5)>#]!^$FI&;VM!HJ
M"*Z(3\YTHX'_<U3QM69SY*#97GR+B27AK<5\>M6$39@5WL'-/R3OAZ0.0#:2
M40IJ^[I$<]>50XN-MZ\FG2^@$0GCU'!IA3!S=(J,\ZZ*?@<>20) ZP(]]VTG
M:B_!NCZ.>8K/JH\XJ,/$UQXH(_@W7+R^T? ^!+ TVN]J&W\$VM?G!%P5\F0M
M1P]5"G1SA4M0P"&<:JA$UXY3@+RV'2P_7&P1DWN5<K19B]59=@X6WZNBD"Q&
M 9:=$X--["1AA8*=6*+UPRX:_-2"R*V^D+="^XV]R2GT $,1L9"@X]\MR^21
MY+*%-567<)DMVI;E0-\.";1D_7#D1@GU5/4C)Q!\OQ,K\/-A)W0N(60!F;H-
M= JQ3$_\<%(3OK5P>&QX$)<-/9EOK0W)JX8. L?<S\/K[BK-DI=;9M>\U\6%
MK.UDKWV3Y10=\C*%P !, ^9A8 )C*3N[=G4EK*S0Y@4TG'PIXDQ.[.HDS2JC
M,M"K9NS&TA[QUT4&)<2DF1V]&TIF!L<_+,C\-^2$0.!?+SQ8ZOLY$AH:5$9&
M#"+JRES,:^#KQS,R0:Y6(7%:%\/8?G__8/E_S((_N7S\Q,^:6:%FF"(Q*$M2
MAZ%::C/<[)(PLP6G.+\6LN&#? F\86DK_ _-"'O)F;EG.K.#05:!MW=KR]8D
M6"(:6*.A,HR@\:,;QT^_;T&$>RM3,4\90Y%*E@_.VY_C6.]Z_C%+\G;G?+*2
M&R6P73$SW/&JQ%JG%)W77!]?Z!:0]&% #+/D[G:U48QO[4,T6SB@-'1&#<'_
MC6\C"S3==%@R>2M:] ZIMVBA82@EW[]ESR+O)57/L\#"L+NEEJ@"<#KH(X8J
M0AV.27;MY&_BY8=Y!@4T=&@#W$U9,4N11G-8<5+=\\Z2GC>)[ 5?]2WF].[
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M%:.9+,%<E#WG3?)I&C[1=1';S])"/,7HXH^2H-C23!HA^[".\8PO+&%]NKH
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MC][?XRRRU/6DSC;,#,[3$5M\%RC0!A$"_D6. C[ONE:^SBL<H0M_V#=Y/VL
M#*&SW<10U(AN\"$],5CH%SEBI[*U9*JYLUJ*\(4)!Q>N\I'6U4T<BHR#* X(
M:TM"$[SIDH_/E*>M?-/>'"^5(OQ(*ER"<9[!PGF/&4G,(840XSMQJG<#*LZ5
M@EU#HZF5C@,B,YF@Y^0[PX;)]H?=IB:I[41 V)!UB/E;T/6'OKL7.]ZI'0#=
M)(G=&X+;^T9-$'HQ#+'58<*E$*PB8;YQ<HP!MT4^T1_UA;C-H%DGI$Q*O'*;
M]I9(810-BK0EP87L#?N?^S<&[OHVG"*RK?3.E03B(","Z,55-69*+10>Z:7
M:IS0(:'])B!\0K$N7CJRG&7U9U\LW',#2U_BO(WMQL0KENHI43M4ZB *R5X\
M2:5,8>EV95&FW7FJ4AXKKBYE"$!QZH->#X'@HO6Q6P&]@S25X="%,9<36F(G
MZBP"68Q?.#>"*,)=6PQE#4L"Y8>=6P:C0JF<AFPHE9;K!$7Q?;J[XL)*!.2,
MA@,P4_((3#SP3U5D)]5,UUT?2<'P;VVOK9+SC;869 RJ(5N*O7[].L]T(.$7
MSZ^ E%[U*Z")ZH\0#BU7_J_K3H/F::L6G/1F(HM)4Z";H>;KM9CY/CLO*:D!
M56*T[/?CS ^KU9-NEY-%??%Q+$R'0]C6-&[6&D79L>*?A(B+%@1L^'+T.'G5
MG5+S>4 )]ZT3*Y2<0UH-/ZO<5 8-HY9?NIU,RRJXX$]ZO>K!\Z6=N)^Q@?D.
M\6(C+M8,F]P!]CHT.*G],]+W) /\X*G0I_)G3.[RNRM7@ 97(?CX\?5Z_28N
ME^7_>?D(^*=27CU&:V53)>4,=RNYQM!?QL:[$1AAA=9LGMPB.5,Z+IM1Q?@N
MW!,? IMGZ;+U2EC*U FT\KN&WUX2E"3E/^-^BHF0:_AW8BQES9PV=TJ%5I6D
MY64>0Z+X?EH1DH1Q!E5E<-@D&7!6L3J>D7_W0'FYTY5&D_^%Q8T/1(E;_%Q#
MT/B^5HG1+F!XM&U<;1GZ.^-OP  =6.P*'BB>#T@H%[]/^]3&YV>R0H7<3*47
M+M+_LR_;E,+:!%U0*'28LB /X7_*+OY";>^?EK?6:D?;&F-'8@A"LOT^;7@<
M-Z<':& -Q7[[@*I_W_2T^]TO.N:F&5=L>4JK.FE"\--X+Q:KVUUVYV&&=W"2
MC(44%C27TR]^1C_P;VK5B>XQLKOO]5UN2T^RKJ!9DV"8G4$(O3M./@F9>L+^
M:>9)8_0A0E$;ZE7J0DSVC14<KN(1V,U];XQ UMG\].SYNF"92["@8V8TQ6NS
M&$O$)<(P)"!L!VX6.M9P7,Q/A<*WLYTK+L\]O5$<D#1I]OC!,!=.*&OH^4L>
M;I]LZ$+FJ#%"DB'=KPV@>G;M8!P\%W=KKX"HDZJ'Y<N1SH+W*E@ILX0BARU5
M *R'DCKOMJ79)IF-"[_$M_-_%_8,ZB<1]?EFS9-",V^=!9/(8T](CF:QS)A?
MW ". 07L5UP!\T8G_:DY%N0F.;C$HPE104;YP%EQ0B@]O1,;Z9;L^]E"VV78
MGQ+A>K.U5Z<OYX2V@AFRJ?90EI)N(VJ2.&:8X7!%\-N*AEG@66C_"JM\6'U;
MH@J25E8CQS".O&7)AG #!W+!BJHQ#^\@P,-O.YW,5ACZV3HBK-VJ@K,PAZ)B
M\\J<RGY/3%AMU2*"!H_XYVTA6'"7?$.:?K]7ZZ;UI^V/7KI*>^E-M?7.<$QQ
MV?PKTR%D75YI93U8OJ^ HUW]Y<!MZ?J2&&UQA""GMQ1LOCMIRW:Q*\H_DG\Q
M@B*E&?SE/]ZZL2-6&OAFW1K( W=/ZIF<7)T(^7P..W^F98QXO5K735/4'S7L
MQ9$2.WRSJ-=J6H,D?7\T0VA$U\@].SB.4K-DS;1J5RU(^43[@VIQO@L(^K/<
M25199R$1X5:=_2#AJ"J#*="S3B9Z665QT^?:09BT3Z^ =Z<GP?EL,[J%\2I&
MN$#(6"X]$(@MKWYBKJ2>.()G%H(B_KR%&S37U$8O#+6^N%#PIU^8[>NPYAL)
M8S?9DP\B@L$>B9/5 +^J$CJD0L%._BP8-61 NF0%+9-WZP#I())@#F&)%4L?
M1T'234.FFSH$XV6>$_<M/3D3@VU:VM3'*\;_:*^6PJ<0GR1OZ];CJ1!LD&[M
MI+K3\;WG?+I-U,L+0M%*<+?8M,P1WVXA@_!A8EAO\*" * EQ5.: 7V9?[6F(
M\OTX2V+)WGJ<9@TO-_>6(8V$AZK!^!60=1/P?R)YH!A@-!QT)GI?M"W*G@2&
M/J/SA!#ED$GQ(0'2]3#6SUT3'.8!1P\TSV=Q?(%(\JV"E(]F;OLE=7RC,!)K
M=0$3CR[ H5"'._ZTZN#)Y[7W92TM,B4NL580*F[*WG?TMDQ>)#JJ1/$58-D*
M@]/WZTL"DA\<IHO,&/HP;7%YUDA625XAYAMG67V2EG4(  WZ;D'6P:MPP#+D
M7MFMU%R2TL2#!!@?KQ(S6RI1%F*B7$JOB03YY2Q%6<_(\9W\LQVL@K,;Z^57
M15'A3>F;$7S\,3+B>J(*A104Y,?A'^L?:E'P]4GJ]IT\I,9T;0@@_1)-8W($
MJH4!>7$&4!(<H0-Y=6%^FBR/KLSX1GY#A'C[2%+R8R*#)I,7PRSEW=UY0"9/
M:[*+0^0"<EI<]H4JZ#ECGERA.Z\*3BW]X_UX6_^)3&A"ZO8.V(U8JIL>]"LT
M3HZS=XU-]NG=PD.JC*B7T%KY%R,%G"1=?N,H;G*T2;J.&G!(=6JV?/-3T>5D
M]701HSM'-K.?^ ,#2C4"Q[P3RS1R9J%7?M%X)'@JA#S8*6(]DE:=U1Y69,D3
MF[=*O+15_;R<F?I--2*<9."3):7@8$']_OZ32G\K3VK1A05.C/"&4%USW$?_
MY_@9VQAI/96>+MQ]'U#%?NAZ=-/ZR)G5A[<4KTJC51-?P*::2*FYF+"1-C5)
M'N7J,  :#\@&'GSR?.;C3F66L+!E)"[FHD"C=T>0M=2:V+##AV3+6.@,!1I3
M/E?^ED_>FK32+ZE.J&]94HU3#,..H@(CLWC\!6I;1<8:3O@1["L;VDS=J]_5
MW?>&:.X7-DZUQ"$%2ME?Q8*1@)9)& [$+NAZ,-/'SLLQSZ*2P?'0R"6;.?"P
M7&Q9AY0)U\E/E@I"V!'AYT&Y!B&R$1M4<?5QU/B401*_&/EO.[%C8F!N9^+#
MC1%^HE1@URH*^/WMKRS<N(LJP=^"CK.EI3F,,U[Z^#Y^#C^PCB$=WR12#Q;H
MN +2C9T*'>0W..:]Y"'.3'>?_PAH: H7?RWZ)) G],:^^'!\$=(E^G*-\[";
M'UQP0+7+5!7@J:_[?GJ:34Y=MD&=M7)\-[$;N6>1#0MS! 315)QX2//CT]&A
MUZ%/YQ606[L9 :OF+XV@81^?I>2R*^[)4L?O1B&24_37MXNJ M)];:M?F+K:
M!/3CW)RX=9+IHNUB//IJZVB'L&;VSRQAOXS#+Q$/R[X>/GWTJF)6*,29'EO7
MF<ZR52*X59R4&"78' 459]:!I*N>*SFS2V.3H5\[;$G;?)IDB1%\(RE"GL4$
M*_ZC?G:<U84T*+@%] IP?//!72OA79?0SX^-X:0T,C@/M)AK29EYC/?;]X;1
MFT;_*I, ;5C0R3LR33: 7CH9O=[[D\DLI$LSIS28+^=!_S/TFC17).=82A2D
M'B=^"*9](,=;38W?'T-2T=GSV5IDT$7G$%9W6_:]VUQBUN] WU-:G4BT/^A(
M=R]]7"Y4>]86:15.4=MN \I.5H8-R>Y\1;%5$LA6;+@/^)UZWHX,TA]NR8W;
M]-C=ZHL6XS1\0#N;BCA*;)Y=:";V?-2T2_'6N7KH>9%3YQ?1@4/9D\?NAH0U
MRK0#E--)S-P:VC 2K6G0-P[B2P&^OA'N9RG,&J,'=QDIP?Q&>$LF1$65H1ZE
M"@F I=1?K]JEEA7SF=?*<>79+JX/CG^KJZEBR\HOPDG>$%\*E,FW&UTS*&.]
MT_-U*E"[UVF,5J*KK6M8H56SI *?G ]>:ZQ?MY&).P;T"'WO"D!]7CV DOH[
MKJO9FN._3R;EG1&RAE.2816 <'Z:-;W+C[W:[SOK\A?;>KUN_EB+E- 4C! 0
M\^-S)/H(D+V*OB!*)9R4D#?X\^IV,O$8?>MR;HKIXIZ8@)PP@X*BIMV"4.DJ
MO6UD'7M9.#_XZ]_+T[4KH)&]\;=?W!:"\/'C7KH=:3+PPY1P4?_[Q;D8N@$/
ME 2X=X7V%]S9T2>9W&301V@M2?I=QVZ.1KGL+TPJ68MP]TDF],R>)OW:4WWW
ME39"+X1$[G[ZQE%G8>9*VZ>]?,ED9]3[[C.A.-;/#N1WLPNTH9W@_TCNO<U+
M,Q3N55^([5LSYRA>E,8AO8O)'%X&$[&I\X80;7:-B <:[M'SSY865' :1R6:
MVVZS+<9>?3>(FA4!:#O6RS,<-+AT.<F2C&$KWJ\,:U:;C6XI./'(>T-DP(2Q
MC5:!Y\I->U-_ ^Y:H$/A5\":8Z](-E7JO<XTY+R_RD*O5::\^ 5^Y<;X5-..
MM1; <]IRL$X5,SUH7SWD'21>H4KF0>(PV^(B-D+=K5B!,R;D1V I%462?@^&
M;V).7W8C&EZ@$F0IFE4\U!<KD MUW6#^!</A.))Y0""D?SXTSR&P5&WO:,*_
M5G&L389:#8YT$WIDOZ@NO5$TA&"KS.QOJUBA'2D<)( [6E(AVVJX<+%K9PB&
MT03V+G+;GTOU# !D8 6SN[_N3'+\)MU;F@Z_MC 2![56+,_BJ>%5V(%[UC1Y
M@/J?KM1+UKSKY3F.>GT%%/;"\4=+GN\-:/OI-9EE-*0L$V_(VG+*J$%*@^&G
MI05T0HG?[EL)2O1],9&"%IEQHA^'OWMOJ";-C"! 21?$67!< =55H34^;0YM
M'W(<24^X%+^8:[)7AC7,4I12X^STW@"L'PKJW8I7<58'M]'1JM%.B( <,1FN
MB^K<6[,\T>3$//Z\7WKR_OE[9(*=[R3^4_%<<4O7+G-LD1M*[9J^P0P=?<8_
MKKXCK_&_APFDW_H=[S1OV!I]YXZP@8\-5V32;<)J':I\[_Q3:8 UXMYW@X\W
M@WF>SCP8(GI+D[2@2V]E:&CPG,%01;VG%!F&2J9J/)U9UX8E-WRY:VL_XBUP
MK[?47Z#/'?:"FEB4Q'Q5U&I;C!!P,-[7W.@Z11_.+BFZ5JT^'N(8:PA/5V=V
M XIH69D7>!28'<X:T0$B_PVYH"J28PTV^A!L=$2>QQMT/YYV+6]_6B[$),4^
M"5"'=[@N&*"9WZTZ@G>H8D.9;E/!G(V$77B3S&YPI[ATV&=GB8_N_-' WU&)
MZS8BJVBG? @\U]RO&OS<(:YN^WYFLYIDN)3'^I&BPLTHQPU+IJT=0C$D./T6
MJ,>YDT.D7=GW9G*4*^U^=_V(QP]"CCZRJ@EJV0UG][/&C@]VH"\$(I"0R:;&
M1_&.R]SUC)_IQ&-+$GC%+1SCU)9XE22WCACP%%%VYN^ZP-7_S;G:SN?Z\^;V
M0WL5.=:9_/5/TC#H+O0(@KBQ9CVW]8L/:AJ?CN0<GH1,UY/P@W?^[Q(%*I;%
M4[DY-Z$?FQU^V3K]C+O=&FU,,MS850;P:_'>_#[P5F>X!<.OFRS.?Q0IQ)U7
M&L?91@ET6:3$U89)XMW/?DCQ(6RDQQW!/\Y5_)3%T>\,W RMO\%9T?W7I+U(
MH"3)XZX.UR/@L K-P;C7P:OD[>U)H$3O_2,NI2XEL9^9+@]/ACLUO*;T N]F
M4..A _+UFR&4GX1]SF</G-T)[1Y8MA]J7.JOVJ4S**K-4?SI4=H*UX'(KW/,
MBSS97W]='/2JY&XP+O I3MHL;P$>KK[8*2Y!, D8 ^Q*6"K+ Z8^TYNWFG^9
MD:N_&ZWIYD)ET;JF"1)T^^>#-A'>^0O^=]'!%?L+UT@NV1#XKMOJ]O>'L,3B
M!,_#]&PHJMZCT0,;25@J$MZW<POTZYK\M6OR_(FWL.@]YA6KQZER1VR5(L-'
M%6TV05FB1.)*@$*A*E;S8,7DH 3'03Z+/*[&Z[[):XRC!,$-2V+<I)%V"\Z<
M5C 9-0GC->/!LX:V[<E?.>ZUW\B;*=HP;@82Z=V+^B>6XHT[ZH 0LQT8>'KA
M>CJ^0LE;G?PTT%@B13:)K;T9.X 4* LWH[5E]VR"P_T!5J/*Z\2!Y<>UXSUR
M_PT5:T^^]QG^44%(]WY-1'UQ-,ETZH B73WZF7&/>X+S 9/V<T5^-G9I9&(1
M%*,I4('&7#,VH\>,LV!;NK!F='#W =7U5FS<?-H_%CDU8H?TNIDY.B-!;)I[
M!929$G^9DA+H-O0/&RJD*@MA./U],J NE-D:G &"&1*^U513XZFN9'4AN&A?
MC4:BO5ZC9<H) R"[<>OJG#5-T[N]]4UU80T&<K\P98?GC1N" P;\0]VP'UT3
M%ON0B.)].PQ+,)\@U))QT\U:4^U4:'9QLU%<<>=O3ZA5=L+#8,.-G(6B]R%C
MK&T*\^('0D;N!>_3SW+?D<C[Y'K50W^'A''<#OGTA#?'N+EV_V/-[&>]^X<2
MC 8RFV**)672.FO9W4K# R-XKK#\[ZL6!/.G[!^%WJ:Z. _Q9?I)+7'G0FL&
M^=  62$_0"!]!22'P&+Z6&ZN:TEL*2"_H,R'#VZDJ"%9'8C,F'E@:&[I0@>&
M<_A3W),OE:R)Z=%[)AO,X*?I27I28'E9C)=7X( ' +!6_:C</$TV^?@KX"1Q
MFN.FF>.9,"].OQEZT3NLVVMIU[J/@KP*^1!Z*+P<NM!YF::,8C/N"3T#?[T"
M?JTY70$O]?Z^+ 9WGYL$Z[1'P_X)K;G[J!TKL@ /S;@0.J?;-*1H\0CQ6S/;
MFA" [H80GI[K=9@]%]C1?/%),.B^47/6<%A[O5J7H2,]HTU$?7//GK2,!TH@
M8.$X*?LG<EI6WO'$/P6ONY0>R6\XQ;Q*W:]$B_DQQ=4(][Y1""WM='ROW^VO
MNW#Z>@@1[T*?0:NF(PZ+I1)-)7RW962L?!W^M@C!7\PTZ]N5,W@IDXK2TZ*-
M],29:?Z?1SO"X)&2D%DFEE=M2,80OR+D$<G-=5I1M0Q1_![*/KW)#8_*-K0.
M[LSTD/A\21;0J7=@F#-1L?#GA6]>BOYP!FNA&MZUMD[L+#M:E=6F]!;H"SW)
MZ5^!?='S#=C+J>5A9_/4-B'W&)R7>CR33MGE*;L9/LDLVK5P4N)+550G_34"
M/$3Z/WO\20P9>,1C?Y:%)2 *L.9+[$O!-@,;'H54+*<QZZ="%Y:?G\5AS+XV
MX@W5EI"1_1VWE:4I1%^LBO_I*L\9@I/K$%?%7@%.#_U[>646EOB5K 3%7TK[
M%GB5P4TG%GG"[*C(,E!^.T1?P%^J_N.-QNUW%\$=!PP?&N48ZC5[B6=N]E93
MAU(+=,JBCA(K.[?GSW73((6V3RC_%+F[--!/M:LZWGS':T>CSOC MF.*-J7U
M0;3KR+8@%DXVW&:.AKS70112 >[SJ3_N/(IJ/SZ?)Z]OK ^G:PVT.!G6M&O1
M.^ ?YKRQ+; V1!@A\4MDGL]L/V+0M](I7)!T@>:'S0X"*4JI6;W,/8'_3NH'
MV7.U!.Y=_K0(_S17E=W=9/+@M?+9YQ'R]N:YO%YW;C>ON_9A[.0<U^EZP+:B
MK,3K,RSO[O3B/C.Z0/A^S0"&_/F*V%Q:= ]:&2S9 ;N<TBY=SF,R1YNN5+@2
MTG+Y(]< ZP5UO3;*'=-G%13XMZ#*@RM@?6FE]U1^RA6)58<6?$4E"T"DU(;@
MR*'%KK4>08]RDSTRT'IG756?N7:/GX5=_;1#N_J>Z;2="*NI98J-9]0D,)5;
M8PF1'B MI"J^%+PP;CAU?^KFIO45SL6LT(OOK?X>!2-:#*>GZ;8N[V(W+ ]^
M<N"6#G\J\56G,GY=Q;QOO(:6$D['"*6_&+6&BYIB 13PJRK*@@YQFFC;]&FU
M:%%/;0&' \B%/<!04<X8'17%1@,@T*"SP6/FI_N/G2;A_<6$("DKZ/3PZC#&
M/&X>Y(LB*+/J!-EVWP(5E(=,OQB,L(\W=]=2>[OGSYS.P4166,13NYMAX$$F
MKFB:;-!-#_H>RA3"/;$J:-<:/JS9W=(^EMA@HZS7OQCE!TYJ\T-3[NC7BT)&
MK@#0)?^W9^#E%>4WVJ7PH902'(^O+E<VV]%6+]?F64O70EB2J#+P7.& 8YWP
MDGK*]N,C0)B6.2ZJP*L$)\ZI-W32(W'4!.]991A'$5?U6M!,K+O>G3_>$Z.O
M4WR'KVSQ"#1BS25^+*6GKK-@@B,M5$WNW(67GDX'5K:+6 H3"I'FV\]C<I.;
M'[%%Y:01*_8;X-![)-#A _E=5^_"!777>UD1QM&.&P$E0I/I@BW;< _/E"CS
MT_DOWY%HT4(JPS]%OYJFZN%S-D!&Y'U_V\2ZNST[X=)DFTES PJLU&0%=2IH
M'W/B*7,"V?C#1LFMR*0Q..Z]>H+#$Q1(2PP-^D;_]\DS@0/&T9/:^^KK\?9W
MO18]FX1T9?UF(8PG?K$DG0AEZ.>/ =0D7DS*\0:\'CXDN>UZ4S9NTV#%O:6]
MO17,7:ON461HDBLYMJ0$O$;?8UJOZL/+L<[=_M4E[$^8='NU/9*V(I>ZF$S=
M9A*,'HM"L&M> >0+?2':QX/'&J%V9R'VLA/_)&8-7.PM-?E/M.$',\?]+@_1
M=RVB+>I)3F,JANP<T::OL.GF$:28G)?0-WGE3*/\*(H,\^$M-7K0\.6<OG;I
MZ[Q79J4VWEY;JBKB_&H;.II$P-F.],\(+ @/:0CH[#^VH/R1V-]-HT!;KLH"
MD"*LN!*)B3U$@2Z 5J,<!V*_?;VDH/[6#_+SC"P&7&,;1]R4 ^KQ84/ 0[J.
M'[1A-D1I[R;G""/N,:TV#63)\2L@4P:L7C 2F,0M Z[+9I#YHC"R( (2!,;5
M_F^YCG7 3/]^P-UIL_/:^[K\-^O=K-7)RB%EUL 00)>!L$534=>=;JW+L]1I
M%SK%N@R2G4"(+OWAZ9CJHO-F.VT)&P+RW'AB7PMB>4>I"V]NIY.:/YDZR8@^
M=0+%XI,<)6!XN+N.SBX]$#K[O!!F4?^YGWR"8F',ABAUB/ XY\F/GZ*#VW7W
M\1XY_JX#B\UG>5XE'EVL5\"/I8U=C?'E$=7+D2R4?],"ZPBK#%O^\XT3Z)LM
M%[Z)&-=.\6@\\-LHC @(_KC!=@7 &]9*WK"XY?!^C_ZSQ^-A^$0B$2VII!*#
MB*+%8[JB"JWVE799Y!-N)]R0,\@<SWTS[)T]M>J"23EO&1I073Z+5@4X-":Y
MMRUF>^:?W_RE"<>4A3LR%"^U&#T8Q]D0OM/J(F533%(C",L?.8A8-PBENG4F
M8I%-:1/FET$A*$A/$=YLD5;'FIQ&36I=B/8HJ-WIE2AZQ/;D1V9[IRZWQ*Z]
MR6RF18%0WU *-TY%JVL81HI@66F0[+B52+SFGQ8XSY_JMFJ2"?V:_@6J<38.
M@NGGKJ)=@T&3G36W!)F;W)> 3*F%R^;LXPV^O;,<[Q58US@ \?=WS(R=TBB:
M^E A>+W+*F38 $02B2P-*CDEA";@FWR8\7Q&:GG;F69,[#LS;_YAUT1-@?JI
MNXVF:<+]QO)+Q'Z=Q++DOAOO%=H-W[[!STF*JA_1FR^\Q$(%H@SQF/21&@E+
MMG==',I_<25-UM?O!5^25?-'DYME)O.,:3&)QGA;%7 *,Q-GDM9D938E9 PU
MH?VG,$1P_DN&MY-G0;V%^<#Q5W?8$E>VOJ,#.:Y=BK]YB1/!/["M0])!=&I^
MR>!(J_T<IS$2B'Q:<E<$]V:X-WTD*AGKA^ZK4FA&>UK4-L9>BK2U']P[H)(8
M/5"1=L4HMD>Z0X<)Q%79.3CO%#'W_QTXK7H%<.WN_&F[ K[>-P!"1@H.A>>N
M@(7!RS1-%*MQHASU[,7-J:H&6O:]L]6 Y74'F9/'N^&JNO@GCYMD2A"U,!)K
M1W#UGPP?4(FCY&YU\?CT\'D305^+0? =E+7!@"A)+W0'"?Y42JT#&66YEWDA
M]!,V)ELTUI@=A=('9&\VZ-328,9MT^_0FAJ4F;>007_+]]V==Y2<>:)!JL:)
M,R(/[]?5Q(JCQB$PA$-SH2HZI.\9EY*5;P#I"L]P7V]BFW6BN=J&].A8OEH7
M,S@WXM[,@!QEX\'SNKEEA(^O):FAO8H 'OGP6_=C8ADS&'$8Q[W+WM82G-)S
M%[,3=22MP*K'-"G#N&=J"BV4+BP)&,)+?/U-^)_K8\FI!I><!^T*>N]ZX)9Y
MYP\7:\OL!=XX$CA^8-A!R,80D<YA2<3YY9V)/PH+N10U'KJ][J0V[Y<\%A/)
MBCM<5<V025[N5E$QPH2_1=WK',@7B>C^A%M9PG'%*;@6>].J&>K<TZ0F5@-R
M:\!( EDES=/==7GZ@=:D[))BDW?^T:G!5=6I?!G^][4Y!';CM7.I[U#K@&_)
MPLZUJ>!/,Q@9/8F2 NR<\\XQ<5PE&&Y%R3+P""0$[M4,M['C0HMWNI2]^:"O
M-5WY0:REQ:NX&$:/]"SE"4<''^6>=..!3?#"A?ZZI@7(Y/V'7KN&]J<$*N^)
M%5592KM@2($D>EO;*$*T:OS74+9VU?6LS[HSM]*<&<;WI]W3CVEM#\>_Q&UL
MF=>H'X43KY,!]C$1\DYK&ZYZ/3WCB)H):*5WIV<*TB ETE'E(R+0\F>OFS'8
MQ:5$!^)[$+IQKZJ764\S*I G9Y1&)0(>#ZC;RPJ$#Y.>Y6P/%UNN@L=\.1+E
M;DQF[IZ\T'@>N><:;S9QGW_\U7![E&18ID,4JIN0DQM@@_3_3/K,SC:SUEY=
ME[W>6G_$N+E+ZF9K>-B$K@WO:N:Q>"K64R$_5@\>"G6PB&TMB/S1,>)4,A&0
MNEA7,OQ$JK:;:V"#O!!4+&W=1>F-H4-Q/+C0.$UWWC_\O-O4-@QCO&WRV;M.
M4HM8H_3,,"L#84E-BB0 ;7A<.!S8=])9.,T;.#LU>9'>J7_E)[CW>(1<@](K
MBKM[_.-BUR3DY07SZ5?G@[N2)!T//P2*@%P'W3R01CT_GZ#X@ H/%3()P/9"
MY?2CKT.PST.RS[O/P@?8%7=<Q*""B7,WVOB?_52&XD%^/ #A$^ T<1WF2UC]
MJ7Z*1>-5Y/Z>F H!/L2/2IQVM BU'.6-@WM-0JP.+-;?5_4&Z7M[^:O-4?=0
MLJNPQ3SFQPMO4A<FD3,8 8>5^NLG"3ZE"[H%&E$NQK3B>[R^L5B/V:QJRS?;
M-M1SX:-H @!2&2QPF@WI<^;I:"*B7,>I+*9A 5-O-+-5&/1NN#A#;2%X5-[Q
M"CB#!@1==DY<)M474H7^;ZG>D7%$TX7;YZ2W%TZM+CFNGT^:T[OMU8G]@#ER
M;@P!O3*\@N!16,P/A^/$.^>:#YO/0B9D39.W9.SD7+PN1J[9<+GNAZJ1]&_J
MP(E%[*/'+SIR ET)]C+,-&.GO(A-B^UT<2@8$HJ#E!6JXBX'F-SE$KG:&$F#
M! J1V(JMGG.59Q2C8V$#ZO?4"QT4SM4O#-D)9UY(954N3;=[4,.W./@S'@X;
M.QFZ8R/RMK2FBZI!1?OD:XH7=V<^W8&UYKAD$D;BK8MI"%J&WR""1\F9K-"S
M "O?[INJA(?BY*BM)T'8?N)5=JFIA!V.&Z!YB8@/JVB_32 H)O(?D5/5'[L_
MFMP/$?$W3Q?:K F7,+D.L &M>P\). ^:HF;ZC?1GU=&\49,2_!YO5?'GZC"!
M62N\-!!.=0MTN-+MGI1R(5CS?N;V;6]O5YDST>B;+7%S2 1Z:J""*\-^46&Y
MWS#+*BP__5PNF+^U ?<P]#'\%WDN_1'DI[4>"3*) 98614+/C"4<WO/1H?HK
M4N/@#[[;]A ^\+G8T)(GY8V9#2>EO]I!/5GE$1'OXJX"UB.X*%P1ZV!X_C#X
M081!0RB5T^K2\J(H%!NRW\>%5>L.)^8Y@A%!!, 2NR EP-=O^ H@E)4X[^'-
M^,38;2@#K1WV@S+JZ:CS$VZ9E H!?*Z MT4M1WC'A!UO@\>RW=B/Y*.:Y36:
M64G33+^=- GYT6XTIB"+!9!WM3@#=U\!%M>TY4OV%_#,)>P1SW:<#7TY&X=6
MHY$1*#VM"_W_]H@$?9S_=YW/-ZLB?SL>R&/>^9+3DSL3?A;^ 2M1$:ZBW/(@
MVU:U$7B'(F^^P:FB4&#^%X&SY!TJ1$Y-'NU> 7&\E+I(0=<6R>?[NBHZ/VZR
MDM%D;D]D,>>N8AUJ+WP^S:A,B;S"TK+,JT4OTK5:;19M)H&E^#HDT-J$X+0_
M.)_[,_7,KQ35FU\$6DAU66ZS0D%AC3RRFYOYGFC@+E5RQS4",:;X?28A[W:]
M5:/>\" 6W^'&D*VN,R!:A6%\C$DB 3:N !M7/<TEAN*4VNJE$58;P%6O9E@5
M<-A)2=+2EAH' /"2(\W@A?E![RE<L_F#M0)W7UF#";8M[Y.HEC2"<0A,&(9Y
MYP7*-[0[UU@^?<>_^P^<SC=HL\\A)2QI^@:98.UAUP;7??BR?+;*#$(6S0[Z
M\_9EOF#Z9V[&)LD*7#R'3^7[]&*313LVK8\"X^H\N;O*KH6P2^3IG_6'C&)E
M8Z^0=P-30*;DV5WCGZ#^@KS;A(+MG"J;S"Z)71R*IT%F#Y_-P_%AI+)BPT75
MS(*E'G^;A^\08DYND1Q4,81,GAB_B&P5B7E[^=&7<75:;8'+2*6OL&PNG<-#
M1@W= E*B:.O.:NW<50Y:XW_3\$DHDN6%8A4)84/[JQ7@XM4^@U: 'Z7N3+![
M5"&51?U![[O8UKY2V$"N<#9]FMZRZ@L#NN92/K36.J02"(3\7ZQ3N]N9? 70
MOSYU?5.Y5.^$K+I[O\-^-R'=7T@1:Q:) $:&('S,"-;G*[N@TM/N>7FR67AD
M8JQS]A7@3SKO8:@0,*!F:]72N\LG1ED(?G4*.>B\9,2(GV'/)!;.%!^^\7%M
MEX1Y'XF,)A[F[L)#_)"K8./U*V @R"):M"23[%#S3M8U2[E##^!& PR)TNB.
M[HREJW1W0;+,KQ'&+O=AF>8KE0S^_CFS9XM""OL*Q.:K4=^VV0I#CNR'_S)M
M#H;=$.2CA!R;1N6N%[1>!S4_GMEID:H"Q, ^LW@IA'0].>EN4F607/9:#J<W
M3X5UX"L9+BBYH HHH&51E+G#S'E71;<#+7E)?X'ZU!!4YN+[7O['CY1,N@$X
M7OY;SP"EK8I[=E8Z]A_!>NJ'@&/PX],92.\4JR"LY7U>FM+3&,JNQJ6^*.O"
M?*8MGH4M'91U(;MSY873@7'XY).GOVTY;(W(MOEZ";JB1H1F?L!K1C@)U[Q@
M44#0F_ +"PC&E:NS'MDO@&N+_D1(^[;D630A*RTI3$^%E#!@!=.Y&3@C_[U'
M^P_Q85C^%?"W[[%@OT7]O8_;1<():]_E&\R5FV_A)/'I*37\ GYVJHN4TPAA
ME$ZOV[Z]<-6Y[I-3C1N[O@F<Q*^Q%3V@F^XW_+OD;P03Z>>S1:3YK,#7',%+
MLC25'>^MG /Y03N-X4;DV*+\VU[$ZE)#&\A<_ULD^Q;_1=F$?734N<+3>=XW
MQ*GK</[UH->Q*I:>Z;0R*F][Q])-F ".;#+T( 66'SS?[K1^*LOF=///'!=_
M&N/\'3%DE"'X0PU@BR8=H19'<?>[=MP-B.CK/5=2F^[]6CZ6RDTE9Z@B,PSB
M.C3> NE9(J&%+7"41'SR(#;8ZD RA0M&*[5&.;GSY_$![#7"UM5R^7&@'5!K
MR?96M)#C7Y&/YT]Q!Z_FZCE/8QU1E;MI4:3PGU6:F!1):"91N@X!Y3;T#I&
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M(V:T6'E?T)47)CLL&+_D\\UTA()5CC3W1JX[1'%^LCUN,- ^D"3/P6I&,="
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M#GI@58W&<@N+W*0)$Z)./X0"RS+!<]O;..IZ51^.C-"JY.[UOOJ1)5B -O4
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MO"48FUGEJKS>M>&Y/"$UJ 2W7O.(@LWDH<M?VU65U*;'#K^MC6R'53K2*Q^
MR&#D[:F@CAOB1^\^"GR29H^OJ0*Q"20RRKV*M63B*F)85>O.Q80=8)W HTKT
M9T;Y;'9L;K&9AX_NXN%W^TK@41G2^/9U#XG8F-8BY-/R994 )(.*XSCEHM5)
M]O::L?+SZ5:**>WW'V#9JFP!]DFD37?SXQV%"EB@702 W(7XL$!4H'6!\SXJ
MW.V\*1JKK&'JO$%8),+Z-ERVU&LH&\P$O5*J+U.3?KGWKEBZC3J\AAI_;"EM
MDZ(G>&HPH"6Y&Q/N5H%IUJ!WR920VJWXSR!<Q@F\58'+64N^H"(O,-L0R.;\
MH>QI@!A)BX?P#!JFKMEL>/<@P/+6X=QLK5)[GR6/GKGT-SEU#7M.=G\X74!R
M._$PJW1]4"L_^/ZF"+QTP1#H4G/R>NMY%+\>;'AILT3,[P<^%JMR3.43M^@$
M'@QV'I4][K[W_E64C=K1T3"95E5TI;!PE2F4LYAW<&/W-$++A!L1 4Q,J[@.
M*Q;A;B!F-G7ZN[JPO*YB/4)A&T.[3_=*$/UD9%N>P-=@1_&P@Q/$-8\ZCBR-
MKZ]'/QMHJ%/U<SU\)6*YLK#;J0AB3\""F%\H*RSZO^KQ8Y/6YZD)&Z/D.>6_
MR?3)4<'7U%!\Z(V1[(R)/*X#_<R80.K\YOMW86XRZ[G)H:Q\-HTBQ@Q-8#C%
MLA>6^%DT<!+Z8XWR5;P,4]N^D.[19+&%"TIRH\B])7.8WA&M9<G*SBH4"8..
M/ZK]4_VO'$!]\Y7\H@I94D),@!;XKPZ_P,_V.&6:G#ZV&].QN<2.9D/$BJK7
MA+0:!- H V)/A :*%0KN:J._^&3RF>3CVM0O,_?8WAHM5JAPUINX:5[-V(1W
M@1_2>-0PM,=&X)MJD^7*RH\F'QWKM]Z[4;_B7E'WHH!3RT3CH;)WL/]0@6S_
M^JY(RQ=P^Y_\(*G!O<\STG66BY:GH7)0!@S_XJ[JV>AA+#JV:= U?*Z#BWGO
MY>KLRW/Z&'R1A]@3V<]3"XB^.6?EDSNSW/IVL!'7>I3)'*#\XL3Z3&TN4+/)
M15%^2Q-US\#>;-HWXA;4-7',>ZU>,ML)S-RO4NMW+OQ'P^6&]I1']?F[SZLR
MEX#Y66/Z+!V#"6X,GVX=GZ+M*(KD*(QJ=ZF;Y9%M)JH;7M)*Y#I)K,?0C16S
M#UBA68'8O!^R:BDV5-U']B<JXMUX+7CKT*)E]6FB/:NMV7!DAZ"9)$\,?:9-
M>(>0#J"^0AWG=Y]OG[,OEH'$=?DP#!6DE=!;QSIFE?)I^*#(F+(N)4ZV$LHU
M?44&*M;NKYS<7<U2.S2+\Z47615]8Y4AE\[&1+2HJLKQ3(,4IS%"D \X3F3T
M]Q2T3#C,N!WC'::<>0ZG:;L?I-+7IAHVU2>S\G2+@1:C_R6!'*7]N4,_ZDW2
MV)1AU.?-0/02 K79C8IG98%EK@-4-X^*KVIOG-ENO>[["DD;OJJ]T:3!Z08]
MV)#<\$1\" # S7]*6SE]5I]#13-8N=C3"B1+:@:&ZU9YC!FC_EY]/T$W.?ZB
MAYC<H/GKEO5M]KB1AFL<%FMF?7"?GNR[ARQ$ADEG?3<;6!;F&?Y"5;(+0>[(
M*-%/)E,WG<I*":M3*"4[#SUCLMZPN TX4/@,V-L#G--79OZ6_X.;3&;^BVQ6
MWH>-%(R?WL"@F.7]!(UG;,"I^$I_?/DEX%CL\%'FM3,;3BL&GKCFOG%;JL?<
M2)LE !FZ;0M.H=*>D&IN_5.ZOB\E6O%2A#_[:_/I$ 'T<TQCF>Z\=5KHR'X)
M73X6(0@N^/.N%?)L=8>5MX' >3E#(=^(2"<\[E:P**E/9MMR>%0'E,F5&%@[
M%SYSFNMUH=NF6:B;ZGMK$OO SH&#F;LUGKVJ,3;W&I\&DA"MOM??==S.5.>U
M>N,AF+)6F+4F/GG0A$Y-<XCMEE7O<-:;!703<B"7[MPZ58_NI%W[XVHB&?[4
MAQ$>B"G_.$2J;R:E3N9FLI:B1"R"5$;O.[1< B1_LGIW%R]NT0W7*/JYJIWY
MA&'66#O[W^1JOKSHS0!J/PJT"!IO-0EQ[(+68AGXI0X2./-9.755!=P!*>&C
M6J]5X3_"ZN;1K._^K*Y$%Z6B5J(-FHP?2O(3>Q-K#K'#P5/MSL\#OS13XF$O
M AAY+7>&23E-;H&:DY@N,M'D%+90<-\%[<6$RUY;GZB465TZ,M:AWC]4+IUA
MHX#";R"OE(-1H!E1"G,'ZM[H>9W==*&]KT,URM6G@2MG%@LRF9LWH1HSIHA4
MOA6SL=@4A@(UG-G>L\)1JAC5&L8HY#LD UUR#B^Z>CCVS$D&B7S"E:I#06+%
M9X8-,7DN*I0XR\' $[(I3:Z!3PGO#.LU.>@ \7H)E".<L@P4=<;V)>)9EJ9^
M<GJ.]ZT&E0_"_)M^::$K.G0F<HH1>R0#5CTTE-0Q!X.KULQ?[P4:\%@$BSW,
MCT],P06H"I$3.[VY4[+@78CNC81,M/',?%2MSSC0UU:EP%9:,@E%6X9@B3WE
M!\$W>@F4P$>P23IV\M(.W5,Q$WX.-SS#HVU-UC$'UP,-H(-CG25H7G^\D#^K
M!%]IZ.:]HF=")Z$%LR%+@09 %'Z$A))V$%7,MW3X;!^.KF89<=<N2IV2=&^8
MX9T/30,<]4V/O2@PMZCD8,4 M]K$50,3$:7'EP#XU^*=.D$[%XNOV6;K<0@_
MV4,A(F<V:1X#[VI;+^I:, 9+\6,W^-$W4;7@*F>FPR7+%J$>!I*'WIX6FSX?
M",JU1+F(I[1(#R>(K/'BUK)L:A9YX7+,@F4Y8ENQC/GRD$Q20KN4/E(@4Y8$
M4G$"N_6<N&MFS("\TXWPMBF?#OS1"PS:*[$/*?_]*O7^3V6(8$5KW)9.\R=I
MPR-U7Z,L>";/)9"J78'MX$Z_^?VAA.]: ' -2E#8H1=O$@35N<%$XGY[_YY&
MW ;]H+40E#6&E)Q(A*!8"#&2NYP!; 0^JQC=R^E%?#.5:)E;[$BLZ</T!.T@
MD2.V&)U-BP@ALXLO29ALX/K[FT<=4Q>H[ZM-3=FH3_G.+-:?Z]4Z>NIW\)6D
ML7;W@PRVHH&?UNS^;ZVX-;(O;EM8BB8UFMAY<?2I),K15@TDA',\& ,@\KE_
M06"\M.;'6CV9 =[536=#U@%])@Z.D+!F?B4[FSB?!$"1.CZ;]75/,]_B^\K%
M:[%6IA0Z =[P B-!>!6)&EKA(83SBF)F"?KDJ\Q=%:\W;>#D7K8L64G+6?9
M^=XMXH,N@USWS[3@B,&[(4BN5WL-:P;G6AEZ5;B15*_^0TOMNSYBFKMJUP+/
M7WK9+(F#DMT-.KBLSU"6X\L?_.[L ^/SDR8"@BUI1 $4Q8< NM6@4B^-SG@
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M+\& C5N4GH*"0*8-0,UV<F/?/@BB]2S_T5<IMRQM$=0+8J!T,)V-7V@;)AA
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M/7T9X[;';.E3MN-- <[8&RX,44HR ,'<<(]B25URR,-TFS/GGC$%H1S5+::
M53E3RSO&_D]2_.;DGZ.H;X'\;[? [$0_UEG\<.1=K\AFF3E@8=0O26"8>ON!
MWZ_E*X)'Y]<Y>E9"-LED;C4O'I4Y*RT]ZT\CYK,-2LB+RB"<]V"(#57-&<]J
M-S_POW?SH-KS4D_&6T2DEZ\O#L220^X]S*N#-G.A),1^F;$!$!A<%[%_[&ZC
MX+.;DC.QMB"6I5M,)5=HDQ$89,4U\8OK<0 A 4<#/!^BI2N9C^5YK7$*5 \$
MU(WKPJ)3'90/D(U.%P#OC'LW*]!*7]03!;(_=:W^<*C?XK'Z[3WLRZ'./>G!
MXTZ.NWDL]5[5&L8?U%:J!#GJ7J"%#")N =+]"GO-[OM$\[Y\D)J[E9(%(ETD
MOR]N7O5.,VB&=C^1Z<#7[+\%:O"R@W;-/[<M.G'D1(QOM^1HI,K91(&#W5;%
MW;6$F8=C@W^FF=F0WK,VYBDR6U32J]3U*!D(;VS).\KXLP&C 5T7UA/3;F+0
MCAKV^!%^:-KOM5^<XHC=3<+"5S@U50,C_'D"^B3@NQ;@#8-@WWL4*[)SM6_.
MX[SDD;%UK56#EY.AX8(P5^;CSHL$!9HCF7FTBKGUB@%TP<OF@Z*GIKMB K<1
M+JE+)L!$"64ZU\",S1!@WR!UG^)\@X+? A2K-(1>ZB_?[A/ 6-Y9S#L!2N:9
M;BS!##E2??B@#DRE-4"L($=V6&7N9QHA3(U5@.B-H9 LUW[/'?LEFA*=W ?!
MQ20PND OJ:-NXBXYWM\'H$Z$ACA\$4QL&ON2RUR=P+'FS_Q9;$%T/-V!*VM/
MMD,<Q$!:H9X.M3!K42U11LEIT+K0*0G=Q_)6^,6]\6AJN^TZW47>:T!?C]V#
M5 %-X60Z(B5?IZ94VO+*W,(^'5V !,:+O:!'9,/]*KAOX(\C2_1%_-A,-FQC
M00Q*:GZS58ELC4BBS5L ?L.ZJ+]4$<R+J+^QN6/&:!CTQ".0>:=E^.+-^R<5
M1,$)D>BQ_YU?[^060+LH&JR)%1;)YBL@"?5U\VL6N5ZR<>8-;O0W&034U0<^
M3YHAX>Y!\H+VVW%][C)V[%CO#-KA#9%K:. 21OIW5#>!N2N-'CO&Y2$J1 #G
M6Z J4-GYI9L'6[7P\.O.@";3!80LM_/8*;?7KCP;J:@@,-YTI#Z]!_(ZO?^J
MPC9O?GV/N'B6=[6;?<%E;H53_64MN[Z*C@D*'',^>%C/X3=H7_1UNJ;?X<2&
M:3\H$R"^&ZBV$#Z4^SGQ\YL'CI-HT?BU_M[T"FQWGX>HPF1O1ZIF3.;C7K;8
M@WBFO=A:UCV\%GP23H0+X-!&?9U8WFK]$C_/T\.%86^TUBE5._$33Q_,,$3#
M%:= [>:0#+<3A0*H?U_AP!M=+64J9[>CWE=;;O;@M_<>&^%I6CC$?I8D OJ8
M W&??L,^Y4OU[7L$>4%\*5J"94EO?D_@JVMU/8$ [6_T?MF2?Y36@A5A:1>'
MIZENKE$(][UW%HOU*_*5H6UG0_+>.>#,'K^ #!5H^,V0&%/E85^,QO'I%_ZT
M+6TI6Q%+^O>?0K$T620><'<7L:AM9P!FC'M4ZT4W# LOW-UD7V6FN;C%.AT%
MLZAS?M5A*=H_CBDC 8VI?P(L?#Y'_,!*+;0@,Y(EYGZ[&N:F\TINBKLHS\,L
M5B<";X"S"0'0/)G3P573FD:R!&&F9E9B86D/FHD5A"&/Y7FQ+W96\AOT:8]D
M*CP='_Q6?V*K=G>HN%%,M0ALH5)9_YJXWW%!.Q+,W6[-<7_4N-C2M=[J0(3[
MX5!OL,6&,WT9V*K2S'"RL0_4O:JDM0)^W"U>HY%7O#BW\Z+WPKIQ*]P\L##M
MGDV;?1SE$U)9?2)7.B2M*1 #N];_H1RY1-LTR="8AB<T)?A8FIJHP"(_DKQ-
MH?CZVT)0 !#*&;X[BJ*:1HN;_7:(E9.<=*_FC4/A:(,7$:MMK%H-7:1#2Z?*
MLU#:&(\5<.)UKHN@2Z:O[!21"=.#<+?CQ4^5EO5)/>ZF7/E*72BGW!3_1B3:
MFP85G>EK_,VNKNZ3B^>@R'13%I)->;P9:683@8E;KXY]#PU2(0'%F*G_?GW6
MKV>T-C;V;65R3]R-56KU:<FLQF5$EP%G'L1LQ)IP0=.1E193.?06@!VTW7GQ
M83_(A:O:8DDXI< QP=+Q_E@ZQ-B! 3#%D#+5U^=>18DF_[GHMYC#N>/['6JQ
MSX\P)PO<7W[(]CICYY>' 4-5M,)17V;.I1^W,+50$<'16"%]RD$U5W %;V/%
M#QD+\GS#J7HWEDA#!JB%02H\SVD'(:;4X>9D 5YJ$[>X]R(JG:$W<_=+I#7E
MQX8$QZW R/27IDSKA1"^)7D3(Y(BZ+A!S5DG[BUP5UOT^GV>6!:U4;JQ/)"H
M A/;3'O8P2,4A0WA_,6.,Y.FE'V="7.P]Q!IG.0?F,^WS<$;F8$;1U3M.UD0
MV:'%A*_+KU@]+=T(?NB><2V-;+&JWM%:A%B4A(=8W]TB;$3-K+ZIX2$TK_;B
M/+_GL3(?NI6MWM3DSS144+44<[T8CI.:KUJ2OZ>"1<X,Q?4'#;B?]#=']T2:
MG/M*-/(=2I:?-G7,K,;]C.6SQ(2%5DR*03.51D9T'5C*$;ZF)H?J =]?Z&U\
M\[3&?3*F)5-62N'1*5)' &?-;#(GOR!??8,F4+_.]'F@?(3[]%)Z!L/BG85>
MLA^=FLP)'QHCCA(#"H=$Y@2I$*CDR#XZ(NBJ.7\[66YKMU$3FXJ=1I?4(<CB
MH=%Y"YC&;,,9W%@!+[]+<:^'[>?H,\V)966S[T/E0F'P=Y9W/$@&&"+B<$HY
MAXFUY?OA6)X<>YC0*[HLLDO,GH]Z"LB8WNT!-V'QU--@,[:>H!Z;$NY>F5[D
M2AW@+/[_1C7P]S4Y7*XC7V8_4Y15;S3LV]H$4T>8J!S+]6#B@$[ZN)81 "C&
M?/(W[ O-T]>WP)N0->%K'^54^O'$EHU8KX5^@J%LNGD,;C[YC8 3FA2P6$F.
M[+A!_8<Y]D1[(D.J"O5$)WY2K0)8APLMF8HR2LN\*,?<M3D_B_BP>61T0QDK
MGGJ9$Y.9J0$G7+V/WR-%)=]I1I?8$44Y_@_H6?=)?O5B",)\>+T$/C1/[]6F
M5IBWW&-#RKBPOY0W<_&BKQ]AD6T*QY[&/7NFB3:?HL'U(=%W%[-D_/!IW[Y!
MMHI8<NW1!IEM!5N3':#*MT)&N;\"WK[<,]K1/?+>31,1WK]Q-XI3(EZ,1=0G
M;?KO:ZB4K#XV(?[JRK/&#<H]"EAY..[W4+PA]Y-YTBD9M=?82!QW$V%N9 !/
M,4XG.4^EZ2 F"KN#!J5U]5CQGF2 UB>MV%-62U-3%>TL*26,]R1DKH#W9\BQ
MN@0MN/^*9T6G?0XB5ERFB+SOR4665"G'R<?#F#*?F(S84NUU:V*3&>AB!9Q_
MV";\A":MBK9Y7\^(E6V%)<W\HE,KY5 )U>\ ETA(;E>NVAP%<V8'C=XO@>Y$
M']Y;H+?W2"\IU,-_V3PE^IAYH=TBV_J!P5;0,QFY[B@^?ZT L8*_IZXG50LZ
M_KP<^HAF#JS25/V1/;(^%J?(#;=NV:GY.#=)EICJ%J SE;CO_QT)<')7]/PL
M5K97\2I.OP1YB-B#:1.$F=DBZ3'!1BR5! U. J:.@WV+9:"#7X_O<",XM?<[
M7$7FN'1?'?E^PS4B-@O%X 0:!-8?1L00)-U06C?W1]<I2KRRU">W-U\6'8Z<
M>@QPE\GAK]?5BQ&I[ ^Q]TO)& )>>H<FRV .MM]Q*9H*LKSW!&,J3ZCYP^7Y
M24S-PF5>-O,A#YUVE5#0PCDOII;SJ3?%.\G<$M;<(?55?L&?)'E((D;@\"&>
MN\=VW02IP'$"<!V_Y,VB]UPNSIB-CY\EUL000]\EQB].C2N";R$&7VXS)09?
M<UTSBGV^UZ'['3)N85Y'A$LVME91A)M&\+'=4Y8G$9MHB,SC&/0CP.I\_M0Y
MDZWPBPN>C(>+')W'E+1 &,QX['B")@.X/.4F[]H@(N]4!7VEJ2&(9CQ*BJEP
M51B&C(/E^IWE2)]]C@;'O">);ZS2&^FIRB$0:FMO.]\IT]6>712Y+UJXOVF1
MP9RHP[+LF**P16(8,1MI1!&^SV "%!_1K&:>=;)J?IAX_XY/D:+?F>0]=R0[
M0ONC880=) >6(Q=1.MRGRP0MN?I9IX<CNLE.%JZ&2?,;V! ;"49GM'CS/K81
M("C85<9Q%'"'=NC@>?83CII;OCJMMQ6)U]5#OS!/[#$W].Z<;4.-UL7CC)B8
M+82CA/",5Z^R,5U&N7A;4H/*=X]DZ86#V374Y<$E;^GTXO$"_8=Z0UDDTX#O
M[=;7,CN/;T8^T6ZQ>M8[E?FZFNI%8VW <!WBG(0PNA%NM#^A8*E5[#?"06=A
MVW"F)5F;NT$JVE$ <@7# 23F[T<-NF0K6V)J_M3ZF+51)VS$FB!E#(N+<321
MHAY!+]41P7Y4B\$$_W5 \A98/\U^=!/DE710U8,YN#"<((E,=,K)3GMDVB\S
M1@'$HT9^(LZDO?U6<9,I+B,R4\PP1JMQ>OJ3&28<* H ^Z&H0:O1X=7?L]BC
MGYO%EC,VQ4T1^WWABZ;650A!H,<IISC,;"_!A$S@Y5O XA8()5C)I-=^.9#F
M2BC5C3 6JC(?,#6E(PTGBJ.QAYBA>6[(;<]E5XNV/S54),.3I*F-.;G;5&FC
M(R-/6*I75>2;4H['4"+3G;[X=>+1SR*5=5M>55E2##:$6 74#K2@-Y];$^=F
MFB0F<"+QRE#<K<:6+I>/#'0&"\=.OIU1O^2;:E!]R\7N6H3J9U%55^FFT'X2
ML 6\GMXS7PN9J)65.\8;F>S0ULI5I\OW"=B"526P=M!%.0G04DUW13ZL+7\P
M!-74U)'C+PL:+B51'7*+ZX;)X7:@,-   'A G!;= _IE^.(Y+0]YWMY%ES)4
ML]H"AE5QAO(BB>1CI!IH^NN&1[7!75]& MH4DA*5*5Q[*1#@,>?49$HBM),L
M'/BM@N:\C2!@CCN1(8*SX$/ER];6-W BZ'RE\9VF,4VTZU6O&MI#,Z -O.BE
M4:^HW-,07S-4<GK4,UF2;U-Z0E25I[K"/!?>"-QCF D$-NU$1$L+0U]]N*N:
MH>N=MK$POR!H=/RX\<E\E';-352G>K5Z=<N()SG@'?8+_!E^/L@_7US#S236
M"<OY6(Y(X'VV>E\C7&[RS49S]E+F@!8G=@#V^Y%/L/U6T"5_(?H1I+7R0X9.
MD)AMRTJ8CDUX02K,.F@)QS]" A(P#L#_*0A(61%]"YA1B./.C)=Z-V\82,"S
MQ]U0Y=PQLY10V$&7SV&EZ_-D! STM;V&X,V!U_-\MCD_MF\\_901V)8(]:>"
MC <QO3&-WS6WAH.1X+%V4WO&GM=]%:7]K78Q%U;SLH..O'&9'>9;U*I1%."'
MT_X P3]DL_OAX_=+?NA2YUSC=&J?YK>F?>,/J2,:^<15S=B3ZJ3X7QA'Z!S\
MJKKOF9G1CIN<OSQD/^EL(!H5*W5VACQ+5##^0'?90D+*(U>@+C^7 ^-4Q;\'
M ??:U[TI=^X]J[8X/&BY6 V7%U!PE8J:TTG";=*6+ W"BU'(G1D/'?A9"A.@
M&\0@M3=+(<^R=&:T/$Z$N>6&-B2#^6!C^:P0P['.9"0I@ "\:5;%26Z!GJQE
MU3;?"X=PCXWY6^"I5!S?)YKG0=0=KCD$A%-&+==YVTF6IG'34D$1"C [2(W
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MZ__.9<[V^H:PMM["^9EBA^F[R0(",G+)6QH;YMNQY#"BQ,%.,"UYY*6HU2U
M.F$EM/FM(4G&+&IZR)*,Q+ 1]+0(@60:6JD'N+GB'0 :U5_A+86CXJ!-:.<>
MF:N;,E:TY673"T8<4XVAA@4SXHL@<@2?L5;P6DN8-BA1#''%TW;.8'763/JI
M;S#/?=\HL>]908^UD U19$<"*.$.4:*'^W 0<&KPYW3#%]VK?2UE[I=JG^[)
M)*X&GWJ?+#0N(CG!+#WH?6$=XU52_-VWNZ^DS(#[-' QLO%#TX>_1_*=.CLB
MY]E-W2[R8]$)5+D^)F:1PV41%\*@Q<$<@JI?Z@Z1/E]\F+QQI5Y%TRZ,4F(F
MAI.JWI?]*F8X#)=LQ2#?1OC#]MM(+&T++/E4A)J;YR0^F+#K:;U->MZ:1&Z$
MTL< 2'Y6]^ !1-).#[405VUJ@+)?)F$&IO;#6!T+,&9$/(;\1E&?0TDM*/OR
M^?GJ;]>:\O5^R,255/8(%CEMK:%2'#0_\47D)ZI\]"W [D:$ND]S.'JO33AD
M3PS1GEIQ7Z3_OLVQH1&GA H?GVNN(WD$F<;%,MU7C.7=H"/JG5Z-!K[I]R>B
MM;&)2;)+FZ;+Q\0RZW6QH6PC#ITR&#^QEWB1%VOKYZLG:8*?V,VRR#^G'4W.
MYLX%OV*]/#7,306,OH71^&60 3^L.Y<HDE>#@C[WY7J(7DC'F;FQ:\E2>K;6
MRC]P@08+8KH1@QWR !KN*[+#I;HCEB5K;#OJI=["-)W2[-0L;=-(E9[^UZE.
M6-I.]V O)'OZ\L%SY6QYU^FU@F>CIV'(S!&:9A98!7$)@BGF*F^(K=_IJ@F\
M-8<-95W]6=2VDZY&JQTQ[(XP1'MQ]JG8:MRINMF12D]T&@B]<Z&=[KH)P'^0
MY7H>"AL$2&E'CF6[3F*ONPI&/DB-U7*LHS)PM,VSR8LC#3WN$#*8U^E9-OJX
MMZO6:!TVG$&)0"J<L#KQG Q$8&$/;:SXQ8 5SEF+K]0C[46477CE+BQV<W$)
MH^.,S6#PQYAFNMRUN4]"XNEB (7+!]_OU1\46VK6P*4C)J7052Z2L,E*R0Y.
MY47VSRL -PFQ$ZC#Y\L-Z8?:EI!K=L^4 S-GTF)(F9T_K[KTX[JP$VQ=6AN'
MWMG44.@_V03>)<%F J\3!,_=E*_OR:HJ4FT$<=AIR-LM8^8T&(BJBKF]'!IX
MRQE5]DZ$%0+["ILX[SU\KQR@TEGV;7KZP=&VUK8KXBRB8T@GJD2?_H4@++>:
M_V[M/G!607:EIPB5U+--8!VVO=M-1%?#5@2_6V;:P<C1@%>EC5XG 6VT85YG
MOQ=[,/>N8$UA.-FRW=/^OEP^O7SPPV!-Z>7CF-@@[!SP^!":\FI.J0[_P[MS
MWV=-)U-+!WL.0_L]P\39/!S#Q!V/Z7.\JGFX0[A(>4%S-],_(K^$7*<628QH
MG-EL:MWL#K50XPV0DZTB-UYA!LOLHT1O 8W/B"FZN"W7>9)GK5$SC#@Y-92
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M1)H^/;KT?G3 V,COS%M4%O'-EN0C42"6QH"T#(??_2!IP3Y7M#?I8<6JRW*
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M0?;'$'0K) #HRS-OJ\];MJWQ68YL/["P(LQ*"C!+9X+$5D=D\]=SC8H(+WX
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MJ>*/]K)P8E]+9"!W =^[;I3B)MCSYJ#%'.]CAP)#8TB!OUK!9^+C9[!XYA?
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MTF'?4C=A=T]&0 CMG$6<BS]HK+5"E =>YS8'I$O,G-=G'JUP[IQD>RX@VD:
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M)GCC,M#@,&LHL@I#WRSDQMD92$+PV4^[VT*TV%HKE#U%N@BAWS=;B:4"_\H
MU7&Z #8!O::(\Z%/L>.0.2_I.#AEGJ4ENYX$$Q-C4!+@'$-_ R=9AE>%1O[\
M@\+ZWHML,%5_$VF_EL'[FA3,I1.442Y-H#E8AP9O_C'2B<>&J67..-]7/I R
MS^$.'G('<0+7<"1_77G2'/&.FSHY;2L;DC7_XHYM8J]3?BN_%LD>C3CI&U'V
M\&P3?M>6H1DMK5G\?>334$)5+_*L8*G@8-%WH'36CZHR'8H6WW>UN@RR4WG?
ME])2KTRE%C,M[*G5(+SCE (Q(?7%53)CPO*Y(6C O9747YPSY(SED7!ZG-\'
M_IU*N(V:O/];^9RRG4^,GO5"DNV+P/]6H7AU/B;NL+A+/DI80HP+0]JG)*C*
M#R*5Q5<K#GQ^EP.U'L* J*R= .QJ<O3R(1LQL\'0EM:S7=%,JHHV]N<VM!L2
M,SCL)8I,]=WMW]>/<_Z@\?-4]-%E> QV5<YSR!SIKV.F@3^+0IU:4*=34WLS
M_,-K@TUNTQMAQE92E?>0GHGQ/YNJ1N=Z)/N )1G.,[UG*HKCCYUNPB9_Q]:\
MZFN/9#<@GKOWIFW^\&9L)SV<)E)LE0;TEP!.FHDEA-=\?$G2P JH0WG2/%1I
MM^W98*](8I"X[%_B@G&2%T#$0^.LEFP_%X*=-".UB$\>1(:O;>XG81!H6!*T
MZ$HQ4&1?YIE4A]V]:(%'7D]O?6CD7GM^+U%5$$"YL;_E K$=\FN=X0 [IWVW
M3D%? C<8'DI&5S/HEA@W,?K"\6# 1\2%,%H2T1$2U)9/3N[-<FQL>M/H@;C#
M;SW_V5+=-9CXRSEJ%M&HPON1>G$W$<@L8.9/U<X\^?5;RMS,1^SN)*#TP<RC
M'"]DJA$T!O<D",/<NAA[2[2)S,BWX!K:>^S&0/W,C?>.+WO(8(((.-K\YQU[
MZL.R;6S1RC,S];'M?A$BMUNIBKD/ASX=Z!IYZZ*$!:4P\A]R:# B"O_7!FG[
M 8;2:LM_>#2C%'G<UH9T$@^$FS2YV.7,AVEOUAC%Z>S!*X#HH]'(W06U*IJ(
MSP[O8"8#\DC!&WU_,*1,+<XTQ49,ZL SGO])S#D^_9S"\;Z_W+[73AFC=2<C
MWVK_X38,XKVY$=J>Q(:"6"20+*;,@O+^YN'0'7\\%5-9X0DI-M0XPH?WM5?>
M<_Y4BI*V6'&E<GL@']H74\$1E' ^;'9-P&O)L^![?G8)/;'-VB P%&KM14A6
MP@]V'7J= '_= !R:0?QO-^P?M9;,LI\=O9W_F8B_,>_4-8Z5+E^:-"<C#>WS
M@INEDX* GR7QTU&]VDF2M\A*?DS$>T_MN*J]&Q+TTU5A IT86!>.J-""IGSG
MUP7 WQ@>&)YX=R =\%3%D=?[=*,L'E5QR L*'0KUD$CC+@OK/[Q,&O8'7TVE
MLO4GI+N2T NDE8F'/'<AA-ZQ5[*!KB.: P'.R1B6*YFX?P>EC)JJJY33](@C
MWF1FA.IJ"1LDMP$>JE>88^$4^>VS8R#^^O!(;]JR>_8>)+LAS36*H 1!M:1!
M8HK!5\.RCV:_?D:2&0E3G/ _U)5VF:%UCJ&4'+$U=E<&]3-:@\N.#]]=I@N!
M)8=MEQ<=G83O26?*UR")B@IT9"_Z$Z8 *FP/!1<X]5AIC\!N?#%+_>')C2QB
MFSBDP\,YU"'#D-=: ?F@%TBRGW5G$3PF37=ZYUL 76;IT9WA<:S9:(.%:%"D
MWJR,KM9,NONS%EO5D[U+Y))ZM:S2VE/4/%5R]-%VI.D3'=2+Z78LM83RG^NM
M(=LY;B4/N[<?M*$@;5IVQ6<NQZIOS;XQP/A>1VZ[O$EBB*3A4+C>SX71#5BR
MG$E^R6M@L=<&?GY\9]FAII5HH6##9WJQ)8B$U\B\CH8+G?S+OZ,D!HC*IQ#&
MW#:;.H"C/HF Z;T;,D8HE9))">)3'JT1SY1X].8M =0!4S)"\=C/,AW*-LV)
M\G'*])RJ)N??H) ;BPD!_C';-W BYS>.,<>R[>26B^%8EYB@J J:.T,>=QO,
M4G!;;5;2H/[OF#O@(]\PXL=(-L?N\7YTVN))Z-10JY>OH5KA2CYCW3PKL]FI
MI5,KOM5RS&7RV9?Q@GP[5Y$6XG1>@K.M[9&E.KLAP;8QZ-@_2B=2 I<%F>S=
MX%O5HD:T3R1:#HV\O\;;%R:V(FPI:$#9_%*8V&0Q1.3G=L#1;EO8\O;JJ4)'
MU,BTX76Q1H-)SN#V)58:SW4>FVA7-$YM+WH1,OJN732KYD!)E&J04>QS3:/*
MND#&CT$L,NT[@6>2W%P;--^7Y^CIYS,>$9.MI]EO$UKS/#H<P#0?ZOV+7];Q
M+Y[Z#R4?+BY?X8C6-'4/%Q'E8$7R1U(T,2JP[AO!RFW\)8=]PD04R&!]'.5_
MDAKJ/K'>%XC^ZX/,3:H/K>E"#U3Z!K:E\U,)0T2UWDZX2FJW678AQ+<?O6WY
MZ/GZ6X=\I*?G#7$]K>[\6.-2C.4KY5[6Q03B_GR*XIDCSZ<1TMG;9MH9E97]
MM8L%&A\2ZP8?"2 UB'G;#L<8 8K)I<M+;R+5=K.VAZI4GUS$_U"6+*=AE4!'
M2 F?W4!ZV74<CY[*/#Q3MZEW8"8KB%&N!'TDW9T+DU=^E-:NIY V2 ^0 BOG
MH.-#[<\_$6<B[Y-%RTMNJZ=G5AS4(O8\8DH1U^7?J%+G&E)C9$+_UNG]1T]&
MF.P_^S_*_T_NF2S"Y_]H"WEE=_X?8:#,DS^Y,L3J[QT^+00ZS!NURV;-*U55
MP[T2NIMKU_4&>D?[*#6SR?I$_LUTI2RNV<MI\:G^QX_/*LH "I.I#6=[8>%>
M1@H J*+*3R ^-E(:#RRO(>,S,ZI2'-_E]-.3=HZV74HS2']ZHOK1Y'XZ#2NI
M.(]M4)Z'OWK3TSO<OPTR7K])'>2YR3W0P<D6Q!A,R1HGEZ^2%=";Y?C0/OLS
M9MTH\\47*Z%R,N;.8#_NJ#.<^TJ,>8)=O19JW<!"1GA_AN;3(/ES26#;G$#Y
MM7U'@@F_+=\AXTMH@JY>4&[[_KB1.E*Q)0V#=7*X@737^!:>%)XD 5O,/1X!
M25-1"ASS769)"U_A]>]S<S9IY/+/VLOO3YBR<^D0U%/?9$Q"HIEQ@.-Y#SYP
M^K'>L\UYE]FR4.=*"ZMXIQC_#P>NX+S$E%_=@$=KK4J,U1>]&85:9I=/+VP>
MWZLJFGK =10J:7=( C"U@0X2OMN#9\Y<O'.AG]XYZ5%%.W$:D%')5ZI4$OY9
M]V&:T2'JMPKJOZQ!DUM>2WE;P_ Y0?5)[;XEW,D1QPU=JZ!/G_H0K$1][9:7
M&?M/L7\>]8_KRHD<^XURZ\+;+.Q=G[K$DO,R_.[Y&</*3#% ^O_OQ3[9_^G>
M[+S0OD;>VU[WHY/J0U2BCWC:]TD:!EV*#*LUKEEBZ9O]>$+ 1U^VZH%CPK/<
M4YTO&["2=1YC\#7!]I%>E;9981"O"F.2"(8Y>G$7,#@6%J'((Y!_MTM%XMUN
M*2Y%LQO;BXS$4Q!!:8DWN0AX_H=*><7X$J]+U@K7FK!+]J_3-Y? ,ZQC;.Q6
MP.LBN02X)M\?.%C1OUA,@:\V6#5[/[5[36\U3O"IBAT-+$AH;6ZQ&6' )72@
M%C^JU33=34D\K&Z_^-H*"[U#EI;]:A2[*C,'?H#B*,O:G"[.%)Y,/$MU";:2
MKLC9I,!Z"\?<Q]S49[SW[G\>6$M-2;6QN);0%B<'35!A'8.F_\.5 DN:S:!Z
MA+[SN+R<H13;'*ELY##\LG63]JE\3M7)<QS%(G""]1(%;9^+-6F"-\=K2HB5
M:I+?$T:P&:*F"<X/I>*VB\'6%6VKN1CI'T>W]T:/;&-<,SA^%*VZM_F?7J/F
MKFC;W%R%)8"MS2MH00/G$S)7*0:%3?:=8SU$>%^F&/MEI.IEBGDK74JD7\;Z
M?X@HCG\^Y%\ SX,/53_KN>3Z;S')S=4][:;UJ'X:]BB3(#GF;)'Z4$MDTR30
M+*1S[,[<3,12K(]4'>:V]VJ2.X#@Q0(TF'R5D=;*AY349M\;Q^6UAL5W9GAU
M%2M512N(.DJH(PX>)0@&:$VQ=L U8YJ]NZH].BTH,%(&0&(A7K" 02TSVK^7
M2VZ53C>?,G"_+NI:1ZWV0G\P6^@LCR!F"-J7'2'!.W6_79(5T*0EWC>;ZNR
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M'JR\4]_69NCN':S";H^8\I?>$XA -1E]]-&B*> ^UQ$[QL[EN%AQ42O"N=9
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M (1"0G%%,)8&1]&YDM>I=QS^]DZ*$609NQI:8*>CI]=YK5Q(MLE.BQB%9B0
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MIW1;\NI"'3HYK#'2WK_9N9D"@-P!FCL0>LN [37\^\CY>H@B>)M.3D*07JB
MQ*(P%8?I?EB[YL\:#O]*NA+.5M2M'&EL16DM?2#@N_56FRTJ;50^D)K>1J4+
M [!E>SJBX%-ZE^T8R0$^X']_H1+=_=5Y=_6=QLS>P=*UPC)/'7WP2=^Z<)M&
MP!P\+?#*LREI#',&8E3OWYV6?\0"Z@V:7.;)2_2LJ/SQJ[^Q)0X=$ QM)'-B
MO=X84&G8UET/+F""P;:<J?_"5_6=6.Q4C,9+M<2S\D/];A6_R,QD\OPIP<\'
MK^Z':W5"V3C(\FUVXCM^+'F(+-Y)ZTFF;=O04]T.="&%KV',@6Q:8N_F#N [
MW[_Z+8YKJUY8$R6YSRMM[>F2KV<%@O5$-@.MU<1P[+>L)==DX<(L+ZFIAO-'
M'?XOO)O_WA(<1J"*>IX<6XC]I=TFW<3XM5-OEVX[:+I) CLE3[SF@.-T32S;
M9R3V?EO4J4MW."-=]]E?2[VDVY:YF]$!Z6Q=8[[^L$E(8ZG(!<$ '%P0E$-5
M*I)[ZC;.I'$\7('LP]H\F;$7]%D& 'OGPP#2V7\Z39#-*SI+3#$*0;N]*^P:
MT@V)39'A&BO30$*P6+[\=:* !;U<ZBA7XL<,?Z\S<*SS?W%8!W<=\Z1?.?D0
ME1WY#4!+Z+8=9KY'(#WU3&UB9-F27CT'5MK^-++T1%$@G .T.GI993\W,3/_
ME?KUL_V64NX--*8FTLR8KVEUO=^%%.IYE*D.42SK:H-'=QW4F,["U&&N\5U8
MGT]9SGIF268Q$"'M'^C$>_^)-7&>YI]1+H3</D9)?RC04T<EBOF>;$\Q?*)G
M"#"B2NP-/8  /6.24_]RS$"KEM*7P;4*3\%O1W9R'K5%:>#MP "H)!G-1P)$
M20V''R_E DX&80?_['C_SGX'5?6*1BLA=Q_W?#[X-=9=^'Z]))FSC:P!^DJ0
MU"X=%G"4+Y%3KHH')-L/;7;V.*,/Q*?0@1Y#"I%&]S3MTGU)ELKP6NA2TU4I
MT*<Q1#Y,E^E0>I) S:JS)DKF8(O51D*3-$(:#3HXO'TE0 0T N+Y'W9GI3XL
M(OUA0)%T_>Q&:Q:@D$4:XS'=*!;S[ BXW>>WQ3R_K[3DY/:W]M/_\D&PX)M;
MO_67Z]6FL >D&VA KGP=PGWTA#H5(^. =27XB4#MH1^HJ>9NAL>$UII49?#L
M&\PK<DIZ %A;]1-'C'2%_\^WB/\#A_S_E_^__(]8_GYSFG4ECA#3#V>(V#MY
M7'X4P#)N#&/6=7T8X,(R,LM"6+N:!D'/&JV8UMY-KN^<!#2;VM%J^VR"&FYI
M+1TY$(<&,X@QYP;: 4M_*VKXQV >"<.NU<J[JNY'=_U\ [6FJ;LH.338H^_S
M]8NL4><G43 8$_N= U="1;]R"+T]OO89Y^?$F?Y^4\O<&LE,,APGTMPQ8U:7
MG.&YH4=E]'^#YZQ;T;<I]BU]B_G]FWQ@6UOHO07N0.XM8;P12CZ&%4LT,MS"
MP!H(D:.*;%-XNYL@H1-L<RT>E67DH!QBS98XQ+J;S?9Z(<LL:2F?O0(L4\4>
MXC!Q0EUU,!2Q?S>9BQ3O>Y/):*I($#>>Y^HKT<T=GFWRO7DU^5#K^_UYR]/7
M?VAOI&OEU*!T4O5*"\Z!TM\Z\FE*'F/ KS&*I>'P/\[:2:+S'[4TT72S; =Z
M8AYL#5Q6P9FF *AP-',NT6%A4="/X;/W6>_W&H/S4+&)QXWG0+GZ2$!N)D%V
M"ST4>FUW*P/+99ZC:B5P-46#U:W--,I:G*7FMX)-YM6JFU ?JYV/H>SG0-[H
M2?C%%A"*X3.'@GV-EM<C*Q\<A4REJ\$]*I]9,\3TQ!6]@F3;Y;YSIAF[I%YN
MI:$3<L292#6>KXSW[0GXX6Q,4!!N[.<F=&F-0X4>MA4BN5)F1:\JXNZ@_5+F
M*&43BIDU]3<&A0MTB(TB])"JVUM"XX5I6&Y^1T<N(T-8.FH'8,,'@3$*$S\.
MGN^<EM5[/"0S%KC9*U^ITMF-<C!]R("BZ4?I28X_>'>/W?):[LR-]*LCDXEI
M8TLIWH-:,H@G24MQ4*/=ZW$5(:)DS6UI7#%.&WX)*10>^I^>1:($L'UL$#2;
M<<:QUF\LV?&PP&)XW1-N'7)OLO7U&RH?$G!/,;((/<G+ P\U"71Q3!0JIZ'1
MD10G+\VWK^'% &M/.^A!&QEA]9/16Q:OW,9NUA@8\\_[4E+"D0+=8R6()!7N
M\-SXPJ]C7W?+#R90-=(!K>Z5T= G408J%]0V$*K'717;:N2V''3[_>\E,#5E
MR6Q[C+EK4GD//Y<AH\P2RP4\M\]HHC^NF=J]0[_/AM.:WL7HB@IP4V;;)V2#
M!L#AN6GHI+N$=OK?1Z$>+)%=-]XG\ [O40?:-&K #TX*/ ES"4XR]+"RI1^)
M+)H)!6*F\\BA:=*@G#=V>^6ED3OT3YOD-7GA]*"9L?\=)4(IV+G(_/LHL\5M
M.X?KF5+RL5V-!*,IEALA'@YSQRHCVM!B_BC$R.?P?Q:'J\FQ+&'A.-1')^I8
MYE*8?!VUA'=Q^12;_2J00D84A98Y!PY=E2G/@='-,W3S.;!J>'%,&%9G15F[
M)N5"VMQUN!(:)V^)D??8JM\=#Q\1'[6L)UW=/@=<JJAF6C0F\]-L"\KOOEUC
M8Y/0,(I^8:#"AE6_L$G2$,N)$&M5TWF-;;-4#>TD ]5MF21T98>H+)!$I<#V
MMT;.D+AS('*\X''+L>"6]D&[Y-!T]&P[IU_HHFA J$5+7?L:X1Q(#\^I /^%
M-Z/P>6CE)./M21MGTJ0@S%9;1&%)NB26C5,H?W24^S6$;N2[-1OD@L;^&_?W
M_$3AL)TWH4%P2^'>D8^9-LI#.9O5CXQ%BE6:GQ4K;\](T03=N_+O/_:?N:KW
M0>TKQCE+2[=/AWVH2V<I' T*&Z-H*NUMLO?HP[&Z%UX[;TS9V8+**D=8>+M;
M!^FA[KR1P/B]I2#1A#<?NI;--W!QSL>=:0:#)E=R,Y<27^F]T<JLB3C*5:7\
M+MW?K;28FC@UBTO8!(>GA;#OOM+:38VB8"T(?L1%1=<$"S5*TVL#XP,VG==6
MN3'R%'^OZU'PY(E44OCFX[RMDO;AZ1S\4?#(W%&6PKOF,\59\7W//BG8[Z50
MWUR^PS2WY=DR#\5? _[^",,XGH6O1;*9!(VI#!+A25 ,5##M;\&"?WKYNU4<
MH>-/--[)>:8Y72U4<"7XD+EKJ$"\!M@*8WBI.DBU#'0\C8@?DG2/,NBNQ*N_
M?5N/']%P(H;?,0>6Q);-24X+U;*7&&:&2;_\IR)FI:$]X:%C?+%Z@:ZT2.$,
M.-()E)-FEQCWI"$O *U Q/JLV'[NKTG=_Z"AY5<Y,E<I2LK=7^]?C?:1,9X:
M;(%H)2>6M^0YRPX@THC$>IA#3 ZKW'86/L[-Y4Q(WQ![$HV+MIDDEZ!HAO(A
ML;U&E_V,H]J9?E(Q6CQ^_DVKN2YYR'&_0+B:)@&RH<YT?\E#:+IOJ,F/CZ3T
MK]@W)&[W%T%1LL- G?*%=%\&"BA?-X0<$T@IB(2D(5@=#F*&P2?R_UK/D#Q?
M.'%+$@X5I>QC/' >P%NLAS3NY5IGP<*D]0W7I)5"_ WXX%\,22\48,O?(C:]
MV_-G-VB'ZN0#W56/_9XDK,([^U[D4X8M4_7P*R%,$U5UPNK*^E>N[4-;TNY,
M')$_.^H6(1T=RHW0DVSXU_@>7)'1>R3J?Q2BS%YIS-R#OQ_<X7&75D;)3"4O
M5_T6,6_.5(<,\4.C?S%;B=;_<L89).]0;9=<-X81J8=?_/YU3R8QI%-D_6Y]
MF^IK)>\AK.3>Y@OZ_Y,M_H\+A]MNX,I)+OCYR R%58/.(R0A?I/4NZ.G5$(_
M>M@>@BIF7OOCWQH[:/3P6Y]Q&TG#H]G)698=8'T^*8#P!"GDT[$$4(B3DP$<
M;DM4R<^CX[81L?5NSRHV.H\U-L0C!4RU,Z)0@F-K2EK'X;/D':.N_W8N7-_A
MDY6*]"?%:H5W>FY+20RU .IL/F7-P>QQ&-+$W0M+3Y\A1<%[W<(:<F,+Y^+U
M]FY>)W)YB1XKF3-<2S>V%F\1+\,6N L%Y5-V]^9=0 &%66_Q_??'):N+X-(:
MO-[=H)D(L 3I>F-INMZZ+Q^$;CEOB^%UB&KVC/D1[A:3;\%@C#V$I]$C$%H,
M1RRMII :"X"F@LZ!GO0VEIK<KR>>C5K]..FCK&YJK&+1DS?5]Z69\IY%#@ )
M54]P+GG3*4,O^];OZ31WI<S^\A0X'F)TM!XTQ ^+Y?/S,8;G"O[I? 30=A[U
M&>_4B7*$;MC5^=D(Y_QZ/ -<H%09U%R-28-U<V-DJ&!GDW(B36+APY^/JR$C
M<35K*>#TQ+792?DL5X!,2*:?I'9^OO"Y5&WU#76AX1Z!TG!\3RX P>L">LCN
MG[JSO.JUN%>)GH[Z"=ILKC2UH"4=E!?!V_=5B@\.JY(;?[UW7N2*HG_@&PK'
MK0:4($)H-E,Z0G"#+LT3O DTS4/'2$8XZ Z7;7Q6LBHL#YR2)ON#*I*<_+GN
M7;/",<G?)\FP$_D4,'#4X0K\\51EM_#U.^=KK,$J#0);&]7BQ89"E7W#Y(;@
M(A1&3/+#<VAP=&R[6P[3C6<=46Z)S41+ZLY[9$1J6KO;7W*&FDD140I+\,4+
M',JSVP73*49D-6[1(L&U&J;V@OPG&NN#M,R";"R $D_(S8;#8+>#V?EU6#Q+
MN5OS=!8OA,<PI'18AUJ,%(H' 1MMB-#Q/S2Q5@/I=Q4ZJ\?1C!JW&$E\A(H+
M))9>>"SA]I8V,')6T7ETWT,1JD[53P/F7]ZP-M8:@D4Z*,?,-:NJ$=D]0;-P
MB.X6%CW)OQZX%_,25O8&JVTWKEHLU%?2 <50<( 0-&MOK;:>OESHK^EO$BL9
ML<=?XWL#W>/&:VXR,]\=@'<, */>]2TZ/6:VUK]]A9MI.3@@N<+9J#412:3Y
M-^I!O?=#K#]L^9/5-]OOK36%.S[7ENX#$SM_TFNI/DI^'F'M<829;Q%$CPB>
ML>RK'FM._WJ_?D%+^E)#\EI:7H=LMXO^T?[N;/0]FF/()2 CIK:G<_RC1&W*
MX*"&&ECF@NRQT:"3E0^C=X^U=^CJF0S2WQAIB-TH7.OFD A*O*/D+EDRBP7-
M-1,[_78.U!,22Z=OA^#E3G/%]E0'8CM$UU\#/.9^#'!C@9;)8?[GP.RN+D%'
M%/8EY1L36/>J?P0A+G_P5LF&P&I AZI]=C4;-9D,%/(V7Y/A'*!XV'=L=0P1
M/6@7#9Q3L@P(SK7<;FEMSY.93KKN=>0,%XU1$IAVEHN0,_Q^XX.:4$LU5+^/
MI24#-U4,Q"PRSR<V>^1CT3(57@=UXU(M.%<.;8VE"BDM%@;YN&S\X##Q=<=K
MWH:)D<F7?<OK+D!KV4VF@2*SW5_AT9*1L<1-<B]6/8R&"EOC)X-!MDIUP#9$
M\O1E_6C,W2R=, E^[+9AICX,8]_XOG(I#8)B8_,%D?>B%47^#M$/Y^ L#9V6
M$TY-9'/SDTBPU5K52TRA ILA0R6?I+$]24B@A?VL(@V:^$ 0HV@ANU'#Z# '
M@HI]+30EOCNVA-'BBH;2DO:^.>PLFOE*Y^([L#[@!7XOA?=(@L+&2U\$VNQS
M7B/MF-T'M0087^BMDVL;D0?)=3^RABZ43C+?D7)@X*VC^5"KGV&/3O.>8Q1-
M#'>-*M-<9R(F7LZ4V^I>ET\I(4P4^K4$:(PU"VF1DUT(EG4KVA/OZLF0NRX/
M]^6^-.)2:B$R1 F>O5T"9946Z=>9N3X1G[SH('Y\;=GJ@@7'512TU65?:[TU
MA$K@X#$H9:_;*+4FLM;^DG3" @T.+3FV_ZW10,JG8GA0/!:9J"J-5B"S3SP<
MH33TI900TY*<4A!>R0IC,"_<>GJ4HMUBM^4P\IEO3L:84P+7?\I'4W8Y[3<A
M),QNJ;]G)N(+>=Y;,IY9(I69.(JVZ[ M$F=9&;8QDC27L,8[\8^X^[CGNHID
M\5H?7R[1]<=I<V9;V^BBG" HB&+Z#ROLY^FJS,XFTUNOU8\FARA:WTSG='LA
M/7WE',,Y^8(^K'*DK7C132UH2S9FN7 $,CQ#I)*AS!CHO8[/#/"&GOQ11  *
M_I,W0L'!;964:#X^(Z*.SX\-A]4DX; ML::"P^%0)P2&=#:?4KFKG7Y+0?]1
M8)$Y&2S=G5%3'$?CGN9PY2LS3=2,.?3U3R*,I%J?I5S#CF+9PD+;U"2&1.2[
M7Z,4'&Z71 ( 9C%Z6E =EY5#WFH+HUB=@$8F:/60D*.R&)XND.MAY*@";(R$
M_L+80G'$>1R%4J_%)9J3B,D]S=VT\KZ.9P'UMR!X.AG8X&W(U4.W8U67,&K4
ML6)=:R"GN.EKO:1.-$]JF1Q'T?J5=O+W3<[O@0M&(:Y@M:JC2X+V_+%.<P-N
MX@/%][V,U#-+OHLA Q@5P&B2H="_Y+>)'QLM>]'/'I;.B[KG#6-OSW*ZB034
M:"QW51^E)FE^02=+[29O&;T\=%4A[_]U^T1C2BBFE9]37@[II-QA#J6>U>J%
MR'E%A;$\^!'3$<_+;60Q"GMB7]H2M]W!8_I@0,.Z)55Z IU/^?6RZ,$DJ=TE
MD;5S3[$5K_"A[VI?$OV<X=+3=%M<-F<:QK;S#9*K&L9[^EK*_L-(,5X^'R\S
MPZ.[6)Y4V,5@6ZID9-<2T%V#E:?!@N:#/O3N!,E-F!_7WM#G$Z[WM-4F+R4I
ML04& +ITA#U&DV'%:D99:^=GO8GD39WW,(.*MT2/,+4",I0O&C4"M%@W'6"2
MU8U\\(J=T=4[.;O,-/9K-\N:EU/<TTQ\+*:@9929?,-,OE$S6O3_='>495=S
MR^FEL^[ZJP%?-;F:<)"1 /IX0LJU8[_^A35ZQ%M#)0>:QUF?SN@!?>WSR.\@
MJ+5!EA)N%!\]I<?_H%]9'%9>.NB'9O]<4J96H/%AKA]WX\W<GL1+6 JQ60P$
MA9&<"T<G(RX(=.M8V_C!X_W@L/W==4[>[>TO>?)50V=5/\+J]O4DWXZ?"4R[
MR<5_D1ZV3Q-.7R[0@\FSVNAQ*HL+<HL)D&\I/T)@0"]6.3FG#B7$I5_(J19M
M8[4#.O4"7F)_)';+J\Q0WB&1(ET.(3G6=>&0R+Z'U(96#M:4?RU%V>6EF;%_
MY!"#, B9&072Q1'[GP.4;3SW3M!1.EGL9X9^K?(Y =L"#$W% _):WA<>^>M+
M#)_KQ99OB1RLZN8,*E94YP8SV_(8Z$%' B7SQ$G)"]@[543WQHC#NJN2_PCK
MH1@0<C?V&"?L!2?%U=26E3J$^I[\@!(;R7P%K6"DE*Z&N'QH8\.(WL\T"T2)
M)^[5;E.T0"/U)XFFU3RL6V*X+\4%Z.S#C&9"$6/,A(I@;;F;7&DL\^:ZL:8_
M20+0J\-H9-&S@E$T_KN>7+GB[//#JQF^PFH#?',,KV,AJD4^=_%F9AC"=T(E
M.:ZZ9B4\QZ**D"-WMCU"F!X>?40Q1(<XG5*G]%V/2]%.G'0F2DN-IN@%O [;
M">FYE)CYQ4'N&(G*%3*>9'7R_#J.(H 6$ J"8C2?_Y9W051+[V<9[-VXSF!6
MB*ZNF:.WCG+4\VN1$ #R?P@$Y3NY+?^(:[SW^Z_/N^+Z1=5F:]ZTB-#'4ZA-
M<COK7FR2!)FE,V3SLO4!FY""18D+;O;6!F$A:#U77;)W *=RI%H0_BI1V^1^
MTP_26]2^H-^+PD/Y71;D]Y7K'/=#*G*=!KCM0K?:O]'XY12]]DEZI$=$%9MW
M89S1"(K)J\86 S"[D/(6['8GEZ%_9X#>K*G("NF%[.D(JS_ K?+WOI1*N?F]
MC&6D]*6&[)$1;EYE%1 WZ+VP"IG\?[I/9[4+.4B>4* ]NU6;N7$E*@ZHE;"N
MEH]U4.?*(*+P@B9GD$C!LI:KML@*3]!/OQ^,[,Z%]-IFJLH3 >D&Y;\]S$N5
M/A&4GG\E!?H4--G7:$D:Z>E/%E+\7(79H_+(%H[I<>U[^33;+ND='\T^26=8
MPD.CJ(I2US]21UGGM.,=<8ZXGEO;! DD+5]7.1KR2S52+6%,\EN9#NY!//<:
ML5Z'1*TT:?_@&UC11S$H!REQ.(?+L>8).@SZA7:(\L:':NQ5."O\4[R2FB _
M:;E>0LIQ$%(*MJ;LY!7^\-Z7%*NYWBOSO3T.F5ET/2^R8KJJI^ !F#7LUS/;
M[=E>(/ @#/S[.WG]>..&^._[O>WK\604GLF#&PH,S 9:TW5"VAX$C.+E4(+#
M7SW)NTG;*X.LX8R11<7I>RL29H4S%"GY_$(@#3+,0*K$AMHZ#X3G-.:!Z-61
MO5\!(=.K\8YRP=KM 7XC(=_M(*P/LW> T$\2?2M7=+3&<S4IA):&X[2.'/ R
MKYZFZ%7WO+A#9NDK-H=Y9'(B\)CS+/P@[/ *U3E @V9]R!M=44\O;M;-1FI:
M8XJS,^@!3", )P#VLX,CE70LGRI;V664:71%,"N,W*5'*D,H:C5Q5F-IO$2P
M.47D@U">B"K4.B ="O_ZEJ1CBU4]7/CS(!E81&' -LG,]*?0R!!>>[.:G9X(
M *BH3I\KKVBOW#:YW70D;++%G/PCK*29IG=?VGS=C-E_4]8]A11HVHTW?+KR
MN84DRB/KE')!'?_E(UB-3\EE 9H5\"K8E51_4]R$9!T!F6E?ONG<ICM]UNE1
M-S2=QQ\R;.<9,AR<57/RJ&ES8S[7&=)]#M@FALS.NM(,+WLL.SL,>1BI#B%P
M0VS6'K%^3S%,"O9K8-&H&=T3T<>NCYWTDOTC*Y%-B1FNC<SU6DO$)C,%K66M
M)]M/B)&-&'FJ&9/EW,PBYT FQH,4=:';$&0O[8V.3+PD/MR7O)E9%MYYF9VL
M/LUJT+ZF"![4SO(C71#S)AEBJZ*WP\AQ@W*+X*CLY\#OI="0SK_V@/ MJYU"
M*2O>[^> ]653@='4-D?Q)B5'A?=39XJS^_N>HU*@R]GF&FT>6PVD&]Z-._42
M%WKUA4.*UGJ2F'1/\T '1:Z$+XBIVX/WC*FM0:FN6/-MUR3-+&&HP1QV#^4-
M$=PRL#1:" U4>4(SBV:/WA+<&;WUH5X^/OZ1%G?ZU7#<2BRW]:T!^ "ZF>A^
M EO"TBJ"&@A"KI3L5#U9^EC)+%5"T4N>\LJOO%8-[$%TG<B(:"?0W=A3ZRI&
M\AQPTGTR]HUQS^WA1WX?_T<H/%\F0RI2>NO,'*$W,FW=0;.>.F4H"0;UG7VV
MY&C<N3:2]:BPF[V^L]"])R[^+6/DJBW&'27)<7,M@;C_XMQ47EY"Y=Q97<DI
MZI%Z;DYSM=]1/#UH4' WI?\AM::,C#_S0GRS+^P"$8QJ#_V -VUV&1XU!(Q4
M9=!\/>TK<DI3/+#DY,>'8!>I*-4L4.,9WFKD>Q7,7GV'0<51!GB*(>N _D$.
M#?YP-O['#9:0AZD3SWH&-V28^9L]*KC#RC3<P>-BE%JWEB3Y_Z*76OSZO%[N
MAH?B<"R]3N(H4@ Q #@\PTAH013[Z4EW+>X>#(R[%SBOFF>FVM%JLD2X8X)H
M!RZ3+<5K;/;6*4X506H7<"&.L9BZR1-3)[)$RA5M)- AD1L-!:O 9! I&B9_
M00ZI9!LW'9O]]MRBOX$*]<K;^#GJ"GE.[QUM!T<(:QW+&P&-KKXXX*<%Q.I)
MCQC/_*M8+EP@LDI5+G"-VI=41D %"B;-UX@$'(*R>HW;F"+F%F^F]$CNRQ*T
MB!J+OPZKXAE4[)) ^52HQM/JW[6+]EA';\QUCSJ'QT-DW 6EWKC[[#GAWHC*
M$#^R*)RQY!ZB(]'4&QR\<*!P&.D25A;JK0Y6<.M9;!B)?WG+6NT:80Z[PUT?
M#,6^* CZ]6!D?2Z"6HW#&_;CC"-$M^8PG"RWZ_9L0"Q-N!E22((A]0SINTX&
M8TBZ JBO4%U (N4+RC1Y&JFQ(9'O('H?0N7Z6H  P'V=<-W.T]P9D4)IHG):
M5)_X\-#4O#Z"(>!83:#/DX';Q2(6]^DCD0$9'['FKU!78+?J'P:=Q*(]RLDS
MNIB<_+>I#5VEXE@>T:O,NT][7'WV;7+NS%%3KO<3AR8?WW*>J4B='$!63:]2
MH82>98//[EF#C9K$]=-LR]Z%=&5>D-\+NJIK_;:,-GW+783,)MUT.-0&=75;
M]2=%;A \7Y-KY^H/C4\>#N_&EO9HS19'#%KN:XD%Y&6F\AG#XJ)MHQ!$/)$0
M8;7=#SHNHG9X*WYWE.DZ_A:W)(Z+GWGDE\VZS R3D&8_L_48R;67H1<\I\37
M0V> >L[(,0W<U>>MCX5GJHQ\[R\&/VDMN6!)Z9?E^D-_85H'[. <.#3\0_D4
M<N&Z=E@XS[@QW+OOABU))D0*ZO:V(J0_U',9T5Y+*:/O6G6\%6%MMV&70!L,
M[%E-6RU[Y&PGB%155!2Y;*:MNG!K6^@']-9GJ"7G2B/ &J2*V@#8*CFL+BK'
MQ\&G>*I'>)LKLE @VIZRF/X-'P.&6\JC!0S>%+GC"\BU3T?W/3T<TC)IX5G'
M.H47V#47D!=_[0OO-R'7GC.MW+ U'2/1V7VR8AA&)74D:I5):1<>D'Y%4)#^
M"O:-56H=6W(J-9EM/B8D?$69XO;.IP<YED?L5:];GG^UQV7:<\L*+\A,X0_M
M]N7%]9;ZC3KYT9P/+P@_[/2_FM-!Q?,/H>JB"6<\]PXUW'3<$C?,IS\SIS$I
MX$LM8A%$1!\Y=/SV2CH[2!A6.6?*U'<^8AEPVUF'B=5F-$$&2@$/-$;",(VD
M7(VX..!WJ_]7$8CTB2U1&H?8)Z^*'1RXTE(3HJ#>*FQ8&>YPCM!S@+/^&<=/
MQU1"NJ0F?:U<3@4R@Q5)\5830>ALLXPS=0"Y$NOLO%JUR.M9E/^N+1',87D.
M7-/W:P^=<\>= V_\L@.^H>'G +6R\RFR4W1MB#_7>LHYGP)YE0+R)MW0 .ZM
MU[BC=>3MAZ8+N7;Z0JH]AO9Q[O2"?/*S\KM\FM;YM(-&.51W]Z(6(QUGZQTQ
MUT_,=@4FNYJ, TSDNQ?Z=WLZ Q$.4X!GX)7AK_D8C3NFQ?!\RLIP-I/(,U'3
MPPR]Y@F/H=.7D_)[$4@/:[R'\G=9\D"B =G;0T_1W2N<!$7)Y3/&,X_:>O<O
MM&4*"21WZ&U\@PS6#5."CTPQE&&=8?6$Q)7"E/)DBEZV6BF_JVQ]+%Z!%I&?
MJIOE540C[>H@4J"90PI"]>'"H+#JM(5M1N@X0F_5K=Z)RRS:2*93P>Y"8P.G
M::V7HXO:JCAVWZJMEWEP\O1,W P$Y3T+OBGC#FNR)"5^6-53-4.G<QC&.[UM
ML?;F2$>=/-H?1@;KS:1^P,GO<>C@T7+'&6P5>0YP7$CQ[;'I3%I[8SOZDH9&
M,.8-GX5X<P=A:WIT*,D9,OZW! *'6^'9N-RUK?*,'\IIX#L[)2DV:_SK^%U"
M2X%#3VGH;PXD(J5\\+PEY9E'6KNI*^,L6CP!1HE.1OI(MI/2_NW\70QSB>U@
MV9ML/9+"_]9(%:>J0Y,+/A GZOG[-QLN_'ML_X8$MS"^_,4[-;#8K(YUZD)^
M-3"V.YE4$4+E^JNIJO':$FBHA6TKD5C#=#6\ V"TI:<%,?Z>1Z=6/-U7[#2$
MU:(-Z3<*>(5X*N1K:*/[?H1$8?4YL'OZ9V!='63>*WTFT*0SR[N/>!K0-S.4
M4Z[_QKM<R0&)^T,/:8R1.7VTDO,ZMGC6>8^,96-=AT]KJ+3J?92O+)!FD\+,
M9S#AKOO\0D;.SYB]TA&$WC 8'E8M+88+:2\!LJ@=(K!L7K05;44H0HWG?=(Y
M(""[P#[2$LA /OO1/J= !NEM_%,?/5P<*N?BP?/=5V==."*>K58[0L,7Q8.$
M+WQ7*&)578\Y@L!8@(UZW9G1&Y]$;I<$<[/&E4_DFYINDXNI2?+)SF<R 'J!
M:0IZ)+5CW']_,!33:E@?!163ZSW[@ ^R-4VYLDZX6[N^]GJA>B4(YU4#HTGA
MXRXZ*-L3I=0=T5YA^;Y0IP/W!:^TNN$CU"VO^:936Q&_^M]'Q$==_U*@_:_&
ML\B!_>/1\(>6KXJ'RBS4#V+7I_>&HB,#^M9].,#9Q= ?BU% Y0?T*-%I]0FD
M*.BQL(C0:M*"DPMU+_TCQAMZS,W3$43,X1_\8DED;@%4WKM,/24*\.7#G_(_
M#D^.49S(8@VWC,10@\SD5_B1,FQQ)?K(!\T1=BP7PA%MVO34_/,+G?BR:13N
M1G_Y"WB3U]XT."I@B!A(%GK=]>(9-:7R0>W.SZ;PR@>S\R+,6Z^O"#JB#"W&
MZD59Z2$V7,_V3%#6TFC@<NB*5ZFV<&);FOOB%Z9)'T+-4NBNX2;K,X_[-\?]
MFG7;YC^"F+;DBZ:#[G;;$OA4BW*@ <N&-*Q1$DQ#[!VI9J!0L_B<Z3D"1LZ*
M/40M:SG@J1O;DZU[J;AN+Q9B)XEA:L%^OUB+0/^.N>'^(I?''< AUT[C:G=H
M0%&9]J9K8-:M\H"F]%<XVFK.VYU:R>OJ*HUBPZ"O]:1\D+X3NV,CYS:6%-5:
MQ0]A-(T4W*+DFB,C,=.C.XR=4.D)<?1(UG(>(4=^18Q[H#_-Q*\;,2U0N=)2
M36;,+J'_3&3]2GT*'WBRQRJ>):S[H\E'E("]&4RK>'M$C]^!F57E*/7*NH:N
M'@@!V6R?]EI)SUSN]U1:O% /SA;S"2<9= -\74=A/FR,$@IY6S4*F^OY5!5\
M- Q_QU" H,D_S1)].:/>+2Q*L&8*H(VU%1IZ R:U^72S&E;THA-(4:,D1='T
MA]R\!(KHO<>YZPLZR:GU>L6!>ATIPV8X$I6]],4HX]GZC?#H;JM+CQK..[V5
ML_KF**Y7(B* '"14:#;V4YG/X]#8HT7#&1*V8M)39A6=WN[Q;D&OOZ:4T)*3
M6>LM8:0Y6-Y3 P$PV@AJ2K6^O/H#W-+T^U?U3P<3AK@[2KNDF8_,<L:U-Z'\
MMH5FYB[,EP.-<@Z7'1@2"3@GZ6,"SC:5RW]O4KY@*')J>G9=CGATI+/MFS#P
MH!U\)O+ENG&ZW TFHLK>>E<[A^R<;XQ')H\JYV#2@$<^4+(720^:"E$[['L=
MHMRU^+[1.#&'V\@)A_G2E2"B2WZ_%$^E+$@-&CT4/7@VWFI8RX!;#GJ5KI%D
MW_UL]?;VM^JWC4R\SCP[Y0'6CAAY*U#09T[6:?5B<\%R@Q\S*'(VCX"$-4&Q
MKT7,O F/^6AZ@ZRLQEIUJNZ?YG(>/K]'T-_@0UL7:')9^C23T60XF @$O)(*
MSG?2^4O\7=#\M/SWVR)K]Z+Q^F\$;],21]Y9*4+5UH$2IQ/O,R!M['J!AY7A
M59TKS+3;XSTI_2VXR1?L\GNDLE V!@06!-5#JF)D=>$G-QMV$CZG3[(.-]65
MBPN(!/,8MM"BR2F*%=(WU^\^P3C](VC38?1N\JW#L,CV+/<*5KD;I:-(T(=(
MYONY],U&*(Y08P3\+[U?Z:TV";/;K\Z!+G37C8:9/C<^B;6;-A0-9AE"JY"-
M/D2-/AZ0JZ)R<ZDR5PNFYN*-DC64AA#Y4X(ZD3(*2[C<C7"VR3BE"Y;BIM<X
MX4EQ^O(;JUC$RVU;W+;RUAL!Z:A.^..R)^@A2\G+.A5XA7#E]4PO)U-;P_M[
M-TL"4!AZ)KU@X='!(A* S20AS+6"J=N U%CSK=>*=*>]^K+6T?0XJ^P9> H1
M-:/!!ZG.6MG.(,Y]VS)'5!<P@V=(8?08SE)EV"<;; +Y8<RWL<Z0Y!W1+9V"
MPZXO0J_HU%#97)EVAHZK--A:)>9S@%0&>I*_+4!ZV9VL-^3V\?W?WJ((4,G[
M'OVB8$'-%"T!%LWDP%O;%OTJ4/%-8.0<6-[L.>:,H<[\CIIO<L8Q,^ ENKG,
M=%>NB^BE=)HNC4$M$8=E#OE?J;_<K:&[#:O=[J#19'/=MM2TS0<C0^P"I-<;
ML62713$78#BQK5X<S,.*K1]'.!MN"_CJ"(HQSS_[U&D@S7@!AL4NH0(-GSQ,
M]*(,W8P3!C8V78G@<Z:-TEN=<ZQ$6EP81!PTI&RW?34R.KY!6$+>)7MJ=I2M
MKO]U4+,$GS*?88J43XG M_3393(LI4K>S2"FE?2<U7;)8VFOZX/3&R'XJ]>W
M9\]JF&1G'CHQ;S8 WAQ73RL?6-#:@>&5TFM,X0RO^E$,5Y!]+:\#1=806.9]
M#)7Z8=@NY8>^SXON-;;]K&[$!@G)#?=?C$(QW3PZ(@_%\S4O[S89?FK0^CW&
MOCFGL9?>"]E(UE4LU ?0>H-D@#R5"_*V$V8UEJ';_*F^./2]U\;-7[*J[+?<
MWH636ZV3!G)KW.2S95!CI(?M6K&$V$VTWEYYQ#IP->"#!W)DI0Y*&XZ*YWYY
MH9+#!@UN)O:*=>1#,8^UEZG@]PZ[0(&VZ\M"@VQ]*&M<9]^S4E,(04-#!=Z/
M $O_!AEIXSH)G0B!;A%]+*QDT$^@X0\6ZTO(1=Y-SH)]#5C"!(JH9/ZAO"7^
MRK7QKA4JJ=TI02&EUM:;XL@%0V8\UZMA%%?Y<Y_\PNN4Z3)U*F*_EM\T;ZA^
MPQ-E9B=^%)&2U4SQ421XR3&<[>X_*GS3OJH<:]Q&\WQB9C4X_< _BD=]%%6:
M8:L%4O$GP<^=E'I[@SZ-(>-VVGN_<=)^99*[W1Q6?V\S5"_"HYSV=M%I-->=
MI69>_F9?9_AE62+Y\\82#APL0[)QZF7B6D"GC!'1LR7P'8 7H/N-#S(L>@ZX
M;'%W$5B/6-!.)LX5!R5O!/#/,F,H]37648S>S) F(7*,D_^2*$OWZB.^!@H'
M_SB+XQOA:HF5X]F1CNR&J]#=Y$*PPN1_/YIBOIN<_#T$SIREE\-U]Y<*JL6Z
M6%Y?)9"PG)._1<(+>0X-KHH*NT!8\V?H#;?'4Z!-==,]+9".QI['MYSW#0 T
MG<T>_KWI[Q29DN[\*9/^L["7)D6YVQ^,=2O,[B)<BZ7FA'O\Y.QQ 4<O)?SV
MQ707N!SX(O )*)E\)Z/"D)L-'QOD$^&!\67.$QJ#)PGEQ=/&T--%<148_=K)
M"PP*>,#R7VP*S>C)M0O/N$LYN=5HWD7&(FW&Y%8F0DE)P7]D9LJ LL9H(3"P
M-87@RXS8E>P9>6V%XN%:(?)RI$UR6N8\?:ZW:KJ 4=HE8/RF!#]Q^="&! ME
MQQH%*DA<P9=N"[9<$/\//'#LMMZL-OB"M-$%E4YV[61E?3%@C@IUDAD &C^Q
MF\48J!8+^71(D>Z=TAW4C5_3>>IJJ16U4B95S,@HCTV@'AZD#'141].SK^O2
MPS;:8,$SYT!<0X[* 5&T?PW$FY=6R(>:,@P[]4.64YR960;@5-=#$MK=/#RD
MMHA-LVD]KV)1!#%FF2Q>E+5';#1<%IE@CW$4C3X3=0DC?M B+/W;\"\=J)<0
M>?CKQ-=7)*/GUTMMGF$BCL)OX@O8/X*^YE$I\4Z=H"-&;:YNM=R(Z2C'I</)
M!\-HFGTCHLC[B#%49!=PNVOT:3VM<>_  .5;8U%LUH1ERNES0_*C0+@T(5(I
MT(O5"WM>^J;MM3U <R._<;PY%B50S%$8 T$!=TS#\2 2[(D528('=WL]JE<
MWQ+U&4I;7O P"LI&2P8WT" #FJJ^[00])&EI\6$3K]P,^(WDSAS^#@#AB07
M6O2@O>C84!E3MS;^^G?!.0]FM?K-0-E@PG7;90:C29$AU@3JKT]"]98@2GD[
M)LGNK5X4][_L'=4(14G,6HAU"-+$,NAJD,CT*3X<0VZT8\[X:S[\:/"B6Y#O
M=-^O]ZXKZ0[>EQK.TI-U,>2F+;[SB2=&, H8O;?#N:58$#3HXYR(HFT1(-25
M%N.20HWL _6".F"&-0Y&<W?X()^+:5;:_LS5.X7M[*\\3NXAO75 ZSE;KY5
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M0-3 >,@/08^144FOK/7_Q=Q[1345=EVC.P0()1 ZA!H@%&G2I$B T)L"(E5
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MM,#2G<A5V4(G-EJ!TF9Y4::&3:5:2@K@\6<"E.)QW4GD)>,T43F4P;PO*%K
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M1\P:V8JQZXH3PX98".%E9RX_5J?OA$W(7F.'F-(_[+ ][;_&CKCEWS((MF:
M?65%GOR2^DSNB?#\>337BQ"IO=E0:3L^>)]W2N)]=&+>)94:7PS&JG2;IB_"
M_7Q !5!0-S'E0H@)P5]'_!$_&*8$$R$&VEV0['PSO^(Y5\1Y-X*ETGD*TZUK
MXOBA!0;$MAW[I(HB"TF4W<>M,\]J_?A>>/RLTX.:C4DM9_VQ@RAN-ZPE?LP^
M" .5O0TRJALG?<5OZY_Z77Q32#9E%$<<S.@R["'>?/J$M@[4\<\+0NO+K^+I
MU1A"ZFVEXIBC#>&1LJ;1Y/#-VX0"LLMT*!NE?-B#VI.R-U\7U!R(%B3TI*X
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M6PU0$7< J0R@SAJ7IA^00 =X7P'5;[%NDE%-?F0>(I9IEY;CS )]XAHR-*0
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MK8JM9B)RHMD#N^),^6$=$*4S+<2!0GN1"XPT65IPL*Y:F+66*-4&[4"6),$
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MI+1NBG+-@]%[^3#_DS<''N,KY6+C3SZVSDEQ:50->)$ZXO>R[G782H0-R4U
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MV-)(5/;TC]]]]% [K$W\6QOCA'OV@C)4*CDJ3/RU+S^@^5JHC,'%1X>*;GW
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MC>M_=<^5UGV4E*C#/=:JR0JSN6VK9X]W@<_^CZN><)\K&CX3HQ*PA>?OM8>
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M=W<GT=-3!W&*\LYU-4Q97="3>FJ[WI=]*C/F.3H(7T.KAW;;JL:S328<7<5
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M@3'"D!EDE%X;I3  !8O-NDB9SXFEH K.4D=KM)0*4TP#GG.==!-A'E19&YG
MV!\B8!0&IX/%IEK]UWX"KIKKAQ9'[3E:?3]:VE\^W5#6L5SA\B<Z7_O##;-U
MFQG_I;6BN,_#,_7GY"F7OV@]G-[PU46:0V"Z7!EO?3R&(?$1C9#S8:@?.77G
MP;XMC75THN[-\(),%&>M.U[;,IZ8E.C9_8M(Q:(2)'[+2F#O&+I.(^<[[XK9
MF[NGN2FKFXU[^'/$Z2;P+J2?;H;Y0Q*I 57AHTMA2\^3;2S!&YZZ*]9T ^K"
MS9VTD@6$\X ";-H(M-Y>F]:UP2 1?8XE@71M9$JCA&87;S0Z0N,$-'EAA_D\
M+<0_ .<_8+E>A_]RI.KKA"'I!,^A*1FT:-DF'6//T)9/FIV!D8$BD2;XUJ*(
M!&=7PVRXM9L>(E%\XY(DC+@N=W4BJL]K3#\%U/A7/)!K%$O&C=L_5F=3RY3%
MB_949N0'YAJ;DHY-O?-%08LP7PXN0^FWN&"0_8I"CU(XC73"4UW>UP+HV0^:
MC_UP)'Y/#C*PY(_Y"41:;G\Z.OP)K ;E'BNCQBX>#\?=^"XM/M#:+BKJT%OO
M54<AE7H6VY6*J.3@!V/AUK3;K&FAO+?<526$!1,'KOFTF448^?!+O2/:*ZP4
M70>>K%1&//6//VHG"06_%0E)VQM(?]OH_ZW1<L/E8Y9]_&?8AW=,&]?_Z)K)
MFZ-TB3YYN2!>>=AL6JND.I52T-A0H^\4'X[10^$2:4QA@ 64^D<(22^RCWFU
MME,XHGIRJE-"YH+8:FGU*R%-9QC- (*4N)K'/VPBMKZ,.1_2>9\QK/-5DMEU
M,%^TKE6_#S/:R>Z>'K,^ &0)08!?]V0S=QBZ8WF8+#N#_.&!Y1G73ZY?+,%Q
M*-C&+,DTP? %58 <>?L'2I#.[CPT.!X@C Z1!)J:9V/W ]DN"=UQE:^1'RJ4
M3E=IV[2MV"6.&1QH+D$6?PB^ZNVD3PQ#V)5IQ5_"5UQ;0RA+<HP!WG<3Z;NP
M?QVJS_PMWZ#T?>K?]5SF\K/CJ<@%MH_#9MUQTR;&9B_XG.UNL @)$4D#HS0#
MT#>\!U[VRR+I$AXK$N=J132"!TVNA%'!F"P%_4%X8P) .4 V0'HHKB+L?;;W
M;Z![:K4W=EL7<IS'^#><2.T?3U?']3^6R0DRE,'\R%<]&^+0)\NI>S1'TE [
M:WQ4_$1*<DOT8NB(=[$T.-%\ !#!W+&A4&71V7[3Z[X=Y_T3.-=3PC ZHP#W
M\",J7]L*&R:9^I'I]O'XJ?DVV>8'77<#!-9="EM3_91ZJ=V6L(K0TS5<*<C
MFX6M\X94E0<278P!2I,B="BM*V?IFK;LT*(C!D_LR&C\9 1@"V@O #[6_\3;
MD;&R(AE='8#[^[RB[E S._+X)FI67$RN?_'@$@D^J[THZ:WPCZ[^O,;DA.B$
M7;0&GY")"<C$&$9!-BM<@ (8RQU2>4Q6QW;EA?GKE 3M^<V:RQQB"PW]?!4&
M1JA!17L\FNCT.K2-S36'>M[WNV_T0\60C%4$:>A38BWI4'TNNQG>Y^T"[%22
M9=?W73_/ U^SPK"'Q)R8MMI)O=<NI>S3>$9A] 3@8_J[5!/F/.1_%&;/74F(
M_!82?X7_A>U)ZND:KJ?2>$G/@:%I%0=G*$970!LXYWL"S," (A"B^"//S48]
M SZ^Q:,'D:O52#Q:$,.W(Q_A'GR%IJ$M6C!J8\TKBYEVZ^I+,TJ$=&+W+SX4
M\@]\*);HPAAP%UI7I\XE5?'BPCLJZR.\/OJ,0#3Y>;+4:W^,WR4.;C-H!5VY
ML:_%2,-VB3+)*L,_0HRO*6D;Z0F1(@L&X "V_C)7+P9X7;.A]"UMKO!P;-P3
M:(G+S\Y!YWKCRS'P 4L6HPAPRFP+[:*AC,CO,09DLIAI]U6AY(_\+P$K6-1D
MW?H(7FX)V:4--\Q+35%+C7AW15.9L=<>&"L6^^NEL)#]RO;S6:KL_81JP9^
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MC$4K%+1PM)[(XF95/#_:;VB5F,'LV##B@)XPPU"O[K1^9 ?;?G#^Z;R>XF"
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MGH,G7!69/;8HQ;>%5PQ.\%BFT4% 361$-\!LJ4[NH['] \'W2;YPQP%'DY<
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MW241P(;YSOS#Y4'ZAU(6>">#7PPT?(F4H8' J]G%:(A[GGEE'I0EU)N[/V/
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MQ.> 4U+0LD_RVF:6!G7?F7^,>\%]-XG/DWL1;PN(U.W^[/CU/&8[K:))*24
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M:8]FCYY'I;"6\ELN&B6 N7?<\$0ISPPQ/CFT$P]_I)3UK'VLHN@(&ZY/ )X
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M2=&+:G 8P:!"EN$5;QOUA?Q<[ES%G[>;!Y><M'L7O<M"A[X,==XG=;Y9!S=
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M.N9KLFXM&///9GK##/Z%#L"%X9D9AJL0,]7I]$45)AJ=3!&/4-;7CV6!#=G
MD[FDX!9$H!&%G%^KKN@FB5 7BK/!^:$<V7F6+]F5C?<D2&$\%T9Q:KM(9H5+
MO0LYV)18+/O]]6<AP[9S<IJ1^1$H+GGADXR3!NB3EEOO_><O?I6WLA5\X@RR
MZ]5L?!\Q1,'M67VH!MU1JGD#U0^P@D@:Z*R,[.I,6F-@J]T0^S?8!!%Y:<:"
MYAR5GQ,SM0JST1WD8;RX"P I@&%;B]5LOWY^^-_8>\^HIMON7? 70B?T&NDD
M]%ZD1@@@$(J *$UZ!Z6C%$4(O4,(@G104!'I'4%ZKU)$.H0BBH !E"*(!Y]W
MSIDSL^;_/L]:\YZSYL-\^GW+@ON^]][7M?>U]SZZMKES_,AB%ZXC%;,UU#BW
MX;S<[R=[P$GJDSX(O#[3#/QYV/=^8?#1B\794RG%8BSSP<((4&.WFO+IUZQP
M]&?6384A].."O^DM^N]9!N/]T)\D*:(KAI](#D+&VX_CY=0F>NLU=PN^(%,[
MYG\#K:OLTY"?IKW*3(W[QBUSUJ^R"',"7GZRW+7].L1H=RB X)P,XQ2ZF"Z@
MN.]%8+[P*YQ3:-M\3#EH19)'+NMXZ8E=MHJFPGK2-.3()N'N!3&^;&8_E3MZ
MB-5HI)C8Y& WKXHUHCX.# <G[H$Q%#:UFNC[5L035@2(^(,&V<W(Y%%6[#OM
M!!=K)$A?$@WZU$YXM?%]JVZ%A26(0>\C,]6D$WF9'S8E@XM0<LP2*Z$Y0TA5
M2'<N&W/!]"UVZV,Q:YF[#V.%Z:8S='9%1EU^6$^5![6T!N4R)";IH22YM5^9
M\"G!((,A?XC4FBGK]G,!5$[8)HJ"C%_DQ9-T1#AY!7!-Q>)$M"PPB>C=42-L
M(8/#7N,>8XLBC?'[5J_WKV$0J%_XS2H!\'MESG-$'9ZR<7;G=BG38F]FB]+N
M;3&_#KC @.&;_'@!6IQ-#6/"UX^*&2T^+-2(!>-IS+.\Q*E"JYYU/AX*QW5T
M_Z="Y[]-L3R*B?PN?J*UL[O3Z'7 %2]ZLM!B3[B4F.L"[=._=H/@JBLX^R2K
MLH#:[6F ZYI<\KQSTH(G80YIPK?@XJ?S@,(BBD6A%PAZM1/T7#GO>5"%*C.S
MM$[FF!JZ:G4#PCXAN0XC],M%0_ZFS8%:X\08YW6B<;]%ER??HI\@**[%G]>N
MS=.WXV(_$^__&PA(-"2)#73J3T $^"CJF8L\>UP8#1.\8J%-LZCYGC=]@8L&
M!7?QWP;$/'CW^5/\!YZ;E3TS 87;T5C$:&X1Q39E2B"JX+3H5N QQ5HEO3KN
MD;E7A3Y/M*S_IJK\YS=-)2+]Y(6I&5P!A5I1(;WSH7DN026HO</Q@!JUT18E
M&A0KW%/DCO.BML+ZLT&NH0+FS;2>-O')NI-BM88+RUYM3IAPW4'X;2;(A%J.
M<=.F 2B!YB\=,NC/V#!PA@'=28[I!T0/%KY"7I-Z**Q#2.2?5/9<.-ASS& H
MQ#T-.?YPOZWA)V74APTD<_A\T&U9G0S47(<\USHLE\9GT1#6]QMP$*<(=7'S
M77[K\2AK[.-2WL1U67$ (\G]Y#[DT89'H3/_KNMZC^E/D_A:!ND;9[W=C#=%
M4KL97OB6]MCK038@*4]D443M"\30'T\GOY>8";QMQMBU?<O*+$J*(S<#;<GZ
MS&X1AJ&IGNJ>F*[)U5L$U3^).'96$:.0]^<Y**6=5AN.ZB,O940(KEX!OH0P
MGU/7X2GJ)UO3EH?*^)K2XUP6;Q90Y!4R6ZW(;@URM9 #W__"K"1AB +&P$]'
MG[UL:K7$WOLGMNHRYFQ]<PIQ$0ZG7N)G*_]KO/]0>_UOX*?FBY<:C\_>(?:6
MA ZYEG@H\HG7#_I@3J<*(B''R#]#U=@^]MAPJ*Y:"'I5D'8)'KS/>ZDMH7-=
M@F4S=ALT+]6_:80D20KI;:-*TZLN,,3@/#=4K^P?VXF].&#Y$>#4"21E;4@4
M.IONE&^<I)A]^!%XG#3)*6KA>BK&A[W5!#GO'KK9;>OT%H_\2R@)_E29DJJ]
M9D/O=L4F WL]A\_)5MG)33M7=KW^B8977M/@:<PH1@"Z:T-_P:&^3]"G2S:V
M-.N($:K5W/:M )T;5ZD*F*M#/J&5']T(M?B5OQ4MJCJZA]FYB1IF!),_TSV?
M>/N<V"R!)7:19D.ZD.2#R5.WP 01/79V=6%!2%FQHP0LG'2#MO.O:/WU*&9F
M1?.]EU,BP1U:VB6L[,A7BGS2#6&LD@N4T%LUZY(/,T>UXSC?EQ_S#?(O*9TO
M-'JIM'@60[I@JP[L'1[3H"T;>LO -WW9#^+UD UF>4\AQHXWCJ\#*&C@C(2Y
M7Y\T-L>58.5OB=.$R7])7$/7BF$]R[)3N[NS7F$>B3F- ,2 =T',_T#/# :%
M<M$I=$BM[%+;7TCL<Z07U=FCU,HJF@5Z.6X=H2V\5S6\4ALI<U>QMP'JHA\>
M1M=XH&(N'M4:K .[X=ZE%)(=A+F /L#_WA"VU3Y;>R.HO+(>ZBAVN%@JNY.Q
M="6+(@.>(>*R!5. 7C*34>H3]6"_WX"JDLH93N64"GU-\)MX*__SX6L[K_T>
M>[DA*ODZ4FM+6^-;;CG?]FX&Z8):R/4!DNR+/FNFB[')S7?WYX^E\RI;E)['
MNEN#N.S5!3ZS' \L(!E5/-C5QVIKI]:U@K9:5EB,E_)B'831 4RB4KL V^'[
M51JR4#>G4)) >TH%4@Q377V D*HP@],QP+++^\R:S!8$JR %OEN)"2) N _"
M5^!'V7;^*<"K;,S3QPND)%($9A&'=/J^?D@VDK^!_Z"XLSOR^XP7Z<_+>B%3
M(?O>O;=UX=Z]@I:EU2QI8 4P;),2"YJ\F%,LSK@CU,]JY]P2KT ,6GSF^(1*
MM7_\2FXBAV0N'2E)2?#?MI1Q4*S?N,/)>C+3-^KHQUA@6/:"<(),S,)+1+%4
MBQ]4$Z4O&X$<I?X[CO;=)B4[YAQFS=%R)L53$F9[>R'R=BJ6@$&0I4MA(1D$
M#I<O)"_X#SQ?X.2'FW@<XE;QEX7K5:6]@G'A'D+._DW\ <O$ L2WL:26 L,T
M2.7TEA9=&3<GV]AX\ZQ88V,P;QP"(('G X5:HS8UO^8#6\P__,B;I!MADMB@
MX\G6>F!RMEC:%5\H^P$*AK$0_S4:BQPX^ W,V]@HBD7X#^ X-%!/E7R[M(Q3
M <_BWO977 3=+ /$E_8NHS51QRI0S)41.22[D52KI!>!42!?Y9@;(V/#4%_]
M5?.RX.8-)9U&P[Y/FT/)B8Z&J7V%&>2@PS&_%1(N,(;ZV;_;MPO;HIZK[X_[
M\<O&5#LQKAE[K3/.=3.S3DM$7>!VV&U!-@*2X49"Z.@_3D<##RM:\/0W]SUG
MZQ_;N^UJ!O0RT,Y_^VS*"TVO&BJ3*UHG\9ST0[)_^)%H0R43UY?'<KV^H3D#
M;K_7$M[:Q)L31'18D",O3^B#Y+ [@P9:G"GI9OR8NK<XYM^VLQ?/71U(&!8'
M*2IT6(%Y '=^U3S0%JDS3I;M&@U@\(6 F]4&!=@B4O*O*K @'.3A-.".=M)S
MK>=W7KS^\*P!U6:V'CT)3?,BX<WC\>B-$\5HJTC:FZV""T_\SI073DQ6[YK>
M&GU4 OD-%.N,2![4!8M]XC]V9_CFIOQ9N/$%\-=TW]/7?Y-K)?Y3-\AN=Q^O
MNVLS]]:C??0H;K,G5&!)X* HX9.[PZ][5,]"W!N12.DO_^7FG>!A_&_ )*:_
M[6ISJS;[6GVX =>>B7H5;ZU'I]VF)%:;V0TJPO+#5C6;L^'VU+;@*S>3;9;%
MQ>:;$XGQ=/+3=)U(Y:"Q1ZL;@"_H.U_:B_YB=?8ZB@:!(M2$KSXCTA@*3T,#
M@_"?V83!N#/9IGWE]C?;7R13Y:2TFB1%V6J98C=CG<@Q0E$P-/+4?S7BKS&6
MG%)?9<77.=F+C?JN"),Z>)(9,3K0:VY]NL1!69K,X9+I7))<X\];_PW=^<-8
M9;ZDG7@A/SP(G"UJE3I5T <U1FN:J[J_2=HS9>D04!WG O/\RE6&?O5R%-L1
M?U9;W[P\1Z/EHR3C:0]J'?A(<5#-@@G+9Q;K 1Z:GDN[G,.9.>_N4WZ?3U[Y
MX>-Q)B.</K\BXNF3*_AK+D6D^?&I#&CW]F7@[?X-_$U#[/-S(7SC.<];JQ>I
M!J+K88B>I1:ZJA4Y!=O0P)% I="6/@%P#T)JO3=?J2F/3R3#L.V].NV3)-'B
M6$^8*]W0+H843B?=\@#0^7D_7V!_G<P?82(!*VUB$\=&^>/TS0R4\1:ITYSI
M&G\5E#+:G<TT6];8+8P;;6<V7Y*'V([P-TEI=C"RL-HKC)'"(0\ZI/\2WQ^*
M[]QS$RO]F5SI^RP_*#5XA\M^H[6VA"*\\&E2+" HW^>/A^R&WOT-L+R,>#[H
MU5KV4:]:DQ%M_RQ]D_\39:VMP"RATP<SNQ+PFQ/FYWQ)S\UZH?"K=;YYL_SW
MN\=\.MB(?4F"'>#Y*)*4DX55D_)5[:T/K9+>QE;Y6G7&P/I9' NQ8/@WW]BA
M%P!(KHT2>%C9L9+P>E]J>%P(UA07;L#"A9XE5$S,(%W<71K@?BK:Z /@0OC/
M@3;=+U?'J19/F0VB S5Y3+D\W25.+1[Q,"4;SXZ9Y^%]D*R7\&*K+PCAQY9Q
M)_ST850%82$Z&DEF=";OY&37<#.IM!?5MQH/&E"'_#Q.,<L@$O&H :W&SB]I
M3D1MG#;RMCE,(?!O+@GZ?G>?(.X:SS8NMZA.G('73"3?/?XF^?F0;_$W)?W5
MTA%0+^!;4*,?F^T?P5"B+4=O(+S% F'K#D-+R/:\RLU-&Y, 2!C/N,W:WOF]
MOM=(BSX<K;?2)H?.CBH2+>I+V7,UZ,M#0NX"/ZC_)O])&NJ<!'Q^2_G\+6$0
MXZ:[QS 9>[8<[\,TIK%6-$&N P >4;G+?H>3X>Z\<\0GY2E$J"OI<-A6J\\K
MJ+O.Z]:DX:X!T@%[ ?!,N^MCC^\>Q$=F';S/:-GG8.YC5<VKR6K-L 8?C!8A
M6.7(_O*-PGXRMFW,P<]>A>;X[VX=>TR'95X/AC@T4;Z]A'5K]U(8 Z?TJ[5C
MF8;I:W#Q97%MG]%D8/$K?11B@7V^MSP W?UN_;1>:Z')^WVS[T7<)).1Y#3P
MU"V23=Y&+<#PE3"&!*@NO*09M)_:ZY)?\V456@]2>#A<T=0'G3JF\V!\J6_[
M2D^[<$5$(,=E_L/)LQV&OS#R_(7YU<&ZT2MD-%=[=G0DV:09XLE8@;>5XUP#
M+/*>9-:@ IWWL']24=^U8;FZ7^C&W$@TXN3QXO:#11;4U\W>\-:(3U+H1QS:
M@#,:\715M#6?"1\U^ITNY,=Z6[-Z77#2%98G?DUR$M$;#I<T"0L:NACCA/QH
MK&'V9WX_-[_XS3T6UI27+2<)+#O>BSHU2T0AQRF>V@/7A"^@M1=T%"GU@=$_
M/;2\?C8U_,IF'-KURI"3'V.XV.G/L&P[SP:.2O_8=>5N_5:H\X+'W,;CRJVQ
M;]*A&1?6*[B%QI&E?+]:-L]"E_K@:P>AM>X7P^T#9[SMZ9\\#F6#[M7ZKSSU
M7_3LAX[)%VK]J0P%>T\5[YO&U^5)-LA07-%SP!!$DL&#.D^U/28Z& 2'-D =
M(J[0[^4$RG?P([">_&M-38VV1G.6@WE#VKKWZQX E7"=V2T C>)/C!#]>]_.
MT;D_97&#]7I;!A)USXV'U5O_2PPV!BL/6<T_&0,A:*A4CK3P(XK.<>S3#L>-
M1CH'DA0%6*TX!AK0/($C@3XT-]'SCSW^ Y9+]?2H>V9%?P)1#"0D9-H';W$C
MW6HD-*D^/_%+#0\<NX2]-E'63'_UG=35"&ZV>O-GYC3:F[!^VA*A_@9-(?$Z
M#NP% FU2RMIQTOOO7K2J?MRYV3'9,#J$>/X1B0\T64[=<[=;>+;N3=@HBSU)
MZV]QO"EB8O@&Z)2(%>TN\@OOL=1CX3"C(^VP!I2C]DWCGN'?E35^Y*=59U7R
M+<R];[QXF\DARA U3*/T'M;5;K^K,E;;.@T/N(3Q<]S.ES >3HF58Q*5]H3G
M[K_?P#B'U-I?2.[/:XC8/:^*EEU-YS:1E/$,L35+B'MB%PB#&H'I0'__5.5M
MYJC5+D;?8ZT6VB80D^LL"^%<"[FYOX'2I7SE(\D^%(D@/L,<(;Q6?G=^[;K9
M%07/8@40( 6OKI4&3-W]JCS5-G(W@$M0^_>5Y'\U.X=?S!VE*">Q\F20/:)7
M #!O-D=RDA4I1]ZD]:'8484N*OO4?>+[1C=@W=LXR@W98]-E"T:0GG7 DW;I
MU5T(#FXDO2'KDX:\PD%Y<-\+NAWJ*\ S!;O8UHQ-G?O%:'S[$4#R M# B_&?
M9)5;G3SW#LXTZW0N+GBZV:\*\^#A&ZX@EQX9:1)&TIP'Q__)=* FS^NP\#EI
M8="AL(X>KI']3Z9CM\]@1-D]#,DNOAM3WI;W/ @%8F:6Z#D=4T-/.=HFLD\(
M;,$(]W-I0+-N/MJKU%2OS2;XZZ8HZ@*)$-.1+7NS2 4,70]G)M8O+1O A3K<
M &;=J+T_,RQ:M@B?M^3+&"<Z)GO#Z0!6%CA&8HZ+X\>_Q!N8,AOKYNGZA=B.
MH$_S%<51D!WG/((]?J@DC04_&['*5;"2S?R"Q0TEU0Q^PIRXPCC)1&(JOL'!
MR^ANUZ>/6H=R@0L^U@V>DZTZD-K7_,J2B[Y1]OS3 ZD>X]IP)N?$?"I-7-UW
M8/Q_B7.UR-$.UEY?JA'($!8P1MMF7F?"331WVHOQ0:A%R AMQ8'Q9\'&:Z[!
MXO=$?PSV&/:-+9;PLS,&,!)EXF[32?50?2?%5\ZV&!R6?;M*QKX<M'>$,F]T
ML2<#.R;U)N@MQ/$C[BO H05EL^V)P?ZINBRN9=Q)3;PHX\0;K 693#QK3BS6
MI'VWT3WHQXQK[!XRK&Z5O(3%-(/"1)WV)2\&H%PNX$2,]*(AK$/%/I3B77KZ
MZ-D&15PJK0Z&O(MU"V(P0H$:[N@0T-0>  9"'4F+/_)-_\A:1WZD+Z$J]!ZQ
M-E^WQ&ZW(UP(5W%!O(' 9K T+L^F+P0^_:WN+-,V8W[W69!C$OQ!;$M/VQV6
M+%W29PNY11*K[2-]Z/^$>$:S_-\-YK_HJQHO>5E4NBCAX.<;EJ(I)1 $MR>(
M D[76;ZEHH$!B5]5=@7FC\5UHL(3WF01L^Z=9L7+SV)>H#G\7-B3O5$LP$^A
M_VI!+:?X^>W(P)R^^<?O6BCQHM5I_JN@N(T6I[%E[01"!QB<0$N>^+'N/Q<>
MJ9A\@$UR8S_Y+S#<;$V>Y2<OK&4#M#L(5PD>$Q$H/_J5(/,Q>_[L9H;:MVM#
M19Z#'A.O,<WVVO9](;[2J;FY>,CZ^7_VX"ELKL@TG1/A'KWQN!J<B96\4J&7
M:?[*^(FS6O\G.HDQ7^F#U# T)?5<$?*20;M6A'%H!%FP7C)HYZ1!Z^+>VDHN
MX!5+!W!(/1]C$M-[I2&K\#2E;IQSGD!J->@;FUN?!5VI%\P77T,@Q1(/O/]?
M? ^N(1\/!BMNO'1]CPJKX+>_&8O++#9$S1)]" DB1G9V>^O@07\"]MUIGK1>
M#L3UP(FUZC#M@4L>X:A-:N_;%?31[6;J06[PBQ(H<_^;2UM>R^/7G^>-,A'4
MTZ-WNR5=WZG4AI=$2A5CU'":9N&7O[4T;UZD*TQXW6AD1*VT!"JBO0HHP/&7
M]WCWU].]J=[YL<JR/4R&;74,5RK#I%)IX_*F"8,QJ*%D ,K2(663<#"X9L/\
MY4ZP$;=%J)A]<4IJ^GR0JA %L>NS&Z6+OJ_0O;$DDW6D)Q^/@O#1C6NOQ:XF
M" ]XM'[9T(W3DQQ5<"=+GG8]BG)^,&"JVH=28C"4GKU*/;>VWGL+]G4^]V,5
MWR07:F9&:DB;*-)]*,3$"2XT&+V&!!A 7W_^797T?]H2\P1!BU_OY21]]39!
MIR%\3_ .0F<G'GHK2(UA47,HQ)>%+3'E2>HAC7-H#^?<<8^R5*JXEZQN@ \7
MA,G83)0'L)=B_>25-4[KM5"=F95OB:9^V<9G-ESRY:G_T7Z64\:\:RK#<^PD
M-](/QH.6<]S8 E;IT:ILKW8V\0<V!&["7O=?B,&SS9W4!G!FF'B07B++!+61
MKP&LD-C/AO6"8UM9:D:FF[U&]]6"-NO0R,1O@&UX2UBX2>2Y_/2JX)A9\!)
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MMX,P78WI6GC':3;]X]%G:^HZ;7Y,&;[-R#S;=)$G2*+;W>&;0\;9$E+*)KF
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M^Y'.]I>AT7L!?>WB3YMKZ"XC?NQ/G]_<+BF]AM1(_"(9>5'ETR8, V8C/'
MV"6LB9 ,H=1=>\376#U=+EI8'0Z"8B3<,K584!USB @?+B9>M5W*<*KW2*'
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M T$%$GAP6'BZ&T$UY!(]B)\+OL.++SB^2Q@PWXC58-5)0S&I2&QF2]#\!LK
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MFT9!*N5@^<JY1ISHM^CLQ^IF5HU);"83%8:[X0+KAG[T3Q1F$P86$:T;WV1
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M'"NVT=L"#EAY7CE2EKS^87MK]SJD=_5N4H,'5,\>?0V,<\_GGG;&;EG1+/3
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M++%;C3Q<5P48W&811.=^IF(63@^$TR/^6#KW#M_H?,A@7U1%6>+)S1OOR)+
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MQA9C7 94Q%F"HA8C(/3OBDEC&33<V>Y2KKCW#80A43!K%F@<,.J&"[C0F^S
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M"9=)X;6FVZ$A4'L=MH*G0Y$CE1S0HE7%]+TKZ4?,N3[@:E(^I$H2?%SDSK7
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MR9",R&G!4Y<"1]D'^FW6\PSE)D(YCHVUE#9S*ZS*B6AQJ$>9\!:A7^]RV&I
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MR6-W3F<[)MFH^FQ)GS(28:8/CGMOR3UUAW2"5)+<.]O&/ML'[U,5D]QM<4C
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M  7G=J^*'*+#$0 N\#XU43NZVQ#$*38:5\),>/NKXTT/N\R4F.H!4?V+.7Y
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MC+';<W/E#,L>,(=R6!L"#;0!@P^O!GZ+Q'0ZY%I&2$#BN/NCJP2)LH?NQ;F
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M\<3'$ RD[\#=\?#4]TL7YY,Z11)X,1AK*_[#,FM6.:*W3W/18D);<?JK,0!
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M0WI,>"3K6.D3E3JC&&VY@A3.?EX?&ZM^!1?)#1HBC<&F<B8W#1'0)C/TBMK
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M^F^.?5 *M=MUZG/<[:L/#,_VHUXO]]A@_N?CZC?VG_-BOGR]^K"6__F?KYO
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M1LIP*\89& (M!Z=Z&97KSZCZE,C//=[3X%VPLKS1?V7V_NWZIOAL"[-_V&:
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M!91\6FZC\$/B[4T:0(27B3GM%+3ZY1NV5MN8V9E02F<JS2&BJ88X22-(HEC
M3#.-(QW'W"^3X<CR_W]Z:0S\*0P<PS#\ $]@B0RX0E:/  L&V%T[F$#$Q&7C
M^-+!%#VEG]:".<S0A [0ZRM&SV*EJ^6WKZJX>Z/X>L=IVJQ?#*<,$I8BL^O#
M,:0(49B(V 9L$X2CW*M.Z;%>IK8(O2W7\[LJR$I;XJ@+6:TTD$9HSU*E1T%U
M6R@NAFIH'YR1#UH!@97P:A"2[<0@5%G2HWV,6Y&T2\UGQ4@['^XW^3^J]?NE
M6-VI*@4T%9JI**-0J-S8M AA2*6B4..8H82R'+%XMK:)JMTF_4'K7I-]V\>
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M]<+?C06'0G5@^FL!K03?5NBR/ZB$![7T=BN_)W_ A,8]4 N5S]BGZW'3&?<
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MDYBE*5'<,P%)7UFF9I<T$@)5W[4KJVWTJBZ2V[<T[B5#U9>H!AF EZ&Q.D-
MJPMHE*D3"32C]<%A: (PG3>H@_&@NR0OS)+>D)WG4/\F>X2Q'5[V>F^V@N9+
M7]\L%X^FQ_HR[MH0Q'RU_%15-9QQI9%DD3';2*HA3M(4DE0FD&0DI9D@TO&N
M5:_>I\:BK<1P940&][7,AE,;H4%="=(C&LQ[.+IY<W"0!V;*9U=66^F!%1\T
M\H.M N#3X(![1.<-"?Q(P7NA!\ OSJ\O@)UA@-Z-CA<EV%??@R#"WHT,D)RF
MB6A-L?G.1$XA$9&$F% &N=0IU&ELEA(J\BA/@B6AF6:X] C)9GQK7X:$<.!U
MX&SRF$&*8+H"-$8BF!<JB.D*@5=BER"QS57P 3>&LK3A":;9.C7A+@W7J\?=
M(PWS7?_&"GES7V7F^HLAQ2JE3$6"V["Z>)8I&F&*"<19+B"F<0RIE!BF)$&(
ML2Q7D9>C8BA!I\9P503L0Q4!N])@50L/'BKI[?;6QQ8>?)#=2'(*0S<PLU;R
MPU=6 ;"OY$'N0OX(]I]KK;Y*59OWH%+V"OQE.]:UPE=@%Q4=, AMX$$)%8HV
ME)CC!J0-#/:SL+2A^^N9KM9V\=6\6^>UUHED+$VAB/,48DPEI#A7,$DU%3%#
M@A"O2R\'K4^-UBOA@)6N5V3*(7)NM-L;CX&YTAT*_Y2MQU0.E9#UH.UQTZT>
M4^M9,M6C#_6<J)<%LU[?V</668Q2GG(AH19F;F.98,ABGD*:\,CL8^-<$>F7
MW"^(7#Y389P4?X>7"\I=U+HZB%I?W]H$?P>1Z]5+YO>_*5O>Q/RESL("5IMU
MN3:[/)M&J7=REC!?@2-9C3VR0Y-<F'L(5Z#6+"!%A@0Z%+4&D6E<2@X)XS,J
M#]KX!0<#K\Z;D*^>FI"V!-/Z<7=T6E8.N*^W;-D8EU6H9-D:E[.(4Z14FD&$
M$8=8:059KC",,ZESG?&8Y-+[H& $P:=F8=81J/*"7%QCC;C'J<'$QG'ZIPBU
M\GN^IG*_9,+VC*&&8'?&$/A<8<1A"WG.,(;8XY\[C#@81\\AQNR_1^C&U\_O
MOWPR0MRQ-G%,*JGD$D.4);;>%H\AD8A @6.5YQ$7&KM7>G_:^M16#2L?J 7T
M</<_P\PA?N(2) ;FW3T0^N0>>OX%N0<W7(+*2,$+7NCX12:<TKXS\N#92^-%
M%IR2]R!RX.1#_0QQ6]KTHQF>YM8ISFFB):<04WN5-R,2$AM'QBE/TUPCJ3/D
M8RX?-C\U>K+2 2M>SQP^3\!SLSS[0S(P3WF@X6VW'5<ZD'7UI/%1;:#CBCVU
M5$X\Y3=EI9K/WC2D_+\WK# S9/'X6=VOBO6,)3+&6C,814J;R9O;<U!!()4T
M$WDL.1+:9=YV]#&UR=N*";9R@EI0MSG<A6;W1 Z$T<"SV1\>YTGM ,"1F5TJ
M\>.WU<-/YNUZ4IN_[.9R5YNC3&@'I=I9[?+HA;D FVQ1U>9D^\/_-5>%C==Y
M;-8;$9F-1,HH3%4402RH,EN)C,*8,\*SC)*<>IUM>?4^-3K8R^VVE;2*1/MX
M_9=+4_0YC8;;ZC\8Q@/3R67P]L^<YP-3Z"QX3GV_3$8['UA.9J?S:N1E @!O
M=I[&OS9.R.L'(^ W]5E9\<S/7Z^6ZX*)]88MOJKB+IG1+!6<*P6U^3_$1$>0
MFI]!DL8L9E$D,N95AO@%=)@:N;9R U8+#HI6<B!VH@,CRMVXL8-]O@\/!\%T
M1WWZOH*M-V /B2NP_9(:,, 6#; '!_C:]26-'HUXP5A.)%"QCP:_JQC&"X8H
M='CC):(,4([OS\NVF*>2;[_;RJQ-Z S2*$]Q;K8/*,40QV:=)-HLFPG..$\P
M9UJ1'KD]>@GC1'WCY_RPNH#YW?UB7H5,U[>T A;D.SDV;FO4<%!/IRC?OAJ@
MUB-XU-)%.(Y1B>^D#-.IQ7<.)J]J?&<;Z^&)K<I2*UG: *>V'.J--A1_MUI6
M!;2^WA:KS;?;ZZ^_F$>_%>QNQJ(TRS 1D,=9#+'$&G+!-22,"IS(6#JF0^O9
M_]1V :T&=71AV924$Y4&3:F^^TUA-5O;6II&$=!HXI$RJ>]8.?B(AQV!H;TS
M+?A6^EVU9S, M0)U:3_0J+ /_K"X>WBCA\5_)'_U ./@Y]7NCV*GW[M'L^-Y
MQOOK?. [OZ"9GH;Y:OG-'HK8Z_[V\D1S5!P;(30G&4R2&-GLN69)R;B$))8X
M1RR2.%%>:3:/=C.UY<-*":V85<'ZJ^:.3J^3^1.X.EK-%Z,UM%EL@?KJ"Y2_
MU=N)0RBS]G@GX]JMG8H^,TR[G_;WV;]=KHU)^VZ^4'6)UED4,YZA+(5,"0:Q
M,2DAU3*%/)-:(,%$XA8">*SQJ4WZ6CY@!6RJ#KN[YY\!=]XO?PD< \]J#R2\
M//&G5.[E@G_6V&B^]U-J[#O=3S[STF60;-:WF4)9'J<Y@U1DRL;."4@$S6%$
M59JA-.4<>26R#"O>U(AAN+(ZGK9$X*_ T;OT8F,[M./H!8;U!4LD[:,_N?)(
ME7"_T])(^\ .5Q;IH)<!?"^-=ZA\LU'7VK#J?RM6O#.RSH3B+$8X@T2CI"Z7
MQYDB4!*&998G,A9^.\ ^4DQM2?AZJPK%K(0!72PGAR" BR4$L!-PL:Q7@"OP
MB<WE%:C@!U818#49R<=R#L@Q?"PG99B.C^4<3%X^EK.-]>/#$[V]WA2%Z6U&
MM4@Q1@AF$3;$AQB&7",-8Y[P..%*,>55.*J[NZDQ7$="=U%+W#^Q^QG@62+B
M&-N*K#FRZ5(R HDRNY-8X52C-$XBG?NE2PD'_3AY4.K*/HL=[S60!X79;54)
M!]W RT?7LO'Z#'S>2X0;*H'6@C.=C4KZ;HH_97?'M_I[+KXVIZ"_L'5C67]6
M3?KT\D9_*N9+,;]GB_=+NW1\->.B9CK/),L2!C-NTVU0F4*&DQ2J3&M*5:JD
M\"L@UDN,J=&^^?@R?P='#_C='2##@CJR@Z11PG!29;A6XH;UD_2'*Z ?I8<0
MH_M9^@-US ]S06L](H2NU</\9[5<W<W%+TK.Q7RIWB]%FQX]R7'..(-8\-C>
M*D@A$8GY6RPQ)QBE$78ZW3W;T]3(R\KJ$4+2"6(W/P6%9F *LF*"1D[0"@J,
MI'U2/'1BYA%@$PJ[D4)I+L#0+V3&!9?.X)C.!L8+@W'1XR#@Q>F%GLXS&R]C
M@VB4?&.X>?FMSI53G:N6;^_N%ZM'6[#6//3)?"^WQD*UE^#+&2(*T2BU%*J,
MA<A3!'E,&!0B%I3E+-/$*\-$3SFFQK*UO#9^LI)1@G430*8:%78!EM4#X-YF
M:^B?C:WGZ#EZMX8?DZ'=6!78M0J@UF&;+[U6XPJTBC01?ZTJH-(EH+/J,C!#
M>:5Z2C&N^^DRJ)[YF2YLKF=VY+M5L9[_HW%9O3>K\/+;W%:5*TNUMN4RDR1A
M$8$ZBK#98;,8,LD(E%$<*8(BQG.OVZW=W4V-)O>E;4]1/=,.=\/K1G#A0!O:
M3-W':Z7!3E10RQHP]:\3)J%R^G9W-FZR7B?%GV7A=7NK;[CAEUNU6%CG-UL^
MSE"6(XIP#EG.#6<0DD'*(@YE)HE,1<)0E/L%'.XW/S6.: +M*A%!(Z-OT.$!
M?-V<<#DH W. %QX]0@^/J7U!\.%!<R.''QY3Y7D XM&GAHT>V1WQ9A$1<200
M5$FL(%:9@BS-,X@2$K-,9%HJK[HFWA),;;KW.%SW!MWQ7'U(*(<^4O>,$QGD
MH+TO?B.'A[S4\7I?>/J&A5QZJ-[V]U']UE3(MGNH8K4T?Q5UVJ%/J\5</-9_
M?E7?UZ^,PG^;*143A9& &-O[41EBD,980AIE:1:K/"694_GJO@),C>)VPH-#
MZ<&U7-TWY=SLY^S'@][CXD:#0Z(], L:T<%)L*] +3CXM?F_U0!4*@2,3>Z+
M7B .].Y^5 KL"\Y3!NS=3J^\ ^K=9BF5_"LKJK3RC5^'B222>9K#F"H"<:IB
M2&F2P32+<L53PDE,/)(+'.UD:D1FQ(2UG* 5U.MV^G$D';R* ? 9F'J.0-/'
ME7@*(Z]K^A=C-=I=?/?/R?>2?2<&9V[2'W]WS.ORG=(_N1/?_6P/QGO-[N=K
MMJA.QNO#\NO-^G95S/^AY,SL79FDG$)!LRIZ(H7,&'O6U,-9EDJ1N668/]O3
MU+BOOK)H#V';*GH:B%K^QK?'MK+;K=;<.A[\/7SG1\"!+D/A.C!G-F(V#KC&
MA;J3-!1@'MP9"KBQBF_<*G#'OL_O-G=@N?T^#[[**[.WL->IZER?>ZE^;.CZ
MO>%!512V,F3];&F$7SP"MJ[*2=;UQ6V3]E_5!UW\T=88OYNOU_57SIN?2YM-
MDBV!JD[8_D<)Q&V56+OJAC\NV&_ECX&XW66,.@F^LX'Q6-Y%CP.J=WK!C^_+
M8CW[K-J@A.MOA:JLZ-=5ZJ[BW@SAXUZ!C#B*$ZG3&,:<&L9/60Z9RK6Q>X5$
ML5D4<NFTK_?J=6KKP+Z4?8J/^$'>3?:# 3DT\?MCZ,P1O3#IVGV;!O=VWN9?
MNUVW7U^C4$LO]5N:Z?=R#Q/S\^J1+=:/VQ[JR(SJ'MNG#3=[]P_,[.AOOZYL
M!/%\R=8[868H)BSF*(:<9,Q8H!A!+G0*48ZESC B!#M=0;M4D*D14RUZ<P/T
MOA(>+"KI[4*];N4'K%7 P[ZZ9+P<[-611F%@5FNT %O9KIJ8,U!I FI5P(?M
MF&RUV;TRTIAXF,0CC<U(%O.@8^1GQP8 MM/,O:3]\:S@ "@<&,DAVKLT'=%G
M92N3BG45='B]E)_5PF:\?KTJUV6=92;*N<J2B-A[=@CB2'#(493"5"4)C3&/
M:>3E(?/H>VK+UG[&F0/AJZUC(SZHY+\T0=#Y<7'SD V$]L#+4TB@+TC9XPQ9
M\'P\YWM^H60[SI"<SJ3CWD0_<GO-REO[GRV]_, 6UM-6=3D7MA?SBZK/_1_L
M/3FC:9K'+)8P13F%6*$(LCS+H8@EB>)$,:S1[+Z.SEZ;788;Z5TDD\_$?"K9
MD">BY>T5$.9/H':R7E4SM-BJ4C_ UH"K;_-E57S%S.G[[EKM PRKP"ECS PF
MISB%F,G,[,2D@"A5-.4\U2S6S;"^7<I)#FHKUV2&5-F,(B\RF$R9?;6M'R)2
M"7%*$60*QU#'1.LT9D1:DV2U9HN)#>1.I@$/VFT?U1@]'\IC(SGFP+G9+*,-
MQ^ ^(SL&]D_P=G\Z[60']2.U47/PP_TWPIDV09 -9.Q<)LNHYD\0V)X:1&$:
M'2$6_+?5+),1RP6V&9UBZTU)&&1QBB%E.<HRCA6.G *(>O8_M7V@^9;3 >/
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MF$F=4'R7.%(U<OJ>ICZ!T?4LM3\X@Y^DEDU&];?G$.EQB'I<[6!'J$^:'_D
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M,$5SD&,."Y)32IEGOJ_S'4UM$G=7"9VP!Y<(6X%];V(NX.MZ!7,[:N/<O00
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MBRG9U(ADJ]N!OZ;Y21S<$3:NGKO<B<8.VAPHF3PW6IIW6C7OFB.YL'2*43\
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M(@5((@HH%!ID6:H+H34J;)T"]SWH0=O3W'<&[S,/47/CGD L!J:5CPX ^!<
M.%4U5FK_@Y;'3=I_JM)).OXSCX1-R?NZ5NM[\8]-55>-5ZSUG\R(*%*&$("T
MV<0(#LR61@*JL<"0-%DW?"R0<YU,S<IH9$P.A QR1CT+I]NDO16D@6>O-S[>
M4[D/@$AS^FP7HT[N/B5?SO+>9T<.7?J95:O&2\P(M7EJ_>+?__ZLA$VTOYR;
M9NRYRF>V5C.H$12""2 $:O8O$# &<U!HE&6,%B1#3E'Y(\H\-3+:2ME%S#>%
M%9/O.Y%'BG'R&'/'/=&T1G+H;=3MT4]6[Z[HR('F=\GN^]@KGUCM)Q *Y3]4
MKQT7Y2'Q'R-(RG\(HD5,!70=X")X/U\O.T^MM(2$$8P!(AK;Q<;6$T4I2)DL
M">2P@+F35_&+=J>V(%C)//S:#@#J9^8;U![:WC1"A;CT':CNX<47!L%8Q:*=
MH/#SV3M5N-=-[^#Q\3SS3F4\<L8[\\]A1O$VM< [U?[Y8='X_E3RG=)JM5+2
M,IA-X[^0#[9,=F.7US.6L5)!5(!<T P@C2$P?*, R;("2V'^&9, +[TP:9P^
MVU?RY:MDHEJ9ZX-:XZR1V\^4#1PI-^MT0.!'RA:YS2GSTU:%/]E0N>T8=.(W
M0] HD-SW#X&WT7@;@I'LP$ A1C7M;@/JI;5V8VLW5^A\RYZK-9NW>5D^JUJM
MOBOY\W+57M!M<Q?.,D)2G+$42&98$@F$ $/,V&N(8I9RQ OM=2[@+<'4C+I]
MTL^C'+TVHE6W=YO5-D5H<"5S_V%R(\M!P1^8)X\K?';B;[-P;15HAJ&[8M[J
M,$B]3S_XXE?_=.S_M6J!^L'34QG4LZ$P5MSM?P_<27ZV!<?50OSH')ARJ:FR
M)8M9)G* $,X D40"DC*5804SJ)WRF7OT.37F.W1\VHD:Z"KF KD;IT4&<F 6
M"\30FZH\4(E$3BX]CDI''A"\)""?5\,H9^OU]&797!6M5&/C/:ZLG_OZQZ/Y
M9M;&\'MO_NG9/C>#U@A#"AJ^R839M@H-."X(R+7$F"E8Z@(%;%L]Q9CJ?K7+
MD]!F)VYE;S9,:BNX'SGY#HX;40V!]3BDM97<ICWM9._VHEOI[Y)&_KL&]?=7
M4?>FLT#L(E&;;^^CTEP@-"\I+[09_T)27ZJU]5W[L)#5]TINV+QQM^ ZDT(K
M9O:9MB([H=;2@AB8/:;F&8***N1:1.IL#U.SIAHA+6/MQ?1R7KD,93\=10%H
M8,()P,:KE%2O_C>4D3K?[F@EI'K5.BP?U?]@H$5C1M"6I6H^08F(+AD7@.<(
M B2$V2AE! &4EGG)1:D8<YK-YQJ?VD2VLB56N"#?LR/8' V)0#"&MA)<<?!?
M_<\H'&MI/VQZW'7[C%(GB_*Y9P)]R)B=\<V9RE'B[=\69HI\JY[?*+U<J2\K
MMJAM<=7E8D8$E>;_"F20$H!P@0&1@H R+:E,J<SRS.O$PUN"R4WTXQ(I6[D]
M_;J\Q\&-% 9%=V#FL++O*EO?O2RBL-4@X8T*R8$.$3VG0N&+Y0?EW?^X7DVA
M\)SX* 4W%)ZP^5U5B_G2GN/<\[H)1)LIF!.2:P$@LMS&: :8M"'_199)@J1F
MTHO;SG<S-0)KPK_V8IIUNA,T('GS&5#=B.IVJ 9FHP"4@A(Y7P8A8C+G,YV,
MGM#YLJ+GDCKW/!VX,;ETAG$0GDX*2E/# $ PI0P?* BH(!PHK;$2",&,>\7.
M./0Y-7)X<91W?))W=TM: )<!<-SYQ(5U8")IXFX_5O9:^HOY?66C;MN G/CW
M/1[(Q-HY.?0X[H;*'8*3?9;'JR&>S__QY?\4*>P<7"%CHJ18@XRDQO;(,P%(
M9OXJE=E8902G2%!WY^?#IJ=&*58X8*3S<00^@JJ?%6X#8.#)O]4]R!OZ" 0?
MA^A0,,;RB;[V07BZ0Y]3M]\C^NB-$9VBSTEZ[!=]]HDPB^<]6RVJQ5=;8:UQ
MG-E9Z 430NI" IN+%""A2T 8E0!G+#/_TU3D7L7*+G4T-2+:RFF/%KI"CZ%[
MGXO8NEDP,1 ;F+G"P/*V6*XA$<E,N=C-J+;)-65?&B17GP\M \Y[PL/XC_TC
M9PIJO?]=K415V]0B?U/5UV]K)>^_JQ7[JO[-%F]YQ]9JYS<SPS!'&:<4Y"C7
M !5I"5A.!8 Z@SDN2U8HIPW5Z))/CKKVLC?^Q'(YG[-54Z^[]2UV="T>_Q-P
M,-ZF.K!#GW<WL</<,<:8]U98/(#@+MF"D'0H) T,B<7A("IYJA^,;]7K"7XX
M8]:TGN '%%"M>N1!O%Z+>BR!1JXT/3+.IW6DQQ;@Y@"IEI2$TFF)<PE(P8TA
M VT5 E028.8HDU1##C.O E@O.YB:O?'V(*CIG_^)9##[\_^3_DN:PN29K9+O
M5N0_)T:DN[3]_[:Z']M5]K9%[O]]LU!)GMXE=I(U1\GOE&BVMDD.F]]F?TX@
MNDMS?$=1VCQ![Y!YH\B+7<' NMYTQ>R6!W6$W9J_2TP3-H5!]5W-/7.OG'P$
M;GN[6X9V8(OC.'BJD>ZN"9!2<I#PJ"$*_ITT_UK!3;VE^RX^%WANC.'V'+!@
M$*8I4X!AA@#B(@6,PQ*H$A(I--=*>23-.&QZ:AS4'!,:Z3R/3/=0.9X;!P$P
MQKFQ$2STW'@/@N>Y<1 88YX;]WT0_N?&)^I>/3?>OS'NN?&)I"?GQJ=/!%8>
M67UEB^J_F\%\:^RNY;R2K:FVD(]F/+<#_:!_KA9L(2HV_\7\IC'AZMU!:)YE
M""&;^KH@#"#*,: YRH!@6*2\8(:KL(_%%$6JJ5'<H5)WR9%:C3USJ)CU@MNI
MENQU"S[#CC/.;D;1Z*,W,#^/-7#^Y41B AVK^$@4F<8M51(3QI/")E$;#[ H
M/RO31F7SNKUE]3?3J_W#>CN8C5W3AY1-TE(VM__PN%H*I:3Y[7]MZK458N^S
M.2.E+!6BQA(M& <(0V8(7Y8@UZPD&A:<$/<3_GAR38WH]Y+;#>FZT3$11HD[
M>X1_X.?,OGY=-2&SS;_:.-9&1P_S+^+@.AC0KS-D [/[7JG$2MTP>O/#@6)W
MR<&8-O^X52[9:W?HQ?XZ0^AA_K_.4(ZT=QAW2/TV(O&![]W%1.QNO"U0?(R.
M]D\#-!^P+I\F _O8_F';KKZK>B9E3C,B4H %40#)3 -:%"D@U/P"<IT5@GDD
M@'#KU6DZCY_OH9$RJ;9B>O#K=9P=5KXXL+UJ=L$6P;W$42'T6'FB0CG2@G(K
MI'Y+A#-"O<Q_O97Q"-U9HR.>=G_KAAH+?7>4;_KO*#\M%T8(0X!7;RAW!R@8
M*Y5B34".N/7&+#/ TAP!)2D5&J9%5BKOD@NCJC"US=;.?8%U[@M?&_<%:7=5
MVKHO-/>7>]^I@)(,XWXB;F=LTQ[X49RI;BK8L/.%V0'AZ@DSR$G>ZPUGS*(.
MXRHP?HV'5QF@LR4?7D>2V_+>_;Q<=:D]/SP]KY;?VR/.&=%%"1D4H$22FEU.
MJ0"#6 &<FQV/5 (6?)?FSFU1[.\P8(,SQM[FVW(ND^I SK#\=1= =EM4(@ W
M<G8ZF_MWFQ?X@PMXP6GH^C&)G'7N0F>ODF2N7_%+.>6NO!5X6=TD11=BM3%S
M<E]9\>UFM5)-$*?A-M'^929S0C$K,2"E=>+3K  ,900PE=*TQ%)#[56<V:/O
MJ9G(C>B>U\4>2#M>"@^#W]!7OVWYA5;L9)#"J ' Q+JJ]>AYW M9?TA.KET#
MF@@D);.U-";8XFNSC&_[^K%O?W>=>W#%^[AL*T6^_WUM+#B;)N!C5:]G(M?*
M,), 4)$,(%0H0$O& ,(4YI(2E?GET(LHV^1(;:M:>PIWMYN</YH]7:??W=X%
MX]@S8ZMD\NM>S>3]8O/4M+KTS7<1\R-PY-/7&=JA^?:U1M6?MN/C'XO6(THV
M+NW'A_1D61B@BQOJ>6_7HUFF4X)AFH.2E<AL@@L-&"]LZG=("TBS5&)CK=KR
M]&[$?]2Z%W7O^AANDG^Q?20=X$'EQ8[!<R/,8$@&IKQ6KKNDDRQRF>Z7"L>L
MS[UK>_S"W"_5.EN1^^2AL)GZ67U7BXWZV4CR=KEH3L3^5JV_O=W4ZZ596'8'
M]T)KKK# @&ELC#>>$D RR$&*$90%20N4>Y7-<NQW:H99)W9B1R[9"I[\9B1/
MMJ('>S&[#H4;(PP \,!<$0E;;RKQ1"H2R;CV.BK]>$+QDIA\7P^\V=X\/\\;
M,Z;U8?IYOOSMPT(O5T_M9<%VGFB5LCQC$DBDK5<OEH HE )89'F:9459$N%U
M'>W6[]0HZU#L1.Z24;85_ZQKH#9Z)-5>$<]+9,?1<+SYC8_QT->UA_ VKI96
MYN1 Z&'N5/V BG41ZMCKN+>7?E"<7#EZOAX4I=#PXF=E$R^:_=FC6C7M&_4>
M^+SZVG3T'VQ5V8P -HZBDMV>_OYIN3&; )&6"A$;*IMFALH4+@ 5* -*Z0QQ
MG+,<.Z5WCB+-U CN+^SWZFGSM(LP: V(IVJNS+*S\/(%O'F@^EEN=/C'L=CN
MDITRR8$VR5X=&Z+?*I0<:92T*HTY0EYA!..-U&C! P./F&^\0!R$KT0)W-C)
MF+$!<?!X$1$0J=$;[K4_+1?+[>GDAX4PNX&N&OB,8Y:5G*6 %3 %J%0*<)E3
MH$7)<FNBEQF<?5<KOO2ZS+[8H<^D/.QVZ&M8U8IWERR49W7'*P![W&!' 6V4
M2^M#29-6U.2G3MC+"03#KJ^OHA+SQOIR9^-?4E]5_.R]]/6W_'A$JFKV?K&N
MUC]^-B;=ZBU;JZ_+U8\9S456I(0"7F;<V,2R )Q1!3!"&56\*#+H=)U\H?VI
M6;FMB$DC8[(5THTH+B'8SPP1<!F8"OP@<9[\5Q0_,]MK)?[EZ_+[_S1OMA/=
M_+"?WY?:&V5"7U%F.X.O/19ZN6#VSANQWJP,%[Q=UM8UI:MYWY0'U AKGG,,
MRBS+;&858P78N'M6\,+&_YG?>.6BN]+?U*;TD;A=09* BHO74':]+XB&W>"[
M3E_8 JX$G,"(=A70W]O(5P!.JI\>_;N]%GCDOW5<^&+W*#.<PI1BE@/*2[-G
M2+,4<)(A(%*:<I7R7$NOM/_'S4^-)O;N0+\V\GG2PPOL',_A@Q$9^KC=&0S_
M(_6S.L<Z.3]N?-P#\K.*G9R#GW_*WUCO'!-^KFK!YO^IV.K]0MK0FQG!A,F\
MA  Q:"QVK31@-@- H7*1<LZ0<BN)WM?)U"9O)V?2"II829/W-K^KD=7=>K\(
MZ743/@90 \_I((R\S/EK( 39]!<;'<VPOZ;6H75_]=G0_-)-P'I[7OBYJ@^J
MH,)9(73&[!*="6PFO*V]S');-1V5A$@->2ZX7Z[IRYU-;N(?RIJLC+ '^;%\
MTS?W8.RVGL=";F@F. +-RADW29$/'-&R//=T-7+&Y^M*GV9_=G@GC#EVD;A_
M4<PZI%C3PWH+_76QY';?8*V0#XOGS;K^K*R&U;QJI+!_-5QFMAEO6%W5.S?G
M-K,Y(BG&&4]!*:@&*,_-UD!"!E+.L()EB0N<S<Q$K);2&#RKM1OQ#"*KS[Q[
M*?%P4_"-^EHMFHM!SN;VCLB/JX89549(#C$K08H*FYLQ9X!1 4'*TI3DF>*(
ME]VHFF7M#S6F6WF'/":5$QM.MS7KU0=HX,5NGW7C+CE0L?5X/50R:;5,CM6T
M=_B=GDFCZ$$\4:RR-J,,1:2%=A@91UVA!X7YY=(^;&>AI<V55F:?(IMZ$TVF
MC_I^5XAE1G*2ZQPJLYI# A"5&M!,$4 +HO.4L%*77ON)_NZFMJ/82=L6L[D[
M4ZG&%M1K?^M81<\1>#?"C@?GP,R[1[(K(-/*FNR%C5G(W 64:#7,>SL;N7RY
MB^*GE<N=WKHA)]Z;Z]F%WERLV_5<M5NA^L/BL3'?9B5-%4X1- 9I7@+$BPP0
M9I-R"(U0 6$A4^Z1QW1 49TFX/C)3QM);^&N(4;5\9;DE0;ICY>([D!3FUNT
MU35RAKEA!B)F"KG($HZ?(VX8B,\F@1NHJ["%X\VFFMM-]+8259&3K"P1$(Q(
M@$B> P(Q P+B-".95B7R2K]TW/S4[,ZM='ZL_ (R-T(-!V)@+MP*=KV*F3=W
MG=<Y$NV\:'Q4QCBOV,O)?N&I@"BKCZJNE3I.@O'94@/O+K:[M3TML"[+@H(2
M91@@Q@4@*N. 8*BS'&<,8J=0=I].IS:G/S?)*;8R)L_]ZW$XUOW3?B@$!R:#
M5F)KW;S(Y].@NI/[FI43CJI'#-, Z(X4JA0)9;^ )$^X>N..7-L:+[S(4[NC
M*"+?=\,,K4]JW94E^5Y))=_\^*LQ\3XL=MW>V_K'3;*[6987659D.;#W?0#1
ME &.\P)HEL."F&^*BL(GJY![UUYD/D+*(2-Y&\F_L5LPL[W:A\:PG=!^UIO'
M.!19234MC0FLS7\0@A00@DM TIQ#59 48:^L_P.-PPB+ZNN.@YN%/0RZ R^X
M%MAM%:M&;'OL\--?6Y3_=+!"W%^'V=L^]T<LDNWNT?&H=KT_("]M_H 6;O0;
M?SMG=?V@FT/E)B@BU[G()"T!E%B9+3PC@&JM 6.8IPJFJ!1YD OYRYZF1E*-
M?#;W2R-A4,#)950=CTUC8#4PY?C!%.YK?@F"V&[G)_V\C@?Z)74O.J-??"$P
M,>6NSEW]9;DOA??(*L,_74[W\\>/C03= >-G]8]-55=K]8M:?:^$:DU?>TW^
M==&T.,MPEND4V5PM:6JKVV6 (RP @5*7E#*LN5?-\)'DGAI9-<*#IMA'(@Z4
M\DRH.=*@N['?!(=R8"Z]?_SP]N[\-='^3'][6727[.K1-?4OEO4Z.5 K8@;1
M<<<A5F[2D:0>-^OIN$-QDD]UY.X#SK;O5T^5+;:MNNN4S-8/*FD..($,("8*
M0(DB(-<%(1H1+J33#=2YQJ>V".S$\SA)?8F7PSGT#2@,S9];R:[?/EU'PN/L
M^ 9$1CHC]D#&[QSX@NJ]Y[TOWQGO7/>"M$?GMY>>"2"COVQ3ZWWY;=E]53P7
M6$G"0)Y+;(Q> @&S9[-%IAG*I:(,.GEF7FA_:I2TDS Q(GI,QC/(.3#3;7@,
M3$Y'4(00U!E,/#CJ-FQ&HBE/C/RHZC("O6QUYK7Q".NRS$><U?-8X/426V]6
MZD%W)XW&:IL1Q;(\DQ008?;GQI)B@'%2 )3R(H/*\%GJE27ZM(NID=>;35TM
M5.U[$W$*G>.-PTV #'VST AGS_GVXB6_?E&_KY,WYFO]>\0CO\LXQ+HO..U@
MW'N!BPJ>G/]??C)L7K]3SRLEVO@4\_-<-0Z#"WG_M%RMJ_]NUQ&N;?U5Q(#$
MU-9B%<JFCA. (X$+CF5!E%<)"Y=.IS;W#V5.V$(F[$!8/T)PPMR-(F(C.3!I
M'(I[E^P$;O"\=\'3FSM\ (K$)DY=CLHO/B"\9!RO=T,YB*\_+&P6+&M1?EB8
MZ6R,E\]LK9K+#+F/G)_AO! %@LALCS@'*&,,D#3+ &9:IT+K$J7,CXE<NYX:
M'VUE35;.^7 "\'9EH2%0')R+^#K92VU/SSM$K>!=+4$Y2!(-?[RB49-SQR,3
ME"\@IS3EW4)0.8J#7'V/YG-Z,#NLZDE]4:NG:M%PX1NU4+I:U]V&G"A";?(,
M4&+% .(J RQ-,>",%#E66987[L<[WMU/C;2.$U!:#>X2HP.P2B0'6B1;-;SJ
M&_B.C<,!TJ"(#TQPWF"'G$'YH^Y51F) ]$>K&Q'KD_<M$!&(W96*$+ZMCED"
M(E#C%S4?0ENYT='N3&7970FPDFA9Z%P!B'((C(W+ *<YLP79<%XBS8TA'.1S
MU]/IU-:.J[6= XM'.@V FQT<&]:!%X@(B(:[[SE %-N3KZ_+UW'J<P#AHG^?
MR[NAE+04?_^VG)LWZO?_V%3K'S.(H,:I31Z&$0:(%A3PHK2U9F0I*1><V"*V
M[B$CIUUXT<UHU:CK SG_^9](!LL_)]*0OZ@\2\V<P1055$I5""!*@0RI%R4@
M5&/ :"DP+B&$2OLGW+L-V1&SY;5)U1*V3M;?5,*WR?-NAU5E)1:" 6J+_:$2
M0T"S- =Y"I42 I50:]^,=S% '3Y=W0M(U<(Q@K('3-=U[Q9X!E[E6H'NDOOU
M>E7QS;K)"[=>)H\L;EWURR!$6\=..AAYU;JDX.D:=?')@$.7M\NY^7EI[[N^
MJP._U\_5UV_K^GXA][78ZNZ8YT%W?K*UK:C\R\8\8'Y=&WJ945:D4F);A#U+
M <H+#(C"&$ E2EQ*\P>DS@<R446;FL'="6R-P^=.Y&2EA#*JRK92:'T@O<>9
M0=P!=3C%>;5A&IC:CO0Z=@EO56LNU@Z4V^6$MH.Z53"Q&B:_3&$L/<Z&7FU,
M1SHW&GUL_8Z7!H&_]^@I;H_C'4L-@M31D=4P/02LU(VK/^])/\5_[!\YDW[J
MTW+Q7=5K=92.2LF_*:N(DO??U8I]5?]FFEO; @R[/*RS/"-0E;H$R"8U18A)
MP''*0,849@)3GN9.KFBOJL74UO_#](+2?F*KVJ:[:5,-.F8:?-W/PL$T^",,
M]M#'@$UX&7?,5LA[LQ7NX-C^*ND N4NVD"0=)DD#2E.J)MDG]/XC?%8>5LH?
MX?,:R:#Y8WQF?E;0:P]OK\'T:L*-9UN]-OY'9MBK"Q,2D,3^:[EZNZG7RR>U
M^K2Q]YD'H4FLT#G-%)!048"@L:]HFD* J10LRV%6$NT>FM33T]0LGT;69"ML
MTDKK&[#4AZR#81(+KX&-AXM0!04T]6'F$]H4";NQ@IS",?0,>'+ I3_TJ:^!
M$8.@'/0X#H=R>2'PLE1\4W(S5P_Z:O+E^E+VY;:^+"PY5Y@7@%'$#=VJ'%"2
M44 TA1D1K"BU5SJX:))-C9ZWBC5)AARLRKK7K RL#1QMV!VOV%YC,(?>>)Z,
M8W_*_+HW9_X 98UC8Q[K(C":7./>'\:&\^3:,7H'84M"XT)8"6.SVUQ]]XOF
M#WL/^IW-;=^S3*<*YEJ#HH00(&TXGY>0 T/P>8F9SF"9^3#]M0ZG1N![>=NL
MG_: 43U;)Z:$";'<]%S+AP'NQK$Q81R8.@\0;-)[VKN@YH<#<>,1H2LPD?CM
M:G>CTI:K\B_9R/F]F^U.ZVWQYD>3[Z\U*3*"8*HA JG.I<TID@%C2!(@RP*Q
MD@N:"C]WX<M]38U:CFR*)@&EL1G:E)2WVGDG,'M;;K> -Z8MYH?;+7;5)43B
M6THG/;V6[7-)Y1YKYN(KD2K/O_GQQ;34Y*%-14I*RDJ ,-;&-#'\P3*:@A(R
M) C*BH*2FPK/[_N:&G6<EE!/K*A!B7[[(':CC4C #4P;@9C=7G;^%(VAJLX?
M]/2Z1>=/5;Y:<_[,*V&4\6$AED_JX[)N_$5,/^MJL:D67_=Y2-XHO5RI]KDO
M['=5O__="&+ZJ!9L]>/#6CW9"PZC^]J 8'KZNHW1G>$B+5C*$)""*H!*Q !E
M+ ,%D@@CK'*J4I_8@@%E]:*L$8(4K)();[1)UE81/Y8:<E3=6&XB8S4P2[;2
M)S]9/?_4NL[N53W,G]0-9?=\HVYSV7V@WBY-03QR'6$0(I'SD)*.2NXC0/YR
M<1BCRX&]^__"_J[^]LW W)W8/:K57Q?5>L80HJ6$!4"Y-O_!1 *"BPQ0SGF6
M*5[0S/VB.H) 4[-LK9C);U;.K2=_X\BW,:+>[MT78P =[L-''I;![69O[^YF
M$!NM=O<>1J_$*C;R: WDI1]AU*;KFQ\R>L-YY%^!.IH?_J5^INE]?P658)_[
M:^W><,NT351A.ORLYC;1T;X"U+NJ%O-EO5DIFY6S2<HYR[!4&2\T($71>,OG
M@##SGQ+E$N5<X()Z97(,$6)JJV-7*$,:->PAALWY$7#]Y#L2'E=2 ^([QC75
M+OF-)<5.@8-Z<\E>A8'RQ]X"8LPK+5\1QK_F"@3I[-57:%N!Y:GJ6JWO15M(
MQ$QCL[^I*]GM;+X8>JZU6JVL/X#=]WPU+'STQ$RJDN50V3P,RFPA6$8 YZ4"
MB N-"D21+KS.O6^49WH<N14S$8=R>I:3NG&0W#AS1.@'IL]&D^1 E;OD2-3D
M0)N[Y&",WCJ-D7_AISC(QBKH=*,TXQ9JB@/=20&F2,V&D>[CRM;I7?^P)M/:
M\+SU;GBV%N[!;5>>ED(0"D%1E@0@8BB6E<8 +7($I=:,Y,++XG3H<VKDN17Y
MKK$MUXT=M!/[+OR2T05^-\J,#.K M/AQN?@*/C9I*+Z8WU<VH4M+E;&O'3UP
MB41J+CV.2EP>$+PD)Y]7 TZ./RHSYFI7^OBCK7SXL6*\FE?K'_>+Q8;-K7OG
M9]/A#,+4IM/"(-/"['L)R0'']B=-J! V%Z]P\JWW[7AJ5-1*EU@W^*0W_=%M
M<#N<YPX$XM#4TTA]=U XO1'\+MF)?I=T&%OID\_#8>QQ"CL0UB.=MD;%W.],
M-0"XWK-3G_;&.R,-T/+H+#3D_3"#<Q?S^F'QO%G7']5W-<^Z^$#$: J;;']*
M2X!020&C3 .>DI(0G!=IX70)Z-#7U%C]E^KKHM*5,,OL/_\3Q.F?E^MO:I4L
M>:U6WYM\=U6C0_)3HT7[3.9XR>>"O9N5&0G1@2E^GR3 EH2P@AJFL:(F6<1X
M3 ],(EF6?3V-:E$ZJ/S2DG1YQ8]1I*IF[\V>>/WC_9-:?36T]6^KY6_K;S9>
MB"U^S%A1DHPR"7*M%4 %EX ASD&9R=S8D)JG;B6OKO0S-29I14VVLB:ML$DG
MK1MA7(.VGRPB C8P401BY4P1CDB<H8=:B7_YNOS^/TT++3.8'_:$<*W=4<C
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M2AG$!;%N4-#FK2@!$[9X 14%Q["@!*<^!N[97J9FCNXWH_-V,ZI:.?V6D/.
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M,L-H%_!^0Q;6/9S7;]XB@#0P!P;@<T/^U1,$(F1?W;?Y2KE73Y2ZG'GU]-$
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MW<C)]LZ!/5=K-K=ZW27W3\N-78U&2=$RT A$3^$26\Y72O$R$-R74\ ,U6&
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M_K(]#S2_VQ\([J)=F$0T5;8D+[?9%G)*___NOJTY;AQ)]_W\"KYM3X0PAQ>
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ME6,=9760?S?7.WUW9(V-QAT&1CW[[Z8T^U9-(R?R%HS68/+5WP;;?I0C3-!
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M-?B4/0-[@8/9]R@.GJESG_#JMU_$1JR_B38">*L[2C)UQ4QMF/."(@9( 6,
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M+,G#*VU)CN0 6#\MDLT#1R1$<M#SD K)Y0$.:\&_DS6=+\GB]F$MJMJUYB-
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M<:?FF#5BJ6]Z^4(6$:FDU[96:@:MI[JGP;>ZB:B,MH^BHEDFRY__LMF9X\I
M;'4+4J)\O/5VSN;/FE/DB?R,"&-K=:^^<:UILC>:::1]ZVR.5H*_1R:G7E-Z
M.T*;?:U(9-@V+CK3-J[;?_9V]UIU%(_JE:51?5+O@LW9W)3>B;$.]*;R;EB>
M"HXU5?U'B<&E&/'\<2Q$#P\M1QO5O8#DODE/_Z10W)5RYA3%0@*9(MT$,*8
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M?<^!1XSG:IKI<N!9&M[B*R#1_&O3_'/3N*XZ<*?#(;,4EH*S1"<L)P3 %")
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MO=(\^F*\&EO\<5FS7FER3IBW7DL.1Q]\LQ';S8S+!#&8"U"6$.MT;PK*),E
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M/.(T62^-D7(FPS0?P;%%=IMG]W[)5D_BPVJC=O<BAI!C#FA2J-T]0P*4$I>
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M1_-%?!/+%[&YI;H<FFUG1<%%SED.,BQ2 #.H3$Y>)*#(,I@718H1,J(WNC3
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M]DLR81O!OR?YXXO%^7R]_/9BD7'"G#%"JP0R"0>T[T4(U@NP6G$F%>=&N0;
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M^E=,_$+?64V22"PDD@03AC9'37;.64$!MB@LQZ#1J^-N-!]X\7Z@Z/B4LX5
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M=YB06(HS_ W7%U?2R?+D+?GRZ+P 9:,#GSPQI*53T;*,/+6V2H_0,TZ7C.$
MU4SV'>#H3?5&KQA97>/$DKGVTB,(;LF,(W-DQNF#1&F-8X+1(FF,HH>I&:>U
MQG 8:B3W#A#T>OZ%J%XLOQ$+$R-22-$)X$74\P2*5*/S%JS,EJ.,(N;6_M#U
M]X_3;6,XE!PLVPYP\7:)G\,TO_KZN8:UM %O(']#1A.GC%!"29#*)5"A&'"Y
M8"T*M[E8=-H]ELE\"%SV(&N<;AW#H:BU)CH USLDN4S3&O-^WETH0F*Q$G16
M%+<&%<$5):IWEXBY*!U[K-KV$* ]D<1QFH,,![HA-=0! &^N'HZ*0MY P4.I
MF>3U6"26+,&J)!C&;#)[+"G_Z&. <3J&#.AA'RS=PZ&Q6(?94="HA\AD:Q>?
M<;G^]G862!;S7!'_N9ZJ5;-+/PDUN?Q7#"M\5_O!OBF_DT6NW#XK!$Z*+,[/
MSF?UZ/<E$OUINE7B/#\[JWGI_[GY<D++(7I=C74V#!2M#:A]#X!9)2.7DI;2
MK<N/NP?<)Z.VA^COJ*.I/O7:@0W\VV*1_YC.9I.@G(LZ:0IWB60ER2F-B=/*
M-RP8-,J51VN2#C%_%^_N(2YL<O!YD# [ ,'W]OG?%O-T42D1%4=-\J@W!17>
M"ESD#(2@8 :=CSRWOF#9G[H>0L<F0!I((1U ;2NDB2[".*TE&.EHE134X%5*
MD)VP*&34)K0^-]^^N8>XL.$ERY,$.:)?=4'UK],0I[/I>HHK0O4F1_;38D9"
M7U5TK[]=BL:;K JSU=\4Y"\JVE#I6YS4:B3GNO L56. [$O;N,[0X%>\@ZBH
M \MSC:_;88YVVL@<"]A"]"ND#\&8 IR+K+DP$4OKNY:'J1GWZFX8[3\,L6-4
MT0&H+JZ1WH9O]0K@(MHU1>?B=0&,U2H;\O]\,0Y"D4X4RQ!EZZ.J^RGI!DQ'
MZ?F!N[LCA-X!=%XLYAM1_&.Z_O3B?+5>G.'R0F#?+F\B><J1%PM2!Q*39XK6
MFV0@G5/)I)PQ/99<?U!^P1YTC;L%#@2KY@KI &2T5);G]-8;5GUS=7#M6Y,2
MK9/!>N!9"5#.D[M08U;M.,=(J\GIYEES^Q V[L' <-:KL4HZP-EOBS7>ML<U
M[YS;G$@JY!PH4R(X2XM&8"(OU/N,IK4+?P\9XYX)#(2A8\7= 6+N2F:"0K%@
M:]5]JAMXYAY\CA(0BPS9Q)!9ZV25NU2,>T P$%Z.%'8/!P>+^<</N#R[COR)
M$TY+C0I$$**&N09"I*C7H"?1I"B9;[UOW4='-][0@!';L>+OP.+L-MYWBV]A
M=GV!S?.UXU2C1";[R<BUXQ94J#>>==&)(NF_13GV:.?F(URA1^GJQA,:#F+-
MU=,!Y%[N7EOG:)SAA_#UFB1K.EC01B5?)[,EYD#IZ&KSVMJ^,C+//-9>UXW1
M]AV2NG&7A@-:2Z5T@;'E]$NH'<VN\W&U9$(TB$)J*&S3(1<%A&JJE2270:1<
MD+>^V/T.2=VX6$-BK)U2.L#8[?#T&B="%.&Y%&"<JRE".1,G,8&.O"09O67F
ML=YS!V>8'XZLP1+P3H*L1JKH %37CSNRY8E%]""2K8U0<B%7,@L2B\$Z%:8V
M/Q@N]!LW]>[45RY/$G8'H=]C$B&2;9 6,@^$>!NJ&54"+/,&&46XG#_6C.BP
MHN:C[H6;=Y@X*8H:J:(#XW.M2=<V=QE+L1(CKRDT],%(6A3")6!D57,*+!,;
MS6]:;M(P=NUX&]W>N54Y0M = .59SIO<BC![&Z84,[P(GZ=DV2;:<^08-62!
MM06D*>",#+39!I)*D$G;YNGB]Y,R=C[*(+!I(?8.T/,.UV$ZQ_PJ+.?3^<?5
MC23B,DW3]21)69*O37MJ=R=5! ,GI8(4O"LF**-,ZRO>[U,U[GG30)AJK(P.
MX'574).H%6KM,E HX&A[I[7A4!A:(,D*&Q4J_]ADL38NT;BG2 /!YTAA=^!)
M?\]'G&#6F*0)4%1-7M<DJ+C)<\C%.&$5R_&QCEQ#9%V.,P!UK-CL>+4T@]EX
MO;[>;E3S">GOR+NYP5>KQE\W7W'J+F"/,'C*EF!HD,R=T-N>@4K5#A?*2A"Z
M6"Z\M^V;99VB)=BUB(,$_6:Y>6?>!!]O<;EIR3Q).BI;N #:[2VH.NS>%\F
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MV::_U+2J2>;,VTP!K"PIDSRL(>.I,_&A3;'.,8?-&Y?<):.3H\W&(>"!8NX
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MR,'Z*(62K'7E1QO*Q[7$IXZGAE1K!X["._R\VU>V95B3F%&P3-N&EO7*@?,
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MI>D7?(_I?+E)$WKUM4X1P+RMKSW[?'[1)N7A^CA/81/3Z$!R3DY$T8;V"%,
ML]0:A;2Z^?5">R[&W8$'1O0HJNY^A[ZWNO#P??JQQYV@+'+ /?O1(CB>G>!H
M,T@3*7H@/PV"" PL)G0Q*8.Z=3K\D,615XOF\BW/5BO<G"%=RQ/?23Z_F;^K
MZZDF76ZBK5N;0]#*R+)I/U K!+.4$"TWM7]40A&,(:]V,-/8@(&.BR^?@KN'
M+>.IE=R!!W#)\AZ<_CY?Q!4NOU2&7\]IAZ ?+^:)_FH#@FLR,-I&ZQWDI&.5
M 85NS'L0L=@L>-8"^5!6H"$?XWH!@^%]=)5W[POL*BP/WOQO_/T0]<H#;N^W
MZE:=2*)H;2$;PT&E3+&,J],A.3-**5=T:'U&VZ9J>3-YX#X[OJVFO66U!5.*
MT8("+ EI/1'#WC@&AG,7H@ZR>/T]K3_IC5T5)S]%R3<F.PPBWPYVQ8U\:GK5
M+3:\2B286)M_)A*4=H$V]V*AJ%J:&"C^,JW=VP=(&7=O:H"?EJ+N C%W:_0O
M%L6WO]?FK_3O+1:3PA@L<B#Q*%!!:'")9\C,FX)(VV=J[28=0.:XT[J;(FU8
M%77OUNS=AN!PS^>IKQBIS\* _M/3*MI]*C'7Y#S+40 AF/"<O :CI=%.<ZG3
M .T#AN^VL/$.KATY/OC.!W1S;06&R'3Q%-K$>A_M(P460M&7S$KMG1#^=E'?
M YY9"VI&3PP8"%HWG+J3JZU[PWF]8O>(J]N[3QFNL'A "_=0>6EQ,DEDP(6M
M5U\*(3+I06HGZJF7$JYUI#A,>?$5_NOS;^.:8S9"><BB)E>7R"!X@\"=\J*H
MS-I7SSQ&3Y^%QD] PL.'L4<*OX.8X(J7G7=)9O)-^74Q__@!EV?W\%>B4-G;
M!-R45$<<>O"2(223LK0.;0FM"]B?2N.X<>>@@!M 2=WO;+<KR@_?W1YXTK %
M\$.F)MTL>4ZUJ@8%!8)EX\\P X[[ DYQ8XV33+K69::-R^ O<7Y_!?;%G-4W
MRW?3CY_6-_H+HO.^U/GEI6:$1@D^ZPP"H\*444K>N@?LP<1V52;_%,P\;):&
M5%?W]NG^.O3#K=2CSSM%"?V0?OEQA<I&T$99- >5ZX&:+;&V6S"091*\]G]*
MNGGWG%$+Z:_E^!%T%M\0W^/RRS3A54GU=:*>S3:/W.1$U5O0C_/I?Q)1F^&5
M&TJOEB Z9D3"S2CUFKH<"P17?&T4'W0VR)AHO5D,QLP/77S_%$P_D@(Z(CRZ
M"F/NYWQCZ-Y\W@RUVW68NWV,S@WM@XQBML3K0$X7/#B& :1"[KUF/D4<SH4X
MD.J10YT>D'\2A7<*\9U(G_T1EODZQS5U9HN"U>K\;/N]6]PK@R5IU,!Y[:3(
MF0/GDX40E;'>9E)-ZXN]MAR,>^?7&?1/!(3N??&+J;\O<1VFLZ/F$5\\8IBQ
MQ/<2V-5TXA)EM,IID+6H7 63P:%48#B+BJ'1J7EM3Q?3B>MQVNMY[4U;'[M9
M+)/ DQ,^"C"T6D@6FI:',J+VEC-"Z>Q%\Y'K]Y#Q9YA/_!14W=?@\QC-=+")
MUS/;]<69+?W-LZ_3U4321I"-"F""L[0C9 9.^@PHD]5"ZFR;]R.YCX[Q[VF.
M4N[M3)IC)=TA6EXNSL)T/HDF*FNSJ6)QM&.[ JZH36O;6OU>A%"M+?/]E(R<
M('JTAK\#F0/$W05HPOSBAOWO>!9Q.6$BF*ASWN6A&>+%YQB@6,4]BJA2;GUL
M=I>*OL!RB&[OP.4H07< E9LV=[-^F!.2:Z\@,8H!E$ 2"&W*P#QR4:)2(C?O
MO'F'BO$O<%ON1$=*N3N<_!;.+I>/EL85Q\&@2Z"\4;7$)T.2RF) CH&W;H'P
M$"T]>2]/U_&CD#E0X","9Y.C]]\7R^E_+N9O%W_0\]+B?+G>)'_M3"5:9HWG
M ;32H0Y+LA YU^!$C-$@"P)O]6Q_(&?RT=?TA(I#U;@81*8=F)7WYW&%_W%.
MHGGUI5K:2Q^.J%>ZMB-.G%9.P4#&-B30UJOL7$H\-N\J<C\I(Y\Q-MZ(6LB[
M3]CLEE5RIOCD)(AH:5G)H"$PZT$SM)FSR!5K?J;]$#'C6IXFJOX^? Z0>W\
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M<;5;B%+YY-7F,B5R4+Y..K+6 T6AF(3@R>@!LDD?)VKTY,!V$-@?7@?HHP^
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MO[2^A]XP[KGU<'AI(M$.ML2K@9(;)GZ?3]>K=^]_OQB;4IQDEGFPK!YX9N?
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MRUT^WS$7^Z<AK&T>P C";)0V</G6:[W7+B]R'2H*-GF!7%" RB*"#Z6FJ9A
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M:@?JI0.H/3\GB9+K>)$DIX3@.M76)$+5,>,9O/81F'/%1(M9^=8M6F]2T"F
M#E7PHIFT1Z[MO1RG_#=<?"1W]-,TA6UV2=$RV)@<A))J'9H5M6ECO?.W/%"
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MB@LZ&6M_S]I@K!B0D2G&B9K(6ULK!Q=CG#1?ZI@KZ&A.=XB6W5$RCCQNTJA
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M=F*^ZU#\9)CXO@[%DRZA23*A00]%JD)L263R:J4@R6ASUD'RV'JBQHE(&W:
M_AW)/QU^>CE61SB,C[/E+=;"FNO>I-MQ/U?AXCVN+L7,&,%5J!,K.:8Z6D.!
M<];3%QZRYMQ^T[QX\M>& \@<=MR^U_R#WG'5R]$[1$(__=?5?//YY\5ZL[K:
ME@.]KL/LWG\,BP?CV3/G<TFLB-H[HH:R77W%J17>Q6!T.@7%NTE VY.V88?L
MWWD/)T10#R>K/K3\O%Y?8?[Q:G6;@7<=D+O["G-S=>=:Q:!%(@IE+!:4# :(
MZ Q.H9>".9YB\[C3WKL<AO;O-G]A7*GV@-O1SO.KY:K@_,[3_BP%QER0%DPV
M'%0V 5RJWJ )9+X:[;EI/O3R=.0-.RG?=1Y#ASCJY8@=8I?>EO9?CW6F?WVY
M7%P7_>^*0,G*]%P5!SJXVJR+60BEUE[+E*(F'BGLILSE66J&54I^UVD)TZ.D
ME_-RB"!VG<!O7_JOXCJMYELM\C9L<!9L] 6)#V11"E!(5W.TA@$3Q2HN5+&\
M]9S!L6@9=E:^ZY2#J1'2?5%]?(0)MRD6+RZ75XO-LMQY^-CJC1V79DIJPY07
MX .OU:.)[MGB<O7(?*CC2I4>-@!G]*T..P[?6_9 AS#HX/JX<P&^#+_/-^'B
MVEW;==*HD=I75YNK%5:_+BP2SI0J)2;!:FUT'4N)=.JS$U!;)?FHC-3W6Z<<
M?2_LO<EA"/]>@_?CRK1[3?YHQ>?59GE)OYQN.F.\7U[SY4O/C-N&,>$#&8?W
MC_B+S4^+_+J\66'"^I?_B6$U2Y)9]$S0K6<TJ!(T1&WJ)(U,]Y\JTN721NV?
ME*YA)^A["^9W*(B] -;!A7)X&+>^9&Q_=,.^'W'7P<:+9+6) 7A6!E3. F(5
M:@BH#)H<U+ >TB<)^3]*QK C]>_P_CBX:'8T_N>?OI$?<>@?VQ]M?U+_U5LL
M_U?]_U_?_OS5YX=/X6)9"0J_XQ5IBO5_I.7E]3I;#? -@VZ:#BZONV-^\^2Q
MJQ/_$3=A?K'^FMCUG#PW?.[R:;+NG[Z0?Y\QN^6_P?))68'_W. B8_Z_CU-N
M/\[7Z6*Y)M-I^W1TN_2V>W?=S7JS_N;=:?TBKK=Q\%G0W 9''G(PG,Y/'=L5
M>0@0O6=TA# FQAOKL>-V?/1ET*QEIHB:?"E36Y=%1:I'Q]K*3X),S')T*O,O
MP8)65T"KS4_;S?&$F/U&YT\B_@Z,(+JIEI?;(4=;XGZI_Z#2NVV"S;(IZ H0
M*T.MQ5;@'7E=B)H5JY&GYN^J3VQGXDZCTP!D.8ZT^@7>KH>V8T((H@9""1E4
MW([[%*'._*P3IUU$T7I0PI,;FA9\S<0^#$X'R* #0-4W(]K QQ>+_"-^PHOE
M[Y6FG:EU,TC$FUB\Y)"]K6W]K0./IH#3M9>UER+:UAIMP+:Z!-<A(%B.*Y$.
M0/8.+^A''_Z,"_(&+HBP%_EROIA7"V0S_X0[VM9?FO4[OIUS+5DDKT^FFC,D
MH8@<#1U5;6WS H!]-CAM#^/Q@#>>E'J X/&O(RIF+:PU("VKSW..V!I\;>TO
MM= V.ZY'22\Y:M<3-]SNPOX[L>P[0/O YH,I^:1YCB!$3J \$D%!2$C)ZL1S
MD=JU?J]HV#FRYWR.O?!R6.?(?81W]H^CU]F/+Q)=1'5PWGBOH0\O=-KGSP'$
M=O+>J8*WC)0R<XF!8L@@"DDX-")D##KRV#I5X/MY[W18/'K(8AN1+Q*<5!Y0
MZ1)BC%S[YDT=__W>N2=FQWSO'"[^'NR)[<[IE[>/)R79[$TH!#%?*VS)!76<
MKCG#=:8_<>%+ZW*VKS;P_;QI[@&"^T;"P1+I $Z',^X+V8M<9_S5:8([UU<I
M[W7Q&K8L52YH\A#('BI,F9)B5LR.TO^S,1W3@OL(6.WK=(TMX\GSV*Y;ZVS)
MVQ7O[)Y.&/%46W)C$[>6KB"GP64?R7S73ME$IGM1S]FQ3R_1N?\TNNB7S>5P
M#EKS>;=4&^UC9 @JT#VC>&'@6$204O'(E3.<=S,BZSM\PCK\NC^Q[,\9[=_V
MKWB[O+AXM5S5'\Y""E($':#PFE*F10 73(1@BX@V!9Y%;^V-'Z:D<Q7?&(_C
M]1(Z%!S?UQ'9M21CKL0@R,PKEJP^19*A&U$[D *-EIS5\0+]GHY]VM1U=S :
M(G/TSG7[P.3@<_+[=7.)35AMNC@M#\VH\58XXPN'M&W&PG0-AR961SC5!A<H
MDM:=G9=#1Q?U5R[8[XDY%BK?P=WR90#EER9&$:5V*9*KA4Z2"V<$.$%\$$X:
MGJU/QH_2=JXM&6<ZF[??TW(L5/8_+?[ZM"SP0XT8O._FT'Q[TUI;?$WH@A!K
M'3Y/&:+2%J0Q6G.?2)ET[*[L89#U5VG8[X$Y#B9'&F0_+7(79V778ZR^K.R8
M4**7Q/D (GM.7J7,X!63=,V*8G)"4[!U-DMS(L[4%.O#JS\.$M^!T36P17+5
M8V6GQRQ:Q;6PP#/2;6OKL[KT#)0/*B<=HS"]'9K]J3Q3DZV/4S4RJ/YUCMU,
M*EV;7@:0MMH,H997I]H>V8:@O4%4L>,A$,=WMN_N@)T(X1,UPM\';N?S2O=H
MD.W!MY<G&92%+[%*S2:--4E7@BNU<;F6PN6BA,>3MYUH1]Z9FI*=GLF)8'<.
MM^-SK'G@?>=)_G@=0XS:0'))@XK<D-ZB+]Y81]8[#PE/WBV_,8UG:I">Z=D<
M$X#G<$ ;V1/<:J68MY"2(&UE7'5"D+@DBDW&.,V:=S?IR7P]AQ?*+H[C!'#[
M_MXTGV0-LRBBEQJPR$!V XO@N?& )BL??2S,==.Z>3_2SO0D]O%2,P9\>KG?
MXO-LB8^PY7:,Z3VF;$WV'\,&O_3^O2D2XB;ZXDH!6TJU *P 'Z4 EG)V.I<@
M_"B>X4FI''36>FY7>/19ZQ=4_U+';B84)Y_79>!"%%#(!#CG!* 2U@KNDK6C
MI%&=A+H.WD8[QOEDQW(OT)W/\^@QSU0/,$EZ,K5%,*"EKQU84R)7.#KZ([>Q
M2.E%ZJ;GR6$D=O!,>F;'LU/X35[O]YPHXT!1WGVU&J+(F+3.&!LAZ>K,1ZT@
M8."0ZW\)G1'IWNWY5(?Z"2CHX#6T_R-X/AC[U[)= TL2);%"*EMC.+5&6M?I
MXT9C22QXS9HW+N[+=AWW.:;_D]DYZ"9^&VVBMQY_V7J .;I8G4/6->7!@?)*
M@TM: ]UUTDAAF;H_27BD^W"?70\Z:3W/JC_D,:9O;/1RCQUA;[_(>5Z_"1=?
MNB;=:85DD&=;,FBK&"B!$H+"#-:7I!0&=*5UN^A1"1ITAGH>13]E\* =5'HY
M-T=<Q8_'*-]B[49"?_]RN=BRYBI<O,?5I9A%CD[JF( %5GW56'N5H@(N'7)E
M4*?8S?3AP\GLX#6S#Y W-O[&1MQW<"@?O^@?8Q&?I62*P.0@>IEJ 0B#D%(!
MQ0QZSZW,9I2&-Z<ELX,WS._R4(Z-N+-OR_O%@5ZOKRZOF5:6JQW[1FS3.VSA
MT[;M/8 9?;3QY3H:PS0=+,_HB%FA(9"C!%:X[)UPSC?O8O&]M/&-F:O(8P:1
M99V3;ATX8S2@T"Q(;80,S4MZ_MW&=T_,CM?&=Q_Q=V"!?=W=,SHE8S8>BI-D
M/J)W=+-F!CD*[5 +*T/K+,+OLHWO7B!XLHWO/A+I $Z',^Z)/I\<O0BQYB66
M(.D+67X^8P#$G#U/5G U2CRE,1T]M?'="U:G:..[CXPG#^L_VCXV"QZBRA9$
M?496PE@(H3;U#-8F'TJPZED[]U^NC>]>HA_6QG<?.4R(IO5J,WM;6;<]DZ9(
M+F+($$.=]:Z=!:^+AMK92'GM(MY/VGA8S=&GWE%Q]*<OZNVK!;^7)KJ'7+:'
M<[X'N-R@W")SAAE@LKXK"!\@&"E &)F45Y%%.:@3U!# 3*E]CA#6?7$?P+F)
M!?[K?#&_O+K<;3SI(I7W"%@S;U0J :+)LA;P"Z=YEJ(,BB@\(_*O%IU8Z(>(
M;-F"?U,+/OSSSL9%T8D)'4%[;@GU.D%D/H+';!71$NF>;"'XNXM.<T$T$_S!
M_#L'/^KYR'%*M2@Y*1"J\%JR+ CEEO#.K,K:1,>:3^(Z?M<3YWUV\0!P8MEW
M@/:_A]4V"YQ\@[<UIG(W]%E#*#/O"Q<R)DB%.*FDXN"9\!!JXXS"HF;-V[(\
MMZ?.';'&&%F.*+"# ?@)5W$YM<)]*,13YW&F#>:_+2_H8R[FF\]OPP9G@6LR
M5R4#NM&V#4(-!*D8:)L8N;U"A-2-1AY.UIE&FML<A-Y@TX$R;\J2M_/U/UZM
M$']>T 9QO=DR1$J>F2;C342;0063(& I4%(0TFJ'L?V@S+&)ZJ#@Y3LY14=#
MYGL[0S=JY<?YIWE&NK$K0WC*3G!/6B15AI14>QG) LQ%[1.)BZ[KGL_00T1U
M4)KRG9RAHR'3?1H3,>EROMEZ<F2VUI0M,EUQD>9X3([2@$]MFX"T+QF-LHON
M+/OB_K*W21RWB1D%E>"U((G)4)4OYQ!%JK%'D;2R64?9.B-FKPVVRQUZ_3O6
MKG*+#[]@/69THG"SOGX1*%P;[5("9K'4\16U/JLPB#KHX$)P4C2?=#)@7].Z
ML>/AZ/$$GT8RFOAU^,UJF:_2YO5J%P2]#HT(46MOB2TZT_UA>  G?0"6#)>Q
MA&B'S?)\YI'XH;5[R=QI)=UE0U;W 95ZPG84K'>1=^^#%%I+4%E84#P+B"DS
M"-DZ'TQFB37$R[<;F"ZR=+Q,OP7(D0R>.JOEQ=_>_W^2\==7FU^(@L7Z)OY"
MAI[G(DC@04?B2I000F3T1U=*"$IC8,_914\M,#D(CI7;LC$3>P""8F9' &G0
M^8=%O:)WI*#UQ7JIP+F"Q)O@P/&L@?@5O>'>^^@&X^'Q=:8+/HX$BT8L[0$=
MCO'K_PGBT?5W\B;.JCDYAI:!477"@+3$(BX1M+?:&L^]N5\X\ 0Z'E]GFN>R
M$='1B*4]H,/SFYU[99@WQD&RF0SVC((L+JO!8+91)6:+'I8.^=7'3O/,,Z+L
M#V/8Q%;ER^55?6 EIFT^UV3.K06%F- SHILGXT%YGB%&FT X9KS*!-=AG6^>
M,2@?6KN7;,81')"C63UUSB+^?K5*'XD=+SZL</L8>9^DFV-43#%>:/!9*5!)
M$OZ]=)"#$,$IC*XT28$=NJ'I;-/C9;X<6P!3WS5_^;S\(_QEOIHO7BY_V>2_
M_.7E3HNR[(1T&B$D)#^.#AUX)PPPGY25SF5OAW7[>6R%"3,BQY'DLC5;I\;&
MB_4&+R["^LW'L+H,/R_2S5_<6-R1.;*K!$A5F_[(Z""J[($+*55$Z4J,PRR3
MIQ>:,(5R?*2T9/+4@'D7%H7$\</5:O$Q7+Y98?Q,9.1YNFY!L/R$J\\_+]:;
M^>9J<^/4!RLS*L[!^NV@C!JI4\)#D<J60N9:5G(0B Y8?#H'Z 3 &EL84X/M
MQ<5F>>/<*>%480S0UD(\$SCX& SDZ%+./)22[#!%=/N9T_E'I] YA[%N:HG_
M]&ZW:>M4%)J1>RCK")O@'7C!+6AE2O(:H_3#;).;3YQF9,.)I'T0VZ:6]?NW
M/[^[OA)O'W"2=T%KLI24I7LP>#*<E(,0.%V*Y.\K/<S8N/_)TW2(/)'LCV)C
M!SE<M=CU=;F3@+-UX7(*="O) L+2_I6Q%<A$!!K/I769YS*H9F^/-( '-])+
MH47CYY)VS.\ 07?+35XL\F_+1?CR-^_INW5(=ZN>@_!:!%/GH26Z$%-&B,9P
M(,YYKHH*\7ZD[OCN'?MM<=HL@0:@N-^K8T0)37V-U9=IQ@3Y_S=AJQM-OR.F
M".F+L)Y0$30H2Q0%Q1%"'6*KDO4V#@_U/+72Q(TSQI3Q_5! ,X;W@1YS\R+P
M"$7*.FD+,BB9T97N.#EMWOBJYS62?>"UXGM Z)GEI@T1G!A'+5G?!YC<0\\"
MCU#G6"ZRQ #"1+(=I""^B>Q EH"H%&87S1[ VF/I:0VK$X-L+)%,#;B_A%6<
M+\+%?1IL3-''P*'8FL936"%G1GB(5G-E:WU62H-@]<@"TU8PG P\+=@[-41^
MG5_@>K-<7$?F4F(L:94A:Y%K9(Z!5U*!Y"ZA9E:4,NPB^^IC)RYH&<M).Y)_
MW4A^]\)1BDC1ED(>@R,6Z&S!294 I:^#XITK(N\G^RF#S\<*YT$9'\"I;J3\
M>G$38HC.614T@O0R7Z?I><<4"#08O QHV;#,QV\_NP=9'R*D!Z5]&,>Z$?C[
M/VXB##FC298NH&SK\ UO#<14,C@R5HPNV0<V+/7YV\^>QA<92>"'<:P?@9/L
M;A%K?1!)U$%?$4&9;&HU /E&.N4B/&$Y[WF1W_GT:7R#L81^(-=Z>%BM!LR+
M]%]7\_5VS,#VEF/.Q("B@!3;]M'>D?%I$R0F7,;BK4^MN\P^M(^)1["/_3!_
M-.L[A,_N2$595-*,KKC,0XU1>O!:6] Z1E:R16P^6.3AG4S\7GJTA)^!S 'L
MGOJJ>8&?YG_&Q?)RGK9Y++7B?Y%NTJ28)(TI!!$BB! 1+,2,"(S%4+RP@;-A
MCPI/K=(7)@X1X7(,?DX-C)_3Q^6*&')C/I%O9:1!8D.JO4T-'9/,-/!:(I:3
MB^)^_O,C4/CZ<R=^^&XL_"-X-J&X,\YGO^"'</'38C/??-YI16;0I@)<E!IZ
MK+FUW!-<H],!,7!;GFIKM\;T'Q^6G_Y$'WU]6= W7^Z(!Q:<>*+H6+;%L:R=
M&!77N]Z="I=+SJ4X,*D.?>120RP\0@D!$Y/"I?OY87M"XNYJTUP*1XMKV8!W
M4RO^)V^PHBP3R@@0L78/-=Q#B*0I#3*FR+U6Q0U,"NW.(CA.:(-M@'TX.'%U
MU#MB^C8(\B[A(M#%MCT0@1?%4"OB2"2#62L+P7 +R>?@G8XRX:!>D<]40CVX
M^,1#<\<LI3N>V5.C9;?OOR[6OV.:ESGFW4%"E)[I4AO;"4[VE,!:?9I!:LZ=
M*UK+)K67CVY@NJ*H!D)=MN9P)S!YM5QA"NN; *L.BN?:6\Z1;@7%H@&W[858
M9-'&1E_2H$Y< S'R]>H3 J2-2!\ R1'\[> AZT$%^\MM.T*AB\1L F27ZS!A
MC!"-%F"S,O1_TL#WZRB/?M!Z>D>#$.3.[F(:01Q3F[<OEQ?T5\M*SB>\DU=R
MW2W\Q2*_CA?S#UO1K?_Z._%ZL7F%..-8!_G&#$'S6M)#? PFUZD/Z!!K YV!
MO88.6W_:1[*6XE^>5A;G!+?=7) 7'SZLR G=X&U ZV:@Z,RSK+-U$G*HJ9$L
M67!%$J<5,J]2ML+ZYBA\=EO3/N+U ,ZVDCLGS+[!%1D<F]?EAM)7)*!W5_0+
M-=62I#)S%EDH) !;M*OWC@"GC 8ZIERSHE+ ]IKSV6U-FPS; V;;2JX#F_$M
MR9 V\)'(_!$_X<7R]TI6;1B]6-.EH=!8ILB4QNVP)L?(LKX>UD064$RYV-8Q
MT"<W-&T&Y0@ ;"^&<]*#+Z\NKRZVOWA?]^\H?XMI^6$Q_V_,[Y<_UJ;E"2-W
M 8F]' 6=KAH6-#Y!TKRPS)3+?EARYJC;G#;IHP<].:YDSPGC;XBX6DV])GN&
MI9A\B@A"!@6J$->#(+]2)Q9]5"S:,*Q;P($;F#9@V ,N#Y7&U(A[2Y?"XHI.
M37WF(A:2'5*6J\NP2/B%NK^%U;R^6KPD0N=YRVR2[&4MY)\5[GFQTH'UEHZ7
M3AIBS!&X=R%++2+'8= [=B?31B/&PN!)Y3,U&&MC_]K!_^_SS<>75Z3<+W%U
MRX"OU7HUC[_UZX0.W#@=P3I'?EU4LC;(E:3PT=!_&)08J@>/V\FT+Y#C*<03
MRF=J,-Y/1[J=.K'93L'97@*_7=7G_-?EEM+US OMZ+\,+"L&2B4%D2D/!J.J
M@X.MCV$0! ];?Q#P_+D![P2RZ,!E?H#*+^I\6U=YO:TOU'_U&[,B(Q>E#CJQ
MANP.4V,*.1406'M<%6V#;#W]],@M#WM(9V<$UREDV2=T'R+K%S)3M@,K9YBL
MCJP8\$0)*"32G%0!HF,Y9^E,RF,GP3^WQV'@/*<PSTFD-?6]O3,V7BU7^Y)Y
MR_$7B3P^^B=TA=@89<B^-@^,1+F3L6:'()B<G$+GK;J?"?'(==YT6\.@>79!
MGNE$-S5H[]-[8\R\66&B?U [FK[?#O:KA'FTY-6% )AB),** %^8!1V0,U?-
MZ*%-2_98=1CDSBY&,QKCIT;4V^7G<+'Y?-LZ8W>VR$_#^2?,,RZQE.I[155I
M\36?U@@%3NO:(-=9JX<% I]9:!ANSBFTTIR]W4$%5_-E?E'HX]]L(Y"_A*M%
M^OA^^1Y7E_,%>?>WOSJSTB1A6 $F=:T/#@ZB#QQ<<#6!VG&-P^(F1VQB&,3.
M+BQR*K'T!K\?KCXOKS:OMQ.&=V'Q\ %?E]]P\^9:MENG_W79_</;UR6%EAL5
M-:"7M3B$//V(9+0Z+\E^M<D['%85UVI'PX!Y=G&12036@9/[RW+QH9ZU-[N6
MQE^FTOY*EL+EU>7_>Q6V)2MOD>P)VM_,JEAJ5V/(C+PEQ7.!R"*"#3%843O.
MYT'5&7MXN7MO<AA(SREP<AIY3:TV]\N(^P?^_2,MOCMZ=$K_NIAO9L14SA1G
M(+'Z]3(8"!P9<==+]+J$$H<5D#78S# <GF',Y+1B:@;+__FG;P1![/C'__H?
MNQ_4+Y%8];_^Q_\/4$L#!!0    ( '@X U?@\CK3,P@  +@H   0    97@M
M,S$Q,G$R,#(S+FAT;>U:;7/;N!'^WE^!.M.</2/)>HULV?&,SE&NFKG:.47I
M73]U0'(IHB8)'@!*5G]]=P'HS9(N\B1-5$\]8]DD=H%=[(/=!Q"N$Y.E-]<)
M\.CF3]=_KE;9.QF6&>2&A0JX@8B56N03]FL$^H%5JU[J5A9S)2:)8<UZL\5^
ME>I!3+EK-\*D<+/HY_K</5^?VT&N QG-;ZXC,64B>GLB@D8'+NOA1=AM!.U6
MYS((X[AU$;3J$'9XN]O]9^,$55'<Z6@S3^'M22;R:@(T?J_=K'4[A;F:B<@D
MO4:]_I>335&N)B@=2&-DANTH:N#15'DJ)GG/^H *L42/O48H4ZEZK^KVYXI:
MJC'/1#KO_3 6&6AV!S,VDAG/?ZAHGNNJ!B5B)ZC%O\$-8A]GSL8N]I.*'!8V
M-YIDY> Q$8$PKU\UWM2O6HU:X_J<E!;N;CF]9G:($POJ.]E].QB-A^^'M_WQ
M\/Z.W;]G'T;#N]OAA_[/;/#;X/;3>/CW ;Y&B<%HTZ4C=.;#I]''3_V[,1O?
MLX^#6W+)!Z3>)-_&?QVPC_W1C_V[P<?J_6\_#_[!^K=C:FG6Z\W#W7.@$WF$
M3[TWK>+K@Z[]Q-_V3G^=<WOMWEPM;S87R[]*;40\_Z]':K?EPXJS_2>NU!P[
M%6F%A:#((F82CNNH<_$<QPH>19C9JBG$.,3%3E<WHE8EH>_D?*.V\.S;C_YD
MINJU#DW#D"5\"DS!5, ,RX1)A&:_E%PAV-,Y&T$AE6$R9^^ERESD&O7J+TS&
MK#_EJ63C!!0OH#0BU#ZTPSRLL5.3 'O]ZJ+9K%\IF AM%,^-?=&X.L,H7[[8
M*#>/+LH_<HVQQ2AF<_:0RUD*T00J+MC*A3B2:$(ND3#@"%SDC.=S5N9&E8 >
M((6P; +#SEF&3TKPE,4\Q%>*R4P89J23VQ+((02M.:YV%,GX S""QK)/C>\B
M- :'3"T5P3%((!0*J0>*Y:B.ED2@V"P18<)T21\K_1DH\)V0 YG0*7(4HCLS
M81)T4!<06@.IWP)-DQ&Z.46UB 7S]6EXT;AL_>_@$E@L<HP\@6@5Z0J"$L6Q
M6:VUBSS&W,2-P'Y$'J9EA'TBFM;"6D$D"LIG!8*!<$SX3M,54#U&]).A<2U$
M@CJND$29H@"B4R*$['#:VA-RG; XE3.]@.XJWS%.+YW=:&5E#8%Z8<R6M2\:
MA.VC ^%X(V)4H1K=*^UAYJD))1,9QP(?;2R'C"NPJ$$4B" %BBX#A&J0"IV0
M.(EEF$@IF=)S)'282EVB'J58)5,'GT+)$")\K=DIHB4"A)^#Q. Q3'@^ =;'
M[#4J4]"^ +=XM=$YA3/W2)TT.I%[=6;[%,15<P=@&HE1LEO#M<,96?79(9D?
M+78]^X%B'(@\?HIVE" ^\44DKM,^;@3SLR-"<+--\_ .-,X4AM"6QL\CK4)5
M.^2E/ER%RF< B!4_DBO(LE38 2:TJ= V3:(4Y+8?(O.K!+N>I!6DW(+/5^05
M@"H^@5.CP&2+MFB9BLB>8.@RT"(27 ER0#C>8,M&3CV5FFJY7;7:%GZ;5*4&
M-,A@$B>E GFM",N44RU MZP1*TZ &HYAK!,C_"\ $L1TC?H0?5%Z/G9P!T<#
M[LO:F^XVM@_.;%L0/SPG'HQT7!U3$1& N98YIS+ -8*?*"NAFJMH@3#$O."!
M2(69$TO8-2RM-PM&BS.W5#9$URBOK3:/WJ&B5 7B7%M6$X921=8 2WXGD"-9
M21'NV (%K2,206+O((WK312VLKQ@4(=' ^IEQA[@YKFT:8U"#G&,[%-,,5AZ
M!XM<<I(#TK1[W$TL+8A1$5.L=O0UD*79;\$AA80OI8&X>?SY/18+%JS?KDMP
M,X'V6 S2 "\5A]'1X'"97%V$MY%"NW]/!6W+3C@^(Z42&9!A6"K"PUKEW=%K
M)K7!]W3@BGWI$#OZW1U(N4.E'2HQ AN3W1-I;SCNS\ >7-"91EXN[3IS5B5<
M+VD*I4F[$""R]</.A\_M<Y:*!TC]*<83^<H73]$7@__8-WZ=%[+QL^>ET6+=
M5%;9C)+K.G97B8W0]PSBLD6+EZ9QI,9&*KWD"O8%=IEEPAB /R@=@40V0NV1
M0/ML)Z>(<,S4FBH!_B6"OEB6\'LIT'R[!,L\M(<=9__?U7U;CM!/D?/A7 F$
M'^VN:9\>"D"\^#J_W%W-@#]0X78<T)9NRU[MX>SBM.I9*/0;(7?*L2,#\@@5
M-2P3X%[$>LZ+*@@[I*85QQXT4@==9@@:G"7KC"\\.\_U7CPS.+YM5Q\)0*PP
MOU00"F!3(H+)GJ][U%5<_13Y5*93H"*:\XG_FD#Y+ I9D<HY8.LLD2YU\@U,
M(P:_"L.H'8B,IS<'=@*A[>K#\7^S:[WQKXPL>LYL8W>B7B' -0>JBN:GO-#0
M6_QSA26L2/F\)W)KA%6ZVNR>+F1,J0XBJ_+S9>?)-?N[&I>7M6Z]2]<UC,+?
M:#&PO\E1LS<YSDVTW=:^J%W6]S?7:XV];5^IVW-KLC,;)T87/'][TCI9*/B%
MT6L6CZRQB1M:*UMS(XMOGSZLI^]P2=KJS/KE!!'-6A5[HV<)(S\1S_-QL3:>
MN.FB_YT\??VJC7G!?K+U*P1_J[VK;7A[_*$]T-^-=+ _CGZ=4Q:P]);9@U-&
M!EX]T]EO%."MFSS6X:V@!NKF-A$0L\$CA"4=4;![1\BIZ72T730^N%,M+ ];
M*F>[,+)PT=O1<M=Z_G":?8)L;LSS^E37::)/#HG8\[JR)I_;9+VC.CRY3%=(
M;;^][+D3]RGLO5[GC:BO5'B UI1FO\J^JU\W%)9==^#\I[LY>&YO+/X'4$L#
M!!0    ( '@X U?U&3"!#P@  .(G   0    97@M,S$R,G$R,#(S+FAT;>U:
M;6_;.!+^?K^"E^*Z"6 [\EN3.&D ;^I@#2R2KN/%[GTZT-+(XH42M21EQ_?K
M;X:4WV)[ZR#=UA=<@3J6.!S.<![./*1YE=A47E\EP*/KOUW]O5IEGU18I)!9
M%FK@%B)6&)&-V6\1F$=6K992-RJ?:3%.+&L$C2;[3>E',>&^W0HKX7JNY^K4
M/U^=ND&N1BJ:75]%8L)$]/%(0'QQ!@#M*&Z$K6:[.0KB^GF[WC@/VXV@SNO_
MJA]A5Q3W?8R=2?AXE(JLF@"-WVDU:F?MW%Y.16233CT(_G&T)FKAR5:Y%..L
MXPS&UEBA>V5SJ*32G7>!^W=)+=68IT+..C\,10J&W<&4#53*LQ\JAF>F:D"+
MV L:\1_ $7%P]SCU!IVA'BDRF!M8;Y!)O:=$C(1]_Z[^(;ALUFN-JU/J-/=M
MP\,5LT.<1=#?R>Z;WF#8O^W?=(?]^SOV>="_N^E_[O[,;OMW7?R*W^YOL;DW
M6/?G #WY_.O@X=?NW9 -[]E#[X;\*:,1-- )-ORIQQZZ@Q^[=[V'ZOWO/_?^
MR;HW0VII!$%CIWLIUV-$XTA9JU)ORX;'_HW((GSJ?&CF7Q^$K6=3T-HZ!=[?
M/5WYL.[)OPMC13S[RX.WW?)^A=TD6ABK\@0T>RBDQ'R355@(FLQB-N&XN-KG
M+_$NYU&$N:TJ(<9QSK?ZNQ:Z*@E]IQFHU^:>??O1G\U44&O3-/19PB? -$P$
M3+%0V$08]DO!-2)>SM@ <J4M4QF[53KUT*L'U5^8BEEWPJ5B0PPESZ&P(C05
M+]#/PAH[M@FP]^_.&XW@4L,8HZYY9MV+^N4)1OGBS4:Y<7!1_I$;C"U&,9VQ
MQTQ-)41CJ/A@:Q_B2*$)F4+*@"-PD3&>S5B165T >H DPO$)##MG*3YIP26+
M>8BO-%.IL,PJ+[<AD$$(QG ](Y&4/P(C:"QT&GP7H3$XI'1D!,<@@5!H)!\H
MEF%WM"3"E#%-1)@P4]#'LO\4-)1*R(%4&(DLA0C/5-@$'30YA,Y TINC:2I"
M-R?8+6*CV>HTO&E<-O]W< DL%AE&GD"TC'0%08GBEJK'LEUD,>8F;@7J$5DH
MBPAU(II6PEI!) K*9SF"@7!,^)9R"=02(^;9T+@6(D&**R112!1 ="J$D!O.
M.'M";A(62S4U<^@N\QWC]-+;C5965A!HYL9L6/NF0=@Z.! .UR)&%:I^=FE*
MF)74A)*)BF.!CRZ6?<8U.-0@"L1( D67 4)U)(5)2)S$4DRDE$SI.1(FE,H4
MV(]2K%;2PR?7*H0(7QMVC&B) .'G(=%["A.>C8%U,7L-"@FF+,!-7JVWC^'$
M/Y*2>CORKTZ<3D&$-?, II$8);L57'N<D55?')*5H\5><SE0C .1Q\_1CA+$
M)UY%XMJMPT8P/SD@!#=:- ^?P.!,80A=:?PRTBI4M4->F/V[4/D< 6*E',D7
M9%5H5( );2*,2Y,H!9G30V1^F6!7D[0&R1WXRHJ\!%"E3.#4*##9HBU&21&Y
M,PQ3C(R(!->"'!">-[BRD9&FPE M=ZO6N,+ODJHR@ 993.+4*4=>*\)"<JH%
MZ)8S8LD)L(=G&*O$"+^-@ 0Q76-_B%Z5G@\=W*.# ?=%[</9)K;WSFP;$-\_
M)^Z-=%P=$Q$1@+E1&:<RP V"GR@KH9KK:(XPQ+S@(R&%G1%+V#8LK3<'1H<S
MOU361%<HKZLV3Z5#>:%SQ+EQK"8,E8Z< 8[\CB%#LB(1[M@".:TC$D%B[R&-
MZTWDKK*\85"'!P/J1<;NX>:Y<&F-0@YQC.Q33#!89@N+7'"2/=*T?]Q.+!V(
ML2.F6./IZT@5=K<%^Q02OI &XN;QE_=8;#1G_6Y=@I\)M,=AD 9XJSB,#@:'
MB^3J([R)%-K]EU30M6R%XPM2*I$!%8:%)CRL5-XM6E-E++ZG4U?494)4](<_
MD/*'2ENZQ AL3';/I$O#<7\&[N""SC2R8F'7B;<JX69!4RA-NH4 D:L?;C[*
MW#YC4CR"+$\QGLE77CU%KP;_H6_\VF]DX^?.2Z/YNJDLLQDEUU7L+A,;H>\%
MQ&6#%B],XTB-K=)FP17<"U29IL):@#\I'2.%;(3:(X'V.27'B'#,U(8J ?XE
M@CY?EO!'(=!\MP2++'2''2?_W]5]6X[0E<CY<*X$PH]VU[1/#P4@7LHZO]A=
M38$_4N'V'-"5;L=>W>'L_+3J12@L-T+^E&-+!N01=C2P2( [$5MR7NR"L$-J
M6O'LP2!U,$6*H,%9<LZ4A6?KN=Z;9P:'M^WJ(@&(->:7"D(!7$I$,+GS]1)U
M%5\_1391<@)41#,^+G\FT&46A327:@;8.DV43YU\#=.(P:_",&K[_K;K0FS=
M7JT4&"$J05=QLB7/#73F7RXQR>>2SSHB<U/F.EVNJZ-+"Q.J%,@[2F@Y2/GF
M\C[#Q47M+#BC*PU6X_]H/G!YVZ'F;CN<VFBSK75>NPAV-P>U^LZVKZ3VU)GL
MS<:),3G//AXUC^8=2NAT&OD3JZ\O,4+3QMRH_-LO,.?I)P2MJU^L6XQQ\;-F
MQ=UZ6<"FG(C7^^A#_YW<?/^NA<O&?6[]K7W-W<./[9X^KUV(V!W(<J&CH:29
MN9-%-C?O,*.\<0O&>;PULB.-[P7$[':1'>\]<:6FX\%F<OWL3W]0<*/+R3:@
MS-TL;6GZ.S!_.M=EFFSLG.Z ^8S\Y;"]3)4S^=2E["TUX=FULUP9]RM?QY],
M3V#G1;32B&#9A8_0FL+N[K+KZM0UA67;!;+RT]^Q.W5W^_X+4$L#!!0    (
M '@X U<,SCMT@08  -TJ   0    97@M,S(Q,G$R,#(S+FAT;>U:;5/C-A#^
MWE^Q#5,.9A)C.P2<EV,F%T*;SC5P2>A=/W446T[4LRU7EH'TUW<EVR&!A.:8
M'N\,9()WM6]Z=K62W)K*,#AJ32GQCGYH_5BIP#%WTY!&$EQ!B:0>I F+)O#9
MH\E7J%1RK@Z/9X)-IA)LTZ["9RZ^L@N2T263 3TJY+3VLO];>UI):\R]V5'+
M8Q? O/<E1EQ2<ZGC>!8U]^MNG?@^<>QZW77&ING6Z)]6"8<B>S8FD;. OB^%
M+*I,J=+?V+>-PUHLFY?,D].&99H_E998);V2%1*P2=30!B/5Y^A>3G9YP$5C
MR]0_346I^"1DP:SQ;L1"FD"?7L* AR1Z5TY(E%02*IB?,2;L'XH:4;G^]S(S
MZ!#E!"RBA8&6K4SJ7DW9F$FHVH;5VE/\A5NWG2-B@OY)'N-8%+[@@8L!I>*1
M7.AT!Z/>2:_3'O5.^W!Z F>#7K_3.VM_A.Z7;N=\U/N]BX^1HSMHC<51NW^\
MP'+2Z[?Q*WXK6):BL'K&'M7?L_/!\+S='\'H],G;:CEP;@R-C@'#;D?/CU6M
MF>4G;W=[".WCT[-1%Z'RC,)=!+EN'JA$&/W2A6%[\*'=[PXKIU\^=O^ =F>D
M*+9IVFN]N2/1_TH3R?S9=W=O?Z5[O0A<'D74E8Q'<,GD%.24PJ>4"(QY,(,!
MC;F0P'UH7Y" PVA*!8EI*IF;E*$7N0;LJ!';6XYMF\T!G;!$"A))_<!J[@+*
M/>$B!,NL? *?"ZT@1G.Y!S3R<-WY-8TH5,URML*0!'P6X..Y-4/JIH))AFZ3
MR(/NE3LET83BTA2&+$F4Y?BK.#U<QP MI&COLEG*B\(DM+L,/Q,A9AA&%I2A
M,V741[FH1[(+"J>^SUPJ8"<6+')93 *@<R+/B+LJ)DK%M<ME;5Y/R1/XB,=H
M"0S3(, %,RJTG+"(H$P4N4*+/R?>I842=ZJ]',\ >11\RA"G(DF1#)+#0HW(
M9U;7"!5:XO%8K?6+[ 63PGBN;DC$F$0TJ9Q>!70&;5=#0&&\C'2"1N"X< 9?
M(WZ)<S6AVULUI[D1_A4P8^)YV&M4 NHC$IV5&9$]8HB02#8JBNF1<L0R"K\>
M7ON-2)E&385AI &A$]-'>"$*>!@'*C_F.2/HWRD35/5EB9JZ:R#L$ 25 *NV
MX\W1M9!A\^S*Y]RJ5_<SY(0Z6W&BZTT%])<YV?:3G&P68>$,B9Y!K->2X$@/
MG^:E(4,"8:I@QX(F:M++BDR" ' 8&H,E!0DQHB IZU'7I08%>DR+)E*3<)X+
M8.1UVN476&X\P(*SH%%5NPQK21ID,.,X0)N9W"Y<-XI_LEJJ<7=+D$/DH/H=
M$&)OA)#M+>O W*C4Z>EK23(.:$$=<^%144%; Q(GM%%\:7HLB0,R:[!(:]2#
MFKFL,9>2ATI<\T*5>Y<$>?;HD&3D?%M4KQM.K:IV1E+@GU<HSC=-AMXT[4GO
M-@VW5XY=74LV#6LM[2ZQ->/063_ROE+W'<.L'VPD=D\'(@L&ACN)2?2^5"T5
M _*<:]CQ%5C+M4FEX<V(A\SS OKPQ4GO=H\QE?5""^UT@H43JEG/- =C'HMG
M[N:'V7(W\;]YE67*(WFUO;5_V$STYU+S^9MQ;"RY^H( >Z-6O@QX]K$3VA2@
M>;W7O5",EO* >5"8^#2=OK4/UDX_>\0ZKQ>P(W4L^[Q+ZFI0KMFWJR/)G>63
M" M++YS-]]FWANR^X?D)^/2:5Y453CT'&+YUKJ^K<UUUM/GL0/N*:^>\><V\
MV]C'%]/(O@'XB?KTULRNO![Z[V;VUI 5S>R>/E!\C$/5S8[=-S]4??#[4RVQ
MP22J<S?P1!W7^US0"5<OTV37<PBQ[$R<" H1E^!1&E+O'O><Z@@]3D7,$ZI/
MV)/L6B<+G^7<XSX'=A8Y=K,[S,).R6&L;A]<CBJ%?DEH/ -!?2IHY"H*<I!H
MICQ1[G+_\6Y/2D?PG95_(Q(Z&"0,G+XD?\RP+.?6TXA-BM 3-Z%ZC=#J(D++
MD-\;+0*U#)=3*M4B'A*/(DI5SBE&XLM<\L++ &7$[(0(7+42G38*LA,:48%%
M\QK=*L$"5)"2B8(V)*D[S9&]_E9JH]+TX'= ^U;M/G= EF/4S?7D^][6O(G]
M-K%Y"UHP%)F3WR<N=#I6;56#;B\UZ//NW%0M4&FCKN#&&Y>XW.@+XH:@ 5''
M9FO?P<QA:EX/(6,T)97KAZQ[T^M(=3ZK7J#,/[/72_?T:ZW_ E!+ 0(4 Q0
M   ( '@X U?2TY^)M",! -$8#P 1              "  0    !A=G1X+3(P
M,C,P-C,P+FAT;5!+ 0(4 Q0    ( '@X U?G7J&7CA0  #+@   1
M      "  >,C 0!A=G1X+3(P,C,P-C,P+GAS9%!+ 0(4 Q0    ( '@X U=5
M#[J@!1H  *_\   5              "  : X 0!A=G1X+3(P,C,P-C,P7V-A
M;"YX;6Q02P$"% ,4    " !X. -7#BN:S\9P   ZU 0 %0
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M;6Q02P$"% ,4    " !X. -7X/(ZTS,(  "X*   $               @ $
MB@D 97@M,S$Q,G$R,#(S+FAT;5!+ 0(4 Q0    ( '@X U?U&3"!#P@  .(G
M   0              "  6&2"0!E>"TS,3(R<3(P,C,N:'1M4$L! A0#%
M  @ >#@#5PS..W2!!@  W2H  !               ( !GIH) &5X+3,R,3)Q
>,C R,RYH=&U02P4&      H "@"& @  3:$)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
